Method of evaluating pancreatic cancer, pancreatic cancer-evaluating apparatus, pancreatic cancer-evaluating method, pancreatic cancer-evaluating program product, pancreatic cancer-evaluating system, and information communication terminal apparatus

ABSTRACT

A method of evaluating pancreatic cancer includes (I) an obtaining step of obtaining amino acid concentration data on a concentration value of an amino acid in blood collected from a subject to be evaluated, and (II) an evaluating step of evaluating a state of pancreatic cancer in the subject by calculating a value of a formula using the amino acid concentration data of the subject obtained at the obtaining step and the formula previously established for evaluating the state of pancreatic cancer, including an explanatory variable to be substituted with the concentration value of the amino acid. The amino acid concentration data includes the concentration values of at least two amino acids of Asn, His, Thr, Ala, Cit, Arg, Tyr, Val, Met, Lys, Trp, Gly, Pro, Orn, Ile, Leu, Phe, Ser, and Gln, and the formula includes at least two explanatory variables to be substituted with the concentration values of at least two amino acids of Asn, His, Thr, Ala, Cit, Arg, Tyr, Val, Met, Lys, Trp, Gly, Pro, Orn, Ile, Leu, Phe, Ser, and Gln.

CROSS-REFERENCE TO RELATED APPLICATION

This application is based upon and claims the benefit of priority fromPCT Application PCT/JP2013/081981, filed Nov. 27, 2013, which claimspriority from Japanese Patent Application No. 2012-259167, filed Nov.27, 2012, the entire contents of which are incorporated herein byreference.

BACKGROUND OF THE INVENTION

1. Field of the Invention

The present invention relates to a method of evaluating pancreaticcancer, a pancreatic cancer-evaluating apparatus, a pancreaticcancer-evaluating method, a pancreatic cancer-evaluating programproduct, a pancreatic cancer-evaluating system, and an informationcommunication terminal apparatus.

2. Description of the Related Art

In Japan, the number of male deaths from pancreatic cancer in 2009 is14094, which ranks fifth in the total number of male deaths from cancerand the number of female deaths from pancreatic cancer in 2009 is 12697,which ranks fourth in the total number of female deaths from cancer. Thelifetime incidence rate of pancreatic cancer is 2%.

Pancreatic cancer has few symptoms in some cancer sites and is oftenfound at an advanced stage. Even when detected at a size of 2 cm orsmaller using image diagnosis, pancreatic cancer has often spread toadjacent tissues outside the pancreas and has an extremely poorprognosis. It is desired that pancreatic cancer should be found at anoperable earlier stage.

Pancreatic cancer is diagnosed using abdominal ultrasonography, CT(computed tomography), or MRI (magnetic resonance imaging), in all ofwhich the detection rate is not high.

Serum tumor markers include CA19-9, CEA, SPan-1, DUPAN-2, and the like.These markers have relatively high sensitivity and specificity foradvanced cancer but have a low positive rate for early cancer and may bepositive even in cancers other than pancreatic cancer.

Image diagnosis using an endoscopy, such as ERCP (endoscopic retrogradecholangiopancreatography) and EUS (endoscopic ultrasonography), is knownto be effective with a high detection rate for pancreatic cancer butincreases the patient's physical burden and is unsuitable for populationscreening and may have a risk of bleeding. Histologic diagnosis bybiopsy provides a definite diagnosis, but is a highly invasive test.Performing a biopsy at the screening is not practical.

It is therefore desirable from the viewpoints of a physical burdenimposed on patients and of cost-benefit performance to narrow down thetarget range of subjects with a high possibility of onset of pancreaticcancer and to subject those people to treatment. Specifically, it isdesirable to narrow the target range of subjects by selecting subjectsin accordance with a less invasive method and subjecting the selectedsubjects to image diagnosis, and to treat the subjects who aredefinitively diagnosed as having pancreatic cancer.

It is known that the concentrations of amino acids in blood change as aresult of onset of cancer. For example, Cynober (“Cynober, L. ed.,Metabolic and therapeutic aspects of amino acids in clinical nutrition.2nd ed., CRC Press”) has reported that the amount of consumptionincreases in cancer cells, for glutamine mainly as an oxidation energysource, for arginine as a precursor of nitrogen oxide and polyamine, andfor methionine through the activation of the ability of cancer cells totake in methionine. Schrader et al. (“Schrader H, Menge B A, Belyaev O,Uhl W, Schmidt W E, Meier J J., Amino acid malnutrition in patients withchronic pancreatitis and pancreatic carcinoma. Pancreas. 2009 May;38(4):416-21.”) and Vissers et al. (“Vissers Y L, Dejong C H, Luiking YC, Fearon K C, von Meyenfeldt M F, Deutz N E. Plasma arginineconcentrations are reduced in cancer patients: evidence for argininedeficiency? Am J Clin Nutr. 2005 May; 81(5):1142-6.”) have reported thatthe amino acid composition in plasma in pancreatic cancer patients isdifferent from that of healthy subjects.

JP-A-2011-247869 discloses that “of biogenic substances in a samplecollected from a subject, a specified finite number of analysis objectsubstances are selected, the quantity is determined, a multivariateanalysis is performed to perform metabolome analysis, and the analysisresult is compared with the analysis results of a healthy subject groupand a disease patient group obtained beforehand. Thus, the inspectionsof specific diseases, such as early diagnosis, determination oftherapeutic effect and prognosis for instance, can be easily performed.”The example described in JP-A-2011-247869 describes that “a multivariateanalysis using 61 components is performed using SIMCA-P+ (Umetrics). Thedifference is examined using the score plot of principal componentanalysis (PCA). Of, in total, 61 analyzed biomoleculars, PC1(t[1]),PC2(t[2]), and PC3(t[3]) are of 20 (32.3%), 15 (24.7%), and 7 (12.0%),respectively, in the 61 components (A=3, R2X=0.69). It is thus confirmedthat the distributions of analyzed biomoleculars in pancreatic cancerpatients and healthy subjects are different,” on data of serummetabolomes measured by GCMS (gas chromatography and mass spectroscopy)for healthy subjects and pancreatic cancer.

WO 2004/052191, WO 2006/098192, and WO 2009/054351 related to a methodof relating an amino acid concentration and a biological state aredisclosed as previous patents. WO 2008/016111 related to a method ofevaluating a state of lung cancer using an amino acid concentration, WO2008/075662 related to a method of evaluating a state of breast cancerusing an amino acid concentration, WO 2008/075663 related to a method ofevaluating a state of colorectal cancer using an amino acidconcentration, WO 2008/075664 related to a method of evaluating a stateof cancer using an amino acid concentration, WO 2009/099005 related to amethod of evaluating a state of gastric cancer using an amino acidconcentration, WO 2009/110517 related to a method of evaluating a cancertype using an amino acid concentration, WO 2009/154296 related to amethod of evaluating a state of female genital cancer using an aminoacid concentration, and WO 2009/154297 related to a method of evaluatinga state of prostatic disease including at least one of prostatic cancerand prostatic hypertrophy using an amino acid concentration aredisclosed as previous patents.

However, neither “Schrader H, Menge B A, Belyaev O, Uhl W, Schmidt W E,Meier J J., Amino acid malnutrition in patients with chronicpancreatitis and pancreatic carcinoma. Pancreas. 2009 May;38(4):416-21.” nor “Vissers Y L, Dejong C H, Luiking Y C, Fearon K C,von Meyenfeldt M F, Deutz N E. Plasma arginine concentrations arereduced in cancer patients: evidence for arginine deficiency? Am J ClinNutr. 2005 May; 81(5):1142-6.” search for a combination of biomolecularsor an index formula using multivariate analysis optimum for evaluating astate of pancreatic cancer.

The example described in JP-A-2011-247869 merely shows the tendency ofgeneral components of a large number of analyzed biomolecular componentsusing the principal component analysis, which is one of multivariateanalyses, and does not search for a combination of biomoleculars or anindex formula using multivariate analysis optimum for evaluating a stateof pancreatic cancer.

Even when the index formulae disclosed in WO 2004/052191, WO2006/098192, WO 2009/054351, WO 2008/016111, WO 2008/075662, WO2008/075663, WO 2008/075664, WO 2009/099005, WO 2009/110517, WO2009/154296, and WO 2009/154297 are used for evaluating a state ofpancreatic cancer, evaluation results having sufficient reliabilitycannot be obtained because diseases to be evaluated are different. Inparticular, WO 2009/110517 describes a method of evaluating a cancertype but does not describe a blood marker or an index formulaspecifically suitable for classification into subjects with a highpossibility of being affected with pancreatic cancer and subjects with ahigh possibility of being affected with cancers other than pancreaticcancer. WO 2009/110517 does not describe an index formula thataccurately classifies subjects into subjects with a high possibility ofbeing affected with pancreatic cancer and subjects with a lowpossibility of being affected with pancreatic cancer and that issuitable for classification into subjects with a high possibility ofbeing affected with pancreatic cancer and subjects with a highpossibility of being affected with cancers other than pancreatic cancer.

No blood marker has been reported for classification into subjects witha high possibility of being affected with pancreatic cancer and subjectswith a high possibility of being affected with cancers other thanpancreatic cancer, such as colorectal cancer, lung cancer, breastcancer, prostatic cancer, gastric cancer, uterine cancer (cervicalcancer, endometrial cancer), and ovarian cancer.

There is a problem that a method of evaluating a state of pancreaticcancer using a formula including at least two explanatory variables tobe substituted with the concentration values of at least two amino acidshas not been developed nor put into practice.

SUMMARY OF THE INVENTION

It is an object of the present invention to at least partially solve theproblems in the conventional technology.

The present invention has been made in view of the problems describedabove, and an object of the present invention is to provide a method ofevaluating pancreatic cancer, a pancreatic cancer-evaluating apparatus,a pancreatic cancer-evaluating method, a pancreatic cancer-evaluatingprogram product, a pancreatic cancer-evaluating system, and aninformation communication terminal apparatus, which can provide reliableinformation that may be helpful in knowing a state of pancreatic cancer.

To solve the problem and achieve the object described above, a method ofevaluating pancreatic cancer according to one aspect of the presentinvention includes an obtaining step of obtaining amino acidconcentration data on a concentration value of an amino acid in bloodcollected from a subject to be evaluated, and an evaluating step ofevaluating a state of pancreatic cancer in the subject by calculating avalue of a formula (hereinafter referred sometimes as the value of theevaluation formula or the evaluation value) using the amino acidconcentration data of the subject obtained at the obtaining step and theformula (hereinafter referred sometimes as the evaluation formula)previously established for evaluating the state of pancreatic cancer,including an explanatory variable to be substituted with theconcentration value of the amino acid, wherein the amino acidconcentration data includes the concentration values of at least twoamino acids of Asn, His, Thr, Ala, Cit, Arg, Tyr, Val, Met, Lys, Trp,Gly, Pro, Orn, Ile, Leu, Phe, Ser, and Gln, and the formula includes atleast two explanatory variables to be substituted with the concentrationvalues of at least two amino acids of Asn, His, Thr, Ala, Cit, Arg, Tyr,Val, Met, Lys, Trp, Gly, Pro, Orn, Ile, Leu, Phe, Ser, and Gln.

In the present specification, various amino acids are mainly written inabbreviations, the formal names of these are as follows.

(Abbreviation) (Formal name) Ala Alanine Arg Arginine Asn Asparagine CitCitrulline Gln Glutamine Gly Glycine His Histidine Ile Isoleucine LeuLeucine Lys Lysine Met Methionine Orn Ornithine Phe Phenylalanine ProProline Ser Serine Thr Threonine Trp Tryptophan Tyr Tyrosine Val Valine

The method of evaluating pancreatic cancer according to another aspectof the present invention is the method of evaluating pancreatic cancer,wherein the state of pancreatic cancer is the degree of the possibilityof being affected with pancreatic cancer, and evaluating the state ofpancreatic cancer in the subject is evaluating the degree of thepossibility that the subject is affected with pancreatic cancer.

In the present specification, as an example of the state of pancreaticcancer, for example, the degree of progress of pancreatic cancer isincluded in addition to the degree of the possibility being affectedwith pancreatic cancer.

The method of evaluating pancreatic cancer according to still anotheraspect of the present invention is the method of evaluating pancreaticcancer, wherein a plurality of categories defined considering at leastthe degree of the possibility of being affected with pancreatic cancer,and one or more thresholds are previously established, and evaluatingthe degree of the possibility that the subject is affected withpancreatic cancer is classifying the subject into any one of thecategories using the value of the formula and the threshold.

The method of evaluating pancreatic cancer according to still anotheraspect of the present invention is the method of evaluating pancreaticcancer, wherein the categories include at least one category definedconsidering at least the degree of the possibility of being affectedwith pancreatic cancer and the degree of the possibility of beingaffected with a cancer other than pancreatic cancer.

The method of evaluating pancreatic cancer according to still anotheraspect of the present invention is the method of evaluating pancreaticcancer, wherein the categories include a category (hereinafter, alsoreferred to as the category X) to which a subject with a highpossibility of being affected with pancreatic cancer (for example, asubject assumed to be affected with pancreatic cancer) belongs and acategory (hereinafter, also referred to as the category Y) to which asubject with a low possibility of being affected with pancreatic cancer(for example, a subject assumed to be not affected with pancreaticcancer) belongs.

The method of evaluating pancreatic cancer according to still anotheraspect of the present invention is the method of evaluating pancreaticcancer, wherein the category to which a subject with a low possibilityof being affected with pancreatic cancer belongs, includes a healthycategory to which a subject with a high possibility of being healthy(for example, a subject assumed to be healthy) belongs, other cancercategory to which a subject with a high possibility of being affectedwith a cancer other than pancreatic cancer (for example, a subjectassumed to be affected with a cancer other than pancreatic cancer)belongs, or a healthy/other cancer category to which a subject with ahigh possibility of being healthy and a subject with a high possibilityof being affected with a cancer other than pancreatic cancer belong.

The method of evaluating pancreatic cancer according to still anotheraspect of the present invention is the method of evaluating pancreaticcancer, wherein the category to which a subject with a low possibilityof being affected with pancreatic cancer belongs includes the healthycategory to which a subject with a high possibility of being healthybelongs and the other cancer category to which a subject with a highpossibility of being affected with a cancer other than pancreatic cancerbelongs.

The method of evaluating pancreatic cancer according to still anotheraspect of the present invention is the method of evaluating pancreaticcancer, wherein the formula is any one of a logistic regressionequation, a fractional expression, a linear discriminant, a multipleregression equation, a formula prepared by a support vector machine, aformula prepared by a Mahalanobis' generalized distance method, aformula prepared by canonical discriminant analysis, and a formulaprepared by a decision tree.

The method of evaluating pancreatic cancer according to still anotheraspect of the present invention may be the method of evaluatingpancreatic cancer, wherein evaluating the state of pancreatic cancer inthe subject is deciding that the value of the formula reflects the stateof pancreatic cancer in the subject.

The method of evaluating pancreatic cancer according to still anotheraspect of the present invention may be the method of evaluatingpancreatic cancer, wherein at the evaluating step, the value of theformula is converted by a predetermined method, and it is decided thatthe converted value reflects the state of pancreatic cancer in thesubject.

The method of evaluating pancreatic cancer according to still anotheraspect of the present invention may be the method of evaluatingpancreatic cancer, wherein at the evaluating step, a positionalinformation about a position of a predetermined mark corresponding tothe value of the formula or the converted value is generated on apredetermined scale visually presented on a display device such as amonitor or a physical medium such as paper for evaluating the state ofpancreatic cancer, using the value of the formula or the convertedvalue, and it is decided that the generated positional informationreflects the state of pancreatic cancer in the subject.

The method of evaluating pancreatic cancer according to still anotheraspect of the present invention may be the method of evaluatingpancreatic cancer, wherein at the evaluating step, the value of theformula is converted by a predetermined method, and the subject isclassified into any one of the categories using the converted value.

The method of evaluating pancreatic cancer according to still anotheraspect of the present invention may be the method of evaluatingpancreatic cancer, wherein the categories are the category X and thecategory Y, and at the evaluating step, the subject is classified intoone of the category X and the category Y. When the classification isexecuted, the category X may be written as for example, a pancreaticcancer category, and the category Y may be written as for example, apancreatic cancer-free category.

The method of evaluating pancreatic cancer according to still anotheraspect of the present invention may be the method of evaluatingpancreatic cancer, wherein (I) the formula is named as a first formula,a second formula that is different from the first formula and includesat least two explanatory variables to be substituted with theconcentration values of at least two amino acids of Asn, His, Thr, Ala,Cit, Arg, Tyr, Val, Met, Lys, Trp, Gly, Pro, Orn, Ile, Leu, Phe, Ser,Gln is previously established, and (II) at the evaluating step, thevalue of the first formula and the value of the second formula arecalculated, and the subject is classified into one of the category X andthe category Y using the calculated values of the first formula and thesecond formula.

The method of evaluating pancreatic cancer according to still anotheraspect of the present invention may be the method of evaluatingpancreatic cancer, wherein (I) the category Y includes the healthycategory to which a subject with a high possibility of being healthybelongs and the other cancer category to which a subject with a highpossibility of being affected with a cancer other than pancreatic cancerbelongs, the first formula is a formula for classifying a subject intoone of the category X and the healthy category, the second formula is aformula for classifying a subject into one of the category X and theother cancer category, and (II) at the evaluating step, (i) the value ofthe first formula is first calculated, (ii) the subject is classifiedinto one of the category X and the healthy category using the calculatedvalue of the first formula, (iii) then if the classification result isthe category X, the value of the second formula is calculated, (iv) thesubject classified in the category X using the value of the firstformula is further classified into one of the category X and the othercancer category using the calculated value of the second formula, andthen (v) the subject classified in the healthy category and the subjectclassified in the other cancer category is finally classified into thecategory Y.

The method of evaluating pancreatic cancer according to still anotheraspect of the present invention may be the method of evaluatingpancreatic cancer, wherein at the evaluating step, the subject isclassified into one of the category X and the healthy category. When theclassification is executed, the category X may be written as forexample, the pancreatic cancer category.

The method of evaluating pancreatic cancer according to still anotheraspect of the present invention may be the method of evaluatingpancreatic cancer, wherein at the evaluating step, the subject isclassified into one of the category X and the other cancer category.When the classification is executed, the category X may be written asfor example, the pancreatic cancer category.

The method of evaluating pancreatic cancer according to still anotheraspect of the present invention may be the method of evaluatingpancreatic cancer, wherein at the evaluating step, the subject isclassified into one of the category X and the healthy/other cancercategory. When the classification is executed, the category X may bewritten as for example, the pancreatic cancer category.

The method of evaluating pancreatic cancer according to still anotheraspect of the present invention may be the method of evaluatingpancreatic cancer, wherein at the evaluating step, the subject isclassified into any one of the category X, the healthy category, and theother cancer category. When the classification is executed, the categoryX may be written as for example, the pancreatic cancer category.

The method of evaluating pancreatic cancer according to still anotheraspect of the present invention may be the method of evaluatingpancreatic cancer, wherein (I) the formula is named as a first formula,a second formula that is different from the first formula and includesat least two explanatory variables to be substituted with theconcentration values of at least two amino acids of Asn, His, Thr, Ala,Cit, Arg, Tyr, Val, Met, Lys, Trp, Gly, Pro, Orn, Ile, Leu, Phe, Ser,Gln is previously established, and (II) at the evaluating step, thevalue of the first formula and the value of the second formula arecalculated, and the subject is classified into any one of the categoryX, the healthy category, and the other cancer category using thecalculated values of the first formula and the second formula.

The method of evaluating pancreatic cancer according to still anotheraspect of the present invention may be the method of evaluatingpancreatic cancer, wherein (I) the first formula is a formula forclassifying a subject into one of the category X and the healthycategory, the second formula is a formula for classifying a subject intoone of the category X and the other cancer category, and (II) at theevaluating step, (i) the value of the first formula is first calculated,(ii) the subject is classified into one of the category X and thehealthy category using the calculated value of the first formula, (iii)then if the classification result is the category X, the value of thesecond formula is calculated, (iv) the subject classified in thecategory X using the value of the first formula is further classifiedinto one of the category X and the other cancer category using thecalculated value of the second formula, and then (v) the subjectclassified in the category X using the value of the first formula andclassified in the other cancer category using the value of the secondformula is finally classified into the other cancer category.

A pancreatic cancer-evaluating apparatus according to one aspect of thepresent invention includes a control unit and a memory unit to evaluatea state of pancreatic cancer in a subject to be evaluated, wherein thecontrol unit includes an evaluating unit that evaluates the state ofpancreatic cancer in the subject by calculating a value of a formulausing previously obtained amino acid concentration data of the subjecton a concentration value of an amino acid and the formula previouslystored in the memory unit for evaluating the state of pancreatic cancer,including an explanatory variable to be substituted with theconcentration value of the amino acid, wherein the amino acidconcentration data includes the concentration values of at least twoamino acids of Asn, His, Thr, Ala, Cit, Arg, Tyr, Val, Met, Lys, Trp,Gly, Pro, Orn, Ile, Leu, Phe, Ser, and Gln, and the formula includes atleast two explanatory variables to be substituted with the concentrationvalues of at least two amino acids of Asn, His, Thr, Ala, Cit, Arg, Tyr,Val, Met, Lys, Trp, Gly, Pro, Orn, Ile, Leu, Phe, Ser, and Gln.

The pancreatic cancer-evaluating apparatus according to another aspectof the present invention may be the pancreatic cancer-evaluatingapparatus, wherein (I) the control unit further includes an evaluationformula-preparing unit that prepares the evaluation formula stored inthe memory unit, based on prostatic cancer state information stored inthe memory unit, including the amino acid concentration data andprostatic cancer state index data on an index for indicating the stateof prostatic cancer, wherein (II) the evaluation formula-preparing unitfurther includes (i) a candidate formula-preparing unit that prepares acandidate formula that is a candidate of the evaluation formula, basedon a predetermined formula-preparing method from the pancreatic cancerstate information, (ii) a candidate formula-verifying unit that verifiesthe candidate formula prepared by the candidate formula-preparing unit,based on a predetermined verifying method, and (iii) an explanatoryvariable-selecting unit that selects the explanatory variable of thecandidate formula based on a predetermined explanatoryvariable-selecting method thereby selecting a combination of the aminoacid concentration data included in the pancreatic cancer stateinformation used in preparing the candidate formula, and (iv) theevaluation formula-preparing unit prepares the evaluation formula byselecting the candidate formula used as the evaluation formula, from aplurality of the candidate formulae, based on the verification resultsaccumulated by repeatedly executing the candidate formula-preparingunit, the candidate formula-verifying unit, and the explanatoryvariable-selecting unit.

A pancreatic cancer-evaluating method according to one aspect of thepresent invention is a method of evaluating a state of pancreatic cancerin a subject to be evaluated, which method is carried out with aninformation processing apparatus including a control unit and a memoryunit, wherein the method includes an evaluating step of evaluating thestate of pancreatic cancer in the subject by calculating a value of aformula using previously obtained amino acid concentration data of thesubject on a concentration value of an amino acid and the formulapreviously stored in the memory unit for evaluating the state ofpancreatic cancer, including an explanatory variable to be substitutedwith the concentration value of the amino acid, wherein the amino acidconcentration data includes the concentration values of at least twoamino acids of Asn, His, Thr, Ala, Cit, Arg, Tyr, Val, Met, Lys, Trp,Gly, Pro, Orn, Ile, Leu, Phe, Ser, and Gln, the formula includes atleast two explanatory variables to be substituted with the concentrationvalues of at least two amino acids of Asn, His, Thr, Ala, Cit, Arg, Tyr,Val, Met, Lys, Trp, Gly, Pro, Orn, Ile, Leu, Phe, Ser, and Gln, and theevaluating step is executed by the control unit.

A pancreatic cancer-evaluating program product according to one aspectof the present invention has a non-transitory computer readable mediumincluding programmed instructions for making an information processingapparatus including a control unit and a memory unit execute a method ofevaluating a state of pancreatic cancer in a subject to be evaluated,wherein the method includes an evaluating step of evaluating the stateof pancreatic cancer in the subject by calculating a value of a formulausing previously obtained amino acid concentration data of the subjecton a concentration value of an amino acid and the formula previouslystored in the memory unit for evaluating the state of pancreatic cancer,including an explanatory variable to be substituted with theconcentration value of the amino acid, wherein the amino acidconcentration data includes the concentration values of at least twoamino acids of Asn, His, Thr, Ala, Cit, Arg, Tyr, Val, Met, Lys, Trp,Gly, Pro, Orn, Ile, Leu, Phe, Ser, and Gln, the formula includes atleast two explanatory variables to be substituted with the concentrationvalues of at least two amino acids of Asn, His, Thr, Ala, Cit, Arg, Tyr,Val, Met, Lys, Trp, Gly, Pro, Orn, Ile, Leu, Phe, Ser, and Gln, and theevaluating step is executed by the control unit.

A non-transitory computer-readable recording medium according to oneaspect of the present invention includes the programmed instructions formaking an information processing apparatus execute the pancreaticcancer-evaluating method.

A pancreatic cancer-evaluating system according to one aspect of thepresent invention includes (I) a pancreatic cancer-evaluating apparatusincluding a control unit and a memory unit to evaluate a state ofpancreatic cancer in a subject to be evaluated and (II) an informationcommunication terminal apparatus including a control unit to provideamino acid concentration data of the subject on a concentration value ofan amino acid that are connected to each other communicatively via anetwork, wherein (III) the control unit of the information communicationterminal apparatus includes an amino acid concentration data-sendingunit that transmits the amino acid concentration data of the subject tothe pancreatic cancer-evaluating apparatus and an evaluationresult-receiving unit that receives an evaluation result on the state ofpancreatic cancer in the subject, transmitted from the pancreaticcancer-evaluating apparatus, and (IV) the control unit of the pancreaticcancer-evaluating apparatus includes an amino acid concentrationdata-receiving unit that receives the amino acid concentration data ofthe subject transmitted from the information communication terminalapparatus, an evaluating unit that evaluates the state of pancreaticcancer in the subject by calculating a value of a formula using theamino acid concentration data of the subject received by the amino acidconcentration data-receiving unit and the formula previously stored inthe memory unit for evaluating the state of pancreatic cancer, includingan explanatory variable to be substituted with the concentration valueof the amino acid, and an evaluation result-sending unit that transmitsthe evaluation result of the subject obtained by the evaluating unit tothe information communication terminal apparatus, wherein (V) the aminoacid concentration data includes the concentration values of at leasttwo amino acids of Asn, His, Thr, Ala, Cit, Arg, Tyr, Val, Met, Lys,Trp, Gly, Pro, Orn, Ile, Leu, Phe, Ser, and Gln, and the formulaincludes at least two explanatory variables to be substituted with theconcentration values of at least two amino acids of Asn, His, Thr, Ala,Cit, Arg, Tyr, Val, Met, Lys, Trp, Gly, Pro, Orn, Ile, Leu, Phe, Ser,and Gln.

An information communication terminal apparatus according to one aspectof the present invention includes a control unit to provide amino acidconcentration data of a subject to be evaluated on a concentration valueof an amino acid, being connected communicatively via a network to apancreatic cancer-evaluating apparatus that evaluates a state ofpancreatic cancer in the subject, wherein the control unit includes anamino acid concentration data-sending unit that transmits the amino acidconcentration data of the subject to the pancreatic cancer-evaluatingapparatus, and an evaluation result-receiving unit that receives anevaluation result on the state of pancreatic cancer in the subject,transmitted from the pancreatic cancer-evaluating apparatus, wherein theevaluation result is the result of (I) receiving the amino acidconcentration data of the subject transmitted from the informationcommunication terminal apparatus and (II) evaluating the state ofpancreatic cancer in the subject by calculating a value of a formulausing the received amino acid concentration data of the subject and theformula previously stored in the pancreatic cancer-evaluating apparatusfor evaluating the state of pancreatic cancer, including an explanatoryvariable to be substituted with the concentration value of the aminoacid, wherein the (I) and (II) are executed by the pancreaticcancer-evaluating apparatus, wherein the amino acid concentration dataincludes the concentration values of at least two amino acids of Asn,His, Thr, Ala, Cit, Arg, Tyr, Val, Met, Lys, Trp, Gly, Pro, Orn, Ile,Leu, Phe, Ser, and Gln, and the formula includes at least twoexplanatory variables to be substituted with the concentration values ofat least two amino acids of Asn, His, Thr, Ala, Cit, Arg, Tyr, Val, Met,Lys, Trp, Gly, Pro, Orn, Ile, Leu, Phe, Ser, and Gln. An informationcommunication terminal apparatus according to one aspect of the presentinvention includes a control unit to provide amino acid concentrationdata of a subject to be evaluated on a concentration value of an aminoacid, wherein the control unit includes an evaluation result-receivingunit that receives an evaluation result on a state of pancreatic cancerin the subject, wherein the evaluation result is the result ofevaluating the state of pancreatic cancer in the subject by calculatinga value of a formula using the amino acid concentration data of thesubject and the formula for evaluating the state of pancreatic cancer,including an explanatory variable to be substituted with theconcentration value of the amino acid, wherein the amino acidconcentration data includes the concentration values of at least twoamino acids of Asn, His, Thr, Ala, Cit, Arg, Tyr, Val, Met, Lys, Trp,Gly, Pro, Orn, Ile, Leu, Phe, Ser, and Gln, and the formula includes atleast two explanatory variables to be substituted with the concentrationvalues of at least two amino acids of Asn, His, Thr, Ala, Cit, Arg, Tyr,Val, Met, Lys, Trp, Gly, Pro, Orn, Ile, Leu, Phe, Ser, and Gln.

A pancreatic cancer-evaluating apparatus according to one aspect of thepresent invention includes a control unit and a memory unit to evaluatea state of pancreatic cancer in a subject to be evaluated, beingconnected communicatively via a network to an information communicationterminal apparatus that provides amino acid concentration data of thesubject on a concentration value of an amino acid, wherein the controlunit includes an amino acid concentration data-receiving unit thatreceives the amino acid concentration data of the subject transmittedfrom the information communication terminal apparatus, an evaluatingunit that evaluates the state of pancreatic cancer in the subject bycalculating a value of a formula using the amino acid concentration dataof the subject received by the amino acid concentration data-receivingunit and the formula previously stored in the memory unit for evaluatingthe state of pancreatic cancer, including an explanatory variable to besubstituted with the concentration value of the amino acid, and anevaluation result-sending unit that transmits an evaluation result onthe state of pancreatic cancer in the subject obtained by the evaluatingunit to the information communication terminal apparatus, wherein theamino acid concentration data includes the concentration values of atleast two amino acids of Asn, His, Thr, Ala, Cit, Arg, Tyr, Val, Met,Lys, Trp, Gly, Pro, Orn, Ile, Leu, Phe, Ser, and Gln, and the formulaincludes at least two explanatory variables to be substituted with theconcentration values of at least two amino acids of Asn, His, Thr, Ala,Cit, Arg, Tyr, Val, Met, Lys, Trp, Gly, Pro, Orn, Ile, Leu, Phe, Ser,and Gln.

A method of searching for preventing/ameliorating substance forpancreatic cancer according to one aspect of the present inventionincludes (I) an obtaining step of obtaining amino acid concentrationdata on a concentration value of an amino acid in blood collected from asubject to be evaluated to which a desired substance group consisting ofone or more substances has been administered, (II) an evaluating step ofevaluating a state of pancreatic cancer in the subject by calculating avalue of a formula using the amino acid concentration data of thesubject obtained at the obtaining step and the formula previouslyestablished for evaluating the state of pancreatic cancer, including anexplanatory variable to be substituted with the concentration value ofthe amino acid, and (III) a judging step of judging whether or not thedesired substance group prevents pancreatic cancer or ameliorates thestate of pancreatic cancer, using an evaluation result obtained at theevaluating step, wherein the amino acid concentration data includes theconcentration values of at least two amino acids of Asn, His, Thr, Ala,Cit, Arg, Tyr, Val, Met, Lys, Trp, Gly, Pro, Orn, Ile, Leu, Phe, Ser,and Gln, and the formula includes at least two explanatory variables tobe substituted with the concentration values of at least two amino acidsof Asn, His, Thr, Ala, Cit, Arg, Tyr, Val, Met, Lys, Trp, Gly, Pro, Orn,Ile, Leu, Phe, Ser, and Gln.

According to the present invention, (I) the amino acid concentrationdata on the concentration value of the amino acid in blood collectedfrom the subject (the one including the concentration values of at leasttwo amino acids of the 19 kinds of amino acids composed of Asn, His,Thr, Ala, Cit, Arg, Tyr, Val, Met, Lys, Trp, Gly, Pro, Orn, Ile, Leu,Phe, Ser, and Gln) is obtained, and (II) the state of pancreatic cancerin the subject is evaluated by calculating the value of the formulausing the obtained amino acid concentration data of the subject and theformula previously established for evaluating the state of pancreaticcancer, including the explanatory variable to be substituted with theconcentration value of the amino acid (the one including at least twoexplanatory variables to be substituted with the concentration values ofat least two amino acids of the 19 kinds of amino acids). Hence,reliable information that may be helpful in knowing the state ofpancreatic cancer can be provided. Both improvement in reliability ofthe information and reduction in various burdens imposed on users (forexample, mental, physical, temporal, financial, or other burdens) can beachieved.

According to the present invention, the state of pancreatic cancer isthe degree of the possibility of being affected with pancreatic cancer,and evaluating the state of pancreatic cancer in the subject isevaluating the degree of the possibility that the subject is affectedwith pancreatic cancer. Hence, reliable information that may be helpfulin knowing the degree of the possibility of being affected withpancreatic cancer can be provided.

According to the present invention, the categories defined consideringat least the degree of the possibility of being affected with pancreaticcancer, and one or more thresholds are previously established, andevaluating the degree of the possibility that the subject is affectedwith pancreatic cancer is classifying the subject into any one of thecategories using the value of the formula and the threshold. Hence,reliable information that may be helpful in knowing the degree of thepossibility of being affected with pancreatic cancer can be provided ineasily understandable form.

According to the present invention, the categories include at least onecategory defined considering at least the degree of the possibility ofbeing affected with pancreatic cancer and the degree of the possibilityof being affected with a cancer other than pancreatic cancer. Hence,reliable information can be provided in easily understandable form,which may be helpful in knowing not only the degree of the possibilityof being affected with pancreatic cancer but also the degree of thepossibility of being affected with a cancer other than pancreaticcancer.

According to the present invention, the categories include the categoryX and the category Y. Hence, reliable information that may be helpful inknowing whether the possibility of being affected with pancreatic canceris high or low can be provided in easily understandable form.

According to the present invention, the category Y includes the healthycategory to which a subject with a high possibility of being healthybelongs, the other cancer category to which a subject with a highpossibility of being affected with a cancer other than pancreatic cancer(for example, lung cancer, colorectal cancer, prostatic cancer, breastcancer, gastric cancer, uterine cancer (cervical cancer, endometrialcancer), ovarian cancer, or the like) belongs, or the healthy/othercancer category to which a subject with a high possibility of beinghealthy and a subject with a high possibility of being affected with acancer other than pancreatic cancer belong. Hence, reliable informationcan be provided in easily understandable form, which may be helpful inknowing not only whether the possibility of being affected withpancreatic cancer is high but also whether the possibility of beinghealthy is high, whether the possibility of being affected with a cancerother than pancreatic cancer is high, or whether the possibility ofbeing healthy or being affected with a cancer other than pancreaticcancer is high.

According to the present invention, the category Y includes the healthycategory to which a subject with a high possibility of being healthybelongs and the other cancer category to which a subject with a highpossibility of being affected with a cancer other than pancreatic cancerbelongs. Hence, reliable information can be provided in easilyunderstandable form, which may be helpful in knowing not only whetherthe possibility of being affected with pancreatic cancer is high butalso whether the possibility of being healthy is high and whether thepossibility of being affected with a cancer other than pancreatic canceris high.

According to the present invention, the formula is any one of a logisticregression equation, a fractional expression, a linear discriminant, amultiple regression equation, a formula prepared by a support vectormachine, a formula prepared by a Mahalanobis' generalized distancemethod, a formula prepared by canonical discriminant analysis, and aformula prepared by a decision tree. Hence, further improvement inreliability of information that may be helpful in knowing the state ofpancreatic cancer can be achieved.

According to the present invention, evaluating the state of pancreaticcancer in the subject may be deciding that the value of the formulareflects the state of pancreatic cancer in the subject. Hence, reliableinformation that may be helpful in knowing the state of pancreaticcancer can be provided.

According to the present invention, the value of the formula may beconverted by the predetermined method, and it may be decided that theconverted value reflects the state of pancreatic cancer in the subject.Hence, reliable information that may be helpful in knowing the state ofpancreatic cancer can be provided.

According to the present invention, the positional information about theposition of the predetermined mark (for example, a circle sign or a starsign) corresponding to the value of the formula or the converted valuemay be generated on the predetermined scale (for example, a graduatedscale at least marked with graduations corresponding to the upper limitvalue and the lower limit value in the possible range of the value ofthe formula or the converted value, or part of the range) visuallypresented on the display device such as a monitor or the physical mediumsuch as paper for evaluating the state of pancreatic cancer, using thevalue of the formula or the converted value, and it may be decided thatthe generated positional information reflects the state of pancreaticcancer in the subject. Hence, reliable information that may be helpfulin knowing the state of pancreatic cancer can be provided.

According to the present invention, the value of the formula may beconverted by the predetermined method, and the subject may be classifiedinto any one of the categories using the converted value. Hence,reliable information that may be helpful in knowing the state ofpancreatic cancer can be provided.

According to the present invention, the categories may be the category Xand the category Y, and the subject may be classified into one of thecategory X and the category Y. Hence, reliable information that may behelpful in knowing whether the possibility of being affected withpancreatic cancer is high or low can be provided in easilyunderstandable form.

According to the present invention, (I) the formula may be named as thefirst formula, the second formula that is different from the firstformula and includes at least two explanatory variables to besubstituted with the concentration values of at least two amino acids ofthe 19 kinds of amino acids may be previously established, and (II) thevalue of the first formula and the value of the second formula may becalculated, and the subject may be classified into one of the category Xand the category Y using the calculated values of the first formula andthe second formula. Hence, further improvement in reliability ofinformation that may be helpful in knowing whether the possibility ofbeing affected with pancreatic cancer is high or low can be achieved.

According to the present invention, (I) the category Y may include thehealthy category and the other cancer category, the first formula may bea formula for classifying a subject into one of the category X and thehealthy category, the second formula may be a formula for classifying asubject into one of the category X and the other cancer category, and(II) (i) the value of the first formula may be first calculated, (ii)the subject may be classified into one of the category X and the healthycategory using the calculated value of the first formula, (iii) then ifthe classification result is the category X, the value of the secondformula may be calculated, (iv) the subject classified in the category Xusing the value of the first formula may be further classified into oneof the category X and the other cancer category using the calculatedvalue of the second formula, and then (v) the subject classified in thehealthy category and the subject classified in the other cancer categorymay be finally classified into the category Y. Hence, furtherimprovement in reliability of information that may be helpful in knowingwhether the possibility of being affected with pancreatic cancer is highor low can be achieved.

According to the present invention, the subject may be classified intoone of the category X and the healthy category. Hence, reliableinformation that may be helpful in knowing whether the possibility ofbeing affected with pancreatic cancer is high or the possibility ofbeing healthy is high can be provided in easily understandable form.

According to the present invention, the subject may be classified intoone of the category X and the other cancer category. Hence, reliableinformation that may be helpful in knowing whether the possibility ofbeing affected with pancreatic cancer is high or whether the possibilityof being affected with a cancer other than pancreatic cancer is high canbe provided in easily understandable form.

According to the present invention, the subject may be classified intoone of the category X and the healthy/other cancer category. Hence,reliable information that may be helpful in knowing whether thepossibility of being affected with pancreatic cancer is high or whetherthe possibility of being healthy or being affected with a cancer otherthan pancreatic cancer is high can be provided in easily understandableform.

According to the present invention, the category Y may include thehealthy category and the other cancer category, and the subject may beclassified into any one of the category X, the healthy category, and theother cancer category. Hence, reliable information that may be helpfulin knowing whether the possibility of being affected with pancreaticcancer is high, whether the possibility of being healthy is high, orwhether the possibility of being affected with a cancer other thanpancreatic cancer is high can be provided in easily understandable form.

According to the present invention, (I) the formula may be named as thefirst formula, the second formula that is different from the firstformula and includes at least two explanatory variables to besubstituted with the concentration values of at least two amino acids ofthe 19 kinds of amino acids may be previously established, and (II) thevalue of the first formula and the value of the second formula may becalculated, and the subject may be classified into any one of thecategory X, the healthy category, and the other cancer category usingthe calculated values of the first formula and the second formula. Thisleads to further improvement in reliability of information that may behelpful in knowing whether the possibility of being affected withpancreatic cancer is high, whether the possibility of being healthy ishigh, or whether the possibility of being affected with a cancer otherthan pancreatic cancer is high.

According to the present invention, (I) the first formula may be aformula for classifying a subject into one of the category X and thehealthy category, the second formula may be a formula for classifying asubject into one of the category X and the other cancer category, and(II) (i) the value of the first formula may be first calculated, (ii)the subject may be classified into one of the category X and the healthycategory using the calculated value of the first formula, (iii) then ifthe classification result is the category X, the value of the secondformula may be calculated, (iv) the subject classified in the category Xusing the value of the first formula may be further classified into oneof the category X and the other cancer category using the calculatedvalue of the second formula, and then (v) the subject classified in thecategory X using the value of the first formula and classified in theother cancer category using the value of the second formula may befinally classified into the other cancer category. This leads to furtherimprovement in reliability of information that may be helpful in knowingwhether the possibility of being affected with pancreatic cancer ishigh, whether the possibility of being healthy is high, or whether thepossibility of being affected with a cancer other than pancreatic canceris high.

According to the present invention, the evaluation formula may beprepared based on the pancreatic cancer state information previouslystored in the memory unit including the amino acid concentration dataand the pancreatic cancer state index data on the index for indicatingthe state of pancreatic cancer. Specifically, (I) the candidate formulamay be prepared based on the predetermined formula-preparing method fromthe pancreatic cancer state information, (II) the prepared candidateformula may be verified based on the predetermined verifying method,(III) the explanatory variables of the candidate formula may be selectedbased on the predetermined explanatory variable-selecting method,thereby selecting the combination of the amino acid concentration datacontained in the pancreatic cancer state information used in preparingof the candidate formula, and (IV) the candidate formula used as theevaluation formula may be selected from a plurality of the candidateformulae based on the verification results accumulated by repeatedlyexecuting the (I), (II) and (III), thereby preparing the evaluationformula. Hence, the evaluation formula most appropriate for evaluatingthe state of pancreatic cancer can be prepared.

According to the present invention, (I) the amino acid concentrationdata on the concentration value of the amino acid in blood collectedfrom the subject to which the desired substance group consisting of oneor more substances has been administered (the one including theconcentration values of at least two amino acids of the 19 kinds ofamino acids) may be obtained, (II) the state of pancreatic cancer in thesubject may be evaluated by calculating the value of the formula usingthe obtained amino acid concentration data of the subject and theformula previously established for evaluating the state of pancreaticcancer, including the explanatory variable to be substituted with theconcentration value of the amino acid (the one including at least twoexplanatory variables to be substituted with the concentration values ofat least two amino acids of the 19 kinds of amino acids), and (III)whether or not the desired substance group prevents pancreatic cancer orameliorates the state of pancreatic cancer may be judged using theobtained evaluation result. Hence, reliable information on a substancepreventing pancreatic cancer or a substance ameliorating the state ofpancreatic cancer can be provided by applying the method of evaluatingpancreatic cancer which can provide reliable information that may behelpful in knowing the state of pancreatic cancer. Both improvement inreliability of the information and reduction in various burdens imposedon users can be achieved. An existing animal model partially reflectingthe state of progress of pancreatic cancer or a clinically effectivechemical at an early stage can be selected by using typical data onvariation patterns of the concentration values of amino acids of anindividual being affected with pancreatic cancer and the formulaappropriate for evaluating the state of pancreatic cancer.

In the present invention, when the state of pancreatic cancer isevaluated, the concentration value of an amino acid other than the 19kinds of amino acids may be additionally used. In the present invention,when the state of pancreatic cancer is evaluated, a value of otherbiological information (for example, the values listed in 1. through 5.below) may be used in addition to the concentration values of aminoacids. In the present invention, the formula described above mayadditionally include one or more explanatory variables to be substitutedwith the concentration value of an amino acid other than the 19 kinds ofamino acids. In the present invention, the formula described above mayadditionally include one or more explanatory variables to be substitutedwith the value of other biological information (for example, the valueslisted in 1. through 5. below), in addition to the explanatory variablesto be substituted with the concentration values of amino acids.

1. the concentration values of metabolites in blood other than aminoacids (amino acid metabolites, carbohydrates, lipids, and the like),proteins, peptides, minerals, hormones, and the like

2. the values of tumor markers in blood (CA19-9, CEA, CA125, SPan-1,DUPAN-2, SLX, SCC, CYFRA, ProGRP, p53, elastase, and the like)

3. blood test values such as albumin, total protein, triglyceride,HbAlc, LDL cholesterol, HDL cholesterol, amylase, total bilirubin, anduric acid

4. the values obtained from image information of ultrasonography, Xrays, CT, MRI, and the like

5. the values of biological indices such as age, height, weight, BMI,blood pressure, gender, smoking information, dietary information,drinking information, exercise information, stress information, sleepinginformation, family medical history, disease history information(diabetes, pancreatitis, and the like)

The above and other objects, features, advantages and technical andindustrial significance of this invention will be better understood byreading the following detailed description of presently preferredembodiments of the invention, when considered in connection with theaccompanying drawings.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a principle configurational diagram showing a basic principleof a first embodiment;

FIG. 2 is a flowchart showing an example of a method of evaluatingpancreatic cancer according to the first embodiment;

FIG. 3 is a principle configurational diagram showing a basic principleof a second embodiment;

FIG. 4 is a diagram showing an example of an entire configuration of apresent system;

FIG. 5 is a diagram showing another example of an entire configurationof the present system;

FIG. 6 is a block diagram showing an example of a configuration of apancreatic cancer-evaluating apparatus 100 in the present system;

FIG. 7 is a chart showing an example of information stored in a userinformation file 106 a;

FIG. 8 is a chart showing an example of information stored in an aminoacid concentration data file 106 b;

FIG. 9 is a chart showing an example of information stored in apancreatic cancer state information file 106 c;

FIG. 10 is a chart showing an example of information stored in adesignated pancreatic cancer state information file 106 d;

FIG. 11 is a chart showing an example of information stored in acandidate formula file 106 e 1;

FIG. 12 is a chart showing an example of information stored in averification result file 106 e 2;

FIG. 13 is a chart showing an example of information stored in aselected pancreatic cancer state information file 106 e 3;

FIG. 14 is a chart showing an example of information stored in anevaluation formula file 106 e 4;

FIG. 15 is a chart showing an example of information stored in anevaluation result file 106 f;

FIG. 16 is a block diagram showing a configuration of an evaluationformula-preparing part 102 h;

FIG. 17 is a block diagram showing a configuration of an evaluating part102 i;

FIG. 18 is a block diagram showing an example of a configuration of aclient apparatus 200 in the present system;

FIG. 19 is a block diagram showing an example of a configuration of adatabase apparatus 400 in the present system;

FIG. 20 is a flowchart showing an example of a pancreatic cancerevaluation service processing performed in the present system; and

FIG. 21 is a flowchart showing an example of a evaluationformula-preparing processing performed in the pancreaticcancer-evaluating apparatus 100 in the present system.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

Hereinafter, an embodiment (first embodiment) of the method ofevaluating pancreatic cancer according to the present invention and anembodiment (second embodiment) of the pancreatic cancer-evaluatingapparatus, the pancreatic cancer-evaluating method, the pancreaticcancer-evaluating program, the recording medium, the pancreaticcancer-evaluating system, and the information communication terminalapparatus according to the present invention are described in detailwith reference to the drawings. The present invention is not limited tothese embodiments.

First Embodiment 1-1. Outline of First Embodiment

Here, an outline of the first embodiment will be described withreference to FIG. 1. FIG. 1 is a principle configurational diagramshowing a basic principle of the first embodiment.

Amino acid concentration data on a concentration value of an amino acid(the one including concentration values of at least two amino acids ofthe 19 kinds of amino acids composed of Asn, His, Thr, Ala, Cit, Arg,Tyr, Val, Met, Lys, Trp, Gly, Pro, Orn, Ile, Leu, Phe, Ser, and Gln) inblood (including, for example, plasma or serum) collected from a subjectto be evaluated (for example, an individual such as animal or human) isobtained (step S11).

In step S11, for example, the amino acid concentration data determinedby a company or the like that performs amino acid concentration valuemeasurements may be obtained, or the amino acid concentration data maybe obtained by determining the concentration value of the amino acid bya measurement method such as, for example, the following method (A) or(B) from blood collected from the subject. Here, the unit of theconcentration value of the amino acid may be, for example, a molarconcentration, a weight concentration, or one obtained by addition,subtraction, multiplication, and division of any constant with theseconcentrations.

(A) Plasma is separated from blood by centrifuging a collected bloodsample. All plasma samples are frozen and stored at −80° C. until anamino acid concentration value is measured. At the time of measuring anamino acid concentration value, acetonitrile is added to perform aprotein removal treatment, pre-column derivatization is then performedusing a labeled reagent (3-aminopyridyl-N-hydroxysuccinimidylcarbamate), and an amino acid concentration value is analyzed by liquidchromatograph mass spectrometer (LC/MS) (see International PublicationWO 2003/069328 and International Publication WO 2005/116629).

(B) Plasma is separated from blood by centrifuging a collected bloodsample. All plasma samples are frozen and stored at −80° C. until anamino acid concentration value is measured. At the time of measuring anamino acid concentration value, sulfosalicylic acid is added to performa protein removal treatment, and an amino acid concentration value isanalyzed by an amino acid analyzer based on post-column derivatizationusing a ninhydrin reagent.

A state of pancreatic cancer in the subject is evaluated using, asevaluation values for evaluating a state of pancreatic cancer, theconcentration values of at least two amino acids of the 19 kinds ofamino acids included in the amino acid concentration data obtained instep S11 (step S12). Before step S12 is executed, data such as defectiveand outliers may be removed from the amino acid concentration dataobtained in step S11.

According to the first embodiment described above, in step S11, theamino acid concentration data of the subject is obtained, and in stepS12, the state of pancreatic cancer in the subject is evaluated using,as the evaluation values, the concentration values of at least two aminoacids of the 19 kinds of amino acids included in the amino acidconcentration data of the subject obtained in step S11. Hence, reliableinformation that may be helpful in knowing the state of pancreaticcancer can be provided. Both improvement in reliability of theinformation and reduction in various burdens imposed on users (forexample, mental burden, physical burden, temporal burden, or financialburden) can be achieved.

The state of pancreatic cancer may be the degree of the possibility ofbeing affected with pancreatic cancer. Evaluating the state ofpancreatic cancer in the subject may be evaluating the degree of thepossibility that the subject is affected with pancreatic cancer. Hence,reliable information that may be helpful in knowing the degree of thepossibility of being affected with pancreatic cancer can be provided.

In step S12, it may be decided that the concentration values of at leasttwo amino acids of the 19 kinds of amino acids included in the aminoacid concentration data of the subject obtained at step S11 reflect thestate of pancreatic cancer in the subject. The concentration values maybe converted, for example, by the methods listed below, and it may bedecided that the converted values reflect the state of pancreatic cancerin the subject. In other words, in step S12, the concentration values orthe converted values may be treated per se as the evaluation result onthe state of pancreatic cancer in the subject. Hence, reliableinformation that may be helpful in knowing the state of pancreaticcancer can be provided.

The concentration value may be converted such that the possible range ofthe concentration value falls within a predetermined range (for example,the range from 0.0 to 1.0, the range from 0.0 to 10.0, the range from0.0 to 100.0, or the range from −10.0 to 10.0), for example, byaddition, subtraction, multiplication, and division of any given valuewith the concentration value, by conversion of the concentration valueby a predetermined conversion method (for example, index transformation,logarithm transformation, angular transformation, square roottransformation, probit transformation, or reciprocal transformation), orby performing a combination of these computations on the concentrationvalue. For example, the value of an exponential function with theconcentration value as an exponent and Napier constant as the base(specifically, the value of p/(1−p) where a natural logarithmln(p/(1−p)) is equal to the concentration value when the probability pof being affected with pancreatic cancer is defined) may be furthercalculated, and a value (specifically, the value of probability p) maybe further calculated by dividing the calculated value of exponentialfunction by the sum of 1 and the value of exponential function.

The concentration value may be converted such that the converted valueis particular value when a particular condition is met. For example, theconcentration value may be converted such that the converted value is5.0 when the specificity is 80% and the converted value is 8.0 when thespecificity is 95%.

In step S12, the positional information about the position of apredetermined mark (for example, a circle sign or a star sign)corresponding to the concentration value or the converted value may begenerated on a predetermined scale (for example, a graduated scale atleast marked with graduations corresponding to the upper limit value andthe lower limit value in the possible range of the concentration valueor the converted value, or part of the range) visually presented on adisplay device such as a monitor or a physical medium such as paper forevaluating the state of pancreatic cancer, using the concentrationvalues of at least two amino acids of the 19 kinds of amino acidsincluded in the amino acid concentration data of the subject obtained instep S11 or, if the concentration values are converted, the convertedvalues. Then it may be decided that the generated positional informationreflects the state of pancreatic cancer. Hence, reliable informationthat may be helpful in knowing the state of pancreatic cancer can beprovided.

In step S12, the state of pancreatic cancer in the subject may beevaluated by calculating the value of the evaluation formula using theamino acid concentration data of the subject and the previouslyestablished formula for evaluating the state of pancreatic cancer,including the explanatory variable to be substituted with theconcentration value of the amino acid (the one including at least twoexplanatory variables to be substituted with the concentration values ofat least two amino acids of the 19 kinds of amino acids). Hence,reliable information that may be helpful in knowing the state ofpancreatic cancer can be provided.

In step S12, it may be decided that the calculated value of the formulareflects the state of pancreatic cancer in the subject. The value of theformula may be converted, for example, by the methods listed below, andit may be decided that the converted value reflects the state ofpancreatic cancer in the subject. In other words, in step S12, the valueof the formula or the converted value may be treated per se as theevaluation result on the state of pancreatic cancer in the subject.Hence, reliable information that may be helpful in knowing the state ofpancreatic cancer can be provided.

The value of the evaluation formula may be converted such that thepossible range of the value of the evaluation formula falls within apredetermined range (for example, the range from 0.0 to 1.0, the rangefrom 0.0 to 10.0, the range from 0.0 to 100.0, or the range from −10.0to 10.0), for example, by addition, subtraction, multiplication, anddivision of any given number with the value of the evaluation formula,by conversion of the value of the evaluation formula by a predeterminedconversion method (for example, index transformation, logarithmtransformation, angular transformation, square root transformation,probit transformation, or reciprocal transformation), or by performing acombination of these computations on the value of the evaluationformula. For example, the value of an exponential function with thevalue of the evaluation formula as an exponent and Napier constant asthe base (specifically, the value of p/(1−p) where a natural logarithmln(p/(1−p)) is equal to the value of the evaluation formula when theprobability p of being affected with pancreatic cancer is defined) maybe further calculated, and a value (specifically, the value ofprobability p) may be calculated by dividing the calculated value ofexponential function by the sum of 1 and the value of exponentialfunction.

The value of the evaluation formula may be converted such that theconverted value is a particular value when a particular condition ismet. For example, the value of the evaluation formula may be convertedsuch that the converted value is 5.0 when the specificity is 80% and theconverted value is 8.0 when the specificity is 95%.

In step S12, the positional information about the position of apredetermined mark (for example, a circle sign or a star sign)corresponding to the value of the formula or the converted value may begenerated on a predetermined scale (for example, a graduated scale atleast marked with graduations corresponding to the upper limit value andthe lower limit value in the possible range of the value of the formulaor the converted value, or part of the range) visually presented on adisplay device such as a monitor or a physical medium such as paper forevaluating the state of pancreatic cancer, using the value of theformula or, if the value of the formula is converted, the convertedvalue. Then it may be decided that the generated positional informationreflects the state of pancreatic cancer in the subject. Hence, reliableinformation that may be helpful in knowing the state of pancreaticcancer can be provided.

When a plurality of categories defined considering at least the degreeof the possibility of being affected with pancreatic cancer, and one ormore thresholds are previously established, in step S12, the subject maybe classified into any one of the categories using the concentrationvalues of at least two amino acids of the 19 kinds of amino acids or, ifthe concentration values are converted, the converted values, and athreshold.

Alternatively, the subject may be classified into any one of thecategories using the value of the formula or, if the value of theformula is converted, the converted value, and a threshold. Hence,reliable information that may be helpful in knowing the degree of thepossibility of being affected with pancreatic cancer can be provided ineasily understandable form.

The categories may include at least one category defined considering atleast the degree of the possibility of being affected with pancreaticcancer and the degree of the possibility of being affected with a cancerother than pancreatic cancer (for example, lung cancer, colorectalcancer, prostatic cancer, breast cancer, gastric cancer, uterine cancer(cervical cancer, endometrial cancer), or ovarian cancer). Hence,reliable information that may be helpful in knowing not only the degreeof the possibility of being affected with pancreatic cancer but also thedegree of the possibility of being affected with a cancer other thanpancreatic cancer can be provided.

In a set of the concentration values of at least two amino acids of the19 kinds of amino acids included in the amino acid concentration data ofa plurality of test subjects proved to be not affected with pancreaticcancer (for example, to be healthy), the boundary value when thespecificity is a predetermined value (for example 80 or 95) may beestablished as a threshold. In a set of a plurality of values of theevaluation formula calculated for each test subject using the amino acidconcentration data and the evaluation formula, the boundary value whenthe specificity is a predetermined value may be established as athreshold.

In a set of the concentration values of at least two amino acids of the19 kinds of amino acids included in the amino acid concentration data ofa plurality of test subjects proved to be affected with pancreaticcancer, the boundary value when the sensitivity is a predetermined value(for example, 80 or 95) may be established as a threshold. In a set of aplurality of values of the evaluation formula calculated for each testsubject using the amino acid concentration data and the evaluationformula, the boundary value when the sensitivity is a predeterminedvalue may be established as a threshold.

The categories may include a category X to which a subject with a highpossibility of being affected with pancreatic cancer belongs and acategory Y to which a subject with a low possibility of being affectedwith pancreatic cancer belongs. Hence, reliable information that may behelpful in knowing whether the possibility of being affected withpancreatic cancer is high or low can be provided in easilyunderstandable form.

The category Y may include a healthy category to which a subject with ahigh possibility of being healthy belongs, other cancer category towhich a subject with a high possibility of being affected with a cancerother than pancreatic cancer belongs, or a healthy/other cancer categoryto which a subject with a high possibility of being healthy and asubject with a high possibility of being affected with a cancer otherthan pancreatic cancer belong. Hence, reliable information can beprovided in easily understandable form, which may be helpful in knowingnot only whether the possibility of being affected with pancreaticcancer is high but also whether the possibility of being healthy ishigh, whether the possibility of being affected with a cancer other thanpancreatic cancer is high, or whether the possibility of being healthyor being affected with a cancer other than pancreatic cancer is high.

The category Y may include the healthy category and the other cancercategory. Hence, reliable information can be provided in easilyunderstandable form, which may be helpful in knowing not only whetherthe possibility of being affected with pancreatic cancer is high butalso whether the possibility of being healthy is high and whether thepossibility of being affected with a cancer other than pancreatic canceris high.

When the categories are the category X and the category Y, in step S12,the subject may be classified into one of the category X and thecategory Y, using the concentration values of at least two amino acidsof the 19 kinds of amino acids or, if the concentration values areconverted, the converted values, and a threshold. Alternatively, thesubject may be classified into one of the category X and the category Y,using the value of the formula or, if the value of the formula isconverted, the converted value, and a threshold. Hence, reliableinformation that may be helpful in knowing whether the possibility ofbeing affected with pancreatic cancer is high or low can be provided ineasily understandable form.

When a first formula and a second formula that are different from eachother and each include at least two explanatory variables to besubstituted with the concentration values of at least two amino acids ofthe 19 kinds of amino acids are previously established as evaluationformulae, in step S12, the value of the first formula and the value ofthe second formula may be calculated, and the subject may be classifiedinto one of the category X and the category Y using the calculatedvalues of the first formula and the second formula. This leads tofurther improvement in reliability of information that may be helpful inknowing whether the possibility of being affected with pancreatic canceris high or low.

Specifically, when the healthy category and the other cancer categoryare previously established as the category Y, a formula for classifyinga subject into one of the category X and the healthy category ispreviously established as the first formula, and a formula forclassifying a subject into one of the category X and the other cancercategory is previously established as the second formula, in step S12,the value of the first formula may be first calculated, and the subjectmay be classified into one of the category X and the healthy categoryusing the calculated value of the first formula. Then if theclassification result is the category X, the value of the second formulamay be calculated, and the subject classified in the category X usingthe value of the first formula may be further classified into one of thecategory X and the other cancer category using the calculated value ofthe second formula. Then the subject classified in the healthy categoryand the subject classified in the other cancer category may be finallyclassified into the category Y.

When the healthy category is previously established as the category Y,in step S12, the subject may be classified into one of the category Xand the healthy category, using the concentration values of at least twoamino acids of the 19 kinds of amino acids or, if the concentrationvalues are converted, the converted values, and a threshold.Alternatively, the subject may be classified into one of the category Xand the healthy category using the value of the formula or, if the valueof the formula is converted, the converted value, and a threshold.Hence, reliable information that may be helpful in knowing whether thepossibility of being affected with pancreatic cancer is high or whetherthe possibility of being healthy is high can be provided in easilyunderstandable form.

When the other cancer category is previously established as the categoryY, in step S12, the subject may be classified into one of the category Xand the other cancer category using the concentration values of at leasttwo amino acids of the 19 kinds of amino acids or, if the concentrationvalues are converted, the converted values, and a threshold.Alternatively, the subject may be classified into one of the category Xand the other cancer category using the value of the formula or, if thevalue of the formula is converted, the converted value, and a threshold.Hence, reliable information that may be helpful in knowing whether thepossibility of being affected with pancreatic cancer is high or whetherthe possibility of being affected with a cancer other than pancreaticcancer is high can be provided in easily understandable form.

When the healthy/other cancer category is previously established as thecategory Y, in step S12, the subject may be classified into one of thecategory X and the healthy/other cancer category using the concentrationvalues of at least two amino acids of the 19 kinds of amino acids or, ifthe concentration values are converted, the converted values, and athreshold. Alternatively, the subject may be classified into one of thecategory X and the healthy/other cancer category using the value of theformula or, if the value of the formula is converted, the convertedvalue, and a threshold. Hence, reliable information that may be helpfulin knowing whether the possibility of being affected with pancreaticcancer is high or whether the possibility of being healthy or beingaffected with a cancer other than pancreatic cancer is high can beprovided in easily understandable form.

When the healthy category and the other cancer category are previouslyestablished as the category Y, in step S12, the subject may beclassified into any one of the category X, the healthy category, and theother cancer category using the concentration values of at least twoamino acids of the 19 kinds of amino acids or, if the concentrationvalues are converted, the converted values, and a threshold.Alternatively, the subject may be classified into any one of thecategory X, the healthy category, and the other cancer category usingthe value of the formula or, if the value of the formula is converted,the converted value, and a threshold. Hence, reliable information thatmay be helpful in knowing whether the possibility of being affected withpancreatic cancer is high, whether the possibility of being healthy ishigh, or whether the possibility of being affected with a cancer otherthan pancreatic cancer is high can be provided in easily understandableform.

When the first formula and the second formula that are different fromeach other and each include at least two explanatory variables to besubstituted with the concentration values of at least two amino acids ofthe 19 kinds of amino acids are previously established as evaluationformulae, in step S12, the value of the first formula and the value ofthe second formula may be calculated, and the subject may be classifiedinto any one of the category X, the healthy category, and the othercancer category using the calculated values of the first formula and thesecond formula. This leads to further improvement in reliability ofinformation that may be helpful in knowing whether the possibility ofbeing affected with pancreatic cancer is high, whether the possibilityof being healthy is high, or whether the possibility of being affectedwith a cancer other than pancreatic cancer is high.

Specifically, when a formula for classifying a subject into one of thecategory X and the healthy category is previously established as thefirst formula, and a formula for classifying a subject into one of thecategory X and the other cancer category is previously established asthe second formula, in step S12, the value of the first formula may befirst calculated, and the subject may be classified into one of thecategory X and the healthy category using the calculated value of thefirst formula. Then if the classification result is the category X, thevalue of the second formula may be calculated, and the subjectclassified in the category X using the value of the first formula may befurther classified into one of the category X and the other cancercategory using the calculated value of the second formula. Then thesubject classified in the category X using the value of the firstformula and classified in the other cancer category using the value ofthe second formula may be finally classified into the other cancercategory.

The evaluation formula may be any one of the logistic regressionequation, the fractional expression, the linear discriminant, themultiple regression equation, the formula prepared by the support vectormachine, the formula prepared by the Mahalanobis' generalized distancemethod, the formula prepared by the canonical discriminant analysis, andthe formula prepared by the decision tree. This leads to furtherimprovement in reliability of information that may be helpful in knowingthe state of pancreatic cancer.

In addition to the formulae described in the present specification, theformulae described in the international patent applications, filed bythe present applicant, WO 2008/016111, WO 2008/075662, WO 2008/075663,WO 2009/099005, WO 2009/154296, and WO 2009/154297 can be additionallyemployed as evaluation formulae to evaluate the state of pancreaticcancer.

The formula employed as the evaluation formula may be prepared by amethod described in WO 2004/052191 that is an international applicationfiled by the present applicant or by a method described in WO2006/098192 that is an international application filed by the presentapplicant. Any formulae obtained by these methods can be preferably usedin the evaluation of the state of pancreatic cancer, regardless of theunit of the amino acid concentration value in the amino acidconcentration data as input data.

The formula employed as the evaluation formula refers to a form ofequation used generally in multivariate analysis and includes, forexample, fractional expression, multiple regression equation, multiplelogistic regression equation, linear discriminant function, Mahalanobis'generalized distance, canonical discriminant function, support vectormachine, decision tree, and an equation shown by the sum of differentforms of equations. In the multiple regression equation, the multiplelogistic regression equation, and the canonical discriminant function, acoefficient and a constant term are added to each explanatory variable,and the coefficient and the constant term may be preferably realnumbers, more preferably values in the range of 99% confidence intervalfor the coefficient and the constant term obtained from data for thevarious kinds of classifications described above, more preferably in therange of 95% confidence interval for the coefficient and the constantterm obtained from data for the various kinds of classificationsdescribed above. The value of each coefficient and the confidenceinterval thereof may be those multiplied by a real number, and the valueof the constant term and the confidence interval thereof may be thosehaving an arbitrary actual constant added or subtracted or thosemultiplied or divided by an arbitrary actual constant. When anexpression such as a logistic regression, a linear discriminant, and amultiple regression analysis is used as an evaluation formula, a lineartransformation of the expression (addition of a constant andmultiplication by a constant) and a monotonic increasing (decreasing)transformation (for example, a logit transformation) of the expressiondo not alter evaluation performance and thus are equivalent to beforetransformation. Therefore, the expression includes an expression that issubjected to a linear transformation and a monotonic increasing(decreasing) transformation.

In the fractional expression, the numerator of the fractional expressionis expressed by the sum of the amino acids A, B, C etc. and thedenominator of the fractional expression is expressed by the sum of theamino acids a, b, c etc. The fractional expression also includes the sumof the fractional expressions α, β, γ etc. (for example, α+β) havingsuch constitution. The fractional expression also includes dividedfractional expressions. The amino acids used in the numerator ordenominator may have suitable coefficients respectively. The amino acidsused in the numerator or denominator may appear repeatedly. Eachfractional expression may have a suitable coefficient. A value of acoefficient for each explanatory variable and a value for a constantterm may be any real numbers. In a fractional expression and the one inwhich explanatory variables in the numerator and explanatory variablesin the denominator in the fractional expression are switched with eachother, the positive and negative signs are generally reversed incorrelation with objective explanatory variables, but because theircorrelation is maintained, the evaluation performance can be assumed tobe equivalent. The fractional expression therefore also includes the onein which explanatory variables in the numerator and explanatoryvariables in the denominator in the fractional expression are switchedwith each other.

In the first embodiment, when the state of pancreatic cancer isevaluated, the concentration value of an amino acid other than the 19kinds of amino acids may be additionally used. In the first embodiment,when the state of pancreatic cancer is evaluated, a value of otherbiological information (for example, the values listed in 1. through 5.below) may be used in addition to the concentration values of aminoacids. In the first embodiment, the formula employed as the evaluationformula may additionally include one or more explanatory variables to besubstituted with the concentration value of an amino acid other than the19 kinds of amino acids. In the first embodiment, the formula employedas the evaluation formula may additionally include one or moreexplanatory variables to be substituted with the value of otherbiological information (for example, the values listed in 1. through 5.below), in addition to the explanatory variables to be substituted withthe concentration values of amino acids.

1. the concentration values of metabolites in blood other than aminoacids (amino acid metabolites, carbohydrates, lipids, and the like),proteins, peptides, minerals, hormones, and the like

2. the values of tumor markers in blood (CA19-9, CEA, CA125, SPan-1,DUPAN-2, SLX, SCC, CYFRA, ProGRP, p53, elastase, and the like)

3. blood test values such as albumin, total protein, triglyceride,HbAlc, LDL cholesterol, HDL cholesterol, amylase, total bilirubin, anduric acid

4. the values obtained from image information of ultrasonography, Xrays, CT, MRI, and the like

5. the values of biological indices such as age, height, weight, BMI,blood pressure, gender, smoking information, dietary information,drinking information, exercise information, stress information, sleepinginformation, family medical history, disease history information(diabetes, pancreatitis, and the like)

When, before step S11 is executed, a desired substance group consistingof one or more substances is administered to the subject, and then bloodis collected from the subject, and in step S11, the amino acidconcentration data of the subject is obtained, a substance preventingpancreatic cancer or a substance ameliorating the state of pancreaticcancer may be searched by judging whether or not the administeredsubstance group prevents pancreatic cancer or ameliorates the state ofpancreatic cancer, using the evaluation result obtained in step S12.Hence, reliable information on a substance preventing pancreatic canceror a substance ameliorating the state of pancreatic cancer can beprovided by applying the method of evaluating pancreatic cancer whichcan provide reliable information that may be helpful in knowing thestate of pancreatic cancer.

Before step S11 is executed, a suitable combination of an existing drug,amino acid, food and supplement capable of administration to humans (forexample, a suitable combination of drugs known to be effective inprevention or amelioration of pancreatic cancer (for example,gemcitabine, erlotinib, and TS-1)) may be administered over apredetermined period (for example in the range of 1 day to 12 months) ina predetermined amount at predetermined frequency and timing (forexample 3 times per day, after food) by a predetermined administrationmethod (for example, oral administration). The administration method,dose, and dosage form may be suitably combined depending on thecondition of a patient. The dosage form may be determined based on knowntechniques. The dose is not particularly limited, and for example, adrug containing 1 μg to 100 g active ingredient may be given.

When the judgement result that the administered substance group preventspancreatic cancer or ameliorates the state of pancreatic cancer isobtained, the administered substance group may be searched as asubstance preventing pancreatic cancer or a substance ameliorating thestate of pancreatic cancer. The substance group searched by thesearching method includes, for example, the amino acid group includingat least two amino acids of the 19 kinds of amino acids.

Substances that restore normal value to the concentration values of theamino acid group including at least two amino acids of the 19 kinds ofamino acids or the value of the evaluation formula can be selected usingthe method of evaluating pancreatic cancer in the first embodiment orthe pancreatic cancer-evaluating apparatus in the second embodiment.

Searching for a substance preventing pancreatic cancer or a substanceameliorating the state of pancreatic cancer includes not only discoveryof a novel substance effective in preventing and ameliorating pancreaticcancer, but also (i) new discovery of use of a known substance inpreventing and ameliorating pancreatic cancer, (ii) discovery of a novelcomposition consisting of a combination of existing drugs, supplementsetc. having efficacy expectable for prevention and amelioration ofpancreatic cancer, (iii) discovery of the suitable usage, dose andcombination described above to form them into a kit, (iv) presentationof a preventing and therapeutic menu including a diet, exercise etc.,and (v) presentation of a necessary change in menu for each individualby monitoring the effect of the preventing and therapeutic menu.

1-2. Specific Example of the First Embodiment

Here, a specific example of the first embodiment will be described withreference to FIG. 2. FIG. 2 is a flowchart showing the specific exampleof the first embodiment.

The amino acid concentration data on the concentration values of theamino acids in blood collected from an individual such as animal orhuman (the one including the concentration values of at least two aminoacids of the 19 kinds of amino acids) is obtained (step SA11). In stepSA11, for example, the amino acid concentration data determined by acompany or the like that performs amino acid concentration valuemeasurements may be obtained, or the amino acid concentration data maybe obtained by determining the concentration values of the amino acidsby the measurement method such as, for example, the above described (A)or (B) from blood collected from the individual.

Data such as defective and outliers is then removed from the amino acidconcentration data of the individual obtained in step SA11 (step SA12).

The value of the formula is calculated using (i) the amino acidconcentration data of the individual from which the data such as thedefective and the outliers have been removed in step SA12 and (ii) theformula previously established as an evaluation formula, including atleast two explanatory variables to be substituted with the concentrationvalues of at least two amino acids of the 19 kinds of amino acids. Anyone of the classifications of 1. through 6. below is then executed usingthe calculated value of the formula (evaluation value) and a previouslyestablished threshold (step SA13).

1. When a plurality of categories defined considering at least thedegree of the possibility that a subject is affected with pancreaticcancer (the categories may include at least one category definedconsidering at least the degree of the possibility that a subject isaffected with pancreatic cancer and the degree of the possibility that asubject is affected with a cancer other than pancreatic cancer), and oneor more thresholds are previously established, the individual isclassified into any one of the categories using the evaluation value andthe threshold(s).

2. When the pancreatic cancer category and the pancreatic cancer-freecategory, and a threshold are previously established, the individual isclassified into one of the pancreatic cancer category and the pancreaticcancer-free category using the evaluation value and the threshold.

When the first formula and the second formula different from each otherare previously established as evaluation formulae, the value of thefirst formula and the value of the second formula may be calculated, andthe individual may be classified into one of the pancreatic cancercategory and the pancreatic cancer-free category using the calculatedvalues of the first formula and the second formula.

When the healthy category and the other cancer category are previouslyestablished as the pancreatic cancer-free category, a formula forclassifying a subject into one of the pancreatic cancer category and thehealthy category is previously established as the first formula, and aformula for classifying a subject into one of the pancreatic cancercategory and the other cancer category is previously established as thesecond formula, the value of the first formula may be first calculated,and the individual may be classified into one of the pancreatic cancercategory and the healthy category using the calculated value of thefirst formula. Then if the classification result is the pancreaticcancer category, the value of the second formula may be calculated, andthe individual classified in the pancreatic cancer category using thevalue of the first formula may be further classified into one of thepancreatic cancer category and the other cancer category using thecalculated value of the second formula. Then the individual classifiedin the healthy category and the individual classified in the othercancer category may be finally classified into the pancreaticcancer-free category. The individual classified into the pancreaticcancer category using the value of the first formula and classified intothe pancreatic cancer category using the value of the second formula isfinally classified into the pancreatic cancer category, as a matter ofcourse.

3. When the pancreatic cancer category and the healthy category, and athreshold are previously established, the individual is classified intoone of the pancreatic cancer category and the healthy category using theevaluation value and the threshold.

4. When the pancreatic cancer category and the other cancer category,and a threshold are previously established, the individual is classifiedinto one of the pancreatic cancer category and the other cancer categoryusing the evaluation value and the threshold.

5. When the pancreatic cancer category and the healthy/other cancercategory, and a threshold are previously established, the individual isclassified into one of the pancreatic cancer category and thehealthy/other cancer category using the evaluation value and thethreshold.

6. When the pancreatic cancer category, the healthy category, and theother cancer category, and a threshold are previously established, theindividual is classified into any one of the pancreatic cancer category,the healthy category, and the other cancer category using the evaluationvalues and the threshold.

When the first formula and the second formula that are different fromeach other are previously established as evaluation formulae, the valueof the first formula and the value of the second formula may becalculated, and the individual may be classified into any one of thepancreatic cancer category, the healthy category, and the other cancercategory using the calculated values of the first formula and the secondformula.

when a formula for classifying a subject into one of the pancreaticcancer category and the healthy category is previously established asthe first formula, and a formula for classifying a subject into one ofthe pancreatic cancer category and the other cancer category ispreviously established as the second formula, the value of the firstformula may be first calculated, and the individual may be classifiedinto one of the pancreatic cancer category and the healthy categoryusing the calculated value of the first formula. Then if theclassification result is the pancreatic cancer category, the value ofthe second formula may be calculated, and the individual classified inthe pancreatic cancer category using the value of the first formula maybe further classified into one of the pancreatic cancer category and theother cancer category using the calculated value of the second formula.Then the individual classified in the pancreatic cancer category usingthe value of the first formula and classified in the other cancercategory using the value of the second formula may be finally classifiedinto the other cancer category. The individual classified in the healthycategory using the value of the first formula is finally classified intothe healthy category, as a matter of course, and the individualclassified in the pancreatic cancer category using the value of thefirst formula and classified in the pancreatic cancer category using thevalue of the second formula is finally classified into the pancreaticcancer category, as a matter of course.

Second Embodiment 2-1. Outline of the Second Embodiment

Here, outlines of the second embodiment will be described in detail withreference to FIG. 3. FIG. 3 is a principle configurational diagramshowing a basic principle of the second embodiment.

A control device evaluates a state of pancreatic cancer in a subject tobe evaluated (for example, an individual such as animal or human) bycalculating a value of a formula using (i) the concentration values ofat least two amino acids of the 19 kinds of amino acids composed of Asn,His, Thr, Ala, Cit, Arg, Tyr, Val, Met, Lys, Trp, Gly, Pro, Orn, Ile,Leu, Phe, Ser, and Gln, including previously obtained amino acidconcentration data of the subject on the concentration value of an aminoacid and (ii) the formula previously stored in a memory device forevaluating the state of pancreatic cancer, including an explanatoryvariable to be substituted with the concentration value of the aminoacid (the one including at least two explanatory variables to besubstituted with the concentration values of at least two amino acids ofthe 19 kinds of amino acids) (step S21).

According to the second embodiment described above, in step S21, thestate of pancreatic cancer in the subject is evaluated by calculatingthe value of the evaluation formula using the amino acid concentrationdata of the subject and the formula stored in the memory device as theevaluation formula. Hence, reliable information that may be helpful inknowing the state of pancreatic cancer can be provided. Both improvementin reliability of the information and reduction in various burdensimposed on users (for example, mental burden, physical burden, temporalburden, or financial burden) can be achieved.

The state of pancreatic cancer may be the degree of the possibility ofbeing affected with pancreatic cancer. Evaluating the state ofpancreatic cancer in the subject may be evaluating the degree of thepossibility that the subject is affected with pancreatic cancer. Hence,reliable information that may be helpful in knowing the degree of thepossibility of being affected with pancreatic cancer can be provided.

In step S21, it may be decided that the calculated value of the formulareflects the state of pancreatic cancer in the subject. The value of theformula may be converted, for example, by the methods listed below, andit may be decided that the converted value reflects the state ofpancreatic cancer in the subject. In other words, in step S21, the valueof the formula or the converted value may be treated per se as theevaluation result on the state of pancreatic cancer in the subject.Hence, reliable information that may be helpful in knowing the state ofpancreatic cancer can be provided.

The value of the evaluation formula may be converted such that thepossible range of the value of the evaluation formula falls within apredetermined range (for example, the range from 0.0 to 1.0, the rangefrom 0.0 to 10.0, the range from 0.0 to 100.0, or the range from −10.0to 10.0), for example, by addition, subtraction, multiplication, anddivision of any given number with the value of the evaluation formula,by conversion of the value of the evaluation formula by a predeterminedconversion method (for example, index transformation, logarithmtransformation, angular transformation, square root transformation,probit transformation, or reciprocal transformation), or by performing acombination of these computations on the value of the evaluationformula. For example, the value of an exponential function with thevalue of the evaluation formula as an exponent and Napier constant asthe base (specifically, the value of p/(1−p) where a natural logarithmln(p/(1−p)) is equal to the value of the evaluation formula when theprobability p of being affected with pancreatic cancer is defined) maybe further calculated, and a value (specifically, the value ofprobability p) may be calculated by dividing the calculated value ofexponential function by the sum of 1 and the value of exponentialfunction.

The value of the evaluation formula may be converted such that theconverted value is a particular value when a particular condition ismet. For example, the value of the evaluation formula may be convertedsuch that the converted value is 5.0 when the specificity is 80% and theconverted value is 8.0 when the specificity is 95%.

In step S21, the positional information about the position of apredetermined mark (for example, a circle sign or a star sign)corresponding to the value of the formula or the converted value may begenerated on a predetermined scale (for example, a graduated scale atleast marked with graduations corresponding to the upper limit value andthe lower limit value in the possible range of the value of the formulaor the converted value, or part of the range) visually presented on adisplay device such as a monitor or a physical medium such as paper forevaluating the state of pancreatic cancer, using the value of theformula or, if the value of the formula is converted, the convertedvalue. Then it may be decided that the generated positional informationreflects the state of pancreatic cancer in the subject. Hence, reliableinformation that may be helpful in knowing the state of pancreaticcancer can be provided.

When a plurality of categories defined considering at least the degreeof the possibility of being affected with pancreatic cancer, and one ormore thresholds are previously established, in step S21, the subject maybe classified into any one of the categories using the value of theformula or, if the value of the formula is converted, the convertedvalue, and a threshold. Hence, reliable information that may be helpfulin knowing the degree of the possibility of being affected withpancreatic cancer can be provided in easily understandable form.

The categories may include at least one category defined considering atleast the degree of the possibility of being affected with pancreaticcancer and the degree of the possibility of being affected with a cancerother than pancreatic cancer (for example, lung cancer, colorectalcancer, prostatic cancer, breast cancer, gastric cancer, uterine cancer(cervical cancer, endometrial cancer), or ovarian cancer). Hence,reliable information that may be helpful in knowing not only the degreeof the possibility of being affected with pancreatic cancer but also thedegree of the possibility of being affected with a cancer other thanpancreatic cancer can be provided.

In a set of a plurality of values of the evaluation formula calculatedfor each test subject using the amino acid concentration data of theplurality of test subjects proved to be not affected with pancreaticcancer (for example, to be healthy) and the evaluation formula, theboundary value when the specificity is a predetermined value (forexample 80 or 95) may be established as a threshold.

In a set of a plurality of values of the evaluation formula calculatedfor each test subject using the amino acid concentration data of theplurality of test subjects proved to be affected with pancreatic cancerand the evaluation formula, the boundary value when the sensitivity is apredetermined value (for example, 80 or 95) may be established as athreshold.

The categories may include a category X to which a subject with a highpossibility of being affected with pancreatic cancer belongs and acategory Y to which a subject with a low possibility of being affectedwith pancreatic cancer belongs. Hence, reliable information that may behelpful in knowing whether the possibility of being affected withpancreatic cancer is high or low can be provided in easilyunderstandable form.

The category Y may include a healthy category to which a subject with ahigh possibility of being healthy belongs, other cancer category towhich a subject with a high possibility of being affected with a cancerother than pancreatic cancer belongs, or a healthy/other cancer categoryto which a subject with a high possibility of being healthy and asubject with a high possibility of being affected with a cancer otherthan pancreatic cancer belong. Hence, reliable information can beprovided in easily understandable form, which may be helpful in knowingnot only whether the possibility of being affected with pancreaticcancer is high but also whether the possibility of being healthy ishigh, whether the possibility of being affected with a cancer other thanpancreatic cancer is high, or whether the possibility of being healthyor being affected with a cancer other than pancreatic cancer is high.

The category Y may include the healthy category and the other cancercategory. Hence, reliable information can be provided in easilyunderstandable form, which may be helpful in knowing not only whetherthe possibility of being affected with pancreatic cancer is high butalso whether the possibility of being healthy is high and whether thepossibility of being affected with a cancer other than pancreatic canceris high.

When the categories are the category X and the category Y, in step S21,the subject may be classified into one of the category X and thecategory Y, using the value of the formula or, if the value of theformula is converted, the converted value, and a threshold. Hence,reliable information that may be helpful in knowing whether thepossibility of being affected with pancreatic cancer is high or low canbe provided in easily understandable form.

When a first formula and a second formula that are different from eachother and each include at least two explanatory variables to besubstituted with the concentration values of at least two amino acids ofthe 19 kinds of amino acids are previously established as evaluationformulae, in step S21, the value of the first formula and the value ofthe second formula may be calculated, and the subject may be classifiedinto one of the category X and the category Y using the calculatedvalues of the first formula and the second formula. This leads tofurther improvement in reliability of information that may be helpful inknowing whether the possibility of being affected with pancreatic canceris high or low.

Specifically, when the healthy category and the other cancer categoryare previously established as the category Y, a formula for classifyinga subject into one of the category X and the healthy category ispreviously established as the first formula, and a formula forclassifying a subject into one of the category X and the other cancercategory is previously established as the second formula, in step S21,the value of the first formula may be first calculated, and the subjectmay be classified into one of the category X and the healthy categoryusing the calculated value of the first formula. Then if theclassification result is the category X, the value of the second formulamay be calculated, and the subject classified in the category X usingthe value of the first formula may be further classified into one of thecategory X and the other cancer category using the calculated value ofthe second formula. Then the subject classified in the healthy categoryand the subject classified in the other cancer category may be finallyclassified into the category Y.

When the healthy category is previously established as the category Y,in step S21, the subject may be classified into one of the category Xand the healthy category using the value of the formula or, if the valueof the formula is converted, the converted value, and a threshold.Hence, reliable information that may be helpful in knowing whether thepossibility of being affected with pancreatic cancer is high or whetherthe possibility of being healthy is high can be provided in easilyunderstandable form.

When the other cancer category is previously established as the categoryY, in step S21, the subject may be classified into one of the category Xand the other cancer category using the value of the formula or, if thevalue of the formula is converted, the converted value, and a threshold.Hence, reliable information that may be helpful in knowing whether thepossibility of being affected with pancreatic cancer is high or whetherthe possibility of being affected with a cancer other than pancreaticcancer is high can be provided in easily understandable form.

When the healthy/other cancer category is previously established as thecategory Y, in step S21, the subject may be classified into one of thecategory X and the healthy/other cancer category using the value of theformula or, if the value of the formula is converted, the convertedvalue, and a threshold. Hence, reliable information that may be helpfulin knowing whether the possibility of being affected with pancreaticcancer is high or whether the possibility of being healthy or beingaffected with a cancer other than pancreatic cancer is high can beprovided in easily understandable form.

When the healthy category and the other cancer category are previouslyestablished as the category Y, in step S21, the subject may beclassified into any one of the category X, the healthy category, and theother cancer category using the value of the formula or, if the value ofthe formula is converted, the converted value, and a threshold. Hence,reliable information that may be helpful in knowing whether thepossibility of being affected with pancreatic cancer is high, whetherthe possibility of being healthy is high, or whether the possibility ofbeing affected with a cancer other than pancreatic cancer is high can beprovided in easily understandable form.

When the first formula and the second formula that are different fromeach other and each include at least two explanatory variables to besubstituted with the concentration values of at least two amino acids ofthe 19 kinds of amino acids are previously established as evaluationformulae, in step S21, the value of the first formula and the value ofthe second formula may be calculated, and the subject may be classifiedinto any one of the category X, the healthy category, and the othercancer category using the calculated values of the first formula and thesecond formula. This leads to further improvement in reliability ofinformation that may be helpful in knowing whether the possibility ofbeing affected with pancreatic cancer is high, whether the possibilityof being healthy is high, or whether the possibility of being affectedwith a cancer other than pancreatic cancer is high.

Specifically, when a formula for classifying a subject into one of thecategory X and the healthy category is previously established as thefirst formula, and a formula for classifying a subject into one of thecategory X and the other cancer category is previously established asthe second formula, in step S21, the value of the first formula may befirst calculated, and the subject may be classified into one of thecategory X and the healthy category using the calculated value of thefirst formula. Then if the classification result is the category X, thevalue of the second formula may be calculated, and the subjectclassified in the category X using the value of the first formula may befurther classified into one of the category X and the other cancercategory using the calculated value of the second formula. Then thesubject classified in the category X using the value of the firstformula and classified in the other cancer category using the value ofthe second formula may be finally classified into the other cancercategory.

The evaluation formula may be any one of the logistic regressionequation, the fractional expression, the linear discriminant, themultiple regression equation, the formula prepared by the support vectormachine, the formula prepared by the Mahalanobis' generalized distancemethod, the formula prepared by the canonical discriminant analysis, andthe formula prepared by the decision tree. This leads to furtherimprovement in reliability of information that may be helpful in knowingthe state of pancreatic cancer.

In addition to the formulae described in the present specification, theformulae described in the international patent applications, filed bythe present applicant, WO 2008/016111, WO 2008/075662, WO 2008/075663,WO 2009/099005, WO 2009/154296, and WO 2009/154297 can be additionallyemployed to evaluate the state of pancreatic cancer.

The formula employed as the evaluation formula may be prepared by amethod described in WO 2004/052191 that is an international applicationfiled by the present applicant or by a method described in WO2006/098192 that is an international application filed by the presentapplicant. Any formulae obtained by these methods can be preferably usedin the evaluation of the state of pancreatic cancer, regardless of theunit of the amino acid concentration value in the amino acidconcentration data as input data.

The formula employed as the evaluation formula refers to a form ofequation used generally in multivariate analysis and includes, forexample, fractional expression, multiple regression equation, multiplelogistic regression equation, linear discriminant function, Mahalanobis'generalized distance, canonical discriminant function, support vectormachine, decision tree, and an equation shown by the sum of differentforms of equations. In the multiple regression equation, the multiplelogistic regression equation, and the canonical discriminant function, acoefficient and a constant term are added to each explanatory variable,and the coefficient and the constant term may be preferably realnumbers, more preferably values in the range of 99% confidence intervalfor the coefficient and the constant term obtained from data for thevarious kinds of classifications described above, more preferably in therange of 95% confidence interval for the coefficient and the constantterm obtained from data for the various kinds of classificationsdescribed above. The value of each coefficient and the confidenceinterval thereof may be those multiplied by a real number, and the valueof the constant term and the confidence interval thereof may be thosehaving an arbitrary actual constant added or subtracted or thosemultiplied or divided by an arbitrary actual constant.

When an expression such as a logistic regression, a linear discriminant,and a multiple regression analysis is used as an evaluation formula, alinear transformation of the expression (addition of a constant andmultiplication by a constant) and a monotonic increasing (decreasing)transformation (for example, a logit transformation) of the expressiondo not alter evaluation performance and thus are equivalent to beforetransformation. Therefore, the expression includes an expression that issubjected to a linear transformation and a monotonic increasing(decreasing) transformation.

In the fractional expression, the numerator of the fractional expressionis expressed by the sum of the amino acids A, B, C etc. and thedenominator of the fractional expression is expressed by the sum of theamino acids a, b, c etc. The fractional expression also includes the sumof the fractional expressions α, β, γ etc. (for example, α+β) havingsuch constitution. The fractional expression also includes dividedfractional expressions. The amino acids used in the numerator ordenominator may have suitable coefficients respectively. The amino acidsused in the numerator or denominator may appear repeatedly. Eachfractional expression may have a suitable coefficient. A value of acoefficient for each explanatory variable and a value for a constantterm may be any real numbers. In a fractional expression and the one inwhich explanatory variables in the numerator and explanatory variablesin the denominator in the fractional expression are switched with eachother, the positive and negative signs are generally reversed incorrelation with objective explanatory variables, but because theircorrelation is maintained, the evaluation performance can be assumed tobe equivalent. The fractional expression therefore also includes the onein which explanatory variables in the numerator and explanatoryvariables in the denominator in the fractional expression are switchedwith each other.

In the second embodiment, when the state of pancreatic cancer isevaluated, the concentration value of an amino acid other than the 19kinds of amino acids may be additionally used. In the second embodiment,when the state of pancreatic cancer is evaluated, a value of otherbiological information (for example, the values listed in 1. through 5.below) may be used in addition to the concentration values of aminoacids. In the second embodiment, the formula employed as the evaluationformula may additionally include one or more explanatory variables to besubstituted with the concentration value of an amino acid other than the19 kinds of amino acids. In the second embodiment, the formula employedas the evaluation formula may additionally include one or moreexplanatory variables to be substituted with the value of otherbiological information (for example, the values listed in 1. through 5.below), in addition to the explanatory variables to be substituted withthe concentration values of amino acids.

1. the concentration values of metabolites in blood other than aminoacids (amino acid metabolites, carbohydrates, lipids, and the like),proteins, peptides, minerals, hormones, and the like

2. the values of tumor markers in blood (CA19-9, CEA, CA125, SPan-1,DUPAN-2, SLX, SCC, CYFRA, ProGRP, p53, elastase, and the like)

3. blood test values such as albumin, total protein, triglyceride,HbAlc, LDL cholesterol, HDL cholesterol, amylase, total bilirubin, anduric acid

4. the values obtained from image information of ultrasonography, Xrays, CT, MRI, and the like

5. the values of biological indices such as age, height, weight, BMI,blood pressure, gender, smoking information, dietary information,drinking information, exercise information, stress information, sleepinginformation, family medical history, disease history information(diabetes, pancreatitis, and the like)

Here, the summary of the evaluation formula-preparing processing (steps1 to 4) is described in detail. The processing described below is merelyone example, and the method of preparing the evaluation formula is notlimited thereto.

First, the control device prepares a candidate formula (e.g.,y=a₁x₁+a₂x₂+ . . . +a_(n)x_(n), y: pancreatic cancer state index data,x₁: amino acid concentration data, a₁: constant, i=1, 2, . . . , n) thatis a candidate for the evaluation formula, based on a predeterminedformula-preparing method from pancreatic cancer state informationpreviously stored in the memory device containing the amino acidconcentration data and pancreatic cancer state index data on an indexfor indicating the state of pancreatic cancer (step 1). Data containingdefective and outliers may be removed in advance from the pancreaticcancer state information.

In step 1, a plurality of the candidate formulae may be prepared fromthe pancreatic cancer state information by using a plurality of thedifferent formula-preparing methods (including those for multivariateanalysis such as principal component analysis, discriminant analysis,support vector machine, multiple regression analysis, logisticregression analysis, k-means method, cluster analysis, and decisiontree). Specifically, a plurality of the candidate formulae may beprepared simultaneously and concurrently by using a plurality ofdifferent algorithms with the pancreatic cancer state information whichis multivariate data composed of the amino acid concentration data andthe pancreatic cancer state index data obtained by analyzing bloodobtained from a large number of healthy groups and pancreatic cancergroups. For example, the two different candidate formulae may be formedby performing discriminant analysis and logistic regression analysissimultaneously with the different algorithms. Alternatively, thecandidate formula may be formed by converting the pancreatic cancerstate information with the candidate formula prepared by performingprincipal component analysis and then performing discriminant analysisof the converted pancreatic cancer state information. In this way, it ispossible to finally prepare the most suitable evaluation formula.

The candidate formula prepared by principal component analysis is alinear expression including each amino acid explanatory variablemaximizing the variance of all amino acid concentration data. Thecandidate formula prepared by discriminant analysis is a high-poweredexpression (including exponential and logarithmic expressions) includingeach amino acid explanatory variable minimizing the ratio of the sum ofthe variances in respective groups to the variance of all amino acidconcentration data. The candidate formula prepared by using supportvector machine is a high-powered expression (including kernel function)including each amino acid explanatory variable maximizing the boundarybetween groups. The candidate formula prepared by multiple regressionanalysis is a high-powered expression including each amino acidexplanatory variable minimizing the sum of the distances from all aminoacid concentration data. The candidate formula prepared by logisticregression analysis is a linear model expressing logarithmic odds ofprobability, and a linear expression including each amino acidexplanatory variable maximizing the likelihood of the probability. Thek-means method is a method of searching k pieces of neighboring aminoacid concentration data in various groups, designating the groupcontaining the greatest number of the neighboring points as itsdata-belonging group, and selecting the amino acid explanatory variablethat makes the group to which input amino acid concentration data belongagree well with the designated group. The cluster analysis is a methodof clustering (grouping) the points closest in entire amino acidconcentration data. The decision tree is a method of ordering amino acidexplanatory variables and predicting the group of amino acidconcentration data from the pattern possibly held by the higher-orderedamino acid explanatory variable.

Returning to the description of the evaluation formula-preparingprocessing, the control device verifies the candidate formula preparedin step 1 based on a particular verifying method (step 2). Theverification of the candidate formula is performed on each other to eachcandidate formula prepared in step 1.

In step 2, at least one of discrimination rate, sensitivity,specificity, information criterion, ROC_AUC (area under the curve in areceiver operating characteristic curve), and the like of the candidateformula may be verified by at least one of the bootstrap method, holdoutmethod, N-fold method, leave-one-out method, and the like. In this way,it is possible to prepare the candidate formula higher in predictabilityor reliability, by taking the pancreatic cancer state information andthe evaluation condition into consideration.

The discrimination rate is the rate of the states of pancreatic cancerjudged correct according to the present embodiment in all input data.The sensitivity is the rate of the states of pancreatic cancer judgedcorrect according to the present embodiment in the states of pancreaticcancer declared pancreatic cancer in the input data. The specificity isthe rate of the states of pancreatic cancer judged correct according tothe present embodiment in the states of pancreatic cancer declaredhealthy in the input data. The information criterion is the sum of thenumber of the amino acid explanatory variables in the candidate formulaprepared in step 1 and the difference in number between the states ofpancreatic cancer evaluated according to the present embodiment andthose declared in input data. ROC_AUC (area under the curve in areceiver operating characteristic curve) is defined as an area under thecurve in a receiver operating characteristic curve (ROC) which is acurve prepared by plotting (x,y)=(1-specificity, sensitivity) on atwo-dimensional coordinate, the value of ROC_AUC is equal to 1 forperfect discrimination, and discrimination performance becomes higher asthe value becomes closer to 1. The predictability is the average of thediscrimination rate, sensitivity, or specificity obtained by repeatingverification of the candidate formula. Alternatively, the reliability isthe variance of the discrimination rate, sensitivity, or specificityobtained by repeating verification of the candidate formula.

Returning to the description of the evaluation formula-preparingprocessing, the control device selects a combination of the amino acidconcentration data contained in the pancreatic cancer state informationused in preparing the candidate formula, by selecting the explanatoryvariable of the candidate formula based on a predetermined explanatoryvariable-selecting method (step 3). The selection of the amino acidexplanatory variable may be performed on each candidate formula preparedin step 1. In this way, it is possible to select the amino acidexplanatory variable of the candidate formula properly. The step 1 isexecuted once again by using the pancreatic cancer state informationincluding the amino acid concentration data selected in step 3.

In step 3, the amino acid explanatory variable of the candidate formulamay be selected based on at least one of the stepwise method, best pathmethod, local search method, and genetic algorithm from the verificationresult obtained in step 2.

The best path method is a method of selecting an amino acid explanatoryvariable by optimizing an evaluation index of the candidate formulawhile eliminating the amino acid explanatory variables contained in thecandidate formula one by one.

Returning to the description of the evaluation formula-preparingprocessing, the control device prepares the evaluation formula byrepeatedly performing the steps 1, 2 and 3, and based on verificationresults thus accumulated, selecting the candidate formula used as theevaluation formula from a plurality of the candidate formulae (step 4).In the selection of the candidate formula, there are cases where theoptimum formula is selected from the candidate formulae prepared in thesame formula-preparing method or the optimum formula is selected fromall candidate formulae.

As described above, in the evaluation formula-preparing processing, theprocessing for the preparation of the candidate formulae, theverification of the candidate formulae, and the selection of theexplanatory variables in the candidate formulae are performed based onthe pancreatic cancer state information in a series of operations in asystematized manner, whereby the evaluation formula most appropriate forevaluating the state of pancreatic cancer can be prepared. In otherwords, in the evaluation formula-preparing processing, the amino acidconcentration is used in multivariate statistical analysis, and forselecting the optimum and robust combination of the explanatoryvariables, the explanatory variable-selecting method is combined withcross-validation to extract the evaluation formula having highevaluation performance.

Logistic regression equation, linear discriminant, support vectormachine, Mahalanobis' generalized distance method, multiple regressionanalysis, cluster analysis, Cox proportional-hazards model, and the likecan be used as the evaluation formula.

2-2. System Configuration

Hereinafter, the configuration of the pancreatic cancer-evaluatingsystem according to the second embodiment (hereinafter referred tosometimes as the present system) will be described with reference toFIGS. 4 to 19. This system is merely one example, and the presentinvention is not limited thereto.

First, an entire configuration of the present system will be describedwith reference to FIGS. 4 and 5. FIG. 4 is a diagram showing an exampleof the entire configuration of the present system. FIG. 5 is a diagramshowing another example of the entire configuration of the presentsystem. As shown in FIG. 4, the present system is constituted in whichthe pancreatic cancer-evaluating apparatus 100 that evaluates the stateof pancreatic cancer in the individual as the subject, and the clientapparatus 200 (corresponding to the information communication terminalapparatus of the present invention) that provides the amino acidconcentration data of the individual on the concentration values ofamino acids, are communicatively connected to each other via a network300.

In the present system as shown in FIG. 5, in addition to the pancreaticcancer-evaluating apparatus 100 and the client apparatus 200, thedatabase apparatus 400 storing, for example, the pancreatic cancer stateinformation used in preparing the evaluation formula and the evaluationformula used in evaluating the state of pancreatic cancer in thepancreatic cancer-evaluating apparatus 100, may be communicativelyconnected via the network 300. In this configuration, reliableinformation that may be helpful in knowing the state of pancreaticcancer, or the like is provided via the network 300 from the pancreaticcancer-evaluating apparatus 100 to the client apparatuses 200 and thedatabase apparatus 400, or from the client apparatuses 200 and thedatabase apparatus 400 to the pancreatic cancer-evaluating apparatus100. The reliable information that may be helpful in knowing the stateof pancreatic cancer is, for example, information on the measured valuesof particular items as to the state of pancreatic cancer of organismsincluding human. The reliable information that may be helpful in knowingthe state of pancreatic cancer is generated in the pancreaticcancer-evaluating apparatus 100, client apparatus 200, or otherapparatuses (e.g., various measuring apparatuses) and stored mainly inthe database apparatus 400.

Now, the configuration of the pancreatic cancer-evaluating apparatus 100in the present system will be described with reference to FIGS. 6 to 17.FIG. 6 is a block diagram showing an example of the configuration of thepancreatic cancer-evaluating apparatus 100 in the present system,showing conceptually only the region relevant to the present invention.

The pancreatic cancer-evaluating apparatus 100 includes (I) a controldevice 102, such as CPU (Central Processing Unit), that integrallycontrols the pancreatic cancer-evaluating apparatus, (II) acommunication interface 104 that connects the pancreaticcancer-evaluating apparatus to the network 300 communicatively viacommunication apparatuses such as a router and wired or wirelesscommunication lines such as a private line, (III) a memory device 106that stores various databases, tables, files and others, and (IV) aninput/output interface 108 connected to an input device 112 and anoutput device 114, and these parts are connected to each othercommunicatively via any communication channel. The pancreaticcancer-evaluating apparatus 100 may be present together with variousanalyzers (e.g., amino acid analyzer) in a same housing.

The memory device 106 is a storage means, and examples thereof includememory apparatuses such as RAM (Random Access Memory) and ROM (Read OnlyMemory), fixed disk drives such as a hard disk, a flexible disk, anoptical disk, and the like. The memory device 106 stores computerprograms giving instructions to the CPU for various processings,together with OS (Operating System). As shown in the figure, the memorydevice 106 stores the user information file 106 a, the amino acidconcentration data file 106 b, the pancreatic cancer state informationfile 106 c, the designated pancreatic cancer state information file 106d, an evaluation formula-related information database 106 e, and theevaluation result file 106 f.

The user information file 106 a stores user information on users. FIG. 7is a chart showing an example of information stored in the userinformation file 106 a. As shown in FIG. 7, the information stored inthe user information file 106 a includes user ID (identification) foridentifying a user uniquely, user password for authentication of theuser, user name, organization ID for uniquely identifying anorganization of the user, department ID for uniquely identifying adepartment of the user organization, department name, and electronicmail address of the user that are correlated to one another.

Returning to FIG. 6, the amino acid concentration data file 106 b storesthe amino acid concentration data on the concentration values of aminoacids. FIG. 8 is a chart showing an example of information stored in theamino acid concentration data file 106 b. As shown in FIG. 8, theinformation stored in the amino acid concentration data file 106 bincludes individual number for uniquely identifying an individual(sample) as a subject to be evaluated and amino acid concentration datathat are correlated to one another. In FIG. 8, the amino acidconcentration data is assumed to be numerical values, i.e., on acontinuous scale, but the amino acid concentration data may be expressedon a nominal scale or an ordinal scale. In the case of the nominal orordinal scale, any number may be allocated to each state for analysis.The amino acid concentration data may be combined with the concentrationvalue of an amino acid other than the 19 kinds of amino acids or thevalue of other biological information (for example, the values listedin 1. through 5. below).

1. the concentration values of metabolites in blood other than aminoacids (amino acid metabolites, carbohydrates, lipids, and the like),proteins, peptides, minerals, hormones, and the like

2. the values of tumor markers in blood (CA19-9, CEA, CA125, SPan-1,DUPAN-2, SLX, SCC, CYFRA, ProGRP, p53, elastase, and the like)

3. blood test values such as albumin, total protein, triglyceride,HbAlc, LDL cholesterol, HDL cholesterol, amylase, total bilirubin, anduric acid

4. the values obtained from image information of ultrasonography, Xrays, CT, MRI, and the like

5. the values of biological indices such as age, height, weight, BMI,blood pressure, gender, smoking information, dietary information,drinking information, exercise information, stress information, sleepinginformation, family medical history, disease history information(diabetes, pancreatitis, and the like)

Returning to FIG. 6, the pancreatic cancer state information file 106 cstores the pancreatic cancer state information used in preparing theevaluation formula. FIG. 9 is a chart showing an example of informationstored in the pancreatic cancer state information file 106 c. As shownin FIG. 9, the information stored in the pancreatic cancer stateinformation file 106 c includes individual (sample) number, pancreaticcancer state index data (T) on index (index T₁, index T₂, index T₃ . . .) for indicating the state of pancreatic cancer, and amino acidconcentration data that are correlated to one another. In FIG. 9, thepancreatic cancer state index data and the amino acid concentration dataare assumed to be numerical values, i.e., on a continuous scale, but thepancreatic cancer state index data and the amino acid concentration datamay be expressed on a nominal scale or an ordinal scale. In the case ofthe nominal or ordinal scale, any number may be allocated to each statefor analysis. The pancreatic cancer state index data is a single knowncondition index serving as a marker of the state of pancreatic cancer,and numerical data may be used.

Returning to FIG. 6, the designated pancreatic cancer state informationfile 106 d stores the pancreatic cancer state information designated ina pancreatic cancer state information-designating part 102 g describedbelow. FIG. 10 is a chart showing an example of information stored inthe designated pancreatic cancer state information file 106 d. As shownin FIG. 10, the information stored in the designated pancreatic cancerstate information file 106 d includes individual number, designatedpancreatic cancer state index data, and designated amino acidconcentration data that are correlated to one another.

Returning to FIG. 6, the evaluation formula-related information database106 e is composed of (I) the candidate formula file 106 e 1 storing thecandidate formula prepared in a candidate formula-preparing part 102 h 1described below, (II) the verification result file 106 e 2 storing theverification results obtained in a candidate formula-verifying part 102h 2 described below, (III) the selected pancreatic cancer stateinformation file 106 e 3 storing the pancreatic cancer state informationcontaining the combination of the amino acid concentration data selectedin an explanatory variable-selecting part 102 h 3 described below, and(IV) the evaluation formula file 106 e 4 storing the evaluation formulaprepared in the evaluation formula-preparing part 102 h described below.

The candidate formula file 106 e 1 stores the candidate formulaeprepared in the candidate formula-preparing part 102 h 1 describedbelow. FIG. 11 is a chart showing an example of information stored inthe candidate formula file 106 e 1. As shown in FIG. 11, the informationstored in the candidate formula file 106 e 1 includes rank, andcandidate formula (e.g., F₁ (Gly, Leu, Phe, . . . ), F₂ (Gly, Leu, Phe,. . . ), or F₃ (Gly, Leu, Phe, . . . ) in FIG. 11) that are correlatedto each other.

Returning to FIG. 6, the verification result file 106 e 2 stores theverification results obtained in the candidate formula-verifying part102 h 2 described below. FIG. 12 is a chart showing an example ofinformation stored in the verification result file 106 e 2. As shown inFIG. 12, the information stored in the verification result file 106 e 2includes rank, candidate formula (e.g., F_(k) (Gly, Leu, Phe, . . . ),F_(m) (Gly, Leu, Phe, . . . ), F₁ (Gly, Leu, Phe, . . . ) in FIG. 12),and verification result of each candidate formula (e.g., evaluationvalue of each candidate formula) that are correlated to one another.

Returning to FIG. 6, the selected pancreatic cancer state informationfile 106 e 3 stores the pancreatic cancer state information includingthe combination of the amino acid concentration data corresponding tothe explanatory variables selected in the explanatory variable-selectingpart 102 h 3 described below. FIG. 13 is a chart showing an example ofinformation stored in the selected pancreatic cancer state informationfile 106 e 3. As shown in FIG. 13, the information stored in theselected pancreatic cancer state information file 106 e 3 includesindividual number, pancreatic cancer state index data designated in thepancreatic cancer state information-designating part 102 g describedbelow, and amino acid concentration data selected in the explanatoryvariable-selecting part 102 h 3 described below that are correlated toone another.

Returning to FIG. 6, the evaluation formula file 106 e 4 stores theevaluation formulae prepared in the evaluation formula-preparing part102 h described below. FIG. 14 is a chart showing an example ofinformation stored in the evaluation formula file 106 e 4. As shown inFIG. 14, the information stored in the evaluation formula file 106 e 4includes rank, evaluation formula (e.g., F_(p) (Phe, . . . ), F_(p)(Gly, Leu, Phe), F_(k) (Gly, Leu, Phe, . . . ) in FIG. 14), a thresholdcorresponding to each formula-preparing method, and verification resultof each evaluation formula (e.g., evaluation value of each evaluationformula) that are correlated to one another.

Returning to FIG. 6, the evaluation result file 106 f stores theevaluation results obtained in the evaluating part 102 i describedbelow. FIG. 15 is a chart showing an example of information stored inthe evaluation result file 106 f. The information stored in theevaluation result file 106 f includes individual number for uniquelyidentifying the individual (sample) as the subject, previously obtainedamino acid concentration data of the individual, and evaluation resulton the state of pancreatic cancer (for example, the value of theevaluation formula calculated by a calculating part 102 i 1 describedbelow, the converted value of the evaluation formula by a convertingpart 102 i 2 described below, the positional information generated by agenerating part 102 i 3 described below, or the classification resultobtained by a classifying part 102 i 4 described below), that arecorrelated to one another.

Returning to FIG. 6, the memory device 106 stores various Web data forproviding the client apparatuses 200 with web site information, CGIprograms, and others as information other than the information describedabove. The Web data include data for displaying the Web pages describedbelow and others, and the data are generated as, for example, a HTML(HyperText Markup Language) or XML (Extensible Markup Language) textfile. Files for components and files for operation for generation of theWeb data, and other temporary files, and the like are also stored in thememory device 106. In addition, the memory device 106 may store asneeded sound files of sounds for transmission to the client apparatuses200 in WAVE format or AIFF (Audio Interchange File Format) format andimage files of still images or motion pictures in JPEG (JointPhotographic Experts Group) format or MPEG2 (Moving Picture ExpertsGroup phase 2) format.

The communication interface 104 allows communication between thepancreatic cancer-evaluating apparatus 100 and the network 300 (orcommunication apparatus such as a router). Thus, the communicationinterface 104 has a function to communicate data via a communicationline with other terminals.

The input/output interface 108 is connected to the input device 112 andthe output device 114. A monitor (including a home television), aspeaker, or a printer may be used as the output device 114 (hereinafter,the output device 114 may be described as a monitor 114). A keyboard, amouse, a microphone, or a monitor functioning as a pointing devicetogether with a mouse may be used as the input device 112.

The control device 102 has an internal memory storing control programssuch as OS (Operating System), programs for various processingprocedures, and other needed data, and performs various informationprocessings according to these programs. As shown in the figure, thecontrol device 102 includes mainly a request-interpreting part 102 a, abrowsing processing part 102 b, an authentication-processing part 102 c,an electronic mail-generating part 102 d, a Web page-generating part 102e, a receiving part 102 f, the pancreatic cancer stateinformation-designating part 102 g, the evaluation formula-preparingpart 102 h, the evaluating part 102 i, a result outputting part 102 jand a sending part 102 k. The control device 102 performs dataprocessings such as removal of data including defective, removal of dataincluding many outliers, and removal of explanatory variables for thedefective-including data in the pancreatic cancer state informationtransmitted from the database apparatus 400 and in the amino acidconcentration data transmitted from the client apparatus 200.

The request-interpreting part 102 a interprets the requests transmittedfrom the client apparatus 200 or the database apparatus 400 and sendsthe requests to other parts in the control device 102 according toresults of interpreting the requests. Upon receiving browsing requestsfor various screens transmitted from the client apparatus 200, thebrowsing processing part 102 b generates and transmits web data forthese screens. Upon receiving authentication requests transmitted fromthe client apparatus 200 or the database apparatus 400, theauthentication-processing part 102 c performs authentication. Theelectronic mail-generating part 102 d generates electronic mailsincluding various kinds of information. The Web page-generating part 102e generates Web pages for users to browse with the client apparatus 200.

The receiving part 102 f receives, via the network 300, information(specifically, the amino acid concentration data, the pancreatic cancerstate information, the evaluation formula, etc.) transmitted from theclient apparatus 200 and the database apparatus 400. The pancreaticcancer state information-designating part 102 g designates objectivepancreatic cancer state index data and objective amino acidconcentration data in preparing the evaluation formula.

The evaluation formula-preparing part 102 h generates the evaluationformula based on the pancreatic cancer state information received in thereceiving part 102 f and the pancreatic cancer state informationdesignated in the pancreatic cancer state information-designating part102 g. Specifically, the evaluation formula-preparing part 102 hgenerates the evaluation formula by selecting the candidate formula usedas the evaluation formula from a plurality of the candidate formulae,based on verification results accumulated by repeating processings inthe candidate formula-preparing part 102 h 1, the candidateformula-verifying part 102 h 2, and the explanatory variable-selectingpart 102 h 3 from the pancreatic cancer state information.

If the evaluation formulae are stored previously in a predeterminedregion of the memory device 106, the evaluation formula-preparing part102 h may generate the evaluation formula by selecting the desiredevaluation formula out of the memory device 106. Alternatively, theevaluation formula-preparing part 102 h may generate the evaluationformula by selecting and downloading the desired evaluation formula fromthe evaluation formulae previously stored in another computer apparatus(e.g., the database apparatus 400).

Hereinafter, a configuration of the evaluation formula-preparing part102 h will be described with reference to FIG. 16. FIG. 16 is a blockdiagram showing the configuration of the evaluation formula-preparingpart 102 h, and only a part in the configuration related to the presentinvention is shown conceptually. The evaluation formula-preparing part102 h includes the candidate formula-preparing part 102 h 1, thecandidate formula-verifying part 102 h 2, and the explanatoryvariable-selecting part 102 h 3, additionally. The candidateformula-preparing part 102 h 1 generates the candidate formula that is acandidate of the evaluation formula, from the pancreatic cancer stateinformation based on a predetermined formula-preparing method. Thecandidate formula-preparing part 102 h 1 may generate a plurality of thecandidate formulae from the pancreatic cancer state information, byusing a plurality of the different formula-preparing methods. Thecandidate formula-verifying part 102 h 2 verifies the candidate formulaprepared by the candidate formula-preparing part 102 h 1 based on aparticular verifying method. The candidate formula-verifying part 102 h2 may verify at least one of the discrimination rate, sensitivity,specificity, information criterion, and ROC_AUC (area under the curve ina receiver operating characteristic curve) of the candidate formulaebased on at least one of the bootstrap method, holdout method, N-foldmethod, and leave-one-out method. The explanatory variable-selectingpart 102 h 3 selects the combination of the amino acid concentrationdata contained in the pancreatic cancer state information used inpreparing the candidate formula, by selecting the explanatory variablesof the candidate formula based on a particular explanatoryvariable-selecting method. The explanatory variable-selecting part 102 h3 may select the explanatory variables of the candidate formula based onat least one of the stepwise method, best path method, local searchmethod, and genetic algorithm from the verification results.

Returning to FIG. 6, the evaluating part 102 i evaluates the state ofpancreatic cancer in the individual by calculating the value of theevaluation formula using the previously obtained formula (for example,the evaluation formula prepared by the evaluation formula-preparing part102 h or the evaluation formula received by the receiving part 102 f)and the amino acid concentration data received by the receiving part 102f.

Hereinafter, a configuration of the evaluating part 102 i will bedescribed with reference to FIG. 17. FIG. 17 is a block diagram showingthe configuration of the evaluating part 102 i, and only a part in theconfiguration related to the present invention is shown conceptually.The evaluating part 102 i includes the calculating part 102 i 1, theconverting part 102 i 2, the generating part 102 i 3, and theclassifying part 102 i 4, additionally.

The calculating part 102 i 1 calculates the value of the evaluationformula using (i) the concentration values of at least two amino acidsof the 19 kinds of amino acids, including the amino acid concentrationdata and (ii) the evaluation formula including at least two explanatoryvariables to be substituted with the concentration values of at leasttwo amino acids of the 19 kinds of amino acids. The evaluating part 102i stores the value of the evaluation formula calculated by thecalculating part 102 i 1 as an evaluation result in a predeterminedregion of the evaluation result file 106 f. The evaluation formula maybe any one of a logistic regression equation, a fractional expression, alinear discriminant, a multiple regression equation, a formula preparedby a support vector machine, a formula prepared by a Mahalanobis'generalized distance method, a formula prepared by canonicaldiscriminant analysis, and a formula prepared by a decision tree.

The converting part 102 i 2 converts the value of the evaluation formulacalculated by the calculating part 102 i 1, for example, by theconversion method described above. The evaluating part 102 i stores theconverted value by the converting part 102 i 2 as an evaluation resultin a predetermined region of the evaluation result file 106 f.

The generating part 102 i 3 generates the positional information aboutthe position of a predetermined mark (for example, a circle sign or astar sign) corresponding to the value of the formula or the convertedvalue on a predetermined scale (for example, a graduated scale at leastmarked with graduations corresponding to the upper limit value and thelower limit value in the possible range of the value of the formula orthe converted value, or part of the range) visually presented on adisplay device such as a monitor or a physical medium such as paper forevaluating the state of pancreatic cancer, using the value of theformula calculated by the calculating part 102 i 1 or the convertedvalue by the converting part 102 i 2. The evaluating part 102 i storesthe positional information generated by the generating part 102 i 3 asan evaluation result in a predetermined region of the evaluation resultfile 106 f.

The classifying part 102 i 4 classifies the individual into any one of aplurality of categories previously defined considering at least thedegree of the possibility of being affected with pancreatic cancer,using the value of the evaluation formula calculated by the calculatingpart 102 i 1 or the converted value by the converting part 102 i 2.

The categories may include at least one category defined considering atleast the degree of the possibility that a subject is affected withpancreatic cancer and the degree of the possibility that a subject isaffected with a cancer other than pancreatic cancer.

When the category X and the category Y are previously established as thecategories, the classifying part 102 i 4 classifies the individual intoone of the category X and the category Y using the evaluation value anda threshold. When the first formula and the second formula that aredifferent from each other are previously established as evaluationformulae, the calculating part 102 i 1 may calculate the value of thefirst formula and the value of the second formula, and the classifyingpart 102 i 4 may classify the individual into one of the category X andthe category Y using the values of the first formula and the secondformula. When the healthy category and the other cancer category arepreviously established as the category Y, a formula for classifying asubject into one of the category X and the healthy category ispreviously established as the first formula, and a formula forclassifying a subject into one of the category X and the other cancercategory is previously established as the second formula, thecalculating part 102 i 1 may first calculate the value of the firstformula, and the classifying part 102 i 4 may classify the individualinto one of the category X and the healthy category using the calculatedvalue of the first formula. Then if the classification result is thecategory X, the calculating part 102 i 1 may calculate the value of thesecond formula, and the classifying part 102 i 4 may further classifythe individual classified in the category X using the value of the firstformula into one of the category X and the other cancer category, usingthe calculated value of the second formula. Then the classifying part102 i 4 may finally classify the individual classified in the healthycategory and the individual classified in the other cancer category intothe category Y.

When the category X and the healthy category are previously establishedas the categories, the classifying part 102 i 4 classifies theindividual into one of the category X and the healthy category using theevaluation value and a threshold.

When the category X and the other cancer category are previouslyestablished as the categories, the classifying part 102 i 4 classifiesthe individual into one of the category X and the other cancer categoryusing the evaluation value and a threshold.

When the category X and the healthy/other cancer category are previouslyestablished as the categories, the classifying part 102 i 4 classifiesthe individual into one of the category X and the healthy/other cancercategory using the evaluation value and a threshold.

When the category X, the healthy category, and the other cancer categoryare previously established as the categories, the classifying part 102 i4 classifies the individual into any one of the category X, the healthycategory, and the other cancer category, using the evaluation value anda threshold. When the first formula and the second formula that aredifferent from each other are previously established as the evaluationformulae, the calculating part 102 i 1 may calculate the value of thefirst formula and the value of the second formula, and the classifyingpart 102 i 4 may classify the individual into any one of the category X,the healthy category, and the other cancer category, using thecalculated values of the first formula and the second formula. When aformula for classifying a subject into one of the category X and thehealthy category is previously established as the first formula, and aformula for classifying a subject into one of the category X and theother cancer category is previously established as the second formula,the calculating part 102 i 1 may first calculate the value of the firstformula, and the classifying part 102 i 4 may classify the individualinto one of the category X and the healthy category using the calculatedvalue of the first formula. Then if the classification result is thecategory X, the calculating part 102 i 1 may calculate the value of thesecond formula, and the classifying part 102 i 4 may further classifythe individual classified in the category X using the value of the firstformula into one of the category X and the other cancer category, usingthe calculated value of the second formula. Then the classifying part102 i 4 may finally classify the individual classified in the category Xusing the value of the first formula and classified in the other cancercategory using the value of the second formula into the other cancercategory.

Returning to FIG. 6, the result outputting part 102 j outputs, into theoutput device 114, the processing results in each processing part in thecontrol device 102 (including the evaluation results obtained by theevaluating part 102 i) etc.

The sending part 102 k transmits the evaluation results to the clientapparatus 200 that is a sender of the amino acid concentration data ofthe individual, and transmits the evaluation formulae prepared in thepancreatic cancer-evaluating apparatus 100 and the evaluation results tothe database apparatus 400.

Hereinafter, a configuration of the client apparatus 200 in the presentsystem will be described with reference to FIG. 18. FIG. 18 is a blockdiagram showing an example of the configuration of the client apparatus200 in the present system, and only the part in the configurationrelevant to the present invention is shown conceptually.

The client apparatus 200 includes a control device 210, ROM 220, HD(Hard Disk) 230, RAM 240, an input device 250, an output device 260, aninput/output IF 270, and a communication IF 280 that are connectedcommunicatively to one another through a communication channel.

The control device 210 has a Web browser 211, an electronic mailer 212,a receiving part 213, and a sending part 214. The Web browser 211performs browsing processings of interpreting Web data and displayingthe interpreted Web data on a monitor 261 described below. The Webbrowser 211 may have various plug-in softwares, such as stream player,having functions to receive, display and feedback streaming screenimages. The electronic mailer 212 sends and receives electronic mailsusing a particular protocol (e.g., SMTP (Simple Mail Transfer Protocol)or POPS (Post Office Protocol version 3)). The receiving part 213receives various kinds of information, such as the evaluation resultstransmitted from the pancreatic cancer-evaluating apparatus 100, via thecommunication IF 280. The sending part 214 sends various kinds ofinformation such as the amino acid concentration data of the individual,via the communication IF 280, to the pancreatic cancer-evaluatingapparatus 100.

The input device 250 is for example a keyboard, a mouse or a microphone.The monitor 261 described below also functions as a pointing devicetogether with a mouse. The output device 260 is an output means foroutputting information received via the communication IF 280, andincludes the monitor 261 (including home television) and a printer 262.In addition, the output device 260 may have a speaker or the likeadditionally. The input/output IF 270 is connected to the input device250 and the output device 260.

The communication IF 280 connects the client apparatus 200 to thenetwork 300 (or communication apparatus such as a router)communicatively. In other words, the client apparatuses 200 areconnected to the network 300 via a communication apparatus such as amodem, TA (Terminal Adapter) or a router, and a telephone line, or aprivate line. In this way, the client apparatuses 200 can access to thepancreatic cancer-evaluating apparatus 100 by using a particularprotocol.

The client apparatus 200 may be realized by installing softwares(including programs, data and others) for a Web data-browsing functionand an electronic mail-processing function to an information processingapparatus (for example, an information processing terminal such as aknown personal computer, a workstation, a family computer, Internet TV(Television), PHS (Personal Handyphone System) terminal, a mobile phoneterminal, a mobile unit communication terminal or PDA (Personal DigitalAssistants)) connected as needed with peripheral devices such as aprinter, a monitor, and an image scanner.

All or a part of processings of the control device 210 in the clientapparatus 200 may be performed by CPU and programs read and executed bythe CPU. Computer programs for giving instructions to the CPU andexecuting various processings together with the OS (Operating System)are recorded in the ROM 220 or HD 230. The computer programs, which areexecuted as they are loaded in the RAM 240, constitute the controldevice 210 with the CPU. The computer programs may be stored inapplication program servers connected via any network to the clientapparatus 200, and the client apparatus 200 may download all or a partof them as needed. All or any part of processings of the control device210 may be realized by hardware such as wired-logic.

The control device 210 may include an evaluating part 210 a (including acalculating part 210 a 1, a converting part 210 a 2, a generating part210 a 3, and a classifying part 210 a 4) having the same functions asthe functions of the evaluating part 102 i in the control device 102 ofthe pancreatic cancer-evaluating apparatus 100. When the control device210 includes the evaluating part 210 a, the evaluating part 210 a mayconvert the value of the formula in the converting part 210 a 2,generate the positional information corresponding to the value of theformula or the converted value in the generating part 210 a 3, andclassify the individual into any one of the categories using the valueof the formula or the converted value in the classifying part 210 a 4,in accordance with information included in the evaluation resulttransmitted from the pancreatic cancer-evaluating apparatus 100.

Hereinafter, the network 300 in the present system will be describedwith reference to FIGS. 4 and 5. The network 300 has a function toconnect the pancreatic cancer-evaluating apparatus 100, the clientapparatuses 200, and the database apparatus 400 mutually,communicatively to one another, and is for example the Internet, anintranet, or LAN (Local Area Network (including both wired andwireless)). The network 300 may be VAN (Value Added Network), a personalcomputer communication network, a public telephone network (includingboth analog and digital), a leased line network (including both analogand digital), CATV (Community Antenna Television) network, a portableswitched network or a portable packet-switched network (includingIMT2000 (International Mobile Telecommunication 2000) system, GSM(registered trademark) (Global System for Mobile Communications) system,or PDC (Personal Digital Cellular)/PDC-P system), a wireless callingnetwork, a local wireless network such as Bluetooth (registeredtrademark), PHS network, a satellite communication network (including CS(Communication Satellite), BS (Broadcasting Satellite), ISDB (IntegratedServices Digital Broadcasting), and the like), or the like.

Hereinafter, the configuration of the database apparatus 400 in thepresent system will be described with reference to FIG. 19. FIG. 19 is ablock diagram showing an example of the configuration of the databaseapparatus 400 in the present system, showing conceptually only theregion relevant to the present invention.

The database apparatus 400 has functions to store, for example, thepancreatic cancer state information used in preparing the evaluationformulae in the pancreatic cancer-evaluating apparatus 100 or in thedatabase apparatus, the evaluation formulae prepared in the pancreaticcancer-evaluating apparatus 100, and the evaluation results obtained inthe pancreatic cancer-evaluating apparatus 100. As shown in FIG. 19, thedatabase apparatus 400 includes (I) a control device 402, such as CPU,which integrally controls the entire database apparatus, (II) acommunication interface 404 connecting the database apparatus to thenetwork 300 communicatively via a communication apparatus such as arouter and via wired or wireless communication circuits such as aprivate line, (III) a memory device 406 storing various databases,tables and files (for example, files for Web pages), and (IV) aninput/output interface 408 connected to an input device 412 and anoutput device 414, and these parts are connected communicatively to eachother via any communication channel.

The memory device 406 is a storage means, and may be, for example,memory apparatus such as RAM or ROM, a fixed disk drive such as a harddisk, a flexible disk, an optical disk, and the like. The memory device406 stores, for example, various programs used in various processings.The communication interface 404 allows communication between thedatabase apparatus 400 and the network 300 (or a communication apparatussuch as a router). Thus, the communication interface 404 has a functionto communicate data via a communication line with other terminals. Theinput/output interface 408 is connected to the input device 412 and theoutput device 414. A monitor (including a home television), a speaker,or a printer may be used as the output device 414 (hereinafter, theoutput device 414 may be described as a monitor 414). A keyboard, amouse, a microphone, or a monitor functioning as a pointing devicetogether with a mouse may be used as the input device 412.

The control device 402 has an internal memory storing control programssuch as OS (Operating System), programs for various processingprocedures, and other needed data, and performs various informationprocessings according to these programs. As shown in the figure, thecontrol device 402 includes mainly a request-interpreting part 402 a, abrowsing processing part 402 b, an authentication-processing part 402 c,an electronic mail-generating part 402 d, a Web page-generating part 402e, and a sending part 402 f.

The request-interpreting part 402 a interprets the requests transmittedfrom the pancreatic cancer-evaluating apparatus 100 and sends therequests to other parts in the control device 402 according to resultsof interpreting the requests. Upon receiving browsing requests forvarious screens transmitted from the pancreatic cancer-evaluatingapparatus 100, the browsing processing part 402 b generates andtransmits web data for these screens. Upon receiving authenticationrequests transmitted from the pancreatic cancer-evaluating apparatus100, the authentication-processing part 402 c performs authentication.The electronic mail-generating part 402 d generates electronic mailsincluding various kinds of information. The Web page-generating part 402e generates Web pages for users to browse with the client apparatus 200.The sending part 402 f transmits various kinds of information such asthe pancreatic cancer state information and the evaluation formulae tothe pancreatic cancer-evaluating apparatus 100.

2-3. Specific Example of the Second Embodiment

Here, a specific example of the second embodiment will be described withreference to FIG. 20. FIG. 20 is a flowchart showing the example of thepancreatic cancer evaluation service processing according to the secondembodiment.

The amino acid concentration data used in the present processing is dataconcerning the concentration values of amino acids obtained byanalyzing, by professionals or ourselves, blood (including, for example,plasma or serum) previously collected from an individual by themeasurement method such as the following (A) or (B). Here, the unit ofthe amino acid concentration may be, for example, a molar concentration,a weight concentration, or one obtained by addition, subtraction,multiplication, and division of any constant with these concentrations.

(A) Plasma is separated from blood by centrifuging a collected bloodsample. All plasma samples are frozen and stored at −80° C. until anamino acid concentration is measured. At the time of measuring an aminoacid concentration, acetonitrile is added to perform a protein removaltreatment, pre-column derivatization is then performed using a labeledreagent (3-aminopyridyl-N-hydroxysuccinimidyl carbamate), and an aminoacid concentration is analyzed by liquid chromatograph mass spectrometer(LC/MS) (see International Publication WO 2003/069328 and InternationalPublication WO 2005/116629).

(B) Plasma is separated from blood by centrifuging a collected bloodsample. All plasma samples are frozen and stored at −80° C. until anamino acid concentration is measured. At the time of measuring an aminoacid concentration, sulfosalicylic acid is added to perform a proteinremoval treatment, and an amino acid concentration is analyzed by anamino acid analyzer based on post-column derivatization using aninhydrin reagent.

First, the client apparatus 200 accesses the pancreaticcancer-evaluating apparatus 100 when the user specifies the Web siteaddress (such as URL) provided from the pancreatic cancer-evaluatingapparatus 100, via the input device 250 on the screen displaying the Webbrowser 211. Specifically, when the user instructs update of the Webbrowser 211 screen on the client apparatus 200, the Web browser 211sends the Web site address provided from the pancreaticcancer-evaluating apparatus 100 by a particular protocol to thepancreatic cancer-evaluating apparatus 100, thereby transmittingrequests demanding a transmission of Web page corresponding to an aminoacid concentration data transmission screen to the pancreaticcancer-evaluating apparatus 100 based on a routing of the address.

Then, upon receipt of the request transmitted from the client apparatus200, the request-interpreting part 102 a in the pancreaticcancer-evaluating apparatus 100 analyzes the transmitted requests andsends the requests to other parts in the control device 102 according toanalytical results. Specifically, when the transmitted requests arerequests to send the Web page corresponding to the amino acidconcentration data transmission screen, mainly the browsing processingpart 102 b in the pancreatic cancer-evaluating apparatus 100 obtains theWeb data for display of the Web page stored in a predetermined region ofthe memory device 106 and sends the obtained Web data to the clientapparatus 200. More specifically, upon receiving the requests totransmit the Web page corresponding to the amino acid concentration datatransmission screen by the user, the control device 102 in thepancreatic cancer-evaluating apparatus 100 demands inputs of user ID anduser password from the user. If the user ID and password are input, theauthentication-processing part 102 c in the pancreatic cancer-evaluatingapparatus 100 examines the input user ID and password by comparing themwith the user ID and user password stored in the user information file106 a for authentication. Only when the user is authenticated, thebrowsing processing part 102 b in the pancreatic cancer-evaluatingapparatus 100 sends the Web data for displaying the Web pagecorresponding to the amino acid concentration data transmission screento the client apparatus 200. The client apparatus 200 is identified withthe IP (Internet Protocol) address transmitted from the client apparatus200 together with the transmission requests.

Then, the client apparatus 200 receives, in the receiving part 213, theWeb data (for displaying the Web page corresponding to the amino acidconcentration data transmission screen) transmitted from the pancreaticcancer-evaluating apparatus 100, interprets the received Web data withthe Web browser 211, and displays the amino acid concentration datatransmission screen on the monitor 261.

When the user inputs and selects, via the input device 250, for examplethe amino acid concentration data of the individual on the amino acidconcentration data transmission screen displayed on the monitor 261, thesending part 214 of the client apparatus 200 transmits an identifier foridentifying input information and selected items to the pancreaticcancer-evaluating apparatus 100, thereby transmitting the amino acidconcentration data of the individual to the pancreatic cancer-evaluatingapparatus 100 (step SA21). In step SA21, the transmission of the aminoacid concentration data may be realized for example by using an existingfile transfer technology such as FTP (File Transfer Protocol).

Then, the request-interpreting part 102 a of the pancreaticcancer-evaluating apparatus 100 interprets the identifier transmittedfrom the client apparatus 200 thereby interpreting the requests from theclient apparatus 200, and requests the database apparatus 400 to sendthe evaluation formula.

Then, the request-interpreting part 402 a in the database apparatus 400interprets the transmission requests from the pancreaticcancer-evaluating apparatus 100 and transmits, to the pancreaticcancer-evaluating apparatus 100, the evaluation formula (for example,the updated newest evaluation formula) stored in a predetermined regionof the memory device 406 (step SA22). Specifically, in step SA22, one ormore evaluation formulae including at least two explanatory variables tobe substituted with the concentration values of at least two amino acidsof the 19 kinds of amino acids (for example, any one of a logisticregression equation, a fractional expression, a linear discriminant, amultiple regression equation, a formula prepared by a support vectormachine, a formula prepared by a Mahalanobis' generalized distancemethod, a formula prepared by canonical discriminant analysis, and aformula prepared by a decision tree) are transmitted to the pancreaticcancer-evaluating apparatus 100.

Then, the pancreatic cancer-evaluating apparatus 100 receives, in thereceiving part 102 f, the amino acid concentration data of theindividual transmitted from the client apparatuses 200 and theevaluation formula transmitted from the database apparatus 400, andstores the received amino acid concentration data in a predeterminedmemory region of the amino acid concentration data file 106 b and thereceived evaluation formula in a predetermined memory region of theevaluation formula file 106 e 4 (step SA23).

Then, the control device 102 in the pancreatic cancer-evaluatingapparatus 100 removes data such as defective and outliers from the aminoacid concentration data of the individual received in step SA23 (stepSA24).

The evaluating part 102 i then uses the amino acid concentration data ofthe individual from which the data such as defective and outliers hasbeen removed in step SA24 and one or more evaluation formulae receivedin step SA23 to calculate one or more values of the evaluationformula(e) in the calculating part 102 i 1 (step SA25).

When the first formula and the second formula different from each otherare received as evaluation formulae in step SA23, the evaluating part102 i may calculate the value of the first formula and the value of thesecond formula in the calculating part 102 i 1.

When the first formula for classifying a subject into one of thepancreatic cancer category and the healthy category and the secondformula for classifying a subject into one of the pancreatic cancercategory and the other cancer category are received in step SA23, theevaluating part 102 i may first calculate the value of the first formulain the calculating part 102 i 1, and, if the classification resultobtained in the classifying part 102 i 4 is the pancreatic cancercategory, may calculate the value of the second formula.

The evaluating part 102 i then executes any one of the classificationsof 1. through 6. below using the value of the evaluation formula(evaluation value) calculated in step SA25 and the previouslyestablished threshold in the classifying part 102 i 4 and stores theobtained classification result into a predetermined storage area of theevaluation result file 106 f (step SA26).

1. When a plurality of categories defined considering at least thedegree of the possibility that a subject is affected with pancreaticcancer (the categories may include at least one category definedconsidering the degree of the possibility that a subject is affectedwith pancreatic cancer and the degree of the possibility that a subjectis affected with a cancer other than pancreatic cancer), and one or morethresholds are previously established, the evaluating part 102 iclassifies the individual into any one of the categories using theevaluation value and the threshold(s) in the classifying part 102 i 4.

2. When the pancreatic cancer category and the pancreatic cancer-freecategory, and a threshold are previously established, the evaluatingpart 102 i classifies the individual into one of the pancreatic cancercategory and the pancreatic cancer-free category using the evaluationvalue and the threshold in the classifying part 102 i 4.

When the first formula and the second formula different from each otherare received as evaluation formulae in step SA23, the evaluating part102 i may classify the individual into one of the pancreatic cancercategory and the pancreatic cancer-free category, using the value of thefirst formula and the value of the second formula calculated in thecalculating part 102 i 1, in the classifying part 102 i 4.

When the healthy category and the other cancer category are previouslyestablished as the pancreatic cancer-free category, and the firstformula for classifying a subject into one of the pancreatic cancercategory and the healthy category and the second formula for classifyinga subject into one of the pancreatic cancer category and the othercancer category are received in step SA23, the evaluating part 102 i mayclassify the individual into one of the pancreatic cancer category andthe healthy category using the value of the first formula calculated inthe calculating part 102 i 1 in the classifying part 102 i 4. If theclassification result is the pancreatic cancer category, the evaluatingpart 102 i may further classify the individual classified in thepancreatic cancer category using the value of the first formula into oneof the pancreatic cancer category and the other cancer category usingthe value of the second formula calculated in the calculating part 102 iin the classifying part 102 i 4. The evaluating part 102 i may finallyclassify the individual classified in the healthy category and theindividual classified in the other cancer category into the pancreaticcancer-free category in the classifying part 102 i 4. The individualclassified into the pancreatic cancer category using the value of thefirst formula and classified into the pancreatic cancer category usingthe value of the second formula is finally classified into thepancreatic cancer category, as a matter of course.

3. When the pancreatic cancer category and the healthy category, and athreshold are previously established, the evaluating part 102 iclassifies the individual into one of the pancreatic cancer category andthe healthy category, using the evaluation value and the threshold inthe classifying part 102 i 4.

4. When the pancreatic cancer category and the other cancer category,and a threshold are previously established, the evaluating part 102 iclassifies the individual into one of the pancreatic cancer category andthe other cancer category, using the evaluation value and the thresholdin the classifying part 102 i 4.

5. When the pancreatic cancer category and the healthy/other cancercategory, and a threshold are previously established, the evaluatingpart 102 i classifies the individual into one of the pancreatic cancercategory and the healthy/other cancer category, using the evaluationvalue and the threshold in the classifying part 102 i 4.

6. When the pancreatic cancer category, the healthy category, and theother cancer category, and a threshold are previously established, theevaluating part 102 i classifies the individual into one of thepancreatic cancer category, the healthy category, and the other cancercategory, using the evaluation values and the threshold in theclassifying part 102 i 4.

When the first formula and the second formula different from each otherare received as evaluation formulae in step SA23, the evaluating part102 i may classify the individual into one of the pancreatic cancercategory, the healthy category, and the other cancer category, using thevalue of the first formula and the value of the second formulacalculated in the calculating part 102 i 1, in the classifying part 102i 4.

When the first formula for classifying a subject into one of thepancreatic cancer category and the healthy category and the secondformula for classifying a subject into one of the pancreatic cancercategory and the other cancer category are received in step SA23, theevaluating part 102 i may classify the individual into one of thepancreatic cancer category and the healthy category using the value ofthe first formula calculated in the calculating part 102 i 1, in theclassifying part 102 i 4. If the classification result is the pancreaticcancer category, the evaluating part 102 i may further classify theindividual classified in the pancreatic cancer category using the valueof the first formula into one of the pancreatic cancer category and theother cancer category, using the value of the second formula calculatedin the calculating part 102 i, in the classifying part 102 i 4. Theevaluating part 102 i may finally classify the individual classified inthe pancreatic cancer category using the value of the first formula andclassified in the other cancer category using the value of the secondformula, into the other cancer category, in the classifying part 102 i4. The individual classified in the healthy category using the value ofthe first formula is finally classified into the healthy category, as amatter of course, and the individual classified in the pancreatic cancercategory using the value of the first formula and classified in thepancreatic cancer category using the value of the second formula isfinally classified into the pancreatic cancer category, as a matter ofcourse.

Returning to the description of FIG. 20, the sending part 102 k in thepancreatic cancer-evaluating apparatus 100 sends, to the clientapparatus 200 that has sent the amino acid concentration data and to thedatabase apparatus 400, the classification results obtained in step SA26(step SA27). Specifically, the pancreatic cancer-evaluating apparatus100 first generates a Web page for displaying the classification resultsin the Web page-generating part 102 e and stores the Web datacorresponding to the generated Web page in a predetermined memory regionof the memory device 106. Then, the user is authenticated as describedabove by inputting a predetermined URL (Uniform Resource Locator) intothe Web browser 211 of the client apparatus 200 via the input device250, and the client apparatus 200 sends a Web page browsing request tothe pancreatic cancer-evaluating apparatus 100. The pancreaticcancer-evaluating apparatus 100 then interprets the browsing requesttransmitted from the client apparatus 200 in the browsing processingpart 102 b and reads the Web data corresponding to the Web page fordisplaying the classification results, out of the predetermined memoryregion of the memory device 106. The sending part 102 k in thepancreatic cancer-evaluating apparatus 100 then sends the read-out Webdata to the client apparatus 200 and simultaneously sends the Web dataor the classification results to the database apparatus 400.

In step SA27, the control device 102 in the pancreatic cancer-evaluatingapparatus 100 may notify the classification results to the user clientapparatus 200 by electronic mail. Specifically, the electronicmail-generating part 102 d in the pancreatic cancer-evaluating apparatus100 first acquires the user electronic mail address by referencing theuser information stored in the user information file 106 a based on theuser ID and the like at the transmission timing. The electronicmail-generating part 102 d in the pancreatic cancer-evaluating apparatus100 then generates electronic mail data with the acquired electronicmail address as its mail address, including the user name and theclassification results. The sending part 102 k in the pancreaticcancer-evaluating apparatus 100 then sends the generated electronic maildata to the user client apparatus 200.

Also in step SA27, the pancreatic cancer-evaluating apparatus 100 maysend the classification results to the user client apparatus 200 byusing, for example, an existing file transfer technology such as FTP.

Returning to the description of FIG. 20, the control device 402 in thedatabase apparatus 400 receives the classification results or the Webdata transmitted from the pancreatic cancer-evaluating apparatus 100 andstores (accumulates) the received classification results or the receivedWeb data in a predetermined memory region of the memory device 406 (stepSA28).

The receiving part 213 of the client apparatus 200 receives the Web datatransmitted from the pancreatic cancer-evaluating apparatus 100, and thereceived Web data is interpreted with the Web browser 211, to display onthe monitor 261 the Web page screen displaying the classificationresults of the individual (step SA29). When the classification resultsare sent from the pancreatic cancer-evaluating apparatus 100 byelectronic mail, the electronic mail transmitted from the pancreaticcancer-evaluating apparatus 100 is received at any timing, and thereceived electronic mail is displayed on the monitor 261 with the knownfunction of the electronic mailer 212 in the client apparatus 200.

In this way, the user can confirm the classification results by browsingthe Web page displayed on the monitor 261. The user may print out thecontent of the Web page displayed on the monitor 261 by the printer 262.

When the classification results are transmitted by electronic mail fromthe pancreatic cancer-evaluating apparatus 100, the user reads theelectronic mail displayed on the monitor 261, whereby the user canconfirm the classification results. The user may print out the contentof the electronic mail displayed on the monitor 261 by the printer 262.

As described in detail above, the client apparatus 200 transmits theamino acid concentration data of the individual to the pancreaticcancer-evaluating apparatus 100. Upon receiving a request from thepancreatic cancer-evaluating apparatus 100, the database apparatus 400transmits the evaluation formula to the pancreatic cancer-evaluatingapparatus 100. The pancreatic cancer-evaluating apparatus 100 (i)receives the amino acid concentration data from the client apparatus 200and receives the evaluation formula from the database apparatus 400,(ii) calculates the evaluation value using the received amino acidconcentration data and evaluation formula, (iii) executes any one of theclassifications 1. through 6. using the calculated evaluation value andthe threshold, and (iv) transmits the obtained classification result tothe client apparatus 200 and the database apparatus 400. The clientapparatus 200 then receives and displays the classification resulttransmitted from the pancreatic cancer-evaluating apparatus 100. Thedatabase apparatus 400 receives and stores the classification resulttransmitted from the pancreatic cancer-evaluating apparatus 100.

Hence, reliable information that may be helpful in knowing the degree ofthe possibility of being affected with pancreatic cancer can be providedin easily understandable form. Reliable information that may be helpfulin knowing not only the degree of the possibility of being affected withpancreatic cancer but also the degree of the possibility of beingaffected with a cancer other than pancreatic cancer can be provided ineasily understandable form.

Reliable information that may be helpful in knowing whether thepossibility of being affected with pancreatic cancer is high or low canbe provided in easily understandable form.

Reliable information that may be helpful in knowing whether thepossibility of being affected with pancreatic cancer is high or whetherthe possibility of being healthy is high can be provided in easilyunderstandable form.

Reliable information that may be helpful in knowing whether thepossibility of being affected with pancreatic cancer is high or whetherthe possibility of being affected with a cancer other than pancreaticcancer is high can be provided in easily understandable form.

Reliable information that may be helpful in knowing whether thepossibility of being affected with pancreatic cancer is high or whetherthe possibility of being healthy or being affected with a cancer otherthan pancreatic cancer is high can be provided in easily understandableform.

Reliable information that may be helpful in knowing whether thepossibility of being affected with pancreatic cancer is high, whetherthe possibility of being healthy is high, or whether the possibility ofbeing affected with a cancer other than pancreatic cancer is high can beprovided in easily understandable form.

Given the foregoing description, the explanation of the pancreaticcancer evaluation service processing is finished.

In the present description, the pancreatic cancer-evaluating apparatus100 executes the reception of the amino acid concentration data, thecalculation of the value of the evaluation formula, the classificationof the individual into the category, and the transmission of theclassification result, and the client apparatus 200 executes thereception of the classification result, by way of example. However, whenthe client apparatus 200 includes the evaluating part 210 a, thepancreatic cancer-evaluating apparatus 100 only has to execute thecalculation of the value of the evaluation formula, and, for example,the execution of conversion of the value of the evaluation formula, thegeneration of the positional information, and the classification of theindividual into the category, and the like may be appropriately sharedbetween the pancreatic cancer-evaluating apparatus 100 and the clientapparatus 200.

For example, when the client apparatus 200 receives the value of theformula from the pancreatic cancer-evaluating apparatus 100, theevaluating part 210 a may convert the value of the formula in theconverting part 210 a 2, generate the positional informationcorresponding to the value of the formula or the converted value in thegenerating part 210 a 3, and classify the individual into any one of theplurality of categories using the value of the formula or the convertedvalue in the classifying part 210 a 4.

When the client apparatus 200 receives the converted value from thepancreatic cancer-evaluating apparatus 100, the evaluating part 210 amay generate the positional information corresponding to the convertedvalue in the generating part 210 a 3 and classify the individual intoone of the plurality of categories using the converted value in theclassifying part 210 a 4.

When the client apparatus 200 receives the value of the formula or theconverted value and the positional information from the pancreaticcancer-evaluating apparatus 100, the evaluating part 210 a may classifythe individual into one of the plurality of categories using the valueof the formula or the converted value in the classifying part 210 a 4.

2-4. Other Embodiments

In addition to the second embodiment described above, the pancreaticcancer-evaluating apparatus, the pancreatic cancer-evaluating method,the pancreatic cancer-evaluating program product, the pancreaticcancer-evaluating system, and the information communication terminalapparatus according to the present invention can be practiced in variousdifferent embodiments within the technological scope of the claims.

Of the processings described in the second embodiment, all or a part ofthe processings described as automatically performed ones may bemanually performed, or all or a part of the processings described asmanually performed ones may be also automatically performed by knownmethods.

In addition, the processing procedures, the control procedures, thespecific names, the information including parameters such as registereddata of various processings and retrieval conditions, the screenexamples, and the database configuration shown in the description andthe drawings may be arbitrarily modified unless otherwise specified.

The components of the pancreatic cancer-evaluating apparatus 100 shownin the figures are functionally conceptual and therefore not bephysically configured as shown in the figures.

For example, for the operational functions provided in the pancreaticcancer-evaluating apparatus 100, in particular, for the operationalfunctions performed in the control device 102, all or part thereof maybe implemented by a CPU (Central Processing Unit) and programsinterpreted and executed in the CPU, or may be implemented bywired-logic hardware. The program is recorded in a non-transitorycomputer-readable recording medium including programmed instructions formaking an information processing apparatus execute the pancreaticcancer-evaluating method according to the present invention, and ismechanically read as needed by the pancreatic cancer-evaluatingapparatus 100. More specifically, computer programs to give instructionsto the CPU in cooperation with an OS (operating system) to performvarious processes are recorded in the memory device 106 such as ROM or aHDD (hard disk drive). The computer programs are executed by beingloaded to RAM, and form the control unit in cooperation with the CPU.

The computer programs may be stored in an application program serverconnected to the pancreatic cancer-evaluating apparatus 100 via anarbitrary network, and all or part thereof can be downloaded asnecessary.

The pancreatic cancer-evaluating program according to the presentinvention may be stored in the non-transitory computer-readablerecording medium, or can be configured as a program product. The“recording medium” mentioned here includes any “portable physicalmedium” such as a memory card, a USB (universal serial bus) memory, anSD (secure digital) card, a flexible disk, a magneto-optical disc, ROM,EPROM (erasable programmable read only memory), EEPROM (electronicallyerasable and programmable read only memory), CD-ROM (compact disk readonly memory), MO (magneto-optical disk), DVD (digital versatile disk),and a Blu-ray Disc.

The “program” mentioned here is a data processing method described in anarbitrary language or description method, and therefore any form such asa source code and a binary code is acceptable. The “program” is notnecessarily limited to a program configured as a single unit, and,therefore, includes those dispersively configured as a plurality ofmodules and libraries and those in which the function of the program isachieved in cooperation with separate programs represented as OS(operating system). Any known configuration and procedures can be usedas a specific configuration and reading procedure to read a recordingmedium by each apparatus shown in the embodiments or as an installationprocedure after the reading, or the like.

The various databases and the like stored in the memory device 106 is astorage unit which is a memory device such as RAM and ROM, a fixed diskdrive such as a hard disk, a flexible disk, and an optical disc, or thelike. The memory device 106 stores therein various programs, tables,databases, files for Web (World Wide Web) pages, and the like used toperform various processes and to provide Web sites.

The pancreatic cancer-evaluating apparatus 100 may be configured as aninformation processing apparatus such as known personal computer andwork station, or may be configured as the information processingapparatus connected to an arbitrary peripheral device. The pancreaticcancer-evaluating apparatus 100 may be provided by installing software(including the programs and the data, etc.) to cause the informationprocessing apparatus to implement the pancreatic cancer-evaluatingmethod according to the present invention.

Furthermore, a specific configuration of dispersion or integration ofthe apparatuses is not limited to the shown one. The apparatuses can beconfigured by functionally or physically dispersing or integrating allor part of the apparatuses in arbitrary units according to various typesof additions or the like or according to functional loads. In otherwords, the embodiments may be implemented in arbitrary combinationsthereof or an embodiment may be selectively implemented.

Finally, an example of the evaluation formula-preparing processingperformed in the pancreatic cancer-evaluating apparatus 100 is describedin detail with reference to FIG. 21. The processing described below ismerely one example, and the method of preparing evaluation formula isnot limited thereto. FIG. 21 is a flowchart showing an example of theevaluation formula-preparing processing. The evaluationformula-preparing processing may be performed in the database apparatus400 handling the pancreatic cancer state information.

In the present description, the pancreatic cancer-evaluating apparatus100 stores the pancreatic cancer state information previously obtainedfrom the database apparatus 400 in a predetermined memory region of thepancreatic cancer state information file 106 c. The pancreaticcancer-evaluating apparatus 100 shall store, in a predetermined memoryregion of the designated pancreatic cancer state information file 106 d,the pancreatic cancer state information including the pancreatic cancerstate index data and the amino acid concentration data (the oneincluding the concentration values of the 19 kinds of amino acids)designated previously in the pancreatic cancer stateinformation-designating part 102 g.

The candidate formula-preparing part 102 h 1 in the evaluationformula-preparing part 102 h first prepares the candidate formulae basedon a predetermined formula-preparing method from the pancreatic cancerstate information stored in a predetermine memory region of thedesignated pancreatic cancer state information file 106 d, and storesthe prepared candidate formulae in a predetermined memory region of thecandidate formula file 106 e 1 (step SB21). Specifically, the candidateformula-preparing part 102 h 1 in the evaluation formula-preparing part102 h first selects a desired method out of a plurality of differentformula-preparing methods (including those for multivariate analysissuch as principal component analysis, discriminant analysis, supportvector machine, multiple regression analysis, logistic regressionanalysis, k-means method, cluster analysis, and decision tree) anddetermines the form of the candidate formula to be prepared (the form offormula) based on the selected formula-preparing method. The candidateformula-preparing part 102 h 1 in the evaluation formula-preparing part102 h then performs various calculation corresponding to the selectedformula-selecting method (e.g., average or variance), based on thepancreatic cancer state information. The candidate formula-preparingpart 102 h 1 in the evaluation formula-preparing part 102 h thendetermines the parameters for the calculation result and the determinedcandidate formula. In this way, the candidate formula is generated basedon the selected formula-preparing method. When the candidate formulaeare generated simultaneously and concurrently (in parallel) by using aplurality of different formula-preparing methods in combination, theprocessings described above may be executed concurrently for eachselected formula-preparing method. Alternatively when the candidateformulae are generated in series by using a plurality of differentformula-preparing methods in combination, for example, the candidateformulae may be generated by converting the pancreatic cancer stateinformation with the candidate formulae prepared by performing principalcomponent analysis and performing discriminant analysis of the convertedpancreatic cancer state information.

The candidate formula-verifying part 102 h 2 in the evaluationformula-preparing part 102 h verifies (mutually verifies) the candidateformula prepared in step SB21 according to a particular verifying methodand stores the verification result in a predetermined memory region ofthe verification result file 106 e 2 (step SB22). Specifically, thecandidate formula-verifying part 102 h 2 in the evaluationformula-preparing part 102 h first generates the verification data to beused in verification of the candidate formula, based on the pancreaticcancer state information stored in a predetermined memory region of thedesignated pancreatic cancer state information file 106 d, and verifiesthe candidate formula according to the generated verification data. If aplurality of the candidate formulae is generated by using a plurality ofdifferent formula-preparing methods in step SB21, the candidateformula-verifying part 102 h 2 in the evaluation formula-preparing part102 h verifies each candidate formula corresponding to eachformula-preparing method according to a particular verifying method.Here in step SB22, at least one of the discrimination rate, sensitivity,specificity, information criterion, ROC_AUC (area under the curve in areceiver operating characteristic curve), and the like of the candidateformula may be verified based on at least one method of the bootstrapmethod, holdout method, N-fold method, leave-one-out method, and thelike. Thus, it is possible to select the candidate formula higher inpredictability or reliability, by taking the pancreatic cancer stateinformation and evaluation condition into consideration.

Then, the explanatory variable-selecting part 102 h 3 in the evaluationformula-preparing part 102 h selects the combination of the amino acidconcentration data contained in the pancreatic cancer state informationused in preparing the candidate formula by selecting the explanatoryvariable of the candidate formula according to a predeterminedexplanatory variable-selecting method, and stores the pancreatic cancerstate information including the selected combination of the amino acidconcentration data in a predetermined memory region of the selectedpancreatic cancer state information file 106 e 3 (step SB23). When aplurality of the candidate formulae is generated by using a plurality ofdifferent formula-preparing methods in step SB21 and each candidateformula corresponding to each formula-preparing method is verifiedaccording to a predetermined verifying method in step SB22, theexplanatory variable-selecting part 102 h 3 in the evaluationformula-preparing part 102 h may select the explanatory variable of thecandidate formula for each candidate formula according to apredetermined explanatory variable-selecting method in step SB23. Herein step SB23, the explanatory variable of the candidate formula may beselected from the verification results according to at least one of thestepwise method, best path method, local search method, and geneticalgorithm. The best path method is a method of selecting an explanatoryvariable by optimizing an evaluation index of the candidate formulawhile eliminating the explanatory variables contained in the candidateformula one by one. In step SB23, the explanatory variable-selectingpart 102 h 3 in the evaluation formula-preparing part 102 h may selectthe combination of the amino acid concentration data based on thepancreatic cancer state information stored in a predetermined memoryregion of the designated pancreatic cancer state information file 106 d.

The evaluation formula-preparing part 102 h then judges whether allcombinations of the amino acid concentration data contained in thepancreatic cancer state information stored in a predetermined memoryregion of the designated pancreatic cancer state information file 106 dare processed, and if the judgment result is “End” (Yes in step SB24),the processing advances to the next step (step SB25), and if thejudgment result is not “End” (No in step SB24), it returns to step SB21.The evaluation formula-preparing part 102 h may judge whether theprocessing is performed a predetermined number of times, and if thejudgment result is “End” (Yes in step SB24), the processing may advanceto the next step (step SB25), and if the judgment result is not “End”(No in step SB24), it may return to step SB21. The evaluationformula-preparing part 102 h may judge whether the combination of theamino acid concentration data selected in step SB23 is the same as thecombination of the amino acid concentration data contained in thepancreatic cancer state information stored in a predetermined memoryregion of the designated pancreatic cancer state information file 106 dor the combination of the amino acid concentration data selected in theprevious step SB23, and if the judgment result is “the same” (Yes instep SB24), the processing may advance to the next step (step SB25) andif the judgment result is not “the same” (No in step SB24), it mayreturn to step SB21. If the verification result is specifically theevaluation value for each candidate formula, the evaluationformula-preparing part 102 h may advance to step SB25 or return to stepSB21, based on the comparison of the evaluation value with a particularthreshold corresponding to each formula-preparing method.

Then, the evaluation formula-preparing part 102 h determines theevaluation formula by selecting the candidate formula used as theevaluation formula based on the verification results from a plurality ofthe candidate formulae, and stores the determined formula (the selectedcandidate formula) in particular memory region of the evaluation formulafile 106 e 4 (step SB25). Here, in step SB25, for example, there arecases where the optimal evaluation formula is selected from thecandidate formulae prepared in the same formula-preparing method or theoptimal evaluation formula is selected from all candidate formulae.

Given the foregoing description, the explanation of the evaluationformula-preparing processing is finished.

Example 1

In the present Example 1 and the following examples, data of theconcentration values of amino acids (nmol/ml) in plasma measured usingthe amino acid analysis method from a blood sample in each of the groupsbelow is used. Pancreatic cancer patients (51 people) with definitediagnosis of pancreatic cancer are divided into a pancreatic cancergroup. Healthy individuals with no anamnesis or history of cancer aredivided into a healthy group (255 people). The cancer patients withdefinite diagnosis of lung cancer, colorectal cancer, prostatic cancer,and breast cancer are divided into a lung cancer group (320 people), acolorectal cancer group (252 people), a prostatic cancer group (87people), and a breast cancer group (121 people), respectively, and thesefour groups form the other cancers group (780 people).

The capability of discriminating between the pancreatic cancer group andthe healthy group for each amino acid is evaluated with ROC_AUC (thearea under the curve in a receiver operating characteristic curve).Amino acids with significant ROC_AUC (p<0.05) in examination with a nullhypothesis of “ROC_AUC=0.5” under the assumption of non-parametric areAsn, His, Thr, Ala, Cit, Arg, Tyr, Val, Met, Lys, and Trp. These aminoacids significantly decreased in the pancreatic cancer group. Theconcentration values of these amino acids are thought to be useful inevaluation of the state of pancreatic cancer with consideration of thehealthy state, because ROC_AUC is significant.

Example 2

The sample data used in Example 1 is used. A multivariate discriminant(multivariate function) including an explanatory variable to besubstituted with the concentration value of an amino acid in plasma isobtained for discriminating between two groups: the pancreatic cancergroup and the healthy group. As for the obtained multivariatediscriminant, the capability of discriminating between the pancreaticcancer group and the other cancers group, between the pancreatic cancergroup and the lung cancer group, between the pancreatic cancer group andthe colorectal cancer group, between the pancreatic cancer group and theprostatic cancer group, and between the pancreatic cancer group and thebreast cancer group is also shown.

A logistic regression equation is used as a multivariate discriminant.The 19 kinds of amino acids (specifically, Asn, His, Thr, Ala, Cit, Arg,Tyr, Val, Met, Lys, Trp, Gly, Pro, Orn, Ile, Leu, Phe, Ser, and Gln) aresearched for a combination of six or less explanatory variables to beincluded in the logistic regression equation. The Leave-One-Out methodis employed as validation to explore a logistic regression equationhaving a good capability of discriminating between the pancreatic cancergroup and the healthy group.

List of Logistic Regression Equations Searched in Example 2 (ROC_AUCvalue: 0.500 or greater) provided later shows (i) a list of logisticregression equations with two explanatory variables where the ROC_AUCvalue for the pancreatic cancer group and the healthy group withvalidation is equal to or greater than 0.500, (ii) a list of logisticregression equations with three explanatory variables where the ROC_AUCvalue for the pancreatic cancer group and the healthy group withvalidation is equal to or greater than 0.500, (iii) a list of logisticregression equations with four explanatory variables where the ROC_AUCvalue for the pancreatic cancer group and the healthy group withvalidation is equal to or greater than 0.500, (iv) a list of logisticregression equations with five explanatory variables where the ROC_AUCvalue for the pancreatic cancer group and the healthy group withvalidation is equal to or greater than 0.500, and (v) a list of logisticregression equations with six explanatory variables where the ROC_AUCvalue for the pancreatic cancer group and the healthy group withvalidation is equal to or greater than 0.500. These logistic regressionequations are thought to be useful in the evaluation because the ROC_AUCvalue is high.

The logistic regression equations where the ROC_AUC value for thepancreatic cancer group and the healthy group with validation is equalto or greater than 0.750 are shown later in List (1) of LogisticRegression Equations Searched in Example 2. These logistic regressionequations are thought to be useful in the evaluation because the ROC_AUCvalue is extremely high. When the amino acid explanatory variablesincluded in these logistic regression equations are listed in thedescending order of occurrence frequency from the highest to the tenth,they are arranged in the following order: Met, Phe, Trp, Ile, Ser, Val,His, Thr, Asn, Ala (see Table 1 below). These amino acids are thought tobe useful in the evaluation as with the equations because they areexplanatory variables included in the equations thought to be useful inthe evaluation. For these logistic regression equations, the averagevalue of the ROC_AUC values for the pancreatic cancer group and the lungcancer group, for the pancreatic cancer group and the colorectal cancergroup, for the pancreatic cancer group and the prostatic cancer group,and for the pancreatic cancer group and the breast cancer group is equalto or greater than 0.775, and the capability of discriminating betweenthe pancreatic cancer group and a variety of other cancer groups isgood. These logistic regression equations are thought to be useful inevaluation of the state of pancreatic cancer with additionalconsideration of the state of cancers other than pancreatic cancer,because the ROC_AUC value is extremely high. Among these logisticregression equations, for example, the index formula 1“(−1.3217)+(0.0545)Ser+(−0.0544)Val+(−0.3973)Met+(0.1922)Ile+(0.1506)Phe+(−0.1179)Trp”having a set of explanatory variables “Ser, Val, Met, Ile, Phe, Trp”(the multivariate discriminant including Ser, Val, Met, Ile, Phe, Trp asexplanatory variables) has a good discriminating capability withROC_AUC(Validation)=0.902, ROC_AUC(No Validation)=0.923,sensitivity=0.902, specificity=0.804. The sensitivity and thespecificity are the values when the maximum discriminate point, wherethe average of sensitivity and specificity is highest, is a cutoffvalue.

TABLE 1 Pancreatic cancer group vs Healthy group Logistic regressionequation Linear discriminant Average of Average of Healthy other Healthyother Amino acid Univariate group cancers group cancers Ser 66 70 Asn O13 75 23 79 Gly Gln 100 98 His O 45 24 46 28 Thr O 38 38 Ala O 11 36 33Cit O 52 10 58 Arg O Pro Tyr O 23 Val O 54 23 47 28 Met O 90 46 81 38Orn Lys O 17 Ile 66 61 17 Leu Phe 79 48 90 45 Trp O 75 100 71 100 (Oindicates the amino acid that varies significantly. The numeralindicates the frequency of occurrence of the amino acid explanatoryvariable.)

The value of the formula is calculated using the index formula 1 and theamino acid concentration values (μmol/L) of the pancreatic cancer group,and each case in the pancreatic cancer group is classified into any oneof a plurality of categories established as shown below, using thecalculated value of the formula and a previously established cutoffvalue. As candidates for the cutoff value, the value of the formula whenthe specificity is 80% and the value of the formula when the specificityis 95% are found to be −2.002 and −0.528, respectively. When thesevalues are set as cutoff values, the sensitivities are 86% and 71%,respectively.

The amino acid concentration values of a case having the highest valueof the formula are Ser:166.3, Val:149.9, Met:18.5, Ile:69.0, Phe:44.1,Trp:33.6, and the value of the formula in this case is 8.2. Therelational expression “logarithm odds ln(p/(1−p))=value of formula”(where p is the probability of cancer) is defined, and the odds p/(1−p),calculated from the value 8.2 of this formula, are 3508.0. Theprobability p, calculated from the odds, is 1.0.

When the value −0.528 of the formula when the specificity is 95% isestablished as a cutoff value, and when the value of the formula higherthan the cutoff value is defined positive (equivalent to the pancreaticcancer category), and when the value of the formula lower than thecutoff value is defined negative (equivalent to the healthy category),then the case in which the value of the formula is 8.2 is classifiedeither as positive or as negative.

This case is classified as positive because the value of the formula ishigher than the cutoff value.

When the value −2.002 of the formula when the specificity is 80% isestablished as a first cutoff value, and the value −0.528 of the formulawhen the specificity is 95% is established as a second cutoff value, andwhen the value of the formula lower than the first cutoff value isdefined rank A (the category meaning that the possibility (probability,risk) of pancreatic cancer is low), when the value of the formula higherthan the first cutoff value and lower than the second cutoff value isdefined rank B (the category that means the possibility of havingpancreatic cancer is moderate), and when the value of the formula higherthan the second cutoff value is defined rank C (the category meaningthat the possibility of pancreatic cancer is high), then the case inwhich the value of the formula is 8.2 is classified into any one of thethree ranks. This case is classified into the rank C because the valueof the formula is higher than the second cutoff value.

A linear discriminant is used as a multivariate discriminant. The 19kinds of amino acids are searched for a combination of six or lessexplanatory variables to be included in the linear discriminant, and thebootstrap method is employed as validation to explore a lineardiscriminant with a good capability of discriminating between thepancreatic cancer group and the healthy group.

A list of linear discriminants where the ROC_AUC value for thepancreatic cancer group and the healthy group with validation is equalto or greater than 0.750 is shown later in List (1) of LinearDiscriminants Searched in Example 2. These linear discriminants arethought to be useful in evaluation of the state of pancreatic cancerwith consideration of the healthy state, because the ROC_AUC value isextremely high. When the amino acid explanatory variables included inthese linear discriminants are listed in the descending order ofoccurrence frequency from the highest to the tenth, they are arranged inthe following order: Phe, Met, Trp, Ser, Ile, Val, His, Thr, Asn, Cit(see Table 1 above). The concentration values of these amino acids arethought to be useful in the evaluation as with the formula, because theyare explanatory variables included in the formula thought to be usefulin the evaluation. As for these linear discriminants, the average valueof the ROC_AUC values for the pancreatic cancer group and the lungcancer group, for the pancreatic cancer group and the colorectal cancergroup, for the pancreatic cancer group and the prostatic cancer group,and for the pancreatic cancer group and the breast cancer group is equalto or greater than 0.762, and the capability of discriminating betweenthe pancreatic cancer group and a variety of other cancer groups isgood. These linear discriminants are thought to be useful in evaluationof the state of pancreatic cancer with additional consideration of thestate of cancers other than pancreatic cancer, because the ROC_AUC valueis extremely high. Among these linear discriminants, for example, theindex formula 2“(−1.0207)+(0.0564)Ser+(−0.0410)Val+(−0.4144)Met+(0.1407)Ile+(0.1786)Phe+(−0.1154)Trp”having a set of explanatory variables “Ser, Val, Met, Ile, Phe, Trp”(the multivariate discriminant including Ser, Val, Met, Ile, Phe, Trp asexplanatory variables) has a good discriminating capability withROC_AUC(Validation)=0.912, ROC_AUC(No Validation)=0.926,sensitivity=0.800, and specificity=0.902. The sensitivity and thespecificity are the values when the maximum discriminate point, wherethe average of sensitivity and specificity is the highest, is a cutoffvalue.

The value of the formula is calculated using the index formula 2 and theamino acid concentration values (μmol/L) of the pancreatic cancer group,and each case in the pancreatic cancer group is classified into any oneof a plurality of categories established as shown below, using thecalculated value of the formula and a previously established cutoffvalue. As candidates for the cutoff value, the value of the formula whenthe specificity is 80% and the value of the formula when the specificityis 95% are found to be −0.434 and 1.093, respectively. When these valuesare set as cutoff values, the sensitivities are 90% and 69%,respectively.

The amino acid concentration values in a case having the highest valueof the formula are Ser:166.3, Val:149.9, Met:18.5, Ile:69.0, Phe:44.1,Trp:33.6, and the value of the formula in this case is 8.2.

When the value 1.093 of the formula when the specificity is 95% isestablished as a cutoff value, and when the value of the formula higherthan the cutoff value is defined positive, and when the value of theformula lower than the cutoff value is defined negative, then the casein which the value of the formula is 8.2 is classified either aspositive or negative. This case is classified as positive because thevalue of the formula is higher than the cutoff value.

In addition, when the value −0.434 of the formula when the specificityis 80% is established as a first cutoff value, and the value 1.093 ofthe formula when the specificity is 95% is established as a secondcutoff value, and when the value of the formula lower than the firstcutoff value is defined rank A, when the value of the formula higherthan the first cutoff value and lower than the second cutoff value isdefined rank B, and when the value of the formula higher than the secondcutoff value is defined rank C, then the case in which the value of theformula is 8.2 is classified into any one of the three ranks. This caseis classified into rank C because the value of the formula is higherthan the second cutoff value.

List (2) of Logistic Regression Equations Searched in Example 2 providedlater shows a list of logistic regression equations in which the ROC_AUCvalue for the pancreatic cancer group and the healthy group withvalidation is equal to or greater than 0.750 and the capability ofdiscriminating between the pancreatic cancer group and a variety ofother cancer groups is also good. These logistic regression equationsare thought to be useful in evaluation of the state of pancreatic cancerwith consideration of both the healthy state and the state of cancersother than pancreatic cancer, because the ROC_AUC value is extremelyhigh. When the amino acid explanatory variables included in theselogistic regression equations are listed in the descending order ofoccurrence frequency from the highest to the tenth, they are arranged inthe following order: Trp, Gln, Asn, Cit, Phe, Met, Ala, His, Val, Tyr(see Table 1 above). The concentration values of these amino acids arethought to be useful in the evaluation as with the formula because theyare explanatory variables included in the formula thought to be usefulin the evaluation. Among these logistic regression equations, forexample, the index formula 3“(2.2508)+(0.0135)Gln+(−0.1156)His+(−0.0544)Cit+(−0.1821)Met+(0.1518)Phe+(−0.1151)Trp”having a set of explanatory variables “Gln, His, Cit, Met, Phe, Trp”(the multivariate discriminant including Gln, His, Cit, Met, Phe, Trp asexplanatory variables) has a good discriminating capability withROC_AUC(Validation)=0.862, ROC_AUC(No Validation)=0.894,sensitivity=0.831, and specificity=0.843. The sensitivity and thespecificity are the values when the maximum discriminate point, wherethe average of sensitivity and specificity is the highest, is a cutoffvalue.

The value of the formula is calculated using the index formula 3 and theamino acid concentration values (μmol/L) of the pancreatic cancer group,and each case in the pancreatic cancer group is classified into any oneof a plurality of categories established as shown below, using thecalculated value of the formula and a previously established cutoffvalue. As candidates for the cutoff value, the value of the formula whenthe specificity is 80% and the value of the formula when the specificityis 95% are found to be −1.659 and −0.288, respectively. When thesevalues are set as cutoff values, the sensitivities are 84% and 57%,respectively.

The amino acid concentration values of a case having the highest valueof the formula are Gln:484.6, His:32.4, Cit:17.7, Met:18.4, Phe:56.6,Trp:30.4, and the value of the formula in this case is 5.8. The odds,calculated from the value 5.8 of this formula, are 341.5. Theprobability p, calculated from the odds, is 1.0.

When the value −0.288 of the formula when the specificity is 95% isestablished as a cutoff value, and when the value of the formula higherthan the cutoff value is defined positive, and when the value of theformula lower than the cutoff value is defined negative, then the casein which the value of the formula is 5.8 is classified either aspositive or negative. This case is classified into a positive becausethe value of the formula is higher than the cutoff value.

When classifying each case either as positive or negative using theamino acid concentration values of the other cancers group when thevalue −1.659 of the formula when the specificity is 80% is establishedas a cutoff value and when the value −0.288 of the formula when thespecificity is 95% is established as a cutoff value, then the falsepositive rates for the other cancers group are 24% and 10%,respectively. These values are lower than the false positive rates of40% and 22% for the other cancers group when the index formula 1 isused. The index formula 3 is therefore useful in evaluation of the stateof pancreatic cancer with consideration of both the healthy state andthe state of cancers other than pancreatic cancer.

When the value −1.659 of the formula when the specificity is 80% isestablished as a first cutoff value, and the value −0.288 of the formulawhen the specificity is 95% is established as a second cutoff value, andwhen the value of the formula lower than the first cutoff value isdefined rank A, when the value of the formula higher than the firstcutoff value and lower than the second cutoff value is defined rank B,and when the value of the formula higher than the second cutoff value isdefined rank C, then the case in which the value of the formula is 5.8is classified into any one of the three ranks. This case is classifiedinto the rank C because the value of the formula is higher than thesecond cutoff value.

List (2) of Linear Discriminants Searched in Example 2 provided latershows a list of linear discriminants in which the ROC_AUC value for thepancreatic cancer group and the healthy group with validation is equalto or greater than 0.750 and the capability of discriminating betweenthe pancreatic cancer group and a variety of other cancer groups is alsogood. These linear discriminants are thought to be useful in evaluationof the state of pancreatic cancer with consideration of both the healthystate and the state of cancers other than pancreatic cancer, because theROC_AUC value is extremely high. When the amino acid explanatoryvariables included in these linear discriminants are listed in thedescending order of occurrence frequency from the highest to the tenth,they are arranged in the following order: Trp, Gln, Asn, Cit, Phe, Met,Ala, Val, His, Ile, Lys, in total eleven (see Table 1 above). Theconcentration values of these amino acids are thought to be useful inthe evaluation as with the formula because they are explanatoryvariables included in the formula thought to be useful in theevaluation. Among these linear discriminants, for example, the indexformula 4“(2.6773)+(0.0131)Gln+(−0.0833)His+(−0.0369)Cit+(−0.1942)Met+(0.1325)Phe+(−0.1189)Trp”having a set of explanatory variables “Gln, His, Cit, Met, Phe, Trp”(the multivariate discriminant including Gln, His, Cit, Met, Phe, Trp asexplanatory variables) has a good discriminating capability withROC_AUC(Validation)=0.876, ROC_AUC(No Validation)=0.897,sensitivity=0.831, specificity=0.804. The sensitivity and thespecificity are the values when the maximum discriminate point, wherethe average of sensitivity and specificity is the highest, is a cutoffvalue.

The value of the formula is calculated using the index formula 4 and theamino acid concentration values (μmol/L) of the pancreatic cancer group,and each case in the pancreatic cancer group is classified into any oneof a plurality of categories established as shown below, using thecalculated value of the formula and a previously established cutoffvalue. As candidates for the cutoff value, the value of the formula whenthe specificity is 80% and the value of the formula when the specificityis 95% are found to be −0.092 and 1.103, respectively. When these valuesare set as cutoff values, the sensitivities are 80% and 55%,respectively.

The amino acid concentration values of a case with the highest value ofthe formula are Gln:484.6, His:32.4, Cit:17.7, Met:18.4, Phe:56.6,Trp:30.4, and the value of the formula in this case is 6.0.

When the value 1.103 of the formula when the specificity is 95% isestablished as a cutoff value, and when the value of the formula higherthan the cutoff value is defined positive, and when the value of theformula lower than the cutoff value is defined negative, then the casein which the value of the formula is 6.0 is classified either aspositive or negative. This case is classified as positive because thevalue of the formula is higher than the cutoff value.

When each case is classified either as positive or negative using theamino acid concentration values of the other cancers group when thevalue −0.092 of the formula when the specificity is 80% is establishedas a cutoff value and when the value 1.103 of the formula when thespecificity is 95% is established as a cutoff value, then the falsepositive rates for the other cancers group are 23% and 10%,respectively. These values are lower than the false positive rates of40% and 20% for the other cancers group when the index formula 2 isused. The index formula 4 is therefore useful in evaluation of the stateof pancreatic cancer with consideration of both the healthy state andthe state of cancers other than pancreatic cancer.

When the value −0.092 of the formula when the specificity is 80% isestablished as a first cutoff value, and the value 1.103 of the formulawhen the specificity is 95% is established as a second cutoff value, andwhen the value of the formula lower than the first cutoff value isdefined rank A, when the value of the formula higher than the firstcutoff value and lower than the second cutoff value is defined rank B,and when the value of the formula higher than the second cutoff value isdefined rank C, then the case in which the value of the formula is 6.0is classified into any one of the three ranks. This case is classifiedinto the rank C because the value of the formula is higher than thesecond cutoff value.

Example 3

The sample data used in Example 1 is used. The capability ofdiscriminating between the pancreatic cancer group and the other cancersgroup for each amino acid is evaluated with ROC_AUC. Amino acids withsignificant ROC_AUC (p<0.05) in examination with a null hypothesis of“ROC_AUC=0.5” under the assumption of non-parametric are Asn, Gly, His,Thr, Ala, Cit, Arg, Pro, Tyr, Val, Met, Orn, Lys, Ile, Leu, Phe, andTrp. These amino acids significantly decreased in the pancreatic cancergroup.

The concentration values of these amino acids are thought to be usefulin evaluation of the state of pancreatic cancer with consideration ofthe state of cancers other than pancreatic cancer, because ROC_AUC issignificant.

The capability of discriminating between the pancreatic cancer group andthe lung cancer group for each amino acid is evaluated with ROC_AUC.Amino acids with significant ROC_AUC (p<0.05) in examination with a nullhypothesis of “ROC_AUC=0.5” under the assumption of non-parametric areSer, Asn, Gly, His, Thr, Ala, Cit, Arg, Pro, Tyr, Val, Met, Orn, Lys,Ile, Leu, Phe, and Trp. These amino acids significantly decreased in thepancreatic cancer group. The concentration values of these amino acidsare thought to be useful in evaluation of the state of pancreatic cancerwith consideration of the state of lung cancer, because ROC_AUC issignificant.

The capability of discriminating between the pancreatic cancer group andthe colorectal cancer group for each amino acid is evaluated withROC_AUC. Amino acids with significant ROC_AUC (p<0.05) in examinationwith a null hypothesis of “ROC_AUC=0.5” under the assumption ofnon-parametric are Asn, Gly, Gln, His, Thr, Ala, Cit, Arg, Pro, Tyr,Val, Met, Lys, Ile, Leu, Phe, and Trp. These amino acids significantlydecreased in the pancreatic cancer group. The concentration values ofthese amino acids are thought to be useful in evaluation of the state ofpancreatic cancer with consideration of the state of colorectal cancer,because ROC_AUC is significant.

The capability of discriminating between the pancreatic cancer group andthe prostatic cancer group for each amino acid is evaluated withROC_AUC. Amino acids with significant ROC_AUC (p<0.05) in examinationwith a null hypothesis of “ROC_AUC=0.5” under the assumption ofnon-parametric are Asn, His, Thr, Ala, Cit, Arg, Pro, Tyr, Val, Met,Lys, Leu, Phe, and Trp. These amino acids significantly decreased in thepancreatic cancer group. The concentration values of these amino acidsare thought to be useful in evaluation of the state of pancreatic cancerwith consideration of the state of prostatic cancer, because ROC_AUC issignificant.

The capability of discriminating between the pancreatic cancer group andthe breast cancer group for each amino acid is evaluated with ROC_AUC.Amino acids with significant ROC_AUC (p<0.05) in examination with a nullhypothesis of “ROC_AUC=0.5” under the assumption of non-parametric areSer, Asn, Gly, His, Thr, Ala, Val, Met, Lys, Ile, and Trp. These aminoacids significantly decreased in the pancreatic cancer group. Theconcentration values of these amino acids are thought to be useful inevaluation of the state of pancreatic cancer with consideration of thestate of breast cancer, because ROC_AUC is significant.

Example 4

The sample data used in Example 1 is used. A multivariate discriminant(multivariate function) including an explanatory variable to besubstituted with the concentration value of an amino acid in plasma isobtained for discriminating between two groups: the pancreatic cancergroup and the other cancers group. As for the obtained multivariatediscriminant, the capability of discriminating between the pancreaticcancer group and the healthy group is also shown.

A logistic regression equation is used as a multivariate discriminant.The 19 kinds of amino acids are searched for a combination of six orless explanatory variables to be included in the logistic regressionequation. The Leave-One-Out method is employed as validation to explorea logistic regression equation having a good capability ofdiscriminating between the pancreatic cancer group and the other cancersgroup.

The logistic regression equations where the ROC_AUC value for thepancreatic cancer group and the other cancers group with validation isequal to or greater than 0.750 are shown later in List (1) of LogisticRegression Equations Searched in Example 4. These logistic regressionequations are thought to be useful in evaluation of the state ofpancreatic cancer with consideration of the state of cancers other thanpancreatic cancer because the ROC_AUC value is extremely high. When theamino acid explanatory variables included in these logistic regressionequations are listed in the descending order of occurrence frequencyfrom the highest to the tenth, they are arranged in the following order:Trp, Gln, Asn, Cit, Ala, Phe, Gly, Val, Met, Pro (see Table 2 below).These amino acids are thought to be useful in the evaluation as with theequations because they are explanatory variables included in theequations thought to be useful in the evaluation. For these logisticregression equations, the ROC_AUC value for the pancreatic cancer groupand the healthy group is equal to or greater than 0.760, and thecapability of discriminating between the pancreatic cancer group and thehealthy group is good. These logistic regression equations are thoughtto be useful in evaluation of the state of pancreatic cancer withadditional consideration of the healthy state, because the ROC_AUC valueis extremely high. Among these logistic regression equations, forexample, the index formula 5“(1.7072)+(−0.0985)Asn+(0.0115)Gln+(−0.0063)Ala+(−0.0582)Cit+(0.0212)Phe+(−0.0792)Trp”having a set of explanatory variables “Asn, Gln, Ala, Cit, Phe, Trp”(the multivariate discriminant including Asn, Gln, Ala, Cit, Phe, Trp asexplanatory variables) has a good discriminating capability withROC_AUC(Validation)=0.854, ROC_AUC(No Validation)=0.873,sensitivity=0.740, specificity=0.882. The sensitivity and thespecificity are the values when the maximum discriminate point, wherethe average of sensitivity and specificity is highest, is a cutoffvalue.

TABLE 2 Pancreatic cancer group vs Other cancers group Logisticregression equation Linear discriminant Other Other cancers Healthycancers Healthy Amino acid Univariate group group group group Ser 47 AsnO 95 20 97 31 Gly O 32 41 Gln 100 84 100 38 His O 80 61 Thr O Ala O 3941 Cit O 54 27 48 23 Arg O Pro O 18 18 Tyr O Val O 29 26 27 20 Met O 1841 22 73 Orn O Lys O Ile O 37 26 Leu O 23 Phe O 37 78 36 99 Trp O 100100 100 99 (O indicates the amino acid that varies significantly. Thenumeral indicates the frequency of occurrence of the amino acidexplanatory variable.)

The value of the formula is calculated using the index formula 5 and theamino acid concentration values (μmol/L) of the pancreatic cancer group,and each case in the pancreatic cancer group is classified into any oneof a plurality of categories established as shown below, using thecalculated value of the formula and a previously established cutoffvalue. As candidates for the cutoff value, the value of the formula whenthe specificity is 80% and the value of the formula when the specificityis 95% are found to be −2.650 and −1.316, respectively. When thesevalues are set as cutoff values, the sensitivities are 76% and 39%,respectively.

The amino acid concentration values of a case having the highest valueof the formula are Asn:35.2, Gln:697.3, Ala:249.3, Cit:26.0, Phe:44.1,Trp:33.6, and the value of the formula in this case is 1.5. The odds,calculated from the value 1.5 of this formula, are 4.3. The probabilityp, calculated from the odds, is 0.8.

When the value −1.316 of the formula when the specificity is 95% isestablished as a cutoff value, and when the value of the formula higherthan the cutoff value is defined positive (equivalent to the pancreaticcancer category), and when the value of the formula lower than thecutoff value is defined negative (equivalent to the other cancercategory), then the case in which the value of the formula is 1.5 isclassified either as positive or as negative. This case is classified aspositive because the value of the formula is higher than the cutoffvalue.

When the value −2.650 of the formula when the specificity is 80% isestablished as a first cutoff value, and the value −1.316 of the formulawhen the specificity is 95% is established as a second cutoff value, andwhen the value of the formula lower than the first cutoff value isdefined rank A (the category meaning that the possibility of pancreaticcancer is low and the possibility of a cancer other than pancreaticcancer is high), when the value of the formula higher than the firstcutoff value and lower than the second cutoff value is defined rank B(the category that means both the possibility of having pancreaticcancer and the possibility of having a cancer other than pancreaticcancer are moderate), and when the value of the formula higher than thesecond cutoff value is defined rank C (the category meaning that thepossibility of pancreatic cancer is high and the possibility of a cancerother than pancreatic cancer is low), then the case in which the valueof the formula is 1.5 is classified into any one of the three ranks.This case is classified into the rank C because the value of the formulais higher than the second cutoff value.

A linear discriminant is used as a multivariate discriminant. The 19kinds of amino acids are searched for a combination of six or lessexplanatory variables to be included in the linear discriminant, and thebootstrap method is employed as validation to explore a lineardiscriminant with a good capability of discriminating between thepancreatic cancer group and the other cancers group.

A list of linear discriminants where the ROC_AUC value for thepancreatic cancer group and the other cancers group with validation isequal to or greater than 0.750 is shown later in List (1) of LinearDiscriminants Searched in Example 4. These linear discriminants arethought to be useful in evaluation of the state of pancreatic cancerwith consideration of the state of cancers other than pancreatic cancer,because the ROC_AUC value is extremely high. When the amino acidexplanatory variables included in these linear discriminants are listedin the descending order of occurrence frequency from the highest to thetenth, they are arranged in the following order: Trp, Gln, Asn, Cit,Gly, Ala, Phe, Val, Met, Pro (see Table 2 above). The concentrationvalues of these amino acids are thought to be useful in the evaluationas with the formula, because they are explanatory variables included inthe formula thought to be useful in the evaluation. As for these lineardiscriminants, the ROC_AUC value for the pancreatic cancer group and thehealthy group is equal to or greater than 0.784, and the capability ofdiscriminating between the pancreatic cancer group and the healthy groupis good. These linear discriminants are thought to be useful inevaluation of the state of pancreatic cancer with additionalconsideration of the healthy state, because the ROC_AUC value isextremely high. Among these linear discriminants, for example, the indexformula 6“(5.4468)+(−0.1111)Asn+(0.0122)Gln+(−0.0083)Ala+(−0.0524)Cit+(0.0345)Phe+(−0.1015)Trp”having a set of explanatory variables “Asn, Gln, Ala, Cit, Phe, Trp”(the multivariate discriminant including Asn, Gln, Ala, Cit, Phe, Trp asexplanatory variables) has a good discriminating capability withROC_AUC(Validation)=0.859, ROC_AUC(No Validation)=0.874,sensitivity=0.742, and specificity=0.902. The sensitivity and thespecificity are the values when the maximum discriminate point, wherethe average of sensitivity and specificity is the highest, is a cutoffvalue.

The value of the formula is calculated using the index formula 6 and theamino acid concentration values (μmol/L) of the pancreatic cancer group,and each case in the pancreatic cancer group is classified into any oneof a plurality of categories established as shown below, using thecalculated value of the formula and a previously established cutoffvalue. As candidates for the cutoff value, the value of the formula whenthe specificity is 80% and the value of the formula when the specificityis 95% are found to be 0.109 and 1.780, respectively. When these valuesare set as cutoff values, the sensitivities are 73% and 37%,respectively.

The amino acid concentration values in a case having the highest valueof the formula are Asn:35.2, Gln:697.3, Ala:249.3, Cit:26.0, Phe:44.1,Trp:33.6, and the value of the formula in this case is 4.7.

When the value 1.780 of the formula when the specificity is 95% isestablished as a cutoff value, and when the value of the formula higherthan the cutoff value is defined positive, and when the value of theformula lower than the cutoff value is defined negative, then the casein which the value of the formula is 4.7 is classified either aspositive or negative. This case is classified as positive because thevalue of the formula is higher than the cutoff value.

In addition, when the value 0.109 of the formula when the specificity is80% is established as a first cutoff value, and the value 1.780 of theformula when the specificity is 95% is established as a second cutoffvalue, and when the value of the formula lower than the first cutoffvalue is defined rank A, when the value of the formula higher than thefirst cutoff value and lower than the second cutoff value is definedrank B, and when the value of the formula higher than the second cutoffvalue is defined rank C, then the case in which the value of the formulais 4.7 is classified into any one of the three ranks. This case isclassified into rank C because the value of the formula is higher thanthe second cutoff value.

List (2) of Logistic Regression Equations Searched in Example 4 providedlater shows a list of logistic regression equations in which the ROC_AUCvalue for the pancreatic cancer group and the other cancers group withvalidation is equal to or greater than 0.750 and the capability ofdiscriminating between the pancreatic cancer group and the healthy groupis also good. These logistic regression equations are thought to beuseful in evaluation of the state of pancreatic cancer withconsideration of both the healthy state and the state of cancers otherthan pancreatic cancer, because the ROC_AUC value is extremely high.When the amino acid explanatory variables included in these logisticregression equations are listed in the descending order of occurrencefrequency from the highest to the tenth, they are arranged in thefollowing order: Trp, Gln, His, Phe, Met, Ile, Cit, Val, Leu, Asn (seeTable 2 above). The concentration values of these amino acids arethought to be useful in the evaluation as with the formula because theyare explanatory variables included in the formula thought to be usefulin the evaluation. Among these logistic regression equations, forexample, the index formula 7“(0.8883)+(0.0101)Gln+(−0.0453)His+(−0.1983)Met+(0.0032)Ile+(0.0304)Phe+(−0.0647)Trp”having a set of explanatory variables “Gln, His, Met, Ile, Phe, Trp”(the multivariate discriminant including Gln, His, Met, Ile, Phe, Trp asexplanatory variables) has a good discriminating capability withROC_AUC(Validation)=0.832, ROC_AUC(No Validation)=0.854,sensitivity=0.690, and specificity=0.902. The sensitivity and thespecificity are the values when the maximum discriminate point, wherethe average of sensitivity and specificity is the highest, is a cutoffvalue.

The value of the formula is calculated using the index formula 7 and theamino acid concentration values (μmol/L) of the pancreatic cancer group,and each case in the pancreatic cancer group is classified into any oneof a plurality of categories established as shown below, using thecalculated value of the formula and a previously established cutoffvalue. As candidates for the cutoff value, the value of the formula whenthe specificity is 80% and the value of the formula when the specificityis 95% are found to be −2.626 and −1.306, respectively. When thesevalues are set as cutoff values, the sensitivities are 75% and 43%,respectively.

The amino acid concentration values of a case having the highest valueof the formula are Gln:697.3, His:54.0, Met:18.5, Ile:69.0, Phe:44.1,Trp:33.6, and the value of the formula in this case is 1.2. The odds,calculated from the value 1.2 of this formula, are 3.3. The probabilityp, calculated from the odds, is 0.8.

When the value −1.306 of the formula when the specificity is 95% isestablished as a cutoff value, and when the value of the formula higherthan the cutoff value is defined positive, and when the value of theformula lower than the cutoff value is defined negative, then the casein which the value of the formula is 1.2 is classified either aspositive or negative. This case is classified into a positive becausethe value of the formula is higher than the cutoff value.

When classifying each case either as positive or negative using theamino acid concentration values of the healthy group when the value−2.626 of the formula when the specificity is 80% is established as acutoff value and when the value −1.306 of the formula when thespecificity is 95% is established as a cutoff value, then the falsepositive rates for the healthy group are 22% and 2%, respectively. Thesevalues are lower than the false positive rates of 28% and 5% for thehealthy group when the index formula 5 is used. The index formula 7 istherefore useful in evaluation of the state of pancreatic cancer withconsideration of both the healthy state and the state of cancers otherthan pancreatic cancer.

When the value −2.626 of the formula when the specificity is 80% isestablished as a first cutoff value, and the value −1.306 of the formulawhen the specificity is 95% is established as a second cutoff value, andwhen the value of the formula lower than the first cutoff value isdefined rank A, when the value of the formula higher than the firstcutoff value and lower than the second cutoff value is defined rank B,and when the value of the formula higher than the second cutoff value isdefined rank C, then the case in which the value of the formula is 1.2is classified into any one of the three ranks. This case is classifiedinto the rank C because the value of the formula is higher than thesecond cutoff value.

List (2) of Linear Discriminants Searched in Example 4 provided latershows a list of linear discriminants in which the ROC_AUC value for thepancreatic cancer group and the other cancers group with validation isequal to or greater than 0.750 and the capability of discriminatingbetween the pancreatic cancer group and the healthy group is also good.These linear discriminants are thought to be useful in evaluation of thestate of pancreatic cancer with consideration of both the healthy stateand the state of cancers other than pancreatic cancer, because theROC_AUC value is extremely high. When the amino acid explanatoryvariables included in these linear discriminants are listed in thedescending order of occurrence frequency from the highest to the tenth,they are arranged in the following order: Trp, Phe, Met, His, Ser, Gln,Asn, Ile, Cit, Val (see Table 2 above). The concentration values ofthese amino acids are thought to be useful in the evaluation as with theformula because they are explanatory variables included in the formulathought to be useful in the evaluation. Among these lineardiscriminants, for example, the index formula 8“(5.7313)+(0.0114)Ser+(−0.0226)Val+(−0.2232)Met+(0.0489)Ile+(0.0676)Phe+(−0.0795)Trp”having a set of explanatory variables “Ser, Val, Met, Ile, Phe, Trp”(the multivariate discriminant including Ser, Val, Met, Ile, Phe, Trp asexplanatory variables) has a good discriminating capability withROC_AUC(Validation)=0.833, ROC_AUC(No Validation)=0.849,sensitivity=0.837, specificity=0.784. The sensitivity and thespecificity are the values when the maximum discriminate point, wherethe average of sensitivity and specificity is the highest, is a cutoffvalue.

The value of the formula is calculated using the index formula 8 and theamino acid concentration values (μmol/L) of the pancreatic cancer group,and each case in the pancreatic cancer group is classified into any oneof a plurality of categories established as shown below, using thecalculated value of the formula and a previously established cutoffvalue. As candidates for the cutoff value, the value of the formula whenthe specificity is 80% and the value of the formula when the specificityis 95% are found to be 0.019 and 1.739, respectively. When these valuesare set as cutoff values, the sensitivities are 78% and 31%,respectively.

The amino acid concentration values of a case with the highest value ofthe formula are Ser:166.3, Gln:697.3, Asn:35.2, Ile:69.0, Cit:26.0,Val:149.9, and the value of the formula in this case is 3.8.

When the value 1.739 of the formula when the specificity is 95% isestablished as a cutoff value, and when the value of the formula higherthan the cutoff value is defined positive, and when the value of theformula lower than the cutoff value is defined negative, then the casein which the value of the formula is 3.8 is classified either aspositive or negative. This case is classified as positive because thevalue of the formula is higher than the cutoff value.

When each case is classified either as positive or negative using theamino acid concentration values of the healthy group when the value0.019 of the formula when the specificity is 80% is established as acutoff value and when the value 1.739 of the formula when thespecificity is 95% is established as a cutoff value, then the falsepositive rates for the healthy group are 17% and 1%, respectively. Thesevalues are lower than the false positive rates of 28% and 4% for thehealthy group when the index formula 6 is used. The index formula 8 istherefore useful in evaluation of the state of pancreatic cancer withconsideration of both the healthy state and the state of cancers otherthan pancreatic cancer.

When the value 0.019 of the formula when the specificity is 80% isestablished as a first cutoff value, and the value 1.739 of the formulawhen the specificity is 95% is established as a second cutoff value, andwhen the value of the formula lower than the first cutoff value isdefined rank A, when the value of the formula higher than the firstcutoff value and lower than the second cutoff value is defined rank B,and when the value of the formula higher than the second cutoff value isdefined rank C, then the case in which the value of the formula is 3.8is classified into any one of the three ranks. This case is classifiedinto the rank C because the value of the formula is higher than thesecond cutoff value.

Example 5

The sample data used in Example 1 is used. A multivariate discriminant(multivariate function) including an explanatory variable to besubstituted with the concentration value of an amino acid in plasma isobtained for discriminating between two groups: the pancreatic cancergroup and the lung cancer group.

A logistic regression equation is used as a multivariate discriminant.The 19 kinds of amino acids are searched for a combination of six orless explanatory variables to be included in the logistic regressionequation. The Leave-One-Out method is employed as validation to explorea logistic regression equation having a good capability ofdiscriminating between the pancreatic cancer group and the lung cancergroup.

The logistic regression equations where the ROC_AUC value for thepancreatic cancer group and the lung cancer group with validation isequal to or greater than 0.750 are shown later in List (1) of LogisticRegression Equations Searched in Example 5. These logistic regressionequations are thought to be useful in evaluation of the state ofpancreatic cancer with consideration of the state of lung cancer becausethe ROC_AUC value is extremely high. When the amino acid explanatoryvariables included in these logistic regression equations are listed inthe descending order of occurrence frequency from the highest to thetenth, they are arranged in the following order: Gln, Asn, Trp, Val,Ala, Phe, Cit, Arg, Pro, Leu (see Table 3 below). These amino acids arethought to be useful in the evaluation as with the equations becausethey are explanatory variables included in the equations thought to beuseful in the evaluation. For these logistic regression equations, theROC_AUC value for the pancreatic cancer group and the healthy group isequal to or greater than 0.725, and the capability of discriminatingbetween the pancreatic cancer group and the healthy group is good.

These logistic regression equations are thought to be useful inevaluation of the state of pancreatic cancer with additionalconsideration of the healthy state, because the ROC_AUC value isextremely high. Among these logistic regression equations, for example,the index formula 9“(2.5017)+(−0.1544)Asn+(0.0144)Gln+(−0.0136)Pro+(−0.0179)Val+(0.0647)Phe+(−0.0751)Trp”having a set of explanatory variables “Asn, Gln, Pro, Val, Phe, Trp”(the multivariate discriminant including Asn, Gln, Pro, Val, Phe, Trp asexplanatory variables) has a good discriminating capability withROC_AUC(Validation)=0.879, ROC_AUC(No Validation)=0.901,sensitivity=0.831, specificity=0.902. The sensitivity and thespecificity are the values when the maximum discriminate point, wherethe average of sensitivity and specificity is highest, is a cutoffvalue.

TABLE 3 Pancreatic cancer group vs Lung cancer group Logistic regressionequation Linear discriminant Lung cancer Healthy Lung cancer HealthyAmino acid Univariate group group group group Ser O 44 66 Asn O 97 40 9240 Gly O Gln 100 43 100 32 His O 35 38 Thr O Ala O 46 50 Cit O 23 42 1829 Arg O 22 12 Pro O 21 25 Tyr O 14 Val O 67 65 Met O 66 19 73 Orn O LysO 16 15 Ile O 12 Leu O 15 22 Phe O 31 98 28 98 Trp O 96 100 98 100 (Oindicates the amino acid that varies significantly. The numeralindicates the frequency of occurrence of the amino acid explanatoryvariable.)

The value of the formula can be calculated using the index formula 9 aswith Example 4, and each case can be classified using the calculatedvalue of the formula and a previously established cutoff value as withExample 4.

A linear discriminant is used as a multivariate discriminant. The 19kinds of amino acids are searched for a combination of six or lessexplanatory variables to be included in the linear discriminant, and thebootstrap method is employed as validation to explore a lineardiscriminant with a good capability of discriminating between thepancreatic cancer group and the lung cancer group.

A list of linear discriminants where the ROC_AUC value for thepancreatic cancer group and the lung cancer group with validation isequal to or greater than 0.750 is shown later in List (1) of LinearDiscriminants Searched in Example 5. These linear discriminants arethought to be useful in evaluation of the state of pancreatic cancerwith consideration of the state of lung cancer, because the ROC_AUCvalue is extremely high. When the amino acid explanatory variablesincluded in these linear discriminants are listed in the descendingorder of occurrence frequency from the highest to the tenth, they arearranged in the following order: Gln, Trp, Asn, Val, Ala, Phe, Pro, Leu,Met, Cit (see Table 3 above). The concentration values of these aminoacids are thought to be useful in the evaluation as with the formula,because they are explanatory variables included in the formula thoughtto be useful in the evaluation. As for these linear discriminants, theROC_AUC value for the pancreatic cancer group and the healthy group isequal to or greater than 0.727, and the capability of discriminatingbetween the pancreatic cancer group and the healthy group is good.

These linear discriminants are thought to be useful in evaluation of thestate of pancreatic cancer with additional consideration of the healthystate, because the ROC_AUC value is extremely high. Among these lineardiscriminants, for example, the index formula 10“(5.6262)+(−0.1579)Asn+(0.0147)Gln+(−0.0133)Pro+(−0.0175)Val+(0.0680)Phe+(−0.1047)Trp”having a set of explanatory variables “Asn, Gln, Pro, Val, Phe, Trp”(the multivariate discriminant including Asn, Gln, Pro, Val, Phe, Trp asexplanatory variables) has a good discriminating capability withROC_AUC(Validation)=0.889, ROC_AUC(No Validation)=0.900,sensitivity=0.828, and specificity=0.882. The sensitivity and thespecificity are the values when the maximum discriminate point, wherethe average of sensitivity and specificity is the highest, is a cutoffvalue.

The value of the formula can be calculated using the index formula 10 aswith Example 4, and each case can be classified using the calculatedvalue of the formula and a previously established cutoff value as withExample 4.

List (2) of Logistic Regression Equations Searched in Example 5 providedlater shows a list of logistic regression equations in which the ROC_AUCvalue for the pancreatic cancer group and the lung cancer group withvalidation is equal to or greater than 0.750 and the capability ofdiscriminating between the pancreatic cancer group and the healthy groupis also good. These logistic regression equations are thought to beuseful in evaluation of the state of pancreatic cancer withconsideration of both the healthy state and the state of lung cancer,because the ROC_AUC value is extremely high. When the amino acidexplanatory variables included in these logistic regression equationsare listed in the descending order of occurrence frequency from thehighest to the tenth, they are arranged in the following order: Trp,Phe, Met, Ser, Gln, Cit, Asn, His, Lys, Ile, Arg, in total eleven (seeTable 3 above). The concentration values of these amino acids arethought to be useful in the evaluation as with the formula because theyare explanatory variables included in the formula thought to be usefulin the evaluation. Among these logistic regression equations, forexample, the index formula 11“(0.7428)+(−0.0948)Asn+(0.0147)Gln+(−0.0250)His+(−0.1901)Met+(0.0579)Phe+(−0.0741)Trp”having a set of explanatory variables “Asn, Gln, His, Met, Phe, Trp”(the multivariate discriminant including Asn, Gln, His, Met, Phe, Trp asexplanatory variables) has a good discriminating capability withROC_AUC(Validation)=0.858, ROC_AUC(No Validation)=0.882,sensitivity=0.747, and specificity=0.902. The sensitivity and thespecificity are the values when the maximum discriminate point, wherethe average of sensitivity and specificity is the highest, is a cutoffvalue.

The value of the formula can be calculated using the index formula 11 aswith Example 4, and each case can be classified using the calculatedvalue of the formula and a previously established cutoff value as withExample 4.

List (2) of Linear Discriminants Searched in Example 5 provided latershows a list of linear discriminants in which the ROC_AUC value for thepancreatic cancer group and the lung cancer group with validation isequal to or greater than 0.750 and the capability of discriminatingbetween the pancreatic cancer group and the healthy group is also good.These linear discriminants are thought to be useful in evaluation of thestate of pancreatic cancer with consideration of both the healthy stateand the state of lung cancer, because the ROC_AUC value is extremelyhigh. When the amino acid explanatory variables included in these lineardiscriminants are listed in the descending order of occurrence frequencyfrom the highest to the tenth, they are arranged in the following order:Trp, Phe, Met, Ser, Asn, His, Gln, Cit, Lys, Tyr (see Table 3 above).The concentration values of these amino acids are thought to be usefulin the evaluation as with the formula because they are explanatoryvariables included in the formula thought to be useful in theevaluation. Among these linear discriminants, for example, the indexformula 12“(6.6327)+(0.0159)Ser+(−0.0688)Asn+(−0.0166)Cit+(−0.1442)Met+(0.0618)Phe+(−0.0996)Trp”having a set of explanatory variables “Ser, Asn, Cit, Met, Phe, Trp”(the multivariate discriminant including Ser, Asn, Cit, Met, Phe, Trp asexplanatory variables) has a good discriminating capability withROC_AUC(Validation)=0.841, ROC_AUC(No Validation)=0.858,sensitivity=0.825, specificity=0.804. The sensitivity and thespecificity are the values when the maximum discriminate point, wherethe average of sensitivity and specificity is the highest, is a cutoffvalue.

The value of the formula can be calculated using the index formula 12 aswith Example 4, and each case can be classified using the calculatedvalue of the formula and a previously established cutoff value as withExample 4.

Example 6

The sample data used in Example 1 is used. A multivariate discriminant(multivariate function) including an explanatory variable to besubstituted with the concentration value of an amino acid in plasma isobtained for discriminating between two groups: the pancreatic cancergroup and the colorectal cancer group.

A logistic regression equation is used as a multivariate discriminant.The 19 kinds of amino acids are searched for a combination of six orless explanatory variables to be included in the logistic regressionequation. The Leave-One-Out method is employed as validation to explorea logistic regression equation having a good capability ofdiscriminating between the pancreatic cancer group and the colorectalcancer group.

The logistic regression equations where the ROC_AUC value for thepancreatic cancer group and the colorectal cancer group with validationis equal to or greater than 0.750 are shown later in List (1) ofLogistic Regression Equations Searched in Example 6. These logisticregression equations are thought to be useful in evaluation of the stateof pancreatic cancer with consideration of the state of colorectalcancer because the ROC_AUC value is extremely high. When the amino acidexplanatory variables included in these logistic regression equationsare listed in the descending order of occurrence frequency from thehighest to the tenth, they are arranged in the following order: Trp,Cit, Tyr, Met, Asn, Orn, Gln, Pro, Ala, Gly (see Table 4 below). Theseamino acids are thought to be useful in the evaluation as with theequations because they are explanatory variables included in theequations thought to be useful in the evaluation. For these logisticregression equations, the ROC_AUC value for the pancreatic cancer groupand the healthy group is equal to or greater than 0.803, and thecapability of discriminating between the pancreatic cancer group and thehealthy group is good.

These logistic regression equations are thought to be useful inevaluation of the state of pancreatic cancer with additionalconsideration of the healthy state, because the ROC_AUC value isextremely high. Among these logistic regression equations, for example,the index formula 13“(5.6692)+(−0.0719)Asn+(0.0072)Gln+(−0.0715)Cit+(0.0674)Tyr+(−0.1878)Met+(−0.1103)Trp”having a set of explanatory variables “Asn, Gln, Cit, Tyr, Met, Trp”(the multivariate discriminant including Asn, Gln, Cit, Tyr, Met, Trp asexplanatory variables) has a good discriminating capability withROC_AUC(Validation)=0.851, ROC_AUC(No Validation)=0.874,sensitivity=0.889, specificity=0.804. The sensitivity and thespecificity are the values when the maximum discriminate point, wherethe average of sensitivity and specificity is highest, is a cutoffvalue.

TABLE 4 Pancreatic cancer group vs Colorectal cancer group Logisticregression equation Linear discriminant Colorectal Healthy ColorectalHealthy Amino acid Univariate cancer group group cancer group group Ser12 37 Asn O 43 32 41 21 Gly O 14 13 Gln O 24 83 33 42 His O 89 61 Thr O22 12 40 Ala O 14 Cit O 100 19 97 25 Arg O Pro O 16 Tyr O 99 96 Val OMet O 70 39 75 82 Orn 27 19 21 Lys O Ile O 16 Leu O 22 Phe O 77 20 97Trp O 100 100 100 100 (O indicates the amino acid that variessignificantly. The numeral indicates the frequency of occurrence of theamino acid explanatory variable.)

The value of the formula can be calculated using the index formula 13 aswith Example 4, and each case can be classified using the calculatedvalue of the formula and a previously established cutoff value as withExample 4.

A linear discriminant is used as a multivariate discriminant. The 19kinds of amino acids are searched for a combination of six or lessexplanatory variables to be included in the linear discriminant, and thebootstrap method is employed as validation to explore a lineardiscriminant with a good capability of discriminating between thepancreatic cancer group and the colorectal cancer group.

A list of linear discriminants where the ROC_AUC value for thepancreatic cancer group and the colorectal cancer group with validationis equal to or greater than 0.750 is shown later in List (1) of LinearDiscriminants Searched in Example 6. These linear discriminants arethought to be useful in evaluation of the state of pancreatic cancerwith consideration of the state of colorectal cancer, because theROC_AUC value is extremely high. When the amino acid explanatoryvariables included in these linear discriminants are listed in thedescending order of occurrence frequency from the highest to the tenth,they are arranged in the following order: Trp, Cit, Tyr, Met, Asn, Gln,Orn, Phe, Gly, Thr, Ser, in total eleven (see Table 4 above). Theconcentration values of these amino acids are thought to be useful inthe evaluation as with the formula, because they are explanatoryvariables included in the formula thought to be useful in theevaluation. As for these linear discriminants, the ROC_AUC value for thepancreatic cancer group and the healthy group is equal to or greaterthan 0.793, and the capability of discriminating between the pancreaticcancer group and the healthy group is good. These linear discriminantsare thought to be useful in evaluation of the state of pancreatic cancerwith additional consideration of the healthy state, because the ROC_AUCvalue is extremely high. Among these linear discriminants, for example,the index formula 14“(6.7413)+(−0.0941)Asn+(0.0093)Gln+(−0.0666)Cit+(0.0561)Tyr+(−0.1268)Met+(−0.1224)Trp”having a set of explanatory variables “Asn, Gln, Cit, Tyr, Met, Trp”(the multivariate discriminant including Asn, Gln, Cit, Tyr, Met, Trp asexplanatory variables) has a good discriminating capability withROC_AUC(Validation)=0.862, ROC_AUC(No Validation)=0.876,sensitivity=0.861, and specificity=0.824. The sensitivity and thespecificity are the values when the maximum discriminate point, wherethe average of sensitivity and specificity is the highest, is a cutoffvalue.

The value of the formula can be calculated using the index formula 14 aswith Example 4, and each case can be classified using the calculatedvalue of the formula and a previously established cutoff value as withExample 4.

List (2) of Logistic Regression Equations Searched in Example 6 providedlater shows a list of logistic regression equations in which the ROC_AUCvalue for the pancreatic cancer group and the colorectal cancer groupwith validation is equal to or greater than 0.750 and the capability ofdiscriminating between the pancreatic cancer group and the healthy groupis also good. These logistic regression equations are thought to beuseful in evaluation of the state of pancreatic cancer withconsideration of both the healthy state and the state of colorectalcancer, because the ROC_AUC value is extremely high. When the amino acidexplanatory variables included in these logistic regression equationsare listed in the descending order of occurrence frequency from thehighest to the tenth, they are arranged in the following order: Trp,His, Gln, Phe, Met, Asn, Leu, Thr, Cit, Orn (see Table 4 above). Theconcentration values of these amino acids are thought to be useful inthe evaluation as with the formula because they are explanatoryvariables included in the formula thought to be useful in theevaluation. Among these logistic regression equations, for example, theindex formula 15“(4.0457)+(0.0070)Gln+(−0.0515)His+(0.0059)Thr+(−0.1935)Met+(0.0373)Phe+(−0.0815)Trp”having a set of explanatory variables “Gln, His, Thr, Met, Phe, Trp”(the multivariate discriminant including Gln, His, Thr, Met, Phe, Trp asexplanatory variables) has a good discriminating capability withROC_AUC(Validation)=0.822, ROC_AUC(No Validation)=0.849,sensitivity=0.762, and specificity=0.843. The sensitivity and thespecificity are the values when the maximum discriminate point, wherethe average of sensitivity and specificity is the highest, is a cutoffvalue.

The value of the formula can be calculated using the index formula 15 aswith Example 4, and each case can be classified using the calculatedvalue of the formula and a previously established cutoff value as withExample 4.

List (2) of Linear Discriminants Searched in Example 6 provided latershows a list of linear discriminants in which the ROC_AUC value for thepancreatic cancer group and the colorectal cancer group with validationis equal to or greater than 0.750 and the capability of discriminatingbetween the pancreatic cancer group and the healthy group is also good.These linear discriminants are thought to be useful in evaluation of thestate of pancreatic cancer with consideration of both the healthy stateand the state of colorectal cancer, because the ROC_AUC value isextremely high. When the amino acid explanatory variables included inthese linear discriminants are listed in the descending order ofoccurrence frequency from the highest to the tenth, they are arranged inthe following order: Trp, Phe, Met, His, Gln, Thr, Ser, Cit, Asn, Ile(see Table 4 above). The concentration values of these amino acids arethought to be useful in the evaluation as with the formula because theyare explanatory variables included in the formula thought to be usefulin the evaluation. Among these linear discriminants, for example, theindex formula 16“(4.7750)+(0.0066)Gln+(−0.0466)His+(0.0084)Thr+(−0.1967)Met+(0.0666)Phe+(−0.1057)Trp”having a set of explanatory variables “Gln, His, Thr, Met, Phe, Trp”(the multivariate discriminant including Gln, His, Thr, Met, Phe, Trp asexplanatory variables) has a good discriminating capability withROC_AUC(Validation)=0.835, ROC_AUC(No Validation)=0.856,sensitivity=0.730, specificity=0.882. The sensitivity and thespecificity are the values when the maximum discriminate point, wherethe average of sensitivity and specificity is the highest, is a cutoffvalue.

The value of the formula can be calculated using the index formula 16 aswith Example 4, and each case can be classified using the calculatedvalue of the formula and a previously established cutoff value as withExample 4.

Example 7

Among the sample data used in Example 1, only the sample data of malesis used. A multivariate discriminant (multivariate function) includingan explanatory variable to be substituted with the concentration valueof an amino acid in plasma is obtained for discriminating between twogroups: the pancreatic cancer group and the prostatic cancer group.

A logistic regression equation is used as a multivariate discriminant.The 19 kinds of amino acids are searched for a combination of six orless explanatory variables to be included in the logistic regressionequation. The Leave-One-Out method is employed as validation to explorea logistic regression equation having a good capability ofdiscriminating between the pancreatic cancer group and the prostaticcancer group.

The logistic regression equations where the ROC_AUC value for thepancreatic cancer group and the prostatic cancer group with validationis equal to or greater than 0.750 are shown later in List (1) ofLogistic Regression Equations Searched in Example 7. These logisticregression equations are thought to be useful in evaluation of the stateof pancreatic cancer with consideration of the state of prostatic cancerbecause the ROC_AUC value is extremely high. When the amino acidexplanatory variables included in these logistic regression equationsare listed in the descending order of occurrence frequency from thehighest to the tenth, they are arranged in the following order: Ile,Val, Ala, Ser, Met, Cit, Gln, Asn, Pro, Thr (see Table 5 below). Theseamino acids are thought to be useful in the evaluation as with theequations because they are explanatory variables included in theequations thought to be useful in the evaluation. For these logisticregression equations, the ROC_AUC value for the pancreatic cancer groupand the healthy group is equal to or greater than 0.816, and thecapability of discriminating between the pancreatic cancer group and thehealthy group is good. These logistic regression equations are thoughtto be useful in evaluation of the state of pancreatic cancer withadditional consideration of the healthy state, because the ROC_AUC valueis extremely high. Among these logistic regression equations, forexample, the index formula 17“(3.0499)+(0.0406)Ser+(−0.0121)Ala+(−0.0402)Val+(−0.1789)Met+(0.1361)Ile”having a set of explanatory variables “Ser, Ala, Val, Met, Ile” (themultivariate discriminant including Ser, Ala, Val, Met, Ile asexplanatory variables) has a good discriminating capability withROC_AUC(Validation)=0.877, ROC_AUC(No Validation)=0.907,sensitivity=0.828, specificity=0.903. The sensitivity and thespecificity are the values when the maximum discriminate point, wherethe average of sensitivity and specificity is highest, is a cutoffvalue.

TABLE 5 Pancreatic cancer group vs Prostatic cancer group Logisticregression equation Linear discriminant Prostatic Healthy ProstaticHealthy Amino acid Univariate cancer group group cancer group group Ser61 100 99 Asn O 23 15 Gly Gln 33 20 His O Thr O 17 30 15 Ala O 81 92 CitO 41 21 Arg O 15 8 15 Pro O 17 25 Tyr O 14 8 15 Val O 91 45 96 32 Met O54 100 41 100 Orn 14 Lys O 19 Ile 100 81 100 35 Leu O 9 14 Phe O 43 93Trp O 65 86 (O indicates the amino acid that varies significantly. Thenumeral indicates the frequency of occurrence of the amino acidexplanatory variable.)

The value of the formula can be calculated using the index formula 17 aswith Example 4, and each case can be classified using the calculatedvalue of the formula and a previously established cutoff value as withExample 4.

A linear discriminant is used as a multivariate discriminant. The 19kinds of amino acids are searched for a combination of six or lessexplanatory variables to be included in the linear discriminant, and thebootstrap method is employed as validation to explore a lineardiscriminant with a good capability of discriminating between thepancreatic cancer group and the prostatic cancer group.

A list of linear discriminants where the ROC_AUC value for thepancreatic cancer group and the prostatic cancer group with validationis equal to or greater than 0.750 is shown later in List (1) of LinearDiscriminants Searched in Example 7. These linear discriminants arethought to be useful in evaluation of the state of pancreatic cancerwith consideration of the state of prostatic cancer, because the ROC_AUCvalue is extremely high. When the amino acid explanatory variablesincluded in these linear discriminants are listed in the descendingorder of occurrence frequency from the highest to the tenth, they arearranged in the following order: Ile, Val, Ala, Met, Pro, Cit, Gln, Asn,Leu, Arg, Tyr, in total eleven (see Table 5 above). The concentrationvalues of these amino acids are thought to be useful in the evaluationas with the formula, because they are explanatory variables included inthe formula thought to be useful in the evaluation. As for these lineardiscriminants, the ROC_AUC value for the pancreatic cancer group and thehealthy group is equal to or greater than 0.818, and the capability ofdiscriminating between the pancreatic cancer group and the healthy groupis good. These linear discriminants are thought to be useful inevaluation of the state of pancreatic cancer with additionalconsideration of the healthy state, because the ROC_AUC value isextremely high. Among these linear discriminants, for example, the indexformula 18“(5.0859)+(0.0109)Gln+(−0.0171)Ala+(−0.0452)Cit+(−0.0389)Val+(−0.1548)Met+(0.1284)Ile”having a set of explanatory variables “Gln, Ala, Cit, Val, Met, Ile”(the multivariate discriminant including Gln, Ala, Cit, Val, Met, Ile asexplanatory variables) has a good discriminating capability withROC_AUC(Validation)=0.889, ROC_AUC(No Validation)=0.914,sensitivity=0.862, and specificity=0.871. The sensitivity and thespecificity are the values when the maximum discriminate point, wherethe average of sensitivity and specificity is the highest, is a cutoffvalue.

The value of the formula can be calculated using the index formula 18 aswith Example 4, and each case can be classified using the calculatedvalue of the formula and a previously established cutoff value as withExample 4.

List (2) of Logistic Regression Equations Searched in Example 7 providedlater shows a list of logistic regression equations in which the ROC_AUCvalue for the pancreatic cancer group and the prostatic cancer groupwith validation is equal to or greater than 0.750 and the capability ofdiscriminating between the pancreatic cancer group and the healthy groupis also good. These logistic regression equations are thought to beuseful in evaluation of the state of pancreatic cancer withconsideration of both the healthy state and the state of prostaticcancer, because the ROC_AUC value is extremely high. When the amino acidexplanatory variables included in these logistic regression equationsare listed in the descending order of occurrence frequency from thehighest to the tenth, they are arranged in the following order: Met,Ser, Ile, Trp, Val, Phe, Thr, Lys, Arg, Tyr (see Table 5 above). Theconcentration values of these amino acids are thought to be useful inthe evaluation as with the formula because they are explanatoryvariables included in the formula thought to be useful in theevaluation. Among these logistic regression equations, for example, theindex formula 19“(−0.4061)+(0.0399)Ser+(−0.2141)Met+(0.1298)Ile+(−0.0658)Leu+(0.0402)Phe+(−0.0539)Trp”having a set of explanatory variables “Ser, Met, Ile, Leu, Phe, Trp”(the multivariate discriminant including Ser, Met, Ile, Leu, Phe, Trp asexplanatory variables) has a good discriminating capability withROC_AUC(Validation)=0.787, ROC_AUC(No Validation)=0.856,sensitivity=0.851, and specificity=0.774. The sensitivity and thespecificity are the values when the maximum discriminate point, wherethe average of sensitivity and specificity is the highest, is a cutoffvalue.

The value of the formula can be calculated using the index formula 19 aswith Example 4, and each case can be classified using the calculatedvalue of the formula and a previously established cutoff value as withExample 4.

List (2) of Linear Discriminants Searched in Example 7 provided latershows a list of linear discriminants in which the ROC_AUC value for thepancreatic cancer group and the prostatic cancer group with validationis equal to or greater than 0.750 and the capability of discriminatingbetween the pancreatic cancer group and the healthy group is also good.These linear discriminants are thought to be useful in evaluation of thestate of pancreatic cancer with consideration of both the healthy stateand the state of prostatic cancer, because the ROC_AUC value isextremely high. When the amino acid explanatory variables included inthese linear discriminants are listed in the descending order ofoccurrence frequency from the highest to the tenth, they are arranged inthe following order: Met, Ser, Phe, Trp, Ile, Val, Tyr, Arg, Thr, Orn,Leu, in total eleven (see Table 5 above). The concentration values ofthese amino acids are thought to be useful in the evaluation as with theformula because they are explanatory variables included in the formulathought to be useful in the evaluation. Among these lineardiscriminants, for example, the index formula 20“(1.6394)+(0.0387)Ser+(−0.0455)Val+(−0.2545)Met+(0.1283)Ile+(0.0546)Phe+(−0.0299)Trp”having a set of explanatory variables “Ser, Val, Met, Ile, Phe, Trp”(the multivariate discriminant including Ser, Val, Met, Ile, Phe, Trp asexplanatory variables) has a good discriminating capability withROC_AUC(Validation)=0.859, ROC_AUC(No Validation)=0.885,sensitivity=0.908, specificity=0.742. The sensitivity and thespecificity are the values when the maximum discriminate point, wherethe average of sensitivity and specificity is the highest, is a cutoffvalue.

The value of the formula can be calculated using the index formula 20 aswith Example 4, and each case can be classified using the calculatedvalue of the formula and a previously established cutoff value as withExample 4.

Example 8

Among the sample data used in Example 1, only the sample data of femalesis used. A multivariate discriminant (multivariate function) includingan explanatory variable to be substituted with the concentration valueof an amino acid in plasma is obtained for discriminating between twogroups: the pancreatic cancer group and the breast cancer group.

A logistic regression equation is used as a multivariate discriminant.The 19 kinds of amino acids are searched for a combination of six orless explanatory variables to be included in the logistic regressionequation. The Leave-One-Out method is employed as validation to explorea logistic regression equation having a good capability ofdiscriminating between the pancreatic cancer group and the breast cancergroup.

The logistic regression equations where the ROC_AUC value for thepancreatic cancer group and the breast cancer group with validation isequal to or greater than 0.750 are shown later in List (1) of LogisticRegression Equations Searched in Example 8. These logistic regressionequations are thought to be useful in evaluation of the state ofpancreatic cancer with consideration of the state of breast cancerbecause the ROC_AUC value is extremely high. When the amino acidexplanatory variables included in these logistic regression equationsare listed in the descending order of occurrence frequency from thehighest to the tenth, they are arranged in the following order: Tyr,Trp, Gly, Ala, Asn, Lys, Met, Val, Orn, Leu (see Table 6 below).

These amino acids are thought to be useful in the evaluation as with theequations because they are explanatory variables included in theequations thought to be useful in the evaluation. For these logisticregression equations, the ROC_AUC value for the pancreatic cancer groupand the healthy group is equal to or greater than 0.796, and thecapability of discriminating between the pancreatic cancer group and thehealthy group is good. These logistic regression equations are thoughtto be useful in evaluation of the state of pancreatic cancer withadditional consideration of the healthy state, because the ROC_AUC valueis extremely high. Among these logistic regression equations, forexample, the index formula 21“(19.7721)+(−0.1860)Asn+(−0.0214)Gly+(−0.0294)Arg+(0.1519)Tyr+(−0.0325)Val+(−0.1932)Trp”having a set of explanatory variables “Asn, Gly, Arg, Tyr, Val, Trp”(the multivariate discriminant including Asn, Gly, Arg, Tyr, Val, Trp asexplanatory variables) has a good discriminating capability withROC_AUC(Validation)=0.945, ROC_AUC(No Validation)=0.965,sensitivity=0.851, specificity=1.000. The sensitivity and thespecificity are the values when the maximum discriminate point, wherethe average of sensitivity and specificity is highest, is a cutoffvalue.

TABLE 6 Pancreatic cancer group vs Breast cancer group Logisticregression equation Linear discriminant Breast Healthy Breast HealthyAmino acid Univariate cancer group group cancer group group Ser O Asn O48 55 Gly O 84 80 16 Gln 37 28 His O 100 14 98 Thr O Ala O 61 63 Cit 3431 Arg 60 69 Pro Tyr 100 33 100 23 Val O 26 26 Met O 30 32 Orn 17 18 LysO 32 30 27 31 Ile O 69 94 Leu 16 34 21 Phe 34 Trp O 100 94 100 100 (Oindicates the amino acid that varies significantly. The numeralindicates the frequency of occurrence of the amino acid explanatoryvariable.)

The value of the formula can be calculated using the index formula 21 aswith Example 4, and each case can be classified using the calculatedvalue of the formula and a previously established cutoff value as withExample 4.

A linear discriminant is used as a multivariate discriminant. The 19kinds of amino acids are searched for a combination of six or lessexplanatory variables to be included in the linear discriminant, and thebootstrap method is employed as validation to explore a lineardiscriminant with a good capability of discriminating between thepancreatic cancer group and the breast cancer group.

A list of linear discriminants where the ROC_AUC value for thepancreatic cancer group and the breast cancer group with validation isequal to or greater than 0.750 is shown later in List (1) of LinearDiscriminants Searched in Example 8. These linear discriminants arethought to be useful in evaluation of the state of pancreatic cancerwith consideration of the state of breast cancer, because the ROC_AUCvalue is extremely high. When the amino acid explanatory variablesincluded in these linear discriminants are listed in the descendingorder of occurrence frequency from the highest to the tenth, they arearranged in the following order: Tyr, Trp, Gly, Ala, Asn, Met, Lys, Val,Orn, His (see Table 6 above). The concentration values of these aminoacids are thought to be useful in the evaluation as with the formula,because they are explanatory variables included in the formula thoughtto be useful in the evaluation. As for these linear discriminants, theROC_AUC value for the pancreatic cancer group and the healthy group isequal to or greater than 0.800, and the capability of discriminatingbetween the pancreatic cancer group and the healthy group is good.

These linear discriminants are thought to be useful in evaluation of thestate of pancreatic cancer with additional consideration of the healthystate, because the ROC_AUC value is extremely high. Among these lineardiscriminants, for example, the index formula 22“(16.5080)+(−0.1847)Asn+(−0.0136)Gly+(0.1059)Tyr+(−0.0166)Val+(−0.0144)Lys+(−0.1261)Trp”having a set of explanatory variables “Asn, Gly, Tyr, Val, Lys, Trp”(the multivariate discriminant including Asn, Gly, Tyr, Val, Lys, Trp asexplanatory variables) has a good discriminating capability withROC_AUC(Validation)=0.947, ROC_AUC(No Validation)=0.963,sensitivity=0.851, and specificity=1.000. The sensitivity and thespecificity are the values when the maximum discriminate point, wherethe average of sensitivity and specificity is the highest, is a cutoffvalue.

The value of the formula can be calculated using the index formula 22 aswith Example 4, and each case can be classified using the calculatedvalue of the formula and a previously established cutoff value as withExample 4.

List (2) of Logistic Regression Equations Searched in Example 8 providedlater shows a list of logistic regression equations in which the ROC_AUCvalue for the pancreatic cancer group and the breast cancer group withvalidation is equal to or greater than 0.750 and the capability ofdiscriminating between the pancreatic cancer group and the healthy groupis also good. These logistic regression equations are thought to beuseful in evaluation of the state of pancreatic cancer withconsideration of both the healthy state and the state of breast cancer,because the ROC_AUC value is extremely high. When the amino acidexplanatory variables included in these logistic regression equationsare listed in the descending order of occurrence frequency from thehighest to the tenth, they are arranged in the following order: His,Trp, Ile, Arg, Gln, Phe, Cit, Leu, Tyr, Lys (see Table 6 above). Theconcentration values of these amino acids are thought to be useful inthe evaluation as with the formula because they are explanatoryvariables included in the formula thought to be useful in theevaluation. Among these logistic regression equations, for example, theindex formula 23“(9.6001)+(0.0010)Gln+(−0.1052)His+(−0.0386)Arg+(0.0762)Tyr+(0.0049)Ile+(−0.1257)Trp”having a set of explanatory variables “Gln, His, Arg, Tyr, Ile, Trp”(the multivariate discriminant including Gln, His, Arg, Tyr, Ile, Trp asexplanatory variables) has a good discriminating capability withROC_AUC(Validation)=0.878, ROC_AUC(No Validation)=0.923,sensitivity=0.876, and specificity=0.900. The sensitivity and thespecificity are the values when the maximum discriminate point, wherethe average of sensitivity and specificity is the highest, is a cutoffvalue.

The value of the formula can be calculated using the index formula 23 aswith Example 4, and each case can be classified using the calculatedvalue of the formula and a previously established cutoff value as withExample 4.

List (2) of Linear Discriminants Searched in Example 8 provided latershows a list of linear discriminants in which the ROC_AUC value for thepancreatic cancer group and the breast cancer group with validation isequal to or greater than 0.750 and the capability of discriminatingbetween the pancreatic cancer group and the healthy group is also good.These linear discriminants are thought to be useful in evaluation of thestate of pancreatic cancer with consideration of both the healthy stateand the state of breast cancer, because the ROC_AUC value is extremelyhigh. When the amino acid explanatory variables included in these lineardiscriminants are listed in the descending order of occurrence frequencyfrom the highest to the tenth, they are arranged in the following order:Trp, His, Ile, Arg, Lys, Cit, Gln, Tyr, Leu, Gly (see Table 6 above).The concentration values of these amino acids are thought to be usefulin the evaluation as with the formula because they are explanatoryvariables included in the formula thought to be useful in theevaluation. Among these linear discriminants, for example, the indexformula 24“(10.5615)+(0.0037)Gln+(−0.1087)His+(−0.0445)Arg+(0.0653)Tyr+(0.0380)Ile+(−0.1489)Trp”having a set of explanatory variables “Gln, His, Arg, Tyr, Ile, Trp”(the multivariate discriminant including Gln, His, Arg, Tyr, Ile, Trp asexplanatory variables) has a good discriminating capability withROC_AUC(Validation)=0.896, ROC_AUC(No Validation)=0.924,sensitivity=0.843, specificity=0.950. The sensitivity and thespecificity are the values when the maximum discriminate point, wherethe average of sensitivity and specificity is the highest, is a cutoffvalue.

The value of the formula can be calculated using the index formula 24 aswith Example 4, and each case can be classified using the calculatedvalue of the formula and a previously established cutoff value as withExample 4.

Example 9

The sample data used in Example 1 is used. First, the index formula 1obtained in Example 2 is established as the first formula, and each casein each group is classified either as positive (equivalent to thepancreatic cancer category) or as negative (equivalent to the healthycategory) using the amino acid concentration values of the pancreaticcancer group (51 cases), the healthy group (255 cases), and the othercancers group (780 cases), and the first formula. When the specificity(the percentage of cases in the healthy group correctly classified intothe healthy category) is 95%, the positive rate for each group is asfollows: 71% for the pancreatic cancer group (36 positive cases), 5% forthe healthy group (13 positive cases), and 22% for the other cancersgroup (170 cases).

The index formula 5 obtained in Example 4 is established as the secondformula, and each case in each group is classified either as positive(equivalent to the pancreatic cancer category) or as negative(equivalent to the other cancer category) using the amino acidconcentration values of the cases in each group found positive with theindex formula 1 (the pancreatic cancer group (36 cases), the healthygroup (13 cases), the other cancers group (170 cases)) and the secondformula. When the specificity (the percentage of cases in the othercancers group correctly classified into the other cancer category) is95%, the positive rate for each group is as follows: 33% (17 positivecases) for the pancreatic cancer group, 2% (4 positive cases) for thehealthy group, and 4% (32 cases) for the other cancers group. When thespecificity is 80%, the positive rate for each group is as follows: 59%(30 positive cases) for the pancreatic cancer group, 4% (9 positivecases) for the healthy group, and 10% (78 cases) for the other cancersgroup.

As described above, a plurality of formulae can be used to reduce thefalse positive rate for the other cancers group without noticeablyreducing the true positive rate for the pancreatic cancer group.

Based on the results described above, the cases that are positive withthe first formula and also positive with the second formula may beclassified into the pancreatic cancer category, and the other cases maybe classified into the pancreatic cancer-free category.

The cases that are positive with the first formula and also positivewith the second formula may be classified into the pancreatic cancercategory, the cases that are positive with the first formula andnegative with the second formula may be classified into the other cancercategory, and the cases that are negative with the first formula may beclassified into the healthy category. The case classified in thepancreatic cancer category may be established as rank C, which is acategory meaning that the possibility of having pancreatic cancer ishigh (for example, a category meaning that the possibility of havingpancreatic cancer is high and the possibility of having a cancer otherthan pancreatic cancer is not high), the case classified in the othercancer category may be established as rank B, which is a categorymeaning that the possibility of having pancreatic cancer is moderate(for example, a category meaning that the possibility of havingpancreatic cancer is moderate and the possibility of having a cancerother than pancreatic cancer is not low), and the case classified in thehealthy category may be established as rank A, which is a categorymeaning that the possibility of having pancreatic cancer is low.

With the index formula 1 established as the first formula, each case ineach group may be classified either as positive (equivalent to thepancreatic cancer category) or as negative (equivalent to the healthycategory), using the amino acid concentration values of the pancreaticcancer group (51 cases), the healthy group (255 cases), and the othercancers group (780 cases), and the first formula. In addition, with theindex formula 5 established as the second formula, each case in eachgroup may be classified either as positive (equivalent to the pancreaticcancer category) or as negative (equivalent to the other cancercategory), using the amino acid concentration values of the pancreaticcancer group (51 cases), the healthy group (255 cases), and the othercancers group (780 cases), and the second formula. Those classificationresults may be comprehensively considered to make a finalclassification.

List (1) of Logistic Regression Equations Searched in Example 2

The logistic regression equations searched in Example 2 above are listedbelow. Before each equation, “the value of ROC_AUC for the pancreaticcancer group and the healthy group with validation”, “the value ofROC_AUC for the pancreatic cancer group and the healthy group withoutvalidation”, “the value of ROC_AUC for the pancreatic cancer group andthe other cancers group”, “the value of ROC_AUC for the pancreaticcancer group and the lung cancer group”, “the value of ROC_AUC for thepancreatic cancer group and the colorectal cancer group”, “the value ofROC_AUC for the pancreatic cancer group and the prostatic cancer group”,“the value of ROC_AUC for the pancreatic cancer group and the breastcancer group”, and “the average value of the value of ROC_AUC for thepancreatic cancer group and the lung cancer group, the value of ROC_AUCfor the pancreatic cancer group and the colorectal cancer group, thevalue of ROC_AUC for the pancreatic cancer group and the prostaticcancer group, and the value of ROC_AUC for the pancreatic cancer groupand the breast cancer group” obtained for the equation are additionallylisted.

0.902, 0.923, 0.809, 0.790, 0.778, 0.870, 0.878, 0.829, (−1.3217)+(0.0545)Ser+(−0.0544)Val+(−0.3973)Met+(0.1922)Ile+(0.1506)Phe+(−0.1179)Trp; 0.900, 0.919, 0.800, 0.780, 0.815, 0.860, 0.7 77,0.808, (1.1114)+(0.0530)Ser+(−0.1384)His+(0.0420)Thr+(−0.3641)Met+(0.1993)Phe+(−0.1237)Trp; 0.899, 0.917, 0.812, 0.798, 0. 789,0.854, 0.864, 0.826, (2.2454)+(0.0452)Thr+(−0.0612)Val+(−0.4741)Met+(0.2021)Ile+(0.1569)Phe+(−0.1267)Trp; 0.894, 0.918, 0. 783,0.749, 0.760, 0.870, 0.859, 0.810, (−1.8219)+(0.0622)Ser+(−0.1003)His+(−0.0447)Val+(−0.4105)Met+(0.1701)Ile+(0.1621)Phe; 0.891,0.913, 0.825, 0.813, 0.822, 0.870, 0.830, 0.834,(−0.7646)+(0.0539)Ser+(0.0080)Gln+(−0.1367)His+(−0.2716)Met+(0.1766)Phe+(−0.1028)Trp; 0.891, 0.910, 0.793, 0.765, 0.776, 0.856, 0.858, 0.814, (2.3264)+(−0.0966)His+(0.0489)Thr+(−0.0552)Val+(−0.4896)Met+(0.1897)Ile+(0.1580)Phe; 0.890, 0.916, 0.807, 0.794, 0.791, 0.854,0.841, 0.820, (−1.8334)+(0.0536)Ser+(−0.3463)Met+(0.1735)Ile+(−0.0820)Leu+(0.1380)Phe+(−0.1330)Trp; 0.890, 0.912, 0.7 85,0.765, 0.749, 0.870, 0.849, 0.808, (−3.2110)+(0.0409)Ser+(0.0284)Thr+(−0.0697)Val+(−0.5814)Met+(0.2181)Ile+(0.1512)Phe; 0. 890,0.914, 0.791, 0.754, 0.794, 0.854, 0.836, 0.810, (−0.4856)+(0.0659)Ser+(−0.1214)His+(−0.2902)Met+(0.0720)Ile+(0.1503)Phe+(−0.1121)Trp;0.889, 0.910, 0.831, 0.819, 0.840, 0.854, 0.829, 0.83 5,(2.1791)+(0.0103)Gln+(−0.1446)His+(0.0467)Thr+(−0.3603)Met+(0.1795)Phe+(−0.1251)Trp; 0.888, 0.909, 0.797, 0.783, 0.752, 0. 872,0.876, 0.821, (−2.0528)+(0.0623)Ser+(−0.1191)Asn+(−0.0671)Val+(−0.3897)Met+(0.2086)Ile+(0.1559)Phe; 0.887, 0.911, 0.79 4, 0.768,0.802, 0.853, 0.801, 0.806, (0.2218)+(0.0663)Ser+(−0.1176)His+(0.0128)Pro+(−0.2882)Met+(0.1713)Phe+(−0.1063)Trp; 0. 885, 0.906,0.770, 0.736, 0.762, 0.850, 0.821, 0.792, (−2.1269)+(0.0641)Ser+(−0.1326)His+(−0.3520)Met+(0.1518)Ile+(−0.0632)Leu+(0.1622)Phe; 0.885, 0.904, 0.807, 0.790, 0.811, 0.859, 0.806, 0.81 6,(0.7826)+(0.0620)Ser+(−0.1170)His+(−0.2419)Met+(0.1752)Phe+(−0.1023)Trp; 0.885, 0.908, 0.812, 0.789, 0.821, 0.865, 0.815, 0. 822,(0.6585)+(0.0637)Ser+(−0.1191)His+(0.0234)Tyr+(−0.2771)Met+(0.1715)Phe+(−0.1085)Trp;0.884, 0.906, 0.805, 0.777, 0.785, 0.883, 0.862, 0.827,(2.1234)+(0.0509)Ser+(0.0590)Tyr+(−0.0488)Val+(−0.3619)Met+(0.1995)Ile+(−0.1244)Trp; 0.884, 0.905, 0.8 10,0.795, 0.815, 0.858, 0.807, 0.819, (1.0354)+(0.0642)Ser+(−0.0298)Asn+(−0.1127)His+(−0.2223)Met+(0.1737)Phe+(−0.1009)Trp; 0.884,0.909, 0.795, 0.777, 0.745, 0.877, 0.887, 0.821,(−3.0328)+(0.0510)Ser+(−0.0050)Ala+(−0.0625)Val+(−0.4487)Met+(0.2107)Ile+(0.1401)Phe;0.883, 0.907, 0.791, 0.769, 0.747, 0.865, 0.888, 0. 817,(−3.0576)+(0.0592)Ser+(−0.0056)Gly+(−0.0640)Val+(−0.4783)Met+(0.2055)Ile+(0.1405)Phe; 0.882, 0.903, 0.805, 0.787, 0.810, 0.855,0.804, 0.814, (0.7088)+(0.0622)Ser+(−0.1177)His+(0.0009)Ala+(−0.2474)Met+(0.1748)Phe+(−0.1026)Trp; 0.882, 0.906, 0.8 04,0.785, 0.812, 0.858, 0.803, 0.814, (0.7718)+(0.0609)Ser+(−0.1195)His+(−0.2422)Met+(0.0111)Orn+(0.1700)Phe+(−0.1017)Trp; 0. 882,0.905, 0.799, 0.771, 0.809, 0.852, 0.813, 0.811, (0.5016)+(0.0636)Ser+(−0.1239)His+(−0.2582)Met+(0.0196)Leu+(0.1610)Phe+(−0.1091)Trp;0.881, 0.904, 0.787, 0.767, 0.743, 0.868, 0.870, 0.81 2,(−3.2208)+(0.0511)Ser+(−0.0642)Val+(−0.4837)Met+(0.2047)Ile+(0.1423)Phe; 0.881, 0.904, 0.802, 0.772, 0.819, 0.829, 0.825, 0. 811,(4.6013)+(−0.1241)His+(0.0491)Thr+(−0.3361)Met+(0.0575)Ile+(0.1484)Phe+(−0.1339)Trp;0.881, 0.904, 0.805, 0.787, 0.811, 0.852, 0.806, 0.814,(0.5622)+(0.0605)Ser+(−0.1208)His+(−0.2627)Met+(0.0083)Lys+(0.1749)Phe+(−0.1088)Trp; 0.881, 0.906, 0.79 0, 0.769,0.755, 0.871, 0.860, 0.814, (−2.7772)+(0.0534)Ser+(−0.0583)Cit+(−0.0611)Val+(−0.4725)Met+(0.2025)Ile+(0.1483)Phe; 0. 881,0.903, 0.805, 0.784, 0.812, 0.856, 0.807, 0.815, (0.7259)+(0.0625)Ser+(−0.1217)His+(0.0048)Val+(−0.2448)Met+(0.1692)Phe+(−0.1064)Trp;0.881, 0.902, 0.798, 0.784, 0.760, 0.859, 0.869, 0.81 8,(1.4747)+(−0.0872)Asn+(0.0451)Thr+(−0.0745)Val+(−0.4746)Met+(0.2248)Ile+(0.1468)Phe; 0.880, 0.904, 0.810, 0.792, 0.812, 0. 857,0.817, 0.819,(0.8210)+(0.0648)Ser+(−0.0022)Gly+(−0.1140)His+(−0.2398)Met+(0.1738)Phe+(−0.1039)Trp;0.880, 0.905, 0.809, 0.792, 0.817, 0.858, 0.800, 0.817,(0.8548)+(0.0627)Ser+(−0.1030)His+(−0.0434)Cit+(−0.2268)Met+(0.1810)Phe+(−0.1120)Trp; 0. 880, 0.902,0.804, 0.783, 0.783, 0.880, 0.849, 0.824, (3.5594)+(0.0437)Ser+(−0.0504)Cit+(−0.0373)Val+(−0.2208)Met+(0.1758)Ile+(−0.1170)Trp;0.880, 0.901, 0.798, 0.783, 0.774, 0.878, 0.833, 0.81 7,(3.5083)+(0.0341)Ser+(0.0217)Thr+(−0.0447)Val+(−0.3282)Met+(0.1883)Ile+(−0.1110)Trp; 0.880, 0.900, 0.831, 0.825, 0.800, 0. 853,0.898, 0.844,(1.6131)+(0.0057)Gln+(−0.0525)Val+(−0.3431)Met+(0.1808)Ile+(0.1304)Phe+(−0.1173)Trp;0.880, 0.904, 0.789, 0.773, 0.750, 0.855, 0.866, 0.811,(1.3300)+(0.0530)Ser+(−0.1787)Asn+(−0.0502)Val+(0.1586)Ile+(0.1013)Phe+(−0.1205)Trp; 0.8 79, 0.903,0.784, 0.768, 0.742, 0.863, 0.861, 0.808, (−3.3275)+(0.0510)Ser+(−0.0566)Val+(−0.4745)Met+(0.2287)Ile+(−0.0295)Leu+(0.1461)Phe;0.879, 0.906, 0.789, 0.765, 0.751, 0.871, 0.874, 0.815,(−3.4771)+(0.0531)Ser+(0.0228)Tyr+(−0.0672)Val+(−0.5232)Met+(0.2117)Ile+(0.1378)Phe; 0.878, 0.897, 0.812, 0.796, 0.830, 0.83 2,0.800, 0.815, (5.1467)+(−0.1179)His+(0.0505)Thr+(−0.3103)Met+(0.1690)Phe+(−0.1253)Trp; 0.878, 0.903, 0.801, 0.777, 0.813, 0. 835,0.817, 0.811, (−1.3020)+(0.0581)Ser+(−0.0917)Cit+(−0.3118)Met+(0.0708)Ile+(0.1355)Phe+(−0.1702)Trp; 0.878, 0.905, 0.78 2, 0.763,0.741, 0.862, 0.860, 0.807, (−3.2369)+(0.0521)Ser+(0.0053)Pro+(−0.0643)Val+(−0.4981)Met+(0.1980)Ile+(0.1419)Phe; 0. 878, 0.904,0.807, 0.792, 0.812, 0.857, 0.802, 0.816, (0.8772)+(0.0632)Ser+(−0.1150)His+(−0.0075)Arg+(−0.2326)Met+(0.1756)Phe+(−0.1014)Trp;0.878, 0.898, 0.758, 0.725, 0.747, 0.823, 0.821, 0.77 9,(1.1231)+(0.0472)Ser+(−0.1274)His+(0.1065)Ile+(−0.0390)Leu+(0.1044)Phe+(−0.1281)Trp; 0.877, 0.903, 0.807, 0.797, 0.795, 0. 855,0.824, 0.818, (1.0488)+(0.0524)Ser+(−0.1170)Asn+(0.0077)Gln+(−0.1332)His+(0.1277)Phe+(−0.1078)Trp; 0.877, 0.900, 0.754, 0.707,0.768, 0.840, 0.783, 0.775, (−1.3972)+(0.0567)Ser+(−0.1699)His+(0.0295)Thr+(−0.4330)Met+(0.0672)Ile+(0.1506)Phe; 0.87 7, 0.904,0.782, 0.761, 0.740, 0.865, 0.866, 0.808, (−2.9436)+(0.0528)Ser+(−0.0012)Gln+(−0.0642)Val+(−0.4767)Met+(0.2056)Ile+(0.1425)Phe;0.877, 0.900, 0.812, 0.798, 0.791, 0.876, 0.848, 0.828,(6.5712)+(0.0336)Thr+(−0.0519)Cit+(−0.0438)Val+(−0.2732)Met+(0.1832)Ile+(−0.1144)Trp; 0.877, 0.903, 0.819, 0.801, 0.795, 0.8 49,0.894, 0.835,(4.9139)+(−0.0543)His+(−0.0452)Val+(−0.2526)Met+(0.1687)Ile+(0.1312)Phe+(−0.0958)Trp;0.877, 0.900, 0.797, 0.784, 0.755, 0.863, 0.875, 0.819,(0.3843)+(0.0393)Thr+(−0.0042)Ala+(−0.0697)Val+(−0.5055)Met+(0.2222)Ile+(0.1346)Phe; 0.8 77, 0.899,0.803, 0.787, 0.768, 0.879, 0.865, 0.824, (3.2446)+(0.0417)Ser+(−0.0046)Ala+(−0.0407)Val+(−0.2260)Met+(0.1885)Ile+(−0.1079)Trp;0.877, 0.896, 0.806, 0.783, 0.828, 0.827, 0.804, 0.81 1,(5.1385)+(−0.1262)His+(0.0512)Thr+(−0.3199)Met+(0.0154)Leu+(0.1582)Phe+(−0.1315)Trp; 0.877, 0.895, 0.811, 0.802, 0.778, 0. 873,0.862, 0.828,(6.3171)+(0.0318)Thr+(−0.0048)Ala+(−0.0466)Val+(−0.2706)Met+(0.1948)Ile+(−0.1108)Trp;0.877, 0.901, 0.770, 0.737, 0.753, 0.844, 0.841, 0.794,(1.5645)+(0.0502)Ser+(−0.1331)His+(−0.0071)Ala+(0.0682)Ile+(0.1022)Phe+(−0.1303)Trp; 0.8 77, 0.904,0.787, 0.767, 0.744, 0.867, 0.870, 0.812, (−3.2265)+(0.0513)Ser+(−0.0640)Val+(−0.4840)Met+(−0.0021)Orn+(0.2050)Ile+(0.1430)Phe;0.876, 0.899, 0.796, 0.776, 0.772, 0.871, 0.847, 0.817,(3.1391)+(0.0431)Ser+(0.0063)Pro+(−0.0420)Val+(−0.2707)Met+(0.1750)Ile+(−0.1119)Trp;0.876, 0.896, 0.800, 0.782, 0.782, 0.85 9, 0.843, 0.817,(7.1237)+(−0.0566)His+(0.0346)Thr+(−0.0375)Val+(−0.2613)Met+(0.1722)Ile+(−0.0947)Trp; 0.876, 0.900, 0.789, 0. 772,0.802, 0.820, 0.788, 0.796, (−1.7780)+(0.0469)Ser+(0.0220)Thr+(−0.4185)Met+(0.0601)Ile+(0.1200)Phe+(−0.1623)Trp; 0.876, 0.900,0.814, 0.814, 0.828, 0.840, 0.768, 0.812,(0.3731)+(0.0463)Ser+(−0.0799)Asn+(0.0272)Thr+(−0.3209)Met+(0.1461)Phe+(−0.1531)Trp; 0.876, 0.898, 0.813, 0.799, 0.830, 0.833, 0.801, 0.816, (5.1380)+(−0.1164)His+(0.0508)Thr+(−0.0016)Val+(−0.3109)Met+(0.1713)Phe+(−0.1240)Trp; 0.876, 0.898, 0.781, 0.748, 0.787, 0.859, 0. 796,0.798, (4.0210)+(0.0445)Ser+(−0.1021)His+(0.0220)Thr+(−0.2402)Met+(0.0941)Ile+(−0.1075)Trp; 0.876, 0.898, 0.804, 0.786, 0. 774,0.882, 0.856, 0.824, (3.7945)+(0.0469)Ser+(−0.0611)Asn+(−0.0421)Val+(−0.2051)Met+(0.1806)Ile+(−0.1024)Trp; 0.876, 0.899, 0.803,0.783, 0.772, 0.871, 0.868, 0.824,(3.1847)+(0.0513)Ser+(−0.0059)Gly+(−0.0407)Val+(−0.2496)Met+(0.1795)Ile+(−0.1110)Trp; 0.876, 0.898, 0.815, 0.806, 0.785, 0.847, 0.882, 0.830, (3.0411)+(0.0040)Gly+(−0.0542)Val+(−0.3097)Met+(0.1869)Ile+(0.1305)Phe+(−0.1123)Trp;0.876, 0.899, 0.777, 0.739, 0.777, 0.852, 0.825, 0.798,(−3.0222)+(0.0578)Ser+(0.0068)Gln+(−0.1683)His+(−0.3616)Met+(0.0626)Ile+(0.1415)Phe; 0.876, 0.900, 0.792, 0.772, 0.76 5,0.863, 0.851, 0.813, (0.6553)+(0.0436)Thr+(−0.0620)Cit+(−0.0694)Val+(−0.5305)Met+(0.2201)Ile+(0.1426)Phe; 0.875, 0.898, 0. 808,0.802, 0.833, 0.838, 0.750, 0.806, (0.0690)+(0.0437)Ser+(0.0320)Thr+(−0.0895)Cit+(−0.3650)Met+(0.1686)Phe+(−0.1704)Trp; 0.875,0.896, 0.820, 0.810, 0.789, 0.844, 0.895, 0.835,(3.7150)+(−0.0537)Val+(−0.2954)Met+(0.1852)Ile+(0.1259)Phe+(−0.1109)Trp; 0.875, 0.895, 0.789, 0.774, 0.751, 0.853, 0.860, 0.810,(0.1159)+(0.0397)Thr+(−0.0717)Val+(−0.5387)Met+(0.2196)Ile+(0.1380)P he;0.875, 0.898, 0.810, 0.795, 0.828, 0.831, 0.799, 0.813, (5.0416)+(0.0077)Asn+(−0.1194)His+(0.0503)Thr+(−0.3161)Met+(0.1699)Phe+(−0.1255)Trp;0.875, 0.899, 0.825, 0.817, 0.787, 0.854, 0.906, 0.841,(3.9291)+(−0.0044)Ala+(−0.0534)Val+(−0.2665)Met+(0.1920)Ile+(0.1248)Phe+(−0.1088)Trp; 0.875, 0.897, 0.794, 0.778, 0.7 63,0.875, 0.845, 0.815, (4.6063)+(0.0465)Ser+(−0.1092)Asn+(−0.0635)Cit+(−0.0374)Val+(0.1596)Ile+(−0.1266)Trp; 0.875, 0.899, 0.781,0.761, 0.783, 0.844, 0.786, 0.793,(2.7059)+(0.0543)Ser+(−0.1114)Asn+(−0.1258)His+(0.0185)Thr+(0.1304)Phe+(−0.1179)Trp; 0.875, 0.903, 0.785, 0.768, 0.746, 0.863, 0.855, 0.808, (−3.1220)+(0.0548)Ser+(−0.0162)Arg+(−0.0640)Val+(−0.4578)Met+(0.2053)Ile+(0.1464)Phe; 0.875, 0.898, 0.806, 0.793, 0.824, 0.832, 0.786,0.809, (4.7360)+(0.0034)Gly+(−0.1236)His+(0.0487)Thr+(−0.3151)Met+(0.1724)Phe+(−0.1208)Trp; 0.875, 0.904, 0.786, 0.767, 0.74 3,0.868, 0.870, 0.812, (−3.2133)+(0.0512)Ser+(−0.0641)Val+(−0.4828)Met+(−0.0003)Lys+(0.2046)Ile+(0.1423)Phe; 0.875, 0.895, 0. 798,0.781, 0.770, 0.873, 0.849, 0.818, (3.1269)+(0.0422)Ser+(−0.0412)Val+(−0.2543)Met+(0.1807)Ile+(−0.1110)Trp; 0.875, 0.895, 0.792,0.776, 0.753, 0.867, 0.864, 0.815,(3.8125)+(0.0350)Ser+(−0.0086)Ala+(−0.0759)Cit+(−0.0342)Val+(0.1732)Ile+(−0.1444)Trp; 0.875, 0.898, 0.808, 0.792, 0.825, 0.827, 0.799, 0.811, (5.0167)+(−0.1163)His+(0.0493)Thr+(0.0042)Pro+(−0.3173)Met+(0.1656)Phe+(−0.1257)Trp;0.874, 0.892, 0.811, 0.795, 0.789, 0.870, 0.856, 0.827,(5.8798)+(0.0306)Thr+(0.0275)Tyr+(−0.0494)Val+(−0.3312)Met+(0.1907)Ile+(−0.1191)Trp; 0.874, 0.898, 0.811, 0.797, 0.82 9,0.831, 0.799, 0.814, (5.1472)+(−0.1179)His+(0.0507)Thr+(−0.0017)Tyr+(−0.3085)Met+(0.1695)Phe+(−0.1249)Trp; 0.874, 0.898, 0. 788,0.761, 0.770, 0.865, 0.842, 0.810, (3.8623)+(0.0473)Ser+(−0.0629)His+(−0.0301)Val+(−0.2091)Met+(0.1648)Ile+(−0.0919)Tr p; 0.874,0.898, 0.792, 0.790, 0.806, 0.814, 0.751, 0.790, (−1.0344)+(0.0456)Ser+(0.0230)Thr+(0.0098)Pro+(−0.4138)Met+(0.1413)Phe+(−0.1577)Trp; 0.874, 0.895, 0.788, 0.774, 0.751, 0.854, 0.859, 0.809, (0.0531)+(0.0005)Gly+(0.0394)Thr+(−0.0716)Val+(−0.5394)Met+(0.2193)Ile+(0.1383)Phe; 0.874, 0.897, 0.812, 0.798, 0.830, 0. 831,0.801, 0.815,(5.1552)+(−0.1177)His+(0.0509)Thr+(−0.3113)Met+(−0.0016)Orn+(0.1700)Phe+(−0.1256)Trp;0.874, 0.896, 0.754, 0.722, 0.735, 0.823, 0.828, 0.777,(1.3999)+(0.0456)Ser+(−0.1187)His+(−0.0254)Val+(0.1124)Ile+(0.1002)Phe+(−0.1271)Trp; 0.8 74, 0.895,0.768, 0.727, 0.765, 0.852, 0.820, 0.791, (−1.5196)+(0.0660)Ser+(−0.1481)His+(−0.0042)Ala+(−0.3256)Met+(0.0732)Ile+(0.1382)Phe;0.873, 0.897, 0.812, 0.814, 0.827, 0.835, 0.756, 0.808,(−0.1619)+(0.0395)Ser+(0.0286)Thr+(−0.0081)Val+(−0.3801)Met+(0.1583)Phe+(−0.1520)Trp; 0.873, 0.895, 0.802, 0.787, 0.773, 0.8 76,0.850, 0.821, (3.6154)+(0.0371)Ser+(−0.0090)Ala+(−0.0871)Cit+(0.1770)Ile+(−0.0599)Leu+(−0.1475)Trp; 0.873, 0.897, 0.812, 0.798,0.829, 0.832, 0.800, 0.815, (5.1575)+(−0.1177)His+(0.0505)Thr+(−0.0002)Ala+(−0.3093)Met+(0.1691)Phe+(−0.1253)Trp; 0. 873, 0.896,0.799, 0.783, 0.771, 0.872, 0.851, 0.819, (3.0224)+(0.0410)Ser+(−0.0428)Val+(−0.2747)Met+(0.0061)Lys+(0.1815)Ile+(−0.1138)Trp;0.873, 0.891, 0.804, 0.793, 0.778, 0.865, 0.845, 0.82 0,(6.1068)+(0.0314)Thr+(−0.0472)Val+(−0.2968)Met+(0.1870)Ile+(−0.1123)Trp; 0.873, 0.897, 0.810, 0.795, 0.829, 0.825, 0.801, 0. 812,(4.9661)+(−0.1202)His+(0.0488)Thr+(−0.3182)Met+(0.0049)Lys+(0.1679)Phe+(−0.1273)Trp;0.873, 0.896, 0.821, 0.812, 0.790, 0.844, 0.896, 0.836,(3.8662)+(−0.0081)Asn+(−0.0538)Val+(−0.2881)Met+(0.1849)Ile+(0.1257)Phe+(−0.1096)Trp; 0.873, 0.897, 0.8 11,0.799, 0.833, 0.830, 0.787, 0.812, (5.5816)+(−0.1144)His+(0.0550)Thr+(−0.0157)Arg+(−0.3019)Met+(0.1705)Phe+(−0.1270)Trp; 0.873,0.896, 0.801, 0.784, 0.773, 0.874, 0.851, 0.821, (2.9282)+(0.0409)Ser+(0.0009)Gln+(−0.0410)Val+(−0.2589)Met+(0.1794)Ile+(−0.1121)Trp;0.873, 0.898, 0.818, 0.808, 0.788, 0.842, 0.891, 0.83 2,(3.7193)+(0.0050)Pro+(−0.0540)Val+(−0.3080)Met+(0.1806)Ile+(0.1269)Phe+(−0.1125)Trp; 0.873, 0.900, 0.837, 0.818, 0.833, 0. 859,0.882, 0.848,(2.0349)+(0.0121)Gln+(−0.1284)His+(−0.2378)Met+(0.0584)Ile+(0.1200)Phe+(−0.1165)Trp;0.873, 0.894, 0.802, 0.801, 0.821, 0.824, 0.749, 0.799,(−0.5508)+(0.0412)Ser+(0.0255)Thr+(−0.3787)Met+(0.1449)Phe+(−0.1587)Trp; 0.873, 0.894, 0.7 96,0.777, 0.771, 0.871, 0.843, 0.816, (3.1019)+(0.0405)Ser+(−0.0430)Val+(−0.2624)Met+(0.0147)Orn+(0.1798)Ile+(−0.1110)Trp; 0. 873,0.898, 0.769, 0.735, 0.765, 0.837, 0.822, 0.790, (1.7038)+(0.0588)Ser+(−0.0844)Asn+(−0.1247)His+(0.0537)Ile+(0.1038)Phe+(−0.1227)Trp;0.872, 0.895, 0.789, 0.774, 0.751, 0.853, 0.860, 0.80 9,(0.1187)+(0.0392)Thr+(−0.0702)Val+(−0.5356)Met+(0.2227)Ile+(−0.0048)Leu+(0.1384)Phe; 0.872, 0.897, 0.808, 0.807, 0.808, 0. 826,0.795, 0.809,(−0.3872)+(0.0586)Ser+(−0.0695)Asn+(0.0110)Pro+(−0.2845)Met+(0.1316)Phe+(−0.1409)Trp

List (1) of Linear Discriminants Searched in Example 2

The linear discriminants searched in Example 2 above are listed below.Before each equation, “the value of ROC_AUC for the pancreatic cancergroup and the healthy group with validation”, “the value of ROC_AUC forthe pancreatic cancer group and the healthy group without validation”,“the value of ROC_AUC for the pancreatic cancer group and the othercancers group”, “the value of ROC_AUC for the pancreatic cancer groupand the lung cancer group”, “the value of ROC_AUC for the pancreaticcancer group and the colorectal cancer group”, “the value of ROC_AUC forthe pancreatic cancer group and the prostatic cancer group”, “the valueof ROC_AUC for the pancreatic cancer group and the breast cancer group”,and “the average value of the value of ROC_AUC for the pancreatic cancergroup and the lung cancer group, the value of ROC_AUC for the pancreaticcancer group and the colorectal cancer group, the value of ROC_AUC forthe pancreatic cancer group and the prostatic cancer group, and thevalue of ROC_AUC for the pancreatic cancer group and the breast cancergroup” obtained for the equation are additionally listed.

0.912, 0.926, 0.816, 0.798, 0.795, 0.864, 0.874, 0.833, (−1.0207)+(0.0564)Ser+(−0.0410)Val+(−0.4144)Met+(0.1407)Ile+(0.1786)Phe+(−0.1154)Trp; 0.910, 0.923, 0.800, 0.780, 0.816, 0.856, 0.7 76,0.807, (1.2502)+(0.0519)Ser+(−0.1044)His+(0.0391)Thr+(−0.3808)Met+(0.2058)Phe+(−0.1332)Trp; 0.906, 0.919, 0.815, 0.803, 0. 802,0.853, 0.847, 0.826, (2.7689)+(0.0555)Thr+(−0.0511)Val+(−0.5140)Met+(0.1555)Ile+(0.1792)Phe+(−0.1223)Trp; 0.904, 0.920, 0. 812,0.798, 0.800, 0.846, 0.847, 0.823, (−1.2604)+(0.0530)Ser+(−0.3551)Met+(0.1373)Ile+(−0.0676)Leu+(0.1759)Phe+(−0.1399)Trp; 0.903,0.919, 0.782, 0.749, 0.760, 0.870, 0.853, 0.808,(−1.6453)+(0.0604)Ser+(−0.0790)His+(−0.0373)Val+(−0.4011)Met+(0.1385)Ile+(0.1636)Phe; 0.902, 0.918, 0.796, 0.762, 0.801, 0.856, 0.831, 0.813, (−0.1304)+(0.0660)Ser+(−0.0940)His+(−0.3073)Met+(0.0543)Ile+(0.1677)Phe+(−0.1190)Trp; 0.901, 0.917, 0.781, 0.760, 0.75 3,0.860, 0.839, 0.803, (−2.7861)+(0.0400)Ser+(0.0326)Thr+(−0.0608)Val+(−0.5850)Met+(0.1830)Ile+(0.1702)Phe; 0.900, 0.914, 0. 824,0.813, 0.821, 0.868, 0.828, 0.833, (−0.3399)+(0.0555)Ser+(0.0065)Gln+(−0.0993)His+(−0.2838)Met+(0.1822)Phe+(−0.1212)Tr p; 0.898,0.912, 0.789, 0.763, 0.776, 0.851, 0.839, 0.807,(2.3150)+(−0.0751)His+(0.0555)Thr+(−0.0488)Val+(−0.4979)Met+(0.1558)Ile+(0.1591)Phe; 0.897, 0.911, 0.828, 0.820, 0.837, 0.842, 0.822, 0.830, (2.6477)+(0.0093)Gln+(−0.1101)His+(0.0480)Thr+(−0.3592)Met+(0.1701)Phe+(−0.1325)Trp; 0.896, 0.909, 0.814, 0.800, 0.818, 0.858,0.809, 0.821, (1.4707)+(0.0650)Ser+(−0.0399)Asn+(−0.0828)His+(−0.2276)Met+(0.1831)Phe+(−0.1217)Trp; 0.895, 0.908, 0.8 07,0.791, 0.813, 0.856, 0.804, 0.816, (1.0068)+(0.0630)Ser+(−0.0875)His+(−0.2579)Met+(0.1830)Phe+(−0.1207)Trp; 0.895, 0.911, 0. 813,0.791, 0.824, 0.864, 0.814, 0.823, (0.7601)+(0.0642)Ser+(−0.0885)His+(0.0236)Tyr+(−0.2880)Met+(0.1795)Phe+(−0.1278)Trp; 0.895,0.911, 0.812, 0.801, 0.783, 0.855, 0.870, 0.827, (2.8531)+(0.0444)Ser+(−0.1615)Asn+(−0.0336)Val+(0.0949)Ile+(0.1195)Phe+(−0.1303)Trp;0.895, 0.910, 0.798, 0.781, 0.751, 0.878, 0.886, 0.82 4,(−2.2067)+(0.0513)Ser+(−0.0059)Ala+(−0.0514)Val+(−0.4276)Met+(0.1741)Ile+(0.1473)Phe; 0.895, 0.911, 0.801, 0.780, 0.808, 0. 853,0.805, 0.812, (0.6315)+(0.0639)Ser+(−0.0888)His+(0.0082)Pro+(−0.2857)Met+(0.1818)Phe+(−0.1202)Trp; 0.894, 0.912, 0.798, 0.783,0.758, 0.867, 0.869, 0.819, (−1.5328)+(0.0563)Ser+(−0.0818)Asn+(−0.0541)Val+(−0.3937)Met+(0.1667)Ile+(0.1569)Phe; 0.8 94, 0.909,0.811, 0.796, 0.817, 0.858, 0.802, 0.818, (1.1779)+(0.0634)Ser+(−0.0818)His+(−0.0228)Cit+(−0.2535)Met+(0.1837)Phe+(−0.1223)Trp;0.894, 0.908, 0.808, 0.792, 0.813, 0.856, 0.804, 0.81 6,(1.0402)+(0.0632)Ser+(−0.0871)His+(−0.2558)Met+(−0.0009)Lys+(0.1834)Phe+(−0.1204)Trp; 0.893, 0.908, 0.806, 0.789, 0.813, 0. 852,0.800, 0.814, (0.9480)+(0.0631)Ser+(−0.0881)His+(0.0006)Ala+(−0.2617)Met+(0.1834)Phe+(−0.1213)Trp; 0.893, 0.909, 0.800, 0.777,0.808, 0.853, 0.807, 0.811, (0.7256)+(0.0651)Ser+(−0.0952)His+(−0.2689)Met+(0.0129)Leu+(0.1735)Phe+(−0.1209)Trp; 0.8 93, 0.908,0.806, 0.788, 0.813, 0.856, 0.804, 0.815, (0.9375)+(0.0634)Ser+(−0.0899)His+(0.0018)Val+(−0.2577)Met+(0.1809)Phe+(−0.1216)Trp;0.893, 0.908, 0.811, 0.795, 0.815, 0.855, 0.815, 0.820,(1.1251)+(0.0658)Ser+(−0.0023)Gly+(−0.0856)His+(−0.2575)Met+(0.1816)Phe+(−0.1211)Trp; 0.892, 0.909, 0.791, 0.767, 0.752, 0.8 60,0.887, 0.816, (−2.4043)+(0.0586)Ser+(−0.0057)Gly+(−0.0530)Val+(−0.4602)Met+(0.1686)Ile+(0.1487)Phe; 0.892, 0.908, 0.815, 0.804,0.804, 0.854, 0.838, 0.825, (2.1627)+(0.0471)Ser+(−0.1168)Asn+(0.0059)Gln+(−0.0954)His+(0.1334)Phe+(−0.1287)Trp; 0.8 92, 0.907,0.784, 0.762, 0.748, 0.860, 0.860, 0.807, (−2.7343)+(0.0512)Ser+(−0.0535)Val+(−0.4634)Met+(0.1686)Ile+(0.1515)Phe; 0. 892,0.908, 0.784, 0.764, 0.748, 0.860, 0.857, 0.807, (−2.7747)+(0.0506)Ser+(−0.0498)Val+(−0.4593)Met+(0.1763)Ile+(−0.0120)Leu+(0.1538)Phe; 0.892, 0.908, 0.808, 0.793, 0.814, 0.856, 0.801, 0.81 6,(1.0417)+(0.0637)Ser+(−0.0871)His+(−0.0031)Arg+(−0.2535)Met+(0.1829)Phe+(−0.1201)Trp; 0.891, 0.909, 0.805, 0.788, 0.811, 0. 856,0.802, 0.814,(0.8987)+(0.0622)Ser+(−0.0896)His+(−0.2581)Met+(0.0100)Orn+(0.1790)Phe+(−0.1200)Trp;0.890, 0.908, 0.781, 0.760, 0.746, 0.858, 0.858, 0.805,(−2.7988)+(0.0513)Ser+(0.0023)Pro+(−0.0534)Val+(−0.4692)Met+(0.1662)Ile+(0.1516)Phe; 0.8 89, 0.908,0.785, 0.761, 0.753, 0.863, 0.857, 0.809, (−2.4869)+(0.0531)Ser+(−0.0401)Cit+(−0.0510)Val+(−0.4534)Met+(0.1694)Ile+(0.1506)Phe;0.889, 0.909, 0.785, 0.760, 0.752, 0.865, 0.865, 0.810,(−2.9300)+(0.0517)Ser+(0.0129)Tyr+(−0.0546)Val+(−0.4830)Met+(0.1714)Ile+(0.1491)Phe; 0.888, 0.906, 0.780, 0.758, 0.745, 0.85 8,0.859, 0.805, (−2.4649)+(0.0528)Ser+(−0.0012)Gln+(−0.0535)Val+(−0.4582)Met+(0.1693)Ile+(0.1524)Phe; 0.888, 0.906, 0.785, 0. 765,0.747, 0.859, 0.862, 0.808,(−2.7176)+(0.0518)Ser+(−0.0532)Val+(−0.4646)Met+(−0.0055)Orn+(0.1704)Ile+(0.1529)Phe;0.888, 0.903, 0.799, 0.788, 0.760, 0.864, 0.864, 0.819,(1.2361)+(0.0468)Thr+(−0.0057)Ala+(−0.0605)Val+(−0.5055)Met+(0.1871)Ile+(0.1435)Phe; 0.887, 0.903, 0.799, 0.785, 0.770, 0.856, 0.854, 0.816, (2.0233)+(−0.0687)Asn+(0.0503)Thr+(−0.0636)Val+(−0.4866)Met+(0.1810)Ile+(0.1515)Phe; 0.887, 0.903, 0.810, 0.804, 0.789, 0.834, 0. 849,0.819, (2.1560)+(0.0423)Ser+(−0.1386)Asn+(0.1029)Ile+(−0.0610)Leu+(0.1253)Phe+(−0.1484)Trp; 0.887, 0.904, 0.814, 0.790, 0. 798,0.885, 0.861, 0.834, (3.2556)+(0.0393)Ser+(0.0476)Tyr+(−0.0321)Val+(−0.3074)Met+(0.1395)Ile+(−0.0999)Trp; 0.887, 0.905, 0.802,0.781, 0.813, 0.833, 0.812, 0.810,(−0.7602)+(0.0589)Ser+(−0.0644)Cit+(−0.3340)Met+(0.0567)Ile+(0.1461)Phe+(−0.1536)Trp;0.887, 0.904, 0.766, 0.728, 0.761, 0.848, 0.817, 0.788, (−1.8629)+(0.0597)Ser+(−0.1027)His+(−0.3399)Met+(0.1177)Ile+(−0.0470)Leu+(0.1542)Phe; 0.887, 0.907, 0.784, 0.763, 0.750, 0.861, 0.85 5,0.807, (−2.5250)+(0.0533)Ser+(−0.0519)Val+(−0.4475)Met+(−0.0066)Lys+(0.1685)Ile+(0.1528)Phe; 0.887, 0.903, 0.795, 0.767, 0. 815,0.822, 0.807, 0.803, (4.6094)+(−0.0974)His+(0.0547)Thr+(−0.3593)Met+(0.0451)Ile+(0.1510)Phe+(−0.1313)Trp; 0.887, 0.901, 0. 806,0.803, 0.819, 0.831, 0.769, 0.806, (0.8909)+(0.0495)Ser+(−0.0804)Asn+(0.0274)Thr+(−0.3250)Met+(0.1731)Phe+(−0.1660)Trp; 0.887,0.902, 0.804, 0.791, 0.784, 0.886, 0.823, 0.821, (4.4196)+(0.0274)Ser+(0.0224)Thr+(−0.0324)Val+(−0.3009)Met+(0.1397)Ile+(−0.0907)Trp;0.886, 0.905, 0.844, 0.843, 0.816, 0.856, 0.897, 0.85 3,(2.0355)+(0.0066)Gln+(−0.0397)Val+(−0.3168)Met+(0.1284)Ile+(0.1311)Phe+(−0.1090)Trp; 0.886, 0.900, 0.804, 0.806, 0.818, 0. 825,0.758, 0.802, (0.4259)+(0.0430)Ser+(0.0297)Thr+(−0.0105)Val+(−0.3931)Met+(0.1880)Phe+(−0.1582)Trp; 0.886, 0.899, 0.796, 0.778,0.794, 0.846, 0.812, 0.808, (3.1351)+(0.0540)Ser+(−0.1002)Asn+(−0.0861)His+(0.1369)Phe+(−0.1276)Trp; 0.886, 0.902, 0.8 09,0.789, 0.793, 0.883, 0.841, 0.827, (4.2488)+(0.0388)Ser+(−0.0459)Cit+(−0.0260)Val+(−0.2229)Met+(0.1326)Ile+(−0.0884)Trp; 0.885,0.901, 0.787, 0.767, 0.767, 0.855, 0.831, 0.805, (1.0928)+(0.0508)Thr+(−0.0475)Cit+(−0.0603)Val+(−0.5411)Met+(0.1843)Ile+(0.1481)Phe; 0.885, 0.902, 0.803, 0.795, 0.827, 0.833, 0.749, 0.80 1,(0.5012)+(0.0459)Ser+(0.0317)Thr+(−0.0619)Cit+(−0.3861)Met+(0.1783)Phe+(−0.1682)Trp; 0.885, 0.903, 0.778, 0.748, 0.758, 0. 852,0.842, 0.800,(2.1169)+(0.0446)Ser+(−0.1004)His+(−0.0073)Ala+(0.0451)Ile+(0.1020)Phe+(−0.1174)Trp;0.885, 0.898, 0.786, 0.772, 0.756, 0.849, 0.842, 0.805,(0.7111)+(0.0469)Thr+(−0.062 5)Val+(−0.5409)Met+(0.1818)Ile+(0.1477)Phe;0.885, 0.905, 0.78 3, 0.764, 0.750, 0.858, 0.849, 0.805,(−2.5667)+(0.0542)Ser+(−0.0117)Arg+(−0.0530)Val+(−0.4456)Met+(0.1685)Ile+(0.1517)Phe; 0. 885,0.902, 0.793, 0.775, 0.794, 0.844, 0.803, 0.804, (3.5394)+(0.0482)Ser+(−0.1125)Asn+(−0.0924)His+(0.0136)Thr+(0.1363)Phe+(−0.1331)Trp;0.885, 0.901, 0.813, 0.800, 0.800, 0.883, 0.826, 0.82 7,(6.9234)+(0.0383)Thr+(−0.0519)Cit+(−0.0325)Val+(−0.2896)Met+(0.1428)Ile+(−0.0934)Trp; 0.885, 0.902, 0.787, 0.769, 0.803, 0. 816,0.782, 0.793, (−1.1723)+(0.0475)Ser+(0.0242)Thr+(−0.4228)Met+(0.0442)Ile+(0.1547)Phe+(−0.1668)Trp; 0.885, 0.900, 0.788, 0.782,0.805, 0.809, 0.754, 0.788, (−0.4771)+(0.0461)Ser+(0.0245)Thr+(0.0063)Pro+(−0.4030)Met+(0.1676)Phe+(−0.1663)Trp; 0.8 84, 0.898,0.786, 0.772, 0.756, 0.850, 0.842, 0.805, (0.7556)+(−0.0003)Gly+(0.0471)Thr+(−0.0625)Val+(−0.5408)Met+(0.1819)Ile+(0.1475)Phe;0.884, 0.901, 0.762, 0.726, 0.760, 0.832, 0.808, 0.782,(2.0817)+(0.0488)Ser+(−0.1010)His+(−0.0148)Lys+(0.0398)Ile+(0.1108)Phe+(−0.1212)Trp;0.884, 0.901, 0.786, 0.772, 0.761, 0.84 9, 0.828, 0.803,(1.1646)+(0.0531)Thr+(−0.0168)Arg+(−0.0631)Val+(−0.5324)Met+(0.1839)Ile+(0.1497)Phe; 0.884, 0.900, 0.785, 0. 772,0.756, 0.842, 0.843, 0.803, (0.8173)+(0.0536)Thr+(−0.0628)Val+(−0.5701)Met+(−0.0240)Orn+(0.1923)Ile+(0.1576)Phe; 0.884, 0.900,0.807, 0.800, 0.807, 0.814, 0.821, 0.811,(2.6359)+(0.0383)Thr+(−0.3763)Met+(0.1339)Ile+(−0.0707)Leu+(0.1592)Phe+(−0.1470)Trp; 0.884, 0.901, 0.844, 0.832, 0.839, 0.854, 0.880, 0.851, (2.0499)+(0.0118)Gln+(−0.0940)His+(−0.2274)Met+(0.0420)Ile+(0.1165)Phe+(−0.1146)Trp; 0.884, 0.900, 0.765, 0.736, 0.756, 0.822, 0. 820,0.783, (1.7752)+(0.0391)Ser+(−0.0937)His+(0.0719)Ile+(−0.0325)Leu+(0.1113)Phe+(−0.1251)Trp; 0.884, 0.898, 0.804, 0.790, 0. 826,0.817, 0.786, 0.805, (5.3455)+(−0.0929)His+(0.0545)Thr+(−0.3233)Met+(0.1661)Phe+(−0.1329)Trp; 0.884, 0.899, 0.788, 0.775, 0. 757,0.849, 0.843, 0.806, (0.4472)+(0.0008)Gln+(0.0460)Thr+(−0.0623)Val+(−0.5433)Met+(0.1812)Ile+(0.1473)Phe; 0.883, 0.899, 0. 804,0.789, 0.796, 0.857, 0.820, 0.816, (3.2583)+(0.0541)Ser+(−0.0948)Asn+(−0.0836)His+(−0.0025)Ala+(0.1386)Phe+(−0.1244)Tr p; 0.883,0.901, 0.784, 0.757, 0.780, 0.839, 0.824, 0.800,(2.6411)+(0.0537)Ser+(−0.1017)Asn+(−0.0912)His+(0.0314)Ile+(0.1210)Phe+(−0.1273)Trp; 0.883, 0.900, 0.797, 0.782, 0.795, 0.846, 0.809, 0.808, (3.2209)+(0.0557)Ser+(−0.0944)Asn+(−0.0840)His+(−0.0055)Lys+(0.1410)Phe+(−0.1256)Trp; 0.883, 0.899, 0.798, 0.782, 0.79 4,0.848, 0.812, 0.809, (3.1873)+(0.0539)Ser+(−0.1013)Asn+(−0.0845)His+(−0.0011)Val+(0.1384)Phe+(−0.1271)Trp; 0.883, 0.899, 0. 814,0.800, 0.780, 0.890, 0.869, 0.835, (4.1970)+(0.0368)Ser+(−0.0056)Ala+(−0.0282)Val+(−0.2090)Met+(0.1393)Ile+(−0.0803)Tr p; 0.883,0.898, 0.794, 0.776, 0.791, 0.844, 0.811, 0.806,(3.0890)+(0.0538)Ser+(−0.1016)Asn+(−0.0866)His+(0.0020)Pro+(0.1351)Phe+(−0.1277)Trp; 0.883, 0.898, 0.798, 0.782, 0.819, 0.815, 0.786, 0.800, (5.1658)+(−0.0933)His+(0.0540)Thr+(0.0051)Pro+(−0.3376)Met+(0.1643)Phe+(−0.1324)Trp; 0.883, 0.900, 0.762, 0.729, 0.754, 0.826,0.821, 0.782, (1.9680)+(0.0396)Ser+(−0.0956)His+(−0.0123)Val+(0.0554)Ile+(0.1032)Phe+(−0.1204)Trp; 0.883, 0.898, 0.78 4, 0.757,0.792, 0.862, 0.785, 0.799, (5.0116)+(0.0365)Ser+(−0.0816)His+(0.0226)Thr+(−0.2202)Met+(0.0714)Ile+(−0.0924)Trp; 0. 883, 0.901,0.792, 0.773, 0.791, 0.847, 0.806, 0.804, (3.0109)+(0.0532)Ser+(−0.1029)Asn+(−0.0884)His+(0.0136)Orn+(0.1319)Phe+(−0.1267)Trp;0.883, 0.900, 0.786, 0.770, 0.757, 0.851, 0.841, 0.80 5,(1.0460)+(0.0493)Thr+(−0.0614)Val+(−0.5303)Met+(−0.0066)Lys+(0.1825)Ile+(0.1493)Phe; 0.883, 0.903, 0.829, 0.818, 0.807, 0. 849,0.892, 0.842, (5.0397)+(−0.0326)His+(−0.0343)Val+(−0.2336)Met+(0.1210)Ile+(0.1267)Phe+(−0.0933)Trp; 0.882, 0.899, 0.78 5, 0.773,0.754, 0.849, 0.837, 0.803, (0.7801)+(0.0474)Thr+(−0.0075)Tyr+(−0.0620)Val+(−0.5326)Met+(0.1806)Ile+(0.1498)Phe; 0. 882, 0.898,0.786, 0.772, 0.756, 0.849, 0.842, 0.805, (0.7094)+(0.0469)Thr+(0.0001)Pro+(−0.0625)Val+(−0.5411)Met+(0.1817)Ile+(0.1477)Phe;0.882, 0.899, 0.786, 0.771, 0.756, 0.849, 0.842, 0.805,(0.7287)+(0.0475)Thr+(−0.0642)Val+(−0.5450)Met+(0.1789)Ile+(0.0050)Leu+(0.1471)Phe;0.882, 0.899, 0.805, 0.789, 0.807, 0.829, 0.823, 0.812,(−0.2954)+(0.0595)Ser+(−0.0653)Asn+(−0.2876)Met+(0.0433)Ile+(0.1463)Phe+(−0.1537)Trp; 0.882, 0.900, 0.819, 0.8 14,0.793, 0.847, 0.868, 0.830, (3.2539)+(0.0061)Gly+(−0.0409)Val+(−0.2897)Met+(0.1335)Ile+(0.1368)Phe+(−0.1032)Trp; 0.882, 0. 898,0.798, 0.780, 0.795, 0.846, 0.817, 0.809, (3.2007)+(0.0557)Ser+(−0.0993)Asn+(−0.0015)Gly+(−0.0850)His+(0.1359)Phe+(−0.12 79)Trp;0.882, 0.900, 0.741, 0.695, 0.759, 0.833, 0.763, 0.762, (−1.5427)+(0.0550)Ser+(−0.1392)His+(0.0297)Thr+(−0.4182)Met+(0.0553)Ile+(0.1512)Phe; 0.882, 0.895, 0.805, 0.788, 0.782, 0.876, 0. 844,0.823, (3.9518)+(0.0364)Ser+(−0.0291)Val+(−0.2346)Met+(0.1321)Ile+(−0.0863)Trp; 0.882, 0.896, 0.757, 0.720, 0.757, 0.824, 0. 805,0.776, (1.8875)+(0.0428)Ser+(−0.1075)His+(0.0302)Ile+(0.1017)Phe+(−0.1267)Trp; 0.882, 0.897, 0.821, 0.819, 0.827, 0.839, 0. 801,0.821,(1.3070)+(0.0603)Ser+(−0.0728)Asn+(−0.0484)Cit+(−0.2247)Met+(0.1651)Phe+(−0.1517)Trp;0.882, 0.896, 0.808, 0.803, 0.811, 0.825, 0.804, 0.811,(0.4379)+(0.0587)Ser+(−0.0718)Asn+(0.0068)Pro+(−0.2643)Met+(0.1589)Phe+(−0.1529)Trp;0.882, 0.8 98, 0.811, 0.798, 0.786, 0.876, 0.849, 0.827,(5.8199)+(0.0366)Ser+(−0.1098)Asn+(−0.0498)Cit+(−0.0238)Val+(0.1071)Ile+(−0.102 3)Trp;0.882, 0.896, 0.794, 0.791, 0.813, 0.811, 0.753, 0.792, (−0.1750)+(0.0452)Ser+(0.0255)Thr+(−0.3843)Met+(0.1693)Phe+(−0.1 668)Trp;0.882, 0.899, 0.797, 0.784, 0.820, 0.822, 0.766, 0.798, (4.7434)+(0.0043)Gly+(−0.0969)His+(0.0516)Thr+(−0.3247)Met+(0.1714)Phe+(−0.1316)Trp; 0.882, 0.899, 0.793, 0.774, 0.792, 0.844, 0. 812,0.805, (3.0641)+(0.0543)Ser+(−0.0998)Asn+(−0.0887)His+(0.0040)Leu+(0.1330)Phe+(−0.1277)Trp; 0.882, 0.898, 0.805, 0.791, 0. 826,0.821, 0.786, 0.806, (5.4643)+(−0.0922)His+(0.0554)Thr+(−0.3198)Met+(−0.0024)Lys+(0.1671)Phe+(−0.1324)Trp; 0.882, 0.896, 0.804,0.790, 0.791, 0.865, 0.823, 0.817,(7.3957)+(−0.0482)His+(0.0382)Thr+(−0.0270)Val+(−0.2600)Met+(0.1258)Ile+(−0.0800)Trp; 0.881, 0.895, 0.817, 0.809, 0.786, 0.885, 0.853, 0.834, (6.6887)+(0.0341)Thr+(−0.0054)Ala+(−0.0345)Val+(−0.2668)Met+(0.1478)Ile+(−0.0845)Trp; 0.881, 0.897, 0.798, 0.794, 0.816, 0.823, 0.7 51,0.796, (0.2587)+(0.0471)Ser+(0.0290)Thr+(−0.3706)Met+(−0.0105)Lys+(0.1761)Phe+(−0.1636)Trp; 0.881, 0.898, 0.805, 0.797, 0. 817,0.827, 0.786, 0.807, (−0.0129)+(0.0566)Ser+(−0.0507)Cit+(0.0079)Pro+(−0.3110)Met+(0.1611)Phe+(−0.1531)Trp; 0.881, 0.897, 0.806,0.792, 0.828, 0.819, 0.789, 0.807,(5.5754)+(−0.0149)Asn+(−0.0911)His+(0.0549)Thr+(−0.3115)Met+(0.1657)Phe+(−0.1333)Trp; 0.881, 0.899, 0.834, 0.829, 0.808, 0.848, 0.894, 0.845, (4.9454)+(−0.0295)Asn+(−0.0406)Val+(−0.2362)Met+(0.1316)Ile+(0.1266)Phe+(−0.0995)Trp

List (2) of Logistic Regression Equations Searched in Example 2

The logistic regression equations searched in Example 2 above are listedbelow. Before each equation, “the value of ROC_AUC for the pancreaticcancer group and the healthy group with validation”, “the value ofROC_AUC for the pancreatic cancer group and the healthy group withoutvalidation”, “the value of ROC_AUC for the pancreatic cancer group andthe other cancers group”, “the value of ROC_AUC for the pancreaticcancer group and the lung cancer group”, “the value of ROC_AUC for thepancreatic cancer group and the colorectal cancer group”, “the value ofROC_AUC for the pancreatic cancer group and the prostatic cancer group”,“the value of ROC_AUC for the pancreatic cancer group and the breastcancer group”, and “the average value of the value of ROC_AUC for thepancreatic cancer group and the lung cancer group, the value of ROC_AUCfor the pancreatic cancer group and the colorectal cancer group, thevalue of ROC_AUC for the pancreatic cancer group and the prostaticcancer group, and the value of ROC_AUC for the pancreatic cancer groupand the breast cancer group” obtained for the equation are additionallylisted.

0.862, 0.894, 0.855, 0.850, 0.855, 0.863, 0.864, 0.858, (2.2508)+(0.0135)Gln+(−0.1156)His+(−0.0544)Cit+(−0.1821)Met+(0.1518)Phe+(−0.1151)Trp; 0.809, 0.842, 0.860, 0.862, 0.869, 0.866, 0.8 30,0.857, (5.7676)+(−0.0593)Asn+(0.0090)Gln+(−0.0683)Cit+(0.0235)Tyr+(−0.0892)Met+(−0.1426)Trp; 0.805, 0.839, 0.859, 0.866, 0.861,0.867, 0.831, 0.856,(6.0629)+(−0.0739)Asn+(0.0084)Gln+(−0.0022)Ala+(−0.0714)Cit+(0.0130)Tyr+(−0.1421)Trp;0.861, 0. 892, 0.852, 0.845, 0.851, 0.860, 0.867, 0.856,(2.3965)+(0.0128)Gln+(−0.1297)His+(0.0154)Tyr+(−0.2172)Met+(0.1374)Phe+(−0.109 4)Trp;0.826, 0.858, 0.859, 0.874, 0.841, 0.836, 0.870, 0.855, (3.3210)+(−0.0919)Asn+(0.0062)Gln+(−0.0041)Ala+(−0.0060)Val+(0.0931)Phe+(−0.1458)Trp; 0.865, 0.892, 0.852, 0.849, 0.848, 0.857, 0. 864,0.854,(2.5117)+(−0.0105)Asn+(0.0128)Gln+(−0.1258)His+(−0.1885)Met+(0.1391)Phe+(−0.1051)Trp;0.832, 0.863, 0.856, 0.865, 0.848, 0.848, 0.856, 0.854,(3.4918)+(−0.0812)Asn+(0.0083)Gln+(−0.0048)Ala+(−0.0926)Cit+(0.1044)Phe+(−0.1577)Trp;0.838, 0. 869, 0.859, 0.865, 0.865, 0.838, 0.846, 0.854,(2.2614)+(−0.0481)Asn+(0.0098)Gln+(−0.0872)Cit+(−0.1772)Met+(0.1247)Phe+(−0.15 33)Trp;0.859, 0.890, 0.851, 0.849, 0.847, 0.857, 0.859, 0.853, (2.4884)+(0.0134)Gln+(−0.1272)His+(−0.0096)Arg+(−0.1820)Met+(0.1400)Phe+(−0.1049)Trp; 0.867, 0.892, 0.850, 0.846, 0.846, 0.857, 0. 862,0.853, (2.4271)+(0.0126)Gln+(−0.1275)His+(−0.1955)Met+(0.1405)Phe+(−0.1055)Trp; 0.864, 0.892, 0.849, 0.846, 0.846, 0.856, 0. 861,0.852, (2.4120)+(0.0126)Gln+(−0.1277)His+(0.0002)Ala+(−0.1968)Met+(0.1405)Phe+(−0.1055)Trp; 0.863, 0.892, 0.849, 0.844, 0. 846,0.853, 0.863, 0.851, (2.4047)+(0.0126)Gln+(−0.1304)His+(0.0029)Val+(−0.1969)Met+(0.1366)Phe+(−0.1080)Trp; 0.835, 0.865, 0.859,0.875, 0.857, 0.820, 0.854, 0.851,(2.1650)+(−0.0499)Asn+(0.0079)Gln+(−0.0068)Val+(−0.2042)Met+(0.1209)Phe+(−0.1369)Trp; 0.857, 0.889, 0.846, 0.840, 0.841, 0.860, 0.862, 0.851, (3.4876)+(−0.0572)Asn+(0.0125)Gln+(−0.1139)His+(−0.0612)Cit+(0.1171)Phe+(−0.1225)Trp; 0.865, 0.893, 0.845, 0.835, 0.844, 0.857, 0.8 67,0.851, (2.3748)+(0.0127)Gln+(−0.1335)His+(−0.2057)Met+(0.0145)Leu+(0.1299)Phe+(−0.1120)Trp; 0.820, 0.855, 0.855, 0.869, 0. 845,0.833, 0.855, 0.850, (3.1828)+(−0.0751)Asn+(0.0067)Gln+(−0.0048)Ala+(−0.0135)Arg+(0.0888)Phe+(−0.1544)Trp; 0.805, 0.839, 0.853,0.857, 0.860, 0.863, 0.821, 0.850,(5.3506)+(0.0073)Gln+(−0.0019)Ala+(−0.0665)Cit+(0.0274)Tyr+(−0.1208)Met+(−0.1440)Trp; 0.805, 0.839, 0.854, 0.866, 0.852, 0.861, 0.821, 0.850, (6.1032)+(−0.0730)Asn+(0.0085)Gln+(−0.0017)Ala+(−0.0706)Cit+(0.0030)Arg+(−0.1376)Trp; 0.810, 0.839, 0.854, 0.867, 0.853, 0.861, 0.81 9,0.850, (6.1036)+(−0.0709)Asn+(0.0086)Gln+(−0.0016)Ala+(−0.0689)Cit+(−0.1374)Trp; 0.810, 0.839, 0.855, 0.868, 0.854, 0.861, 0. 817,0.850,(5.9973)+(−0.0607)Asn+(0.0090)Gln+(−0.0008)Ala+(−0.0658)Cit+(−0.0447)Met+(−0.1345)Trp;0.825, 0.853, 0.852, 0.86 4, 0.838, 0.830, 0.865, 0.849,(3.1978)+(−0.0869)Asn+(0.0061)Gln+(−0.0051)Ala+(0.0844)Phe+(−0.1536)Trp; 0.826, 0.862, 0.855, 0. 868,0.850, 0.823, 0.855, 0.849, (2.1377)+(−0.0445)Asn+(0.0075)Gln+(−0.0022)Ala+(−0.1950)Met+(0.1113)Phe+(−0.1437)Trp; 0.827, 0.863,0.857, 0.872, 0.855, 0.823, 0.847, 0.849, (3.2812)+(−0.0886)Asn+(0.0069)Gln+(−0.0139)Arg+(−0.0078)Val+(0.0929)Phe+(−0. 1487)Trp;0.817, 0.853, 0.852, 0.864, 0.838, 0.829, 0.865, 0.849, (3.1937)+(−0.0876)Asn+(0.0060)Gln+(−0.0051)Ala+(0.0004)Lys+(0.0841)Phe+(−0.1538)Trp; 0.862, 0.892, 0.846, 0.841, 0.843, 0.853, 0. 858,0.849, (2.4961)+(0.0121)Gln+(−0.1282)His+(−0.1947)Met+(0.0089)Orn+(0.1359)Phe+(−0.1050)Trp; 0.808, 0.840, 0.853, 0.865, 0. 854,0.859, 0.816, 0.849, (5.9367)+(−0.0631)Asn+(0.0089)Gln+(−0.0682)Cit+(0.0039)Arg+(−0.0539)Met+(−0.1360)Trp; 0.842, 0.868, 0.838,0.828, 0.823, 0.866, 0.876, 0.848,(4.8214)+(−0.0550)Asn+(0.0081)Gln+(−0.0076)Ala+(−0.0880)Cit+(0.0799)Ile+(−0.1627)Trp; 0.828, 0.856, 0.846, 0.845, 0.844, 0.866, 0.837, 0.848, (6.2674)+(−0.0542)Asn+(0.0120)Gln+(−0.0952)His+(−0.0395)Cit+(0.0220)Tyr+(−0.1092)Trp; 0.858, 0.885, 0.843, 0.841, 0.829, 0.856, 0.8 66,0.848, (3.7749)+(−0.0504)Asn+(0.0112)Gln+(−0.1257)His+(−0.0027)Ala+(0.1070)Phe+(−0.1122)Trp; 0.813, 0.839, 0.853, 0.866, 0. 853,0.859, 0.814, 0.848, (5.9487)+(−0.0612)Asn+(0.0091)Gln+(−0.0660)Cit+(−0.0511)Met+(−0.1357)Trp; 0.873, 0.900, 0.837, 0.818, 0.833,0.859, 0.882, 0.848,(2.0349)+(0.0121)Gln+(−0.1284)His+(−0.2378)Met+(0.0584)Ile+(0.1200)Phe+(−0.1165)Trp;0.818, 0.8 53, 0.851, 0.863, 0.836, 0.828, 0.865, 0.848,(3.1849)+(−0.0865)Asn+(0.0060)Gln+(−0.0052)Ala+(0.0017)Leu+(0.0830)Phe+(−0.154 8)Trp; 0.807,0.836, 0.852, 0.864, 0.850, 0.858, 0.819, 0.848, (5.9789)+(−0.0773)Asn+(0.0083)Gln+(−0.0018)Ala+(−0.0686)Cit+(0.0044)Lys+(−0.1405)Trp; 0.834, 0.865, 0.852, 0.858, 0.855, 0.835, 0. 843,0.848,(2.0349)+(0.0082)Gln+(−0.0027)Ala+(−0.0866)Cit+(−0.1904)Met+(0.1300)Phe+(−0.1549)Trp;0.823, 0.855, 0.845, 0.841, 0.845, 0.870, 0.834, 0.848,(5.8022)+(0.0115)Gln+(−0.0987)His+(−0.0345)Cit+(0.0344)Tyr+(−0.0969)Met+(−0.1080)Trp;0.832, 0. 863, 0.852, 0.860, 0.850, 0.835, 0.845, 0.848,(3.5427)+(−0.0934)Asn+(0.0083)Gln+(−0.0913)Cit+(−0.0035)Val+(0.0985)Phe+(−0.15 88)Trp;0.832, 0.863, 0.854, 0.868, 0.847, 0.820, 0.856, 0.848, (3.3020)+(−0.1020)Asn+(0.0061)Gln+(−0.0083)Val+(0.0893)Phe+(−0. 1476)Trp;0.809, 0.835, 0.852, 0.860, 0.857, 0.854, 0.818, 0.848, (5.9745)+(−0.0783)Asn+(0.0085)Gln+(−0.0724)Cit+(0.0081)Tyr+(−0. 1447)Trp;0.795, 0.830, 0.852, 0.866, 0.845, 0.852, 0.827, 0.848, (5.1777)+(−0.0531)Asn+(0.0075)Gln+(−0.0015)Ala+(0.0202)Tyr+(−0.1137)Met+(−0.1356)Trp; 0.864, 0.892, 0.844, 0.840, 0.841, 0.848, 0. 860,0.847, (2.0904)+(0.0121)Gln+(−0.1342)His+(−0.2275)Met+(0.0111)Lys+(0.1425)Phe+(−0.1118)Trp; 0.802, 0.835, 0.852, 0.860, 0. 856,0.854, 0.819, 0.847, (5.9724)+(−0.0793)Asn+(0.0084)Gln+(−0.0731)Cit+(0.0014)Arg+(0.0078)Tyr+(−0.1447)Trp; 0.821, 0.854, 0. 850,0.862, 0.836, 0.831, 0.861, 0.847, (3.0860)+(−0.0887)Asn+(0.0010)Gly+(0.0059)Gln+(−0.0051)Ala+(0.0855)Phe+(−0.1536)Trp; 0.819,0.852, 0.849, 0.861, 0.834, 0.831, 0.861, 0.847,(3.2964)+(−0.0890)Asn+(0.0057)Gln+(−0.0053)Ala+(0.0094)Orn+(0.0792)Phe+(−0.1521)Trp; 0.825, 0.855, 0.846, 0.851, 0.839, 0.868, 0.829, 0.8 47,(6.3495)+(−0.0438)Asn+(0.0121)Gln+(−0.0878)His+(−0.0359)Cit+(−0.0188)Met+(−0.0982)Trp; 0.807, 0.836, 0.851, 0.859, 0.852, 0.856,0.819, 0.847, (5.8630)+(−0.0663)Asn+(0.0085)Gln+(−0.0027)Ala+(−0.0747)Cit+(0.0053)Val+(−0.1459)Trp; 0.832, 0.862, 0.8 50,0.856, 0.852, 0.836, 0.843, 0.847, (3.5137)+(−0.0865)Asn+(0.0084)Gln+(−0.0950)Cit+(−0.0029)Lys+(0.0955)Phe+(−0.1631)Trp; 0.830,0.857, 0.843, 0.842, 0.838, 0.866, 0.839, 0.846,(5.9220)+(−0.0347)Asn+(0.0121)Gln+(−0.1045)His+(0.0317)Tyr+(−0.0819)Met+(−0.1044)Trp; 0.842, 0.868, 0.836, 0.824, 0.827, 0.864, 0.868, 0. 846,(4.3742)+(0.0074)Gln+(−0.0067)Ala+(−0.0814)Cit+(−0.1076)Met+(0.0844)Ile+(−0.1569)Trp; 0.802, 0.839, 0.845, 0.851, 0.83 0,0.847, 0.856, 0.846, (5.2638)+(−0.0625)Asn+(0.0077)Gln+(−0.0271)Val+(−0.1255)Met+(0.0579)Leu+(−0.1291)Trp; 0.866, 0.895, 0. 843,0.838, 0.841, 0.846, 0.859, 0.846, (2.3031)+(0.0124)Gln+(−0.1264)His+(0.0070)Pro+(−0.2170)Met+(0.1381)Phe+(−0.1083)Trp; 0.814,0.838, 0.850, 0.862, 0.851, 0.855, 0.816, 0.846,(6.0237)+(−0.0754)Asn+(0.0086)Gln+(−0.0705)Cit+(−0.1410)Trp; 0.828, 0.863, 0.852, 0.866, 0.843, 0.822, 0.851, 0.845, (3.1762)+(−0.1039)Asn+(0.0010)Gly+(0.0060)Gln+(−0.0083)Val+(0.0907)Phe+(−0.1474) Trp; 0.812,0.846, 0.844, 0.845, 0.841, 0.849, 0.847, 0.845, (5.8225)+(−0.0862)Asn+(0.0084)Gln+(−0.0688)Cit+(−0.0187)Val+(0.0445)Leu+(−0.1483)Trp; 0.799, 0.833, 0.842, 0.850, 0.819, 0.851, 0.8 61,0.845, (5.5360)+(−0.0888)Asn+(0.0066)Gln+(−0.0032)Ala+(−0.0254)Val+(0.0532)Leu+(−0.1346)Trp; 0.809, 0.841, 0.850, 0.865, 0. 847,0.865, 0.804, 0.845, (5.9980)+(−0.0739)Asn+(0.0019)Gly+(0.0084)Gln+(−0.0016)Ala+(−0.0714)Cit+(−0.1371)Trp; 0.808, 0.838, 0.851,0.863, 0.852, 0.851, 0.813, 0.845,(5.7387)+(−0.0657)Asn+(0.0087)Gln+(−0.0647)Cit+(−0.0687)Met+(0.0064)Lys+(−0.1396)Trp; 0.828, 0.854, 0.844, 0.849, 0.837, 0.865, 0.828, 0.845, (6.3750)+(−0.0487)Asn+(0.0120)Gln+(−0.0891)His+(0.0001)Ala+(−0.0370)Cit+(−0.0999)Trp; 0.830, 0.854, 0.844, 0.850, 0.837, 0.865, 0.8 28,0.845, (6.3815)+(−0.0485)Asn+(0.0120)Gln+(−0.0889)His+(−0.0370)Cit+(−0.0997)Trp; 0.808, 0.838, 0.849, 0.861, 0.850, 0.854, 0. 814,0.845, (6.0191)+(−0.0769)Asn+(0.0085)Gln+(−0.0717)Cit+(0.0021)Arg+(−0.1413)Trp; 0.824, 0.861, 0.851, 0.866, 0.843, 0.816, 0. 855,0.845, (3.2955)+(−0.1079)Asn+(0.0060)Gln+(−0.0091)Val+(0.0032)Lys+(0.0884)Phe+(−0.1481)Trp; 0.849, 0.882, 0.838, 0.832, 0. 827,0.859, 0.861, 0.845, (3.3973)+(0.0107)Gln+(−0.1187)His+(−0.0036)Ala+(−0.0613)Cit+(0.1236)Phe+(−0.1262)Trp; 0.801, 0.838, 0.848,0.853, 0.858, 0.856, 0.812, 0.845,(5.2374)+(0.0073)Gln+(−0.0668)Cit+(0.0001)Arg+(0.0253)Tyr+(−0.1322)Met+(−0.1461)Trp; 0.807, 0.839, 0.848, 0.853, 0.858, 0.856, 0.811, 0.844,(5.2385)+(0.0073)Gln+(−0.0667)Cit+(0.0253)Tyr+(−0.1321)Met+(−0.1460)Trp; 0.861, 0.885, 0.829, 0.818, 0.801, 0.875, 0.883, 0.844, (4.9134)+(0.0066)Gln+(−0.0570)Cit+(−0.0378)Val+(−0.1870)Met+(0.1670)Ile+(−0.1228)Trp; 0.833, 0.861, 0.848, 0.854, 0.849, 0.831, 0.8 42,0.844, (3.4802)+(−0.0912)Asn+(0.0082)Gln+(−0.0940)Cit+(0.0930)Phe+(−0.1645)Trp; 0.788, 0.824, 0.848, 0.864, 0.835, 0.847, 0. 831,0.844,(5.4817)+(−0.0765)Asn+(−0.0006)Gly+(0.0068)Gln+(−0.0028)Ala+(0.0026)Tyr+(−0.1349)Trp;0.803, 0.835, 0.849, 0.858, 0.853, 0.849, 0.816, 0.844,(5.8759)+(−0.0832)Asn+(0.0083)Gln+(−0.0719)Cit+(0.0063)Tyr+(0.0034)Lys+(−0.1467)Trp;0.807, 0.8 37, 0.849, 0.857, 0.856, 0.851, 0.813, 0.844,(5.6996)+(−0.0573)Asn+(0.0089)Gln+(−0.0708)Cit+(0.0045)Val+(−0.0602)Met+(−0.143 5)Trp;0.831, 0.865, 0.844, 0.852, 0.829, 0.820, 0.876, 0.844, (3.5014)+(−0.1103)Asn+(0.0060)Gln+(−0.0296)Val+(0.0453)Leu+(0.0850)Phe+(−0.1518)Trp; 0.827, 0.861, 0.853, 0.866, 0.855, 0.812, 0.8 43,0.844, (2.0627)+(−0.0417)Asn+(0.0081)Gln+(−0.0089)Arg+(−0.2034)Met+(0.1115)Phe+(−0.1455)Trp; 0.809, 0.840, 0.845, 0.849, 0. 845,0.848, 0.834, 0.844, (5.6309)+(−0.0669)Asn+(0.0083)Gln+(−0.0036)Ala+(−0.0762)Cit+(0.0191)Leu+(−0.1522)Trp; 0.880, 0.900, 0.831,0.825, 0.800, 0.853, 0.898, 0.844,(1.6131)+(0.0057)Gln+(−0.0525)Val+(−0.3431)Met+(0.1808)Ile+(0.1304)Phe+(−0.1173)Trp; 0.829, 0.861, 0.848, 0.854, 0.849, 0.831, 0.842, 0.844,(3.4795)+(−0.0908)Asn+(0.0082)Gln+(−0.0937)Cit+(−0.0005)Arg+(0.0930)Phe+(−0.1645)Trp; 0.824, 0.852, 0.843, 0.850, 0.837, 0.865, 0.824,0.844, (6.3859)+(−0.0451)Asn+(0.0123)Gln+(−0.0902)His+(−0.0340)Cit+(−0.0043)Arg+(−0.0988)Trp; 0.817, 0.847, 0.844, 0.850, 0. 839,0.858, 0.828, 0.844, (6.2658)+(−0.0673)Asn+(0.0081)Gln+(−0.0054)Ala+(−0.0773)Cit+(0.0130)Pro+(−0.1416)Trp; 0.824, 0.861, 0.852,0.864, 0.852, 0.812, 0.847, 0.844,(2.0112)+(−0.0454)Asn+(0.0076)Gln+(0.0016)Tyr+(−0.2134)Met+(0.1094)Phe+(−0.1459)Trp; 0.810, 0.841, 0.849, 0.863, 0.849, 0.860, 0.802, 0.844, (5.8487)+(−0.0641)Asn+(0.0019)Gly+(0.0089)Gln+(−0.0685)Cit+(−0.0502)Met+(−0.1355)Trp; 0.836, 0.869, 0.845, 0.851, 0.836, 0.820, 0.86 7,0.844, (1.7715)+(0.0065)Gln+(−0.0319)Val+(−0.2619)Met+(0.0539)Leu+(0.1213)Phe+(−0.1461)Trp; 0.854, 0.879, 0.828, 0.821, 0. 791,0.876, 0.886, 0.844, (5.6074)+(−0.0967)Asn+(0.0077)Gln+(−0.0706)Cit+(−0.0363)Val+(0.1494)Ile+(−0.1313)Trp; 0.866, 0.894, 0.840,0.838, 0.836, 0.858, 0.841, 0.843, (2.0299)+(0.0044)Gly+(0.0119)Gln+(−0.1319)His+(−0.2072)Met+(0.1476)Phe+(−0.1045)Tr p; 0.786,0.824, 0.848, 0.866, 0.837, 0.847, 0.822, 0.843,(5.4570)+(−0.0712)Asn+(0.0072)Gln+(−0.0026)Ala+(−0.0084)Arg+(0.0048)Tyr+(−0.1345)Trp; 0.829, 0.860, 0.847, 0.852, 0.849, 0.831, 0.842,0.843, (3.4683)+(−0.0911)Asn+(0.0082)Gln+(−0.0942)Cit+(0.0018)Leu+(0.0913)Phe+(−0.1660)Trp; 0.833, 0.861, 0.851, 0.863, 0.85 2,0.811, 0.846, 0.843, (2.0143)+(−0.0455)Asn+(0.0076)Gln+(−0.2109)Met+(0.1098)Phe+(−0.1455)Trp; 0.793, 0.831, 0.848, 0.862, 0. 846,0.844, 0.821, 0.843, (5.1177)+(−0.0542)Asn+(−0.0002)Gly+(0.0076)Gln+(0.0182)Tyr+(−0.1223)Met+(−0.1367)Trp; 0.837, 0.865, 0.838,0.826, 0.840, 0.853, 0.853, 0.843,(4.5403)+(−0.0428)Asn+(0.0087)Gln+(−0.0781)Cit+(−0.1229)Met+(0.0689)Ile+(−0.1589)Trp; 0.830, 0.863, 0.849, 0.863, 0.844, 0.821, 0.845, 0.843, (3.4816)+(−0.1074)Asn+(0.0056)Gln+(−0.0101)Val+(0.0148)Orn+(0.0846)Phe+(−0.1431)Trp; 0.835, 0.865, 0.850, 0.856, 0.858, 0.826, 0.83 3,0.843, (1.8996)+(0.0083)Gln+(−0.0849)Cit+(−0.0021)Val+(−0.2102)Met+(0.1306)Phe+(−0.1546)Trp; 0.828, 0.865, 0.849, 0.854, 0. 859,0.826, 0.833, 0.843, (1.8779)+(0.0083)Gln+(−0.0865)Cit+(0.0037)Tyr+(−0.2157)Met+(0.1267)Phe+(−0.1580)Trp; 0.820, 0.849, 0.848,0.859, 0.853, 0.872, 0.788, 0.843,(6.7018)+(−0.0985)Asn+(0.0072)Gln+(0.0206)Thr+(−0.0028)Ala+(−0.0740)Cit+(−0.1456)Trp; 0.788, 0.823, 0.847, 0.865, 0.834, 0.845, 0.829, 0.843, (5.4951)+(−0.0756)Asn+(−0.0007)Gly+(0.0069)Gln+(−0.0027)Ala+(0.0002)Val+(−0.1344)Trp; 0.796, 0.824, 0.847, 0.865, 0.834, 0.845, 0.8 29,0.843, (5.5074)+(−0.0757)Asn+(−0.0007)Gly+(0.0069)Gln+(−0.0027)Ala+(−0.1341)Trp; 0.787, 0.825, 0.847, 0.863, 0.834, 0.847, 0. 827,0.843, (5.4224)+(−0.0774)Asn+(0.0067)Gln+(−0.0028)Ala+(0.0030)Tyr+(0.0001)Val+(−0.1351)Trp; 0.841, 0.866, 0.832, 0.819, 0. 816,0.863, 0.874, 0.843, (4.7910)+(0.0072)Gln+(−0.0086)Ala+(−0.0936)Cit+(−0.0102)Lys+(0.0909)Ile+(−0.1638)Trp; 0.794, 0.825, 0.846,0.863, 0.834, 0.847, 0.827, 0.843,(5.4282)+(−0.0775)Asn+(0.0067)Gln+(−0.0028)Ala+(0.0031)Tyr+(−0.1350)Trp;0.790, 0.8 29, 0.849, 0.863, 0.849, 0.844, 0.815, 0.843,(5.1494)+(−0.0511)Asn+(0.0079)Gln+(−0.0070)Arg+(0.0196)Tyr+(−0.1191)Met+(−0.135 8)Trp;0.827, 0.861, 0.851, 0.863, 0.851, 0.811, 0.846, 0.843, (2.0069)+(−0.0454)Asn+(0.0076)Gln+(−0.2115)Met+(0.0008)Leu+(0.1092)Phe+(−0.1460)Trp; 0.798, 0.831, 0.848, 0.861, 0.846, 0.844, 0.8 20,0.843, (5.0998)+(−0.0544)Asn+(0.0075)Gln+(0.0184)Tyr+(−0.1226)Met+(−0.1367)Trp; 0.804, 0.836, 0.847, 0.854, 0.855, 0.848, 0. 814,0.843, (5.8144)+(−0.0763)Asn+(0.0084)Gln+(−0.0758)Cit+(0.0057)Tyr+(0.0032)Val+(−0.1501)Trp; 0.851, 0.875, 0.833, 0.828, 0. 814,0.868, 0.860, 0.843, (4.8479)+(−0.0763)Asn+(0.0085)Gln+(−0.0834)Cit+(0.1455)Ile+(−0.0584)Leu+(−0.1487)Trp; 0.856, 0.885, 0.840,0.838, 0.833, 0.848, 0.851, 0.843,(3.6081)+(−0.0403)Asn+(0.0126)Gln+(−0.1304)His+(−0.0168)Arg+(0.1065)Phe+(−0.1131)Trp

List (2) of Linear Discriminants Searched in Example 2

The linear discriminants searched in Example 2 above are listed below.Before each equation, “the value of ROC_AUC for the pancreatic cancergroup and the healthy group with validation”, “the value of ROC_AUC forthe pancreatic cancer group and the healthy group without validation”,“the value of ROC_AUC for the pancreatic cancer group and the othercancers group”, “the value of ROC_AUC for the pancreatic cancer groupand the lung cancer group”, “the value of ROC_AUC for the pancreaticcancer group and the colorectal cancer group”, “the value of ROC_AUC forthe pancreatic cancer group and the prostatic cancer group”, “the valueof ROC_AUC for the pancreatic cancer group and the breast cancer group”,and “the average value of the value of ROC_AUC for the pancreatic cancergroup and the lung cancer group, the value of ROC_AUC for the pancreaticcancer group and the colorectal cancer group, the value of ROC_AUC forthe pancreatic cancer group and the prostatic cancer group, and thevalue of ROC_AUC for the pancreatic cancer group and the breast cancergroup” obtained for the equation are additionally listed.

0.876, 0.897, 0.863, 0.862, 0.862, 0.864, 0.866, 0.864, (2.6773)+(0.0131)Gln+(−0.0833)His+(−0.0369)Cit+(−0.1942)Met+(0.1325)Phe+(−0.1189)Trp; 0.815, 0.839, 0.865, 0.874, 0.862, 0.879, 0.8 39,0.864, (6.3554)+(−0.0849)Asn+(0.0097)Gln+(−0.0031)Ala+(−0.0554)Cit+(0.0122)Tyr+(−0.1240)Trp; 0.875, 0.897, 0.861, 0.858, 0. 856,0.868, 0.871, 0.863, (4.1845)+(−0.0886)Asn+(0.0124)Gln+(−0.0795)His+(−0.0439)Cit+(0.1039)Phe+(−0.1254)Trp; 0.844, 0.868, 0.866,0.876, 0.856, 0.852, 0.867, 0.863,(4.2725)+(−0.1063)Asn+(0.0099)Gln+(−0.0038)Ala+(−0.0633)Cit+(0.0905)Phe+(−0.1475)Trp; 0.818, 0.842, 0.865, 0.869, 0.870, 0.872, 0.837, 0.862, (5.8158)+(−0.0671)Asn+(0.0103)Gln+(−0.0536)Cit+(0.0213)Tyr+(−0.0888)Met+(−0.1263)Trp; 0.852, 0.873, 0.867, 0.875, 0.870, 0.842, 0.8 60,0.862, (2.9709)+(−0.0695)Asn+(0.0114)Gln+(−0.0601)Cit+(−0.1650)Met+(0.1155)Phe+(−0.1481)Trp; 0.877, 0.895, 0.861, 0.862, 0. 858,0.856, 0.870, 0.861, (3.0012)+(−0.0367)Asn+(0.0128)Gln+(−0.0871)His+(−0.1691)Met+(0.1301)Phe+(−0.1171)Trp; 0.849, 0.871, 0.866,0.877, 0.860, 0.843, 0.863, 0.861,(4.4184)+(−0.1197)Asn+(0.0097)Gln+(−0.0558)Cit+(−0.0076)Val+(0.1001)Phe+(−0.1461)Trp; 0.846, 0.865, 0.851, 0.844, 0.833, 0.878, 0.888, 0.861, (5.4014)+(−0.0795)Asn+(0.0089)Gln+(−0.0071)Ala+(−0.0725)Cit+(0.0602)Ile+(−0.1221)Trp; 0.850, 0.871, 0.863, 0.870, 0.862, 0.847, 0.8 59,0.860, (4.1784)+(−0.1095)Asn+(0.0102)Gln+(−0.0648)Cit+(−0.0050)Lys+(0.0905)Phe+(−0.1510)Trp; 0.874, 0.895, 0.858, 0.856, 0. 856,0.855, 0.870, 0.859, (2.5573)+(0.0121)Gln+(−0.0909)His+(0.0123)Tyr+(−0.2108)Met+(0.1287)Phe+(−0.1198)Trp; 0.817, 0.839, 0.863,0.878, 0.856, 0.874, 0.827, 0.859,(6.2806)+(−0.0688)Asn+(0.0103)Gln+(−0.0018)Ala+(−0.0528)Cit+(−0.0466)Met+(−0.1161)Trp; 0.816, 0.839, 0.861, 0.875, 0.852, 0.873, 0.833, 0.858, (6.5510)+(−0.0865)Asn+(0.0094)Gln+(−0.0028)Ala+(−0.0594)Cit+(0.0068)Arg+(−0.1198)Trp; 0.816, 0.841, 0.859, 0.868, 0.853, 0.869, 0. 843,0.858,(6.0813)+(−0.0835)Asn+(0.0098)Gln+(−0.0036)Ala+(−0.0596)Cit+(0.0105)Leu+(−0.1236)Trp;0.820, 0.838, 0.861, 0.875, 0.855, 0.872, 0.830, 0.858,(6.4488)+(−0.0822)Asn+(0.0098)Gln+(−0.0026)Ala+(−0.0545)Cit+(−0.1189)Trp;0.815, 0.838, 0.861, 0. 875, 0.854, 0.872, 0.830, 0.858,(6.4299)+(−0.0829)Asn+(0.0098)Gln+(−0.0026)Ala+(−0.0545)Cit+(0.0006)Lys+(−0.1193)Trp; 0.863, 0.881,0.846, 0.844, 0.814, 0.886, 0.888, 0.858, (6.0987)+(−0.1059)Asn+(0.0079)Gln+(−0.0561)Cit+(−0.0246)Val+(0.1006)Ile+(−0. 1051)Trp;0.838, 0.861, 0.862, 0.879, 0.845, 0.838, 0.871, 0.858, (4.5654)+(−0.1123)Asn+(0.0076)Gln+(−0.0024)Ala+(−0.0100)Val+(0.1002)Phe+(−0.1400)Trp; 0.816, 0.838, 0.861, 0.873, 0.856, 0.871, 0. 831,0.858,(6.2809)+(−0.0810)Asn+(0.0098)Gln+(−0.0030)Ala+(−0.0574)Cit+(0.0023)Val+(−0.1217)Trp;0.848, 0.868, 0.865, 0.880, 0.860, 0.826, 0.863, 0.857,(3.3302)+(−0.0714)Asn+(0.0094)Gln+(−0.0103)Val+(−0.1688)Met+(0.1280)Phe+(−0.1379)Trp;0.821, 0. 844, 0.858, 0.865, 0.851, 0.863, 0.849, 0.857,(6.2656)+(−0.1002)Asn+(0.0095)Gln+(−0.0522)Cit+(−0.0132)Val+(0.0269)Leu+(−0.12 04)Trp;0.813, 0.838, 0.859, 0.867, 0.859, 0.872, 0.831, 0.857, (5.3275)+(0.0086)Gln+(−0.0027)Ala+(−0.0507)Cit+(0.0266)Tyr+(−0.1304)Met+(−0.1249)Trp; 0.870, 0.890, 0.853, 0.855, 0.840, 0.857, 0. 876,0.857,(4.2458)+(−0.0784)Asn+(0.0110)Gln+(−0.0865)His+(−0.0023)Ala+(0.1026)Phe+(−0.1193)Trp;0.846, 0.869, 0.862, 0.872, 0.861, 0.839, 0.853, 0.856,(4.1950)+(−0.1153)Asn+(0.0098)Gln+(−0.0611)Cit+(−0.0087)Leu+(0.0973)Phe+(−0.1515)Trp;0.871, 0. 894, 0.855, 0.856, 0.851, 0.852, 0.865, 0.856,(2.6471)+(0.0123)Gln+(−0.0905)His+(−0.0020)Arg+(−0.1937)Met+(0.1307)Phe+(−0.11 58)Trp;0.834, 0.855, 0.855, 0.863, 0.845, 0.878, 0.837, 0.856, (6.7550)+(−0.0609)Asn+(0.0118)Gln+(−0.0620)His+(−0.0012)Ala+(−0.0377)Cit+(−0.0952)Trp; 0.877, 0.896, 0.853, 0.850, 0.850, 0.854, 0. 868,0.856, (2.5522)+(0.0122)Gln+(−0.0940)His+(−0.2001)Met+(0.0059)Leu+(0.1259)Phe+(−0.1162)Trp; 0.874, 0.893, 0.854, 0.854, 0. 850,0.852, 0.865, 0.855, (2.6456)+(0.0121)Gln+(−0.0905)His+(−0.0000)Ala+(−0.1962)Met+(0.1311)Phe+(−0.1162)Trp; 0.820, 0.843, 0.857,0.868, 0.849, 0.868, 0.836, 0.855,(6.4530)+(−0.0810)Asn+(0.0091)Gln+(−0.0041)Ala+(−0.0552)Cit+(0.0059)Pro+(−0.1177)Trp;0.876, 0.893, 0.854, 0.854, 0.850, 0.852, 0.865, 0.855, (2.6445)+(0.0121)Gln+(−0.0905)His+(−0.1963)Met+(0.1311)Phe+(−0.11 62)Trp;0.874, 0.893, 0.854, 0.855, 0.849, 0.852, 0.864, 0.855, (2.6523)+(0.0121)Gln+(−0.0902)His+(−0.0002)Val+(−0.1963)Met+(0.1314)Phe+(−0.1161)Trp; 0.836, 0.858, 0.854, 0.857, 0.851, 0.872, 0. 840,0.855,(6.5444)+(−0.0675)Asn+(0.0117)Gln+(−0.0648)His+(−0.0387)Cit+(0.0131)Tyr+(−0.1028)Trp;0.808, 0.832, 0.853, 0.866, 0.829, 0.864, 0.860, 0.855,(6.4282)+(−0.0939)Asn+(0.0075)Gln+(−0.0029)Ala+(−0.0179)Val+(0.0326)Leu+(−0.1132)Trp;0.843, 0. 866, 0.858, 0.872, 0.844, 0.831, 0.873, 0.855,(4.6216)+(−0.1240)Asn+(0.0075)Gln+(−0.0187)Val+(0.0156)Leu+(0.0954)Phe+(−0.139 1)Trp;0.872, 0.893, 0.854, 0.853, 0.849, 0.852, 0.863, 0.855, (2.6500)+(0.0119)Gln+(−0.0907)His+(−0.1957)Met+(0.0024)Orn+(0.1302)Phe+(−0.1160)Trp; 0.836, 0.857, 0.855, 0.863, 0.848, 0.875, 0.8 32,0.855, (6.5627)+(−0.0499)Asn+(0.0122)Gln+(−0.0619)His+(−0.0363)Cit+(−0.0430)Met+(−0.0935)Trp; 0.874, 0.894, 0.854, 0.853, 0.850,0.850, 0.864, 0.855,(2.5315)+(0.0119)Gln+(−0.0916)His+(−0.2033)Met+(0.0029)Lys+(0.1306)Phe+(−0.1171)Trp;0.821, 0.8 40, 0.859, 0.873, 0.856, 0.867, 0.822, 0.854,(6.1205)+(−0.0704)Asn+(0.0103)Gln+(−0.0531)Cit+(−0.0570)Met+(−0.1186)Trp; 0.803, 0.830,0.857, 0.871, 0.848, 0.859, 0.840, 0.854, (5.7371)+(−0.0592)Asn+(0.0082)Gln+(−0.0024)Ala+(0.0223)Tyr+(−0.0910)Met+(−0. 1242)Trp;0.833, 0.857, 0.853, 0.852, 0.853, 0.876, 0.836, 0.854, (5.7659)+(0.0113)Gln+(−0.0684)His+(−0.0335)Cit+(0.0279)Tyr+(−0.1168)Met+(−0.1013)Trp; 0.844, 0.868, 0.859, 0.867, 0.858, 0.837, 0. 855,0.854,(4.0726)+(−0.1158)Asn+(0.0098)Gln+(−0.0646)Cit+(−0.0003)Pro+(0.0876)Phe+(−0.1537)Trp;0.850, 0.868, 0.859, 0.866, 0.858, 0.837, 0.856, 0.854,(4.0736)+(−0.1158)Asn+(0.0098)Gln+(−0.0646)Cit+(0.0874)Phe+(−0.1537)Trp;0.832, 0.855, 0.859, 0.8 75, 0.845, 0.832, 0.865, 0.854,(4.2884)+(−0.1042)Asn+(0.0075)Gln+(−0.0033)Ala+(−0.0103)Leu+(0.0951)Phe+(−0.1460)Trp; 0.832, 0.856,0.857, 0.870, 0.842, 0.834, 0.870, 0.854, (4.2512)+(−0.0983)Asn+(0.0076)Gln+(−0.0040)Ala+(−0.0036)Lys+(0.0857)Phe+(−0. 1455)Trp;0.850, 0.870, 0.845, 0.837, 0.831, 0.873, 0.876, 0.854, (4.3443)+(0.0086)Gln+(−0.0065)Ala+(−0.0699)Cit+(−0.1457)Met+(0.0719)Ile+(−0.1159)Trp; 0.839, 0.861, 0.849, 0.842, 0.845, 0.865, 0. 863,0.854,(5.3657)+(−0.0871)Asn+(0.0095)Gln+(−0.0723)Cit+(−0.0074)Lys+(0.0506)Ile+(−0.1284)Trp;0.841, 0.864, 0.860, 0.876, 0.849, 0.828, 0.861, 0.853,(4.4599)+(−0.1165)Asn+(0.0079)Gln+(−0.0038)Arg+(−0.0112)Val+(0.1003)Phe+(−0.1418)Trp;0.816, 0. 839, 0.854, 0.867, 0.835, 0.857, 0.855, 0.853,(5.9653)+(−0.0715)Asn+(0.0085)Gln+(−0.0217)Val+(−0.1018)Met+(0.0410)Leu+(−0.10 85)Trp;0.817, 0.840, 0.857, 0.870, 0.852, 0.867, 0.825, 0.853, (6.2031)+(−0.0741)Asn+(0.0099)Gln+(−0.0582)Cit+(0.0072)Arg+(−0.0613)Met+(−0.1196)Trp; 0.852, 0.871, 0.838, 0.841, 0.787, 0.885, 0. 901,0.853,(6.3239)+(−0.0898)Asn+(0.0056)Gln+(−0.0062)Ala+(−0.0277)Val+(0.1121)Ile+(−0.0928)Trp;0.812, 0.838, 0.858, 0.867, 0.860, 0.860, 0.827, 0.853,(6.1992)+(−0.0911)Asn+(0.0097)Gln+(−0.0564)Cit+(0.0078)Tyr+(−0.0007)Lys+(−0.1273)Trp;0.873, 0. 893, 0.852, 0.852, 0.844, 0.849, 0.868, 0.853,(4.0710)+(−0.0792)Asn+(0.0116)Gln+(−0.0890)His+(−0.0058)Arg+(0.1011)Phe+(−0.12 09)Trp;0.868, 0.886, 0.840, 0.833, 0.815, 0.884, 0.881, 0.853, (4.7899)+(0.0075)Gln+(−0.0516)Cit+(−0.0267)Val+(−0.2009)Met+(0.1234)Ile+(−0.0924)Trp; 0.816, 0.838, 0.857, 0.867, 0.859, 0.859, 0. 828,0.853, (6.1771)+(−0.0919)Asn+(0.0096)Gln+(−0.0564)Cit+(0.0076)Tyr+(−0.1277)Trp; 0.814, 0.839, 0.858, 0.870, 0.857, 0.864, 0. 822,0.853, (5.9708)+(−0.0693)Asn+(0.0104)Gln+(−0.0552)Cit+(0.0016)Val+(−0.0603)Met+(−0.1209)Trp; 0.886, 0.905, 0.844, 0.843, 0.816,0.856, 0.897, 0.853,(2.0355)+(0.0066)Gln+(−0.0397)Val+(−0.3168)Met+(0.1284)Ile+(0.1311)Phe+(−0.1090)Trp;0.818, 0.8 40, 0.856, 0.873, 0.848, 0.877, 0.814, 0.853,(6.3593)+(−0.0845)Asn+(0.0024)Gly+(0.0095)Gln+(−0.0027)Ala+(−0.0576)Cit+(−0.118 1)Trp;0.814, 0.838, 0.857, 0.867, 0.859, 0.859, 0.827, 0.853, (6.1678)+(−0.0919)Asn+(0.0096)Gln+(−0.0565)Cit+(0.0075)Tyr+(0.0001)Val+(−0.1278)Trp; 0.873, 0.892, 0.851, 0.852, 0.842, 0.848, 0.8 70,0.853, (4.2347)+(−0.0860)Asn+(0.0110)Gln+(−0.0853)His+(−0.0024)Val+(0.1046)Phe+(−0.1211)Trp; 0.837, 0.858, 0.851, 0.854, 0. 847,0.868, 0.841, 0.853, (6.0881)+(−0.0392)Asn+(0.0112)Gln+(−0.0715)His+(0.0254)Tyr+(−0.0882)Met+(−0.0993)Trp; 0.873, 0.893, 0.844,0.848, 0.810, 0.852, 0.899, 0.852,(4.5526)+(−0.1319)Asn+(0.0058)Gln+(−0.0339)Val+(0.0933)Ile+(0.0918)Phe+(−0.1225)Trp; 0.845, 0.867, 0.842, 0.833, 0.823, 0.873, 0.880, 0.852, (5.0406)+(0.0070)Gln+(−0.0086)Ala+(−0.0741)Cit+(−0.0113)Lys+(0.0691)Ile+(−0.1191)Trp; 0.817, 0.839, 0.857, 0.872, 0.854, 0.862, 0.82 1,0.852, (6.0399)+(−0.0717)Asn+(0.0102)Gln+(−0.0530)Cit+(−0.0614)Met+(0.0019)Lys+(−0.1196)Trp; 0.851, 0.873, 0.851, 0.847, 0. 850,0.840, 0.873, 0.852, (3.7665)+(−0.1162)Asn+(0.0093)Gln+(−0.0729)Cit+(0.0294)Ile+(0.0726)Phe+(−0.1544)Trp; 0.834, 0.855, 0. 852,0.859, 0.845, 0.871, 0.834, 0.852, (6.6903)+(−0.0647)Asn+(0.0118)Gln+(−0.0630)His+(−0.0389)Cit+(0.0013)Arg+(−0.0973)Tr p; 0.871,0.891, 0.850, 0.849, 0.842, 0.848, 0.870, 0.852,(4.1249)+(−0.0832)Asn+(0.0111)Gln+(−0.0888)His+(−0.0006)Pro+(0.1016)Phe+(−0.1222)Trp;0.838, 0.855, 0.852, 0.860, 0.845, 0.871, 0.833, 0.852,(6.6752)+(−0.0637)Asn+(0.0119)Gln+(−0.0633)His+(−0.0379)Cit+(−0.0969)Trp; 0.876, 0.897, 0.851, 0.850, 0.846, 0.848, 0.8 64,0.852, (2.6021)+(0.0118)Gln+(−0.0903)His+(0.0036)Pro+(−0.2057)Met+(0.1298)Phe+(−0.1159)Trp; 0.844, 0.865, 0.847, 0.838, 0. 846,0.862, 0.861, 0.852, (4.6128)+(−0.0559)Asn+(0.0100)Gln+(−0.0691)Cit+(−0.1294)Met+(0.0581)Ile+(−0.1234)Trp; 0.872, 0.892, 0.849,0.849, 0.841, 0.847, 0.870, 0.852,(4.1478)+(−0.0822)Asn+(0.0111)Gln+(−0.0885)His+(−0.0011)Lys+(0.1016)Phe+(−0.1218)Trp;0.812, 0.837, 0.855, 0.865, 0.855, 0.857, 0.830, 0.852, (6.2501)+(−0.0955)Asn+(0.0093)Gln+(−0.0602)Cit+(0.0052)Arg+(0.0070)Tyr+(−0.1284)Trp; 0.876, 0.892, 0.849, 0.848, 0.841, 0.848, 0.86 9,0.852, (4.1266)+(−0.0834)Asn+(0.0110)Gln+(−0.0889)His+(0.1011)Phe+(−0.1222)Trp; 0.832, 0.855, 0.855, 0.869, 0.841, 0.830, 0. 866,0.852,(4.1494)+(−0.1004)Asn+(0.0076)Gln+(−0.0041)Ala+(−0.0032)Arg+(0.0835)Phe+(−0.1466)Trp;0.873, 0.892, 0.849, 0.848, 0.842, 0.848, 0.869, 0.851,(4.1304)+(−0.0835)Asn+(0.0110)Gln+(−0.0887)His+(−0.0003)Leu+(0.1014)Phe+(−0.1222)Trp;0.842, 0. 864, 0.857, 0.873, 0.847, 0.825, 0.861, 0.851,(4.5031)+(−0.1189)Asn+(0.0076)Gln+(−0.0113)Val+(−0.0002)Lys+(0.1006)Phe+(−0.14 25)Trp;0.847, 0.864, 0.857, 0.873, 0.847, 0.825, 0.861, 0.851, (4.5012)+(−0.1192)Asn+(0.0076)Gln+(−0.0114)Val+(0.1005)Phe+(−0. 1425)Trp;0.819, 0.843, 0.855, 0.863, 0.856, 0.858, 0.830, 0.851, (5.6067)+(−0.0680)Asn+(0.0105)Gln+(−0.0579)Cit+(−0.0775)Met+(0.0109)Leu+(−0.1237)Trp; 0.814, 0.839, 0.855, 0.863, 0.855, 0.857, 0. 831,0.851,(5.9974)+(−0.0889)Asn+(0.0099)Gln+(−0.0600)Cit+(−0.0026)Lys+(0.0084)Leu+(−0.1273)Trp;0.856, 0.875, 0.843, 0.840, 0.825, 0.875, 0.865, 0.851,(5.6391)+(−0.0894)Asn+(0.0081)Gln+(−0.0686)Cit+(0.1097)Ile+(−0.0447)Leu+(−0.1169)Trp;0.813, 0. 838, 0.855, 0.866, 0.851, 0.860, 0.828, 0.851,(6.4138)+(−0.0916)Asn+(0.0095)Gln+(−0.0606)Cit+(0.0068)Arg+(−0.0019)Lys+(−0.12 38)Trp;0.884, 0.901, 0.844, 0.832, 0.839, 0.854, 0.880, 0.851, (2.0499)+(0.0118)Gln+(−0.0940)His+(−0.2274)Met+(0.0420)Ile+(0.1165)Phe+(−0.1146)Trp; 0.833, 0.854, 0.852, 0.857, 0.855, 0.876, 0. 816,0.851,(6.3446)+(−0.0858)Asn+(0.0085)Gln+(−0.0036)Ala+(−0.0827)Cit+(0.0399)Orn+(−0.1185)Trp;0.844, 0.867, 0.855, 0.861, 0.854, 0.831, 0.859, 0.851,(4.1532)+(−0.1213)Asn+(0.0093)Gln+(−0.0701)Cit+(0.0073)Arg+(0.0880)Phe+(−0.1552)Trp;0.812, 0.8 38, 0.854, 0.861, 0.857, 0.855, 0.832, 0.851,(5.9157)+(−0.0939)Asn+(0.0096)Gln+(−0.0597)Cit+(0.0054)Tyr+(0.0067)Leu+(−0.130 9)Trp; 0.846,0.868, 0.857, 0.868, 0.857, 0.832, 0.847, 0.851, (2.4549)+(0.0096)Gln+(−0.0020)Ala+(−0.0570)Cit+(−0.2059)Met+(0.1155)Phe+(−0.1458)Trp; 0.842, 0.863, 0.857, 0.871, 0.851, 0.820, 0. 862,0.851,(2.9539)+(−0.0618)Asn+(0.0090)Gln+(−0.0018)Ala+(−0.1665)Met+(0.1105)Phe+(−0.1453)Trp;0.859, 0.878, 0.839, 0.838, 0.806, 0.876, 0.883, 0.851,(5.5211)+(−0.0556)Asn+(0.0071)Gln+(−0.0306)Val+(−0.1601)Met+(0.1221)Ile+(−0.0872)Trp;0.872, 0. 890, 0.837, 0.835, 0.795, 0.862, 0.911, 0.851,(6.1834)+(−0.0880)Asn+(−0.0059)Ala+(−0.0341)Val+(0.1111)Ile+(0.0892)Phe+(−0.10 65)Trp;0.861, 0.879, 0.831, 0.811, 0.804, 0.880, 0.907, 0.851, (6.6747)+(−0.0060)Ala+(0.0404)Tyr+(−0.0328)Val+(−0.1943)Met+(0.1415)Ile+(−0.0867)Trp; 0.801, 0.827, 0.853, 0.869, 0.840, 0.856, 0. 838,0.851, (6.3135)+(−0.0839)Asn+(0.0075)Gln+(−0.0030)Ala+(0.0105)Tyr+(−0.0021)Val+(−0.1222)Trp; 0.834, 0.853, 0.853, 0.866, 0.838,0.829, 0.868, 0.850,(4.1858)+(−0.1024)Asn+(0.0073)Gln+(−0.0042)Ala+(0.0836)Phe+(−0.1471)Trp;0.835, 0.856, 0.850, 0.8 57, 0.845, 0.867, 0.833, 0.850,(6.5698)+(−0.0676)Asn+(0.0116)Gln+(−0.0647)His+(−0.0376)Cit+(0.0032)Lys+(−0.0986)Trp; 0.821, 0.844,0.854, 0.863, 0.853, 0.860, 0.824, 0.850, (5.9896)+(−0.0674)Asn+(0.0099)Gln+(−0.0535)Cit+(0.0049)Pro+(−0.0736)Met+(−0. 1185)Trp;0.818, 0.838, 0.855, 0.868, 0.852, 0.860, 0.820, 0.850, (6.2676)+(−0.0890)Asn+(0.0098)Gln+(−0.0557)Cit+(−0.0003)Lys+(−0.1237)Trp;0.861, 0.878, 0.835, 0.833, 0.794, 0.879, 0.894, 0.850,(5.1510)+(0.0056)Gln+(−0.0053)Ala+(−0.0295)Val+(−0.1808)Met+(0.1311)Ile+(−0.0826)Trp; 0.822, 0.838, 0.854, 0.868, 0.852, 0.8 59,0.821, 0.850, (6.2580)+(−0.0894)Asn+(0.0097)Gln+(−0.0557)Cit+(−0.1239)Trp; 0.806, 0.830, 0.854, 0.867, 0.850, 0.853, 0.830, 0.850,(5.7845)+(−0.0635)Asn+(0.0083)Gln+(0.0215)Tyr+(−0.0025)Val+(−0.0978)Met+(−0.1237)Trp;0.835, 0.861, 0.852, 0.860, 0.843, 0.847, 0.848, 0.850,(3.9364)+(0.0067)Gln+(−0.0053)Ala+(−0.0610)Cit+(−0.0089)Lys+(0.0823)Phe+(−0.1445)Trp; 0.814, 0.837, 0.8 54,0.868, 0.853, 0.858, 0.821, 0.850, (6.2188)+(−0.0885)Asn+(0.0098)Gln+(−0.0566)Cit+(0.0007)Val+(−0.0006)Lys+(−0.1245)Trp; 0.814,0.837, 0.854, 0.868, 0.853, 0.858, 0.821, 0.850,(6.2188)+(−0.0885)Asn+(0.0098)Gln+(−0.0566)Cit+(0.0007)Val+(−0.0006)Lys+(−0.1245)Trp

List (1) of Logistic Regression Equations Searched in Example 4

The logistic regression equations searched in Example 4 above are listedbelow. Before each equation, “the value of ROC_AUC for the pancreaticcancer group and the other cancers group with validation”, “the value ofROC_AUC for the pancreatic cancer group and the other cancers groupwithout validation”, “the value of ROC_AUC for the pancreatic cancergroup and the healthy group”, “the value of ROC_AUC for the pancreaticcancer group and the lung cancer group”, “the value of ROC_AUC for thepancreatic cancer group and the colorectal cancer group”, “the value ofROC_AUC for the pancreatic cancer group and the prostatic cancer group”,“the value of ROC_AUC for the pancreatic cancer group and the breastcancer group”, and “the average value of the value of ROC_AUC for thepancreatic cancer group and the lung cancer group, the value of ROC_AUCfor the pancreatic cancer group and the colorectal cancer group, thevalue of ROC_AUC for the pancreatic cancer group and the prostaticcancer group, and the value of ROC_AUC for the pancreatic cancer groupand the breast cancer group” obtained for the equation are additionallylisted.

0.854, 0.873, 0.835, 0.891, 0.849, 0.888, 0.863, 0.873, (1.7072)+(−0.0985)Asn+(0.0115)Gln+(−0.0063)Ala+(−0.0582)Cit+(0.0212)Phe+(−0.0792)Trp; 0.852, 0.871, 0.832, 0.884, 0.849, 0.896, 0.8 67,0.874, (2.3113)+(−0.1017)Asn+(0.0110)Gln+(−0.0063)Ala+(−0.0568)Cit+(0.0111)Ile+(−0.0719)Trp; 0.851, 0.869, 0.820, 0.889, 0. 845,0.892, 0.850, 0.869, (2.6006)+(−0.1002)Asn+(0.0111)Gln+(−0.0058)Ala+(−0.0561)Cit+(−0.0706)Trp; 0.850, 0.872, 0.823, 0.887, 0.851,0.892, 0.863, 0.873,(2.3468)+(−0.1053)Asn+(0.0111)Gln+(−0.0063)Ala+(−0.0570)Cit+(0.0137)Tyr+(−0.0747)Trp;0.849, 0. 870, 0.846, 0.884, 0.866, 0.869, 0.842, 0.865,(1.2353)+(−0.0844)Asn+(0.0123)Gln+(−0.0572)Cit+(−0.1339)Met+(0.0312)Phe+(−0.08 16)Trp;0.849, 0.870, 0.808, 0.894, 0.845, 0.892, 0.842, 0.868, (2.7671)+(−0.0984)Asn+(0.0120)Gln+(−0.0048)Ala+(−0.0551)Cit+(−0.0068)Pro+(−0.0739)Trp; 0.849, 0.869, 0.784, 0.884, 0.857, 0.847, 0. 870,0.865,(3.8383)+(−0.0962)Asn+(−0.0121)Gly+(0.0143)Gln+(−0.0492)Cit+(−0.0112)Pro+(−0.0942)Trp;0.848, 0.870, 0.819, 0.89 2, 0.845, 0.893, 0.849, 0.870,(2.7323)+(−0.0997)Asn+(0.0111)Gln+(−0.0055)Ala+(−0.0544)Cit+(−0.0019)Val+(−0.0677)Trp; 0.848, 0.870,0.820, 0.889, 0.846, 0.892, 0.850, 0.869, (2.5966)+(−0.0990)Asn+(0.0112)Gln+(−0.0058)Ala+(−0.0560)Cit+(−0.0008)Lys+(−0.0698)Trp;0.848, 0.869, 0.821, 0.888, 0.846, 0.891, 0.851, 0.869,(2.5842)+(−0.1004)Asn+(0.0110)Gln+(−0.0058)Ala+(−0.0575)Cit+(0.0021)Orn+(−0.0706)Trp; 0.848, 0.869, 0.821, 0.887, 0.846, 0.8 91,0.853, 0.869, (2.5115)+(−0.1010)Asn+(0.0112)Gln+(−0.0060)Ala+(−0.0567)Cit+(0.0021)Leu+(−0.0722)Trp; 0.847, 0.871, 0.820, 0.890,0.849, 0.892, 0.850, 0.870, (2.5117)+(−0.0856)Asn+(0.0118)Gln+(−0.0051)Ala+(−0.0536)Cit+(−0.0683)Met+(−0.0633)Trp; 0. 847,0.872, 0.836, 0.889, 0.848, 0.900, 0.855, 0.873, (2.5945)+(−0.0937)Asn+(0.0118)Gln+(−0.0223)His+(−0.0050)Ala+(−0.0487)Cit+(−0.0610)Trp; 0.847, 0.867, 0.816, 0.894, 0.829, 0.878, 0.866, 0.8 67,(2.2693)+(−0.1096)Asn+(0.0092)Gln+(−0.0060)Ala+(−0.0061)Val+(0.0201)Phe+(−0.0668)Trp;0.847, 0.868, 0.804, 0.890, 0.844, 0.880, 0.850, 0.866,(2.9468)+(−0.0090)Ser+(−0.0912)Asn+(0.0121)Gln+(−0.0062)Ala+(−0.0562)Cit+(−0.0724)Trp; 0.846, 0.867, 0. 805,0.889, 0.841, 0.882, 0.855, 0.867, (2.4617)+(−0.0897)Asn+(0.0121)Gln+(−0.0093)Thr+(−0.0056)Ala+(−0.0575)Cit+(−0.0664)Tr p; 0.846,0.869, 0.838, 0.886, 0.858, 0.874, 0.842, 0.865,(2.3818)+(−0.1068)Asn+(0.0100)Gln+(−0.0557)Cit+(−0.0062)Val+(0.0189)Phe+(−0.0831)Trp; 0.846, 0.868, 0.793, 0.881, 0.849, 0.859, 0.882,0.868, (3.3740)+(−0.0924)Asn+(−0.0110)Gly+(0.0134)Gln+(−0.0052)Ala+(−0.0504)Cit+(−0.0788)Trp; 0.845, 0.867, 0.823, 0.888, 0. 858,0.865, 0.833, 0.861, (2.0486)+(−0.1048)Asn+(0.0120)Gln+(−0.0596)Cit+(−0.0115)Pro+(0.0223)Phe+(−0.0965)Trp; 0.845, 0.868, 0.845,0.882, 0.852, 0.886, 0.852, 0.868,(2.8826)+(−0.1094)Asn+(0.0093)Gln+(−0.0522)Cit+(−0.0094)Val+(0.0189)Ile+(−0.0729)Trp; 0.845, 0.865, 0.828, 0.888, 0.820, 0.892, 0.878, 0.869, (2.7136)+(−0.1154)Asn+(0.0087)Gln+(−0.0058)Ala+(−0.0098)Val+(0.0238)Ile+(−0.0565)Trp; 0.844, 0.868, 0.813, 0.890, 0.845, 0.885, 0.8 42,0.866, (2.5586)+(−0.0968)Asn+(0.0118)Gln+(−0.0057)Ala+(−0.0484)Cit+(−0.0106)Arg+(−0.0667)Trp; 0.844, 0.867, 0.858, 0.875, 0.859,0.877, 0.856, 0.867,(1.9144)+(−0.0985)Asn+(0.0116)Gln+(−0.0373)His+(−0.0484)Cit+(0.0186)Phe+(−0.0747)Trp;0.844, 0. 866, 0.760, 0.888, 0.843, 0.840, 0.874, 0.861,(4.8087)+(−0.1039)Asn+(−0.0144)Gly+(0.0131)Gln+(−0.0103)Pro+(−0.0097)Val+(−0.0 762)Trp;0.844, 0.864, 0.788, 0.884, 0.842, 0.828, 0.884, 0.860, (4.1888)+(−0.1114)Asn+(−0.0146)Gly+(0.0118)Gln+(−0.0126)Val+(0.0169)Phe+(−0.0789)Trp; 0.844, 0.865, 0.835, 0.886, 0.847, 0.873, 0. 844,0.863,(0.6243)+(0.0108)Gln+(−0.0056)Ala+(−0.0583)Cit+(−0.1610)Met+(0.0336)Phe+(−0.0779)Trp;0.844, 0.866, 0.807, 0.872, 0.861, 0.838, 0.879, 0.862,(3.0000)+(−0.1069)Asn+(−0.0115)Gly+(0.0129)Gln+(−0.0551)Cit+(0.0147)Phe+(−0.0994)Trp;0.844, 0.8 65, 0.837, 0.882, 0.859, 0.865, 0.832, 0.860,(2.2031)+(−0.1074)Asn+(0.0101)Gln+(−0.0594)Cit+(−0.0084)Leu+(0.0218)Phe+(−0.087 0)Trp;0.843, 0.864, 0.838, 0.875, 0.861, 0.863, 0.840, 0.860, (2.0925)+(−0.1115)Asn+(0.0100)Gln+(−0.0612)Cit+(0.0157)Phe+(−0.0 921)Trp;0.843, 0.866, 0.788, 0.881, 0.849, 0.844, 0.877, 0.863, (4.3296)+(−0.0996)Asn+(−0.0132)Gly+(0.0130)Gln+(−0.0442)Cit+(−0.0091)Val+(−0.0775)Trp;0.843, 0.865, 0.846, 0.882, 0.836, 0.879, 0.873, 0.867,(1.9077)+(−0.1020)Asn+(0.0111)Gln+(−0.0396)His+(−0.0051)Ala+(0.0197)Phe+(−0.0605)Trp;0.843, 0.862, 0.797, 0.8 69, 0.857, 0.840, 0.871, 0.860,(3.5957)+(−0.1052)Asn+(−0.0118)Gly+(0.0126)Gln+(−0.0529)Cit+(−0.0929)Trp; 0.843, 0.866, 0.837, 0.878,0.860, 0.866, 0.843, 0.862, (1.9994)+(−0.1037)Asn+(0.0107)Gln+(−0.0608)Cit+(−0.0051)Lys+(0.0174)Phe+(−0.0879)Trp; 0. 843, 0.861,0.815, 0.885, 0.827, 0.866, 0.864, 0.860, (1.9633)+(−0.1140)Asn+(0.0092)Gln+(−0.0066)Ala+(0.0175)Phe+(−0.0750)Trp; 0.843,0.865, 0.828, 0.894, 0.845, 0.856, 0.838, 0.858,(1.9014)+(−0.0885)Asn+(0.0107)Gln+(−0.0091)Val+(−0.1551)Met+(0.0330)Phe+(−0.0629)Trp; 0.843, 0.865, 0.800, 0.891, 0.833, 0.868, 0.860, 0. 863,(2.0354)+(−0.1115)Asn+(0.0104)Gln+(−0.0053)Ala+(−0.0086)Pro+(0.0203)Phe+(−0.0792)Trp; 0.843, 0.865, 0.776, 0.886, 0.83 4,0.853, 0.883, 0.864, (4.3559)+(−0.1025)Asn+(−0.0135)Gly+(0.0121)Gln+(−0.0040)Ala+(−0.0090)Val+(−0.0661)Trp; 0.843, 0.864, 0.822,0.888, 0.837, 0.865, 0.858, 0.862,(1.2887)+(−0.0886)Asn+(0.0111)Gln+(−0.0052)Ala+(−0.1275)Met+(0.0289)Phe+(−0.0671)Trp; 0.842, 0.862, 0.809, 0.884, 0.852, 0.869, 0.821, 0.856, (2.9444)+(−0.1069)Asn+(0.0115)Gln+(−0.0567)Cit+(−0.0100)Pro+(−0.0 861)Trp;0.842, 0.864, 0.773, 0.882, 0.850, 0.820, 0.878, 0.858, (3.4727)+(−0.1125)Asn+(−0.0128)Gly+(0.0130)Gln+(−0.0131)Pro+(0.0163)Phe+(−0.1001)Trp; 0.842, 0.865, 0.810, 0.882, 0.859, 0.871, 0. 827,0.860,(2.7620)+(−0.1110)Asn+(0.0115)Gln+(−0.0572)Cit+(−0.0106)Pro+(0.0112)Tyr+(−0.0905)Trp;0.842, 0.860, 0.776, 0.880, 0.839, 0.831, 0.876, 0.856,(4.7447)+(−0.1110)Asn+(−0.0145)Gly+(0.0116)Gln+(−0.0116)Val+(−0.0727)Trp;0.842, 0.866, 0.803, 0.8 94, 0.844, 0.863, 0.840, 0.860,(2.6868)+(−0.1155)Asn+(0.0097)Gln+(−0.0111)Pro+(−0.0071)Val+(0.0204)Phe+(−0.0795)Trp; 0.842, 0.859,0.825, 0.885, 0.840, 0.850, 0.836, 0.853, (2.7694)+(−0.1211)Asn+(0.0079)Gln+(−0.0087)Val+(0.0162)Phe+(−0.0747)Trp; 0.8 42, 0.865,0.857, 0.877, 0.854, 0.863, 0.853, 0.862, (1.4326)+(−0.0806)Asn+(0.0122)Gln+(−0.0417)His+(−0.1327)Met+(0.0285)Phe+(−0.0597)Trp;0.842, 0.865, 0.790, 0.876, 0.856, 0.841, 0.867, 0.86 0,(4.0160)+(−0.0989)Asn+(−0.0126)Gly+(0.0126)Gln+(−0.0502)Cit+(−0.0085)Leu+(−0.0855)Trp; 0.842, 0.862, 0.828, 0.879, 0.856, 0.871,0.824, 0.858, (2.6469)+(−0.0905)Asn+(0.0110)Gln+(−0.0547)Cit+(−0.0953)Met+(−0.0724)Trp; 0.842, 0.859, 0.830, 0.873, 0.8 53,0.865, 0.831, 0.855, (2.7424)+(−0.1124)Asn+(0.0099)Gln+(−0.0593)Cit+(−0.0850)Trp; 0.842, 0.862, 0.791, 0.879, 0.840, 0.841, 0. 881,0.860, (4.4765)+(0.0106)Ser+(−0.1173)Asn+(−0.0166)Gly+(0.0111)Gln+(−0.0116)Val+(−0.0712)Trp; 0.842, 0.862, 0.840, 0.882, 0.837,0.868, 0.859, 0.861,(2.6309)+(−0.1229)Asn+(0.0075)Gln+(−0.0125)Val+(0.0183)Ile+(0.0140)Phe+(−0.0711)Trp;0.842, 0.8 66, 0.764, 0.886, 0.842, 0.843, 0.878, 0.862,(3.8741)+(−0.1013)Asn+(−0.0126)Gly+(0.0130)Gln+(−0.0040)Ala+(−0.0094)Pro+(−0.08 31)Trp;0.842, 0.864, 0.816, 0.889, 0.830, 0.870, 0.862, 0.863, (2.0567)+(−0.1122)Asn+(0.0092)Gln+(−0.0063)Ala+(−0.0049)Leu+(0.0206)Phe+(−0.0720)Trp; 0.842, 0.864, 0.807, 0.869, 0.858, 0.844, 0. 876,0.862, (3.3874)+(0.0083)Ser+(−0.1115)Asn+(−0.0134)Gly+(0.0122)Gln+(−0.0519)Cit+(−0.0914)Trp; 0.842, 0.864, 0.802, 0.886, 0.831,0.882, 0.861, 0.865,(2.8366)+(−0.1181)Asn+(0.0090)Gln+(−0.0057)Ala+(0.0141)Tyr+(−0.0059)Val+(−0.0636)Trp;0.841, 0. 861, 0.822, 0.865, 0.851, 0.839, 0.889, 0.861,(3.1733)+(−0.1020)Asn+(−0.0120)Gly+(0.0133)Gln+(−0.0464)His+(0.0135)Phe+(−0.07 57)Trp;0.841, 0.860, 0.803, 0.889, 0.823, 0.879, 0.850, 0.860, (3.0004)+(−0.1129)Asn+(0.0090)Gln+(−0.0055)Ala+(−0.0050)Val+(−0. 0602)Trp;0.841, 0.862, 0.793, 0.878, 0.833, 0.844, 0.891, 0.861, (4.4905)+(−0.1142)Asn+(−0.0146)Gly+(0.0114)Gln+(−0.0160)Val+(0.0206)Ile+(−0.0692)Trp; 0.841, 0.867, 0.830, 0.875, 0.868, 0.873, 0. 838,0.864, (2.2861)+(−0.0896)Asn+(0.0110)Gln+(−0.0546)Cit+(0.0182)Tyr+(−0.1193)Met+(−0.0774)Trp; 0.841, 0.865, 0.799, 0.876, 0.857,0.846, 0.864, 0.861,(3.4698)+(−0.0755)Asn+(−0.0117)Gly+(0.0135)Gln+(−0.0485)Cit+(−0.0992)Met+(−0.0816)Trp;0.841, 0. 864, 0.815, 0.888, 0.830, 0.882, 0.860, 0.865,(2.9758)+(−0.1205)Asn+(0.0094)Gln+(−0.0134)Pro+(−0.0128)Val+(0.0353)Ile+(−0.06 80)Trp;0.841, 0.862, 0.789, 0.878, 0.838, 0.840, 0.887, 0.861, (3.0725)+(−0.1084)Asn+(−0.0117)Gly+(0.0120)Gln+(−0.0057)Ala+(0.0132)Phe+(−0.0835)Trp; 0.841, 0.864, 0.836, 0.881, 0.846, 0.869, 0. 853,0.862,(2.2038)+(−0.1030)Asn+(0.0119)Gln+(−0.0465)His+(−0.0109)Pro+(0.0215)Phe+(−0.0702)Trp;0.841, 0.862, 0.781, 0.880, 0.836, 0.835, 0.887, 0.859,(4.5981)+(−0.1133)Asn+(−0.0147)Gly+(0.0120)Gln+(−0.0199)Val+(0.0168)Leu+(−0.0749)Trp;0.841, 0.8 62, 0.798, 0.874, 0.842, 0.846, 0.881, 0.861,(4.4317)+(−0.0987)Asn+(−0.0137)Gly+(0.0130)Gln+(−0.0332)His+(−0.0082)Val+(−0.06 18)Trp;0.841, 0.865, 0.792, 0.876, 0.848, 0.848, 0.880, 0.863, (4.0089)+(−0.0908)Asn+(−0.0127)Gly+(0.0142)Gln+(−0.0390)His+(−0.0108)Pro+(−0.0739)Trp; 0.841, 0.862, 0.810, 0.875, 0.856, 0.831, 0. 864,0.856,(2.0237)+(−0.0118)Gly+(0.0125)Gln+(−0.0536)Cit+(−0.1846)Met+(0.0262)Phe+(−0.0934)Trp;0.841, 0.856, 0.800, 0.881, 0.821, 0.871, 0.852, 0.856,(2.6648)+(−0.1149)Asn+(0.0090)Gln+(−0.0062)Ala+(−0.0680)Trp; 0.841,0.858, 0.812, 0.863, 0.846, 0.8 42, 0.882, 0.858,(3.7353)+(−0.0993)Asn+(−0.0124)Gly+(0.0130)Gln+(−0.0445)His+(−0.0709)Trp; 0.841, 0.866, 0.819, 0.878, 0.855, 0.884,0.847, 0.866, (1.5472)+(0.0097)Gln+(−0.0061)Ala+(−0.0560)Cit+(0.0283)Tyr+(−0.1648)Met+(−0.0744)Trp; 0.841, 0.866, 0.8 27,0.884, 0.853, 0.882, 0.836, 0.864, (2.9297)+(−0.0966)Asn+(0.0124)Gln+(−0.0298)His+(−0.0464)Cit+(−0.0091)Pro+(−0.0702)Tr p; 0.841,0.865, 0.804, 0.874, 0.843, 0.859, 0.889, 0.866,(3.5734)+(−0.0925)Asn+(−0.0119)Gly+(0.0133)Gln+(−0.0357)His+(−0.0042)Ala+(−0.0643)Trp; 0.841, 0.862, 0.819, 0.882, 0.837, 0.871, 0.85 4,0.861, (2.7968)+(−0.0916)Asn+(0.0109)Gln+(−0.0255)Val+(−0.1691)Met+(0.0379)Leu+(−0.0530)Trp; 0.841, 0.861, 0.844, 0.870, 0. 852,0.877, 0.843, 0.860, (2.7090)+(−0.1006)Asn+(0.0112)Gln+(−0.0339)His+(−0.0474)Cit+(−0.0674)Trp; 0.841, 0.863, 0.804, 0.877, 0.854,0.820, 0.874, 0.856,(2.6558)+(−0.0831)Asn+(−0.0119)Gly+(0.0128)Gln+(−0.1449)Met+(0.0233)Phe+(−0.0864)Trp;0.841, 0.8 62, 0.825, 0.882, 0.850, 0.870, 0.826, 0.857,(3.0838)+(−0.1087)Asn+(0.0098)Gln+(−0.0545)Cit+(−0.0051)Val+(−0.0762)Trp; 0.841, 0.860,0.779, 0.877, 0.834, 0.842, 0.881, 0.859, (3.6115)+(−0.1058)Asn+(−0.0121)Gly+(0.0118)Gln+(−0.0055)Ala+(−0.0788)Trp; 0. 841, 0.864,0.813, 0.868, 0.856, 0.849, 0.882, 0.864, (3.5123)+(−0.0906)Asn+(−0.0116)Gly+(0.0138)Gln+(−0.0336)His+(−0.0414)Cit+(−0.0760)Trp; 0.841, 0.863, 0.828, 0.875, 0.860, 0.856, 0.838, 0.8 58,(2.3351)+(−0.0052)Ser+(−0.1066)Asn+(0.0105)Gln+(−0.0614)Cit+(0.0147)Phe+(−0.0933)Trp; 0.841, 0.864, 0.797, 0.872, 0.858, 0.842,0.872, 0.861, (3.5957)+(−0.1014)Asn+(−0.0117)Gly+(0.0128)Gln+(−0.0525)Cit+(−0.0022)Lys+(−0.0909)Trp; 0.840, 0.865, 0. 809,0.889, 0.852, 0.878, 0.818, 0.859, (3.1554)+(−0.1054)Asn+(0.0114)Gln+(−0.0536)Cit+(−0.0093)Pro+(−0.0034)Val+(−0.0801)Tr p; 0.840,0.861, 0.763, 0.880, 0.846, 0.824, 0.871, 0.855,(4.1032)+(−0.1091)Asn+(−0.0132)Gly+(0.0127)Gln+(−0.0122)Pro+(−0.0937)Trp; 0.840, 0.863, 0.820, 0.879, 0.853, 0.870, 0.836, 0.859, (2.5764)+(−0.1086)Asn+(0.0115)Gln+(−0.0578)Cit+(−0.0123)Pro+(0.0157)Ile+(−0.0898)Trp; 0.840, 0.863, 0.835, 0.877, 0.859, 0.862, 0. 836,0.858,(2.1404)+(−0.1108)Asn+(0.0101)Gln+(−0.0611)Cit+(−0.0034)Ile+(0.0166)Phe+(−0.0918)Trp;0.840, 0.865, 0.837, 0.876, 0.860, 0.872, 0.838, 0.862,(2.3981)+(−0.0898)Asn+(0.0108)Gln+(−0.0551)Cit+(−0.1062)Met+(0.0096)Ile+(−0.0728)Trp;0.840, 0. 864, 0.821, 0.884, 0.854, 0.877, 0.821, 0.859,(2.9704)+(−0.0901)Asn+(0.0110)Gln+(−0.0504)Cit+(−0.0048)Val+(−0.0906)Met+(−0.0 644)Trp;0.840, 0.864, 0.828, 0.882, 0.850, 0.875, 0.839, 0.861, (2.9830)+(−0.1095)Asn+(0.0099)Gln+(−0.0531)Cit+(−0.0103)Val+(0.0105)Leu+(−0.0777)Trp; 0.840, 0.862, 0.813, 0.888, 0.819, 0.883, 0. 867,0.865,(2.8107)+(−0.1126)Asn+(0.0093)Gln+(−0.0058)Ala+(−0.0129)Val+(0.0169)Leu+(−0.0631)Trp;0.840, 0.862, 0.804, 0.887, 0.826, 0.860, 0.871, 0.861,(1.8017)+(−0.1065)Asn+(0.0101)Gln+(−0.0086)Thr+(−0.0064)Ala+(0.0189)Phe+(−0.0711)Trp;0.840, 0. 864, 0.808, 0.886, 0.853, 0.873, 0.820, 0.858,(2.9330)+(−0.1036)Asn+(0.0117)Gln+(−0.0563)Cit+(−0.0098)Pro+(−0.0023)Lys+(−0.0 838)Trp;0.840, 0.862, 0.815, 0.886, 0.828, 0.867, 0.864, 0.861, (1.9363)+(−0.1104)Asn+(0.0096)Gln+(−0.0065)Ala+(−0.0026)Lys+(0.0179)Phe+(−0.0729)Trp; 0.840, 0.859, 0.830, 0.877, 0.829, 0.881, 0. 859,0.861,(2.7153)+(−0.1033)Asn+(0.0106)Gln+(−0.0369)His+(−0.0048)Ala+(−0.0530)Trp;0.840, 0.861, 0.828, 0.876, 0.855, 0.870, 0.830, 0.857,(2.7362)+(−0.1068)Asn+(0.0103)Gln+(−0.0587)Cit+(−0.0038)Lys+(−0.0812)Trp;0.840, 0.862, 0.791, 0.872, 0.857, 0.8 33, 0.867, 0.857,(3.7777)+(−0.1036)Asn+(−0.0120)Gly+(0.0128)Gln+(−0.0523)Cit+(−0.0061)Ile+(−0.0918)Trp; 0.840, 0.861, 0.791, 0.887,0.837, 0.825, 0.869, 0.854, (3.0237)+(−0.0139)Gly+(0.0114)Gln+(−0.0117)Val+(−0.1910)Met+(0.0295)Phe+(−0.0774)Trp; 0. 840, 0.860,0.818, 0.882, 0.826, 0.865, 0.867, 0.860, (1.8745)+(−0.1149)Asn+(0.0092)Gln+(−0.0068)Ala+(0.0049)Ile+(0.0165)Phe+(−0.0754)Trp;0.840, 0.863, 0.852, 0.883, 0.836, 0.878, 0.856, 0.86 3,(0.8547)+(0.0106)Gln+(−0.0386)His+(−0.0043)Ala+(−0.1722)Met+(0.0308)Phe+(−0.0594)Trp; 0.840, 0.861, 0.786, 0.879, 0.848, 0. 811,0.873, 0.853, (3.8030)+(−0.1144)Asn+(−0.0137)Gly+(0.0112)Gln+(−0.0143)Leu+(0.0193)Phe+(−0.0882)Trp; 0.840, 0.859, 0.831, 0.873,0.854, 0.865, 0.831, 0.856, (2.7159)+(−0.1126)Asn+(0.0098)Gln+(−0.0594)Cit+(0.0010)Ile+(−0.0852)Trp; 0.840, 0.860, 0.8 04,0.889, 0.831, 0.859, 0.840, 0.855, (1.7534)+(−0.1031)Asn+(0.0114)Gln+(−0.0064)Ala+(−0.0225)Arg+(0.0201)Phe+(−0.0691)Trp; 0.839,0.862, 0.839, 0.879, 0.836, 0.879, 0.857, 0.863,(2.7140)+(−0.0976)Asn+(0.0093)Gln+(−0.0150)Val+(−0.1446)Met+(0.0379)Ile+(−0.0438)Trp

List (1) of Linear Discriminants Searched in Example 4

The linear discriminants searched in Example 4 above are listed below.Before each equation, “the value of ROC_AUC for the pancreatic cancergroup and the other cancers group with validation”, “the value ofROC_AUC for the pancreatic cancer group and the other cancers groupwithout validation”, “the value of ROC_AUC for the pancreatic cancergroup and the healthy group”, “the value of ROC_AUC for the pancreaticcancer group and the lung cancer group”, “the value of ROC_AUC for thepancreatic cancer group and the colorectal cancer group”, “the value ofROC_AUC for the pancreatic cancer group and the prostatic cancer group”,“the value of ROC_AUC for the pancreatic cancer group and the breastcancer group”, and “the average value of the value of ROC_AUC for thepancreatic cancer group and the lung cancer group, the value of ROC_AUCfor the pancreatic cancer group and the colorectal cancer group, thevalue of ROC_AUC for the pancreatic cancer group and the prostaticcancer group, and the value of ROC_AUC for the pancreatic cancer groupand the breast cancer group” obtained for the equation are additionallylisted.

0.859, 0.874, 0.841, 0.890, 0.853, 0.883, 0.868, 0.873, (5.4468)+(−0.1111)Asn+(0.0122)Gln+(−0.0083)Ala+(−0.0524)Cit+(0.0345)Phe+(−0.1015)Trp; 0.859, 0.874, 0.808, 0.889, 0.852, 0.878, 0.8 78,0.874, (6.8056)+(−0.0977)Asn+(−0.0069)Gly+(0.0132)Gln+(−0.0072)Ala+(−0.0462)Cit+(−0.0919)Trp; 0.858, 0.874, 0.848, 0.892, 0.863,0.868, 0.854, 0.869,(5.6035)+(−0.1337)Asn+(0.0116)Gln+(−0.0452)Cit+(−0.0098)Val+(0.0408)Phe+(−0.1050)Trp;0.858, 0. 872, 0.849, 0.895, 0.857, 0.859, 0.854, 0.866,(4.8108)+(−0.0961)Asn+(0.0115)Gln+(−0.0125)Val+(−0.1461)Met+(0.0663)Phe+(−0.09 71)Trp;0.858, 0.871, 0.811, 0.894, 0.844, 0.895, 0.848, 0.870, (6.5042)+(−0.1023)Asn+(0.0128)Gln+(−0.0067)Ala+(−0.0490)Cit+(−0.0066)Pro+(−0.0903)Trp; 0.857, 0.869, 0.822, 0.890, 0.843, 0.891, 0. 854,0.869,(6.4072)+(−0.1027)Asn+(0.0120)Gln+(−0.0080)Ala+(−0.0507)Cit+(−0.0876)Trp;0.857, 0.872, 0.800, 0.888, 0.861, 0.855, 0.864, 0.867,(6.7332)+(−0.1105)Asn+(−0.0083)Gly+(0.0144)Gln+(−0.0439)Cit+(−0.0102)Pro+(−0.1075)Trp;0.857, 0.874, 0.857, 0. 886, 0.869, 0.867, 0.853, 0.869,(4.0729)+(−0.0942)Asn+(0.0132)Gln+(−0.0523)Cit+(−0.1417)Met+(0.0541)Phe+(−0.1117)Trp; 0.856, 0.870,0.833, 0.885, 0.844, 0.894, 0.868, 0.873, (6.1244)+(−0.1050)Asn+(0.0118)Gln+(−0.0087)Ala+(−0.0540)Cit+(0.0138)Ile+(−0. 0889)Trp;0.856, 0.871, 0.823, 0.891, 0.846, 0.894, 0.852, 0.871, (6.2462)+(−0.0877)Asn+(0.0125)Gln+(−0.0073)Ala+(−0.0497)Cit+(−0.0524)Met+(−0.0833)Trp;0.856, 0.872, 0.835, 0.890, 0.845, 0.901, 0.860, 0.874,(6.4966)+(−0.0951)Asn+(0.0128)Gln+(−0.0248)His+(−0.0074)Ala+(−0.0456)Cit+(−0.0771)Trp;0.856, 0.870, 0.823, 0. 896, 0.850, 0.858, 0.851, 0.864,(5.8194)+(−0.1324)Asn+(0.0113)Gln+(−0.0106)Pro+(−0.0108)Val+(0.0473)Phe+(−0.1078)Trp; 0.855, 0.869,0.829, 0.895, 0.833, 0.878, 0.871, 0.869, (5.9985)+(−0.1172)Asn+(0.0101)Gln+(−0.0073)Ala+(−0.0092)Val+(0.0417)Phe+(−0. 0931)Trp;0.855, 0.870, 0.795, 0.892, 0.838, 0.868, 0.880, 0.870, (7.5122)+(−0.1003)Asn+(−0.0083)Gly+(0.0116)Gln+(−0.0061)Ala+(−0.0076)Val+(−0.0835)Trp;0.855, 0.872, 0.824, 0.885, 0.851, 0.890, 0.868, 0.873,(6.2747)+(−0.1094)Asn+(0.0117)Gln+(−0.0086)Ala+(−0.0521)Cit+(0.0214)Tyr+(−0.0981)Trp;0.855, 0.869, 0.821, 0.8 90, 0.843, 0.891, 0.853, 0.869,(6.4558)+(−0.1023)Asn+(0.0119)Gln+(−0.0079)Ala+(−0.0503)Cit+(−0.0012)Leu+(−0.0868)Trp; 0.855, 0.871,0.867, 0.879, 0.863, 0.872, 0.864, 0.870, (5.1147)+(−0.1213)Asn+(0.0130)Gln+(−0.0367)His+(−0.0468)Cit+(0.0353)Phe+(−0. 1017)Trp;0.855, 0.870, 0.815, 0.891, 0.844, 0.889, 0.855, 0.870, (6.5195)+(−0.0041)Ser+(−0.0995)Asn+(0.0124)Gln+(−0.0080)Ala+(−0.0513)Cit+(−0.0879)Trp;0.855, 0.871, 0.819, 0.892, 0.845, 0.896, 0.850, 0.871,(6.5601)+(−0.0953)Asn+(0.0126)Gln+(−0.0077)Ala+(−0.0510)Cit+(−0.0059)Lys+(−0.0835)Trp;0.855, 0.872, 0.828, 0. 879, 0.869, 0.845, 0.876, 0.867,(5.7732)+(−0.1237)Asn+(−0.0073)Gly+(0.0129)Gln+(−0.0488)Cit+(0.0224)Phe+(−0.1163)Trp; 0.855, 0.870,0.814, 0.890, 0.842, 0.890, 0.858, 0.870, (6.2561)+(−0.0961)Asn+(0.0126)Gln+(−0.0058)Thr+(−0.0078)Ala+(−0.0496)Cit+(−0.0857)Trp;0.855, 0.870, 0.845, 0.887, 0.866, 0.860, 0.843, 0.864,(5.3112)+(−0.1294)Asn+(0.0115)Gln+(−0.0500)Cit+(−0.0135)Leu+(0.0430)Phe+(−0.1112)Trp; 0.855, 0.871, 0.815, 0.881, 0.864, 0.8 58,0.864, 0.867, (6.2662)+(−0.0895)Asn+(−0.0081)Gly+(0.0138)Gln+(−0.0452)Cit+(−0.0844)Met+(−0.0980)Trp; 0.855, 0.868, 0.814, 0.875,0.865, 0.848, 0.867, 0.864, (6.4563)+(−0.1169)Asn+(−0.0081)Gly+(0.0129)Gln+(−0.0471)Cit+(−0.1070)Trp; 0.854, 0.870, 0.8 32,0.888, 0.862, 0.863, 0.845, 0.865, (5.1434)+(−0.1290)Asn+(0.0132)Gln+(−0.0512)Cit+(−0.0113)Pro+(0.0381)Phe+(−0.1204)Trp; 0.854,0.870, 0.807, 0.887, 0.855, 0.856, 0.868, 0.866,(7.1793)+(−0.1140)Asn+(−0.0086)Gly+(0.0129)Gln+(−0.0388)Cit+(−0.0081)Val+(−0.0938)Trp; 0.854, 0.870, 0.818, 0.890, 0.850, 0.834, 0.880, 0.864, (6.6708)+(−0.1247)Asn+(−0.0086)Gly+(0.0115)Gln+(−0.0129)Val+(0.0332)Phe+(−0.1013)Trp; 0.854, 0.870, 0.821, 0.893, 0.84 2,0.892, 0.851, 0.870, (6.6454)+(−0.1031)Asn+(0.0119)Gln+(−0.0075)Ala+(−0.0478)Cit+(−0.0031)Val+(−0.0833)Trp; 0.854, 0.869, 0.819,0.891, 0.844, 0.888, 0.852, 0.869,(6.3509)+(−0.1005)Asn+(0.0122)Gln+(−0.0079)Ala+(−0.0480)Cit+(−0.0040)Arg+(−0.0868)Trp; 0.854, 0.868, 0.785, 0.890, 0.841, 0.861, 0.873, 0.866, (7.0517)+(−0.0993)Asn+(−0.0082)Gly+(0.0125)Gln+(−0.0058)Ala+(−0.0081)Pro+(−0.0971)Trp; 0.854, 0.871, 0.844, 0.882, 0.869, 0.872, 0. 848,0.868,(5.2217)+(−0.1212)Asn+(0.0126)Gln+(−0.0549)Cit+(−0.0099)Lys+(0.0351)Phe+(−0.1109)Trp;0.854, 0.869, 0.810, 0.885, 0.842, 0.857, 0.889, 0.868,(6.1928)+(−0.1069)Asn+(−0.0070)Gly+(0.0112)Gln+(−0.0077)Ala+(0.0243)Phe+(−0.1030)Trp;0.854, 0.8 69, 0.846, 0.883, 0.850, 0.887, 0.859, 0.870,(6.4355)+(−0.1302)Asn+(0.0110)Gln+(−0.0463)Cit+(−0.0135)Val+(0.0270)Ile+(−0.087 1)Trp;0.853, 0.867, 0.846, 0.878, 0.865, 0.857, 0.850, 0.862, (5.0782)+(−0.1336)Asn+(0.0116)Gln+(−0.0542)Cit+(0.0302)Phe+(−0.1 166)Trp;0.853, 0.869, 0.849, 0.886, 0.838, 0.886, 0.877, 0.872, (5.5655)+(−0.1034)Asn+(0.0115)Gln+(−0.0376)His+(−0.0077)Ala+(0.0371)Phe+(−0.0878)Trp; 0.853, 0.869, 0.817, 0.882, 0.842, 0.875, 0. 886,0.871,(7.0111)+(−0.0902)Asn+(−0.0076)Gly+(0.0127)Gln+(−0.0318)His+(−0.0066)Ala+(−0.0799)Trp;0.853, 0.870, 0.826, 0.89 0, 0.845, 0.891, 0.853, 0.870,(6.3910)+(−0.1037)Asn+(0.0118)Gln+(−0.0080)Ala+(−0.0544)Cit+(0.0051)Orn+(−0.0878)Trp; 0.853, 0. 866,0.794, 0.884, 0.838, 0.860, 0.879, 0.865, (6.9138)+(−0.1003)Asn+(−0.0078)Gly+(0.0113)Gln+(−0.0073)Ala+(−0.0936)Trp; 0.853, 0.868,0.807, 0.883, 0.861, 0.849, 0.859, 0.863, (6.9047)+(−0.1110)Asn+(−0.0086)Gly+(0.0129)Gln+(−0.0434)Cit+(−0.0093)Leu+(−0.0997)Trp;0.853, 0.869, 0.874, 0.880, 0.860, 0.865, 0.863, 0.867,(4.2094)+(−0.0824)Asn+(0.0129)Gln+(−0.0437)His+(−0.1432)Met+(0.0582)Phe+(−0.0944)Trp; 0.853, 0.866, 0.818, 0.884, 0.840, 0.8 59,0.881, 0.866, (7.3959)+(−0.1216)Asn+(−0.0093)Gly+(0.0111)Gln+(−0.0164)Val+(0.0236)Ile+(−0.0865)Trp; 0.853, 0.869, 0.835, 0.873,0.873, 0.872, 0.845, 0.866, (5.4341)+(−0.0983)Asn+(0.0123)Gln+(−0.0521)Cit+(0.0295)Tyr+(−0.1187)Met+(−0.1073)Trp; 0. 853, 0.869,0.784, 0.892, 0.847, 0.846, 0.866, 0.863, (7.5590)+(−0.1102)Asn+(−0.0095)Gly+(0.0129)Gln+(−0.0095)Pro+(−0.0086)Val+(−0.0949)Trp; 0.853, 0.868, 0.849, 0.882, 0.854, 0.863, 0.862, 0.8 65,(5.2900)+(−0.1174)Asn+(0.0130)Gln+(−0.0434)His+(−0.0116)Pro+(0.0422)Phe+(−0.1034)Trp;0.853, 0.867, 0.842, 0.878, 0.862, 0.874, 0.843, 0.864,(5.4579)+(−0.0978)Asn+(0.0123)Gln+(−0.0533)Cit+(−0.0961)Met+(0.0109)Ile+(−0.0958)Trp; 0.852, 0.869, 0.8 11,0.880, 0.862, 0.854, 0.865, 0.866, (6.6439)+(−0.1073)Asn+(−0.0078)Gly+(0.0136)Gln+(−0.0476)Cit+(−0.0071)Lys+(−0.1013)Tr p; 0.852,0.868, 0.837, 0.888, 0.841, 0.867, 0.872, 0.867,(4.7054)+(−0.0857)Asn+(0.0111)Gln+(−0.0073)Ala+(−0.1151)Met+(0.0507)Phe+(−0.1001)Trp; 0.852, 0.865, 0.831, 0.880, 0.860, 0.871, 0.829,0.860, (5.7466)+(−0.0986)Asn+(0.0123)Gln+(−0.0508)Cit+(−0.0827)Met+(−0.0949)Trp; 0.852, 0.867, 0.835, 0.894, 0.852, 0.859, 0.8 35,0.860, (5.5823)+(−0.1259)Asn+(0.0113)Gln+(−0.0161)Arg+(−0.0125)Val+(0.0434)Phe+(−0.0987)Trp; 0.852, 0.868, 0.800, 0.889, 0. 848,0.849, 0.865, 0.863, (7.2108)+(−0.0903)Asn+(−0.0095)Gly+(0.0123)Gln+(−0.0096)Val+(−0.0783)Met+(−0.0846)Trp; 0.852, 0.867, 0.848,0.880, 0.860, 0.881, 0.842, 0.866,(5.9090)+(−0.0895)Asn+(0.0133)Gln+(−0.0300)His+(−0.0446)Cit+(−0.0765)Met+(−0.0816)Trp; 0.852, 0.866, 0.816, 0.889, 0.835, 0.871, 0.864, 0.865, (5.5582)+(−0.1148)Asn+(0.0110)Gln+(−0.0070)Ala+(−0.0086)Pro+(0.0373)Phe+(−0.1075)Trp; 0.852, 0.865, 0.834, 0.888, 0.817, 0.899, 0. 879,0.871,(6.8490)+(−0.1135)Asn+(0.0094)Gln+(−0.0080)Ala+(−0.0143)Val+(0.0341)Ile+(−0.0726)Trp;0.852, 0.867, 0.798, 0.885, 0.840, 0.862, 0.877, 0.866,(6.7264)+(−0.0818)Asn+(−0.0079)Gly+(0.0120)Gln+(−0.0065)Ala+(−0.0637)Met+(−0.0885)Trp;0.852, 0. 867, 0.807, 0.882, 0.839, 0.867, 0.885, 0.868,(6.7520)+(0.0088)Ser+(−0.1060)Asn+(−0.0093)Gly+(0.0106)Gln+(−0.0071)Ala+(−0.09 37)Trp;0.852, 0.866, 0.790, 0.886, 0.836, 0.859, 0.880, 0.865, (6.9225)+(−0.0986)Asn+(−0.0076)Gly+(0.0117)Gln+(−0.0073)Ala+(−0.0072)Orn+(−0.0931)Trp; 0.852, 0.867, 0.793, 0.888, 0.838, 0.861, 0. 875,0.865,(7.2368)+(−0.0971)Asn+(−0.0083)Gly+(0.0114)Gln+(−0.0067)Ala+(−0.0075)Leu+(−0.0889)Trp;0.851, 0.866, 0.816, 0.88 0, 0.842, 0.883, 0.865, 0.867,(5.9813)+(−0.0886)Asn+(0.0102)Gln+(−0.0078)Ala+(0.0314)Tyr+(−0.0958)Met+(−0.0966)Trp; 0.851, 0. 869,0.799, 0.887, 0.856, 0.830, 0.873, 0.862, (6.0449)+(−0.1207)Asn+(−0.0084)Gly+(0.0128)Gln+(−0.0119)Pro+(0.0274)Phe+(−0.12 08)Trp;0.851, 0.867, 0.843, 0.878, 0.865, 0.856, 0.849, 0.862, (5.1230)+(−0.0012)Ser+(−0.1325)Asn+(0.0117)Gln+(−0.0544)Cit+(0.0298)Phe+(−0.1166)Trp; 0.851, 0.864, 0.799, 0.885, 0.845, 0.842, 0. 867,0.860,(7.4786)+(−0.1154)Asn+(−0.0095)Gly+(0.0115)Gln+(−0.0106)Val+(−0.0913)Trp;0.851, 0.868, 0.825, 0.875, 0.862, 0.854, 0.871, 0.866,(6.3238)+(0.0080)Ser+(−0.1217)Asn+(−0.0094)Gly+(0.0122)Gln+(−0.0451)Cit+(−0.1068)Trp;0.851, 0.868, 0.845, 0.8 87, 0.846, 0.877, 0.856, 0.866,(3.8638)+(0.0111)Gln+(−0.0080)Ala+(−0.0523)Cit+(−0.1680)Met+(0.0550)Phe+(−0.1007)Trp; 0.851, 0.864,0.850, 0.885, 0.839, 0.861, 0.864, 0.863, (5.8647)+(−0.1415)Asn+(0.0093)Gln+(−0.0178)Val+(0.0218)Ile+(0.0387)Phe+(−0. 0969)Trp;0.851, 0.866, 0.804, 0.885, 0.843, 0.849, 0.875, 0.863, (7.4605)+(−0.1204)Asn+(−0.0092)Gly+(0.0116)Gln+(−0.0167)Val+(0.0117)Leu+(−0.0904)Trp; 0.851, 0.866, 0.826, 0.890, 0.834, 0.869, 0. 864,0.864,(5.7369)+(−0.1126)Asn+(0.0098)Gln+(−0.0078)Ala+(−0.0113)Leu+(0.0425)Phe+(−0.0985)Trp;0.851, 0.868, 0.817, 0.875, 0.866, 0.851, 0.868, 0.865,(6.4428)+(−0.1177)Asn+(−0.0081)Gly+(0.0127)Gln+(−0.0500)Cit+(0.0040)Orn+(−0.1073)Trp;0.851, 0.8 69, 0.828, 0.875, 0.861, 0.861, 0.873, 0.868,(6.5996)+(−0.1055)Asn+(−0.0079)Gly+(0.0140)Gln+(−0.0311)His+(−0.0407)Cit+(−0.09 25)Trp;0.851, 0.867, 0.830, 0.884, 0.855, 0.882, 0.837, 0.865, (6.3333)+(−0.1084)Asn+(0.0139)Gln+(−0.0305)His+(−0.0434)Cit+(−0.0096)Pro+(−0.0899)Trp; 0.851, 0.866, 0.817, 0.880, 0.848, 0.855, 0. 874,0.864,(7.3317)+(−0.1066)Asn+(−0.0091)Gly+(0.0125)Gln+(−0.0265)His+(−0.0076)Val+(−0.0836)Trp;0.851, 0.867, 0.842, 0.87 9, 0.865, 0.854, 0.846, 0.861,(5.1442)+(−0.1324)Asn+(0.0116)Gln+(−0.0530)Cit+(−0.0053)Ile+(0.0323)Phe+(−0.1164)Trp; 0.851, 0. 865,0.824, 0.887, 0.834, 0.874, 0.869, 0.866, (5.6780)+(−0.1058)Asn+(0.0105)Gln+(−0.0082)Ala+(−0.0075)Lys+(0.0355)Phe+(−0.09 81)Trp;0.851, 0.867, 0.799, 0.884, 0.853, 0.841, 0.869, 0.862, (6.6764)+(0.0097)Ser+(−0.1188)Asn+(−0.0107)Gly+(0.0119)Gln+(−0.0107)Pro+(−0.1090)Trp; 0.851, 0.868, 0.815, 0.874, 0.867, 0.850, 0. 871,0.865,(6.4098)+(−0.1188)Asn+(−0.0079)Gly+(0.0128)Gln+(−0.0476)Cit+(0.0044)Tyr+(−0.1093)Trp;0.851, 0.864, 0.814, 0.885, 0.854, 0.868, 0.827, 0.858,(6.1918)+(−0.1194)Asn+(0.0128)Gln+(−0.0497)Cit+(−0.0099)Pro+(−0.1041)Trp;0.851, 0.866, 0.794, 0. 887, 0.841, 0.859, 0.869, 0.864,(6.7304)+(−0.0935)Asn+(−0.0075)Gly+(0.0123)Gln+(−0.0071)Ala+(−0.0112)Arg+(−0.0910)Trp;0.85 1, 0.867, 0.832, 0.889, 0.855, 0.846, 0.849, 0.860, (4.3755)+(−0.0986)Asn+(0.0122)Gln+(−0.0101)Pro+(−0.1241)Met+(0.0556)Phe+(−0.1163)Trp;0.850, 0.864, 0.827, 0.885, 0.851, 0.871, 0.830, 0.859,(6.5123)+(−0.1234)Asn+(0.0114)Gln+(−0.0460)Cit+(−0.0068)Val+(−0.0925)Trp; 0.850, 0.866, 0.793, 0.884, 0.838, 0.863, 0.876, 0.8 65,(7.0363)+(−0.0941)Asn+(−0.0077)Gly+(0.0117)Gln+(−0.0071)Ala+(−0.0050)Lys+(−0.0900)Trp; 0.850, 0.866, 0.844, 0.872, 0.857, 0.844,0.885, 0.865, (5.9570)+(−0.1120)Asn+(−0.0078)Gly+(0.0127)Gln+(−0.0419)His+(0.0257)Phe+(−0.0997)Trp; 0.850, 0.865, 0.8 46,0.886, 0.857, 0.843, 0.842, 0.857, (4.4720)+(−0.0960)Asn+(0.0109)Gln+(−0.1334)Met+(−0.0129)Leu+(0.0625)Phe+(−0.1073)Trp; 0.850,0.865, 0.827, 0.887, 0.839, 0.874, 0.852, 0.863,(6.3928)+(−0.1011)Asn+(0.0112)Gln+(−0.0255)Val+(−0.1199)Met+(0.0330)Leu+(−0.0768)Trp; 0.850, 0.866, 0.812, 0.890, 0.852, 0.877, 0.825, 0. 861,(6.5916)+(−0.1185)Asn+(0.0127)Gln+(−0.0451)Cit+(−0.0091)Pro+(−0.0050)Val+(−0.0959)Trp; 0.850, 0.866, 0.814, 0.884, 0.8 56,0.820, 0.871, 0.858, (6.3242)+(−0.1193)Asn+(−0.0088)Gly+(0.0111)Gln+(−0.0179)Leu+(0.0357)Phe+(−0.1095)Trp; 0.850, 0.866, 0.796,0.884, 0.838, 0.859, 0.881, 0.866,(6.8599)+(−0.1008)Asn+(−0.0077)Gly+(0.0112)Gln+(−0.0075)Ala+(0.0024)Ile+(−0.0938)Trp;0.850, 0.864, 0.851, 0.882, 0.836, 0.883, 0.859, 0.865, (6.2583)+(−0.0987)Asn+(0.0101)Gln+(−0.0189)Val+(−0.1205)Met+(0.0438)Ile+(−0.0702)Trp; 0.850, 0.868, 0.810, 0.878, 0.864, 0.847, 0.8 64,0.863, (6.3784)+(−0.1133)Asn+(−0.0080)Gly+(0.0133)Gln+(−0.0433)Cit+(−0.0057)Arg+(−0.1056)Trp; 0.850, 0.866, 0.808, 0.881, 0.851,0.852, 0.871, 0.864,(6.9842)+(−0.0997)Asn+(−0.0088)Gly+(0.0142)Gln+(−0.0358)His+(−0.0104)Pro+(−0.0923)Trp;0.850, 0. 867, 0.789, 0.887, 0.852, 0.843, 0.863, 0.861,(6.6608)+(−0.0924)Asn+(−0.0092)Gly+(0.0132)Gln+(−0.0095)Pro+(−0.0657)Met+(−0.1 023)Trp;0.850, 0.865, 0.801, 0.883, 0.847, 0.844, 0.870, 0.861, (7.4326)+(−0.1188)Asn+(−0.0092)Gly+(0.0113)Gln+(0.0083)Tyr+(−0.0111)Val+(−0.0950)Trp; 0.850, 0.866, 0.821, 0.879, 0.849, 0.888, 0. 854,0.868, (5.2240)+(0.0101)Gln+(−0.0086)Ala+(−0.0521)Cit+(0.0339)Tyr+(−0.1490)Met+(−0.0969)Trp; 0.850, 0.866, 0.809, 0.886, 0.834,0.884, 0.865, 0.867,(6.8770)+(−0.1141)Asn+(0.0095)Gln+(−0.0078)Ala+(0.0231)Tyr+(−0.0073)Val+(−0.0901)Trp;0.850, 0. 867, 0.830, 0.881, 0.860, 0.828, 0.876, 0.861,(4.9495)+(−0.0883)Asn+(−0.0078)Gly+(0.0124)Gln+(−0.1375)Met+(0.0427)Phe+(−0.11 20)Trp;0.850, 0.866, 0.797, 0.881, 0.841, 0.860, 0.881, 0.866, (6.8237)+(−0.1039)Asn+(−0.0073)Gly+(0.0110)Gln+(−0.0077)Ala+(0.0102)Tyr+(−0.0983)Trp; 0.850, 0.864, 0.855, 0.882, 0.847, 0.858, 0. 855,0.861,(5.6934)+(−0.1257)Asn+(0.0110)Gln+(−0.0323)His+(−0.0091)Val+(0.0426)Phe+(−0.0931)Trp;0.850, 0.867, 0.824, 0.880, 0.862, 0.875, 0.841, 0.864,(6.4621)+(−0.1301)Asn+(0.0111)Gln+(−0.0462)Cit+(0.0181)Tyr+(−0.0079)Val+(−0.1007)Trp;0.850, 0. 867, 0.861, 0.884, 0.840, 0.881, 0.871, 0.869,(4.0370)+(0.0111)Gln+(−0.0441)His+(−0.0071)Ala+(−0.1656)Met+(0.0590)Phe+(−0.08 44)Trp;0.850, 0.864, 0.825, 0.888, 0.830, 0.882, 0.855, 0.864, (6.7756)+(−0.1299)Asn+(0.0106)Gln+(−0.0118)Pro+(−0.0170)Val+(0.0396)Ile+(−0.0859)Trp; 0.850, 0.862, 0.824, 0.883, 0.829, 0.868, 0. 871,0.863, (5.5825)+(−0.1143)Asn+(0.0098)Gln+(−0.0086)Ala+(0.0320)Phe+(−0.1018)Trp; 0.850, 0.864, 0.822, 0.889, 0.851, 0.846, 0. 840,0.856,(5.4733)+(−0.1287)Asn+(0.0109)Gln+(−0.0108)Pro+(−0.0127)Leu+(0.0474)Phe+(−0.1157)Trp

List (2) of Logistic Regression Equations Searched in Example 4

The logistic regression equations searched in Example 4 above are listedbelow. Before each equation, “the value of ROC_AUC for the pancreaticcancer group and the other cancers group with validation”, “the value ofROC_AUC for the pancreatic cancer group and the other cancers groupwithout validation”, “the value of ROC_AUC for the pancreatic cancergroup and the healthy group”, “the value of ROC_AUC for the pancreaticcancer group and the lung cancer group”, “the value of ROC_AUC for thepancreatic cancer group and the colorectal cancer group”, “the value ofROC_AUC for the pancreatic cancer group and the prostatic cancer group”,“the value of ROC_AUC for the pancreatic cancer group and the breastcancer group”, and “the average value of the value of ROC_AUC for thepancreatic cancer group and the lung cancer group, the value of ROC_AUCfor the pancreatic cancer group and the colorectal cancer group, thevalue of ROC_AUC for the pancreatic cancer group and the prostaticcancer group, and the value of ROC_AUC for the pancreatic cancer groupand the breast cancer group” obtained for the equation are additionallylisted.

0.832, 0.854, 0.860, 0.867, 0.842, 0.862, 0.842, 0.853, (0.8883)+(0.0101)Gln+(−0.0453)His+(−0.1983)Met+(0.0032)Ile+(0.0304)Phe+(−0.0647)Trp; 0.811, 0.827, 0.859, 0.830, 0.819, 0.841, 0.82 2,0.828, (1.4317)+(0.0059)Gln+(−0.0615)His+(0.0176)Phe+(−0.0 796)Trp;0.838, 0.862, 0.859, 0.873, 0.856, 0.875, 0.834, 0.859, (0.7688)+(0.0114)Gln+(−0.0347)His+(−0.0488)Cit+(−0.1734)Met+(0.0327)Phe+(−0.0727)Trp; 0.832, 0.855, 0.859, 0.868, 0.842, 0.863, 0. 839,0.853, (0.9479)+(0.0102)Gln+(−0.0459)His+(−0.1951)Met+(0.0005)Leu+(0.0306)Phe+(−0.0647)Trp; 0.835, 0.855, 0.858, 0.869, 0. 842,0.863, 0.838, 0.853, (0.9606)+(0.0101)Gln+(−0.0456)His+(−0.1946)Met+(0.0308)Phe+(−0.0646)Trp; 0.830, 0.854, 0.858, 0.868, 0. 842,0.862, 0.837, 0.852, (0.9492)+(0.0100)Gln+(−0.0463)His+(−0.1974)Met+(0.0010)Lys+(0.0310)Phe+(−0.0651)Trp; 0.832, 0.856, 0. 858,0.867, 0.846, 0.864, 0.843, 0.855, (0.8859)+(0.0101)Gln+(−0.0449)His+(0.0079)Tyr+(−0.2036)Met+(0.0287)Phe+(−0.0666)Trp; 0.844,0.867, 0.858, 0.875, 0.859, 0.877, 0.856, 0.867,(1.9144)+(−0.0985)Asn+(0.0116)Gln+(−0.0373)His+(−0.0484)Cit+(0.0186)Phe+(−0.0747)Trp; 0.810, 0.833, 0.858, 0.844, 0.822, 0.847, 0.820, 0. 833,(1.4444)+(0.0069)Gln+(−0.0551)His+(−0.0066)Lys+(−0.0012)Leu+(0.0192)Phe+(−0.0744)Trp; 0.813, 0.834, 0.858, 0.842, 0.82 3,0.848, 0.822, 0.834, (1.4226)+(0.0070)Gln+(−0.0556)His+(−0.0070)Lys+(0.0185)Phe+(−0.0747)Trp; 0.801, 0.824, 0.857, 0.836, 0. 809,0.834, 0.814, 0.823, (1.5132)+(0.0064)Gln+(−0.0614)His+(−0.0170)Tyr+(0.0240)Phe+(−0.0738)Trp; 0.838, 0.858, 0.857, 0.878, 0. 831,0.868, 0.853, 0.857, (0.8895)+(0.0079)Gln+(−0.0176)Val+(−0.2523)Met+(0.0391)Ile+(0.0373)Phe+(−0.0600)Trp; 0.842, 0.865, 0. 857,0.877, 0.854, 0.863, 0.853, 0.862, (1.4326)+(−0.0806)Asn+(0.0122)Gln+(−0.0417)His+(−0.1327)Met+(0.0285)Phe+(−0.0597)Tr p; 0.810,0.828, 0.857, 0.837, 0.820, 0.838, 0.814, 0.827,(1.5141)+(0.0058)Gln+(−0.0585)His+(−0.0046)Leu+(0.0205)Phe+(−0.0777)Trp;0.813, 0.835, 0.856, 0.838, 0.835, 0.855, 0.815, 0.836, (1.2693)+(0.0080)Gln+(−0.0481)His+(−0.0557)Cit+(0.0201)Phe+(−0.08 74)Trp;0.820, 0.844, 0.856, 0.852, 0.841, 0.864, 0.818, 0.844, (1.2255)+(0.0092)Gln+(−0.0419)His+(−0.0565)Cit+(−0.0074)Lys+(0.0216)Phe+(−0.0828)Trp; 0.803, 0.830, 0.856, 0.844, 0.813, 0.844, 0. 815,0.829,(1.4926)+(0.0073)Gln+(−0.0562)His+(−0.0143)Tyr+(−0.0061)Lys+(0.0236)Phe+(−0.0704)Trp;0.800, 0.824, 0.855, 0.838, 0.810, 0.834, 0.808, 0.823,(1.5624)+(0.0064)Gln+(−0.0594)His+(−0.0159)Tyr+(−0.0031)Leu+(0.0255)Phe+(−0.0730)Trp;0.832, 0. 854, 0.855, 0.865, 0.840, 0.859, 0.851, 0.854,(2.1707)+(−0.1074)Asn+(0.0104)Gln+(−0.0506)His+(−0.0033)Tyr+(0.0180)Phe+(−0.06 52)Trp;0.838, 0.855, 0.855, 0.865, 0.843, 0.858, 0.852, 0.854, (2.1490)+(−0.1092)Asn+(0.0104)Gln+(−0.0504)His+(0.0170)Phe+(−0. 0662)Trp;0.821, 0.844, 0.854, 0.850, 0.833, 0.860, 0.835, 0.845, (3.9190)+(−0.0317)Cit+(−0.0149)Val+(−0.1434)Met+(0.0414)Ile+(0.0240)Phe+(−0.0598)Trp; 0.835, 0.855, 0.853, 0.866, 0.842, 0.859, 0. 853,0.855,(2.1356)+(−0.1071)Asn+(0.0106)Gln+(−0.0493)His+(−0.0017)Lys+(0.0173)Phe+(−0.0654)Trp;0.813, 0.837, 0.853, 0.844, 0.835, 0.858, 0.806, 0.836,(1.3628)+(0.0079)Gln+(−0.0444)His+(−0.0557)Cit+(−0.0054)Leu+(0.0237)Phe+(−0.0854)Trp;0.832, 0. 856, 0.853, 0.874, 0.847, 0.864, 0.822, 0.852,(1.0094)+(0.0114)Gln+(−0.0439)His+(−0.0175)Arg+(−0.1644)Met+(0.0294)Phe+(−0.06 34)Trp;0.801, 0.824, 0.853, 0.841, 0.806, 0.837, 0.810, 0.823, (1.6890)+(0.0062)Gln+(−0.0559)His+(−0.0132)Tyr+(−0.0043)Val+(0.0252)Phe+(−0.0711)Trp; 0.837, 0.856, 0.853, 0.868, 0.843, 0.859, 0. 850,0.855,(2.2231)+(−0.1084)Asn+(0.0103)Gln+(−0.0483)His+(−0.0033)Leu+(0.0190)Phe+(−0.0649)Trp;0.836, 0.855, 0.852, 0.867, 0.843, 0.857, 0.848, 0.854,(2.2347)+(−0.1077)Asn+(0.0105)Gln+(−0.0506)His+(−0.0045)Ile+(0.0180)Phe+(−0.0656)Trp;0.840, 0. 863, 0.852, 0.883, 0.836, 0.878, 0.856, 0.863,(0.8547)+(0.0106)Gln+(−0.0386)His+(−0.0043)Ala+(−0.1722)Met+(0.0308)Phe+(−0.05 94)Trp;0.820, 0.841, 0.852, 0.853, 0.823, 0.854, 0.838, 0.842, (3.4029)+(0.0020)Ser+(−0.0158)Val+(−0.1764)Met+(0.0402)Ile+(0.0268)Phe+(−0.0567)Trp; 0.807, 0.833, 0.852, 0.845, 0.826, 0.850, 0. 807,0.832,(1.3754)+(0.0084)Gln+(−0.0483)His+(−0.0548)Cit+(−0.0155)Tyr+(0.0254)Phe+(−0.0821)Trp;0.804, 0.825, 0.852, 0.835, 0.807, 0.843, 0.821, 0.827,(1.7109)+(0.0059)Gln+(−0.0552)His+(−0.0101)Val+(0.0099)Leu+(0.0178)Phe+(−0.0744)Trp;0.813, 0.8 37, 0.851, 0.846, 0.831, 0.858, 0.808, 0.836,(1.4770)+(0.0078)Gln+(−0.0429)His+(−0.0539)Cit+(−0.0043)Val+(0.0228)Phe+(−0.083 7)Trp;0.835, 0.857, 0.851, 0.877, 0.840, 0.866, 0.835, 0.854, (1.2210)+(0.0100)Gln+(−0.0383)His+(−0.0054)Val+(−0.1938)Met+(0.0342)Phe+(−0.0607)Trp; 0.809, 0.836, 0.851, 0.855, 0.826, 0.848, 0. 797,0.832,(1.4109)+(0.0092)Gln+(−0.0555)His+(−0.0276)Arg+(−0.0080)Tyr+(0.0226)Phe+(−0.0720)Trp;0.819, 0.840, 0.851, 0.854, 0.821, 0.847, 0.839, 0.840,(3.2389)+(−0.0194)Val+(−0.2122)Met+(0.0097)Lys+(0.0427)Ile+(0.0309)Phe+(−0.0610)Trp;0.810, 0.82 8, 0.851, 0.840, 0.813, 0.840, 0.817, 0.827,(1.6683)+(0.0058)Gln+(−0.0547)His+(−0.0054)Val+(0.0212)Phe+(−0.0746)Trp;0.810, 0. 833, 0.851, 0.846, 0.820, 0.849, 0.817, 0.833,(1.6012)+(0.0066)Gln+(−0.0516)His+(−0.0041)Val+(−0.0055)Lys+(0.0210)Phe+(−0.07 20)Trp;0.816, 0.837, 0.851, 0.853, 0.830, 0.849, 0.799, 0.833, (1.3773)+(0.0091)Gln+(−0.0556)His+(−0.0286)Arg+(0.0199)Phe+(−0. 0745)Trp;0.839, 0.857, 0.850, 0.872, 0.838, 0.863, 0.852, 0.856, (2.4322)+(−0.1072)Asn+(0.0102)Gln+(−0.0444)His+(−0.0050)Val+(0.0189)Phe+(−0.0612)Trp; 0.816, 0.842, 0.850, 0.852, 0.840, 0.858, 0. 806,0.839,(1.2382)+(0.0096)Gln+(−0.0473)His+(−0.0416)Cit+(−0.0197)Arg+(0.0214)Phe+(−0.0817)Trp;0.835, 0.859, 0.850, 0.869, 0.847, 0.886, 0.836, 0.860,(2.1595)+(0.0080)Gln+(−0.0500)Cit+(−0.0125)Val+(−0.1881)Met+(0.0368)Ile+(−0.0598)Trp;0.811, 0. 838, 0.850, 0.855, 0.830, 0.851, 0.801, 0.835,(1.3783)+(0.0092)Gln+(−0.0549)His+(−0.0280)Arg+(−0.0010)Lys+(0.0199)Phe+(−0.07 39)Trp;0.818, 0.838, 0.850, 0.843, 0.840, 0.849, 0.813, 0.836, (3.6030)+(−0.0400)Cit+(−0.1257)Met+(0.0411)Ile+(−0.0228)Leu+(0.0269)Phe+(−0.0700)Trp; 0.824, 0.846, 0.850, 0.851, 0.832, 0.862, 0. 851,0.849, (3.4958)+(0.0197)Tyr+(−0.0169)Val+(−0.1900)Met+(0.0398)Ile+(0.0212)Phe+(−0.0598)Trp; 0.828, 0.855, 0.849, 0.863, 0. 850,0.877, 0.826, 0.854, (1.9611)+(0.0097)Gln+(−0.0329)His+(−0.0475)Cit+(−0.1561)Met+(0.0101)Ile+(−0.0631)Trp; 0.827, 0.849, 0.849,0.861, 0.823, 0.868, 0.855, 0.852,(3.6056)+(−0.0029)Ala+(−0.0139)Val+(−0.1476)Met+(0.0386)Ile+(0.0243)Phe+(−0.0529)Trp;0.832, 0.858, 0.849, 0.873, 0.838, 0.883, 0.844, 0.860, (1.0945)+(0.0090)Gln+(−0.0329)His+(−0.0066)Ala+(−0.0546)Cit+(0.0224)Phe+(−0.0770)Trp; 0.810, 0.832, 0.849, 0.845, 0.822, 0.843, 0.8 11,0.830, (1.6167)+(0.0072)Gln+(−0.0573)His+(−0.0057)Lys+(−0.0092)Ile+(0.0202)Phe+(−0.0740)Trp; 0.801, 0.824, 0.848, 0.841, 0. 810,0.832, 0.801, 0.821, (1.7185)+(0.0069)Gln+(−0.0622)His+(−0.0146)Tyr+(−0.0106)Ile+(0.0253)Phe+(−0.0729)Trp; 0.812, 0.836, 0.848,0.844, 0.836, 0.852, 0.805, 0.834,(1.4235)+(0.0083)Gln+(−0.0485)His+(−0.0547)Cit+(−0.0084)Ile+(0.0221)Phe+(−0.0860)Trp; 0.811, 0.824, 0.848, 0.831, 0.815, 0.846, 0.809, 0.825, (2.1163)+(0.0056)Gln+(−0.0577)His+(−0.0737)Trp; 0.809, 0.824, 0.848, 0. 832,0.815, 0.846, 0.809, 0.825, (2.1319)+(0.0056)Gln+(−0.0574)His+(−0.0004)Leu+(−0.0735)Trp; 0.833, 0.858, 0.848, 0.879, 0.840, 0.853,0.847, 0.855, (0.9592)+(0.0121)Gln+(−0.0472)His+(−0.1920)Met+(−0.0243)Orn+(0.0373)Phe+(−0.0657)Trp; 0.815, 0.838, 0.8 48,0.858, 0.828, 0.851, 0.797, 0.833, (1.4616)+(0.0090)Gln+(−0.0524)His+(−0.0286)Arg+(−0.0046)Leu+(0.0226)Phe+(−0.0727)Trp; 0.806,0.833, 0.848, 0.840, 0.827, 0.847, 0.819, 0.833, (1.3150)+(0.0086)Gln+(−0.0506)His+(−0.0475)Cit+(−0.0116)Orn+(0.0226)Phe+(−0.0866)Trp; 0.808, 0.827, 0.848, 0.839, 0.819, 0.834, 0.807, 0.8 25,(1.6962)+(0.0065)Gln+(−0.0624)His+(−0.0126)Ile+(0.0203)Phe+(−0.0774)Trp; 0.821, 0.840, 0.848, 0.852, 0.823, 0.849, 0.836, 0.840,(3.5940)+(−0.0158)Val+(−0.1719)Met+(0.0401)Ile+(0.0260)Phe+(−0.0568)Trp;0.817, 0.839, 0.847, 0.852, 0.822, 0.848, 0.836, 0.840,(3.5883)+(0.0003)His+(−0.0159)Val+(−0.1724)Met+(0.0403)Ile+(0.0261)Phe+(−0.0568)Trp; 0.830, 0.852, 0.847, 0.868, 0.83 9,0.855, 0.838, 0.850, (1.2919)+(−0.0059)Ser+(0.0107)Gln+(−0.0456)His+(−0.1879)Met+(0.0293)Phe+(−0.0657)Trp; 0.807, 0.828, 0. 847,0.842, 0.814, 0.838, 0.810, 0.826, (1.7332)+(0.0061)Gln+(−0.0570)His+(−0.0039)Val+(−0.0062)Ile+(0.0215)Phe+(−0.0749)Tr p; 0.835,0.857, 0.847, 0.872, 0.841, 0.854, 0.856, 0.855,(2.1735)+(−0.1012)Asn+(0.0115)Gln+(−0.0525)His+(−0.0183)Orn+(0.0209)Phe+(−0.0669)Trp;0.824, 0.844, 0.847, 0.855, 0.825, 0.855, 0.845, 0.845,(4.1964)+(−0.0366)Asn+(−0.0156)Val+(−0.1313)Met+(0.0398)Ile+(0.0227)Phe+(−0.0531)Trp; 0.822, 0.841, 0.847, 0.848, 0.8 39,0.849, 0.824, 0.840, (4.4190)+(−0.0614)Asn+(−0.0403)Cit+(0.0345)Ile+(−0.0238)Leu+(0.0191)Phe+(−0.0731)Trp; 0.822, 0.849, 0.847,0.856, 0.842, 0.865, 0.834, 0.849,(1.7543)+(0.0088)Gln+(−0.0415)His+(0.0185)Tyr+(−0.2011)Met+(0.0057)Ile+(−0.0612)Trp; 0.804, 0.822, 0.847, 0.833, 0.811, 0.844, 0.804, 0.823,(2.2437)+(0.0057)Gln+(−0.0571)His+(−0.0067)Tyr+(−0.0705)Trp; 0.838, 0.861, 0.847, 0.870, 0.853, 0.877, 0.844, 0.861, (2.6610)+(−0.1010)Asn+(0.0111)Gln+(−0.0339)His+(−0.0475)Cit+(0.0018)Ile+(−0.06 78)Trp;0.801, 0.822, 0.847, 0.832, 0.810, 0.844, 0.805, 0.823, (2.2188)+(0.0057)Gln+(−0.0578)His+(−0.0072)Tyr+(0.0008)Leu+(−0. 0708)Trp;0.827, 0.848, 0.846, 0.862, 0.815, 0.876, 0.858, 0.853, (1.2964)+(0.0071)Gln+(−0.0476)His+(−0.0067)Ala+(0.0194)Phe+(−0. 0686)Trp;0.818, 0.839, 0.846, 0.852, 0.822, 0.848, 0.836, 0.840, (3.5995)+(−0.0002)Thr+(−0.0158)Val+(−0.1712)Met+(0.0401)Ile+(0.0259)Phe+(−0.0567)Trp; 0.824, 0.848, 0.846, 0.863, 0.827, 0.874, 0. 835,0.850,(2.2081)+(0.0080)Gln+(−0.0295)His+(−0.0082)Val+(−0.1935)Met+(0.0236)Ile+(−0.0479)Trp;0.843, 0.865, 0.846, 0.882, 0.836, 0.879, 0.873, 0.867,(1.9077)+(−0.1020)Asn+(0.0111)Gln+(−0.0396)His+(−0.0051)Ala+(0.0197)Phe+(−0.0605)Trp;0.826, 0. 852, 0.846, 0.869, 0.816, 0.878, 0.858, 0.856,(1.2862)+(0.0078)Gln+(−0.0444)His+(−0.0064)Ala+(−0.0050)Lys+(0.0198)Phe+(−0.06 50)Trp;0.822, 0.849, 0.846, 0.855, 0.842, 0.864, 0.834, 0.849, (1.7216)+(0.0091)Gln+(−0.0451)His+(0.0175)Tyr+(−0.1988)Met+(0.0045)Leu+(−0.0625)Trp; 0.818, 0.840, 0.846, 0.852, 0.820, 0.851, 0. 840,0.841, (3.7058)+(−0.0188)Val+(−0.1737)Met+(0.0369)Ile+(0.0073)Leu+(0.0243)Phe+(−0.0565)Trp; 0.849, 0.870, 0.846, 0.884, 0. 866,0.869, 0.842, 0.865, (1.2353)+(−0.0844)Asn+(0.0123)Gln+(−0.0572)Cit+(−0.1339)Met+(0.0312)Phe+(−0.0816)Trp; 0.827, 0.853, 0.846,0.861, 0.851, 0.872, 0.823, 0.852,(1.9652)+(0.0102)Gln+(−0.0374)His+(−0.0467)Cit+(−0.1531)Met+(0.0058)Leu+(−0.0647)Trp; 0.806, 0.828, 0.846, 0.837, 0.818, 0.850, 0.811, 0.829, (2.0237)+(0.0067)Gln+(−0.0541)His+(−0.0073)Lys+(0.0032)Leu+(−0.069 9)Trp; 0.822,0.845, 0.846, 0.858, 0.831, 0.862, 0.825, 0.844, (2.0596)+(0.0087)Gln+(−0.0426)His+(−0.1785)Met+(0.0077)Ile+(−0.0 551)Trp;0.838, 0.861, 0.845, 0.870, 0.852, 0.877, 0.844, 0.861, (2.6642)+(−0.1008)Asn+(0.0112)Gln+(−0.0346)His+(−0.0474)Cit+(0.0010)Leu+(−0.0680)Trp; 0.804, 0.826, 0.845, 0.837, 0.819, 0.833, 0. 807,0.824, (1.7177)+(0.0067)Gln+(−0.0653)His+(−0.0171)Ile+(0.0040)Leu+(0.0188)Phe+(−0.0782)Trp; 0.817, 0.845, 0.845, 0.858, 0. 831,0.862, 0.825, 0.844, (2.0573)+(0.0087)Gln+(−0.0424)His+(−0.1778)Met+(−0.0003)Lys+(0.0078)Ile+(−0.0550)Trp; 0.825, 0.848, 0.845,0.864, 0.814, 0.876, 0.853, 0.852,(1.3320)+(0.0071)Gln+(−0.0466)His+(−0.0066)Ala+(−0.0020)Leu+(0.0207)Phe+(−0.0677)Trp; 0.815, 0.838, 0.845, 0.858, 0.831, 0.848, 0.795, 0.833, (1.5171)+(0.0093)Gln+(−0.0560)His+(−0.0277)Arg+(−0.0073)Ile+(0.0213)Phe+(−0.0735)Trp; 0.838, 0.862, 0.845, 0.870, 0.855, 0.877, 0.84 5,0.862, (2.6256)+(−0.1026)Asn+(0.0111)Gln+(−0.0338)His+(−0.0476)Cit+(0.0045)Tyr+(−0.0693)Trp; 0.829, 0.853, 0.845, 0.869, 0. 836,0.856, 0.842, 0.850, (0.9474)+(0.0108)Gln+(−0.0459)His+(−0.0074)Thr+(−0.1743)Met+(0.0289)Phe+(−0.0619)Trp; 0.817, 0.841, 0.845,0.854, 0.821, 0.847, 0.845, 0.842,(3.7672)+(−0.0158)Val+(−0.1671)Met+(−0.0097)Orn+(0.0439)Ile+(0.0270)Phe+(−0.0574)Trp;0.821, 0.844, 0.845, 0.856, 0.833, 0.858, 0.825, 0.843, (1.9866)+(0.0092)Gln+(−0.0476)His+(−0.1771)Met+(0.0064)Leu+(−0.05 76)Trp;0.819, 0.845, 0.845, 0.864, 0.810, 0.874, 0.848, 0.849, (1.3242)+(0.0074)Gln+(−0.0483)His+(−0.0064)Ala+(−0.0097)Tyr+(0.0233)Phe+(−0.0659)Trp; 0.824, 0.847, 0.845, 0.854, 0.829, 0.879, 0. 843,0.851,(4.5234)+(−0.0035)Ala+(−0.0342)Cit+(−0.0106)Val+(−0.1031)Met+(0.0385)Ile+(−0.0523)Trp;0.823, 0.845, 0.845, 0.8 66, 0.831, 0.842, 0.822, 0.840,(0.8426)+(0.0071)Gln+(−0.2328)Met+(0.0264)Ile+(−0.0171)Leu+(0.0352)Phe+(−0.0745)Trp; 0.845, 0. 868,0.845, 0.882, 0.852, 0.886, 0.852, 0.868, (2.8826)+(−0.1094)Asn+(0.0093)Gln+(−0.0522)Cit+(−0.0094)Val+(0.0189)Ile+(−0.07 29)Trp;0.818, 0.844, 0.844, 0.857, 0.833, 0.857, 0.825, 0.843, (1.9930)+(0.0092)Gln+(−0.0479)His+(−0.1765)Met+(−0.0009)Ile+(0.0068)Leu+(−0.0577)Trp; 0.841, 0.861, 0.844, 0.870, 0.852, 0.877, 0. 843,0.860,(2.7090)+(−0.1006)Asn+(0.0112)Gln+(−0.0339)His+(−0.0474)Cit+(−0.0674)Trp;0.806, 0.830, 0.844, 0.835, 0.831, 0.838, 0.810, 0.829,(3.5322)+(0.0038)Ser+(−0.0221)His+(−0.1374)Met+(0.0091)Ile+(0.0199)Phe+(−0.0684)Trp;0.816, 0.840, 0.844, 0.86 3, 0.825, 0.855, 0.798, 0.835,(1.5894)+(0.0090)Gln+(−0.0487)His+(−0.0284)Arg+(−0.0051)Val+(0.0232)Phe+(−0.0702)Trp; 0.824, 0. 847,0.844, 0.867, 0.811, 0.875, 0.850, 0.851, (1.4335)+(0.0070)Gln+(−0.0441)His+(−0.0064)Ala+(−0.0035)Val+(0.0220)Phe+(−0.06 55)Trp;0.835, 0.854, 0.844, 0.866, 0.842, 0.852, 0.852, 0.853, (2.3932)+(−0.0049)Ser+(−0.1052)Asn+(0.0109)Gln+(−0.0504)His+(0.0160)Phe+(−0.0671)Trp; 0.828, 0.847, 0.844, 0.855, 0.831, 0.875, 0. 840,0.850,(3.4379)+(−0.0060)Ala+(−0.0470)Cit+(0.0336)Ile+(−0.0206)Leu+(0.0211)Phe+(−0.0711)Trp;0.829, 0.853, 0.844, 0.867, 0.854, 0.850, 0.815, 0.847,(0.6734)+(0.0097)Gln+(−0.0603)Cit+(−0.2015)Met+(0.0053)Ile+(0.0327)Phe+(−0.0882)Trp;0.839, 0.8 62, 0.844, 0.872, 0.852, 0.878, 0.843, 0.861,(2.7071)+(−0.0988)Asn+(0.0113)Gln+(−0.0330)His+(−0.0475)Cit+(−0.0013)Lys+(−0.06 65)Trp

List (2) of Linear Discriminants Searched in Example 4

The linear discriminants searched in Example 4 above are listed below.Before each equation, “the value of ROC_AUC for the pancreatic cancergroup and the other cancers group with validation”, “the value ofROC_AUC for the pancreatic cancer group and the other cancers groupwithout validation”, “the value of ROC_AUC for the pancreatic cancergroup and the healthy group”, “the value of ROC_AUC for the pancreaticcancer group and the lung cancer group”, “the value of ROC_AUC for thepancreatic cancer group and the colorectal cancer group”, “the value ofROC_AUC for the pancreatic cancer group and the prostatic cancer group”,“the value of ROC_AUC for the pancreatic cancer group and the breastcancer group”, and “the average value of the value of ROC_AUC for thepancreatic cancer group and the lung cancer group, the value of ROC_AUCfor the pancreatic cancer group and the colorectal cancer group, thevalue of ROC_AUC for the pancreatic cancer group and the prostaticcancer group, and the value of ROC_AUC for the pancreatic cancer groupand the breast cancer group” obtained for the equation are additionallylisted.

0.833, 0.849, 0.880, 0.860, 0.830, 0.861, 0.852, 0.851, (5.7313)+(0.0114)Ser+(−0.0226)Val+(−0.2232)Met+(0.0489)Ile+(0.0676)Phe+(−0.0795)Trp; 0.843, 0.860, 0.879, 0.871, 0.852, 0.863, 0.84 9,0.859, (3.2393)+(0.0037)Ser+(0.0106)Gln+(−0.0517)His+(−0.2085)Met+(0.0643)Phe+(−0.0934)Trp; 0.847, 0.866, 0.875, 0.874, 0. 863,0.873, 0.848, 0.865, (3.3463)+(0.0126)Gln+(−0.0436)His+(−0.0447)Cit+(−0.1986)Met+(0.0623)Phe+(−0.0962)Trp; 0.831, 0.849, 0.875,0.860, 0.832, 0.859, 0.847, 0.849,(6.5393)+(0.0075)Thr+(−0.0236)Val+(−0.2243)Met+(0.0503)Ile+(0.0644)Phe+(−0.0798)Trp; 0.831, 0.848, 0.875, 0.846, 0.855, 0.862, 0.829, 0.848,(5.6907)+(0.0141)Ser+(−0.0317)His+(0.0235)Tyr+(−0.1891)Met+(0.0540)Phe+(−0.1005)Trp; 0.845, 0.862, 0.874, 0.868, 0.858, 0.859, 0.858, 0.861, (3.3530)+(0.0109)Gln+(−0.0510)His+(0.0190)Tyr+(−0.2214)Met+(0.0579)Phe+(−0.1003)Trp; 0.853, 0.869, 0.874, 0.880, 0.860, 0.865,0.863, 0.867, (4.2094)+(−0.0824)Asn+(0.0129)Gln+(−0.0437)His+(−0.1432)Met+(0.0582)Phe+(−0.0944)Trp; 0.847, 0.860, 0.8 74,0.871, 0.851, 0.858, 0.851, 0.858, (3.4357)+(0.0110)Gln+(−0.0515)His+(−0.2021)Met+(0.0618)Phe+(−0.0934)Trp; 0.843, 0.862, 0. 873,0.875, 0.854, 0.860, 0.846, 0.859, (3.3761)+(0.0122)Gln+(−0.0510)His+(−0.0129)Arg+(−0.1828)Met+(0.0603)Phe+(−0.0912)Tr p; 0.827,0.842, 0.873, 0.852, 0.837, 0.846, 0.824, 0.840,(5.1029)+(0.0103)Ser+(−0.1930)Met+(0.0483)Ile+(−0.0349)Leu+(0.0703)Phe+(−0.0947)Trp; 0.842, 0.860, 0.873, 0.871, 0.851, 0.858, 0.851, 0.858, (3.4428)+(0.0110)Gln+(−0.0515)His+(−0.2017)Met+(−0.0004)Ile+(0.0619)Phe+(−0.0934)Trp; 0.831, 0.847, 0.873, 0.854, 0.84 7,0.858, 0.822, 0.845, (6.5948)+(0.0166)Ser+(−0.0568)Asn+(−0.0244)His+(−0.1212)Met+(0.0564)Phe+(−0.0924)Trp; 0.823, 0.841, 0. 873,0.845, 0.845, 0.852, 0.813, 0.839, (5.9004)+(0.0127)Ser+(−0.0325)His+(0.0022)Thr+(−0.1690)Met+(0.0591)Phe+(−0.0924)Trp; 0.821,0.840, 0.872, 0.842, 0.842, 0.851, 0.818, 0.838, (5.7918)+(0.0136)Ser+(−0.0319)His+(−0.1675)Met+(0.0041)Ile+(0.0574)Phe+(−0.0919)Trp;0.843, 0.861, 0.872, 0.873, 0.851, 0.860, 0.851, 0.85 9,(3.5849)+(0.0113)Gln+(−0.0496)His+(−0.1909)Met+(−0.0042)Lys+(0.0619)Phe+(−0.0920)Trp; 0.849, 0.863, 0.872, 0.883, 0.834, 0. 865,0.868, 0.862, (3.5810)+(0.0087)Gln+(−0.0238)Val+(−0.2622)Met+(0.0473)Ile+(0.0706)Phe+(−0.0865)Trp; 0.841, 0.860, 0.871, 0.871,0.850, 0.857, 0.852, 0.857, (3.4364)+(0.0111)Gln+(−0.0511)His+(−0.0013)Thr+(−0.1980)Met+(0.0611)Phe+(−0.0931)Trp; 0. 825, 0.840,0.870, 0.844, 0.843, 0.850, 0.813, 0.838, (5.8961)+(0.0135)Ser+(−0.0317)His+(−0.1628)Met+(0.0582)Phe+(−0.0919)Trp; 0.824,0.843, 0.870, 0.846, 0.850, 0.857, 0.809, 0.841, (6.1358)+(0.0136)Ser+(−0.0254)His+(−0.0246)Cit+(−0.1553)Met+(0.0573)Phe+(−0.0933)Trp; 0.843, 0.860, 0.870, 0.875, 0.850, 0.858, 0.846, 0.8 57,(3.5663)+(0.0108)Gln+(−0.0477)His+(−0.1968)Met+(−0.0060)Leu+(0.0661)Phe+(−0.0927)Trp; 0.822, 0.840, 0.870, 0.845, 0.844, 0.850,0.812, 0.838, (5.9269)+(0.0139)Ser+(−0.0312)His+(−0.0025)Arg+(−0.1585)Met+(0.0579)Phe+(−0.0915)Trp; 0.822, 0.840, 0.8 69,0.845, 0.843, 0.852, 0.814, 0.838, (5.9641)+(0.0138)Ser+(−0.0308)His+(−0.1585)Met+(−0.0016)Lys+(0.0583)Phe+(−0.0914)Trp; 0.847,0.865, 0.868, 0.880, 0.851, 0.854, 0.863, 0.862, (3.3457)+(0.0126)Gln+(−0.0513)His+(−0.2042)Met+(−0.0199)Orn+(0.0685)Phe+(−0.0938)Trp; 0.847, 0.864, 0.868, 0.881, 0.847, 0.865, 0.850, 0.8 61,(3.8166)+(0.0108)Gln+(−0.0403)His+(−0.0082)Val+(−0.2049)Met+(0.0696)Phe+(−0.0882)Trp; 0.836, 0.851, 0.867, 0.857, 0.857, 0.857,0.818, 0.847, (6.6277)+(0.0157)Ser+(−0.0622)Asn+(−0.0280)Cit+(−0.1182)Met+(0.0533)Phe+(−0.1019)Trp; 0.823, 0.842, 0.8 67,0.847, 0.844, 0.851, 0.817, 0.840, (5.9967)+(0.0140)Ser+(−0.0306)His+(−0.1613)Met+(−0.0068)Orn+(0.0602)Phe+(−0.0920)Trp; 0.838,0.855, 0.867, 0.858, 0.842, 0.863, 0.870, 0.858, (6.6808)+(0.0304)Tyr+(−0.0240)Val+(−0.2256)Met+(0.0495)Ile+(0.0541)Phe+(−0.0870)Trp;0.855, 0.871, 0.867, 0.879, 0.863, 0.872, 0.864, 0.87 0,(5.1147)+(−0.1213)Asn+(0.0130)Gln+(−0.0367)His+(−0.0468)Cit+(0.0353)Phe+(−0.1017)Trp; 0.831, 0.848, 0.866, 0.845, 0.863, 0. 854,0.821, 0.846, (5.5721)+(0.0124)Ser+(−0.0334)Cit+(0.0250)Tyr+(−0.1942)Met+(0.0498)Phe+(−0.1139)Trp; 0.837, 0.854, 0.866, 0.856,0.861, 0.854, 0.836, 0.852, (6.1112)+(0.0162)Ser+(−0.0693)Asn+(0.0246)Tyr+(−0.1529)Met+(0.0489)Phe+(−0.1123)Trp; 0.8 23, 0.841,0.865, 0.843, 0.849, 0.847, 0.812, 0.838, (5.5939)+(0.0121)Ser+(−0.0340)Cit+(−0.1749)Met+(0.0079)Ile+(0.0527)Phe+(−0.1049)Trp;0.823, 0.841, 0.865, 0.850, 0.843, 0.850, 0.806, 0.837,(6.0598)+(0.0126)Ser+(−0.0268)His+(−0.1552)Met+(−0.0084)Leu+(0.0638)Phe+(−0.0910)Trp; 0.832, 0.849, 0.864, 0.857, 0.835, 0.8 60,0.849, 0.850,(7.0685)+(−0.0221)Cit+(−0.0209)Val+(−0.1817)Met+(0.0477)Ile+(0.0568)Phe+(−0.0783)Trp;0.830, 0.849, 0.864, 0.848, 0.849, 0.843, 0.855, 0.849,(6.4939)+(0.0249)Ser+(−0.0090)Gly+(−0.0267)His+(−0.1616)Met+(0.0530)Phe+(−0.0933)Trp; 0. 836, 0.852,0.864, 0.869, 0.840, 0.843, 0.838, 0.847, (3.2359)+(0.0076)Gln+(−0.2239)Met+(0.0412)Ile+(−0.0322)Leu+(0.0708)Phe+(−0.1031)Trp;0.842, 0.859, 0.863, 0.869, 0.848, 0.852, 0.856, 0.85 7,(5.2008)+(0.0008)Ser+(−0.1224)Asn+(0.0111)Gln+(−0.0451)His+(0.0345)Phe+(−0.0989)Trp; 0.826, 0.844, 0.862, 0.858, 0.840, 0. 854,0.809, 0.840,(6.3284)+(0.0121)Ser+(−0.0201)His+(−0.0086)Val+(−0.1642)Met+(0.0656)Phe+(−0.0865)Trp;0.842, 0.859, 0.862, 0.869, 0.850, 0.852, 0.858, 0.857,(5.2386)+(−0.1225)Asn+(0.0111)Gln+(−0.0451)His+(0.0025)Tyr+(0.0332)Phe+(−0.0998)Trp; 0.8 45, 0.859,0.862, 0.870, 0.849, 0.851, 0.856, 0.856, (5.2312)+(−0.1218)Asn+(0.0112)Gln+(−0.0451)His+(0.0342)Phe+(−0.0988)Trp; 0. 829,0.846, 0.862, 0.859, 0.826, 0.851, 0.849, 0.846, (6.7116)+(−0.0200)Val+(−0.1902)Met+(0.0516)Ile+(−0.0070)Leu+(0.0608)Phe+(−0.0785)Trp;0.824, 0.841, 0.862, 0.847, 0.850, 0.844, 0.804, 0.83 6,(5.7739)+(0.0112)Ser+(0.0015)Thr+(−0.0327)Cit+(−0.1711)Met+(0.0548)Phe+(−0.1054)Trp; 0.829, 0.845, 0.862, 0.852, 0.846, 0. 843,0.823, 0.841, (6.2199)+(0.0156)Ser+(−0.0681)Asn+(−0.1302)Met+(0.0034)Ile+(0.0527)Phe+(−0.1034)Trp; 0.831, 0.845, 0.862, 0.853,0.848, 0.844, 0.819, 0.841, (6.3132)+(0.0149)Ser+(−0.0690)Asn+(0.0018)Thr+(−0.1309)Met+(0.0540)Phe+(−0.1040)Trp; 0.8 28, 0.846,0.861, 0.859, 0.826, 0.851, 0.851, 0.847, (6.8200)+(−0.0004)His+(−0.0224)Val+(−0.1919)Met+(0.0475)Ile+(0.0589)Phe+(−0.0777)Trp;0.829, 0.846, 0.861, 0.859, 0.826, 0.852, 0.852, 0.84 7,(6.6545)+(−0.0232)Val+(−0.2023)Met+(0.0028)Lys+(0.0480)Ile+(0.0598)Phe+(−0.0786)Trp; 0.850, 0.867, 0.861, 0.884, 0.840, 0. 881,0.871, 0.869, (4.0370)+(0.0111)Gln+(−0.0441)His+(−0.0071)Ala+(−0.1656)Met+(0.0590)Phe+(−0.0844)Trp; 0.847, 0.864, 0.861, 0.880,0.851, 0.865, 0.850, 0.862, (3.6131)+(0.0121)Gln+(−0.0505)His+(−0.0094)Pro+(−0.1825)Met+(0.0649)Phe+(−0.0977)Trp; 0. 833, 0.846,0.861, 0.859, 0.826, 0.852, 0.850, 0.847, (6.8122)+(−0.0225)Val+(−0.1923)Met+(0.0477)Ile+(0.0589)Phe+(−0.0778)Trp; 0.835,0.851, 0.861, 0.864, 0.832, 0.857, 0.854, 0.852,(7.8537)+(−0.0508)Asn+(−0.0220)Val+(−0.1418)Met+(0.0466)Ile+(0.0553)Phe+(−0.0753)Trp; 0.835, 0.852, 0.861, 0.862, 0.835, 0.879, 0.842, 0. 854,(6.5739)+(0.0127)Ser+(−0.0243)His+(−0.0067)Ala+(−0.1254)Met+(0.0548)Phe+(−0.0833)Trp; 0.826, 0.845, 0.861, 0.854, 0.84 6,0.846, 0.818, 0.841, (6.3177)+(0.0157)Ser+(−0.0674)Asn+(−0.0012)Arg+(−0.1247)Met+(0.0533)Phe+(−0.1030)Trp; 0.826, 0.843, 0. 861,0.850, 0.842, 0.847, 0.824, 0.841, (6.5117)+(−0.0332)Cit+(−0.1536)Met+(0.0533)Ile+(−0.0359)Leu+(0.0612)Phe+(−0.0907)Trp; 0.823,0.841, 0.861, 0.847, 0.849, 0.844, 0.804, 0.836, (5.7692)+(0.0117)Ser+(−0.0329)Cit+(−0.1666)Met+(0.0008)Orn+(0.0540)Phe+(−0.1049)Trp;0.821, 0.838, 0.860, 0.842, 0.838, 0.852, 0.819, 0.83 8,(4.4648)+(0.0082)Gln+(−0.0521)His+(−0.0472)Cit+(0.0240)Phe+(−0.1033)Trp; 0.824, 0.842, 0.860, 0.845, 0.845, 0.851, 0.820, 0. 840,(7.6321)+(0.0112)Ser+(−0.0847)Asn+(−0.0205)His+(−0.0262)Cit+(0.0345)Phe+(−0.0975)Trp; 0.832, 0.845, 0.860, 0.854, 0.84 7,0.843, 0.820, 0.841, (6.3080)+(0.0155)Ser+(−0.0680)Asn+(−0.1264)Met+(0.0534)Phe+(−0.1033)Trp; 0.816, 0.827, 0.860, 0.832, 0. 821,0.836, 0.821, 0.828, (4.5801)+(0.0064)Gln+(−0.0606)His+(0.0228)Phe+(−0.1005)Trp; 0.809, 0.826, 0.860, 0.835, 0.817, 0.836, 0. 817,0.826, (4.5675)+(0.0066)Gln+(−0.0604)His+(−0.0091)Tyr+(0.0265)Phe+(−0.0969)Trp; 0.828, 0.846, 0.860, 0.859, 0.826, 0.852, 0. 851,0.847,(6.8341)+(−0.0007)Arg+(−0.0225)Val+(−0.1907)Met+(0.0477)Ile+(0.0588)Phe+(−0.0776)Trp;0.816, 0.838, 0.860, 0.84 5, 0.834, 0.852, 0.818, 0.837,(4.4559)+(0.0084)Gln+(−0.0520)His+(−0.0468)Cit+(−0.0071)Tyr+(0.0269)Phe+(−0.1005)Trp; 0.825, 0. 841,0.860, 0.850, 0.843, 0.854, 0.808, 0.839, (6.2539)+(0.0133)Ser+(−0.0296)His+(−0.0058)Pro+(−0.1457)Met+(0.0590)Phe+(−0.09 45)Trp;0.846, 0.862, 0.860, 0.873, 0.852, 0.858, 0.859, 0.860, (5.3365)+(−0.1137)Asn+(0.0118)Gln+(−0.0420)His+(−0.0073)Lys+(0.0373)Phe+(−0.0959)Trp; 0.825, 0.842, 0.860, 0.849, 0.850, 0.848, 0. 802,0.837,(5.9599)+(0.0126)Ser+(−0.0319)Cit+(−0.1558)Met+(−0.0037)Lys+(0.0548)Phe+(−0.1027)Trp;0.828, 0.841, 0.860, 0.847, 0.849, 0.843, 0.804, 0.836,(5.7741)+(0.0118)Ser+(−0.0322)Cit+(−0.1667)Met+(0.0543)Phe+(−0.1048)Trp;0.831, 0.847, 0.860, 0.8 59, 0.827, 0.852, 0.854, 0.848,(6.8895)+(−0.0222)Val+(−0.1915)Met+(−0.0055)Orn+(0.0496)Ile+(0.0595)Phe+(−0.0778)Trp; 0.845, 0.863,0.859, 0.877, 0.854, 0.857, 0.850, 0.860, (4.9605)+(−0.1109)Asn+(0.0129)Gln+(−0.0448)His+(−0.0163)Arg+(0.0359)Phe+(−0. 0953)Trp;0.830, 0.850, 0.859, 0.859, 0.844, 0.867, 0.827, 0.849, (4.7362)+(0.0100)Gln+(−0.0440)His+(−0.0493)Cit+(−0.0136)Lys+(0.0313)Phe+(−0.0978)Trp; 0.823, 0.845, 0.859, 0.854, 0.842, 0.858, 0. 817,0.843,(4.2587)+(0.0100)Gln+(−0.0524)His+(−0.0345)Cit+(−0.0181)Arg+(0.0267)Phe+(−0.0985)Trp;0.831, 0.846, 0.859, 0.856, 0.847, 0.844, 0.820, 0.842,(6.3562)+(0.0158)Ser+(−0.0655)Asn+(−0.1269)Met+(−0.0048)Orn+(0.0549)Phe+(−0.1031)Trp;0.818, 0. 838, 0.859, 0.846, 0.837, 0.841, 0.814, 0.834,(7.4338)+(0.0120)Ser+(−0.0844)Asn+(−0.0261)His+(−0.0053)Arg+(0.0350)Phe+(−0.09 49)Trp;0.823, 0.841, 0.859, 0.846, 0.849, 0.842, 0.806, 0.836, (5.7600)+(0.0112)Ser+(−0.0349)Cit+(0.0033)Arg+(−0.1716)Met+(0.0546)Phe+(−0.1056)Trp; 0.831, 0.846, 0.859, 0.855, 0.847, 0.846, 0. 820,0.842,(6.3922)+(0.0159)Ser+(−0.0665)Asn+(−0.1215)Met+(−0.0021)Lys+(0.0537)Phe+(−0.1022)Trp;0.819, 0.840, 0.859, 0.855, 0.831, 0.849, 0.811, 0.837,(4.2627)+(0.0095)Gln+(−0.0580)His+(−0.0238)Arg+(−0.0038)Tyr+(0.0284)Phe+(−0.0936)Trp;0.844, 0. 861, 0.859, 0.873, 0.849, 0.849, 0.864, 0.859,(5.1561)+(−0.1186)Asn+(0.0122)Gln+(−0.0454)His+(−0.0148)Orn+(0.0385)Phe+(−0.09 92)Trp;0.822, 0.842, 0.859, 0.843, 0.855, 0.846, 0.809, 0.838, (7.1177)+(−0.0245)His+(0.0071)Thr+(−0.0262)Cit+(−0.1480)Met+(0.0513)Phe+(−0.0948)Trp; 0.823, 0.840, 0.859, 0.853, 0.833, 0.848, 0. 812,0.837, (4.2643)+(0.0095)Gln+(−0.0580)His+(−0.0241)Arg+(0.0269)Phe+(−0.0950)Trp; 0.819, 0.839, 0.859, 0.846, 0.836, 0.844, 0. 820,0.836,(7.5330)+(0.0121)Ser+(−0.0841)Asn+(−0.0248)His+(−0.0042)Lys+(0.0364)Phe+(−0.0944)Trp;0.838, 0.853, 0.858, 0.855, 0.853, 0.841, 0.859, 0.852,(6.9057)+(0.0270)Ser+(−0.0612)Asn+(−0.0091)Gly+(−0.1277)Met+(0.0488)Phe+(−0.1027)Trp;0.834, 0. 850, 0.858, 0.852, 0.854, 0.839, 0.847, 0.848,(6.3156)+(0.0231)Ser+(−0.0087)Gly+(−0.0233)Cit+(−0.1668)Met+(0.0499)Phe+(−0.10 44)Trp;0.823, 0.836, 0.858, 0.843, 0.834, 0.837, 0.821, 0.834, (7.4516)+(0.0109)Ser+(−0.0888)Asn+(−0.0270)His+(0.0342)Phe+(−0. 0962)Trp;0.835, 0.851, 0.858, 0.852, 0.854, 0.834, 0.855, 0.849, (5.8771)+(0.0234)Ser+(−0.0091)Gly+(0.0152)Tyr+(−0.1942)Met+(0.0470)Phe+(−0.1114)Trp; 0.818, 0.837, 0.858, 0.841, 0.844, 0.837, 0. 815,0.834, (6.8189)+(−0.0308)His+(0.0060)Thr+(−0.1554)Met+(0.0031)Ile+(0.0508)Phe+(−0.0930)Trp; 0.846, 0.862, 0.858, 0.878, 0. 849,0.851, 0.853, 0.858, (5.4093)+(−0.1206)Asn+(0.0110)Gln+(−0.0380)His+(−0.0110)Leu+(0.0437)Phe+(−0.0973)Trp; 0.837, 0.851, 0.858,0.868, 0.844, 0.854, 0.818, 0.846,(7.0621)+(0.0148)Ser+(−0.0652)Asn+(−0.0106)Val+(−0.1219)Met+(0.0642)Phe+(−0.0901)Trp; 0.821, 0.839, 0.858, 0.842, 0.847, 0.836, 0.819, 0.836, (5.0497)+(0.0117)Ser+(0.0233)Tyr+(−0.2099)Met+(0.0021)Ile+(0.0498)Phe+(−0.1154)Trp; 0.823, 0.842, 0.858, 0.845, 0.851, 0.840, 0.814, 0.837,(5.1803)+(0.0126)Ser+(−0.0051)Arg+(0.0239)Tyr+(−0.1988)Met+(0.0497)Phe+(−0.1142)Trp;0.844, 0.860, 0.858, 0.874, 0.850, 0.849, 0.850, 0.856,(5.3633)+(−0.1193)Asn+(0.0115)Gln+(−0.0448)His+(−0.0111)Ile+(0.0387)Phe+(−0.0985)Trp; 0.822, 0.843, 0.8 57,0.857, 0.833, 0.856, 0.814, 0.840, (4.4823)+(0.0098)Gln+(−0.0544)His+(−0.0190)Arg+(−0.0074)Lys+(0.0300)Phe+(−0.0931)Trp; 0.806,0.828, 0.857, 0.839, 0.798, 0.870, 0.835, 0.835, (4.9288)+(0.0110)Ser+(−0.0175)His+(−0.0279)Val+(−0.2471)Met+(0.0594)Ile+(0.0520)Phe; 0.825, 0.843, 0.857, 0.840, 0.854, 0.844, 0.825, 0.84 1,(6.7583)+(−0.0303)His+(0.0055)Thr+(0.0214)Tyr+(−0.1732)Met+(0.0469)Phe+(−0.1008)Trp; 0.820, 0.839, 0.857, 0.850, 0.832, 0. 855,0.816, 0.838,(4.7194)+(0.0078)Gln+(−0.0458)His+(−0.0439)Cit+(−0.0051)Val+(0.0284)Phe+(−0.1000)Trp;0.841, 0.857, 0.857, 0.869, 0.823, 0.882, 0.875, 0.862,(7.3604)+(−0.0067)Ala+(−0.0199)Val+(−0.1555)Met+(0.0506)Ile+(0.0532)Phe+(−0.0690)Trp; 0.8 20, 0.836,0.857, 0.847, 0.825, 0.847, 0.822, 0.835, (4.8410)+(0.0080)Gln+(−0.0534)His+(−0.0128)Lys+(0.0296)Phe+(−0.0951)Trp; 0. 827,0.844, 0.857, 0.848, 0.850, 0.838, 0.821, 0.839, (7.6779)+(−0.0494)Asn+(−0.0244)His+(0.0079)Thr+(−0.1163)Met+(0.0491)Phe+(−0.0939)Trp;0.835, 0.851, 0.857, 0.866, 0.826, 0.879, 0.843, 0.85 3,(5.3914)+(0.0086)Gln+(−0.0274)His+(−0.0137)Val+(−0.1738)Met+(0.0347)Ile+(−0.0669)Trp; 0.857, 0.874, 0.857, 0.886, 0.869, 0. 867,0.853, 0.869,(4.0729)+(−0.0942)Asn+(0.0132)Gln+(−0.0523)Cit+(−0.1417)Met+(0.0541)Phe+(−0.1117)Trp;0.818, 0.837, 0.857, 0.844, 0.834, 0.837, 0.821, 0.834,(7.4828)+(0.0111)Ser+(−0.0874)Asn+(−0.0267)His+(−0.0032)Orn+(0.0351)Phe+(−0.0962)Trp; 0. 817, 0.838,0.857, 0.843, 0.846, 0.835, 0.809, 0.833, (6.9264)+(−0.0304)His+(0.0064)Thr+(−0.0019)Arg+(−0.1497)Met+(0.0513)Phe+(−0.0928)Trp;0.831, 0.846, 0.857, 0.861, 0.825, 0.856, 0.843, 0.84 6,(7.8869)+(0.0080)Ser+(−0.1053)Asn+(−0.0174)Val+(0.0268)Ile+(0.0379)Phe+(−0.0882)Trp; 0.827, 0.842, 0.856, 0.848, 0.847, 0. 846,0.814, 0.839,(7.4518)+(0.0099)Ser+(−0.0955)Asn+(−0.0369)Cit+(0.0065)Orn+(0.0297)Phe+(−0.1064)Trp

List (1) of Logistic Regression Equations Searched in Example 5

The logistic regression equations searched in Example 5 above are listedbelow. Before each equation, “the value of ROC_AUC for the pancreaticcancer group and the lung cancer group with validation”, “the value ofROC_AUC for the pancreatic cancer group and the lung cancer groupwithout validation”, “the value of ROC_AUC for the pancreatic cancergroup and the healthy group”, “the value of ROC_AUC for the pancreaticcancer group and the other cancers group”, “the value of ROC_AUC for thepancreatic cancer group and the colorectal cancer group”, “the value ofROC_AUC for the pancreatic cancer group and the prostatic cancer group”,“the value of ROC_AUC for the pancreatic cancer group and the breastcancer group”, and “the average value of the value of ROC_AUC for thepancreatic cancer group and the lung cancer group, the value of ROC_AUCfor the pancreatic cancer group and the colorectal cancer group, thevalue of ROC_AUC for the pancreatic cancer group and the prostaticcancer group, and the value of ROC_AUC for the pancreatic cancer groupand the breast cancer group” obtained for the equation are additionallylisted.

0.879, 0.901, 0.799, 0.867, 0.834, 0.859, 0.850, 0.861, (2.5017)+(−0.1544)Asn+(0.0144)Gln+(−0.0136)Pro+(−0.0179)Val+(0.0647)Phe+(−0.0751)Trp; 0.879, 0.900, 0.825, 0.868, 0.840, 0.855, 0.8 49,0.861, (1.5408)+(−0.1050)Asn+(0.0143)Gln+(−0.0196)Val+(−0.1804)Met+(0.0788)Phe+(−0.0595)Trp; 0.879, 0.899, 0.808, 0.865, 0. 818,0.870, 0.869, 0.864, (2.4184)+(−0.1460)Asn+(0.0137)Gln+(−0.0063)Ala+(−0.0174)Val+(0.0542)Phe+(−0.0581)Trp; 0.878, 0.899, 0.806,0.859, 0.832, 0.846, 0.822, 0.850,(2.3121)+(−0.1378)Asn+(0.0149)Gln+(−0.0291)Arg+(−0.0209)Val+(0.0646)Phe+(−0.0644)Trp;0.877, 0.896, 0.794, 0.863, 0.820, 0.895, 0.843, 0.864, (3.0546)+(−0.1157)Asn+(0.0150)Gln+(−0.0065)Ala+(−0.0363)Cit+(−0.0103)Val+(−0.0537)Trp; 0.877, 0.899, 0.770, 0.854, 0.809, 0.880, 0. 810,0.849,(3.2431)+(−0.0996)Asn+(0.0151)Gln+(−0.0064)Ala+(−0.0237)Arg+(−0.0122)Val+(−0.0440)Trp;0.876, 0.898, 0.829, 0.87 0, 0.844, 0.865, 0.854, 0.865,(2.0985)+(−0.1578)Asn+(0.0147)Gln+(−0.0434)Cit+(−0.0184)Val+(0.0625)Phe+(−0.0746)Trp; 0.876, 0. 893,0.817, 0.860, 0.829, 0.849, 0.847, 0.854, (2.9307)+(−0.1647)Asn+(0.0124)Gln+(−0.0209)Val+(0.0566)Phe+(−0.0686)Trp; 0.875, 0.892,0.780, 0.854, 0.803, 0.884, 0.840, 0.855, (3.6223)+(−0.1220)Asn+(0.0132)Gln+(−0.0067)Ala+(−0.0129)Val+(−0.0490)Trp; 0. 874, 0.894,0.805, 0.860, 0.830, 0.841, 0.846, 0.853, (3.2658)+(−0.0073)Ser+(−0.1562)Asn+(0.0131)Gln+(−0.0209)Val+(0.0537)Phe+(−0.0697)Trp;0.874, 0.894, 0.806, 0.860, 0.825, 0.846, 0.851, 0.85 4,(2.7168)+(−0.1504)Asn+(0.0132)Gln+(−0.0088)Thr+(−0.0197)Val(0.0537)Phe+(−0.0663)Trp; 0.874, 0.898, 0.766, 0.857, 0.808, 0. 880,0.836, 0.855,(3.5580)+(−0.1181)Asn+(0.0142)Gln+(−0.0057)Ala+(−0.0086)Pro+(−0.0110)Val+(−0.0528)Trp;0.873, 0.891, 0.80 7, 0.864, 0.828, 0.888, 0.853, 0.865,(2.2278)+(−0.1175)Asn+(0.0154)Gln+(−0.0077)Ala+(−0.0464)Cit+(−0.0694)Trp; 0.873, 0.894, 0. 766,0.854, 0.820, 0.865, 0.816, 0.849, (3.9874)+(−0.1306)Asn+(0.0133)Gln+(−0.0113)Pro+(−0.0132)Val+(−0.0617)Trp; 0.873, 0.894, 0.798,0.863, 0.827, 0.893, 0.838, 0.863,(2.7457)+(−0.1095)Asn+(0.0149)Gln+(−0.0072)Ala+(−0.0424)Cit+(−0.0107)Leu+(−0.0615)Trp; 0.873, 0.893, 0.789, 0.856, 0.803, 0.886, 0.850, 0.858, (3.5353)+(−0.1236)Asn+(0.0131)Gln+(−0.0068)Ala+(−0.0146)Val+(0.0076)Ile+(−0.0475)Trp; 0.873, 0.896, 0.810, 0.855, 0.811, 0.855, 0. 840,0.850,(0.6642)+(0.0125)Gln+(−0.0052)Ala+(−0.0163)Val+(−0.2337)Met+(0.0706)Phe+(−0.0564)Trp;0.873, 0.895, 0.767, 0.856, 0.801, 0.880, 0.851, 0.857,(3.3049)+(−0.1056)Asn+(0.0142)Gln+(−0.0107)Thr+(−0.0066)Ala+(−0.0119)Val+(−0.0475)Trp;0.873, 0. 893, 0.769, 0.851, 0.813, 0.873, 0.806, 0.846,(2.9725)+(−0.0932)Asn+(0.0146)Gln+(−0.0074)Ala+(−0.0245)Arg+(−0.0128)Leu+(−0.0 524)Trp;0.873, 0.894, 0.805, 0.860, 0.819, 0.859, 0.860, 0.858, (2.1851)+(−0.1339)Asn+(0.0128)Gln+(−0.0075)Ala+(−0.0221)Leu+(0.0535)Phe+(−0.0678)Trp; 0.872, 0.896, 0.789, 0.865, 0.829, 0.890, 0. 844,0.865,(2.3256)+(−0.1109)Asn+(0.0163)Gln+(−0.0063)Ala+(−0.0432)Cit+(−0.0095)Pro+(−0.0722)Trp;0.872, 0.893, 0.756, 0.85 2, 0.799, 0.866, 0.840, 0.850,(4.0269)+(−0.0137)Ser+(−0.1075)Asn+(0.0146)Gln+(−0.0071)Ala+(−0.0129)Val+(−0.0515)Trp; 0.872, 0.891,0.793, 0.860, 0.828, 0.879, 0.833, 0.858, (2.1632)+(−0.1039)Asn+(0.0161)Gln+(−0.0077)Ala+(−0.0331)Cit+(−0.0180)Arg+(−0.0639)Trp;0.872, 0.896, 0.760, 0.854, 0.825, 0.869, 0.793, 0.846,(3.6419)+(−0.1091)Asn+(0.0151)Gln+(−0.0226)Arg+(−0.0101)Pro+(−0.0129)Val+(−0.0571)Trp; 0.872, 0.891, 0.819, 0.860, 0.825, 0. 852,0.856, 0.856,(2.9395)+(−0.1699)Asn+(0.0128)Gln+(−0.0274)Val+(0.0126)Leu+(0.0531)Phe+(−0.0668)Trp;0.872, 0.896, 0.785, 0.861, 0.821, 0.877, 0.837, 0.858,(3.7526)+(−0.1329)Asn+(0.0133)Gln+(−0.0127)Pro+(−0.0174)Val+(0.0198)Ile+(−0.0589)Trp; 0. 872, 0.891,0.822, 0.860, 0.829, 0.851, 0.849, 0.855, (2.8423)+(−0.1619)Asn+(0.0127)Gln+(−0.0065)His+(−0.0202)Val+(0.0568)Phe+(−0.0667)Trp;0.871, 0.892, 0.780, 0.854, 0.802, 0.883, 0.841, 0.85 5,(3.6590)+(−0.1254)Asn+(0.0130)Gln+(−0.0067)Ala+(−0.0134)Val+(0.0017)Lys+(−0.0493)Trp; 0.871, 0.892, 0.818, 0.859, 0.828, 0. 847,0.846, 0.853,(2.9627)+(−0.1677)Asn+(0.0123)Gln+(−0.0214)Val+(0.0014)Lys+(0.0567)Phe+(−0.0687)Trp;0.871, 0.893, 0.832, 0.870, 0.859, 0.859, 0.836, 0.862,(1.8582)+(−0.1462)Asn+(0.0139)Gln+(−0.0518)Cit+(−0.0240)Leu+(0.0618)Phe+(−0.0862)Trp; 0. 871, 0.892,0.778, 0.853, 0.801, 0.883, 0.838, 0.854, (3.6602)+(−0.1232)Asn+(0.0130)Gln+(0.0034)His+(−0.0068)Ala+(−0.0132)Val+(−0.0498)Trp;0.871, 0.893, 0.818, 0.860, 0.829, 0.849, 0.848, 0.85 5,(2.9200)+(−0.1649)Asn+(0.0124)Gln+(−0.0211)Val+(0.0010)Ile+(0.0566)Phe+(−0.0684)Trp; 0.871, 0.897, 0.783, 0.863, 0.836, 0. 878,0.821, 0.858,(3.4654)+(−0.1234)Asn+(0.0150)Gln+(−0.0357)Cit+(−0.0107)Pro+(−0.0106)Val+(−0.0669)Trp;0.871, 0.894, 0.75 7, 0.855, 0.818, 0.862, 0.823, 0.849,(3.6841)+(−0.1155)Asn+(0.0142)Gln+(−0.0099)Thr+(−0.0107)Pro+(−0.0124)Val+(−0.0608)Trp; 0.871,0.885, 0.788, 0.848, 0.815, 0.858, 0.814, 0.843,(4.2016)+(−0.1395)Asn+(0.0118)Gln+(−0.0164)Val+(−0.0598)Trp; 0.871, 0.892, 0.786, 0.856, 0.800, 0.884, 0.855, 0.858, (3.5356)+(−0.1318)Asn+(0.0137)Gln+(−0.0064)Ala+(−0.0223)Val+(0.0172)Leu+(−0.047 6)Trp; 0.871,0.895, 0.783, 0.856, 0.809, 0.883, 0.834, 0.855, (3.3196)+(−0.0940)Asn+(0.0137)Gln+(−0.0059)Ala+(−0.0119)Val+(−0.0813)Met+(−0.0441)Trp; 0.871, 0.894, 0.827, 0.871, 0.836, 0.883, 0. 878,0.873,(0.9598)+(−0.1351)Asn+(0.0160)Gln+(−0.0078)Ala+(−0.0520)Cit+(0.0412)Phe+(−0.0816)Trp;0.871, 0.893, 0.764, 0.853, 0.815, 0.869, 0.816, 0.848,(2.4550)+(−0.0982)Asn+(0.0161)Gln+(−0.0067)Ala+(−0.0235)Arg+(−0.0096)Pro+(−0.0644)Trp;0.871, 0. 892, 0.776, 0.849, 0.793, 0.878, 0.831, 0.848,(3.8206)+(−0.1186)Asn+(0.0132)Gln+(−0.0064)Ala+(−0.0133)Tyr+(−0.0124)Val+(−0.0 433)Trp;0.870, 0.895, 0.747, 0.856, 0.822, 0.855, 0.821, 0.849, (4.3566)+(−0.0117)Ser+(−0.1182)Asn+(0.0145)Gln+(−0.0114)Pro+(−0.0134)Val+(−0.0652)Trp;0.870, 0.894, 0.798, 0.863, 0.843, 0.845, 0.839, 0.855,(2.2275)+(−0.1449)Asn+(0.0134)Gln+(−0.0143)Pro+(−0.0207)Leu+(0.0611)Phe+(−0.0880)Trp;0.870, 0.888, 0.802, 0.8 58, 0.833, 0.870, 0.821, 0.853,(3.6506)+(−0.1325)Asn+(0.0136)Gln+(−0.0376)Cit+(−0.0136)Val+(−0.0640)Trp; 0.870, 0.891, 0.757, 0.847,0.810, 0.861, 0.796, 0.840, (2.9262)+(−0.0988)Asn+(0.0150)Gln+(−0.0074)Ala+(−0.0240)Arg+(−0.0184)Ile+(−0.0589)Trp; 0. 870,0.893, 0.804, 0.866, 0.829, 0.892, 0.853, 0.867, (2.2383)+(−0.1100)Asn+(0.0157)Gln+(−0.0076)Ala+(−0.0462)Cit+(−0.0036)Lys+(−0.0673)Trp; 0.870, 0.891, 0.785, 0.856, 0.820, 0.878, 0.825, 0.8 54,(2.7544)+(−0.1122)Asn+(0.0154)Gln+(−0.0070)Ala+(−0.0444)Cit+(−0.0185)Ile+(−0.0670)Trp; 0.870, 0.889, 0.779, 0.853, 0.807, 0.876,0.838, 0.852, (3.3036)+(−0.1156)Asn+(0.0126)Gln+(−0.0077)Ala+(−0.0137)Leu+(−0.0579)Trp; 0.870, 0.891, 0.793, 0.864, 0.8 32,0.829, 0.885, 0.859, (3.9221)+(−0.1340)Asn+(−0.0131)Gly+(0.0158)Gln+(−0.0219)Val+(0.0448)Phe+(−0.0796)Trp; 0.870, 0.887, 0.777,0.851, 0.812, 0.868, 0.825, 0.848,(2.4154)+(−0.1035)Asn+(0.0149)Gln+(−0.0082)Ala+(−0.0250)Arg+(−0.0605)Trp;0.870, 0. 887, 0.776, 0.846, 0.817, 0.862, 0.787, 0.838,(3.8220)+(−0.1157)Asn+(0.0139)Gln+(−0.0248)Arg+(−0.0159)Val+(−0.0531)Trp; 0.869, 0.894,0.769, 0.855, 0.820, 0.865, 0.818, 0.849, (3.9537)+(−0.1292)Asn+(0.0135)Gln+(−0.0032)His+(−0.0113)Pro+(−0.0129)Val+(−0.0608)Trp;0.869, 0.886, 0.770, 0.848, 0.817, 0.844, 0.818, 0.841,(4.5838)+(−0.0110)Ser+(−0.1288)Asn+(0.0129)Gln+(−0.0166)Val+(−0.0625)Trp; 0.869, 0.892, 0.809, 0.859, 0.826, 0.841, 0.852, 0.8 53,(2.7855)+(−0.1607)Asn+(0.0136)Gln+(−0.0189)Val+(−0.0174)Orn+(0.0584)Phe+(−0.0730)Trp;0.869, 0.890, 0.784, 0.858, 0.833, 0.859, 0.825, 0.852,(4.0173)+(−0.0107)Ser+(−0.1216)Asn+(0.0147)Gln+(−0.0370)Cit+(−0.0139)Val+(−0.0667)Trp; 0.869, 0.892, 0. 812,0.847, 0.806, 0.831, 0.825, 0.839, (3.0304)+(−0.1605)Asn+(0.0130)Gln+(−0.0378)Tyr+(−0.0203)Val+(0.0723)Phe+(−0.0542)Tr p; 0.869,0.889, 0.769, 0.854, 0.808, 0.874, 0.846, 0.854,(2.7396)+(−0.1199)Asn+(0.0143)Gln+(−0.0068)Ala+(−0.0106)Pro+(−0.0701)Trp; 0.869, 0.893, 0.809, 0.867, 0.835, 0.891, 0.848, 0.867, (2.0980)+(−0.0922)Asn+(0.0156)Gln+(−0.0068)Ala+(−0.0424)Cit+(−0.0745)Met+(−0.0643)Trp; 0.869, 0.893, 0.766, 0.854, 0.819, 0.864, 0. 816,0.848,(4.0000)+(−0.1318)Asn+(0.0133)Gln+(−0.0113)Pro+(−0.0134)Val+(0.0005)Lys+(−0.0618)Trp;0.869, 0.891, 0.751, 0.863, 0.833, 0.841, 0.868, 0.858,(4.7039)+(−0.0974)Asn+(−0.0145)Gly+(0.0172)Gln+(−0.0123)Pro+(−0.0150)Val+(−0.0765)Trp;0.869, 0. 891, 0.808, 0.850, 0.827, 0.843, 0.797, 0.839,(0.5776)+(0.0144)Gln+(−0.0263)Arg+(−0.0188)Val+(−0.2381)Met+(0.0788)Phe+(−0.06 05)Trp;0.869, 0.891, 0.802, 0.858, 0.817, 0.884, 0.836, 0.857, (2.5560)+(−0.1120)Asn+(0.0154)Gln+(−0.0071)Ala+(−0.0471)Cit+(−0.0183)Tyr+(−0.0614)Trp; 0.869, 0.895, 0.775, 0.858, 0.816, 0.872, 0. 837,0.855,(3.8763)+(−0.1432)Asn+(0.0143)Gln+(−0.0124)Pro+(−0.0277)Val+(0.0274)Leu+(−0.0606)Trp;0.869, 0.890, 0.804, 0.854, 0.844, 0.836, 0.794, 0.841,(2.2097)+(−0.1272)Asn+(0.0134)Gln+(−0.0300)Arg+(−0.0274)Leu+(0.0631)Phe+(−0.0756)Trp;0.868, 0. 883, 0.790, 0.852, 0.806, 0.872, 0.853, 0.853,(2.6780)+(−0.1261)A sn+(0.0130)Gln+(−0.0085)Ala+(−0.0678)Trp; 0.868,0.892, 0.790, 0.863, 0.823, 0.878, 0.860, 0.863,(1.8784)+(−0.0968)Asn+(0.0169)Gln+(−0.0135)Thr+(−0.0073)Ala+(−0.0476)Cit+(−0.0673)Trp; 0. 868,0.890, 0.793, 0.861, 0.821, 0.858, 0.867, 0.859, (1.5610)+(−0.1371)Asn+(0.0149)Gln+(−0.0067)Ala+(−0.0125)Pro+(0.0418)Phe+(−0.0840)Trp;0.868, 0.891, 0.803, 0.862, 0.838, 0.881, 0.818, 0.85 7,(3.2905)+(−0.0971)Asn+(0.0142)Gln+(−0.0331)Cit+(−0.0121)Val+(−0.0973)Met+(−0.0571)Trp; 0.868, 0.891, 0.765, 0.854, 0.804, 0.873,0.848, 0.854, (2.9967)+(−0.0973)Asn+(0.0138)Gln+(−0.0124)Thr+(−0.0074)Ala+(−0.0126)Leu+(−0.0556)Trp; 0.868, 0.886, 0. 725,0.831, 0.773, 0.867, 0.778, 0.826, (2.8819)+(−0.1086)Asn+(0.0152)Gln+(−0.0074)Ala+(−0.0259)Arg+(−0.0170)Val; 0.868, 0.890, 0.767,0.863, 0.821, 0.859, 0.879, 0.862,(4.3460)+(−0.1007)Asn+(−0.0129)Gly+(0.0163)Gln+(−0.0053)Ala+(−0.0153)Val+(−0.0615)Trp; 0.868, 0.892, 0.770, 0.852, 0.798, 0.876, 0.841, 0.852, (3.4683)+(−0.1172)Asn+(0.0145)Gln+(−0.0070)Ala+(−0.0105)Val+(−0.0181)Orn+(−0.0524)Trp; 0.868, 0.884, 0.818, 0.856, 0.842, 0.832, 0. 826,0.846, (2.7211)+(−0.1542)Asn+(0.0111)Gln+(−0.0265)Leu+(0.0551)Phe+(−0.0827)Trp; 0.868, 0.890, 0.760, 0.858, 0.827, 0.838, 0. 853,0.852,(4.5717)+(−0.0861)Asn+(−0.0138)Gly+(0.0171)Gln+(−0.0230)Arg+(−0.0176)Val+(−0.0683)Trp;0.868, 0.889, 0.784, 0.86 2, 0.826, 0.874, 0.854, 0.861,(2.5701)+(−0.0129)Ser+(−0.1025)Asn+(0.0167)Gln+(−0.0081)Ala+(−0.0454)Cit+(−0.0725)Trp; 0.868, 0.891,0.764, 0.844, 0.790, 0.853, 0.824, 0.839, (1.1007)+(−0.1035)Asn+(0.0148)Gln+(−0.0057)Ala+(−0.0213)Val+(−0.1699)Met+(0. 0641)Phe;0.868, 0.886, 0.775, 0.849, 0.811, 0.854, 0.824, 0.844, (3.8432)+(−0.1227)Asn+(0.0129)Gln+(−0.0113)Thr+(−0.0152)Val+(−0.0579)Trp;0.868, 0.885, 0.794, 0.850, 0.816, 0.861, 0.819, 0.845,(4.1486)+(−0.1405)Asn+(0.0117)Gln+(−0.0175)Val+(0.0051)Ile+(−0.0589)Trp;0.867, 0.889, 0.763, 0.846, 0.816, 0.852, 0.789, 0.83 7,(4.1138)+(−0.0085)Ser+(−0.1076)Asn+(0.0146)Gln+(−0.0237)Arg+(−0.0160)Val+(−0.0558)Trp; 0.867, 0.889, 0.802, 0.858, 0.820, 0.878,0.843, 0.857, (3.3758)+(−0.0996)Asn+(0.0143)Gln+(−0.0330)Val+(−0.1527)Met+(0.0356)Leu+(−0.0467)Trp; 0.867, 0.889, 0.7 78,0.846, 0.817, 0.858, 0.787, 0.838, (3.9146)+(−0.1262)Asn+(0.0135)Gln+(−0.0276)Arg+(−0.0178)Val+(0.0066)Lys+(−0.0538)Trp; 0.867,0.890, 0.786, 0.857, 0.825, 0.865, 0.829, 0.852,(3.1465)+(−0.1133)Asn+(0.0153)Gln+(−0.0128)Thr+(−0.0413)Cit+(−0.0123)Val+(−0.0627)Trp; 0.867, 0.887, 0.791, 0.853, 0.823, 0.868, 0.811, 0.847, (3.6993)+(−0.0978)Asn+(0.0128)Gln+(−0.0144)Val+(−0.1127)Met+(−0.0514)Trp; 0.867, 0.892, 0.787, 0.859, 0.826, 0.815, 0.87 2,0.851, (2.2295)+(−0.0139)Gly+(0.0160)Gln+(−0.0198)Val+(−0.2375)Met+(0.0599)Phe+(−0.0726)Trp; 0.867, 0.891, 0.787, 0.852, 0. 826,0.867, 0.794, 0.845, (3.5652)+(−0.1161)Asn+(0.0146)Gln+(−0.0224)Cit+(−0.0204)Arg+(−0.0143)Val+(−0.0567)Trp; 0.867, 0.888, 0.801,0.855, 0.819, 0.850, 0.846, 0.851,(1.3118)+(−0.1192)Asn+(0.0154)Gln+(−0.0083)Ala+(−0.0274)Arg+(0.0394)Phe+(−0.0721)Trp;0.867, 0.893, 0.764, 0.848, 0.809, 0.858, 0.805, 0.841, (4.1690)+(−0.1271)Asn+(0.0134)Gln+(−0.0105)Pro+(−0.0136)Tyr+(−0.0129)Val+(−0.0553)Trp; 0.867, 0.889, 0.767, 0.852, 0.808, 0.863, 0. 836,0.849,(2.2550)+(−0.0915)Asn+(0.0156)Gln+(−0.0097)Thr+(−0.0079)Ala+(−0.0222)Arg+(−0.0592)Trp;0.867, 0.890, 0.813, 0.86 9, 0.853, 0.861, 0.850, 0.864,(1.0150)+(−0.1443)Asn+(0.0168)Gln+(−0.0547)Cit+(−0.0161)Pro+(0.0524)Phe+(−0.1028)Trp; 0.867, 0. 889,0.742, 0.835, 0.778, 0.850, 0.804, 0.830, (1.7622)+(−0.1296)Asn+(0.0158)Gln+(−0.0071)Ala+(−0.0283)Arg+(−0.0220)Val+(0.04 71)Phe;0.867, 0.886, 0.768, 0.859, 0.827, 0.836, 0.869, 0.855, (4.9691)+(−0.1110)Asn+(−0.0143)Gly+(0.0155)Gln+(−0.0184)Val+(−0. 0725)Trp;0.867, 0.889, 0.751, 0.840, 0.778, 0.881, 0.809, 0.839, (2.6674)+(−0.1110)Asn+(0.0152)Gln+(−0.0075)Ala+(−00.0266)Arg+(−0.0212)Val+(0.0204)Ile; 0.867, 0.891, 0.758, 0.855, 0.805,0.871, 0.855, 0.855,(2.5140)+(−0.1026)Asn+(0.0153)Gln+(−0.0113)Thr+(−0.0066)Ala+(−0.0097)Pro+(−0.0680)Trp;0.867, 0.891, 0.804, 0. 864, 0.827, 0.888, 0.853, 0.865,(2.2343)+(−0.1182)Asn+(0.0153)Gln+(0.0022)His+(−0.0078)Ala+(−0.0472)Cit+(−0.0702)Trp; 0.867, 0.890,0.824, 0.861, 0.848, 0.837, 0.832, 0.852, (1.4661)+(−0.1011)Asn+(0.0128)Gln+(−0.1673)Met+(−0.0215)Leu+(0.0716)Phe+(−0. 0740)Trp;0.867, 0.893, 0.761, 0.852, 0.816, 0.855, 0.816, 0.845, (3.8915)+(−0.1273)Asn+(0.0141)Gln+(−0.0109)Pro+(−0.0117)Val+(−0.0127)Orn+(−0.0647)Trp;0.866, 0.891, 0.792, 0.858, 0.815, 0.877, 0.849, 0.858,(2.3274)+(−0.1132)Asn+(0.0163)Gln+(−0.0077)Ala+(−0.0368)Cit+(−0.0186)Orn+(−0.0697)Trp;0.866, 0.891, 0.769, 0. 848, 0.813, 0.860, 0.797, 0.840,(3.6054)+(−0.1070)Asn+(0.0144)Gln+(−0.0076)Thr+(−0.0224)Arg+(−0.0151)Val+(−0.0524)Trp; 0.86 6, 0.884,0.794, 0.849, 0.817, 0.859, 0.816, 0.844, (4.1462)+(−0.1374)Asn+(0.0120)Gln+(−0.0048)His+(−0.0158)Val+(−0.0585)Trp; 0. 866,0.888, 0.782, 0.848, 0.816, 0.865, 0.797, 0.842, (3.7457)+(−0.1167)Asn+(0.0138)Gln+(−0.0250)Arg+(−0.0176)Val+(0.0070)Ile+(−0.0518)Trp;0.866, 0.889, 0.801, 0.857, 0.835, 0.830, 0.836, 0.84 7,(2.4800)+(−0.1360)Asn+(0.0123)Gln+(−0.0118)Thr+(−0.0248)Leu+(0.0514)Phe+(−0.0784)Trp

List (1) of Linear Discriminants Searched in Example 5

The linear discriminants searched in Example 5 above are listed below.Before each equation, “the value of ROC_AUC for the pancreatic cancergroup and the lung cancer group with validation”, “the value of ROC_AUCfor the pancreatic cancer group and the lung cancer group withoutvalidation”, “the value of ROC_AUC for the pancreatic cancer group andthe healthy group”, “the value of ROC_AUC for the pancreatic cancergroup and the other cancers group”, “the value of ROC_AUC for thepancreatic cancer group and the colorectal cancer group”, “the value ofROC_AUC for the pancreatic cancer group and the prostatic cancer group”,“the value of ROC_AUC for the pancreatic cancer group and the breastcancer group”, and “the average value of the value of ROC_AUC for thepancreatic cancer group and the lung cancer group, the value of ROC_AUCfor the pancreatic cancer group and the colorectal cancer group, thevalue of ROC_AUC for the pancreatic cancer group and the prostaticcancer group, and the value of ROC_AUC for the pancreatic cancer groupand the breast cancer group” obtained for the equation are additionallylisted.

0.889, 0.900, 0.816, 0.870, 0.844, 0.860, 0.856, 0.865, (5.6262)+(−0.1579)Asn+(0.0147)Gln+(−0.0133)Pro+(−0.0175)Val+(0.0680)Phe+(−0.1047)Trp; 0.888, 0.899, 0.843, 0.872, 0.850, 0.857, 0.8 55,0.865, (4.4024)+(−0.1075)Asn+(0.0147)Gln+(−0.0196)Val+(−0.1775)Met+(0.0888)Phe+(−0.0925)Trp; 0.887, 0.899, 0.821, 0.868, 0. 824,0.876, 0.872, 0.868, (5.7041)+(−0.1372)Asn+(0.0135)Gln+(−0.0082)Ala+(−0.0168)Val+(0.0597)Phe+(−0.0875)Trp; 0.887, 0.899, 0.823,0.866, 0.842, 0.856, 0.832, 0.857,(5.4488)+(−0.1451)Asn+(0.0149)Gln+(−0.0236)Arg+(−0.0202)Val+(0.0627)Phe+(−0.0933)Trp;0.885, 0.897, 0.781, 0.860, 0.816, 0.883, 0.839, 0.859, (6.9326)+(−0.1143)Asn+(0.0143)Gln+(−0.0069)Ala+(−0.0094)Pro+(−0.0106)Val+(−0.0772)Trp; 0.884, 0.894, 0.781, 0.858, 0.829, 0.869, 0. 819,0.853,(6.9669)+(−0.1335)Asn+(0.0140)Gln+(−0.0121)Pro+(−0.0128)Val+(−0.0870)Trp;0.884, 0.895, 0.765, 0.858, 0.828, 0.857, 0.819, 0.850,(7.2847)+(−0.0106)Ser+(−0.1228)Asn+(0.0152)Gln+(−0.0123)Pro+(−0.0133)Val+(−0.0882)Trp;0.884, 0.897, 0.786, 0. 861, 0.827, 0.872, 0.832, 0.857,(6.9854)+(−0.1425)Asn+(0.0145)Gln+(−0.0126)Pro+(−0.0230)Val+(0.0187)Leu+(−0.0849)Trp; 0.884, 0.895,0.787, 0.866, 0.823, 0.876, 0.873, 0.867, (7.2130)+(−0.1026)Asn+(−0.0072)Gly+(0.0146)Gln+(−0.0076)Ala+(−0.0133)Val+(−0.0770)Trp;0.883, 0.895, 0.795, 0.860, 0.815, 0.888, 0.841, 0.860,(6.5615)+(−0.0887)Asn+(0.0138)Gln+(−0.0076)Ala+(−0.0114)Val+(−0.0771)Met+(−0.0674)Trp; 0.883, 0.897, 0.840, 0.872, 0.851, 0. 867,0.857, 0.868,(5.3307)+(−0.1611)Asn+(0.0143)Gln+(−0.0346)Cit+(−0.0181)Val+(0.0628)Phe+(−0.0999)Trp;0.883, 0.896, 0.786, 0.858, 0.816, 0.887, 0.823, 0.856,(6.6882)+(−0.1000)Asn+(0.0150)Gln+(−0.0080)Ala+(−0.0211)Arg+(−0.0123)Val+(−0.0677)Trp; 0. 883,0.897, 0.820, 0.860, 0.819, 0.864, 0.848, 0.857, (3.8867)+(0.0128)Gln+(−0.0077)Ala+(−0.0159)Val+(−0.2229)Met+(0.0786)Phe+(−0.0839)Trp;0.883, 0.897, 0.804, 0.867, 0.826, 0.897, 0.850, 0.86 7,(6.5607)+(−0.1130)Asn+(0.0146)Gln+(−0.0084)Ala+(−0.0332)Cit+(−0.0101)Val+(−0.0731)Trp; 0.883, 0.896, 0.774, 0.867, 0.839, 0.852,0.859, 0.861, (7.3561)+(−0.1163)Asn+(−0.0086)Gly+(0.0160)Gln+(−0.0122)Pro+(−0.0136)Val+(−0.0918)Trp; 0.882, 0.897, 0. 774,0.858, 0.832, 0.868, 0.802, 0.850, (6.7631)+(−0.1177)Asn+(0.0160)Gln+(−0.0215)Arg+(−0.0116)Pro+(−0.0128)Val+(−0.0819)Tr p; 0.882,0.892, 0.795, 0.858, 0.812, 0.884, 0.846, 0.858,(6.8850)+(−0.1147)Asn+(0.0131)Gln+(−0.0083)Ala+(−0.0123)Val+(−0.0721)Trp; 0.882, 0.895, 0.793, 0.864, 0.840, 0.878, 0.825, 0.859, (6.6455)+(−0.1319)Asn+(0.0155)Gln+(−0.0329)Cit+(−0.0121)Pro+(−0.0107)Val+(−0.0880)Trp; 0.882, 0.895, 0.781, 0.859, 0.809, 0.882, 0. 852,0.859,(6.5441)+(−0.1000)Asn+(0.0143)Gln+(−0.0107)Thr+(−0.0081)Ala+(−0.0118)Val+(−0.0706)Trp;0.882, 0.894, 0.804, 0.86 4, 0.828, 0.894, 0.841, 0.864,(6.2603)+(−0.1068)Asn+(0.0144)Gln+(−0.0090)Ala+(−0.0386)Cit+(−0.0116)Leu+(−0.0788)Trp; 0.882, 0.893,0.820, 0.863, 0.825, 0.864, 0.862, 0.861, (5.3683)+(−0.1256)Asn+(0.0128)Gln+(−0.0090)Ala+(−0.0224)Leu+(0.0598)Phe+(−0. 0956)Trp;0.882, 0.895, 0.773, 0.859, 0.828, 0.862, 0.825, 0.852, (6.6445)+(−0.1193)Asn+(0.0151)Gln+(−0.0100)Thr+(−0.0115)Pro+(−0.0124)Val+(−0.0851)Trp;0.882, 0.895, 0.820, 0.870, 0.844, 0.842, 0.877, 0.864,(6.2093)+(−0.1451)Asn+(−0.0066)Gly+(0.0141)Gln+(−0.0201)Val+(0.0505)Phe+(−0.0993)Trp;0.882, 0.894, 0.780, 0.8 59, 0.824, 0.873, 0.829, 0.855,(5.9832)+(−0.1014)Asn+(0.0159)Gln+(−0.0077)Ala+(−0.0201)Arg+(−0.0106)Pro+(−0.0877)Trp; 0.882, 0.894,0.800, 0.862, 0.827, 0.878, 0.839, 0.860, (6.9095)+(−0.1392)Asn+(0.0139)Gln+(−0.0134)Pro+(−0.0188)Val+(0.0238)Ile+(−0. 0821)Trp;0.882, 0.893, 0.817, 0.862, 0.832, 0.848, 0.853, 0.857, (5.4208)+(−0.1462)Asn+(0.0139)Gln+(−0.0104)Thr+(−0.0195)Val+(0.0586)Phe+(−0.0960)Trp; 0.882, 0.893, 0.813, 0.865, 0.849, 0.842, 0. 842,0.857,(5.2374)+(−0.1489)Asn+(0.0139)Gln+(−0.0137)Pro+(−0.0218)Leu+(0.0661)Phe+(−0.1155)Trp;0.882, 0.895, 0.784, 0.860, 0.832, 0.871, 0.817, 0.854,(6.6358)+(−0.1060)Asn+(0.0146)Gln+(−0.0108)Pro+(−0.0120)Val+(−0.0770)Met+(−0.0810)Trp;0.881, 0. 895, 0.794, 0.868, 0.833, 0.895, 0.847, 0.868,(5.9674)+(−0.1130)Asn+(0.0160)Gln+(−0.0077)Ala+(−0.0415)Cit+(−0.0105)Pro+(−0.0 895)Trp;0.881, 0.894, 0.779, 0.858, 0.828, 0.865, 0.819, 0.852, (6.8969)+(−0.1322)Asn+(0.0143)Gln+(−0.0119)Pro+(−0.0121)Val+(−0.0051)Orn+(−0.0876)Trp;0.881, 0.892, 0.830, 0.863, 0.837, 0.852, 0.849, 0.858,(5.6927)+(−0.1623)Asn+(0.0127)Gln+(−0.0203)Val+(0.0616)Phe+(−0.0985)Trp;0.881, 0.894, 0.781, 0.858, 0.829, 0.86 9, 0.819, 0.853,(6.9665)+(−0.1335)Asn+(0.0140)Gln+(−0.0121)Pro+(0.0001)Tyr+(−0.0128)Val+(−0.0870)Trp; 0.881, 0.893, 0.806, 0. 861,0.809, 0.893, 0.859, 0.863, (6.8469)+(−0.1179)Asn+(0.0129)Gln+(−0.0085)Ala+(−0.0159)Val+(0.0141)Ile+(−0.0686)Trp; 0.881, 0.892,0.793, 0.856, 0.806, 0.884, 0.842, 0.856, (6.9147)+(−0.1130)Asn+(0.0131)Gln+(−0.0083)Ala+(−0.0060)Tyr+(−0.0120)Val+(−0.0693)Trp;0.881, 0.893, 0.778, 0.857, 0.809, 0.877, 0.847, 0.856,(7.1932)+(−0.0103)Ser+(−0.1041)Asn+(0.0142)Gln+(−0.0084)Ala+(−0.0127)Val+(−0.0730)Trp; 0.881, 0.893, 0.823, 0.863, 0.835, 0. 846,0.850, 0.856, (5.8716)+(−0.0044)Ser+(−0.1570)Asn+(0.0131)Gln+(−0.0203)Val+(0.0591)Phe+(−0.0983)Trp; 0.880, 0.894, 0.820, 0.856,0.835, 0.842, 0.810, 0.845, (3.5425)+(0.0140)Gln+(−0.0214)Arg+(−0.0191)Val+(−0.2368)Met+(0.0827)Phe+(−0.0894)Trp; 0. 880, 0.893,0.811, 0.869, 0.834, 0.897, 0.854, 0.870, (5.9734)+(−0.1014)Asn+(0.0154)Gln+(−0.0094)Ala+(−0.0431)Cit+(−0.0076)Lys+(−0.0818)Trp; 0.880, 0.892, 0.797, 0.859, 0.808, 0.888, 0.854, 0.8 60,(6.8944)+(−0.1203)Asn+(0.0133)Gln+(−0.0082)Ala+(−0.0181)Val+(0.0104)Leu+(−0.0710)Trp; 0.880, 0.892, 0.830, 0.864, 0.838, 0.856,0.848, 0.859, (5.7140)+(−0.1570)Asn+(0.0130)Gln+(−0.0195)Val+(−0.0034)Lys+(0.0620)Phe+(−0.0978)Trp; 0.880, 0.892, 0.7 99,0.862, 0.828, 0.885, 0.839, 0.861, (6.0615)+(−0.1104)Asn+(0.0148)Gln+(−0.0090)Ala+(−0.0399)Cit+(−0.0128)Ile+(−0.0850)Tr p; 0.880,0.894, 0.780, 0.858, 0.829, 0.869, 0.817, 0.852,(6.9990)+(−0.1276)Asn+(0.0143)Gln+(−0.0122)Pro+(−0.0119)Val+(−0.0037)Lys+(−0.0862)Trp; 0.880, 0.892, 0.831, 0.863, 0.835, 0.853, 0.85 3,0.858, (5.7311)+(−0.1642)Asn+(0.0128)Gln+(−0.0231)Val+(0.0052)Leu+(0.0599)Phe+(−0.0974)Trp; 0.880, 0.892, 0.811, 0.863, 0. 842,0.879, 0.820, 0.858, (6.2140)+(−0.1028)Asn+(0.0145)Gln+(−0.0295)Cit+(−0.0124)Val+(−0.0968)Met+(−0.0767)Trp; 0.880, 0.892, 0.790,0.857, 0.808, 0.880, 0.846, 0.857,(6.7511)+(−0.1117)Asn+(0.0137)Gln+(−0.0085)Ala+(−0.0108)Val+(−0.0099)Orn+(−0.0730)Trp; 0.880, 0.892, 0.792, 0.858, 0.812, 0.887, 0.843, 0.859, (6.9106)+(−0.1099)Asn+(0.0133)Gln+(−0.0084)Ala+(−0.0115)Val+(−0.0030)Lys+(−0.0713)Trp; 0.880, 0.894, 0.814, 0.863, 0.835, 0.824, 0. 870,0.856,(4.4168)+(−0.0089)Gly+(0.0146)Gln+(−0.0189)Val+(−0.2484)Met+(0.0709)Phe+(−0.0943)Trp;0.880, 0.893, 0.799, 0.867, 0.841, 0.858, 0.860, 0.863,(7.0140)+(−0.1230)Asn+(−0.0077)Gly+(0.0151)Gln+(−0.0252)Cit+(−0.0149)Val+(−0.0879)Trp;0.880, 0. 892, 0.783, 0.863, 0.824, 0.865, 0.866, 0.862,(6.9325)+(−0.0931)Asn+(−0.0076)Gly+(0.0142)Gln+(−0.0083)Ala+(−0.0170)Leu+(−0.0 843)Trp;0.880, 0.894, 0.777, 0.859, 0.814, 0.865, 0.857, 0.857, (6.3357)+(−0.0095)Gly+(0.0145)Gln+(−0.0072)Ala+(−0.0121)Val+(−0.1494)Met+(−0.0731)Trp;0.880, 0.892, 0.827, 0.864, 0.837, 0.850, 0.853, 0.858,(5.5559)+(−0.1603)Asn+(0.0132)Gln+(−0.0191)Val+(−0.0089)Orn+(0.0624)Phe+(−0.0998)Trp;0.879, 0.893, 0.804, 0.8 65, 0.833, 0.886, 0.843, 0.864,(5.6813)+(−0.1039)Asn+(0.0155)Gln+(−0.0094)Ala+(−0.0330)Cit+(−0.0146)Arg+(−0.0837)Trp; 0.879, 0.893,0.791, 0.865, 0.837, 0.854, 0.858, 0.861, (6.8301)+(−0.0783)Asn+(−0.0092)Gly+(0.0155)Gln+(−0.0149)Val+(−0.1177)Met+(−0.0794)Trp;0.879, 0.893, 0.839, 0.871, 0.862, 0.859, 0.839, 0.863,(4.8814)+(−0.1511)Asn+(0.0138)Gln+(−0.0433)Cit+(−0.0242)Leu+(0.0637)Phe+(−0.1101)Trp; 0.879, 0.890, 0.814, 0.865, 0.830, 0.8 89,0.855, 0.866, (5.7663)+(−0.1134)Asn+(0.0147)Gln+(−0.0096)Ala+(−0.0435)Cit+(−0.0861)Trp; 0.879, 0.893, 0.833, 0.864, 0.836, 0.853,0.852, 0.859, (5.6873)+(−0.1634)Asn+(0.0126)Gln+(−0.0215)Val+(0.0047)Ile+(0.0612)Phe+(−0.0973)Trp; 0.879, 0.890, 0.79 3, 0.862,0.832, 0.850, 0.861, 0.858, (7.2952)+(−0.1227)Asn+(−0.0085)Gly+(0.0142)Gln+(−0.0166)Val+(−0.0876)Trp; 0.879, 0.892, 0. 815,0.867, 0.834, 0.892, 0.853, 0.868, (5.5186)+(−0.0871)Asn+(0.0153)Gln+(−0.0088)Ala+(−0.0400)Cit+(−0.0784)Met+(−0.0804)Tr p; 0.879,0.894, 0.784, 0.863, 0.836, 0.856, 0.846, 0.858,(7.0712)+(−0.1079)Asn+(−0.0079)Gly+(0.0161)Gln+(−0.0213)Arg+(−0.0164)Val+(−0.0823)Trp; 0.879, 0.893, 0.831, 0.857, 0.825, 0.840, 0.84 0,0.849, (5.5862)+(−0.1584)Asn+(0.0131)Gln+(−0.0256)Tyr+(−0.0196)Val+(0.0733)Phe+(−0.0894)Trp; 0.879, 0.892, 0.792, 0.857, 0. 810,0.884, 0.846, 0.858, (6.9019)+(−0.1155)Asn+(0.0130)Gln+(0.0022)His+(−0.0084)Ala+(−0.0125)Val+(−0.0726)Trp; 0.879, 0.891, 0.779,0.859, 0.819, 0.882, 0.842, 0.858,(6.3848)+(−0.1030)Asn+(0.0148)Gln+(−0.0078)Ala+(−0.0109)Pro+(−0.0077)Lys+(−0.0876)Trp; 0.879, 0.892, 0.833, 0.872, 0.840, 0.885, 0.879, 0.874, (4.7127)+(−0.1290)Asn+(0.0150)Gln+(−0.0098)Ala+(−0.0476)Cit+(0.0408)Phe+(−0.1005)Trp; 0.879, 0.892, 0.782, 0.855, 0.819, 0.876, 0. 818,0.851,(6.3732)+(−0.0919)Asn+(0.0146)Gln+(−0.0087)Ala+(−0.0218)Arg+(−0.0148)Leu+(−0.0745)Trp;0.879, 0.893, 0.771, 0.86 4, 0.844, 0.838, 0.850, 0.856,(7.0000)+(−0.1097)Asn+(−0.0090)Gly+(0.0155)Gln+(−0.0127)Pro+(−0.0160)Leu+(−0.1017)Trp; 0.878, 0.890,0.793, 0.852, 0.826, 0.861, 0.798, 0.844, (6.6960)+(−0.1224)Asn+(0.0144)Gln+(−0.0230)Arg+(−0.0156)Val+(−0.0775)Trp; 0. 878, 0.893,0.801, 0.867, 0.828, 0.884, 0.864, 0.867, (5.4919)+(−0.0996)Asn+(0.0158)Gln+(−0.0102)Thr+(−0.0093)Ala+(−0.0405)Cit+(−0.0843)Trp; 0.878, 0.894, 0.785, 0.859, 0.830, 0.867, 0.820, 0.8 53,(6.9384)+(−0.1319)Asn+(0.0142)Gln+(−0.0038)His+(−0.0121)Pro+(−0.0124)Val+(−0.0860)Trp; 0.878, 0.892, 0.831, 0.864, 0.838, 0.853,0.850, 0.858, (5.6808)+(−0.1616)Asn+(0.0127)Gln+(−0.0016)His+(−0.0201)Val+(0.0616)Phe+(−0.0980)Trp; 0.878, 0.892, 0.7 82,0.855, 0.813, 0.867, 0.835, 0.852, (5.7538)+(−0.0967)Asn+(0.0156)Gln+(−0.0096)Ala+(−0.0200)Arg+(−0.0165)Orn+(−0.0827)Tr p; 0.878,0.890, 0.811, 0.861, 0.829, 0.877, 0.838, 0.858,(6.3792)+(−0.1045)Asn+(0.0142)Gln+(−0.0279)Val+(−0.1311)Met+(0.0255)Leu+(−0.0702)Trp; 0.878, 0.890, 0.793, 0.856, 0.818, 0.875, 0.835,0.854, (5.7816)+(−0.1013)Asn+(0.0146)Gln+(−0.0096)Ala+(−0.0211)Arg+(−0.0842)Trp; 0.878, 0.890, 0.795, 0.860, 0.837, 0.860, 0.8 26,0.853, (6.8735)+(−0.0096)Ser+(−0.1285)Asn+(0.0147)Gln+(−0.0331)Cit+(−0.0141)Val+(−0.0849)Trp; 0.878, 0.885, 0.801, 0.852, 0.823,0.859, 0.819, 0.847,(6.9114)+(−0.1396)Asn+(0.0122)Gln+(−0.0158)Val+(−0.0828)Trp; 0.878,0.891, 0.817, 0.856, 0.820, 0.8 55, 0.838, 0.851,(3.7293)+(0.0120)Gln+(−0.0088)Ala+(−0.1992)Met+(−0.0195)Leu+(0.0739)Phe+(−0.0925)Trp; 0.878, 0.891, 0.775, 0.853,0.817, 0.871, 0.812, 0.848, (6.1747)+(−0.0969)Asn+(0.0149)Gln+(−0.0088)Ala+(−0.0208)Arg+(−0.0180)Ile+(−0.0824)Trp; 0. 878,0.889, 0.790, 0.855, 0.812, 0.879, 0.838, 0.854, (6.5522)+(−0.1074)Asn+(0.0126)Gln+(−0.0091)Ala+(−0.0142)Leu+(−0.0794)Tr p; 0.878,0.892, 0.778, 0.866, 0.831, 0.868, 0.869, 0.865,(6.4265)+(−0.1040)Asn+(−0.0068)Gly+(0.0156)Gln+(−0.0073)Ala+(−0.0115)Pro+(−0.0982)Trp; 0.878, 0.890, 0.783, 0.854, 0.809, 0.875, 0.84 0,0.853, (6.4197)+(−0.1045)Asn+(0.0135)Gln+(−0.0092)Ala+(−0.0136)Orn+(−0.0117)Leu+(−0.0795)Trp; 0.878, 0.889, 0.776, 0.855, 0.816,0.873, 0.835, 0.853,(6.3761)+(−0.1128)Asn+(0.0142)Gln+(−0.0077)Ala+(−0.0100)Pro+(−0.0099)Ile+(−0.0907)Trp;0.878, 0. 892, 0.778, 0.858, 0.819, 0.881, 0.834, 0.856,(6.5926)+(−0.1089)Asn+(0.0139)Gln+(−0.0076)Ala+(−0.0096)Pro+(−0.0109)Leu+(−0.0 845)Trp;0.878, 0.891, 0.787, 0.863, 0.827, 0.867, 0.861, 0.862, (5.9954)+(−0.0924)Asn+(−0.0058)Gly+(0.0157)Gln+(−0.0091)Ala+(−0.0200)Arg+(−0.0896)Trp;0.878, 0.891, 0.820, 0.860, 0.850, 0.842, 0.808, 0.848,(5.0158)+(−0.1329)Asn+(0.0141)Gln+(−0.0251)Arg+(−0.0276)Leu+(0.0632)Phe+(−0.1045)Trp;0.878, 0.891, 0.816, 0.8 67, 0.852, 0.823, 0.865, 0.858,(5.8682)+(−0.1317)Asn+(−0.0074)Gly+(0.0133)Gln+(−0.0277)Leu+(0.0496)Phe+(−0.1107)Trp; 0.878, 0.892,0.763, 0.845, 0.786, 0.866, 0.829, 0.843, (4.0631)+(−0.0946)Asn+(0.0139)Gln+(−0.0085)Ala+(−0.0210)Val+(−0.1618)Met+(0. 0588)Phe;0.878, 0.890, 0.776, 0.855, 0.808, 0.874, 0.845, 0.854, (6.2087)+(−0.0904)Asn+(0.0140)Gln+(−0.0123)Thr+(−0.0087)Ala+(−0.0144)Leu+(−0.0769)Trp;0.877, 0.891, 0.818, 0.857, 0.834, 0.843, 0.822, 0.848,(3.6186)+(0.0132)Gln+(−0.0103)Pro+(−0.0170)Val+(−0.2461)Met+(0.0860)Phe+(−0.0991)Trp;0.877, 0.891, 0.794, 0.8 52, 0.826, 0.859, 0.799, 0.844,(6.6475)+(−0.1264)Asn+(0.0143)Gln+(−0.0250)Arg+(−0.0165)Val+(0.0035)Lys+(−0.0779)Trp; 0.877, 0.888,0.804, 0.856, 0.830, 0.866, 0.818, 0.851, (6.4700)+(−0.1014)Asn+(0.0133)Gln+(−0.0142)Val+(−0.1045)Met+(−0.0752)Trp; 0. 877, 0.890,0.774, 0.857, 0.813, 0.880, 0.848, 0.858, (6.1290)+(−0.1107)Asn+(0.0150)Gln+(−0.0081)Ala+(−0.0101)Pro+(−0.0146)Orn+(−0.0902)Trp; 0.877, 0.891, 0.795, 0.856, 0.813, 0.881, 0.838, 0.8 56,(6.2061)+(−0.0850)Asn+(0.0132)Gln+(−0.0085)Ala+(−0.0709)Met+(−0.0116)Leu+(−0.0757)Trp; 0.877, 0.892, 0.773, 0.848, 0.805, 0.880,0.800, 0.844, (5.7439)+(0.0138)Gln+(−0.0083)Ala+(−0.0216)Arg+(−0.0111)Val+(−0.1216)Met+(−0.0645)Trp; 0.877, 0.889, 0. 786,0.857, 0.822, 0.841, 0.853, 0.851, (7.4364)+(−0.1144)Asn+(−0.0094)Gly+(0.0147)Gln+(−0.0197)Tyr+(−0.0155)Val+(−0.0789)Tr p; 0.877,0.888, 0.727, 0.835, 0.774, 0.878, 0.791, 0.833,(5.8092)+(−0.1082)Asn+(0.0145)Gln+(−0.0095)Ala+(−0.0245)Arg+(−0.0175)Val; 0.877, 0.887, 0.784, 0.851, 0.821, 0.849, 0.821, 0.844, (7.1934)+(−0.0094)Ser+(−0.1302)Asn+(0.0132)Gln+(−0.0162)Val+(−0. 0838)Trp;0.877, 0.889, 0.814, 0.860, 0.833, 0.872, 0.832, 0.857, (6.6160)+(−0.1436)Asn+(0.0139)Gln+(−0.0312)Cit+(−0.0198)Val+(0.0110)Leu+(−0.0825)Trp; 0.877, 0.890, 0.840, 0.865, 0.853, 0.840, 0. 841,0.856,(4.0702)+(−0.1032)Asn+(0.0135)Gln+(−0.1606)Met+(−0.0231)Leu+(0.0822)Phe+(−0.1055)Trp;0.877, 0.891, 0.806, 0.871, 0.840, 0.883, 0.875, 0.872,(5.9695)+(−0.1050)Asn+(−0.0052)Gly+(0.0156)Gln+(−0.0092)Ala+(−0.0393)Cit+(−0.0909)Trp;0.877, 0. 889, 0.790, 0.849, 0.795, 0.884, 0.830, 0.849,(5.7019)+(0.0122)Gln+(−0.0082)Ala+(−0.0197)Val+(−0.1701)Met+(0.0163)Leu+(−0.06 49)Trp;0.877, 0.890, 0.784, 0.862, 0.819, 0.859, 0.877, 0.861, (6.1519)+(−0.1002)Asn+(−0.0061)Gly+(0.0151)Gln+(−0.0094)Ala+(−0.0174)Orn+(−0.0921)Trp

List (2) of Logistic Regression Equations Searched in Example 5

The logistic regression equations searched in Example 5 above are listedbelow. Before each equation, “the value of ROC_AUC for the pancreaticcancer group and the lung cancer group with validation”, “the value ofROC_AUC for the pancreatic cancer group and the lung cancer groupwithout validation”, “the value of ROC_AUC for the pancreatic cancergroup and the healthy group”, “the value of ROC_AUC for the pancreaticcancer group and the other cancers group”, “the value of ROC_AUC for thepancreatic cancer group and the colorectal cancer group”, “the value ofROC_AUC for the pancreatic cancer group and the prostatic cancer group”,“the value of ROC_AUC for the pancreatic cancer group and the breastcancer group”, and “the average value of the value of ROC_AUC for thepancreatic cancer group and the lung cancer group, the value of ROC_AUCfor the pancreatic cancer group and the colorectal cancer group, thevalue of ROC_AUC for the pancreatic cancer group and the prostaticcancer group, and the value of ROC_AUC for the pancreatic cancer groupand the breast cancer group” obtained for the equation are additionallylisted.

0.858, 0.882, 0.854, 0.866, 0.854, 0.854, 0.858, 0.862, (0.7428)+(−0.0948)Asn+(0.0147)Gln+(−0.0250)His+(−0.1901)Met+(0.0579)Phe+(−0.0741)Trp; 0.850, 0.872, 0.854, 0.852, 0.838, 0.842, 0.8 35,0.847, (0.1340)+(0.0125)Gln+(−0.0287)His+(−0.2660)Met+(0.0561)Phe+(−0.0760)Trp; 0.849, 0.877, 0.853, 0.859, 0.851, 0.853, 0. 835,0.854,(−0.3557)+(0.0142)Gln+(−0.0176)His+(−0.0454)Cit+(−0.2515)Met+(0.0595)Phe+(−0.0844)Trp;0.829, 0.855, 0.852, 0.8 47, 0.854, 0.845, 0.814, 0.842,(4.2366)+(0.0090)Ser+(−0.0506)Asn+(−0.0181)Cit+(−0.1342)Met+(0.0480)Phe+(−0.0762)Trp; 0.847, 0.874,0.852, 0.854, 0.839, 0.849, 0.837, 0.849,(0.1888)+(0.0131)Gln+(−0.0262)His+(−0.2534)Met+(−0.0053)Lys+(0.0573)Phe+(−0.0743)Trp; 0.814, 0.834, 0.851, 0.825, 0.816, 0.835, 0.816, 0.825, (1.8629)+(0.0072)Gln+(−0.0495)His+(0.0085)Phe+(−0.0904)Trp; 0.8 15, 0.842,0.850, 0.835, 0.834, 0.846, 0.812, 0.833, (1.0816)+(0.0096)Gln+(−0.0322)His+(−0.0580)Cit+(0.0197)Phe+(−0.1039)Trp; 0. 862,0.887, 0.849, 0.872, 0.863, 0.864, 0.853, 0.867, (0.4080)+(−0.1010)Asn+(0.0158)Gln+(−0.0511)Cit+(−0.1773)Met+(0.0598)Phe+(−0.0872)Trp;0.854, 0.882, 0.849, 0.872, 0.865, 0.869, 0.860, 0.86 9,(1.3668)+(−0.1519)Asn+(0.0150)Gln+(−0.0162)His+(−0.0523)Cit+(0.0410)Phe+(−0.0924)Trp; 0.842, 0.869, 0.848, 0.843, 0.822, 0. 833,0.821, 0.836, (0.3205)+(0.0127)Gln+(−0.0317)His+(−0.0234)Tyr+(−0.2412)Met+(0.0628)Phe+(−0.0681)Trp; 0.842, 0.866, 0.847, 0.844,0.824, 0.854, 0.821, 0.841, (4.0284)+(0.0066)Ser+(−0.0215)Val+(−0.1905)Met+(0.0235)Ile+(0.0641)Phe+(−0.0531)Trp; 0.8 51, 0.877,0.846, 0.854, 0.846, 0.843, 0.819, 0.846, (−0.0588)+(0.0148)Gln+(−0.0282)His+(−0.0253)Arg+(−0.2362)Met+(0.0598)Phe+(−0.0718)Trp;0.828, 0.853, 0.845, 0.841, 0.846, 0.834, 0.800, 0.83 3,(4.2868)+(0.0091)Ser+(−0.0489)Asn+(−0.0098)Arg+(−0.1330)Met+(0.0480)Phe+(−0.0729)Trp; 0.819, 0.849, 0.844, 0.841, 0.846, 0. 833,0.817, 0.836, (5.0808)+(0.0052)Ser+(−0.0891)Asn+(−0.0263)Cit+(−0.0008)Lys+(0.0305)Phe+(−0.0861)Trp; 0.849, 0.870, 0.844, 0.858,0.845, 0.844, 0.859, 0.855, (1.9743)+(−0.1549)Asn+(0.0132)Gln+(−0.0321)His+(0.0345)Phe+(−0.0834)Trp; 0.827, 0.854, 0.8 44,0.850, 0.850, 0.836, 0.847, 0.847, (4.6405)+(0.0158)Ser+(−0.0352)Asn+(−0.0068)Gly+(−0.1493)Met+(0.0411)Phe+(−0.0800)Trp; 0.847,0.873, 0.844, 0.845, 0.816, 0.831, 0.842, 0.841,(2.1375)+(−0.1449)Asn+(0.0136)Gln+(−0.0342)His+(−0.0424)Tyr+(0.0534)Phe+(−0.0658)Trp; 0.825, 0.848, 0.844, 0.841, 0.846, 0.832, 0.817, 0. 836,(5.0770)+(0.0049)Ser+(−0.0907)Asn+(−0.0265)Cit+(0.0301)Phe+(−0.0866)Trp; 0.825, 0.857, 0.844, 0.845, 0.839, 0.858, 0.817,0.843, (0.8822)+(0.0124)Gln+(−0.0225)His+(−0.0628)Cit+(−0.0158)Lys+(0.0326)Phe+(−0.0992)Trp; 0.818, 0.833, 0.843, 0.823, 0.8 12,0.839, 0.808, 0.823, (2.1373)+(0.0072)Gln+(−0.0478)His+(−0. 0877)Trp;0.848, 0.875, 0.843, 0.860, 0.845, 0.850, 0.859, 0.857, (1.9446)+(−0.1433)Asn+(0.0137)Gln+(−0.0299)His+(−0.0060)Lys+(0.0365)Phe+(−0.0810)Trp; 0.824, 0.852, 0.843, 0.841, 0.843, 0.831, 0. 815,0.835, (4.1715)+(0.0078)Ser+(−0.0549)Asn+(−0.1513)Met+(0.0019)Lys+(0.0463)Phe+(−0.0764)Trp; 0.828, 0.852, 0.842, 0.841, 0. 844,0.833, 0.812, 0.835, (4.2086)+(0.0081)Ser+(−0.0527)Asn+(−0.1471)Met+(0.0468)Phe+(−0.0754)Trp; 0.841, 0.865, 0.842, 0.854, 0. 842,0.863, 0.841, 0.853, (4.3533)+(0.0072)Ser+(−0.0423)Asn+(−0.0047)Ala+(−0.1106)Met+(0.0440)Phe+(−0.0678)Trp; 0.821, 0.846, 0.842,0.836, 0.845, 0.829, 0.798, 0.829,(3.8441)+(0.0056)Ser+(−0.0198)Cit+(−0.1786)Met+(0.0461)Phe+(−0.0797)Trp;0.824, 0.85 1, 0.841, 0.846, 0.849, 0.829, 0.841, 0.843,(4.4498)+(0.0145)Ser+(−0.0073)Gly+(−0.0108)Cit+(−0.1718)Met+(0.0398)Phe+(−0.0827)Trp; 0.816, 0.846, 0.841, 0.836, 0.845, 0.828, 0.798, 0.829, (3.8269)+(0.0055)Ser+(−0.0199)Cit+(−0.1805)Met+(0.0006)Lys+(0.0459)Phe+(−0.0801)Trp; 0.821, 0.849, 0.841, 0.819, 0.794, 0.828, 0.7 84,0.814, (1.0434)+(0.0113)Gln+(−0.0327)His+(−0.0618)Cit+(−0.0563)Tyr+(0.0498)Phe+(−0.0851)Trp; 0.839, 0.864, 0.841, 0.854, 0. 839,0.873, 0.845, 0.855, (5.0156)+(0.0046)Ser+(−0.0661)Asn+(−0.0057)Ala+(−0.0191)Cit+(0.0314)Phe+(−0.0739)Trp; 0.850, 0.873, 0.840,0.853, 0.847, 0.839, 0.821, 0.845,(−0.2044)+(0.0133)Gln+(−0.0518)Cit+(−0.2611)Met+(0.0571)Phe+(−0.0912)Trp;0.824, 0. 858, 0.840, 0.840, 0.836, 0.849, 0.796, 0.835,(0.8827)+(0.0125)Gln+(−0.0379)His+(−0.0341)Cit+(−0.0328)Arg+(0.0302)Phe+(−0.09 28)Trp;0.828, 0.854, 0.840, 0.842, 0.845, 0.829, 0.813, 0.835, (4.2894)+(0.0094)Ser+(−0.0460)Asn+(−0.1485)Met+(−0.0127)Orn+(0.0512)Phe+(−0.0757)Trp; 0.823, 0.849, 0.840, 0.832, 0.817, 0.842, 0. 815,0.831, (1.7645)+(0.0094)Gln+(−0.0404)His+(−0.0142)Lys+(0.0181)Phe+(−0.0838)Trp; 0.835, 0.861, 0.840, 0.851, 0.843, 0.862, 0. 831,0.849,(4.0445)+(0.0049)Ser+(−0.0049)Ala+(−0.0146)Cit+(−0.1341)Met+(0.0436)Phe+(−0.0704)Trp;0.825, 0.852, 0.839, 0.840, 0.842, 0.831, 0.813, 0.834,(4.2041)+(0.0089)Ser+(−0.0500)Asn+(−0.0026)Thr+(−0.1429)Met+(0.0462)Phe+(−0.0746)Trp;0.817, 0. 847, 0.839, 0.833, 0.840, 0.828, 0.789, 0.826,(3.9284)+(0.0063)Ser+(−0.0128)Cit+(−0.0083)Arg+(−0.1698)Met+(0.0466)Phe+(−0.07 70)Trp;0.819, 0.847, 0.838, 0.838, 0.842, 0.825, 0.817, 0.832, (5.1270)+(0.0052)Ser+(−0.0889)Asn+(−0.0228)Cit+(−0.0054)Orn+(0.0310)Phe+(−0.0868)Trp; 0.845, 0.870, 0.838, 0.848, 0.833, 0.829, 0. 835,0.842,(0.6178)+(−0.0085)Ser+(0.0134)Gln+(−0.0277)His+(−0.2538)Met+(0.0513)Phe+(−0.0776)Trp;0.815, 0.845, 0.838, 0.834, 0.843, 0.823, 0.795, 0.826,(3.8019)+(0.0052)Ser+(0.0065)His+(−0.0227)Cit+(−0.1841)Met+(0.0460)Phe+(−0.0827)Trp;0.818, 0.84 6, 0.838, 0.846, 0.850, 0.828, 0.849, 0.843,(5.4768)+(0.0107)Ser+(−0.0790)Asn+(−0.0056)Gly+(−0.0201)Cit+(0.0236)Phe+(−0.0904)Trp; 0.819, 0.842, 0.838, 0.833, 0.831, 0.853, 0.800, 0.831, (1.7423)+(0.0093)Gln+(−0.0296)His+(−0.0545)Cit+(−0.0967)Trp; 0.84 9, 0.875,0.838, 0.856, 0.849, 0.849, 0.824, 0.849, (−0.1630)+(0.0142)Gln+(−0.0518)Cit+(−0.2409)Met+(−0.0071)Lys+(0.0593)Phe+(−0.0880)Trp;0.823, 0.852, 0.838, 0.839, 0.843, 0.825, 0.808, 0.83 2,(4.1903)+(0.0078)Ser+(−0.0549)Asn+(0.0046)His+(−0.1504)Met+(0.0467)Phe+(−0.0772)Trp; 0.820, 0.845, 0.837, 0.824, 0.816, 0. 814,0.790, 0.816, (5.2767)+(0.0061)Ser+(−0.0846)Asn+(−0.0270)Cit+(−0.0375)Tyr+(0.0493)Phe+(−0.0740)Trp; 0.817, 0.839, 0.837, 0.807,0.776, 0.811, 0.782, 0.802, (1.9795)+(0.0084)Gln+(−0.0502)His+(−0.0534)Tyr+(0.0358)Phe+(−0.0708)Trp; 0.817, 0.846, 0.8 37,0.838, 0.845, 0.822, 0.814, 0.832, (5.0582)+(0.0046)Ser+(−0.0958)Asn+(0.0082)His+(−0.0304)Cit+(0.0301)Phe+(−0.0905)Trp; 0. 857,0.881, 0.837, 0.852, 0.827, 0.840, 0.834, 0.845, (1.5102)+(−0.1492)Asn+(0.0153)Gln+(−0.0648)Cit+(−0.0467)Tyr+(0.0627)Phe+(−0.0839)Trp;0.825, 0.852, 0.837, 0.844, 0.846, 0.828, 0.832, 0.84 0,(4.5273)+(0.0152)Ser+(−0.0074)Gly+(−0.0089)Arg+(−0.1647)Met+(0.0400)Phe+(−0.0798)Trp; 0.859, 0.883, 0.837, 0.871, 0.866, 0. 872,0.853, 0.868, (1.4133)+(−0.1411)Asn+(0.0151)Gln+(−0.0593)Cit+(−0.0077)Lys+(0.0430)Phe+(−0.0961)Trp; 0.819, 0.848, 0.837, 0.839,0.841, 0.830, 0.818, 0.834, (4.9911)+(0.0070)Ser+(−0.0822)Asn+(−0.0055)Thr+(−0.0251)Cit+(0.0299)Phe+(−0.0844)Trp; 0. 854, 0.879,0.837, 0.850, 0.835, 0.836, 0.816, 0.841, (0.5649)+(0.0116)Gln+(−0.0186)His+(−0.2464)Met+(−0.0179)Leu+(0.0691)Phe+(−0.0718)Trp;0.852, 0.877, 0.837, 0.857, 0.847, 0.845, 0.835, 0.85 1,(1.5634)+(−0.1301)Asn+(0.0151)Gln+(−0.0298)His+(−0.0280)Arg+(0.0417)Phe+(−0.0789)Trp; 0.830, 0.860, 0.836, 0.825, 0.801, 0. 835,0.777, 0.818, (1.3370)+(0.0122)Gln+(−0.0471)His+(−0.0339)Arg+(−0.0423)Tyr+(0.0450)Phe+(−0.0690)Trp; 0.829, 0.854, 0.836, 0.834,0.825, 0.840, 0.792, 0.828, (1.2668)+(0.0117)Gln+(−0.0469)His+(−0.0386)Arg+(0.0258)Phe+(−0.0838)Trp; 0.816, 0.846, 0.8 36,0.835, 0.841, 0.826, 0.799, 0.828, (3.8669)+(0.0070)Ser+(−0.0040)Thr+(−0.0185)Cit+(−0.1691)Met+(0.0450)Phe+(−0.0781)Trp; 0.820,0.847, 0.835, 0.837, 0.845, 0.827, 0.801, 0.830, (5.0812)+(0.0060)Ser+(−0.0840)Asn+(−0.0173)Cit+(−0.0112)Arg+(0.0323)Phe+(−0.0829)Trp; 0.841, 0.870, 0.835, 0.848, 0.830, 0.846, 0.828, 0.8 43,(5.3439)+(−0.0433)Asn+(−0.0210)Val+(−0.1218)Met+(0.0202)Ile+(0.0593)Phe+(−0.0510)Trp; 0.845, 0.871, 0.835, 0.846, 0.833, 0.848,0.805, 0.839, (4.9169)+(0.0093)Ser+(−0.0553)Asn+(−0.0165)Val+(−0.1210)Met+(0.0656)Phe+(−0.0552)Trp; 0.831, 0.861, 0.8 35,0.852, 0.840, 0.849, 0.855, 0.851, (4.5027)+(0.0121)Ser+(−0.0062)Gly+(−0.0041)Ala+(−0.1428)Met+(0.0381)Phe+(−0.0742)Trp; 0.837,0.866, 0.835, 0.842, 0.822, 0.843, 0.818, 0.837, (4.6202)+(0.0010)Thr+(−0.0212)Val+(−0.1756)Met+(0.0220)Ile+(0.0604)Phe+(−0.0539)Trp;0.858, 0.879, 0.835, 0.867, 0.861, 0.859, 0.851, 0.86 3,(1.5215)+(−0.1583)Asn+(0.0143)Gln+(−0.0586)Cit+(0.0393)Phe+(−0.0991)Trp; 0.856, 0.877, 0.835, 0.857, 0.847, 0.835, 0.843, 0. 850,(1.0599)+(−0.1017)Asn+(0.0131)Gln+(−0.2016)Met+(0.0547)Phe+(−0.0825)Trp; 0.858, 0.884, 0.835, 0.856, 0.848, 0.842, 0.807,0.845, (0.1226)+(0.0129)Gln+(−0.0471)Cit+(−0.2338)Met+(−0.0187)Leu+(0.0725)Phe+(−0.0833)Trp; 0.826, 0.849, 0.834, 0.843, 0.8 42,0.824, 0.842, 0.839, (4.4781)+(0.0146)Ser+(−0.0079)Gly+(−0.1791)Met+(0.0385)Phe+(−0.0826)Trp; 0.853, 0.878, 0.834, 0.859, 0. 848,0.840, 0.844, 0.852, (1.0584)+(−0.0965)Asn+(0.0134)Gln+(−0.1950)Met+(−0.0040)Lys+(0.0558)Phe+(−0.0810)Trp; 0.842, 0.873, 0.834,0.842, 0.828, 0.826, 0.801, 0.832,(−0.0812)+(0.0137)Gln+(−0.0559)Cit+(−0.0258)Tyr+(−0.2345)Met+(0.0654)Phe+(−0.0853)Trp; 0.838, 0.865, 0.834, 0.841, 0.823, 0.842, 0.816, 0.836, (4.5768)+(−0.0192)Val+(−0.1714)Met+(0.0246)Ile+(−0.0048)Leu+(0.0609)Phe+(−0.0537)Trp; 0.823, 0.849, 0.834, 0.843, 0.842, 0.821, 0. 842,0.839, (4.4515)+(0.0144)Ser+(−0.0080)Gly+(−0.1833)Met+(0.0013)Lys+(0.0380)Phe+(−0.0835)Trp; 0.860, 0.885, 0.834, 0.858, 0. 823,0.862, 0.859, 0.857, (0.0513)+(0.0130)Gln+(−0.0179)His+(−0.0065)Ala+(−0.2216)Met+(0.0524)Phe+(−0.0679)Trp; 0.836, 0.865, 0.834,0.840, 0.820, 0.833, 0.825, 0.835,(4.2506)+(−0.0254)Val+(−0.2105)Met+(0.0096)Lys+(0.0272)Ile+(0.0623)Phe+(−0.0545)Trp; 0.863, 0.886, 0.834, 0.853, 0.823, 0.845, 0.837, 0.848, (0.6071)+(0.0117)Gln+(−0.0226)Val+(−0.2849)Met+(0.0182)Ile+(0.0760)Phe+(−0.0599)Trp; 0.817, 0.849, 0.834, 0.834, 0.839, 0.819, 0.795,0.825, (3.9336)+(0.0070)Ser+(−0.0110)Cit+(−0.1814)Met+(−0.0123)Orn+(0.0500)Phe+(−0.0793)Trp; 0.829, 0.857, 0.834, 0.834, 0.8 30,0.826, 0.787, 0.825, (3.8834)+(0.0037)Ser+(−0.1711)Met+(0.0188)Ile+(−0.0302)Leu+(0.0639)Phe+(−0.0667)Trp; 0.864, 0.889, 0. 833,0.864, 0.838, 0.867, 0.852, 0.861, (−0.3713)+(0.0143)Gln+(−0.0066)Ala+(−0.0470)Cit+(−0.2090)Met+(0.0545)Phe+(−0.0788)Tr p; 0.865,0.885, 0.833, 0.860, 0.843, 0.841, 0.840, 0.852,(2.4858)+(−0.1478)Asn+(0.0122)Gln+(−0.0184)His+(−0.0240)Leu+(0.0557)Phe+(−0.0765)Trp; 0.823, 0.853, 0.833, 0.844, 0.844, 0.820, 0.839,0.839, (4.5097)+(0.0151)Ser+(−0.0071)Gly+(−0.1764)Met+(−0.0107)Orn+(0.0427)Phe+(−0.0818)Trp; 0.834, 0.867, 0.833, 0.843, 0.8 23,0.844, 0.818, 0.838, (4.6666)+(−0.0029)Cit+(−0.0208)Val+(−0.1692)Met+(0.0218)Ile+(0.0596)Phe+(−0.0540)Trp; 0.848, 0.876, 0. 833,0.852, 0.846, 0.839, 0.809, 0.843, (−0.2120)+(0.0143)Gln+(−0.0394)Cit+(−0.0184)Arg+(−0.2462)Met+(0.0592)Phe+(−0.0864)Tr p; 0.836,0.863, 0.833, 0.847, 0.836, 0.856, 0.819, 0.843,(4.1396)+(0.0054)Ser+(−0.0050)Ala+(−0.0095)Arg+(−0.1284)Met+(0.0433)Phe+(−0.0674)Trp; 0.840, 0.866, 0.833, 0.842, 0.822, 0.841, 0.818,0.837, (4.6547)+(−0.0210)Val+(−0.1721)Met+(0.0221)Ile+(0.0597)Phe+(−0.0535)Trp; 0.857, 0.882, 0.833, 0.854, 0.830, 0.823, 0.85 3,0.847, (−0.3303)+(0.0173)Gln+(−0.0335)His+(−0.2786)Met+(−0.0450)Orn+(0.0737)Phe+(−0.0766)Trp; 0.821, 0.853, 0.832, 0.817, 0. 784,0.825, 0.788, 0.812, (1.9308)+(0.0100)Gln+(−0.0423)His+(−0.0473)Tyr+(−0.0118)Lys+(0.0402)Phe+(−0.0675)Trp; 0.871, 0.893, 0.832,0.870, 0.859, 0.859, 0.836, 0.862,(1.8582)+(−0.1462)Asn+(0.0139)Gln+(−0.0518)Cit+(−0.0240)Leu+(0.0618)Phe+(−0.0862)Trp; 0.817, 0.847, 0.832, 0.826, 0.822, 0.813, 0.788, 0.817, (4.5513)+(0.0078)Ser+(−0.0595)Asn+(−0.0244)Tyr+(−0.1146)Met+(0.0542)Phe+(−0.0692)Trp; 0.814, 0.841, 0.832, 0.828, 0.831, 0.818, 0.7 95,0.821, (3.8053)+(0.0045)Ser+(−0.0007)His+(−0.1948)Met+(0.0002)Lys+(0.0445)Phe+(−0.0786)Trp; 0.836, 0.867, 0.832, 0.843, 0. 824,0.844, 0.818, 0.838,(4.7117)+(−0.0207)Val+(−0.1706)Met+(−0.0044)Orn+(0.0233)Ile+(0.0602)Phe+(−0.0539)Trp;0.846, 0.873, 0.832, 0.850, 0.823, 0.863, 0.838, 0.849,(4.7306)+(−0.0034)Ala+(−0.0191)Val+(−0.1422)Met+(0.0208)Ile+(0.0562)Phe+(−0.0487)Trp; 0.803, 0.819, 0.832, 0.814, 0.819, 0.816, 0.791, 0.811, (4.3020)+(−0.0257)His+(0.0072)Phe+(−0.0900)Trp; 0.817, 0.841, 0.831, 0.828,0.831, 0.819, 0.794, 0.821, (3.8098)+(0.0046)Ser+(−0.0006)His+(−0.1943)Met+(0.0445)Phe+(−0.0785)Trp; 0.830, 0.858, 0.8 31,0.838, 0.839, 0.833, 0.788, 0.830, (4.2940)+(−0.0156)Cit+(−0.1464)Met+(0.0203)Ile+(−0.0305)Leu+(0.0622)Phe+(−0.0677)Trp; 0.823,0.841, 0.831, 0.828, 0.831, 0.818, 0.793, 0.821, (3.8056)+(0.0045)Ser+(−0.1950)Met+(0.0445)Phe+(−0.0788)Trp; 0.820, 0.850, 0.831,0.842, 0.850, 0.831, 0.810, 0.835,(4.9150)+(−0.0416)Asn+(0.0005)Thr+(−0.0162)Cit+(−0.1231)Met+(0.0424)Phe+(−0.0776)Trp; 0.828, 0.857, 0.831, 0.844, 0.846, 0.838, 0.806, 0.837, (4.3837)+(0.0085)Ser+(−0.0498)Asn+(−0.0070)Pro+(−0.1239)Met+(0.0493)Phe+(−0.0762)Trp; 0.820, 0.841, 0.831, 0.828, 0.831, 0.817, 0.7 93,0.821, (3.8018)+(0.0045)Ser+(−0.1954)Met+(0.0001)Lys+(0.0444)Phe+(−0.0789)Trp; 0.822, 0.846, 0.831, 0.830, 0.835, 0.823, 0. 782,0.821, (3.9368)+(0.0059)Ser+(−0.0112)Arg+(−0.1754)Met+(0.0460)Phe+(−0.0756)Trp; 0.821, 0.849, 0.831, 0.842, 0.841, 0.821, 0. 841,0.838,(4.4750)+(0.0155)Ser+(−0.0076)Gly+(−0.0031)Thr+(−0.1713)Met+(0.0379)Phe+(−0.0813)Trp;0.835, 0.863, 0.831, 0.852, 0.845, 0.856, 0.836, 0.850,(4.9570)+(−0.0325)Asn+(−0.0046)Ala+(−0.0121)Cit+(−0.0899)Met+(0.0399)Phe+(−0.0692)Trp;0.847, 0. 872, 0.831, 0.848, 0.826, 0.836, 0.842, 0.844,(0.1066)+(0.0142)Gln+(−0.0273)His+(−0.0135)Thr+(−0.2376)Met+(0.0514)Phe+(−0.07 20)Trp;0.825, 0.845, 0.831, 0.838, 0.846, 0.821, 0.816, 0.832, (5.4144)+(−0.0821)Asn+(−0.0252)Cit+(0.0280)Phe+(−0.0873)Trp; 0.8 21, 0.846,0.831, 0.838, 0.846, 0.821, 0.815, 0.832, (5.4178)+(−0.0818)Asn+(−0.0252)Cit+(−0.0002)Lys+(0.0280)Phe+(−0.0872)Trp

List (2) of Linear Discriminants Searched in Example 5

The linear discriminants searched in Example 5 above are listed below.Before each equation, “the value of ROC_AUC for the pancreatic cancergroup and the lung cancer group with validation”, “the value of ROC_AUCfor the pancreatic cancer group and the lung cancer group withoutvalidation”, “the value of ROC_AUC for the pancreatic cancer group andthe healthy group”, “the value of ROC_AUC for the pancreatic cancergroup and the other cancers group”, “the value of ROC_AUC for thepancreatic cancer group and the colorectal cancer group”, “the value ofROC_AUC for the pancreatic cancer group and the prostatic cancer group”,“the value of ROC_AUC for the pancreatic cancer group and the breastcancer group”, and “the average value of the value of ROC_AUC for thepancreatic cancer group and the lung cancer group, the value of ROC_AUCfor the pancreatic cancer group and the colorectal cancer group, thevalue of ROC_AUC for the pancreatic cancer group and the prostaticcancer group, and the value of ROC_AUC for the pancreatic cancer groupand the breast cancer group” obtained for the equation are additionallylisted.

0.841, 0.858, 0.864, 0.850, 0.855, 0.851, 0.818, 0.846, (6.6327)+(0.0159)Ser+(−0.0688)Asn+(−0.0166)Cit+(−0.1442)Met+(0.0618)Phe+(−0.0996)Trp; 0.857, 0.877, 0.864, 0.864, 0.858, 0.859, 0.8 44,0.859, (2.5401)+(0.0145)Gln+(−0.0299)His+(−0.0372)Cit+(−0.2512)Met+(0.0650)Phe+(−0.1008)Trp; 0.867, 0.883, 0.863, 0.868, 0. 858,0.855, 0.860, 0.864, (3.5162)+(−0.0924)Asn+(0.0149)Gln+(−0.0277)His+(−0.1837)Met+(0.0640)Phe+(−0.1019)Trp; 0.858, 0.873, 0.863,0.856, 0.843, 0.848, 0.843, 0.852,(2.7828)+(0.0132)Gln+(−0.0366)His+(−0.2574)Met+(0.0629)Phe+(−0.0988)Trp;0.855, 0.87 3, 0.861, 0.854, 0.839, 0.844, 0.840, 0.849,(2.8178)+(0.0132)Gln+(−0.0372)His+(−0.0084)Tyr+(−0.2479)Met+(0.0654)Phe+(−0.0958)Trp; 0.856, 0.873, 0.861, 0.856, 0.842, 0.847, 0.844, 0.851, (2.8477)+(−0.0011)Ser+(0.0133)Gln+(−0.0364)His+(−0.2551)Met+(0.0620)Phe+(−0.0989)Trp; 0.838, 0.856, 0.860, 0.847, 0.848, 0.846, 0. 821,0.843,(6.5646)+(0.0156)Ser+(−0.0681)Asn+(−0.0039)His+(−0.1509)Met+(0.0613)Phe+(−0.0989)Trp;0.858, 0.874, 0.859, 0.857, 0.844, 0.853, 0.845, 0.854,(3.0539)+(0.0137)Gln+(−0.0339)His+(−0.2375)Met+(−0.0072)Lys+(0.0636)Phe+(−0.0971)Trp;0.851, 0. 867, 0.859, 0.847, 0.829, 0.856, 0.827, 0.845,(6.5527)+(0.0108)Ser+(−0.0243)Val+(−0.2233)Met+(0.0285)Ile+(0.0820)Phe+(−0.076 2)Trp;0.842, 0.858, 0.859, 0.853, 0.853, 0.842, 0.849, 0.851, (6.8506)+(0.0218)Ser+(−0.0580)Asn+(−0.0055)Gly+(−0.1580)Met+(0.0561)Phe+(−0.1003)Trp; 0.838, 0.854, 0.859, 0.846, 0.849, 0.842, 0. 819,0.841, (6.5378)+(0.0149)Ser+(−0.0710)Asn+(0.0015)Thr+(−0.1556)Met+(0.0612)Phe+(−0.1009)Trp; 0.860, 0.878, 0.858, 0.858, 0. 849,0.851, 0.832, 0.853, (2.8002)+(0.0151)Gln+(−0.0362)His+(−0.0210)Arg+(−0.2272)Met+(0.0605)Phe+(−0.0951)Trp; 0.840, 0.856, 0.858,0.847, 0.848, 0.846, 0.819, 0.842,(6.6275)+(0.0159)Ser+(−0.0679)Asn+(−0.1463)Met+(−0.0025)Lys+(0.0613)Phe+(−0.0995)Trp; 0.839, 0.856, 0.857, 0.846, 0.848, 0.843, 0.814, 0.841, (6.5993)+(0.0164)Ser+(−0.0669)Asn+(−0.0061)Arg+(−0.1444)Met+(0.0603)Phe+(−0.0990)Trp; 0.828, 0.847, 0.857, 0.839, 0.846, 0.837, 0.80 3,0.833, (6.0634)+(0.0114)Ser+(−0.0078)His+(−0.0158)Cit+(−0.1960)Met+(0.0583)Phe+(−0.0978)Trp; 0.840, 0.854, 0.857, 0.845, 0. 847,0.842, 0.820, 0.841, (6.5342)+(0.0154)Ser+(−0.0700)Asn+(−0.1518)Met+(0.0607)Phe+(−0.1005)Trp; 0.840, 0.857, 0.856, 0.846, 0. 847,0.841, 0.820, 0.842, (6.5852)+(0.0160)Ser+(−0.0647)Asn+(−0.1539)Met+(−0.0093)Orn+(0.0641)Phe+(−0.0997)Trp; 0.866, 0.882, 0.855,0.871, 0.865, 0.867, 0.861, 0.869,(4.4728)+(−0.1505)Asn+(0.0148)Gln+(−0.0207)His+(−0.0467)Cit+(0.0398)Phe+(−0.1103)Trp; 0.834, 0.854, 0.855, 0.841, 0.842, 0.837, 0.813, 0.836, (6.6129)+(0.0151)Ser+(−0.0715)Asn+(−0.0076)Tyr+(−0.1412)Met+(0.0626)Phe+(−0.0979)Trp; 0.828, 0.845, 0.854, 0.836, 0.840, 0.834, 0.8 06,0.831, (6.0074)+(0.0112)Ser+(−0.0117)His+(−0.2017)Met+(0.0579)Phe+(−0.0970)Trp; 0.864, 0.882, 0.854, 0.860, 0.843, 0.838, 0. 855,0.855,(2.4700)+(0.0158)Gln+(−0.0382)His+(−0.2621)Met+(−0.0290)Orn+(0.0747)Phe+(−0.0977)Trp;0.825, 0.845, 0.854, 0.836, 0.839, 0.834, 0.806, 0.831,(6.0072)+(0.0113)Ser+(−0.0116)His+(−0.0002)Thr+(−0.2011)Met+(0.0578)Phe+(−0.0969)Trp;0.832, 0. 851, 0.854, 0.843, 0.847, 0.844, 0.815, 0.839,(7.7895)+(0.0114)Ser+(−0.1007)Asn+(−0.0221)Cit+(−0.0059)Lys+(0.0400)Phe+(−0.10 25)Trp;0.832, 0.851, 0.854, 0.846, 0.846, 0.833, 0.840, 0.842, (6.4730)+(0.0196)Ser+(−0.0067)Gly+(−0.0067)His+(−0.2004)Met+(0.0524)Phe+(−0.0985)Trp; 0.829, 0.848, 0.853, 0.837, 0.840, 0.837, 0. 803,0.832,(6.1598)+(0.0121)Ser+(−0.0100)His+(−0.1917)Met+(−0.0038)Lys+(0.0588)Phe+(−0.0960)Trp;0.828, 0.847, 0.853, 0.836, 0.840, 0.835, 0.801, 0.831,(6.1210)+(0.0127)Ser+(−0.0104)His+(−0.0083)Arg+(−0.1890)Met+(0.0575)Phe+(−0.0954)Trp;0.834, 0. 852, 0.853, 0.846, 0.847, 0.834, 0.837, 0.842,(6.4343)+(0.0190)Ser+(−0.0064)Gly+(−0.0098)Cit+(−0.1997)Met+(0.0521)Phe+(−0.10 08)Trp;0.872, 0.887, 0.853, 0.874, 0.868, 0.864, 0.855, 0.869, (3.3147)+(−0.1054)Asn+(0.0157)Gln+(−0.0455)Cit+(−0.1736)Met+(0.0639)Phe+(−0.1118)Trp; 0.842, 0.858, 0.853, 0.839, 0.835, 0.836, 0. 799,0.832, (6.0315)+(0.0091)Ser+(−0.1951)Met+(0.0271)Ile+(−0.0355)Leu+(0.0809)Phe+(−0.0915)Trp; 0.830, 0.848, 0.852, 0.839, 0. 846,0.840, 0.798, 0.833, (6.1744)+(0.0119)Ser+(−0.0177)Cit+(−0.1875)Met+(−0.0043)Lys+(0.0584)Phe+(−0.0991)Trp; 0.857, 0.871, 0.852,0.850, 0.841, 0.850, 0.815, 0.844,(7.5269)+(0.0155)Ser+(−0.0710)Asn+(−0.0171)Val+(−0.1394)Met+(0.0851)Phe+(−0.0823)Trp; 0.833, 0.847, 0.852, 0.838, 0.845, 0.833, 0.800, 0.831, (5.9829)+(0.0107)Ser+(−0.0181)Cit+(−0.1997)Met+(0.0571)Phe+(−0.101 0)Trp; 0.829,0.847, 0.852, 0.838, 0.846, 0.833, 0.799, 0.831, (5.9827)+(0.0107)Ser+(0.0001)Thr+(−0.0181)Cit+(−0.2000)Met+(0.0571)Phe+(−0.1010)Trp; 0.846, 0.864, 0.852, 0.846, 0.831, 0.851, 0.8 25,0.843, (7.3153)+(0.0069)Thr+(−0.0250)Val+(−0.2210)Met+(0.0290)Ile+(0.0782)Phe+(−0.0768)Trp; 0.830, 0.849, 0.852, 0.838, 0. 841,0.831, 0.808, 0.832, (6.1249)+(0.0124)Ser+(−0.0104)His+(−0.1996)Met+(−0.0122)Orn+(0.0627)Phe+(−0.0963)Trp; 0.829, 0.848, 0.852,0.840, 0.843, 0.837, 0.818, 0.836,(7.6702)+(0.0097)Ser+(−0.1087)Asn+(−0.0011)His+(−0.0228)Cit+(0.0364)Phe+(−0.1051)Trp; 0.822, 0.844, 0.852, 0.834, 0.837, 0.830, 0.803, 0.828, (6.0498)+(0.0110)Ser+(−0.0120)His+(−0.0046)Tyr+(−0.1959)Met+(0.0591)Phe+(−0.0953)Trp; 0.854, 0.874, 0.851, 0.855, 0.838, 0.847, 0.84 6,0.851, (2.7951)+(0.0138)Gln+(−0.0346)His+(−0.0069)Thr+(−0.2353)Met+(0.0586)Phe+(−0.0981)Trp; 0.826, 0.843, 0.851, 0.837, 0. 836,0.851, 0.813, 0.836, (4.0419)+(0.0093)Gln+(−0.0422)His+(−0.0437)Cit+(0.0123)Phe+(−0.1087)Trp; 0.833, 0.848, 0.851, 0.840, 0. 843,0.837, 0.817, 0.836, (7.6646)+(0.0096)Ser+(−0.1092)Asn+(−0.0231)Cit+(0.0363)Phe+(−0.1055)Trp; 0.829, 0.848, 0.851, 0.837, 0. 845,0.833, 0.795, 0.830, (6.0430)+(0.0117)Ser+(−0.0135)Cit+(−0.0058)Arg+(−0.1926)Met+(0.0566)Phe+(−0.0997)Trp; 0.828, 0.848, 0.851,0.836, 0.843, 0.831, 0.796, 0.829,(6.0141)+(0.0105)Ser+(−0.0180)Cit+(−0.0037)Tyr+(−0.1951)Met+(0.0580)Phe+(−0.0997)Trp; 0.854, 0.868, 0.850, 0.856, 0.838, 0.877, 0.849, 0.858, (7.2167)+(0.0136)Ser+(−0.0539)Asn+(−0.0075)Ala+(−0.1121)Met+(0.0565)Phe+(−0.0877)Trp; 0.864, 0.880, 0.850, 0.854, 0.839, 0.840, 0.82 6,0.846, (3.1852)+(0.0124)Gln+(−0.0243)His+(−0.2406)Met+(−0.0196)Leu+(0.0799)Phe+(−0.0976)Trp; 0.856, 0.871, 0.850, 0.858, 0. 847,0.845, 0.857, 0.855, (4.8183)+(−0.1481)Asn+(0.0129)Gln+(−0.0298)His+(0.0351)Phe+(−0.1080)Trp; 0.862, 0.878, 0.850, 0.860, 0. 850,0.836, 0.850, 0.853, (3.4141)+(0.0034)Ser+(−0.1051)Asn+(0.0133)Gln+(−0.1917)Met+(0.0626)Phe+(−0.1123)Trp; 0.835, 0.853, 0.849,0.845, 0.844, 0.834, 0.833, 0.841,(6.5724)+(0.0202)Ser+(−0.0068)Gly+(−0.1935)Met+(−0.0038)Lys+(0.0522)Phe+(−0.0997)Trp; 0.833, 0.852, 0.849, 0.845, 0.844, 0.830, 0.837, 0.841, (6.4109)+(0.0190)Ser+(−0.0070)Gly+(0.0011)Thr+(−0.2079)Met+(0.0513)Phe+(−0.1017)Trp; 0.822, 0.834, 0.849, 0.825, 0.816, 0.833, 0.816,0.824, (4.3714)+(0.0076)Gln+(−0.0504)His+(0.0082)Phe+(−0.106 5)Trp;0.858, 0.875, 0.849, 0.851, 0.827, 0.839, 0.846, 0.847, (4.7114)+(−0.1427)Asn+(0.0136)Gln+(−0.0313)His+(−0.0327)Tyr+(0.0516)Phe+(−0.0951)Trp; 0.834, 0.852, 0.848, 0.845, 0.845, 0.831, 0. 832,0.840,(6.4904)+(0.0202)Ser+(−0.0066)Gly+(−0.0067)Arg+(−0.1937)Met+(0.0510)Phe+(−0.0996)Trp;0.837, 0.851, 0.848, 0.844, 0.844, 0.829, 0.837, 0.840,(6.4094)+(0.0193)Ser+(−0.0069)Gly+(−0.2044)Met+(0.0510)Phe+(−0.1014)Trp;0.831, 0.848, 0.848, 0.8 40, 0.843, 0.835, 0.816, 0.836,(7.6782)+(0.0097)Ser+(−0.1082)Asn+(−0.0210)Cit+(−0.0027)Orn+(0.0369)Phe+(−0.1054)Trp; 0.830, 0.849,0.848, 0.833, 0.828, 0.830, 0.800, 0.827, (7.6726)+(0.0102)Ser+(−0.1049)Asn+(−0.0215)Cit+(−0.0224)Tyr+(0.0475)Phe+(−0. 0967)Trp;0.832, 0.850, 0.848, 0.840, 0.843, 0.834, 0.809, 0.834, (7.6642)+(0.0108)Ser+(−0.1044)Asn+(−0.0174)Cit+(−0.0070)Arg+(0.0365)Phe+(−0.1038)Trp; 0.849, 0.864, 0.848, 0.845, 0.844, 0.839, 0. 802,0.837,(7.0742)+(0.0143)Ser+(−0.0698)Asn+(−0.1241)Met+(−0.0229)Leu+(0.0819)Phe+(−0.0937)Trp;0.858, 0.876, 0.848, 0.862, 0.850, 0.853, 0.855, 0.859,(4.9806)+(−0.1348)Asn+(0.0137)Gln+(−0.0266)His+(−0.0098)Lys+(0.0393)Phe+(−0.1048)Trp;0.831, 0. 851, 0.848, 0.829, 0.810, 0.842, 0.800, 0.825,(3.9499)+(0.0103)Gln+(−0.0433)His+(−0.0418)Cit+(−0.0382)Tyr+(0.0326)Phe+(−0.09 35)Trp;0.873, 0.887, 0.847, 0.858, 0.828, 0.854, 0.849, 0.854, (3.3435)+(0.0120)Gln+(−0.0255)Val+(−0.2885)Met+(0.0255)Ile+(0.0864)Phe+(−0.0863)Trp; 0.831, 0.849, 0.847, 0.840, 0.840, 0.837, 0. 819,0.836,(7.5743)+(0.0115)Ser+(−0.1038)Asn+(−0.0042)Thr+(−0.0212)Cit+(0.0363)Phe+(−0.1040)Trp;0.831, 0.848, 0.847, 0.845, 0.848, 0.832, 0.842, 0.842,(7.8998)+(0.0136)Ser+(−0.1031)Asn+(−0.0038)Gly+(−0.0187)Cit+(0.0317)Phe+(−0.1058)Trp;0.828, 0. 847, 0.846, 0.827, 0.817, 0.817, 0.802, 0.821,(7.6595)+(0.0096)Ser+(−0.1051)Asn+(−0.0073)His+(−0.0238)Tyr+(0.0464)Phe+(−0.09 46)Trp;0.856, 0.872, 0.846, 0.853, 0.849, 0.837, 0.822, 0.845, (2.4879)+(0.0131)Gln+(−0.0435)Cit+(−0.2623)Met+(0.0609)Phe+(−0. 1121)Trp;0.838, 0.860, 0.846, 0.848, 0.840, 0.862, 0.819, 0.845, (4.3920)+(0.0116)Gln+(−0.0329)His+(−0.0451)Cit+(−0.0175)Lys+(0.0243)Phe+(−0.1033)Trp; 0.835, 0.852, 0.846, 0.845, 0.855, 0.831, 0. 813,0.838,(7.6871)+(−0.0588)Asn+(0.0069)Thr+(−0.0175)Cit+(−0.1369)Met+(0.0528)Phe+(−0.1008)Trp;0.832, 0.847, 0.846, 0.834, 0.836, 0.829, 0.797, 0.827,(6.0647)+(0.0113)Ser+(−0.1961)Met+(−0.0045)Lys+(0.0571)Phe+(−0.1000)Trp;0.828, 0.847, 0.846, 0.8 34, 0.836, 0.829, 0.797, 0.827,(6.0645)+(0.0113)Ser+(−0.0001)Thr+(−0.1960)Met+(−0.0045)Lys+(0.0571)Phe+(−0.1000)Trp; 0.830, 0.849,0.846, 0.837, 0.842, 0.828, 0.800, 0.830, (6.0387)+(0.0115)Ser+(−0.0099)Cit+(−0.2015)Met+(−0.0101)Orn+(0.0606)Phe+(−0. 1004)Trp;0.863, 0.880, 0.846, 0.862, 0.852, 0.851, 0.841, 0.856, (4.5737)+(−0.1307)Asn+(0.0152)Gln+(−0.0300)His+(−0.0239)Arg+(0.0364)Phe+(−0.1027)Trp; 0.848, 0.864, 0.846, 0.844, 0.827, 0.844, 0. 827,0.840,(7.4275)+(−0.0203)Val+(−0.1885)Met+(0.0335)Ile+(−0.0100)Leu+(0.0753)Phe+(−0.0765)Trp;0.852, 0.870, 0.845, 0.851, 0.833, 0.849, 0.838, 0.848,(8.4985)+(−0.0543)Asn+(−0.0239)Val+(−0.1338)Met+(0.0268)Ile+(0.0730)Phe+(−0.0742)Trp;0.828, 0.8 47, 0.845, 0.833, 0.837, 0.831, 0.792, 0.827,(6.1009)+(0.0123)Ser+(−0.0073)Arg+(−0.1892)Met+(−0.0028)Lys+(0.0564)Phe+(−0.098 9)Trp;0.834, 0.854, 0.845, 0.845, 0.843, 0.828, 0.836, 0.840, (6.4699)+(0.0196)Ser+(−0.0064)Gly+(−0.2025)Met+(−0.0097)Orn+(0.0553)Phe+(−0.1005)Trp; 0.848, 0.865, 0.845, 0.852, 0.836, 0.875, 0. 836,0.853,(6.8606)+(0.0100)Ser+(−0.0080)Ala+(−0.0146)Cit+(−0.1446)Met+(0.0536)Phe+(−0.0870)Trp;0.827, 0.847, 0.845, 0.833, 0.838, 0.828, 0.791, 0.826,(6.0008)+(0.0117)Ser+(0.0005)Thr+(−0.0090)Arg+(−0.1960)Met+(0.0557)Phe+(−0.0998)Trp;0.827, 0.84 8, 0.845, 0.836, 0.838, 0.832, 0.805, 0.831,(7.6599)+(0.0112)Ser+(−0.1015)Asn+(−0.0057)His+(−0.0108)Arg+(0.0356)Phe+(−0.1015)Trp; 0.832, 0.844, 0.845, 0.832, 0.835, 0.824, 0.798, 0.825, (5.8628)+(0.0101)Ser+(−0.2090)Met+(0.0557)Phe+(−0.1020)Trp; 0.832, 0.847,0.845, 0.833, 0.837, 0.828, 0.792, 0.826, (6.0006)+(0.0118)Ser+(−0.0088)Arg+(−0.1946)Met+(0.0555)Phe+(−0.0997)Trp; 0.86 2, 0.878,0.844, 0.862, 0.845, 0.842, 0.867, 0.858, (4.5811)+(−0.1427)Asn+(0.0147)Gln+(−0.0321)His+(−0.0226)Orn+(0.0425)Phe+(−0.1072)Trp;0.865, 0.879, 0.844, 0.859, 0.849, 0.834, 0.849, 0.853,(3.5861)+(−0.1025)Asn+(0.0136)Gln+(−0.1869)Met+(0.0599)Phe+(−0.1124)Trp;0.854, 0.872, 0.844, 0.858, 0.847, 0.843, 0.857, 0.85 5,(4.9507)+(−0.0032)Ser+(−0.1444)Asn+(0.0132)Gln+(−0.0296)His+(0.0332)Phe+(−0.1080)Trp; 0.826, 0.847, 0.844, 0.837, 0.837, 0. 834,0.814, 0.833, (7.7612)+(0.0107)Ser+(−0.1025)Asn+(−0.0046)His+(−0.0061)Lys+(0.0376)Phe+(−0.1021)Trp; 0.830, 0.845, 0.844, 0.835,0.836, 0.825, 0.818, 0.831, (7.6449)+(0.0090)Ser+(−0.1101)Asn+(−0.0071)His+(0.0341)Phe+(−0.1042)Trp; 0.852, 0.873, 0.8 44,0.852, 0.846, 0.835, 0.822, 0.844, (2.5096)+(0.0130)Gln+(−0.0435)Cit+(−0.0052)Tyr+(−0.2566)Met+(0.0624)Phe+(−0.1103)Trp; 0.828,0.848, 0.844, 0.834, 0.839, 0.823, 0.796, 0.826, (6.0007)+(0.0108)Ser+(0.0017)Thr+(−0.2113)Met+(−0.0133)Orn+(0.0618)Phe+(−0.1012)Trp;0.832, 0.844, 0.844, 0.835, 0.832, 0.854, 0.807, 0.83 4,(4.3936)+(0.0093)Gln+(−0.0402)His+(−0.0427)Cit+(−0.1045)T rp; 0.829,0.850, 0.844, 0.840, 0.837, 0.822, 0.831, 0.835, (6.5152)+(0.0193)Ser+(−0.0073)Gly+(−0.0096)Tyr+(−0.1925)Met+(0.0531)Phe+(−0.0981)Trp; 0.853, 0.869, 0.844, 0.848, 0.842, 0.838, 0.81 0,0.840, (8.5266)+(−0.0643)Asn+(0.0095)Thr+(−0.0179)Val+(−0.1409)Met+(0.0792)Phe+(−0.0835)Trp; 0.828, 0.846, 0.844, 0.832, 0. 834,0.829, 0.793, 0.826, (6.1049)+(0.0111)Ser+(−0.0044)Tyr+(−0.1906)Met+(−0.0046)Lys+(0.0582)Phe+(−0.0985)Trp; 0.824, 0.846, 0.844,0.831, 0.835, 0.825, 0.789, 0.824,(6.0241)+(0.0117)Ser+(−0.0087)Arg+(−0.0030)Tyr+(−0.1911)Met+(0.0562)Phe+(−0.0987)Trp; 0.831, 0.850, 0.843, 0.835, 0.839, 0.827, 0.794, 0.828, (6.0950)+(0.0127)Ser+(−0.0069)Arg+(−0.1950)Met+(−0.0114)Orn+(0.0602)Phe+(−0.0991)Trp; 0.825, 0.841, 0.843, 0.816, 0.794, 0.823, 0.79 3,0.813, (4.2614)+(0.0087)Gln+(−0.0512)His+(−0.0397)Tyr+(0.0295)Phe+(−0.0908)Trp; 0.824, 0.834, 0.843, 0.824, 0.813, 0.837, 0. 808,0.823, (4.6044)+(0.0076)Gln+(−0.0489)His+(−0.1037)Trp; 0. 831, 0.850,0.843, 0.835, 0.837, 0.828, 0.800, 0.829, (6.1095)+(0.0120)Ser+(−0.1986)Met+(−0.0116)Orn+(−0.0027)Lys+(0.0613)Phe+(−0.0997)Trp;0.848, 0.865, 0.843, 0.843, 0.824, 0.843, 0.828, 0.84 0,(8.5066)+(0.0090)Ser+(−0.1145)Asn+(−0.0209)Val+(0.0118)Ile+(0.0597)Phe+(−0.0848)Trp; 0.825, 0.843, 0.843, 0.830, 0.833, 0. 820,0.794, 0.823, (5.8951)+(0.0099)Ser+(−0.0038)Tyr+(−0.2043)Met+(0.0567)Phe+(−0.1007)Trp; 0.858, 0.876, 0.843, 0.858, 0.853, 0.849,0.829, 0.852, (2.8311)+(0.0139)Gln+(−0.0442)Cit+(−0.2353)Met+(−0.0092)Lys+(0.0623)Phe+(−0.1087)Trp; 0.828, 0.844, 0.8 43,0.831, 0.833, 0.823, 0.797, 0.824, (5.8677)+(0.0106)Ser+(−0.0013)Thr+(−0.2051)Met+(0.0553)Phe+(−0.1016)Trp; 0.888, 0.899, 0. 843,0.872, 0.850, 0.857, 0.855, 0.865, (4.4024)+(−0.1075)Asn+(0.0147)Gln+(−0.0196)Val+(−0.1775)Met+(0.0888)Phe+(−0.0925)Tr p; 0.848,0.865, 0.843, 0.854, 0.837, 0.866, 0.851, 0.855,(7.0521)+(0.0156)Ser+(−0.0046)Gly+(−0.0074)Ala+(−0.1536)Met+(0.0496)Phe+(−0.0886)Trp

List (1) of Logistic Regression Equations Searched in Example 6

The logistic regression equations searched in Example 6 above are listedbelow. Before each equation, “the value of ROC_AUC for the pancreaticcancer group and the colorectal cancer group with validation”, “thevalue of ROC_AUC for the pancreatic cancer group and the colorectalcancer group without validation”, “the value of ROC_AUC for thepancreatic cancer group and the healthy group”, “the value of ROC_AUCfor the pancreatic cancer group and the other cancers group”, “the valueof ROC_AUC for the pancreatic cancer group and the lung cancer group”,“the value of ROC_AUC for the pancreatic cancer group and the prostaticcancer group”, “the value of ROC_AUC for the pancreatic cancer group andthe breast cancer group”, and “the average value of the value of ROC_AUCfor the pancreatic cancer group and the lung cancer group, the value ofROC_AUC for the pancreatic cancer group and the colorectal cancer group,the value of ROC_AUC for the pancreatic cancer group and the prostaticcancer group, and the value of ROC_AUC for the pancreatic cancer groupand the breast cancer group” obtained for the equation are additionallylisted.

0.851, 0.874, 0.831, 0.855, 0.845, 0.857, 0.841, 0.854, (5.6692)+(−0.0719)Asn+(0.0072)Gln+(−0.0715)Cit+(0.0674)Tyr+(−0.1878)Met+(−0.1103)Trp; 0.850, 0.871, 0.830, 0.836, 0.811, 0.833, 0.8 34,0.837, (7.7617)+(−0.0729)Asn+(−0.0057)Gly+(−0.0829)Cit+(0.0409)Tyr+(0.0296)Orn+(−0.1265)Trp; 0.850, 0.873, 0.814, 0.859, 0. 857,0.861, 0.832, 0.856, (6.1359)+(−0.1088)Asn+(0.0071)Gln+(−0.0672)Cit+(−0.0111)Pro+(0.0505)Tyr+(−0.1271)Trp; 0.849, 0.870, 0.846,0.846, 0.832, 0.854, 0.826, 0.846,(5.7474)+(−0.1127)Asn+(0.0047)Gln+(−0.0872)Cit+(0.0428)Tyr+(0.0250)Orn+(−0.1255)Trp; 0.849, 0.867, 0.838, 0.831, 0.809, 0.840, 0.808, 0.831, (7.0356)+(−0.0849)Asn+(−0.0858)Cit+(0.0454)Tyr+(0.0272)Orn+(−0.127 2)Trp; 0.849,0.870, 0.835, 0.836, 0.815, 0.852, 0.811, 0.837, (7.1656)+(−0.0396)Asn+(−0.0827)Cit+(0.0644)Tyr+(−0.1539)Met+(0.0221)Orn+(−0.1154)Trp; 0.849, 0.871, 0.816, 0.851, 0.844, 0.858, 0. 824,0.849, (5.8529)+(0.0054)Gln+(−0.0752)Cit+(−0.0083)Pro+(0.0729)Tyr+(−0.2227)Met+(−0.1204)Trp; 0.848, 0.868, 0.825, 0.837, 0.821,0.852, 0.807, 0.837,(7.1319)+(−0.0848)Cit+(−0.0074)Pro+(0.0688)Tyr+(−0.1769)Met+(0.0215)Orn+(−0.1210)Trp;0.848, 0.8 68, 0.841, 0.839, 0.818, 0.853, 0.822, 0.840,(7.0943)+(−0.0793)Asn+(−0.0024)Ala+(−0.0860)Cit+(0.0480)Tyr+(0.0271)Orn+(−0.120 8)Trp;0.848, 0.869, 0.826, 0.836, 0.819, 0.844, 0.805, 0.835, (7.5534)+(−0.0758)Asn+(−0.0856)Cit+(−0.0091)Pro+(0.0501)Tyr+(0.0291)Orn+(−0.1282)Trp; 0.848, 0.868, 0.817, 0.839, 0.827, 0.848, 0. 801,0.836, (7.4652)+(0.0076)Thr+(−0.0677)Cit+(−0.0072)Pro+(0.0744)Tyr+(−0.2094)Met+(−0.1239)Trp; 0.847, 0.869, 0.839, 0.832, 0.811,0.841, 0.809, 0.832,(7.1085)+(−0.0806)Asn+(−0.0868)Cit+(0.0455)Tyr+(0.0281)Orn+(−0.0020)Lys+(−0.1251)Trp;0.847, 0.8 68, 0.803, 0.842, 0.829, 0.839, 0.827, 0.841,(8.0010)+(−0.0032)Gly+(−0.0628)Cit+(−0.0063)Pro+(0.0706)Tyr+(−0.1728)Met+(−0.12 09)Trp;0.847, 0.871, 0.814, 0.857, 0.846, 0.838, 0.869, 0.856, (6.3888)+(−0.1064)Asn+(−0.0072)Gly+(0.0069)Gln+(−0.0612)Cit+(0.0393)Tyr+(−0.1215)Trp; 0.847, 0.868, 0.825, 0.840, 0.824, 0.843, 0. 820,0.839,(7.1977)+(−0.0275)Asn+(−0.0640)Cit+(0.0662)Tyr+(−0.1707)Met+(0.0104)Phe+(−0.1193)Trp;0.847, 0.868, 0.826, 0.837, 0.820, 0.847, 0.812, 0.837,(7.4013)+(−0.0324)Asn+(0.0064)Thr+(−0.0658)Cit+(0.0704)Tyr+(−0.1895)Met+(−0.1172)Trp;0.847, 0. 866, 0.817, 0.837, 0.821, 0.842, 0.816, 0.836,(7.5014)+(−0.0300)Asn+(−0.0653)Cit+(0.0703)Tyr+(−0.1702)Met+(−0.1157)Trp; 0.847, 0.867,0.837, 0.831, 0.810, 0.839, 0.807, 0.831, (7.0571)+(−0.0846)Asn+(−0.0859)Cit+(0.0455)Tyr+(0.0275)Orn+(−0.0010)Ile+(−0. 1269)Trp;0.846, 0.866, 0.809, 0.838, 0.826, 0.844, 0.809, 0.836, (7.5613)+(−0.0672)Cit+(−0.0065)Pro+(0.0737)Tyr+(−0.1847)Met+(−0.1211)Trp;0.846, 0.867, 0.827, 0.849, 0.839, 0.849, 0.836, 0.848,(5.8545)+(−0.1092)Asn+(0.0053)Gln+(−0.0674)Cit+(0.0456)Tyr+(−0.1244)Trp;0.846, 0.866, 0.824, 0.837, 0.822, 0.841, 0.813, 0.83 5,(6.7689)+(−0.0672)Cit+(0.0662)Tyr+(−0.1984)Met+(0.0116)Phe+(−0.1210)Trp; 0.846, 0.870, 0.818, 0.850, 0.838, 0.842, 0.846, 0. 849,(5.9813)+(−0.0053)Gly+(0.0055)Gln+(−0.0705)Cit+(0.0640)Tyr+(−0.2246)Met+(−0.1145)Trp; 0.846, 0.867, 0.811, 0.836, 0.821, 0.839,0.808, 0.834, (7.3261)+(−0.0705)Cit+(−0.0066)Pro+(0.0734)Tyr+(0.0041)Val+(−0.1901)Met+(−0.1275)Trp; 0.846, 0.868, 0.8 32,0.837, 0.821, 0.845, 0.811, 0.836, (6.6000)+(0.0065)Thr+(−0.0678)Cit+(0.0657)Tyr+(−0.2208)Met+(0.0132)Phe+(−0.1230)Trp; 0. 846,0.868, 0.810, 0.841, 0.829, 0.845, 0.814, 0.839, (7.9033)+(−0.0256)Asn+(−0.0642)Cit+(−0.0061)Pro+(0.0731)Tyr+(−0.1593)Met+(−0.1197)Trp; 0.846, 0.869, 0.835, 0.830, 0.810, 0.836, 0.799, 0.8 28,(7.1058)+(−0.0739)Asn+(−0.0798)Cit+(−0.0100)Arg+(0.0471)Tyr+(0.0272)Orn+(−0.1256)Trp; 0.846, 0.867, 0.838, 0.831, 0.809, 0.840,0.808, 0.831, (7.0362)+(−0.0849)Asn+(−0.0858)Cit+(0.0454)Tyr+(0.0273)Orn+(−0.0000)Leu+(−0.1272)Trp; 0.846, 0.867, 0.8 39,0.831, 0.810, 0.840, 0.808, 0.831, (7.0210)+(−0.0847)Asn+(−0.0857)Cit+(0.0452)Tyr+(0.0272)Orn+(0.0006)Phe+(−0.1275)Trp; 0. 846,0.869, 0.816, 0.842, 0.830, 0.845, 0.814, 0.839, (7.2685)+(−0.0656)Cit+(−0.0062)Pro+(0.0694)Tyr+(−0.1834)Met+(0.0102)Phe+(−0.1240)Trp;0.846, 0.868, 0.838, 0.848, 0.838, 0.853, 0.829, 0.84 7,(4.8590)+(0.0051)Gln+(−0.0738)Cit+(0.0627)Tyr+(−0.2409)Met+(0.0172)Phe+(−0.1200)Trp; 0.846, 0.869, 0.826, 0.837, 0.817, 0. 842,0.823, 0.838, (7.2825)+(−0.0044)Gly+(−0.0825)Cit+(0.0609)Tyr+(−0.1763)Met+(0.0222)Orn+(−0.1180)Trp; 0.846, 0.868, 0.818, 0.839,0.821, 0.838, 0.825, 0.838, (7.5424)+(−0.0041)Gly+(0.0071)Thr+(−0.0647)Cit+(0.0670)Tyr+(−0.2093)Met+(−0.1194)Trp; 0. 846, 0.865,0.830, 0.832, 0.813, 0.847, 0.804, 0.832, (6.6662)+(−0.0848)Cit+(0.0660)Tyr+(−0.1954)Met+(0.0189)Orn+(−0.1170)Trp; 0.846,0.866, 0.818, 0.839, 0.823, 0.845, 0.819, 0.838,(7.5068)+(−0.0280)Asn+(−0.0009)Ala+(−0.0654)Cit+(0.0711)Tyr+(−0.1674)Met+(−0.1139)Trp; 0.846, 0.868, 0.817, 0.849, 0.841, 0.842, 0.835, 0.846, (6.1483)+(−0.0060)Ser+(−0.1031)Asn+(0.0058)Gln+(−0.0687)Cit+(0.0451)Tyr+(−0.1261)Trp; 0.846, 0.867, 0.836, 0.828, 0.80 5,0.835, 0.805, 0.828, (6.9378)+(−0.0858)Asn+(−0.0874)Cit+(0.0446)Tyr+(0.0024)Val+(0.0267)Orn+(−0.1316)Trp; 0.846, 0.866, 0. 834,0.830, 0.809, 0.839, 0.807, 0.830, (7.1787)+(−0.0020)Ser+(−0.0817)Asn+(−0.0862)Cit+(0.0453)Tyr+(0.0274)Orn+(−0.1279)Trp; 0.845,0.862, 0.817, 0.833, 0.817, 0.841, 0.806, 0.832,(7.0767)+(−0.0690)Cit+(0.0710)Tyr+(−0.2009)Met+(−0.1171)Trp; 0.845, 0.868, 0.829, 0.849, 0.840, 0.847, 0.838, 0.848, (5.7352)+(−0.1079)Asn+(0.0053)Gln+(−0.0671)Cit+(0.0445)Tyr+(0.0039)Phe+(−0.1263)Trp; 0.845,0.867, 0.833, 0.837, 0.818, 0.854, 0.813, 0.838, (6.7229)+(−0.0016)Ala+(−0.0851)Cit+(0.0669)Tyr+(−0.1865)Met+(0.0196)Orn+(−0.1135)Trp; 0.845, 0.863, 0.819, 0.836, 0.821, 0.846, 0.8 13,0.836, (7.1306)+(−0.0013)Ala+(−0.0689)Cit+(0.0719)Tyr+(−0.1938)Met+(−0.1143)Trp; 0.845, 0.864, 0.822, 0.833, 0.816, 0.845, 0. 803,0.832, (6.9630)+(0.0056)Thr+(−0.0697)Cit+(0.0711)Tyr+(−0.2203)Met+(−0.1186)Trp; 0.845, 0.867, 0.817, 0.840, 0.824, 0.833, 0. 831,0.839,(7.2884)+(−0.0032)Gly+(−0.0631)Cit+(0.0635)Tyr+(−0.1857)Met+(0.0105)Phe+(−0.1213)Trp;0.845, 0.865, 0.825, 0.843, 0.831, 0.851, 0.821, 0.842,(5.5455)+(0.0045)Gln+(−0.0759)Cit+(0.0697)Tyr+(−0.2378)Met+(−0.1148)Trp;0.845, 0.867, 0.823, 0.8 38, 0.820, 0.848, 0.817, 0.838,(7.2506)+(0.0034)Ser+(−0.0336)Asn+(−0.0652)Cit+(0.0711)Tyr+(−0.1743)Met+(−0.1147)Trp; 0.845, 0.864,0.810, 0.837, 0.820, 0.833, 0.828, 0.836, (7.5972)+(−0.0035)Gly+(−0.0645)Cit+(0.0676)Tyr+(−0.1872)Met+(−0.1176)Trp; 0. 845, 0.866,0.833, 0.831, 0.809, 0.839, 0.810, 0.831, (7.1163)+(−0.0798)Asn+(−0.0043)Thr+(−0.0870)Cit+(0.0468)Tyr+(0.0282)Orn+(−0.1251)Trp;0.845, 0.867, 0.825, 0.840, 0.825, 0.847, 0.820, 0.84 0,(6.8272)+(−0.0012)Ala+(−0.0671)Cit+(0.0672)Tyr+(−0.1919)Met+(0.0114)Phe+(−0.1183)Trp; 0.845, 0.866, 0.821, 0.842, 0.825, 0. 841,0.836, 0.842, (7.1813)+(0.0076)Ser+(−0.0052)Gly+(−0.0629)Cit+(0.0674)Tyr+(−0.1982)Met+(−0.1156)Trp; 0.845, 0.866, 0.819, 0.837,0.819, 0.838, 0.820, 0.836, (7.2585)+(−0.0418)Asn+(−0.0659)Cit+(0.0720)Tyr+(−0.1918)Met+(0.0078)Lys+(−0.1212)Trp; 0.8 44, 0.866,0.809, 0.837, 0.824, 0.839, 0.808, 0.834, (7.2430)+(−0.0686)Cit+(−0.0070)Pro+(0.0757)Tyr+(−0.2111)Met+(0.0065)Lys+(−0.1265)Trp;0.844, 0.866, 0.810, 0.840, 0.823, 0.837, 0.833, 0.84 0,(7.8866)+(−0.0257)Asn+(−0.0030)Gly+(−0.0617)Cit+(0.0674)Tyr+(−0.1627)Met+(−0.1162)Trp; 0.844, 0.866, 0.809, 0.839, 0.826, 0.846,0.811, 0.838, (7.5711)+(−0.0005)Ala+(−0.0672)Cit+(−0.0063)Pro+(0.0741)Tyr+(−0.1825)Met+(−0.1199)Trp; 0.844, 0.867, 0. 827,0.846, 0.834, 0.842, 0.833, 0.844, (5.7895)+(−0.1098)Asn+(0.0052)Gln+(−0.0695)Cit+(0.0448)Tyr+(0.0024)Val+(−0.1287)Trp; 0.844,0.865, 0.817, 0.833, 0.814, 0.837, 0.814, 0.832,(7.2967)+(−0.0308)Asn+(−0.0689)Cit+(0.0699)Tyr+(0.0041)Val+(−0.1751)Met+(−0.1225)Trp; 0.844, 0.865, 0.832, 0.832, 0.814, 0.848, 0.801, 0. 832,(6.7648)+(−0.0807)Cit+(−0.0054)Arg+(0.0662)Tyr+(−0.1854)Met+(0.0192)Orn+(−0.1170)Trp; 0.844, 0.865, 0.813, 0.835, 0.81 9,0.839, 0.814, 0.834, (7.2574)+(−0.0687)Cit+(−0.0065)Pro+(0.0745)Tyr+(−0.2011)Met+(0.0089)Leu+(−0.1272)Trp; 0.844, 0.866, 0. 835,0.832, 0.812, 0.850, 0.802, 0.833, (6.6142)+(0.0042)Thr+(−0.0840)Cit+(0.0664)Tyr+(−0.2108)Met+(0.0176)Orn+(−0.1180)Trp; 0.844,0.866, 0.828, 0.838, 0.824, 0.845, 0.814, 0.837, (6.5164)+(0.0026)Ser+(−0.0673)Cit+(0.0664)Tyr+(−0.2045)Met+(0.0125)Phe+(−0.1204)Trp;0.844, 0.865, 0.823, 0.836, 0.820, 0.848, 0.812, 0.83 6,(7.0140)+(0.0055)Thr+(−0.0013)Ala+(−0.0695)Cit+(0.0720)Tyr+(−0.2132)Met+(−0.1160)Trp; 0.844, 0.865, 0.813, 0.838, 0.827, 0. 846,0.807, 0.836, (7.3279)+(0.0029)Ser+(−0.0675)Cit+(−0.0067)Pro+(0.0746)Tyr+(−0.1908)Met+(−0.1206)Trp; 0.844, 0.867, 0.827, 0.848,0.837, 0.856, 0.832, 0.848, (5.5554)+(0.0047)Gln+(−0.0018)Ala+(−0.0757)Cit+(0.0709)Tyr+(−0.2296)Met+(−0.1111)Trp; 0. 844, 0.866,0.835, 0.835, 0.817, 0.850, 0.809, 0.836, (6.4516)+(−0.0822)Cit+(0.0626)Tyr+(−0.1933)Met+(0.0176)Orn+(0.0090)Phe+(−0.1202)Trp;0.844, 0.868, 0.827, 0.851, 0.842, 0.853, 0.837, 0.85 0,(5.8878)+(−0.1052)Asn+(0.0056)Gln+(−0.0679)Cit+(0.0458)Tyr+(−0.0030)Lys+(−0.1214)Trp; 0.844, 0.868, 0.830, 0.857, 0.850, 0. 863,0.851, 0.858, (5.8704)+(−0.1056)Asn+(0.0055)Gln+(−0.0027)Ala+(−0.0676)Cit+(0.0486)Tyr+(−0.1173)Trp; 0.844, 0.864, 0.824, 0.833,0.816, 0.834, 0.812, 0.831, (6.5818)+(−0.0706)Cit+(0.0661)Tyr+(0.0037)Val+(−0.2037)Met+(0.0110)Phe+(−0.1270)Trp; 0.8 43, 0.866,0.811, 0.838, 0.827, 0.844, 0.807, 0.836, (7.6240)+(−0.0643)Cit+(−0.0036)Arg+(−0.0064)Pro+(0.0739)Tyr+(−0.1790)Met+(−0.1208)Trp;0.843, 0.866, 0.832, 0.840, 0.826, 0.854, 0.813, 0.84 0,(5.4494)+(0.0038)Gln+(−0.0864)Cit+(0.0660)Tyr+(−0.2286)Met+(0.0142)Orn+(−0.1149)Trp; 0.843, 0.867, 0.830, 0.849, 0.838, 0. 848,0.838, 0.848, (5.7917)+(−0.1101)Asn+(0.0052)Gln+(−0.0676)Cit+(0.0452)Tyr+(0.0033)Ile+(−0.1253)Trp; 0.843, 0.867, 0.826, 0.849,0.840, 0.849, 0.836, 0.848, (5.8645)+(−0.1092)Asn+(0.0053)Gln+(−0.0673)Cit+(0.0456)Tyr+(−0.0004)Leu+(−0.1240)Trp; 0. 843, 0.864,0.831, 0.829, 0.809, 0.843, 0.801, 0.829, (6.5154)+(−0.0867)Cit+(0.0658)Tyr+(0.0031)Val+(−0.1992)Met+(0.0178)Orn+(−0.1221)Trp;0.843, 0.865, 0.811, 0.840, 0.824, 0.838, 0.831, 0.83 9,(7.6202)+(−0.0033)Gly+(−0.0011)Ala+(−0.0645)Cit+(0.0685)Tyr+(−0.1815)Met+(−0.1151)Trp; 0.843, 0.865, 0.831, 0.855, 0.852, 0.845,0.849, 0.853, (6.4883)+(−0.0903)Asn+(−0.0089)Gly+(0.0069)Gln+(−0.0800)Cit+(0.0290)Orn+(−0.1034)Trp; 0.843, 0.863, 0.8 18,0.833, 0.817, 0.843, 0.806, 0.832, (6.9632)+(0.0013)Ser+(−0.0691)Cit+(0.0713)Tyr+(−0.2039)Met+(−0.1167)Trp; 0.843, 0.863, 0. 816,0.829, 0.811, 0.833, 0.806, 0.828, (6.8562)+(−0.0726)Cit+(0.0706)Tyr+(0.0040)Val+(−0.2062)Met+(−0.1236)Trp; 0.843, 0.865, 0.826,0.840, 0.826, 0.846, 0.817, 0.839,(5.4601)+(0.0042)Gln+(−0.0781)Cit+(0.0694)Tyr+(0.0027)Val+(−0.2395)Met+(−0.1190)Trp; 0.843, 0.859, 0.813, 0.831, 0.815, 0.830, 0.814, 0.830,(7.3478)+(−0.0782)Asn+(−0.0635)Cit+(0.0492)Tyr+(−0.1269)Trp; 0.843, 0.864, 0.820, 0.835, 0.816, 0.841, 0.818, 0.835, (6.8704)+(−0.0023)Ala+(−0.0735)Cit+(0.0723)Tyr+(0.0053)Val+(−0.1964)Met+(−0.12 11)Trp;0.843, 0.866, 0.816, 0.837, 0.821, 0.842, 0.816, 0.836, (7.5175)+(−0.0283)Asn+(−0.0638)Cit+(−0.0021)Arg+(0.0705)Tyr+(−0.1682)Met+(−0.1157)Trp; 0.843, 0.868, 0.819, 0.847, 0.841, 0.838, 0. 825,0.843,(5.7314)+(−0.1002)Asn+(0.0063)Gln+(−0.0577)Cit+(−0.0159)Arg+(0.0480)Tyr+(−0.1216)Trp;0.843, 0.865, 0.831, 0.832, 0.813, 0.847, 0.804, 0.832,(6.6496)+(0.0002)Ser+(−0.0848)Cit+(0.0660)Tyr+(−0.1959)Met+(0.0189)Orn+(−0.1169)Trp;0.843, 0.8 64, 0.822, 0.833, 0.816, 0.845, 0.803, 0.832,(6.9687)+(−0.0001)Ser+(0.0057)Thr+(−0.0697)Cit+(0.0711)Tyr+(−0.2202)Met+(−0.118 6)Trp;0.842, 0.864, 0.820, 0.837, 0.821, 0.847, 0.814, 0.837, (7.0379)+(0.0010)Ser+(−0.0013)Ala+(−0.0690)Cit+(0.0722)Tyr+(−0.1963)Met+(−0.1141)Trp; 0.842, 0.864, 0.829, 0.831, 0.812, 0.845, 0. 803,0.831, (6.5223)+(−0.0839)Cit+(0.0673)Tyr+(−0.2097)Met+(0.0170)Orn+(0.0032)Lys+(−0.1193)Trp; 0.842, 0.866, 0.824, 0.844, 0. 836,0.847, 0.818, 0.842, (5.5207)+(0.0051)Gln+(−0.0681)Cit+(−0.0105)Arg+(0.0701)Tyr+(−0.2261)Met+(−0.1140)Trp; 0.842, 0.863, 0.816,0.833, 0.819, 0.840, 0.804, 0.831,(7.1673)+(−0.0653)Cit+(−0.0046)Arg+(0.0712)Tyr+(−0.1930)Met+(−0.1170)Trp;0.842, 0. 865, 0.819, 0.834, 0.813, 0.838, 0.820, 0.834,(7.2332)+(−0.0306)Asn+(−0.0672)Cit+(0.0712)Tyr+(−0.1868)Met+(0.0092)Leu+(−0.12 26)Trp;0.842, 0.864, 0.823, 0.832, 0.816, 0.839, 0.806, 0.831, (6.7337)+(0.0046)Thr+(−0.0706)Cit+(0.0721)Tyr+(−0.2354)Met+(0.0045)Lys+(−0.1217)Trp; 0.842, 0.866, 0.823, 0.837, 0.822, 0.841, 0. 811,0.835,(6.8536)+(−0.0645)Cit+(−0.0034)Arg+(0.0666)Tyr+(−0.1925)Met+(0.0110)Phe+(−0.1208)Trp;0.842, 0.864, 0.822, 0.830, 0.811, 0.837, 0.802, 0.829,(6.7648)+(0.0052)Thr+(−0.0730)Cit+(0.0706)Tyr+(0.0036)Val+(−0.2233)Met+(−0.1243)Trp;0.842, 0.8 60, 0.819, 0.831, 0.813, 0.828, 0.819, 0.830,(7.2067)+(−0.0803)Asn+(−0.0639)Cit+(0.0484)Tyr+(0.0059)Ile+(−0.1284)Trp; 0.842, 0. 864,0.827, 0.838, 0.818, 0.846, 0.830, 0.840, (6.8917)+(−0.0701)Cit+(−0.0075)Pro+(0.0749)Tyr+(−0.2193)Met+(0.0275)Ile+(−0.12 24)Trp;0.842, 0.866, 0.829, 0.842, 0.829, 0.852, 0.818, 0.841, (5.5687)+(0.0042)Gln+(0.0031)Thr+(−0.0759)Cit+(0.0698)Tyr+(−0.2462)Met+(−0.1160)Trp; 0.842, 0.867, 0.818, 0.851, 0.843, 0.845, 0. 843,0.849,(5.8268)+(−0.1085)Asn+(0.0063)Gln+(−0.0072)Thr+(−0.0685)Cit+(0.0478)Tyr+(−0.1208)Trp;0.842, 0.860, 0.816, 0.838, 0.824, 0.841, 0.827, 0.838,(7.4134)+(−0.0734)Asn+(−0.0023)Ala+(−0.0637)Cit+(0.0521)Tyr+(−0.1207)Trp;0.842, 0.862, 0.817, 0.8 32, 0.816, 0.834, 0.809, 0.830,(6.7789)+(−0.0703)Cit+(0.0723)Tyr+(−0.2235)Met+(0.0053)Lys+(−0.1210)Trp; 0.842, 0.865, 0.811, 0. 834,0.816, 0.826, 0.825, 0.833, (7.3813)+(−0.0034)Gly+(−0.0679)Cit+(0.0672)Tyr+(0.0038)Val+(−0.1928)Met+(−0.1240)Trp; 0.842, 0.862,0.806, 0.835, 0.817, 0.818, 0.840, 0.834, (8.0200)+(−0.0687)Asn+(−0.0050)Gly+(−0.0581)Cit+(0.0458)Tyr+(−0.1260)Trp; 0. 841, 0.863,0.832, 0.828, 0.806, 0.842, 0.807, 0.829, (6.4594)+(−0.0855)Cit+(0.0670)Tyr+(−0.2087)Met+(0.0174)Orn+(0.0076)Leu+(−0.1227)Trp;0.841, 0.864, 0.817, 0.837, 0.822, 0.844, 0.813, 0.83 6,(7.2172)+(−0.0013)Ala+(−0.0653)Cit+(−0.0044)Arg+(0.0722)Tyr+(−0.1864)Met+(−0.1143)Trp

List (1) of Linear Discriminants Searched in Example 6

The linear discriminants searched in Example 6 above are listed below.Before each equation, “the value of ROC_AUC for the pancreatic cancergroup and the colorectal cancer group with validation”, “the value ofROC_AUC for the pancreatic cancer group and the colorectal cancer groupwithout validation”, “the value of ROC_AUC for the pancreatic cancergroup and the healthy group”, “the value of ROC_AUC for the pancreaticcancer group and the other cancers group”, “the value of ROC_AUC for thepancreatic cancer group and the lung cancer group”, “the value ofROC_AUC for the pancreatic cancer group and the prostatic cancer group”,“the value of ROC_AUC for the pancreatic cancer group and the breastcancer group”, and “the average value of the value of ROC_AUC for thepancreatic cancer group and the lung cancer group, the value of ROC_AUCfor the pancreatic cancer group and the colorectal cancer group, thevalue of ROC_AUC for the pancreatic cancer group and the prostaticcancer group, and the value of ROC_AUC for the pancreatic cancer groupand the breast cancer group” obtained for the equation are additionallylisted.

0.862, 0.876, 0.836, 0.862, 0.854, 0.866, 0.850, 0.862, (6.7413)+(−0.0941)Asn+(0.0093)Gln+(−0.0666)Cit+(0.0561)Tyr+(−0.1268)Met+(−0.1224)Trp; 0.861, 0.876, 0.840, 0.849, 0.834, 0.843, 0.8 36,0.847, (8.2510)+(−0.0469)Asn+(−0.0498)Cit+(0.0525)Tyr+(−0.1388)Met+(0.0356)Phe+(−0.1294)Trp; 0.860, 0.874, 0.859, 0.845, 0. 831,0.848, 0.818, 0.843, (6.9429)+(0.0121)Thr+(−0.0594)Cit+(0.0463)Tyr+(−0.2151)Met+(0.0479)Phe+(−0.1367)Trp; 0.860, 0.871, 0.841,0.839, 0.820, 0.854, 0.814, 0.840,(8.8283)+(−0.0615)Asn+(−0.0708)Cit+(0.0534)Tyr+(−0.1019)Met+(0.0231)Orn+(−0.1179)Trp;0.858, 0.871, 0.842, 0.845, 0.832, 0.840, 0.828, 0.843, (7.2291)+(−0.0552)Cit+(0.0477)Tyr+(−0.1719)Met+(0.0417)Phe+(−0.13 18)Trp;0.857, 0.871, 0.832, 0.840, 0.825, 0.849, 0.808, 0.838, (9.1087)+(−0.0640)Asn+(0.0112)Thr+(−0.0561)Cit+(0.0564)Tyr+(−0.1303)Met+(−0.1204)Trp; 0.857, 0.873, 0.836, 0.849, 0.841, 0.843, 0. 829,0.846,(7.6157)+(−0.0525)Cit+(−0.0057)Pro+(0.0502)Tyr+(−0.1580)Met+(0.0417)Phe+(−0.1349)Trp;0.857, 0.875, 0.820, 0.865, 0.865, 0.868, 0.838, 0.862,(7.2197)+(−0.1137)Asn+(0.0090)Gln+(−0.0613)Cit+(−0.0095)Pro+(0.0452)Tyr+(−0.1360)Trp;0.856, 0. 874, 0.857, 0.857, 0.853, 0.851, 0.841, 0.855,(4.7009)+(0.0070)Gln+(−0.0685)Cit+(0.0441)Tyr+(−0.2171)Met+(0.0506)Phe+(−0.138 4)Trp;0.856, 0.872, 0.845, 0.853, 0.841, 0.857, 0.843, 0.853, (7.5089)+(−0.0029)Ala+(−0.0544)Cit+(0.0496)Tyr+(−0.1581)Met+(0.0411)Phe+(−0.1274)Trp; 0.856, 0.870, 0.861, 0.849, 0.837, 0.854, 0. 831,0.848, (6.2989)+(0.0102)Ser+(−0.0563)Cit+(0.0477)Tyr+(−0.1949)Met+(0.0483)Phe+(−0.1330)Trp; 0.855, 0.871, 0.852, 0.843, 0. 828,0.848, 0.821, 0.842, (7.0492)+(−0.0679)Cit+(0.0457)Tyr+(−0.1714)Met+(0.0151)Orn+(0.0379)Phe+(−0.1306)Trp; 0.855, 0.872, 0. 842,0.846, 0.835, 0.843, 0.825, 0.844, (7.3230)+(−0.0543)Cit+(0.0474)Tyr+(−0.1681)Met+(−0.0034)Leu+(0.0436)Phe+(−0.1303)Tr p; 0.855,0.871, 0.843, 0.844, 0.831, 0.840, 0.828, 0.842,(7.1567)+(−0.0553)Cit+(0.0479)Tyr+(−0.1754)Met+(0.0010)Lys+(0.0418)Phe+(−0.1326)Trp; 0.855, 0.867, 0.818, 0.840, 0.826, 0.842, 0.821, 0.839, (9.1261)+(−0.0569)Asn+(−0.0525)Cit+(0.0565)Tyr+(−0.0999)Met+(−0.1178)Trp; 0.855, 0.872, 0.828, 0.855, 0.847, 0.847, 0.84 8,0.853, (6.5246)+(−0.0045)Gly+(0.0065)Gln+(−0.0666)Cit+(0.0437)Tyr+(−0.1509)Met+(−0.1216)Trp; 0.854, 0.869, 0.836, 0.843, 0. 828,0.857, 0.821, 0.844, (8.5671)+(0.0088)Ser+(−0.0642)Asn+(−0.0532)Cit+(0.0577)Tyr+(−0.1104)Met+(−0.1169)Trp; 0.854, 0.868, 0.819,0.841, 0.825, 0.842, 0.822, 0.840,(8.9561)+(−0.0599)Asn+(−0.0525)Cit+(0.0575)Tyr+(−0.1093)Met+(0.0031)Lys+(−0.1203)Trp;0.854, 0.870, 0.831, 0.839, 0.820, 0.832, 0.833, 0.839, (9.2964)+(−0.0799)Asn+(−0.0043)Gly+(−0.0645)Cit+(0.0360)Tyr+(0.0235)Orn+(−0.1248)Trp; 0.854, 0.867, 0.822, 0.847, 0.835, 0.854, 0.8 33,0.847, (9.2762)+(−0.0536)Asn+(−0.0023)Ala+(−0.0523)Cit+(0.0577)Tyr+(−0.0913)Met+(−0.1145)Trp; 0.853, 0.868, 0.819, 0.840, 0.825,0.843, 0.822, 0.839,(9.0817)+(−0.0567)Asn+(−0.0527)Cit+(0.0566)Tyr+(−0.1018)Met+(0.0010)Leu+(−0.1185)Trp;0.853, 0.8 71, 0.841, 0.846, 0.834, 0.838, 0.835, 0.844,(7.4809)+(−0.0015)Gly+(−0.0531)Cit+(0.0461)Tyr+(−0.1652)Met+(0.0405)Phe+(−0.131 4)Trp;0.853, 0.868, 0.830, 0.840, 0.820, 0.846, 0.833, 0.842, (8.7118)+(−0.0562)Asn+(−0.0553)Cit+(0.0576)Tyr+(−0.1194)Met+(0.0147)Ile+(−0.1189)Trp; 0.853, 0.873, 0.821, 0.863, 0.857, 0.847, 0. 870,0.862,(7.5590)+(−0.1142)Asn+(−0.0066)Gly+(0.0091)Gln+(−0.0565)Cit+(0.0337)Tyr+(−0.1305)Trp;0.853, 0.864, 0.832, 0.834, 0.821, 0.846, 0.796, 0.832,(7.9167)+(0.0081)Thr+(−0.0631)Cit+(0.0509)Tyr+(−0.1581)Met+(−0.1203)Trp;0.853, 0.867, 0.818, 0.8 40, 0.826, 0.843, 0.821, 0.839,(9.1439)+(−0.0569)Asn+(−0.0523)Cit+(0.0566)Tyr+(−0.0002)Val+(−0.0998)Met+(−0.1175)Trp; 0.853, 0.869,0.857, 0.868, 0.879, 0.860, 0.841, 0.863, (5.6045)+(−0.0728)Asn+(0.0103)Gln+(−0.0613)Cit+(−0.1429)Met+(0.0505)Phe+(−0. 1170)Trp;0.853, 0.868, 0.834, 0.857, 0.851, 0.866, 0.842, 0.857, (6.3677)+(0.0059)Gln+(−0.0034)Ala+(−0.0708)Cit+(0.0512)Tyr+(−0.1486)Met+(−0.1166)Trp; 0.853, 0.870, 0.823, 0.854, 0.851, 0.862, 0. 823,0.852, (6.3261)+(0.0066)Gln+(−0.0697)Cit+(−0.0076)Pro+(0.0521)Tyr+(−0.1493)Met+(−0.1260)Trp; 0.852, 0.870, 0.828, 0.858, 0.855,0.860, 0.840, 0.856,(7.1920)+(−0.1090)Asn+(0.0084)Gln+(−0.0643)Cit+(0.0397)Tyr+(−0.0067)Lys+(−0.1252)Trp;0.852, 0. 872, 0.841, 0.859, 0.855, 0.855, 0.845, 0.857,(6.6480)+(−0.1169)Asn+(0.0077)Gln+(−0.0620)Cit+(0.0359)Tyr+(0.0126)Phe+(−0.136 7)Trp;0.852, 0.869, 0.827, 0.857, 0.857, 0.858, 0.833, 0.854, (7.2409)+(−0.1157)Asn+(0.0077)Gln+(−0.0619)Cit+(0.0405)Tyr+(−0.0060)Leu+(−0.1268)Trp; 0.852, 0.868, 0.850, 0.843, 0.826, 0.842, 0. 836,0.843, (6.9305)+(−0.0575)Cit+(0.0488)Tyr+(−0.1861)Met+(0.0121)Ile+(0.0401)Phe+(−0.1322)Trp; 0.852, 0.868, 0.834, 0.865, 0. 864,0.872, 0.857, 0.865, (7.2186)+(−0.1085)Asn+(0.0078)Gln+(−0.0040)Ala+(−0.0631)Cit+(0.0432)Tyr+(−0.1247)Trp; 0.852, 0.864, 0.838,0.833, 0.816, 0.848, 0.803, 0.833,(7.6916)+(−0.0762)Cit+(0.0484)Tyr+(−0.1372)Met+(0.0201)Orn+(−0.1184)Trp;0.852, 0.8 66, 0.834, 0.848, 0.840, 0.855, 0.825, 0.846,(6.1119)+(0.0057)Gln+(−0.0714)Cit+(0.0491)Tyr+(−0.1632)Met+(−0.1214)Trp; 0.852, 0. 868,0.813, 0.843, 0.832, 0.843, 0.819, 0.841, (9.4226)+(−0.0544)Asn+(−0.0504)Cit+(−0.0051)Pro+(0.0585)Tyr+(−0.0890)Met+(−0.1 206)Trp;0.852, 0.869, 0.832, 0.855, 0.851, 0.853, 0.839, 0.853, (6.9872)+(−0.1169)Asn+(0.0077)Gln+(−0.0630)Cit+(0.0393)Tyr+(−0. 1315)Trp;0.852, 0.870, 0.828, 0.857, 0.854, 0.853, 0.842, 0.855, (6.9009)+(−0.1142)Asn+(0.0081)Gln+(−0.0036)Thr+(−0.0626)Cit+(0.0405)Tyr+(−0.1301)Trp; 0.852, 0.868, 0.817, 0.842, 0.827, 0.839, 0. 832,0.842,(9.4049)+(−0.0556)Asn+(−0.0020)Gly+(−0.0498)Cit+(0.0541)Tyr+(−0.0933)Met+(−0.1177)Trp;0.852, 0.870, 0.844, 0.8 46, 0.836, 0.844, 0.828, 0.844,(7.3607)+(−0.0531)Cit+(0.0482)Tyr+(−0.0022)Val+(−0.1726)Met+(0.0432)Phe+(−0.1290)Trp; 0.851, 0.863,0.830, 0.836, 0.822, 0.846, 0.807, 0.835,(7.6885)+(0.0043)Ser+(−0.0606)Cit+(0.0517)Tyr+(−0.1403)Met+(−0.1180)Trp;0.85 1, 0.866, 0.842, 0.843, 0.828, 0.862, 0.822, 0.845, (7.9827)+(−0.0033)Ala+(−0.0760)Cit+(0.0503)Tyr+(−0.1224)Met+(0.0209)Orn+(−0.1137)Trp;0.851, 0.870, 0.830, 0.867, 0.871, 0.842, 0.866, 0.863,(7.2500)+(−0.1025)Asn+(−0.0076)Gly+(0.0097)Gln+(−0.0528)Cit+(0.0206)Phe+(−0.1235)Trp; 0.851, 0.869, 0.844, 0.845, 0.834, 0.8 60,0.815, 0.845, (6.0208)+(0.0052)Gln+(−0.0832)Cit+(0.0469)Tyr+(−0.1637)Met+(0.0157)Orn+(−0.1212)Trp; 0.851, 0.867, 0.829, 0. 838,0.826, 0.842, 0.806, 0.836,(9.1413)+(−0.0785)Asn+(−0.0693)Cit+(−0.0081)Pro+(0.0443)Tyr+(0.0264)Orn+(−0.1291)Trp;0.851, 0.865, 0.839, 0.835, 0.818, 0.838, 0.812, 0.833, (8.6994)+(−0.0857)Asn+(−0.0692)Cit+(0.0394)Tyr+(0.0222)Orn+(−0.1261)Trp; 0.8 51, 0.867,0.830, 0.840, 0.826, 0.839, 0.820, 0.838, (8.4478)+(−0.0037)Gly+(0.0101)Thr+(−0.0586)Cit+(0.0465)Tyr+(−0.1508)Met+(−0.1206)Trp;0.851, 0.865, 0.844, 0.834, 0.817, 0.855, 0.795, 0.83 3,(7.6431)+(0.0061)Thr+(−0.0770)Cit+(0.0483)Tyr+(−0.1555)Met+(0.0180)Orn+(−0.1199)Trp; 0.851, 0.866, 0.824, 0.837, 0.829, 0. 849,0.790, 0.834,(8.3241)+(0.0093)Thr+(−0.0606)Cit+(−0.0063)Pro+(0.0535)Tyr+(−0.1467)Met+(−0.1240)Trp;0.851, 0.867, 0.830, 0.837, 0.824, 0.852, 0.798, 0.835,(8.0977)+(−0.0759)Cit+(−0.0069)Pro+(0.0508)Tyr+(−0.1211)Met+(0.0237)Orn+(−0.1221)Trp; 0.8 51, 0.870,0.825, 0.856, 0.853, 0.852, 0.841, 0.854, (7.1163)+(−0.0039)Ser+(−0.1149)Asn+(0.0081)Gln+(−0.0635)Cit+(0.0392)Tyr+(−0.1319)Trp;0.851, 0.861, 0.815, 0.834, 0.822, 0.829, 0.814, 0.83 1,(8.9887)+(−0.0809)Asn+(−0.0516)Cit+(0.0427)Tyr+(−0.1259)T rp; 0.851,0.866, 0.843, 0.846, 0.827, 0.859, 0.848, 0.850, (7.8294)+(−0.0040)Ala+(−0.0625)Cit+(0.0555)Tyr+(−0.1420)Met+(0.0208)Ile+(−0.1141)Trp; 0.850, 0.868, 0.845, 0.860, 0.862, 0.842, 0.85 1,0.856, (5.1235)+(−0.0933)Asn+(0.0077)Gln+(0.0473)Tyr+(−0.1702)Met+(0.0469)Phe+(−0.1384)Trp; 0.850, 0.866, 0.837, 0.847, 0. 838,0.853, 0.827, 0.846, (5.9727)+(0.0058)Gln+(−0.0721)Cit+(0.0493)Tyr+(−0.1686)Met+(0.0031)Leu+(−0.1234)Trp; 0.850, 0.866, 0.832,0.834, 0.820, 0.838, 0.801, 0.831,(8.9450)+(−0.0838)Asn+(−0.0698)Cit+(0.0401)Tyr+(0.0251)Orn+(−0.0095)Ile+(−0.1244)Trp;0.850, 0.867, 0.839, 0.836, 0.819, 0.845, 0.808, 0.835, (9.0091)+(−0.0761)Asn+(−0.0727)Cit+(0.0394)Tyr+(0.0265)Orn+(−0.0063)Lys+(−0.1198)Trp; 0.850, 0.866, 0.834, 0.848, 0.840, 0.856, 0.8 25,0.847, (6.1246)+(0.0057)Gln+(−0.0713)Cit+(0.0492)Tyr+(−0.0002)Val+(−0.1632)Met+(−0.1211)Trp; 0.850, 0.862, 0.824, 0.834, 0.820,0.840, 0.811, 0.833,(7.9490)+(−0.0602)Cit+(0.0516)Tyr+(−0.1365)Met+(0.0020)Leu+(−0.1197)Trp;0.850, 0.865, 0.839, 0.8 34, 0.817, 0.853, 0.802, 0.834,(7.8845)+(−0.0776)Cit+(0.0473)Tyr+(−0.1264)Met+(0.0224)Orn+(−0.0032)Lys+(−0.1160)Trp; 0.850, 0.867,0.834, 0.837, 0.819, 0.843, 0.820, 0.837, (8.1249)+(−0.0030)Gly+(−0.0727)Cit+(0.0448)Tyr+(−0.1265)Met+(0.0210)Orn+(−0. 1183)Trp;0.850, 0.862, 0.823, 0.835, 0.822, 0.841, 0.811, 0.834, (8.0278)+(−0.0598)Cit+(0.0515)Tyr+(−0.1332)Met+(−0.1184)Trp; 0. 850, 0.870,0.826, 0.856, 0.855, 0.850, 0.833, 0.852, (6.8089)+(−0.1125)Asn+(0.0086)Gln+(−0.0566)Cit+(−0.0112)Arg+(0.0406)Tyr+(−0.1280)Trp;0.850, 0.868, 0.832, 0.862, 0.863, 0.852, 0.855, 0.86 0,(7.7324)+(−0.1031)Asn+(−0.0079)Gly+(0.0091)Gln+(−0.0700)Cit+(0.0213)Orn+(−0.1133)Trp; 0.850, 0.867, 0.793, 0.863, 0.866, 0. 833,0.870, 0.859, (7.7024)+(−0.1161)Asn+(−0.0081)Gly+(0.0088)Gln+(−0.0095)Pro+(0.0367)Tyr+(−0.1345)Trp; 0.850, 0.867, 0.839, 0.847,0.838, 0.857, 0.820, 0.846,(6.1803)+(0.0054)Gln+(0.0040)Thr+(−0.0723)Cit+(0.0490)Tyr+(−0.1736)Met+(−0.1222)Trp;0.85 0, 0.866, 0.845, 0.835, 0.819, 0.854, 0.802, 0.835, (7.3709)+(0.0041)Ser+(−0.0769)Cit+(0.0486)Tyr+(−0.1440)Met+(0.0200)Orn+(−0. 1180)Trp;0.850, 0.870, 0.843, 0.853, 0.846, 0.859, 0.833, 0.852, (6.8958)+(−0.1183)Asn+(0.0072)Gln+(−0.0760)Cit+(0.0370)Tyr+(0.0173)Orn+(−0.1312)Trp; 0.850, 0.863, 0.814, 0.838, 0.828, 0.840, 0. 809,0.835,(8.4140)+(−0.0571)Cit+(−0.0057)Pro+(0.0539)Tyr+(−0.1193)Met+(−0.1214)Trp;0.850, 0.870, 0.848, 0.846, 0.830, 0.849, 0.833, 0.845,(7.6348)+(−0.0196)His+(−0.0494)Cit+(0.0488)Tyr+(−0.1613)Met+(0.0422)Phe+(−0.1223)Trp;0.850, 0.864, 0.832, 0.8 38, 0.819, 0.838, 0.837, 0.839,(7.9697)+(−0.0022)Gly+(−0.0592)Cit+(0.0500)Tyr+(−0.1438)Met+(0.0145)Ile+(−0.1193)Trp; 0.850, 0.868,0.875, 0.859, 0.853, 0.858, 0.859, 0.860,(4.5131)+(0.0067)Gln+(−0.0464)His+(0.0415)Tyr+(−0.2036)Met+(0.0584)Phe+(−0.1196)Trp; 0.850, 0.863, 0.825, 0.844, 0.833, 0.850, 0.829, 0.844, (8.3132)+(−0.0031)Ala+(−0.0590)Cit+(0.0534)Tyr+(−0.1191)Met+(−0.1139)Trp;0.850, 0.867, 0.847, 0.848, 0.836, 0.855, 0.836, 0.849,(5.6910)+(0.0057)Gln+(−0.0742)Cit+(0.0503)Tyr+(−0.1833)Met+(0.0155)Ile+(−0.1225)Trp;0.849, 0.865, 0.838, 0.833, 0.816, 0.84 9, 0.802, 0.833,(7.7061)+(−0.0762)Cit+(0.0483)Tyr+(−0.1365)Met+(0.0203)Orn+(−0.0004)Leu+(−0.1182)Trp; 0.849, 0.865, 0.817, 0. 864,0.869, 0.846, 0.860, 0.860,(7.8536)+(−0.1003)Asn+(−0.0078)Gly+(0.0098)Gln+(−0.0540)Cit+(−0.1119)Trp;0.849, 0.867, 0.828, 0.855, 0.854, 0.853, 0.834, 0.852,(7.1131)+(−0.1160)Asn+(0.0078)Gln+(−0.0623)Cit+(0.0398)Tyr+(−0.0050)Ile+(−0.1306)Trp; 0. 849, 0.864,0.834, 0.834, 0.821, 0.849, 0.795, 0.832, (7.7842)+(0.0018)Ser+(0.0075)Thr+(−0.0632)Cit+(0.0510)Tyr+(−0.1594)Met+(−0.1200)Trp;0.849, 0.865, 0.834, 0.843, 0.832, 0.858, 0.815, 0.84 3,(8.2047)+(0.0082)Thr+(−0.0031)Ala+(−0.0623)Cit+(0.0528)Tyr+(−0.1442)Met+(−0.1158)Trp; 0.849, 0.864, 0.816, 0.837, 0.825, 0. 839,0.811, 0.835, (8.3035)+(−0.0577)Cit+(−0.0058)Pro+(0.0541)Tyr+(−0.1240)Met+(0.0031)Leu+(−0.1235)Trp; 0.849, 0.866, 0.842, 0.846,0.831, 0.859, 0.832, 0.847, (8.9582)+(−0.0769)Asn+(−0.0038)Ala+(−0.0696)Cit+(0.0432)Tyr+(0.0230)Orn+(−0.1195)Trp; 0.8 49, 0.863,0.835, 0.835, 0.816, 0.844, 0.824, 0.836, (7.6049)+(−0.0626)Cit+(0.0526)Tyr+(−0.1533)Met+(0.0155)Ile+(−0.1195)Trp; 0. 849,0.866, 0.820, 0.840, 0.825, 0.842, 0.825, 0.840, (9.1048)+(−0.0593)Asn+(−0.0567)Cit+(0.0059)Arg+(0.0570)Tyr+(−0.1096)Met+(−0.1193)Trp;0.849, 0.864, 0.832, 0.834, 0.821, 0.847, 0.795, 0.83 2,(7.9340)+(0.0081)Thr+(−0.0629)Cit+(0.0510)Tyr+(−0.0002)Val+(−0.1580)Met+(−0.1199)Trp; 0.849, 0.868, 0.832, 0.856, 0.854, 0. 856,0.839, 0.854,(7.0675)+(−0.1170)Asn+(0.0077)Gln+(−0.0621)Cit+(0.0397)Tyr+(−0.0011)Val+(−0.1298)Trp;0.849, 0.865, 0.837, 0.835, 0.819, 0.852, 0.804, 0.835,(7.7848)+(−0.0756)Cit+(0.0487)Tyr+(−0.0014)Val+(−0.1369)Met+(0.0208)Orn+(−0.1163)Trp; 0. 849, 0.865,0.830, 0.839, 0.823, 0.844, 0.825, 0.839, (7.9489)+(−0.0602)Cit+(−0.0065)Pro+(0.0557)Tyr+(−0.1420)Met+(0.0190)Ile+(−0.1232)Trp;0.849, 0.865, 0.830, 0.847, 0.840, 0.852, 0.825, 0.84 6,(6.2111)+(−0.0027)Ser+(0.0061)Gln+(−0.0716)Cit+(0.0489)Tyr+(−0.1605)Met+(−0.1218)Trp; 0.849, 0.869, 0.843, 0.852, 0.842, 0. 870,0.833, 0.853, (6.3176)+(0.0071)Gln+(−0.0309)His+(−0.0651)Cit+(0.0504)Tyr+(−0.1529)Met+(−0.1069)Trp; 0.849, 0.864, 0.832, 0.834,0.821, 0.845, 0.795, 0.831, (7.9243)+(0.0083)Thr+(−0.0624)Cit+(−0.0009)Arg+(0.0508)Tyr+(−0.1570)Met+(−0.1201)Trp; 0. 849, 0.864,0.827, 0.844, 0.832, 0.850, 0.828, 0.843, (8.2323)+(−0.0032)Ala+(−0.0600)Cit+(0.0531)Tyr+(0.0013)Val+(−0.1188)Met+(−0.1157)Trp;0.849, 0.862, 0.823, 0.835, 0.822, 0.842, 0.811, 0.83 4,(8.0322)+(−0.0597)Cit+(0.0515)Tyr+(−0.0001)Val+(−0.1332)Met+(−0.1183)Trp; 0.849, 0.864, 0.833, 0.836, 0.820, 0.846, 0.811, 0.835, (7.5334)+(0.0048)Ser+(−0.0612)Cit+(0.0519)Tyr+(−0.1460)Met+(0.0030)Leu+(−0.1198)Trp; 0.849, 0.865, 0.845, 0.836, 0.820, 0.843,0.814, 0.835, (8.4285)+(0.0042)Ser+(−0.0903)Asn+(−0.0695)Cit+(0.0393)Tyr+(0.0222)Orn+(−0.1261)Trp; 0.849, 0.868, 0.84 4, 0.844,0.831, 0.843, 0.830, 0.843, (7.1352)+(−0.0595)Cit+(0.0058)Arg+(0.0478)Tyr+(−0.1841)Met+(0.0431)Phe+(−0.1337)Trp; 0. 849, 0.863,0.830, 0.836, 0.822, 0.846, 0.807, 0.835, (7.6634)+(0.0044)Ser+(−0.0608)Cit+(0.0516)Tyr+(0.0003)Val+(−0.1405)Met+(−0.1184)Trp;0.848, 0.863, 0.846, 0.837, 0.816, 0.850, 0.826, 0.83 9,(7.1469)+(0.0054)Ser+(−0.0638)Cit+(0.0530)Tyr+(−0.1638)Met+(0.0167)Ile+(−0.1191)Trp; 0.848, 0.863, 0.832, 0.845, 0.834, 0. 856,0.827, 0.845, (8.0011)+(0.0039)Ser+(−0.0030)Ala+(−0.0597)Cit+(0.0535)Tyr+(−0.1258)Met+(−0.1136)Trp; 0.848, 0.864, 0.818, 0.838,0.824, 0.833, 0.825, 0.837, (8.4155)+(−0.0026)Gly+(−0.0561)Cit+(0.0485)Tyr+(−0.1238)Met+(−0.1183)Trp

List (2) of Logistic Regression Equations Searched in Example 6

The logistic regression equations searched in Example 6 above are listedbelow. Before each equation, “the value of ROC_AUC for the pancreaticcancer group and the colorectal cancer group with validation”, “thevalue of ROC_AUC for the pancreatic cancer group and the colorectalcancer group without validation”, “the value of ROC_AUC for thepancreatic cancer group and the healthy group”, “the value of ROC_AUCfor the pancreatic cancer group and the other cancers group”, “the valueof ROC_AUC for the pancreatic cancer group and the lung cancer group”,“the value of ROC_AUC for the pancreatic cancer group and the prostaticcancer group”, “the value of ROC_AUC for the pancreatic cancer group andthe breast cancer group”, and “the average value of the value of ROC_AUCfor the pancreatic cancer group and the lung cancer group, the value ofROC_AUC for the pancreatic cancer group and the colorectal cancer group,the value of ROC_AUC for the pancreatic cancer group and the prostaticcancer group, and the value of ROC_AUC for the pancreatic cancer groupand the breast cancer group” obtained for the equation are additionallylisted. 0.822, 0.849, 0.870, 0.853, 0.863, 0.864, 0.828, 0.851, (4.0457)+(0.0070)Gln+(−0.0515)His+(0.0059)Thr+(−0.1935)Met+(0.0373)Phe+(−0.0815)Trp; 0.816, 0.846, 0.867, 0.852, 0.860, 0.857, 0.84 2,0.851, (3.8120)+(0.0071)Gln+(−0.0493)His+(−0.1898)Met+(0.0091)Ile+(0.0363)Phe+(−0.0794)Trp; 0.814, 0.843, 0.865, 0.845, 0. 845,0.853, 0.843, 0.846, (3.9326)+(0.0076)Gln+(−0.0633)His+(−0.1928)Met+(0.0151)Leu+(0.0318)Phe+(−0.0832)Trp; 0.815, 0.845, 0. 864,0.849, 0.857, 0.852, 0.835, 0.847, (3.9733)+(0.0067)Gln+(−0.0552)His+(−0.1915)Met+(0.0066)Lys+(0.0373)Phe+(−0.0839)Trp; 0.829,0.856, 0.862, 0.862, 0.873, 0.865, 0.847, 0.860,(4.3532)+(−0.0698)Asn+(0.0097)Gln+(−0.0451)His+(−0.1329)Met+(0.0325)Phe+(−0.0772)Trp; 0.792, 0.823, 0.861, 0.830, 0.825, 0.849, 0.841, 0. 835,(4.3379)+(0.0035)Gln+(−0.0631)His+(−0.0027)Ala+(0.0100)Leu+(0.0235)Phe+(−0.0977)Trp;0.816, 0.844, 0.861, 0.844, 0.847, 0.850, 0.834, 0.844,(4.0571)+(0.0071)Gln+(−0.0612)His+(0.0065)Val+(−0.1772)Met+(0.0336)Phe+(−0.0857)Trp; 0.819, 0.846, 0.8 60,0.852, 0.862, 0.857, 0.831, 0.849, (4.0114)+(0.0072)Gln+(−0.0503)His+(0.0005)Ala+(−0.1800)Met+(0.0363)Phe+(−0.0804)Trp; 0. 807,0.836, 0.860, 0.833, 0.833, 0.844, 0.817, 0.833, (5.8122)+(−0.0364)His+(0.0086)Thr+(−0.1719)Met+(0.0137)Ile+(0.0317)Phe+(−0.0854)Trp;0.814, 0.843, 0.860, 0.848, 0.851, 0.852, 0.850, 0.84 9,(4.9199)+(−0.0928)Asn+(0.0076)Gln+(−0.0574)His+(0.0073)Leu+(0.0163)Phe+(−0.0871)Trp; 0.822, 0.846, 0.859, 0.853, 0.864, 0. 860,0.834, 0.851,(4.0072)+(0.0073)Gln+(−0.0498)His+(−0.1774)Met+(0.0364)Phe+(−0.0796)Trp;0.817, 0.844, 0.859, 0.851, 0.858, 0.853, 0.846, 0.850,(4.9719)+(−0.0954)Asn+(0.0074)Gln+(−0.0522)His+(0.0021)Lys+(0.0185)Phe+(−0.0856)Trp; 0.791, 0.823, 0.85 9, 0.823,0.816, 0.837, 0.830, 0.826, (4.3739)+(0.0037)Gln+(−0.0629)His+(−0.0049)Lys+(0.0114)Leu+(0.0215)Phe+(−0.1003)Trp; 0. 796, 0.827,0.859, 0.828, 0.822, 0.845, 0.837, 0.833, (4.3455)+(0.0034)Gln+(−0.0670)His+(−0.0028)Ala+(0.0077)Val+(0.0250)Phe+(−0.1011)Trp;0.822, 0.846, 0.858, 0.853, 0.861, 0.855, 0.846, 0.85 2,(4.9586)+(−0.0934)Asn+(0.0076)Gln+(−0.0505)His+(0.0188)Phe+(−0.0842)Trp; 0.818, 0.847, 0.858, 0.855, 0.863, 0.861, 0.848, 0. 855,(4.9370)+(−0.0916)Asn+(0.0076)Gln+(−0.0496)His+(−0.0008)Ala+(0.0196)Phe+(−0.0830)Trp; 0.816, 0.845, 0.858, 0.845, 0.84 6,0.846, 0.845, 0.845, (4.8767)+(−0.0938)Asn+(0.0075)Gln+(−0.0609)His+(0.0063)Val+(0.0188)Phe+(−0.0922)Trp; 0.794, 0.827, 0. 858,0.821, 0.812, 0.831, 0.822, 0.823, (4.3702)+(0.0035)Gln+(−0.0660)His+(0.0077)Val+(−0.0042)Lys+(0.0236)Phe+(−0.1043)Trp; 0.797,0.821, 0.858, 0.819, 0.813, 0.830, 0.826, 0.822, (4.3809)+(0.0030)Gln+(−0.0646)His+(0.0086)Leu+(0.0219)Phe+(−0.1028)Trp; 0.796,0.826, 0.857, 0.837, 0.842, 0.853, 0.832, 0.838, (4.3693)+(0.0036)Gln+(−0.0529)His+(−0.0022)Ala+(−0.0016)Lys+(0.0258)Phe+(−0.0919)Trp; 0.800, 0.826, 0.857, 0.835, 0.839, 0.850, 0.832, 0.8 36,(4.3693)+(0.0034)Gln+(−0.0543)His+(−0.0023)Ala+(0.0258)Phe+(−0.0931)Trp; 0.799, 0.828, 0.857, 0.828, 0.829, 0.837, 0.818, 0.828,(4.4040)+(0.0033)Gln+(−0.0549)His+(−0.0020)Lys+(0.0243)Phe+(−0.0964)Trp;0.803, 0.826, 0.857, 0.826, 0.826, 0.834, 0.819, 0.826,(4.4043)+(0.0030)Gln+(−0.0567)His+(0.0242)Phe+(−0.098 1)Trp; 0.799,0.825, 0.856, 0.817, 0.806, 0.823, 0.823, 0.819, (4.3613)+(0.0029)Gln+(−0.0684)His+(0.0069)Val+(0.0236)Phe+(−0.10 68)Trp;0.811, 0.839, 0.856, 0.835, 0.842, 0.848, 0.800, 0.832, (6.0297)+(0.0019)Ser+(−0.0368)His+(0.0082)Thr+(−0.1534)Met+(0.0322)Phe+(−0.0850)Trp; 0.830, 0.859, 0.856, 0.856, 0.863, 0.866, 0. 825,0.853,(4.6037)+(0.0080)Gln+(−0.0384)His+(−0.0575)Cit+(−0.1601)Met+(0.0318)Phe+(−0.0822)Trp;0.818, 0.847, 0.856, 0.854, 0.862, 0.856, 0.843, 0.852,(4.9921)+(−0.0923)Asn+(0.0077)Gln+(−0.0506)His+(−0.0023)Ile+(0.0190)Phe+(−0.0838)Trp;0.816, 0. 845, 0.855, 0.854, 0.862, 0.856, 0.848, 0.853,(5.0050)+(−0.0914)Asn+(0.0078)Gln+(−0.0507)His+(−0.0043)Orn+(0.0193)Phe+(−0.08 43)Trp;0.827, 0.856, 0.855, 0.857, 0.863, 0.865, 0.841, 0.856, (5.4374)+(−0.0773)Asn+(0.0079)Gln+(−0.0403)His+(−0.0527)Cit+(0.0160)Phe+(−0.0886)Trp; 0.795, 0.826, 0.855, 0.818, 0.808, 0.823, 0. 820,0.819, (4.3684)+(0.0029)Gln+(−0.0676)His+(0.0089)Val+(−0.0044)Leu+(0.0245)Phe+(−0.1068)Trp; 0.818, 0.848, 0.855, 0.857, 0. 871,0.856, 0.839, 0.853, (4.1613)+(0.0081)Gln+(−0.0492)His+(−0.1782)Met+(−0.0128)Orn+(0.0386)Phe+(−0.0807)Trp; 0.807, 0.835, 0.855,0.825, 0.819, 0.837, 0.815, 0.826,(6.2118)+(−0.0495)His+(0.0098)Thr+(−0.1688)Met+(0.0149)Leu+(0.0276)Phe+(−0.0903)Trp; 0.829, 0.857, 0.854, 0.848, 0.848, 0.871, 0.814, 0.848, (5.8334)+(−0.0856)Asn+(0.0070)Gln+(−0.0341)His+(−0.0759)Cit+(0.0252)Orn+(−0.0832)Trp; 0.835, 0.858, 0.854, 0.846, 0.848, 0.856, 0.80 8,0.842, (5.5348)+(−0.0893)Asn+(0.0051)Gln+(−0.0838)Cit+(0.0263)Orn+(0.0084)Phe+(−0.1077)Trp; 0.800, 0.833, 0.854, 0.840, 0. 850,0.860, 0.818, 0.840, (5.1355)+(0.0055)Gln+(−0.0488)His+(0.0041)Thr+(−0.1734)Met+(0.0096)Ile+(−0.0642)Trp; 0.817, 0.846, 0.853,0.852, 0.863, 0.853, 0.834, 0.849,(4.2089)+(−0.0036)Ser+(0.0077)Gln+(−0.0497)His+(−0.1744)Met+(0.0355)Phe+(−0.0801)Trp;0.809, 0.836, 0.853, 0.831, 0.835, 0.837, 0.808, 0.829, (5.9667)+(−0.0448)His+(0.0070)Thr+(−0.1730)Met+(0.0092)Lys+(0.0332)Phe+(−0.0909)Trp; 0.824, 0.848, 0.853, 0.832, 0.830, 0.839, 0.80 1,0.829, (5.9620)+(0.0074)Thr+(−0.0656)Cit+(−0.1745)Met+(0.0231)Ile+(0.0281)Phe+(−0.1031)Trp; 0.800, 0.835, 0.853, 0.833, 0. 829,0.850, 0.826, 0.835, (5.0671)+(0.0062)Gln+(−0.0681)His+(0.0057)Thr+(−0.1904)Met+(0.0201)Leu+(−0.0719)Trp; 0.814, 0.838, 0.853,0.834, 0.840, 0.846, 0.801, 0.831,(6.2023)+(−0.0364)His+(0.0085)Thr+(−0.1512)Met+(0.0316)Phe+(−0.0855)Trp;0.811, 0.8 38, 0.853, 0.831, 0.836, 0.838, 0.797, 0.827,(6.1897)+(−0.0376)His+(0.0087)Thr+(0.0010)Ala+(−0.1574)Met+(0.0315)Phe+(−0.087 2)Trp; 0.802,0.832, 0.853, 0.831, 0.832, 0.840, 0.821, 0.831, (5.5437)+(0.0039)Ser+(−0.0337)His+(−0.1517)Met+(0.0141)Ile+(0.0312)Phe+(−0.0824)Trp; 0.831, 0.858, 0.852, 0.852, 0.845, 0.863, 0.8 46,0.853, (4.3912)+(0.0064)Gln+(−0.0514)His+(0.0516)Tyr+(−0.2316)Met+(0.0226)Phe+(−0.0955)Trp; 0.817, 0.845, 0.852, 0.854, 0. 862,0.854, 0.849, 0.853, (4.8907)+(−0.0922)Asn+(0.0080)Gln+(−0.0490)His+(−0.0038)Thr+(0.0196)Phe+(−0.0830)Trp; 0.799, 0.831, 0.852,0.832, 0.827, 0.848, 0.839, 0.836,(4.5889)+(0.0025)Gln+(−0.0565)His+(−0.0028)Ala+(0.0262)Tyr+(0.0187)Phe+(−0.1029)Trp; 0.820, 0.849, 0.852, 0.857, 0.870, 0.866, 0.836, 0.855,(4.2012)+(0.0079)Gln+(−0.0482)His+(−0.0063)Pro+(−0.1598)Met+(0.0364)Phe+(−0.0837)Trp;0.791, 0.823, 0.852, 0.823, 0.817, 0.829, 0.835, 0.826,(4.2681)+(0.0038)Gln+(−0.0624)His+(−0.0062)Thr+(0.0088)Leu+(0.0231)Phe+(−0.1003)Trp; 0.787, 0.819, 0.852, 0.821, 0.81 8,0.828, 0.828, 0.823, (4.5779)+(0.0037)Gln+(−0.0648)His+(−0.0121)Orn+(0.0092)Leu+(0.0229)Phe+(−0.1034)Trp; 0.816, 0.842, 0. 851,0.837, 0.842, 0.846, 0.807, 0.834, (6.6822)+(−0.0302)Asn+(−0.0328)His+(0.0090)Thr+(−0.1260)Met+(0.0291)Phe+(−0.0845)Trp; 0.795,0.827, 0.851, 0.838, 0.844, 0.849, 0.840, 0.840, (4.2848)+(0.0041)Gln+(−0.0522)His+(−0.0055)Thr+(−0.0021)Ala+(0.0265)Phe+(−0.0911)Trp; 0.817, 0.845, 0.851, 0.853, 0.861, 0.853, 0.847, 0.8 52,(5.1736)+(−0.0042)Ser+(−0.0910)Asn+(0.0080)Gln+(−0.0507)His+(0.0180)Phe+(−0.0846)Trp;0.809, 0.842, 0.851, 0.826, 0.820, 0.849, 0.792, 0.826,(5.1495)+(0.0033)Gln+(−0.0404)His+(−0.0766)Cit+(0.0195)Orn+(0.0172)Phe+(−0.1043)Trp; 0.808, 0.836, 0.85 1, 0.824,0.821, 0.831, 0.805, 0.823, (6.2140)+(−0.0491)His+(0.0083)Thr+(0.0071)Val+(−0.1516)Met+(0.0289)Phe+(−0.0928)Trp; 0. 834, 0.857,0.851, 0.850, 0.853, 0.869, 0.814, 0.848, (5.7897)+(−0.0886)Asn+(0.0053)Gln+(−0.0015)Ala+(−0.0858)Cit+(0.0278)Orn+(−0.0973)Trp;0.823, 0.851, 0.851, 0.851, 0.851, 0.863, 0.842, 0.85 2,(5.7685)+(−0.0813)Asn+(0.0080)Gln+(−0.0472)His+(−0.0543)Cit+(0.0100)Leu+(−0.0856)Trp; 0.793, 0.826, 0.851, 0.813, 0.794, 0. 825,0.829, 0.818, (4.5317)+(0.0021)Gln+(−0.0669)His+(0.0242)Tyr+(0.0088)Leu+(0.0158)Phe+(−0.1140)Trp; 0.826, 0.854, 0.851, 0. 855,0.857, 0.868, 0.840, 0.855, (5.8304)+(−0.0850)Asn+(0.0077)Gln+(−0.0377)His+(−0.0555)Cit+(0.0078)Ile+(−0.0813)Trp; 0.792, 0.825,0.850, 0.837, 0.845, 0.847, 0.833, 0.837,(4.5443)+(0.0041)Gln+(−0.0540)His+(−0.0022)Ala+(−0.0112)Orn+(0.0271)Phe+(−0.0938)Trp; 0.797, 0.825, 0.850, 0.834, 0.843, 0.847, 0.821, 0.834, (4.5421)+(0.0038)Gln+(−0.0550)His+(−0.0018)Ala+(−0.0085)Ile+(0.0260)Phe+(−0.0924)Trp; 0.837, 0.858, 0.850, 0.848, 0.850, 0.866, 0. 807,0.845, (5.8033)+(−0.0866)Asn+(0.0058)Gln+(−0.0883)Cit+(0.0298)Orn+(−0.0049)Lys+(−0.0965)Trp; 0.805, 0.837, 0.850, 0.843, 0.846,0.850, 0.841, 0.843,(5.3970)+(−0.0980)Asn+(0.0075)Gln+(−0.0577)His+(0.0004)Lys+(0.0102)Leu+(−0.0802)Trp;0.811, 0.8 37, 0.850, 0.842, 0.845, 0.850, 0.841, 0.843,(5.3938)+(−0.0977)Asn+(0.0076)Gln+(−0.0576)His+(0.0103)Leu+(−0.0800)Trp; 0.792, 0. 823,0.850, 0.819, 0.813, 0.821, 0.824, 0.820, (4.5738)+(0.0037)Gln+(−0.0693)His+(0.0078)Val+(−0.0139)Orn+(0.0252)Phe+(−0.108 5)Trp;0.827, 0.854, 0.850, 0.846, 0.851, 0.845, 0.815, 0.841, (4.1430)+(0.0054)Gln+(−0.0702)Cit+(−0.1900)Met+(0.0191)Ile+(0.0316)Phe+(−0.1007)Trp; 0.817, 0.848, 0.850, 0.852, 0.867, 0.860, 0.8 18,0.848, (4.1776)+(0.0086)Gln+(−0.0460)His+(−0.0196)Arg+(−0.1497)Met+(0.0332)Phe+(−0.0773)Trp; 0.798, 0.825, 0.849, 0.829, 0. 832,0.835, 0.827, 0.830, (4.3007)+(0.0038)Gln+(−0.0543)His+(−0.0060)Thr+(0.0253)Phe+(−0.0955)Trp; 0.807, 0.837, 0.849, 0.843, 0. 846,0.850, 0.844, 0.844, (5.3904)+(−0.0965)Asn+(0.0076)Gln+(−0.0573)His+(−0.0006)Ala+(0.0108)Leu+(−0.0791)Trp; 0.799, 0.829, 0.849,0.823, 0.816, 0.833, 0.824, 0.825,(4.5722)+(0.0024)Gln+(−0.0569)His+(0.0239)Tyr+(−0.0022)Lys+(0.0180)Phe+(−0.1069)Trp; 0.794, 0.825, 0.849, 0.820, 0.811, 0.825, 0.831, 0.823,(4.2729)+(0.0037)Gln+(−0.0658)His+(−0.0059)Thr+(0.0068)Val+(0.0244)Phe+(−0.1039)Trp; 0.796, 0.828, 0.849, 0.812, 0.793, 0.820, 0.823, 0.816, (4.5205)+(0.0021)Gln+(−0.0693)His+(0.0224)Tyr+(0.0063)Val(0.0176)Phe+(−0.1157)Trp; 0.794, 0.825, 0.849, 0.830, 0.833, 0. 836,0.827, 0.830,(4.3037)+(0.0038)Gln+(−0.0538)His+(−0.0059)Thr+(−0.0005)Lys+(0.0253)Phe+(−0.0951)Trp;0.836, 0.856, 0.849, 0.844, 0.847, 0.859, 0.804, 0.841,(5.7897)+(−0.0922)Asn+(0.0052)Gln+(−0.0857)Cit+(0.0278)Orn+(−0.1020)Trp; 0.801, 0.828, 0.8 49,0.821, 0.812, 0.829, 0.823, 0.823, (4.5646)+(0.0021)Gln+(−0.0589)His+(0.0239)Tyr+(0.0181)Phe+(−0.1088)Trp; 0.810, 0.842, 0. 849,0.847, 0.848, 0.857, 0.844, 0.848, (5.2333)+(−0.0746)Asn+(0.0091)Gln+(−0.0597)His+(−0.1225)Met+(0.0171)Leu+(−0.0685)Tr p; 0.811,0.842, 0.849, 0.830, 0.840, 0.839, 0.776, 0.824,(6.6704)+(−0.0318)His+(0.0119)Thr+(−0.0163)Arg+(−0.1329)Met+(0.0289)Phe+(−0.0854)Trp; 0.803, 0.830, 0.849, 0.827, 0.827, 0.826, 0.823,0.827, (5.7665)+(−0.0422)His+(−0.1658)Met+(0.0094)Lys+(0.0098)Ile+(0.0318)Phe+(−0.0891)Trp; 0.834, 0.856, 0.849, 0.844, 0.84 7,0.859, 0.804, 0.841, (5.7989)+(−0.0921)Asn+(0.0052)Gln+(−0.0858)Cit+(0.0279)Orn+(−0.0006)Ile+(−0.1018)Trp; 0.806, 0.838, 0. 849,0.827, 0.821, 0.842, 0.809, 0.827, (5.1326)+(0.0042)Gln+(−0.0505)His+(−0.0593)Cit+(0.0075)Leu+(0.0181)Phe+(−0.1065)Trp; 0.832,0.856, 0.849, 0.845, 0.847, 0.859, 0.804, 0.842,(5.8035)+(−0.0922)Asn+(0.0052)Gln+(−0.0857)Cit+(0.0279)Orn+(−0.0007)Leu+(−0.1011)Trp; 0.796, 0.832, 0.848, 0.839, 0.847, 0.854, 0.822, 0. 839,(5.1013)+(0.0054)Gln+(−0.0516)His+(−0.1702)Met+(0.0048)Lys+(0.0079)Ile+(−0.0660)Trp;0.791, 0.823, 0.848, 0.829, 0.835, 0.834, 0.820, 0.828,(4.5886)+(0.0039)Gln+(−0.0552)His+(−0.0113)Orn+(−0.0014)Lys+(0.0255)Phe+(−0.0973)Trp; 0.811, 0.840, 0.8 48,0.835, 0.842, 0.843, 0.801, 0.831, (6.4219)+(−0.0355)His+(0.0092)Thr+(−0.1507)Met+(−0.0066)Orn+(0.0324)Phe+(−0.0865)Trp; 0.823,0.854, 0.848, 0.849, 0.840, 0.854, 0.855, 0.851,(5.1755)+(−0.1116)Asn+(0.0070)Gln+(−0.0522)His+(0.0366)Tyr+(0.0104)Phe+(−0.0981)Trp; 0.790, 0.817, 0.848, 0.822, 0.816, 0.847, 0.829, 0.8 28,(4.9852)+(0.0031)Gln+(−0.0632)His+(−0.0023)Ala+(0.0132)Leu+(−0.0876)Trp; 0.812, 0.843, 0.848, 0.843, 0.847, 0.862, 0.818, 0.843, (5.1065)+(0.0045)Gln+(−0.0407)His+(−0.0023)Ala+(−0.0595)Cit+(0.0227)Phe+(−0.0981)Trp; 0.794, 0.823, 0.848, 0.827, 0.83 3,0.831, 0.819, 0.826, (4.5935)+(0.0037)Gln+(−0.0564)His+(−0.0115)Orn+(0.0254)Phe+(−0.0985)Trp; 0.807, 0.838, 0.848, 0.844, 0. 858,0.833, 0.827, 0.839, (3.3646)+(0.0045)Gln+(−0.0045)Val+(−0.2143)Met+(0.0181)Ile+(0.0375)Phe+(−0.0948)Trp; 0.797, 0.827, 0. 848,0.820, 0.814, 0.817, 0.826, 0.821, (4.7359)+(−0.0071)Ser+(0.0039)Gln+(−0.0666)His+(0.0061)Val+(0.0229)Phe+(−0.1070)Trp; 0.828,0.851, 0.848, 0.835, 0.833, 0.850, 0.795, 0.832,(6.9364)+(−0.0552)Asn+(−0.0016)Ala+(−0.0835)Cit+(0.0294)Orn+(0.0112)Phe+(−0.1032)Trp; 0.806, 0.837, 0.848, 0.843, 0.846, 0.847, 0.844, 0. 843,(5.4499)+(−0.0957)Asn+(0.0078)Gln+(−0.0581)His+(−0.0044)Orn+(0.0108)Leu+(−0.0803)Trp; 0.801, 0.830, 0.847, 0.824, 0.82 0,0.835, 0.817, 0.825, (5.8651)+(0.0050)Ser+(−0.0458)His+(−0.1451)Met+(0.0143)Leu+(0.0271)Phe+(−0.0868)Trp; 0.812, 0.837, 0. 847,0.837, 0.844, 0.843, 0.813, 0.834, (6.3477)+(0.0051)Ser+(−0.0331)Asn+(−0.0294)His+(−0.1029)Met+(0.0287)Phe+(−0.0814)Tr p; 0.827,0.853, 0.847, 0.846, 0.843, 0.857, 0.832, 0.846,(5.8232)+(−0.0817)Asn+(0.0079)Gln+(−0.0518)His+(−0.0593)Cit+(0.0090)Val+(−0.0901)Trp;0.814, 0.844, 0.847, 0.854, 0.861, 0.865, 0.846, 0.854,(5.3017)+(−0.0842)Asn+(0.0086)Gln+(−0.0431)His+(−0.1104)Met+(0.0125)Ile+(−0.0628)Trp; 0.805, 0.834, 0.847, 0.824, 0.8 21,0.831, 0.808, 0.823, (5.8236)+(0.0053)Ser+(−0.0478)His+(0.0077)Val+(−0.1340)Met+(0.0287)Phe+(−0.0904)Trp; 0.801, 0.833, 0. 847,0.832, 0.834, 0.847, 0.809, 0.831, (5.2756)+(0.0057)Gln+(−0.0645)His+(0.0040)Thr+(0.0085)Val+(−0.1633)Met+(−0.0737)Trp; 0.833,0.856, 0.847, 0.842, 0.841, 0.854, 0.803, 0.839,(5.7383)+(−0.0931)Asn+(0.0050)Gln+(−0.0875)Cit+(0.0028)Val+(0.0269)Orn+(−0.1075)Trp; 0.800, 0.825, 0.847, 0.826, 0.835, 0.829, 0.803, 0.8 23,(4.6321)+(0.0036)Gln+(−0.0570)His+(−0.0115)Ile+(0.0249)Phe+(−0.0957)Trp; 0.800, 0.833, 0.847, 0.840, 0.850, 0.858, 0.812, 0.838,(5.3399)+(0.0053)Gln+(−0.0529)His+(0.0033)Thr+(−0.1680)Met+(0.0049)Lys+(−0.0673)Trp;0.794, 0.816, 0.847, 0.813, 0.806, 0.831, 0.814, 0.817,(4.9732)+(0.0027)Gln+(−0.0645)His+(0.011 9)Leu+(−0.0927)Trp

List (2) of Linear Discriminants Searched in Example 6

The linear discriminants searched in Example 6 above are listed below.Before each equation, “the value of ROC_AUC for the pancreatic cancergroup and the colorectal cancer group with validation”, “the value ofROC_AUC for the pancreatic cancer group and the colorectal cancer groupwithout validation”, “the value of ROC_AUC for the pancreatic cancergroup and the healthy group”, “the value of ROC_AUC for the pancreaticcancer group and the other cancers group”, “the value of ROC_AUC for thepancreatic cancer group and the lung cancer group”, “the value ofROC_AUC for the pancreatic cancer group and the prostatic cancer group”,“the value of ROC_AUC for the pancreatic cancer group and the breastcancer group”, and “the average value of the value of ROC_AUC for thepancreatic cancer group and the lung cancer group, the value of ROC_AUCfor the pancreatic cancer group and the colorectal cancer group, thevalue of ROC_AUC for the pancreatic cancer group and the prostaticcancer group, and the value of ROC_AUC for the pancreatic cancer groupand the breast cancer group” obtained for the equation are additionallylisted.

0.835, 0.856, 0.885, 0.856, 0.862, 0.858, 0.839, 0.853, (4.7750)+(0.0066)Gln+(−0.0466)His+(0.0084)Thr+(−0.1967)Met+(0.0666)Phe+(−0.1057)Trp; 0.830, 0.847, 0.879, 0.841, 0.844, 0.850, 0.81 1,0.838, (6.3287)+(0.0082)Ser+(−0.0354)His+(0.0106)Thr+(−0.1818)Met+(0.0636)Phe+(−0.1048)Trp; 0.832, 0.854, 0.879, 0.857, 0. 864,0.857, 0.845, 0.855, (4.5078)+(0.0044)Ser+(0.0068)Gln+(−0.0446)His+(−0.1778)Met+(0.0652)Phe+(−0.1034)Trp; 0.850, 0.868, 0.875,0.859, 0.853, 0.858, 0.859, 0.860,(4.5131)+(0.0067)Gln+(−0.0464)His+(0.0415)Tyr+(−0.2036)Met+(0.0584)Phe+(−0.1196)Trp; 0.842, 0.861, 0.874, 0.847, 0.836, 0.858, 0.840, 0.849,(5.8514)+(0.0112)Ser+(−0.0351)His+(0.0451)Tyr+(−0.1899)Met+(0.0558)Phe+(−0.1194)Trp; 0.843, 0.861, 0.874, 0.867, 0.877, 0.860, 0.857, 0.864, (5.4146)+(−0.0732)Asn+(0.0098)Gln+(−0.0393)His+(−0.1330)Met+(0.0569)Phe+(−0.1021)Trp; 0.833, 0.852, 0.873, 0.856, 0.86 4,0.853, 0.846, 0.854, (4.7041)+(0.0072)Gln+(−0.0445)His+(−0.1723)Met+(0.0010)Ile+(0.0629)Phe+(−0.1036)Trp; 0.832, 0.853, 0. 872,0.856, 0.864, 0.853, 0.846, 0.854, (4.7480)+(0.0073)Gln+(−0.0442)His+(−0.1698)Met+(−0.0005)Lys+(0.0629)Phe+(−0.1034)Tr p; 0.832,0.853, 0.872, 0.856, 0.864, 0.853, 0.845, 0.854,(4.7112)+(0.0073)Gln+(−0.0449)His+(−0.1718)Met+(0.0006)Leu+(0.0627)Phe+(−0.1037)Trp; 0.835, 0.853, 0.872, 0.857, 0.865, 0.854, 0.846, 0.854, (4.7280)+(0.0073)Gln+(−0.0444)His+(−0.1713)Met+(0.0630)Phe+(−0.1036)Trp; 0.832, 0.853, 0.872, 0.857, 0.866, 0.854, 0.846,0.855, (4.7677)+(0.0072)Gln+(−0.0432)His+(−0.0008)Val+(−0.1718)Met+(0.0634)Phe+(−0.1030)Trp; 0.834, 0.855, 0.871, 0.861, 0.8 71,0.850, 0.852, 0.857, (4.7622)+(0.0081)Gln+(−0.0434)His+(−0.1739)Met+(−0.0123)Orn+(0.0662)Phe+(−0.1044)Trp; 0.823, 0.842, 0.871,0.839, 0.842, 0.846, 0.821, 0.838,(6.1502)+(0.0114)Ser+(−0.0320)His+(−0.1569)Met+(0.0047)Ile+(0.0595)Phe+(−0.1018)Trp; 0.833, 0.852, 0.871, 0.861, 0.870, 0.863, 0.851, 0.859,(4.8549)+(0.0073)Gln+(−0.0426)His+(−0.0016)Ala+(−0.1636)Met+(0.0627)Phe+(−0.1016)Trp;0.835, 0.857, 0.870, 0.860, 0.870, 0.858, 0.840, 0.856,(4.6757)+(0.0083)Gln+(−0.0434)His+(−0.0124)Arg+(−0.1513)Met+(0.0604)Phe+(−0.1006)Trp; 0.827, 0.846, 0.870, 0.838, 0.8 41,0.840, 0.812, 0.835, (6.8948)+(−0.0343)His+(0.0126)Thr+(−0.1757)Met+(0.0036)Ile+(0.0589)Phe+(−0.1054)Trp; 0.826, 0.847, 0. 870,0.842, 0.848, 0.849, 0.814, 0.839, (7.1174)+(−0.0323)His+(0.0125)Thr+(−0.0016)Ala+(−0.1639)Met+(0.0590)Phe+(−0.1035)Tr p; 0.844,0.864, 0.869, 0.860, 0.866, 0.864, 0.833, 0.857,(5.0647)+(0.0091)Gln+(−0.0334)His+(−0.0581)Cit+(−0.1734)Met+(0.0589)Phe+(−0.1056)Trp;0.829, 0.848, 0.869, 0.838, 0.842, 0.840, 0.807, 0.834,(7.0009)+(−0.0338)His+(0.0125)Thr+(−0.1709)Met+(−0.0004)Leu+(0.0595)Phe+(−0.1054)Trp; 0.826, 0.848, 0.869, 0.838, 0.8 42,0.840, 0.807, 0.834, (7.0012)+(−0.0340)His+(0.0126)Thr+(−0.1710)Met+(−0.0001)Lys+(0.0593)Phe+(−0.1054)Trp; 0.831, 0.847, 0.869,0.838, 0.842, 0.840, 0.807, 0.834,(6.9942)+(−0.0341)His+(0.0126)Thr+(−0.1713)Met+(0.0593)Phe+(−0.1054)Trp;0.827, 0.8 47, 0.869, 0.839, 0.844, 0.842, 0.805, 0.835,(7.0613)+(−0.0318)His+(0.0126)Thr+(−0.0016)Val+(−0.1729)Met+(0.0603)Phe+(−0.104 4)Trp;0.829, 0.851, 0.869, 0.838, 0.843, 0.842, 0.796, 0.833, (7.1912)+(−0.0326)His+(0.0151)Thr+(−0.0095)Arg+(−0.1597)Met+(0.0574)Phe+(−0.1037)Trp; 0.824, 0.843, 0.868, 0.843, 0.851, 0.840, 0. 822,0.839, (6.3042)+(0.0115)Thr+(−0.0104)Val+(−0.2152)Met+(0.0227)Ile+(0.0629)Phe+(−0.1080)Trp; 0.823, 0.843, 0.868, 0.839, 0. 844,0.846, 0.815, 0.837, (6.3043)+(0.0111)Ser+(−0.0316)His+(−0.1509)Met+(−0.0002)Leu+(0.0599)Phe+(−0.1019)Trp; 0.822, 0.842, 0.868,0.839, 0.844, 0.846, 0.816, 0.837,(6.2737)+(0.0110)Ser+(−0.0321)His+(−0.1527)Met+(0.0006)Lys+(0.0599)Phe+(−0.1022)Trp; 0.824, 0.843, 0.868, 0.844, 0.849, 0.854, 0.823, 0.842,(6.4322)+(0.0108)Ser+(−0.0301)His+(−0.0013)Ala+(−0.1441)Met+(0.0594)Phe+(−0.1003)Trp;0.826, 0.843, 0.868, 0.839, 0.844, 0.847, 0.815, 0.837,(6.2988)+(0.0111)Ser+(−0.0317)His+(−0.1511)Met+(0.0599)Phe+(−0.1019)Trp; 0.822, 0.842, 0.868, 0.839, 0.844, 0.847, 0.81 5,0.837, (6.3189)+(0.0111)Ser+(−0.0312)His+(−0.0003)Val+(−0.1512)Met+(0.0600)Phe+(−0.1017)Trp; 0.828, 0.849, 0.868, 0.840, 0. 845,0.840, 0.808, 0.835, (7.1759)+(−0.0328)His+(0.0140)Thr+(−0.1746)Met+(−0.0077)Orn+(0.0613)Phe+(−0.1062)Trp; 0.844, 0.863, 0.867,0.842, 0.830, 0.848, 0.828, 0.842,(6.5893)+(−0.0369)His+(0.0115)Thr+(0.0437)Tyr+(−0.2052)Met+(0.0547)Phe+(−0.1221)Irp; 0.841, 0.861, 0.867, 0.842, 0.842, 0.849, 0.797, 0.837, (7.7857)+(−0.0223)His+(0.0149)Thr+(−0.0491)Cit+(−0.1717)Met+(0.0548)Phe+(−0.1074)Trp; 0.830, 0.848, 0.867, 0.846, 0.851, 0.854, 0.82 3,0.844, (7.0759)+(0.0136)Ser+(−0.0459)Asn+(−0.0257)His+(−0.1226)Met+(0.0554)Phe+(−0.1006)Trp; 0.834, 0.852, 0.866, 0.843, 0. 847,0.842, 0.814, 0.839, (7.9229)+(−0.0447)Asn+(−0.0283)His+(0.0142)Thr+(−0.1444)Met+(0.0542)Phe+(−0.1046)Trp; 0.824, 0.844, 0.866,0.841, 0.845, 0.846, 0.819, 0.838,(6.3750)+(0.0113)Ser+(−0.0310)His+(−0.1507)Met+(−0.0033)Orn+(0.0605)Phe+(−0.1021)Trp; 0.841, 0.857, 0.866, 0.840, 0.844, 0.848, 0.791, 0.835, (6.7740)+(0.0068)Ser+(0.0115)Thr+(−0.0553)Cit+(−0.1877)Met+(0.0567)Phe+(−0.1179)Trp;0.825, 0.845, 0.866, 0.840, 0.845, 0.849, 0.811, 0.837,(6.3684)+(0.0123)Ser+(−0.0303)His+(−0.0065)Arg+(−0.1397)Met+(0.0585)Phe+(−0.1002)Trp; 0.833, 0.850, 0.865, 0.843, 0.8 50,0.839, 0.811, 0.837, (6.7437)+(0.0097)Ser+(−0.0600)Asn+(0.0098)Thr+(−0.1567)Met+(0.0563)Phe+(−0.1173)Trp; 0.826, 0.845, 0. 865,0.854, 0.868, 0.842, 0.844, 0.850, (4.5855)+(0.0053)Gln+(−0.0102)Val+(−0.2080)Met+(0.0200)Ile+(0.0644)Phe+(−0.1098)Trp; 0.820,0.837, 0.865, 0.842, 0.851, 0.841, 0.828, 0.839, (5.7758)+(0.0089)Ser+(−0.0087)Val+(−0.1895)Met+(0.0202)Ile+(0.0618)Phe+(−0.1060)Trp;0.836, 0.852, 0.864, 0.840, 0.840, 0.845, 0.811, 0.83 7,(6.4386)+(0.0108)Ser+(−0.0536)Cit+(−0.1663)Met+(0.0106)Ile+(0.0523)Phe+(−0.1131)Trp; 0.833, 0.853, 0.863, 0.860, 0.872, 0. 859,0.845, 0.857,(4.9038)+(0.0081)Gln+(−0.0419)His+(−0.0071)Pro+(−0.1583)Met+(0.0642)Phe+(−0.1083)Trp;0.842, 0.858, 0.863, 0.839, 0.838, 0.841, 0.798, 0.834,(7.1060)+(0.0135)Thr+(−0.0572)Cit+(−0.1907)Met+(0.0101)Ile+(0.0521)Phe+(−0.1180)Trp; 0.8 29, 0.849,0.863, 0.856, 0.865, 0.851, 0.850, 0.854, (6.3399)+(−0.1007)Asn+(0.0081)Gln+(−0.0420)His+(−0.0000)Val+(0.0309)Phe+(−0.1053)Trp;0.831, 0.849, 0.863, 0.856, 0.865, 0.851, 0.850, 0.85 4,(6.3386)+(−0.1007)Asn+(0.0081)Gln+(−0.0420)His+(0.0308)Phe+(−0.1053)Trp; 0.828, 0.849, 0.863, 0.848, 0.847, 0.840, 0.853, 0. 847,(6.8868)+(0.0203)Ser+(−0.0083)Gly+(−0.0288)His+(−0.1425)Met+(0.0575)Phe+(−0.1048)Trp; 0.833, 0.852, 0.863, 0.842, 0.84 5,0.854, 0.806, 0.839, (7.0529)+(0.0115)Ser+(−0.0199)His+(−0.0457)Cit+(−0.1445)Met+(0.0547)Phe+(−0.1032)Trp; 0.828, 0.849, 0. 862,0.856, 0.865, 0.850, 0.851, 0.854, (6.3566)+(−0.0005)Ser+(−0.1005)Asn+(0.0081)Gln+(−0.0420)His+(0.0307)Phe+(−0.1053)Trp; 0.821,0.839, 0.862, 0.839, 0.849, 0.832, 0.816, 0.834, (5.5659)+(0.0083)Ser+(−0.1741)Met+(0.0220)Ile+(−0.0162)Leu+(0.0645)Phe+(−0.1118)Trp;0.829, 0.849, 0.862, 0.856, 0.865, 0.850, 0.852, 0.85 4,(6.3041)+(−0.0997)Asn+(0.0082)Gln+(−0.0417)His+(−0.0012)Thr+(0.0310)Phe+(−0.1049)Trp; 0.842, 0.861, 0.862, 0.864, 0.870, 0. 868,0.849, 0.862,(6.6307)+(−0.0962)Asn+(0.0095)Gln+(−0.0324)His+(−0.0535)Cit+(0.0266)Phe+(−0.1073)Trp;0.845, 0.862, 0.862, 0.853, 0.864, 0.847, 0.809, 0.845,(4.9646)+(0.0069)Gln+(0.0085)Thr+(−0.0668)Cit+(−0.2085)Met+(0.0592)Phe+(−0.1238)Trp;0.85 6, 0.870, 0.861, 0.849, 0.837, 0.854, 0.831, 0.848, (6.2989)+(0.0102)Ser+(−0.0563)Cit+(0.0477)Tyr+(−0.1949)Met+(0.0483)Phe+(−0. 1330)Trp;0.830, 0.850, 0.861, 0.858, 0.868, 0.856, 0.850, 0.856, (6.4072)+(−0.0961)Asn+(0.0084)Gln+(−0.0397)His+(−0.0046)Lys+(0.0328)Phe+(−0.1032)Trp; 0.842, 0.859, 0.861, 0.836, 0.836, 0.844, 0. 780,0.830, (7.2191)+(0.0113)Thr+(−0.0664)Cit+(−0.1726)Met+(0.0139)Orn+(0.0485)Phe+(−0.1168)Trp; 0.833, 0.851, 0.861, 0.846, 0. 850,0.825, 0.843, 0.842, (6.2953)+(0.0165)Ser+(−0.0095)Gly+(0.0104)Thr+(−0.1883)Met+(0.0594)Phe+(−0.1251)Trp; 0.845, 0.861, 0.861,0.844, 0.847, 0.848, 0.798, 0.839,(8.2542)+(−0.0415)Asn+(0.0150)Thr+(−0.0507)Cit+(−0.1521)Met+(0.0491)Phe+(−0.1149)Trp;0.838, 0.854, 0.861, 0.837, 0.837, 0.851, 0.791, 0.833, (6.5845)+(0.0094)Ser+(−0.0666)Cit+(−0.1530)Met+(0.0177)Orn+(0.0480)Phe+(−0.1126)Trp; 0.830, 0.850, 0.861, 0.858, 0.867, 0.852, 0.85 3,0.856, (6.3558)+(−0.0996)Asn+(0.0084)Gln+(−0.0417)His+(−0.0061)Orn+(0.0322)Phe+(−0.1058)Trp; 0.829, 0.849, 0.861, 0.858, 0. 870,0.852, 0.847, 0.854, (6.4511)+(−0.1005)Asn+(0.0080)Gln+(−0.0378)His+(−0.0054)Leu+(0.0344)Phe+(−0.1046)Trp; 0.840, 0.855, 0.861,0.846, 0.852, 0.855, 0.808, 0.842,(7.4662)+(0.0127)Ser+(−0.0419)Asn+(−0.0466)Cit+(−0.1258)Met+(0.0499)Phe+(−0.1095)Trp; 0.827, 0.849, 0.860, 0.862, 0.872, 0.867, 0.862, 0.862, (6.4302)+(−0.0953)Asn+(0.0081)Gln+(−0.0393)His+(−0.0025)Ala+(0.0326)Phe+(−0.1021)Trp; 0.807, 0.826, 0.860, 0.825, 0.827, 0.827, 0.81 9,0.825, (5.6387)+(0.0034)Gln+(−0.0527)His+(0.0009)Val+(0.0282)Phe+(−0.1097)Trp; 0.824, 0.844, 0.860, 0.841, 0.848, 0.850, 0.8 09,0.838, (6.6200)+(0.0112)Ser+(−0.0287)His+(−0.0049)Pro+(−0.1387)Met+(0.0598)Phe+(−0.1050)Trp; 0.821, 0.840, 0.860, 0.831, 0. 840,0.820, 0.797, 0.824, (5.4732)+(0.0067)Ser+(0.0076)Thr+(−0.1949)Met+(0.0028)Ile+(0.0608)Phe+(−0.1223)Trp; 0.811, 0.826, 0. 860,0.826, 0.828, 0.828, 0.819, 0.826, (5.6897)+(0.0033)Gln+(−0.0513)His+(0.0286)Phe+(−0.1090)Trp; 0.828, 0.847, 0.860, 0.832, 0. 843,0.826, 0.778, 0.823, (5.7500)+(0.0081)Ser+(0.0108)Thr+(−0.0127)Arg+(−0.1771)Met+(0.0594)Phe+(−0.1189)Trp; 0.817, 0.838, 0.859,0.841, 0.846, 0.856, 0.821, 0.840,(6.2129)+(0.0053)Gln+(−0.0482)His+(0.0045)Thr+(−0.1235)Met+(0.0088)Leu+(−0.0845)Trp; 0.837, 0.859, 0.859, 0.864, 0.870, 0.841, 0.876, 0.862,(5.4692)+(−0.0070)Gly+(0.0085)Gln+(−0.0426)His+(−0.1550)Met+(0.0577)Phe+(−0.1064)Trp; 0.809, 0.832, 0.859, 0.832, 0.836, 0.839, 0.818,0.831, (5.7477)+(0.0046)Gln+(−0.0497)His+(0.0028)Val+(−0.0097)Lys+(0.0316)Phe+(−0.1061)Trp; 0.842, 0.858, 0.859, 0.839, 0.84 3,0.843, 0.785, 0.832, (7.5521)+(0.0141)Thr+(−0.0552)Cit+(−0.1713)Met+(−0.0030)Lys+(0.0530)Phe+(−0.1161)Trp; 0.835, 0.854, 0. 859,0.848, 0.842, 0.842, 0.854, 0.848, (6.1029)+(0.0480)Tyr+(−0.0117)Val+(−0.2202)Met+(0.0273)Ile+(0.0526)Phe+(−0.1209)Trp; 0.860,0.874, 0.859, 0.845, 0.831, 0.848, 0.818, 0.843, (6.9429)+(0.0121)Thr+(−0.0594)Cit+(0.0463)Tyr+(−0.2151)Met+(0.0479)Phe+(−0.1367)Trp;0.842, 0.857, 0.859, 0.845, 0.850, 0.852, 0.798, 0.83 9,(7.5772)+(0.0133)Thr+(−0.0022)Ala+(−0.0545)Cit+(−0.1673)Met+(0.0529)Phe+(−0.1141)Trp; 0.841, 0.858, 0.859, 0.840, 0.844, 0. 843,0.787, 0.833, (7.4685)+(0.0135)Thr+(−0.0534)Cit+(−0.0019)Val+(−0.1797)Met+(0.0547)Phe+(−0.1154)Trp; 0.804, 0.826, 0.859, 0.840,0.846, 0.856, 0.843, 0.843, (5.7909)+(0.0039)Gln+(−0.0489)His+(−0.0045)Ala+(0.0024)Val+(0.0309)Phe+(−0.1046)Trp; 0.8 25, 0.843,0.858, 0.837, 0.852, 0.828, 0.794, 0.829, (6.0754)+(0.0056)Ser+(0.0089)Thr+(−0.0053)Val+(−0.1927)Met+(0.0643)Phe+(−0.1147)Trp;0.823, 0.841, 0.858, 0.832, 0.843, 0.823, 0.791, 0.824,(5.7463)+(0.0071)Ser+(0.0085)Thr+(−0.1836)Met+(−0.0035)Lys+(0.0611)Phe+(−0.1201)Trp;0.841, 0.857, 0.858, 0.849, 0.849, 0.84 2, 0.838, 0.847,(7.1001)+(0.0175)Ser+(−0.0066)Gly+(−0.0442)Cit+(−0.1473)Met+(0.0522)Phe+(−0.1150)Trp; 0.844, 0.857, 0.858, 0. 838,0.841, 0.840, 0.788, 0.831, (7.3543)+(0.0132)Thr+(−0.0552)Cit+(−0.1786)Met+(0.0532)Phe+(−0.1179)Trp; 0.840, 0.857, 0.858, 0.838,0.841, 0.839, 0.788, 0.831, (7.3518)+(0.0132)Thr+(−0.0553)Cit+(0.0002)Arg+(−0.1789)Met+(0.0532)Phe+(−0.1180)Trp; 0.8 08, 0.829,0.858, 0.843, 0.850, 0.858, 0.841, 0.844, (5.9101)+(0.0038)Gln+(−0.0456)His+(−0.0043)Ala+(0.0319)Phe+(−0.1032)Trp; 0. 829,0.850, 0.857, 0.840, 0.846, 0.843, 0.801, 0.835, (7.3449)+(−0.0311)His+(0.0137)Thr+(−0.0056)Pro+(−0.1609)Met+(0.0599)Phe+(−0.1093)Trp;0.843, 0.859, 0.857, 0.839, 0.844, 0.841, 0.784, 0.83 2,(7.4594)+(0.0130)Thr+(−0.0542)Cit+(−0.1740)Met+(−0.0037)Leu+(0.0552)Phe+(−0.1163)Trp; 0.835, 0.853, 0.857, 0.839, 0.834, 0. 826,0.832, 0.836, (4.9461)+(0.0090)Ser+(0.0425)Tyr+(−0.2123)Met+(0.0050)Ile+(0.0541)Phe+(−0.1370)Trp; 0.823, 0.843, 0.857, 0. 839,0.854, 0.819, 0.809, 0.831, (4.3521)+(0.0027)Ser+(0.0040)Gln+(0.0054)Thr+(−0.2041)Met+(0.0630)Phe+(−0.1262)Trp; 0.827, 0. 841,0.857, 0.831, 0.840, 0.819, 0.794, 0.823, (5.5659)+(0.0066)Ser+(0.0076)Thr+(−0.1913)Met+(0.0610)Phe+(−0.1223)Trp; 0.821, 0. 841,0.857, 0.837, 0.847, 0.826, 0.807, 0.830, (6.0719)+(0.0090)Thr+(−0.1880)Met+(0.0215)Ile+(−0.0165)Leu+(0.0640)Phe+(−0.115 0)Trp;0.812, 0.833, 0.857, 0.834, 0.840, 0.840, 0.816, 0.832, (5.8826)+(0.0045)Gln+(−0.0459)His+(−0.0090)Lys+(0.0325)Phe+(−0.1 046)Trp;0.853, 0.869, 0.857, 0.868, 0.879, 0.860, 0.841, 0.863, (5.6045)+(−0.0728)Asn+(0.0103)Gln+(−0.0613)Cit+(−0.1429)Met+(0.0505)Phe+(−0.1170)Trp; 0.836, 0.855, 0.857, 0.856, 0.870, 0.836, 0. 834,0.849, (5.3166)+(−0.0835)Asn+(0.0074)Gln+(0.0075)Thr+(−0.1613)Met+(0.0561)Phe+(−0.1225)Trp; 0.848, 0.863, 0.857, 0.850, 0. 842,0.845, 0.845, 0.849, (6.4101)+(0.0131)Ser+(−0.0699)Asn+(0.0499)Tyr+(−0.1645)Met+(0.0474)Phe+(−0.1332)Trp; 0.835, 0.854, 0.857,0.859, 0.874, 0.843, 0.840, 0.853,(4.9875)+(0.0058)Ser+(−0.0829)Asn+(0.0074)Gln+(−0.1472)Met+(0.0560)Phe+(−0.1197)Trp; 0.844, 0.861, 0.857, 0.851, 0.845, 0.823, 0.863, 0.848,(5.7670)+(0.0170)Ser+(−0.0073)Gly+(0.0351)Tyr+(−0.1905)Met+(0.0532)Phe+(−0.1350)Trp; 0.828, 0.845, 0.857, 0.843, 0.851, 0.838, 0.821, 0.839, (6.5849)+(0.0126)Ser+(−0.0559)Asn+(−0.1341)Met+(0.0038)Ile+(0.0530)Phe+(−0.1133)Trp; 0.821, 0.846, 0.857, 0.833, 0.829, 0.851,0.801, 0.832, (6.0414)+(0.0046)Gln+(−0.0396)His+(−0.0673)Cit+(0.0130)Orn+(0.0205)Phe+(−0.1104)Trp; 0.808, 0.832, 0.85 7, 0.834,0.842, 0.840, 0.815, 0.832, (5.9095)+(0.0044)Gln+(−0.0448)His+(−0.0087)Lys+(−0.0016)Leu+(0.0334)Phe+(−0.1045)Trp; 0. 814,0.836, 0.857, 0.842, 0.851, 0.860, 0.816, 0.841, (6.3887)+(0.0050)Gln+(−0.0414)His+(0.0036)Thr+(−0.1159)Met+(0.0058)Ile+(−0.0823)Trp;0.838, 0.859, 0.857, 0.855, 0.859, 0.876, 0.823, 0.85 4,(7.2421)+(−0.0971)Asn+(0.0087)Gln+(−0.0275)His+(−0.0714)Cit+(0.0201)Orn+(−0.0961)Trp; 0.840, 0.859, 0.857, 0.853, 0.861, 0. 847,0.823, 0.847, (4.7303)+(0.0076)Gln+(−0.0666)Cit+(−0.1912)Met+(0.0082)Ile+(0.0548)Phe+(−0.1207)Trp

List (1) of Logistic Regression Equations Searched in Example 7

The logistic regression equations searched in Example 7 above are listedbelow. Before each equation, “the value of ROC_AUC for the pancreaticcancer group and the prostatic cancer group with validation”, “the valueof ROC_AUC for the pancreatic cancer group and the prostatic cancergroup without validation”, “the value of ROC_AUC for the pancreaticcancer group and the healthy group”, “the value of ROC_AUC for thepancreatic cancer group and the other cancers group”, “the value ofROC_AUC for the pancreatic cancer group and the lung cancer group”, “thevalue of ROC_AUC for the pancreatic cancer group and the colorectalcancer group”, and “the average value of the value of ROC_AUC for thepancreatic cancer group and the lung cancer group, the value of ROC_AUCfor the pancreatic cancer group and the colorectal cancer group, and thevalue of ROC_AUC for the pancreatic cancer group and the prostaticcancer group” obtained for the equation are additionally listed.

0.877, 0.907, 0.895, 0.804, 0.799, 0.752, 0.819, (3.0499)+(0.0406)Ser+(−0.0121)Ala+(−0.0402)Val+(−0.1789)Met+(0.1361)Il e; 0.874,0.914, 0.889, 0.824, 0.829, 0.766, 0.836, (1.8050)+(0.0287)Ser+(0.0081)Gln+(−0.0133)Ala+(−0.0421)Val+(−0.2379)Met+(0. 1384)Ile;0.873, 0.911, 0.872, 0.841, 0.854, 0.785, 0.850, (3.2506)+(0.0146)Gln+(−0.0127)Ala+(−0.0711)Cit+(−0.0454)Val+(−0.2177)Met+(0.1443)Ile; 0.872, 0.909, 0.906, 0.801, 0.796, 0.747, 0.817,(3.3965)+(0.0311)Ser+(0.0246)Thr+(−0.0128)Ala+(−0.0466)Val+(−0.2635)Met+(0.1591)Ile;0.872, 0.909, 0.898, 0.804, 0.798, 0.75 2, 0.820,(1.9444)+(0.0409)Ser+(−0.0141)Ala+(−0.0498)Val+(−0.2446)Met+(0.0197)Lys+(0.1613)Ile; 0.871, 0.906, 0.896, 0.810, 0. 813,0.753, 0.824, (3.0424)+(0.0387)Ser+(0.0297)His+(−0.0131)Ala+(−0.0487)Val+(−0.2265)Met+(0.1561)Ile; 0.871, 0.910, 0.897, 0.808,0.801, 0.761, 0.824,(3.3274)+(0.0409)Ser+(−0.0117)Ala+(−0.0293)Cit+(−0.0398)Val+(−0.1603)Met+(0.1354)Ile;0.871, 0. 910, 0.886, 0.795, 0.791, 0.736, 0.812,(2.9136)+(0.0391)Ser+(−0.0129)Ala+(−0.0439)Val+(−0.1895)Met+(0.1445)Ile+(0.0213)Trp; 0.871,0.909, 0.904, 0.809, 0.804, 0.758, 0.824, (2.5705)+(0.0423)Ser+(−0.0115)Ala+(−0.0427)Val+(−0.1878)Met+(0.1360)Ile+(0.0 134)Phe;0.871, 0.907, 0.894, 0.803, 0.797, 0.753, 0.819,(3.0263)+(0.0422)Ser+(−0.0117)Ala+(−0.0466)Val+(−0.1894)Met+(0.1237)Ile+(0.0178)Leu; 0.870, 0.913, 0.906, 0.806, 0.790, 0.766, 0.823,(2.4936)+(0.0432)Ser+(−0.0118)Ala+(0.0462)Tyr+(−0.0485)Val+(−0.2565)Met+(0.1511)Ile;0.870, 0.906, 0.897, 0.803, 0.796, 0.75 4, 0.819,(3.0382)+(0.0402)Ser+(−0.0120)Ala+(−0.0407)Val+(−0.1802)Met+(0.0043)Orn+(0.1345)Ile; 0.869, 0.906, 0.893, 0.800, 0. 794,0.747, 0.816,(3.1053)+(0.0413)Ser+(−0.0187)Asn+(−0.0122)Ala+(−0.0403)Val+(−0.1520)Met+(0.1375)Ile;0.869, 0.911, 0.844, 0.821, 0.852, 0.728, 0.830,(3.6477)+(−0.1046)Asn+(0.0141)Gln+(−0.0129)Ala+(−0.0256)Pro+(−0.0496)Val+(0.1669)Ile;0.868, 0. 906, 0.842, 0.816, 0.830, 0.745, 0.827,(3.9145)+(−0.1050)Asn+(0.0147)Gln+(−0.0158)Ala+(−0.0820)Cit+(−0.0437)Val+(0.1389)Il e; 0.867,0.908, 0.854, 0.793, 0.801, 0.717, 0.808, (2.5456)+(0.0259)Ser+(−0.1002)Asn+(0.0075)Gln+(−0.0164)Ala+(−0.0403)Val+(0. 1270)Ile;0.865, 0.898, 0.867, 0.777, 0.776, 0.711, 0.795, (3.8433)+(0.0389)Ser+(−0.0574)Asn+(−0.0145)Ala+(−0.0373)Cit+(−0.0394)Val+(0.1275)Ile; 0.865, 0.912, 0.902, 0.802, 0.793, 0.753, 0.819,(2.8640)+(0.0372)Ser+(−0.0135)Ala+(0.0205)Arg+(−0.0437)Val+(−0.2293)Met+(0.1532)Ile;0.865, 0.914, 0.884, 0.822, 0.829, 0.76 1, 0.835,(3.6660)+(0.0086)Gln+(0.0244)Thr+(−0.0136)Ala+(−0.0488)Val+(−0.2914)Met+(0.1546)Ile; 0.865, 0.907, 0.891, 0.811, 0. 816,0.749, 0.824, (3.7418)+(0.0379)Ser+(−0.0109)Ala+(−0.0113)Pro+(−0.0427)Val+(−0.1565)Met+(0.1486)Ile; 0.864, 0.917, 0.864, 0.842,0.867, 0.765, 0.850,(3.2795)+(0.0145)Gln+(−0.0114)Ala+(−0.0234)Pro+(−0.0513)Val+(−0.2086)Met+(0.1692)Ile;0.864, 0. 904, 0.880, 0.807, 0.804, 0.757, 0.822,(6.4815)+(−0.0134)Ala+(−0.0621)Cit+(0.0404)Arg+(−0.0464)Val+(−0.1757)Met+(0.1534)Ile; 0.864,0.906, 0.896, 0.807, 0.799, 0.762, 0.822, (6.2885)+(0.0375)Thr+(−0.0124)Ala+(−0.0376)Cit+(−0.0494)Val+(−0.2412)Met+(0. 1628)Ile;0.864, 0.898, 0.861, 0.764, 0.762, 0.690, 0.783, (2.7856)+(0.0404)Ser+(−0.0938)Asn+(−0.0176)Ala+(−0.0470)Val+(0.0160)Lys+(0.1421)Ile; 0.863, 0.898, 0.864, 0.772, 0.771, 0.701, 0.790,(3.4932)+(0.0376)Ser+(−0.0658)Asn+(−0.0152)Ala+(−0.0395)Val+(0.1263)Ile; 0.863, 0.892, 0.848, 0.777, 0.779, 0.711, 0.794, (3.8688)+(0.0304)Ser+(−0.0164)Ala+(−0.0455)Cit+(−0.0380)Val+(0. 1120)Ile;0.862, 0.892, 0.838, 0.768, 0.773, 0.691, 0.785, (3.4307)+(0.0273)Ser+(−0.0177)Ala+(−0.0373)Val+(0.1054)Ile; 0.862, 0. 905,0.831, 0.818, 0.845, 0.732, 0.827, (3.7841)+(0.0113)Gln+(−0.0162)Ala+(−0.0585)Cit+(−0.0201)Pro+(−0.0455)Val+(0.1396)Il e; 0.862,0.892, 0.885, 0.830, 0.830, 0.794, 0.839, (1.4679)+(0.0224)Ser+(0.0106)Gln+(−0.0645)Cit+(−0.0500)Val+(−0.3305)Met+(0. 1556)Ile;0.861, 0.902, 0.862, 0.765, 0.761, 0.694, 0.786, (3.4150)+(0.0353)Ser+(−0.0913)Asn+(−0.0170)Ala+(0.0192)Arg+(−0.0419)Val+(0.1393)Ile; 0.861, 0.911, 0.870, 0.828, 0.842, 0.761, 0.838,(3.2184)+(0.0111)Gln+(−0.0132)Ala+(−0.0439)Val+(−0.2077)Met+(0.1344)Ile; 0.861, 0.894, 0.830, 0.801, 0.823, 0.720, 0.812, (3.7223)+(−0.0870)Asn+(0.0100)Gln+(−0.0160)Ala+(−0.0424)Val+(0. 1267)Ile;0.861, 0.898, 0.864, 0.772, 0.769, 0.706, 0.791, (3.4579)+(0.0372)Ser+(−0.0704)Asn+(−0.0149)Ala+(−0.0403)Val+(0.0085)Orn+(0.1246)Ile; 0.860, 0.903, 0.822, 0.820, 0.840, 0.745, 0.829,(2.5839)+(0.0123)Gln+(−0.0180)Ala+(−0.0933)Cit+(−0.0160)Pro+(0.1735)Ile+(−0.0857)Leu; 0.860, 0.907, 0.895, 0.804, 0.796, 0.7 56,0.820, (3.2301)+(0.0443)Ser+(−0.0029)Gly+(−0.0119)Ala+(−0.0403)Val+(−0.1807)Met+(0.1358)Ile; 0.859, 0.890, 0.905, 0.800, 0. 783,0.774, 0.816, (2.8315)+(0.0312)Ser+(0.0223)Thr+(−0.0416)Cit+(−0.0522)Val+(−0.3341)Met+(0.1697)Ile; 0.859, 0.895, 0.843, 0.785,0.798, 0.705, 0.799,(4.0937)+(0.0273)Ser+(−0.0151)Ala+(−0.0154)Pro+(−0.0408)Val+(0.1272)Ile;0.859, 0.895, 0.825, 0.8 07, 0.838, 0.715, 0.816,(3.6909)+(0.0090)Gln+(−0.0160)Ala+(−0.0233)Pro+(−0.0459)Val+(0.1389)Ile; 0.859, 0.895, 0.897, 0.795, 0. 765,0.780, 0.814, (2.3171)+(0.0426)Ser+(−0.0369)Cit+(0.0544)Tyr+(−0.0577)Val+(−0.3487)Met+(0.1682)Ile; 0.859, 0.905, 0.866, 0.789,0.796, 0.713, 0.805,(4.1103)+(0.0358)Ser+(−0.0610)Asn+(−0.0129)Ala+(−0.0140)Pro+(−0.0425)Val+(0.1452)Ile;0.859, 0. 900, 0.861, 0.766, 0.765, 0.693, 0.786,(3.6380)+(0.0339)Ser+(−0.0808)Asn+(0.0105)Thr+(−0.0161)Ala+(−0.0412)Val+(0.1322)Ile; 0.859,0.894, 0.860, 0.768, 0.767, 0.700, 0.787, (3.4924)+(0.0388)Ser+(−0.0697)Asn+(−0.0149)Ala+(−0.0454)Val+(0.1160)Ile+(0.0 159)Leu;0.858, 0.901, 0.852, 0.829, 0.840, 0.772, 0.838,(1.8392)+(0.0145)Gln+(−0.0164)Ala+(−0.0957)Cit+(−0.1504)Met+(0.1590)Ile+(−0.0746)Leu; 0.858, 0.896, 0.846, 0.822, 0.848, 0.743, 0.829,(3.2627)+(−0.1568)Asn+(0.0168)Gln+(−0.0623)Cit+(−0.0290)Pro+(−0.0560)Val+(0.1759)Ile; 0.858, 0.900, 0.889, 0.804, 0.802, 0.7 52,0.818, (5.9958)+(0.0352)Thr+(−0.0126)Ala+(−0.0500)Val+(−0.2580)Met+(0.1616)Ile; 0.858, 0.885, 0.893, 0.798, 0.782, 0.771, 0. 813,(2.5428)+(0.0397)Ser+(−0.0359)Cit+(−0.0470)Val+(−0.2580)Met+(0.1513)Ile; 0.858, 0.914, 0.874, 0.829, 0.838, 0.769, 0.840,(3.0001)+(0.0109)Gln+(−0.0126)Ala+(0.0335)Tyr+(−0.0501)Val+(−0.2630)Met+(0.1449)Ile;0.858, 0.898, 0.854, 0.775, 0.782, 0.69 6, 0.792,(3.5574)+(0.0359)Ser+(−0.0834)Asn+(0.0225)His+(−0.0163)Ala+(−0.0455)Val+(0.1400)Ile; 0.858, 0.894, 0.886, 0.826, 0. 828,0.787, 0.836, (2.7972)+(0.0118)Gln+(0.0191)Thr+(−0.0733)Cit+(−0.0554)Val+(−0.3788)Met+(0.1690)Ile; 0.858, 0.894, 0.833, 0.770,0.762, 0.712, 0.789,(3.0835)+(0.0252)Ser+(−0.0192)Ala+(−0.0851)Cit+(0.0179)Arg+(0.1508)Ile+(−0.0734)Leu;0.857, 0.8 90, 0.836, 0.776, 0.773, 0.718, 0.793,(3.0854)+(0.0294)Ser+(−0.0175)Ala+(−0.0646)Cit+(0.1380)Ile+(−0.0672)Leu; 0.857, 0.900, 0. 890,0.801, 0.797, 0.750, 0.815, (6.0223)+(0.0410)Thr+(−0.0122)Ala+(−0.0638)Val+(−0.2943)Met+(0.1436)Ile+(0.0347)Leu; 0.857, 0.910,0.870, 0.830, 0.848, 0.760, 0.839,(3.1052)+(0.0120)Gln+(−0.0135)Ala+(−0.0435)Val+(−0.2153)Met+(−0.0102)Orn+(0.1397)Ile; 0.857, 0.897, 0.853, 0.791, 0.800, 0.717, 0.805, (4.2897)+(0.0303)Ser+(−0.0146)Ala+(−0.0342)Cit+(−0.0130)Pro+(−0.0403)Val+(0.1270)Ile;0.857, 0.892, 0.867, 0.828, 0.832, 0.786, 0.837, (2.5832)+(0.0139)Gln+(−0.0769)Cit+(−0.0528)Val+(−0.3151)Met+(0.1 570)Ile;0.857, 0.895, 0.877, 0.827, 0.828, 0.789, 0.837,(2.6930)+(0.0125)Gln+(−0.0905)Cit+(0.0196)Arg+(−0.0556)Val+(−0.3549)Met+(0.1713)Ile;0.857, 0.895, 0.854, 0.765, 0.766, 0.691, 0.784,(3.4388)+(0.0368)Ser+(−0.0683)Asn+(−0.0158)Ala+(−0.0419)Val+(0.1308)Ile+(0.0135)Trp; 0.857, 0.906, 0.875, 0.827, 0.842, 0.76 3,0.837, (2.9477)+(0.0100)Gln+(−0.0140)Ala+(−0.0502)Val+(−0.2536)Met+(0.0138)Lys+(0.1490)Ile; 0.857, 0.900, 0.870, 0.846, 0. 864,0.790, 0.851, (2.5434)+(0.0169)Gln+(−0.0594)Cit+(−0.0230)Pro+(−0.0575)Val+(−0.2953)Met+(0.1812)Ile; 0.857, 0.889, 0.891, 0.799,0.775, 0.780, 0.815,(2.6896)+(0.0379)Ser+(−0.0547)Cit+(−0.0483)Val+(−0.2479)Met+(0.0250)Orn+(0.1398)Ile;0.856, 0.8 93, 0.838, 0.768, 0.772, 0.691, 0.786,(3.4271)+(0.0272)Ser+(−0.0 177)Ala+(−0.0373)Val+(0.0008)Orn+(0.1051)Ile;0.856, 0.899, 0. 836, 0.788, 0.787, 0.726, 0.804,(3.3509)+(0.0284)Ser+(−0.0162)Ala+(−0.0601)Cit+(−0.0084)Pro+(0.1519)Ile+(−0.0706)Leu; 0.856, 0.898,0.871, 0.828, 0.824, 0.795, 0.839,(2.5863)+(0.0143)Gln+(−0.0787)Cit+(0.0496)Tyr+(−0.0626)Val+(−0.4003)Met+(0.1719)Ile; 0.856, 0.898, 0.872, 0.810, 0.818, 0.748, 0.821, (5.9124)+(0.0078)Gly+(−0.0121)Ala+(−0.0412)Cit+(−0.0420)Val+(−0.0905)Met+(0.1313)Ile;0.855, 0.895, 0.843, 0.778, 0.768, 0.725, 0.796, (3.0505)+(0.0335)Ser+(−0.0316)Asn+(−0.0166)Ala+(−0.0603)Cit+(0.1406)Ile+(−0.0641)Leu; 0.855, 0.899, 0.849, 0.775, 0.774, 0.706, 0. 793,(3.8752)+(0.0268)Ser+(−0.0182)Ala+(−0.0618)Cit+(0.0162)Arg+(−0.0393)Val+(0.1173)Ile; 0.855, 0.896, 0.852, 0.781, 0.781, 0.715,0.797,(3.9231)+(0.0304)Ser+(−0.0164)Ala+(−0.0504)Cit+(−0.0319)Val+(0.1240)Ile+(−0.0164)Leu;0.855, 0.903, 0.887, 0.8 03, 0.793, 0.760, 0.819,(5.7717)+(0.0386)Thr+(−0.0122)Ala+(0.0496)Tyr+(−0.0607)Val+(−0.3491)Met+(0.1793)Ile; 0.855, 0.900, 0. 832,0.801, 0.826, 0.712, 0.812, (3.1275)+(0.0128)Ser+(0.0072)Gln+(−0.0164)Ala+(−0.0220)Pro+(−0.0443)Val+(0.1356)Ile; 0.855, 0.897,0.824, 0.809, 0.841, 0.715, 0.817,(3.7322)+(0.0096)Gln+(−0.0155)Ala+(−0.0241)Pro+(−0.0450)Val+(−0.0031)Lys+(0.1382)Ile; 0.855, 0.904, 0.889, 0.812, 0.818, 0.752, 0.825, (6.5665)+(0.0343)Thr+(−0.0114)Ala+(−0.0117)Pro+(−0.0524)Val+(−0.2395)Met+(0.1748)Ile;0.854, 0.907, 0.862, 0.827, 0.841, 0.762, 0.837, (3.2724)+(−0.0426)Asn+(0.0120)Gln+(−0.0133)Ala+(−0.0438)Val+(−0.1613)Met+(0.1368)Ile; 0.854, 0.891, 0.895, 0.793, 0.766, 0.775, 0. 811,(1.8590)+(0.0421)Ser+(0.0528)Tyr+(−0.0584)Val+(−0.3709) Met+(0.1702)Ile;0.854, 0.900, 0.888, 0.802, 0.799, 0.750, 0.816,(6.0654)+(−0.0155)Asn+(0.0360)Thr+(−0.0127)Ala+(−0.0499)Val+(−0.2400)Met+(0.1630)Ile; 0.854, 0.897, 0.869, 0.773, 0.773, 0.7 02,0.791, (3.2158)+(0.0385)Ser+(−0.0678)Asn+(−0.0149)Ala+(−0.0410)Val+(0.1264)Ile+(0.0079)Phe; 0.854, 0.900, 0.889, 0.803, 0. 802,0.749, 0.817, (6.0284)+(0.0359)Thr+(−0.0127)Ala+(−0.0499)Val+(−0.2595)Met+(−0.0029)Orn+(0.1631)Ile; 0.854, 0.898, 0.888, 0.806,0.808, 0.751, 0.819,(5.6950)+(0.0289)Thr+(−0.0136)Ala+(−0.0545)Val+(−0.2696)Met+(0.0117)Lys+(0.1676)Ile;0.854, 0.8 94, 0.845, 0.768, 0.770, 0.694, 0.786,(3.4259)+(0.0290)Ser+(−0.0084)His+(−0.0170)Ala+(−0.0353)Val+(0.1023)Ile; 0.854, 0.893, 0. 837,0.768, 0.773, 0.691, 0.785, (3.4296)+(0.0274)Ser+(−0.0177)Ala+(−0.0383)Val+(0.1035)Ile+(0.0028)Leu; 0.854, 0.901, 0.824, 0. 814,0.824, 0.753, 0.826, (2.5302)+(−0.0860)Asn+(0.0153)Gln+(−0.0185)Ala+(−0.1030)Cit+(0.1517)Ile+(−0.0712)Leu; 0.854, 0.899, 0.848,0.804, 0.824, 0.722, 0.815, (5.9360)+(0.0082)Gly+(−0.0134)Ala+(−0.0388)Cit+(−0.0144)Pro+(−0.0424)Val+(0.1336)Ile; 0. 854, 0.893,0.830, 0.802, 0.824, 0.720, 0.812, (3.7050)+(−0.0869)Asn+(0.0102)Gln+(−0.0161)Ala+(−0.0422)Val+(−0.0021)Orn+(0.12 73)Ile;0.854, 0.891, 0.848, 0.777, 0.779, 0.711, 0.794,(3.8714)+(0.0303)Ser+(0.0005)His+(−0.0164)Ala+(−0.0456)Cit+(−0.0381)Val+(0.1122)Ile; 0.854, 0.894, 0.891, 0.808, 0.793, 0.780, 0.822,(0.8790)+(0.0322)Ser+(0.0063)Gln+(0.0517)Tyr+(−0.0600)Val+(−0.4205)Met+(0.1715)Ile;0.853, 0.895, 0.838, 0.796, 0.809, 0.72 2, 0.809,(3.2537)+(0.0140)Ser+(0.0069)Gln+(−0.0181)Ala+(−0.0663)Cit+(−0.0401)Val+(0.1149)Ile; 0.853, 0.892, 0.899, 0.796, 0. 780,0.764, 0.812, (2.5496)+(0.0324)Ser+(0.0274)Thr+(−0.0707)Val+(−0.4062)Met+(0.1451)Ile+(0.0461)Leu; 0.853, 0.910, 0.872, 0. 824,0.835, 0.760, 0.835, (3.3387)+(0.0097)Gln+(−0.0140)Ala+(0.0136)Arg+(−0.0454)Val+(−0.2275)Met+(0.1422)Ile; 0.853, 0.900, 0.884,0.807, 0.813, 0.747, 0.820,(5.8451)+(0.0314)His+(0.0340)Thr+(−0.0137)Ala+(−0.0592)Val+(−0.3052)Met+(0.1829)Ile;0.85 3, 0.894, 0.855, 0.781, 0.775, 0.727, 0.798,(3.9165)+(0.0302)Ser+(−0.0157)Ala+(−0.0654)Cit+(−0.0399)Val+(0.0235)Orn+(0.1034)Ile; 0.853, 0.892, 0.846, 0.777, 0.778, 0.710, 0.793, (3.8648)+(0.0302)Ser+(−0.0165)Ala+(−0.0456)Cit+(−0.0383)Val+(0.1125)Ile+(0.0023)Trp;0.853, 0.894, 0.899, 0.799, 0.779, 0.773, 0.815, (2.5079)+(0.0358)Ser+(−0.0597)Cit+(0.0250)Arg+(−0.0515)Val+(−0.3189)Met+(0.1728)Ile; 0.853, 0.894, 0.829, 0.801, 0.809, 0.735, 0.8 13,(2.1340)+(0.0131)Ser+(0.0081)Gln+(−0.0194)Ala+(−0.0888)Cit+(0.1439)Ile+(−0.0743)Leu; 0.853, 0.902, 0.861, 0.769, 0.764, 0. 702,0.789, (3.3789)+(0.0378)Ser+(−0.0746)Asn+(−0.0156)Ala+(0.0166)Tyr+(−0.0425)Val+(0.1301)Ile; 0.853, 0.885, 0.891, 0.794, 0. 779,0.762, 0.809,(2.1611)+(0.0392)Ser+(−0.0480)Val+(−0.2807)Met+(0.1521)Ile; 0.852,0.888, 0.897, 0.791, 0.766, 0.770, 0.808,(2.2714)+(0.0316)Ser+(0.0231)Thr+(0.0575)Tyr+(−0.0649)Val+(−0.4616)Met+(0.1911)Ile;0.852, 0.886, 0.889, 0.804, 0.793, 0.77 3, 0.817,(2.5336)+(0.0383)Ser+(0.0215)His+(−0.0411)Cit+(−0.0534)Val+(−0.2934)Met+(0.1659)Ile; 0.852, 0.878, 0.885, 0.795, 0. 787,0.759, 0.808, (5.2691)+(0.0342)Thr+(−0.0406)Cit+(−0.0551)Val+(−0.3347)Met+(0.1739)Ile; 0.852, 0.895, 0.844, 0.785, 0.799, 0.705,0.800,(4.0912)+(0.0270)Ser+(−0.0151)Ala+(−0.0157)Pro+(−0.0411)Val+(0.0034)Orn+(0.1262)Ile;0.852, 0.892, 0.847, 0.77 7, 0.778, 0.711, 0.794,(3.9086)+(0.0303)Ser+(−0.0164)Ala+(−0.0455)Cit+(−0.0377)Val+(0.1120)Ile+(−0.0011)Phe; 0.852, 0.889, 0. 816,0.801, 0.813, 0.734, 0.812, (2.7806)+(0.0089)Gln+(−0.0202)Ala+(−0.1039)Cit+(0.0130)Arg+(0.1532)Ile+(−0.0795)Leu

List (1) of Linear Discriminants Searched in Example 7

The linear discriminants searched in Example 7 above are listed below.Before each equation, “the value of ROC_AUC for the pancreatic cancergroup and the prostatic cancer group with validation”, “the value ofROC_AUC for the pancreatic cancer group and the prostatic cancer groupwithout validation”, “the value of ROC_AUC for the pancreatic cancergroup and the healthy group”, “the value of ROC_AUC for the pancreaticcancer group and the other cancers group”, “the value of ROC_AUC for thepancreatic cancer group and the lung cancer group”, “the value ofROC_AUC for the pancreatic cancer group and the colorectal cancergroup”, and “the average value of the value of ROC_AUC for thepancreatic cancer group and the lung cancer group, the value of ROC_AUCfor the pancreatic cancer group and the colorectal cancer group, and thevalue of ROC_AUC for the pancreatic cancer group and the prostaticcancer group” obtained for the equation are additionally listed.

0.889, 0.914, 0.864, 0.834, 0.844, 0.774, 0.844, (5.0859)+(0.0109)Gln+(−0.0171)Ala+(−0.0452)Cit+(−0.0389)Val+(−0.1548)Met+(0.1284)Ile; 0.888, 0.912, 0.883, 0.817, 0.820, 0.758, 0.830, (4.2244)+(0.0244)Ser+(0.0058)Gln+(−0.0176)Ala+(−0.0382)Val+(−0.1788)Met+(0.1319)Ile; 0.888, 0.907, 0.886, 0.803, 0.798, 0.751, 0. 818,(5.2330)+(0.0342)Ser+(−0.0170)Ala+(−0.0368)Val+(−0.1509)Met+(0.1323)Ile; 0.888, 0.911, 0.905, 0.814, 0.811, 0.763, 0.828,(3.9212)+(0.0380)Ser+(−0.0160)Ala+(−0.0426)Val+(−0.1846)Met+(0.1388)Ile+(0.0358)Phe; 0.887, 0.909, 0.852, 0.820, 0.833, 0.75 2,0.832, (5.2382)+(0.0091)Gln+(−0.0176)Ala+(−0.0397)Val+(−0.1581)Met+(0.1265)Ile; 0.886, 0.907, 0.887, 0.805, 0.799, 0.756, 0. 821,(5.4168)+(0.0347)Ser+(−0.0165)Ala+(−0.0246)Cit+(−0.0361)Val+(−0.1422)Met+(0.1331)Ile; 0.886, 0.911, 0.887, 0.801, 0.79 4,0.747, 0.817, (5.4113)+(0.0284)Ser+(0.0124)Thr+(−0.0177)Ala+(−0.0384)Val+(−0.1808)Met+(0.1375)Ile; 0.886, 0.910, 0.894, 0. 805,0.791, 0.763, 0.822, (4.9603)+(0.0350)Ser+(−0.0175)Ala+(0.0518)Tyr+(−0.0451)Val+(−0.2283)Met+(0.1452)Ile; 0.885, 0.909, 0.885,0.804, 0.800, 0.750, 0.820, (5.1334)+(0.0336)Ser+(0.0076)His+(−0.0172)Ala+(−0.0387)Val+(−0.1574)Met+(0.1365)Ile; 0.88 5, 0.909,0.886, 0.800, 0.794, 0.747, 0.816,(5.0407)+(0.0361)Ser+(−0.0168)Ala+(−0.0446)Val+(−0.1632)Met+(0.1200)Ile+(0.0226)Leu; 0.885, 0.909, 0.881, 0.799, 0.795, 0.741, 0.815, (5.1188)+(0.0337)Ser+(−0.0174)Ala+(−0.0385)Val+(−0.1546)Met+(0.1360)Ile+(0.0103)Trp;0.885, 0.912, 0.859, 0.836, 0.858, 0.761, 0.844, (5.1053)+(0.0114)Gln+(−0.0154)Ala+(−0.0193)Pro+(−0.0456)Val+(−0.1536)Met+(0.1567)Ile; 0.885, 0.909, 0.839, 0.816, 0.831, 0.742, 0. 827,(5.6785)+(−0.0836)Asn+(0.0106)Gln+(−0.0184)Ala+(−0.0445)Cit+(−0.0374)Val+(0.1214)Ile; 0.885, 0.904, 0.855, 0.779, 0.77 6,0.712, 0.797, (5.8722)+(0.0304)Ser+(−0.0707)Asn+(−0.0184)Ala+(−0.0355)Val+(0.1234)Ile; 0.884, 0.907, 0.841, 0.819, 0.846, 0. 732,0.828,(5.7402)+(−0.0940)Asn+(0.0119)Gln+(−0.0163)Ala+(−0.0211)Pro+(−0.0449)Val+(0.1544)Ile;0.884, 0.908, 0.887, 0.803, 0.799, 0.749, 0.819,(4.8169)+(0.0329)Ser+(−0.0175)Ala+(−0.0394)Val+(−0.1681)Met+(0.0072)Lys+(0.1378)Ile; 0.884, 0.908, 0.84 9, 0.797,0.804, 0.725, 0.813, (5.0488)+(0.0206)Ser+(−0.0938)Asn+(0.0061)Gln+(−0.0191)Ala+(−0.0368)Val+(0.1230)Ile; 0.884, 0. 906,0.883, 0.801, 0.797, 0.747, 0.817, (5.4787)+(0.0353)Ser+(−0.0245)Asn+(−0.0168)Ala+(−0.0367)Val+(−0.1284)Met+(0.1335)Il e; 0.883,0.907, 0.887, 0.799, 0.793, 0.747, 0.816, (5.1392)+(0.0305)Ser+(−0.0182)Ala+(0.0142)Arg+(−0.0382)Val+(−0.1711)Met+(0. 1393)Ile;0.883, 0.906, 0.859, 0.793, 0.799, 0.720, 0.808, (6.2281)+(0.0316)Ser+(−0.0654)Asn+(−0.0163)Ala+(−0.0145)Pro+(−0.0397)Val+(0.1469)Ile; 0.883, 0.906, 0.832, 0.816, 0.839, 0.733, 0.826,(5.0766)+(0.0094)Gln+(−0.0180)Ala+(−0.0436)Cit+(−0.0191)Pro+(−0.0418)Val+(0.1394)Ile; 0.883, 0.905, 0.888, 0.801, 0.796, 0.7 48,0.817, (5.2204)+(0.0337)Ser+(−0.0169)Ala+(−0.0373)Val+(−0.1522)Met+(0.0065)Orn+(0.1298)Ile; 0.882, 0.907, 0.886, 0.802, 0. 796,0.751, 0.818, (5.3105)+(0.0362)Ser+(−0.0016)Gly+(−0.0168)Ala+(−0.0368)Val+(−0.1527)Met+(0.1323)Ile; 0.882, 0.910, 0.862, 0.822,0.825, 0.767, 0.834,(5.1908)+(0.0087)Gln+(−0.0179)Ala+(0.0430)Tyr+(−0.0465)Val+(−0.2179)Met+(0.1368)Ile;0.881, 0.9 08, 0.852, 0.820, 0.833, 0.752, 0.831,(5.2315)+(0.0091)Gln+(−0.0176)Ala+(−0.0396)Val+(−0.1582)Met+(−0.0007)Orn+(0.1268)Ile; 0.881,0.907, 0.884, 0.809, 0.814, 0.747, 0.822,(5.5923)+(0.0347)Ser+(−0.0153)Ala+(−0.0130)Pro+(−0.0404)Val+(−0.1363)Met+(0.1521)Ile; 0.880, 0.907, 0.847, 0.822, 0.837, 0.754, 0.833, (5.5183)+(−0.0448)Asn+(0.0101)Gln+(−0.0173)Ala+(−0.0398)Val+(−0.1217)Met+(0.1286)Ile; 0.880, 0.913, 0.862, 0.830, 0.840, 0.769, 0.841,(3.2318)+(0.0105)Gln+(−0.0278)Pro+(0.0580)Tyr+(−0.0620)Val+(−0.2907)Met+(0.1812)Ile;0.880, 0.902, 0.861, 0.784, 0.781, 0.72 1, 0.801,(5.9949)+(0.0308)Ser+(−0.0636)Asn+(−0.0180)Ala+(−0.0257)Cit+(−0.0348)Val+(0.1242)Ile; 0.879, 0.908, 0.850, 0.819, 0. 832,0.749, 0.830, (5.2157)+(0.0090)Gln+(−0.0177)Ala+(−0.0402)Val+(−0.1589)Met+(0.1276)Ile+(0.0029)Trp; 0.879, 0.902, 0.857, 0.780,0.776, 0.717, 0.798,(5.8969)+(0.0298)Ser+(−0.0750)Asn+(−0.0183)Ala+(−0.0364)Val+(0.0106)Orn+(0.1198)Ile;0.879, 0.9 08, 0.853, 0.820, 0.833, 0.753, 0.831,(5.1537)+(0.0013)Gly+(0.0087)Gln+(−0.0177)Ala+(−0.0395)Val+(−0.1569)Met+(0.1267)Ile; 0. 879,0.908, 0.853, 0.822, 0.834, 0.756, 0.833, (5.2667)+(0.0096)Gln+(−0.0091)His+(−0.0174)Ala+(−0.0374)Val+(−0.1528)Met+(0.12 14)Ile;0.879, 0.908, 0.869, 0.817, 0.826, 0.755, 0.830,(5.4077)+(0.0074)Gln+(0.0149)Thr+(−0.0183)Ala+(−0.0410)Val+(−0.1935)Met+(0.1340)Ile; 0.878, 0.907, 0.851, 0.820, 0.832, 0.754, 0.831,(5.1231)+(0.0094)Gln+(−0.0174)Ala+(−0.0455)Val+(−0.1667)Met+(0.1173)Ile+(0.0164)Leu; 0.878, 0.905, 0.865, 0.828, 0.843, 0.76 5,0.838, (4.5753)+(0.0093)Gln+(−0.0170)Ala+(−0.0433)Val+(−0.1757)Met+(0.1299)Ile+(0.0215)Phe; 0.878, 0.904, 0.854, 0.779, 0. 776,0.711, 0.797,(5.8641)+(0.0303)Ser+(−0.0708)Asn+(−0.0185)Ala+(−0.0356)Val+(0.1237)Ile+(0.0008)Trp;0.878, 0.907, 0.857, 0.821, 0.834, 0.754, 0.832,(4.9840)+(0.0086)Gln+(−0.0179)Ala+(−0.0415)Val+(−0.1693)Met+(0.0054)Lys+(0.1307)Ile;0.878, 0.8 99, 0.830, 0.806, 0.825, 0.726, 0.817,(5.8504)+(−0.0870)Asn+(0.0089)Gln+(−0.0189)Ala+(−0.0382)Val+(0.1196)Ile; 0.878, 0.902, 0. 850,0.777, 0.774, 0.711, 0.796, (5.7854)+(0.0316)Ser+(−0.0759)Asn+(−0.0183)Ala+(−0.0410)Val+(0.1144)Ile+(0.0160)Leu; 0.878, 0.904,0.853, 0.778, 0.776, 0.710, 0.797,(5.6760)+(0.0294)Ser+(−0.0768)Asn+(−0.0188)Ala+(−0.0370)Val+(0.0044)Lys+(0.1263)Ile; 0.878, 0.903, 0.852, 0.778, 0.775, 0.712, 0.797, (6.0289)+(0.0274)Ser+(−0.0785)Asn+(0.0059)Thr+(−0.0189)Ala+(−0.0361)Val+(0. 1252)Ile;0.877, 0.894, 0.832, 0.769, 0.771, 0.696, 0.787, (5.1118)+(0.0222)Ser+(−0.0205)Ala+(−0.0349)Val+(0.1105)Ile; 0.877, 0. 904,0.854, 0.780, 0.778, 0.713, 0.798, (5.8368)+(0.0295)Ser+(−0.0708)Asn+(0.0008)Gly+(−0.0185)Ala+(−0.0355)Val+(0.1235)Ile; 0.877,0.904, 0.866, 0.799, 0.795, 0.745, 0.814, (7.4944)+(−0.0188)Ala+(−0.0579)Cit+(0.0387)Arg+(−0.0401)Val+(−0.1376)Met+(0. 1463)Ile;0.877, 0.907, 0.853, 0.778, 0.771, 0.714, 0.797, (5.8649)+(0.0297)Ser+(−0.0799)Asn+(−0.0189)Ala+(0.0165)Tyr+(−0.0379)Val+(0.1256)Ile; 0.877, 0.903, 0.852, 0.776, 0.773, 0.709, 0.795,(5.9419)+(0.0268)Ser+(−0.0879)Asn+(−0.0197)Ala+(0.0149)Arg+(−0.0369)Val+(0.1308)Ile;0.877, 0.902, 0.851, 0.781, 0.781, 0.71 3, 0.798,(5.8149)+(0.0297)Ser+(−0.0780)Asn+(0.0099)His+(−0.0187)Ala+(−0.0380)Val+(0.1289)Ile; 0.876, 0.900, 0.866, 0.782, 0. 781,0.718, 0.800,(5.2550)+(0.0318)Ser+(−0.0782)Asn+(−0.0181)Ala+(−0.0383)Val+(0.1256)Ile+(0.0187)Phe;0.876, 0.896, 0.843, 0.779, 0.780, 0.711, 0.796,(5.3713)+(0.0238)Ser+(−0.0197)Ala+(−0.0335)Cit+(−0.0341)Val+(0.1133)Ile;0.876, 0.907, 0.860, 0.8 17, 0.829, 0.751, 0.829,(5.3043)+(0.0079)Gln+(−0.0184)Ala+(0.0105)Arg+(−0.0404)Val+(−0.1690)Met+(0.1319)Ile; 0.876, 0.909, 0. 847,0.812, 0.810, 0.759, 0.826, (8.3155)+(−0.0147)Ala+(−0.0159)Pro+(0.0616)Tyr+(−0.0523)Val+(−0.1569)Met+(0.1622)Ile; 0.875, 0.902,0.862, 0.836, 0.855, 0.771, 0.843,(3.2313)+(0.0124)Gln+(−0.0465)Cit+(−0.0237)Pro+(−0.0505)Val+(−0.2054)Met+(0.1627)Ile; 0.875, 0.902, 0.880, 0.843, 0.869, 0.773, 0.848, (2.1201)+(0.0112)Gln+(−0.0255)Pro+(−0.0590)Val+(−0.2410)Met+(0.1706)Ile+(0.0439)Phe;0.874, 0.902, 0.874, 0.804, 0.800, 0.755, 0.819, (7.6755)+(0.0283)Thr+(−0.0175)Ala+(−0.0339)Cit+(−0.0403)Val+(−0.1661)Met+(0.1394)Ile; 0.874, 0.895, 0.832, 0.769, 0.771, 0.697, 0. 787,(5.1032)+(0.0217)Ser+(−0.0205)Ala+(−0.0352)Val+(0.0041)Orn+(0.1088)Ile;0.874, 0.900, 0.834, 0.809, 0.829, 0.731, 0.820,(5.9023)+(−0.0868)Asn+(0.0091)Gln+(−0.0186)Ala+(−0.0371)Val+(0.1172)Ile+(−0.0071)Trp; 0.874, 0.895, 0.843, 0.817, 0.842, 0.7 38,0.825, (3.9047)+(−0.1206)Asn+(0.0126)Gln+(−0.0453)Cit+(−0.0265)Pro+(−0.0500)Val+(0.1585)Ile; 0.873, 0.900, 0.847, 0.789, 0. 796,0.716, 0.804, (5.7240)+(0.0252)Ser+(−0.0176)Ala+(−0.0265)Cit+(−0.0142)Pro+(−0.0385)Val+(0.1368)Ile; 0.873, 0.897, 0.867, 0.799,0.799, 0.745, 0.813,(7.4475)+(0.0250)Thr+(−0.0179)Ala+(−0.0408)Val+(−0.1687)Met+(0.1367)Ile;0.873, 0.901, 0.865, 0.8 07, 0.818, 0.739, 0.819,(7.8313)+(0.0255)Thr+(−0.0162)Ala+(−0.0128)Pro+(−0.0444)Val+(−0.1548)Met+(0.1565)Ile; 0.873, 0.894, 0.839,0.769, 0.767, 0.700, 0.787, (5.3222)+(0.0245)Ser+(−0.0152)His+(−0.0197)Ala+(−0.0311)Val+(0.1040)Ile; 0.873, 0.900, 0.8 51,0.796, 0.814, 0.712, 0.809, (6.6258)+(0.0107)Gly+(−0.0172)Ala+(−0.0355)Cit+(−0.0155)Pro+(−0.0396)Val+(0.1411)Ile; 0.873, 0.901,0.834, 0.805, 0.825, 0.722, 0.816,(5.6692)+(−0.0870)Asn+(0.0027)Gly+(0.0082)Gln+(−0.0191)Ala+(−0.0380)Val+(0.1205)Ile; 0.873, 0.902, 0.868, 0.804, 0.798, 0.759, 0.819, (6.2881)+(0.0100)Gly+(−0.0183)Ala+(0.0616)Tyr+(−0.0473)Val+(−0.1885)Met+(0.1411)Ile;0.873, 0.894, 0.842, 0.782, 0.793, 0.703, 0.797, (5.5535)+(0.0241)Ser+(−0.0181)Ala+(−0.0154)Pro+(−0.0394)Val+(0.1 367)Ile;0.872, 0.897, 0.842, 0.784, 0.794, 0.706, 0.799,(5.7455)+(0.0253)Ser+(−0.0177)Ala+(−0.0157)Pro+(−0.0385)Val+(−0.0031)Lys+(0.1358)Ile; 0.872, 0.898, 0.842, 0.785, 0.795, 0.707, 0.800,(5.5167)+(0.0259)Ser+(−0.0027)Thr+(−0.0178)Ala+(−0.0153)Pro+(−0.0391)Val+(0.1362)Ile; 0.872, 0.894, 0.832, 0.769, 0.771, 0.6 96,0.787, (5.1178)+(0.0221)Ser+(−0.0205)Ala+(−0.0347)Val+(0.1109)Ile+(−0.0007)Leu; 0.872, 0.894, 0.837, 0.772, 0.773, 0.702, 0. 790,(5.1793)+(0.0226)Ser+(−0.0203)Ala+(−0.0339)Val+(0.1087)Ile+(−0.0059)Trp;0.872, 0.902, 0.818, 0.819, 0.839, 0.744, 0.828,(4.3698)+(0.0092)Gln+(−0.0190)Ala+(−0.0647)Cit+(−0.0133)Pro+(0.1499)Ile+(−0.0727)Leu; 0.872, 0.895, 0.835, 0.769, 0.772, 0.6 95,0.787, (4.9662)+(0.0223)Ser+(−0.0205)Ala+(−0.0355)Val+(0.1107)Ile+(0.0039)Phe; 0.872, 0.898, 0.827, 0.803, 0.824, 0.721, 0. 814,(5.7877)+(−0.0918)Asn+(0.0092)Gln+(−0.0188)Ala+(−0.0430)Val+(0.1119)Ile+(0.0135)Leu; 0.872, 0.900, 0.847, 0.778, 0.775, 0.714,0.796,(5.4824)+(0.0251)Ser+(−0.0091)His+(−0.0193)Ala+(−0.0317)Cit+(−0.0319)Val+(0.1092)Ile;0.871, 0.899, 0.835, 0.8 07, 0.826, 0.728, 0.818,(5.5960)+(−0.0901)Asn+(0.0090)Gln+(−0.0187)Ala+(−0.0396)Val+(0.1206)Ile+(0.0090)Phe; 0.871, 0.898, 0. 831,0.800, 0.816, 0.722, 0.812, (6.0160)+(−0.0970)Asn+(0.0079)Gln+(0.0082)Thr+(−0.0195)Ala+(−0.0388)Val+(0.1228)Ile; 0.871, 0.897,0.830, 0.805, 0.824, 0.727, 0.816,(5.8935)+(−0.0879)Asn+(0.0087)Gln+(−0.0188)Ala+(−0.0386)Val+(0.0043)Orn+(0.1182)Ile; 0.871, 0.890, 0.849, 0.816, 0.845, 0.734, 0.823, (3.2521)+(−0.1343)Asn+(0.0113)Gln+(−0.0284)Pro+(−0.0560)Val+(0.1630)Ile+(0.0298)Phe;0.871, 0.895, 0.833, 0.771, 0.772, 0.699, 0.789, (5.2033)+(0.0227)Ser+(−0.0203)Ala+(−0.0344)Val+(−0.0015)Lys+(0.1 099)Ile;0.871, 0.893, 0.829, 0.803, 0.829, 0.716, 0.813,(5.2203)+(0.0076)Gln+(−0.0185)Ala+(−0.0199)Pro+(−0.0428)Val+(0.1384)Ile;0.871, 0.894, 0.830, 0.769, 0.771, 0.695, 0.786, (5.0943)+(0.0213)Ser+(−0.0208)Ala+(0.0023)Arg+(−0.0351)Val+(0.1112)Ile; 0. 871,0.898, 0.847, 0.796, 0.815, 0.713, 0.809, (7.3141)+(−0.0436)Asn+(0.0099)Gly+(−0.0163)Ala+(−0.0160)Pro+(−0.0412)Val+(0.14 69)Ile;0.871, 0.897, 0.846, 0.782, 0.776, 0.724, 0.799,(5.4563)+(0.0223)Ser+(−0.0192)Ala+(−0.0504)Cit+(−0.0356)Val+(0.0221)Orn+(0.1055)Ile;0.871, 0.899, 0.836, 0.789, 0.800, 0.711, 0.803,(8.3595)+(−0.0678)Asn+(0.0198)Thr+(−0.0170)Ala+(−0.0144)Pro+(−0.0429)Val+(0.1487)Ile; 0.871, 0.895, 0.837, 0.771, 0.775, 0.6 97,0.789, (5.0555)+(0.0252)Ser+(−0.0045)Thr+(−0.0200)Ala+(−0.0344)Val+(0.1102)Ile; 0.871, 0.900, 0.835, 0.798, 0.813, 0.721, 0. 811,(5.9904)+(−0.0972)Asn+(0.0078)Gln+(−0.0198)Ala+(0.0117)Arg+(−0.0390)Val+(0.1257)Ile;0.871, 0.896, 0.839, 0.795, 0.816, 0.710, 0.807,(4.6855)+(0.0132)Ser+(0.0055)Gln+(−0.0188)Ala+(−0.0190)Pro+(−0.0415)Val+(0.1386)Ile;0.870, 0.893, 0.828, 0.7 75, 0.783, 0.696, 0.791,(4.6677)+(0.0170)Ser+(0.0025)Gln+(−0.0 211)Ala+(−0.0354)Val+(0.1086)Ile;0.870, 0.896, 0.845, 0.781, 0. 782, 0.714, 0.797,(5.4134)+(0.0241)Ser+(−0.0195)Ala+(−0.0334)Cit+(−0.0335)Val+(0.1121)Ile+(−0.0038)Trp;0.870, 0.899, 0.831, 0.806, 0.825, 0.728, 0.817,(5.8480)+(−0.0845)Asn+(0.0091)Gln+(−0.0044)His+(−0.0188)Ala+(−0.0371)Val+(0.1171)Ile;0.870, 0. 896, 0.846, 0.789, 0.798, 0.714, 0.803,(5.6854)+(0.0250)Ser+(−0.0176)Ala+(−0.0157)Pro+(−0.0377)Val+(0.1335)Ile+(−0.0111)Tr p; 0.870,0.898, 0.827, 0.790, 0.790, 0.728, 0.805, (4.9798)+(0.0245)Ser+(−0.0186)Ala+(−0.0457)Cit+(−0.0089)Pro+(0.1426)Ile+(−0.0641)Leu;0.870, 0.900, 0.840, 0.826, 0.838, 0.770, 0.836, (4.3138)+(0.0102)Gln+(−0.0184)Ala+(−0.0642)Cit+(−0.1069)Met+(0.1371)Ile+(−0.0659)Leu; 0.870, 0.898, 0.818, 0.814, 0.824, 0.754, 0.8 25,(4.7702)+(−0.0547)Asn+(0.0099)Gln+(−0.0193)Ala+(−0.0636)Cit+(0.1331)Ile+(−0.0653)Leu;0.870, 0.897, 0.850, 0.791, 0.798, 0.721, 0.805,(7.0384)+(−0.0404)Asn+(0.0099)Gly+(−0.0180)Ala+(−0.0363)Cit+(−0.0356)Val+(0.1222)Ile;0.870, 0.901, 0.866, 0.8 04, 0.794, 0.762, 0.819,(7.2269)+(0.0258)Thr+(−0.0184)Ala+(0.0510)Tyr+(−0.0490)Val+(−0.2458)Met+(0.1496)Ile; 0.870, 0.896, 0. 842,0.782, 0.793, 0.703, 0.797, (5.5448)+(0.0236)Ser+(−0.0181)Ala+(−0.0155)Pro+(−0.0399)Val+(0.0055)Orn+(0.1345)Ile; 0.870, 0.894,0.846, 0.772, 0.772, 0.704, 0.790,(5.3689)+(0.0186)Ser+(−0.0212)Ala+(−0.0488)Cit+(0.0156)Arg+(−0.0351)Val+(0.1190)Ile; 0.869, 0.895, 0.833, 0.770, 0.772, 0.696, 0.788, (5.0899)+(0.0216)Ser+(0.0005)Gly+(−0.0206)Ala+(−0.0349)Val+(0.1106)Ile; 0.8 69, 0.901,0.851, 0.797, 0.788, 0.750, 0.813, (7.1204)+(−0.0191)Ala+(0.0259)Arg+(0.0537)Tyr+(−0.0490)Val+(−0.2142)Met+(0.150 7)Ile

List (2) of Logistic Regression Equations Searched in Example 7

The logistic regression equations searched in Example 7 above are listedbelow. Before each equation, “the value of ROC_AUC for the pancreaticcancer group and the prostatic cancer group with validation”, “the valueof ROC_AUC for the pancreatic cancer group and the prostatic cancergroup without validation”, “the value of ROC_AUC for the pancreaticcancer group and the healthy group”, “the value of ROC_AUC for thepancreatic cancer group and the other cancers group”, “the value ofROC_AUC for the pancreatic cancer group and the lung cancer group”, “thevalue of ROC_AUC for the pancreatic cancer group and the colorectalcancer group”, and “the average value of the value of ROC_AUC for thepancreatic cancer group and the lung cancer group, the value of ROC_AUCfor the pancreatic cancer group and the colorectal cancer group, and thevalue of ROC_AUC for the pancreatic cancer group and the prostaticcancer group” obtained for the equation are additionally listed.

0.787, 0.856, 0.911, 0.807, 0.794, 0.798, 0.816, (−0.4061)+(0.0399)Ser+(−0.2141)Met+(0.1298)Ile+(−0.0658)Leu+(0.0402)Phe+(−0.0539)Trp;0.845, 0.887, 0.907, 0.802, 0.793, 0.768, 0.816, (1.4919)+(0.0330)Ser+(0.0236)Thr+(−0.0587)Val+(−0.3796)Met+(0.1721)Ile+(0.0320)Phe; 0.766, 0.842, 0.907, 0.810, 0.786, 0.825, 0.8 18,(2.7409)+(0.0412)Ser+(−0.0481)His+(0.0105)Thr+(−0.1506)Met+(0.0196)Phe+(−0.0683)Trp; 0.872, 0.909, 0.906, 0.801, 0.796, 0. 747,0.817, (3.3965)+(0.0311)Ser+(0.0246)Thr+(−0.0128)Ala+(−0.0466)Val+(−0.2635)Met+(0.1591)Ile; 0.847, 0.888, 0.906, 0.802, 0. 791,0.769, 0.816,(1.4566)+(0.0427)Ser+(−0.0507)Val+(−0.2852)Met+(0.1486)Ile+(0.0258)Phe+(−0.0079)Trp;0.870, 0.913, 0.906, 0.806, 0.790, 0.766, 0.823,(2.4936)+(0.0432)Ser+(−0.0118)Ala+(0.0462)Tyr+(−0.0485)Val+(−0.2565)Met+(0.1511)Ile;0.840, 0.8 84, 0.906, 0.804, 0.794, 0.774, 0.817,(0.1031)+(0.0419)Ser+(−0.0611)Val+(−0.3616)Met+(0.0157)Lys+(0.1732)Ile+(0.0341)Phe; 0. 837, 0.890,0.905, 0.800, 0.788, 0.766, 0.814, (1.1161)+(0.0402)Ser+(0.0132)Arg+(−0.0550)Val+(−0.3329)Met+(0.1633)Ile+(0.028 0)Phe; 0.859,0.890, 0.905, 0.800, 0.783, 0.774, 0.816, (2.8315)+(0.0312)Ser+(0.0223)Thr+(−0.0416)Cit+(−0.0522)Val+(−0.3341)Met+(0.1697)Ile; 0.840, 0.887, 0.904, 0.798, 0.786, 0.765, 0.813, (2.5575)+(0.0314)Ser+(0.0204)Thr+(−0.0510)Val+(−0.3475)Met+(0.1657)Ile+(−0.0106)Trp; 0.871, 0.909, 0.904, 0.809, 0.804, 0.758, 0. 824,(2.5705)+(0.0423)Ser+(−0.0115)Ala+(−0.0427)Val+(−0.1878)Met+(0.1360)Ile+(0.0134)Phe; 0.769, 0.845, 0.904, 0.837, 0.833, 0.839,0.839,(3.9929)+(0.0400)Ser+(0.0086)Thr+(−0.0166)Val+(−0.1972)Met+(0.0304)Phe+(−0.0775)Trp;0.757, 0.832, 0.903, 0.8 46, 0.848, 0.850, 0.843,(0.6788)+(0.0326)Ser+(0.0074)Gln+(−0.2 186)Met+(0.0155)Phe+(−0.1029)Trp;0.768, 0.840, 0.903, 0.797, 0. 769, 0.813, 0.807,(0.1065)+(0.0395)Ser+(0.0074)Thr+(−0.2230)Met+(0.0523)Ile+(0.0032)Phe+(−0.0885)Trp; 0.783, 0.851, 0.903, 0. 839,0.834, 0.840, 0.842, (0.7685)+(0.0313)Ser+(0.0107)Gln+(−0.0649)His+(−0.1807)Met+(0.0214)Phe+(−0.0676)Trp; 0.865, 0.912, 0.902,0.802, 0.793, 0.753, 0.819, (2.8640)+(0.0372)Ser+(−0.0135)Ala+(0.0205)Arg+(−0.0437)Val+(−0.2293)Met+(0.1532)Ile; 0.7 64, 0.844,0.902, 0.797, 0.769, 0.809, 0.807, (0.2468)+(0.0393)Ser+(0.0081)Thr+(−0.2243)Met+(−0.0048)Orn+(0.0562)Ile+(−0.087 5)Trp; 0.753,0.826, 0.902, 0.826, 0.816, 0.838, 0.827, (2.3570)+(0.0391)Ser+(0.0053)Thr+(−0.1808)Met+(0.0138)Phe+(−0.0941)Trp; 0.849,0.893, 0.902, 0.798, 0.774, 0.778, 0.815,(1.4618)+(0.0434)Ser+(0.0469)Tyr+(−0.0595)Val+(−0.3666)Met+(0.1679)Ile+(0.0143)Phe; 0.845, 0.888, 0.902, 0.818, 0.821, 0.776, 0.828,(0.1275)+(0.0321)Ser+(0.0069)Gln+(−0.0548)Val+(−0.3477)Met+(0.1541)Ile+(0.0292)Phe; 0.750, 0.829, 0.902, 0.829, 0.820, 0.841, 0.830, (2.7046)+(0.0394)Ser+(−0.0334)Asn+(0.0075)Thr+(−0.1510)Met+(0.0156)Phe+(−0.0941)Trp; 0.849, 0.885, 0.901, 0.799, 0.788, 0.765, 0. 813,(1.3699)+(0.0422)Ser+(−0.0521)Val+(−0.2912)Met+(0.1519)Ile+(0.0255)Phe;0.845, 0.894, 0.901, 0.791, 0.772, 0.759, 0.808,(3.2528)+(0.0397)Ser+(−0.0098)Gly+(0.0290)Thr+(−0.0550)Val+(−0.3919)Met+(0.1778)Ile;0.845, 0.888, 0.901, 0.797, 0.785, 0.76 4, 0.812,(1.4189)+(0.0428)Ser+(−0.0176)Asn+(−0.0520)Val+(−0.2679)Met+(0.1528)Ile+(0.0258)Phe; 0.778, 0.846, 0.901, 0.784, 0. 746,0.800, 0.797, (1.0109)+(0.0400)Ser+(−0.0431)His+(0.0099)Ihr+(−0.1847)Met+(0.0516)Ile+(−0.0627)Trp; 0.776, 0.840, 0.901, 0.796,0.767, 0.810, 0.806,(0.2150)+(0.0392)Ser+(0.0071)Thr+(−0.2212)Met+(0.0532)Ile+(−0.0873)Trp;0.766, 0.844, 0.901, 0.813, 0.795, 0.819, 0.819,(0.8719)+(0.0382)Ser+(0.0063)Thr+(−0.0121)Pro+(−0.1778)Met+(0.0598)Ile+(−0.0914)Trp; 0.755, 0.841, 0.9 01,0.796, 0.768, 0.809, 0.806, (0.2359)+(0.0392)Ser+(0.0070)Thr+(−0.0015)Tyr+(−0.2193)Met+(0.0533)Ile+(−0.0869)Trp; 0.842, 0. 885,0.900, 0.799, 0.788, 0.765, 0.813, (1.3987)+(0.0418)Ser+(−0.0522)Val+(−0.2913)Met+(0.0033)Orn+(0.1505)Ile+(0.0246)Phe; 0. 840,0.885, 0.900, 0.803, 0.791, 0.774, 0.817, (1.5211)+(0.0390)Ser+(−0.0520)Val+(−0.3244)Met+(0.0134)Lys+(0.1634)Ile+(−0.014 6)Trp;0.838, 0.888, 0.900, 0.799, 0.784, 0.768, 0.814, (1.7262)+(0.0473)Ser+(−0.0041)Gly+(−0.0517)Val+(−0.2911)Met+(0.1510)Ile+(0.0239)Phe; 0.765, 0.836, 0.900, 0.798, 0.773, 0.812, 0.807, (0.0541)+(0.0418)Ser+(−0.2012)Met+(0.0007)Lys+(0.0512)Ile+(0.0015)Phe+(−0.0851)Trp; 0.755, 0.836, 0.900, 0.798, 0.770, 0.814, 0.8 07,(−0.0500)+(0.0412)Ser+(0.0061)Arg+(−0.2132)Met+(0.0536)Ile+(0.0022)Phe+(−0.0885)Trp; 0.852, 0.887, 0.900, 0.803, 0.791, 0. 774,0.817,(1.7457)+(0.0427)Ser+(−0.0341)Cit+(−0.0509)Val+(−0.2679)Met+(0.1506)Ile+(0.0246)Phe;0.768, 0.839, 0.900, 0.837, 0.836, 0.838, 0.837,(3.7251)+(0.0418)Ser+(−0.0166)Val+(−0.1762)Met+(0.0031)Lys+(0.0287)Phe+(−0.0760)Trp; 0.765, 0.841, 0.90 0, 0.796,0.768, 0.809, 0.806,(0.3181)+(0.0390)Ser+(0.0078)Thr+(−0.2195)Met+(−0.0013)Lys+(0.0529)Ile+(−0.0861)Trp;0.753, 0. 837, 0.900, 0.798, 0.773, 0.811, 0.807,(0.1262)+(0.0418)Ser+(−0.0031)Tyr+(−0.1953)Met+(0.0511)Ile+(0.0022)Phe+(−0.0836)Trp; 0.767,0.849, 0.900, 0.815, 0.800, 0.817, 0.822,(0.7019)+(0.0407)Ser+(−0.0123)Pro+(−0.1573)Met+(0.0573)Ile+(0.0038)Phe+(−0.0896)Trp; 0.783, 0.846, 0.899, 0.785, 0.748, 0.803, 0.799,(0.7119)+(0.0440)Ser+(−0.0418)His+(−0.1561)Met+(0.0480)Ile+(0.0049)Phe+(−0.0595)Trp; 0.832, 0.891, 0.899, 0.796, 0.784, 0.759, 0.811,(1.8597)+(0.0323)Ser+(0.0144)Thr+(−0.0557)Val+(−0.3670)Met+(0.0086)Lys+(0.1750)Ile;0.853, 0.894, 0.899, 0.799, 0.779, 0.773, 0.815,(2.5079)+(0.0358)Ser+(−0.0597)Cit+(0.0250)Arg+(−0.0515)Val+(−0.3189)Met+(0.1728)Ile; 0.763, 0.836, 0.899, 0.808, 0.78 3,0.828, 0.816, (2.3381)+(0.0437)Ser+(−0.0492)His+(−0.1301)Met+(0.0054)Lys+(0.0179)Phe+(−0.0679)Trp; 0.753, 0.838, 0.899, 0. 797,0.770, 0.812, 0.807, (0.0362)+(0.0413)Ser+(0.0071)Arg+(−0.2149)Met+(−0.0048)Orn+(0.0575)Ile+(−0.0880)Trp; 0.831, 0.888, 0.899,0.793, 0.780, 0.757, 0.808,(2.3644)+(0.0309)Ser+(0.0180)Thr+(0.0035)Arg+(−0.0531)Val+(−0.3565)Met+(0.1710)Ile;0.853, 0.892, 0.899, 0.796, 0.780, 0.764, 0.812,(2.5496)+(0.0324)Ser+(0.0274)Thr+(−0.0707)Val+(−0.4062)Met+(0.1451)Ile+(0.0461)Leu; 0.851,0.893, 0.899, 0.797, 0.770, 0.782, 0.815,(1.9332)+(0.0425)Ser+(0.0529)Tyr+(−0.0570)Val+(−0.3650)Met+(0.1672)Ile+(−0.0077)Trp; 0.841, 0.887, 0.899, 0.798, 0.786, 0.764, 0.812,(1.5611)+(0.0426)Ser+(−0.0554)Val+(−0.2950)Met+(0.1435)Ile+(0.0122)Leu+(0.0198)Phe; 0.772, 0.836, 0.899, 0.797, 0.771, 0.811, 0.806, (0.1129)+(0.0416)Ser+(−0.2006)Met+(0.0006)Lys+(0.0516)Ile+(−0. 0846)Trp;0.763, 0.837, 0.899, 0.797, 0.769, 0.812, 0.806, (0.0333)+(0.0410)Ser+(0.0059)Arg+(−0.2123)Met+(0.0542)Ile+(−0.0877)Trp; 0.754,0.839, 0.899, 0.798, 0.770, 0.813, 0.807, (0.0984)+(0.0410)Ser+(0.0065)Arg+(−0.2105)Met+(−0.0010)Lys+(0.0542)Ile+(−0.0868)Trp;0.792, 0.851, 0.899, 0.803, 0.767, 0.826, 0.814, (0.8107)+(0.0383)Ser+(0.0108)Thr+(−0.0446)Cit+(−0.2057)Met+(0.0551)Ile+(−0.0874)Trp; 0.833, 0.882, 0.899, 0.820, 0.798, 0.815, 0. 832,(4.9562)+(0.0414)Ser+(0.0278)Thr+(−0.0638)Val+(−0.3446)Met+(0.0994)Leu+(−0.0711)Trp;0.825, 0.886, 0.899, 0.799, 0.785, 0.770, 0.814,(2.1351)+(0.0379)Ser+(0.0123)Arg+(−0.0482)Val+(−0.3089)Met+(0.1579)Ile+(−0.0124)Trp;0.782, 0.857, 0.899, 0.7 95, 0.771, 0.795, 0.807,(0.5033)+(0.0376)Ser+(0.0252)Tyr+(−0.2367)Met+(0.1213)Ile+(−0.0531)Leu+(−0.0562)Trp; 0.766, 0.838, 0. 899,0.800, 0.775, 0.812, 0.808, (0.1040)+(0.0421)Ser+(−0.1990)Met+(−0.0026)Orn+(0.0523)Ile+(0.0020)Phe+(−0.0842)Trp; 0.842, 0.896,0.899, 0.811, 0.813, 0.759, 0.823,(2.2023)+(0.0398)Ser+(−0.0153)Pro+(−0.0542)Val+(−0.2462)Met+(0.1642)Ile+(0.0285)Phe; 0.838, 0.886, 0.898, 0.793, 0.780, 0.758, 0.808, (2.4345)+(0.0307)Ser+(0.0196)Thr+(−0.0529)Val+(−0.3523)Met+(0.0013)Orn+(0. 1689)Ile;0.779, 0.836, 0.898, 0.799, 0.773, 0.812, 0.807, (0.1169)+(0.0418)Ser+(−0.1989)Met+(0.0510)Ile+(0.0013)Phe+(−0.0842)Trp; 0.760,0.838, 0.898, 0.809, 0.786, 0.825, 0.817, (2.6855)+(0.0431)Ser+(−0.0468)His+(0.0046)Arg+(−0.1275)Met+(0.0172)Phe+(−0.0652)Trp;0.755, 0.836, 0.898, 0.797, 0.772, 0.810, 0.806, (0.1422)+(0.0416)Ser+(−0.0019)Tyr+(−0.1981)Met+(0.0006)Lys+(0.0518)Ile+(−0.0840)Trp; 0.847, 0.887, 0.898, 0.793, 0.781, 0.757, 0. 808,(2.4351)+(0.0308)Ser+(0.0198)Thr+(−0.0529)Val+(−0.3530)Met+(0.1697)Ile;0.839, 0.883, 0.898, 0.802, 0.795, 0.767, 0.815,(1.3018)+(0.0415)Ser+(0.0135)His+(−0.0562)Val+(−0.3154)Met+(0.1609)Ile+(0.0259)Phe;0.830, 0.886, 0.898, 0.795, 0.783, 0.761, 0.810,(1.4446)+(0.0374)Ser+(0.0048)Arg+(−0.0545)Val+(−0.3403)Met+(0.0111)Lys+(0.1701)Ile; 0.769, 0.837, 0.898, 0.798, 0.773, 0.810,0.807,(0.1887)+(0.0416)Ser+(−0.0020)Tyr+(−0.1962)Met+(0.0517)Ile+(−0.0832)Trp;0.761, 0.826, 0.898, 0.826, 0.819, 0.83 5, 0.827,(2.3360)+(0.0405)Ser+(−0.1633)Met+(0.0123)Phe+(−0.0 909)Trp; 0.753,0.838, 0.898, 0.796, 0.768, 0.811, 0.805,(0.1271)+(0.0394)Ser+(0.0055)Thr+(0.0036)Arg+(−0.2243)Met+(0.0544)Ile+(−0.0889)Trp; 0.770, 0.845, 0.898, 0.783, 0.743, 0.804, 0.797, (0.7499)+(0.0421)Ser+(−0.0450)His+(0.0103)Arg+(−0.1751)Met+(0.0545)Ile+(−0.0634)Trp; 0.872, 0.909, 0.898, 0.804, 0.798, 0.752, 0. 820,(1.9444)+(0.0409)Ser+(−0.0141)Ala+(−0.0498)Val+(−0.2446)Met+(0.0197)Lys+(0.1613)Ile; 0.787, 0.851, 0.898, 0.803, 0.765, 0.830,0.815,(0.6431)+(0.0391)Ser+(−0.0590)Cit+(0.0211)Arg+(−0.2103)Met+(0.0617)Ile+(−0.0960)Trp;0.783, 0.851, 0.898, 0.7 96, 0.779, 0.788, 0.806,(0.7806)+(0.0359)Ser+(0.0029)Thr+(−0.2110)Met+(0.1124)Ile+(−0.0447)Leu+(−0.0553)Trp; 0.751, 0.826, 0. 898,0.826, 0.820, 0.836, 0.827, (2.3934)+(0.0405)Ser+(−0.1612)Met+(−0.0008)Lys+(0.0120)Phe+(−0.0899)Trp; 0.767, 0.837, 0.898, 0.793,0.761, 0.813, 0.804,(0.7266)+(0.0451)Ser+(−0.0064)Gly+(0.0122)Thr+(−0.2369)Met+(0.0535)Ile+(−0.0895)Trp;0.755, 0.8 50, 0.898, 0.814, 0.797, 0.816, 0.821,(0.7671)+(0.0404)Ser+(−0.0125)Pro+(0.0052)Tyr+(−0.1625)Met+(0.0579)Ile+(−0.0898)Trp; 0. 771,0.843, 0.898, 0.838, 0.837, 0.835, 0.838, (4.0479)+(0.0425)Ser+(−0.0215)Asn+(−0.0157)Val+(−0.1429)Met+(0.0277)Phe+(−0.07 15)Trp;0.787, 0.838, 0.898, 0.798, 0.773, 0.811, 0.807,(0.1611)+(0.0417)Ser+(−0.1986)Met+(0.0514)Ile+(−0.0838)Trp; 0.765, 0.840, 0.898, 0.819, 0.808, 0.822, 0.823, (−1.3681)+(0.0342)Ser+(0.0072)Gln+(−0.2506)Met+(0.0486)Ile+(0.0053)Phe+(−0.0963)Trp; 0. 762,0.838, 0.898, 0.798, 0.773, 0.811, 0.807, (0.1189)+(0.0419)Ser+(−0.2007)Met+(−0.0023)Orn+(0.0007)Lys+(0.0530)Ile+(−0.084 4)Trp;0.762, 0.845, 0.898, 0.811, 0.794, 0.815, 0.818, (0.7179)+(0.0391)Ser+(0.0082)Arg+(−0.0125)Pro+(−0.1741)Met+(0.0620)Ile+(−0.0939)Trp;0.846, 0.894, 0.898, 0.794, 0.764, 0.778, 0.812, (0.8674)+(0.0411)Ser+(0.0658)Tyr+(−0.0692)Val+(−0.4644)Met+(0.0167)Lys+(0.1956)Ile; 0.772, 0.846, 0.898, 0.783, 0.741, 0.807, 0.7 98,(0.7633)+(0.0441)Ser+(−0.0443)His+(0.0124)Tyr+(−0.1685)Met+(0.0480)Ile+(−0.0602)Trp; 0.774, 0.846, 0.898, 0.819, 0.810, 0. 816,0.824,(3.7367)+(0.0442)Ser+(−0.0356)His+(−0.0123)Val+(−0.1301)Met+(0.0268)Phe+(−0.0542)Trp;0.751, 0.826, 0.897, 0.825, 0.818, 0.835, 0.826,(2.2889)+(0.0405)Ser+(−0.1639)Met+(0.001 1)Leu+(0.0113)Phe+(−0.0913)Trp;0.766, 0.836, 0.897, 0.807, 0.78 6, 0.821, 0.814,(2.6417)+(0.0433)Ser+(0.0083)Asn+(−0.0464)His+(−0.1277)Met+(0.0158)Phe+(−0.0625)Trp; 0.761, 0.826, 0.897, 0. 829,0.823, 0.838, 0.829, (2.6077)+(0.0411)Ser+(−0.0261)Asn+(−0.1345)Met+(0.0131)Phe+(−0.0898)Trp; 0.832, 0.892, 0.897, 0.801, 0. 797,0.756, 0.815, (3.3038)+(0.0284)Ser+(0.0196)Thr+(−0.0147)Pro+(−0.0547)Val+(−0.3097)Met+(0.1831)Ile; 0.782, 0.850, 0.897, 0.796,0.779, 0.789, 0.806,(0.5053)+(0.0367)Ser+(−0.2127)Met+(0.0039)Lys+(0.1158)Ile+(−0.0473)Leu+(−0.0569)Trp;0.776, 0.8 44, 0.897, 0.782, 0.744, 0.799, 0.796,(0.8779)+(0.0432)Ser+(−0.0419)His+(−0.1553)Met+(0.0024)Orn+(0.0482)Ile+(−0.0582)Trp; 0. 770,0.837, 0.897, 0.809, 0.788, 0.823, 0.816, (2.7102)+(0.0435)Ser+(−0.0451)His+(−0.1198)Met+(0.0160)Phe+(−0.0629)Trp; 0.852, 0.889,0.897, 0.801, 0.786, 0.774, 0.816,(1.7797)+(0.0393)Ser+(−0.0363)Cit+(−0.0537)Val+(−0.3102)Met+(0.0125)Lys+(0.1682)Ile; 0.766, 0.842, 0.897, 0.829, 0.809, 0.849, 0.833, (2.8945)+(0.0394)Ser+(0.0095)Thr+(−0.0428)Cit+(−0.1675)Met+(0.0161)Phe+(−0. 0970)Trp;0.757, 0.838, 0.897, 0.798, 0.773, 0.810, 0.807, (0.1935)+(0.0418)Ser+(−0.0016)Tyr+(−0.1966)Met+(−0.0021)Orn+(0.0528)Ile+(−0.0832)Trp; 0.769, 0.842, 0.897, 0.796, 0.770, 0.806, 0.80 6,(0.5416)+(0.0393)Ser+(−0.0291)Asn+(0.0084)Thr+(−0.1912)Met+(0.0538)Ile+(−0.0869)Trp; 0.871, 0.910, 0.897, 0.808, 0.801, 0. 761,0.824,(3.3274)+(0.0409)Ser+(−0.0117)Ala+(−0.0293)Cit+(−0.0398)Val+(−0.1603)Met+(0.1354)Ile;0.859, 0.895, 0.897, 0.795, 0.765, 0.780, 0.814,(2.3171)+(0.0426)Ser+(−0.0369)Cit+(0.0544)Tyr+(−0.0577)Val+(−0.3487)Met+(0.1682)Ile; 0.767, 0.848, 0.8 97,0.812, 0.798, 0.813, 0.819, (0.8303)+(0.0401)Ser+(−0.0123)Pro+(−0.1569)Met+(0.0005)Orn+(0.0582)Ile+(−0.0883)Trp; 0.852, 0. 888,0.897, 0.791, 0.766, 0.770, 0.808, (2.2714)+(0.0316)Ser+(0.0231)Thr+(0.0575)Tyr+(−0.0649)Val+(−0.4616)Met+(0.1911)Ile; 0. 848,0.884, 0.897, 0.795, 0.783, 0.762, 0.810, (1.4167)+(0.0382)Ser+(−0.0543)Val+(−0.3324)Met+(0.0125)Lys+(0.1682)Ile; 0.870, 0. 906,0.897, 0.803, 0.796, 0.754, 0.819, (3.0382)+(0.0402)Ser+(−0.0120)Ala+(−0.0407)Val+(−0.1802)Met+(0.0043)Orn+(0.1345)Ile; 0.775,0.848, 0.897, 0.812, 0.797, 0.812, 0.819,(0.8305)+(0.0402)Ser+(−0.0122)Pro+(−0.1568)Met+(0.0584)Ile+(−0.0883)Trp;0.76 7, 0.849, 0.897, 0.813, 0.800, 0.810, 0.820,(0.9285)+(0.0402)Ser+(−0.0123)Pro+(−0.1530)Met+(−0.0012)Lys+(0.0582)Ile+(−0.0868)Trp

List (2) of Linear Discriminants Searched in Example 7

The linear discriminants searched in Example 7 above are listed below.Before each equation, “the value of ROC_AUC for the pancreatic cancergroup and the prostatic cancer group with validation”, “the value ofROC_AUC for the pancreatic cancer group and the prostatic cancer groupwithout validation”, “the value of ROC_AUC for the pancreatic cancergroup and the healthy group”, “the value of ROC_AUC for the pancreaticcancer group and the other cancers group”, “the value of ROC_AUC for thepancreatic cancer group and the lung cancer group”, “the value ofROC_AUC for the pancreatic cancer group and the colorectal cancergroup”, and “the average value of the value of ROC_AUC for thepancreatic cancer group and the lung cancer group, the value of ROC_AUCfor the pancreatic cancer group and the colorectal cancer group, and thevalue of ROC_AUC for the pancreatic cancer group and the prostaticcancer group” obtained for the equation are additionally listed.

0.859, 0.885, 0.925, 0.819, 0.809, 0.795, 0.830, (1.6394)+(0.0387)Ser+(−0.0455)Val+(−0.2545)Met+(0.1283)Ile+(0.0546)Phe+(−0.0299)Trp;0.819, 0.855, 0.925, 0.822, 0.810, 0.820, 0.829, (0.8073)+(0.0364)Ser+(−0.2030)Met+(0.1178)Ile+(−0.0647)Leu+(0.0578)Phe+(−0.0648)Trp; 0.861, 0.892, 0.917, 0.807, 0.788, 0.786, 0. 822,(1.2830)+(0.0364)Ser+(0.0328)Tyr+(−0.0547)Val+(−0.3122)Met+(0.1451)Ile+(0.0444)Phe;0.855, 0.884, 0.917, 0.805, 0.796, 0. 772, 0.817,(1.1869)+(0.0330)Ser+(0.0086)Thr+(−0.0523)Val+(−0.2940)Met+(0.1427)Ile+(0.0555)Phe; 0.847, 0.881, 0.916, 0.804, 0. 796,0.772, 0.816, (1.1400)+(0.0359)Ser+(0.0037)Arg+(−0.0511)Val+(−0.2757)Met+(0.1404)Ile+(0.0531)Phe; 0.852, 0.882, 0.915, 0. 816,0.818, 0.776, 0.825, (0.5185)+(0.0298)Ser+(0.0040)Gln+(−0.0515)Val+(−0.2886)Met+(0.1379)Ile+(0.0511)Phe; 0.855, 0.885, 0. 914,0.801, 0.787, 0.774, 0.815, (1.4582)+(0.0381)Ser+(−0.0133)His+(−0.0470)Val+(−0.2554)Met+(0.1313)Ile+(0.0525)Phe; 0.781, 0.829,0.914, 0.854, 0.857, 0.865, 0.850, (1.6910)+(0.0271)Ser+(0.0058)Gln+(−0.1824)Met+(−0.0027)Leu+(0.0278)Phe+(−0.0977)Tr p; 0.863,0.888, 0.913, 0.802, 0.792, 0.768, 0.816, (1.6900)+(0.0388)Ser+(−0.0430)Asn+(−0.0504)Val+(−0.2279)Met+(0.1409)Ile+(0. 0530)Phe;0.851, 0.882, 0.913, 0.805, 0.798, 0.772, 0.817, (0.8294)+(0.0361)Ser+(−0.0528)Val+(−0.2835)Met+(0.0048)Lys+(0.1426)Ile+(0.0546)Phe;0.779, 0.823, 0.913, 0.835, 0.826, 0.854, 0.835,(2.6420)+(0.0366)Ser+(0.0049)Tyr+(−0.1614)Met+(0.0250)Phe+(−0.0903)Trp;0.856, 0.879, 0.913, 0.802, 0.794, 0.771, 0.815, (1.2512)+(0.0368)Ser+(−0.0505)Val+(−0.2680)Met+(0.1384)Ile+(0.0 518)Phe;0.776, 0.824, 0.913, 0.834, 0.827, 0.849, 0.833,(2.6819)+(0.0357)Ser+(−0.1556)Met+(0.0061)Orn+(−0.0028)Leu+(0.0262)Phe+(−0.0876)Trp; 0.862, 0.887, 0.913, 0.806, 0.794, 0.777, 0.819,(1.5875)+(0.0375)Ser+(−0.0335)Cit+(−0.0493)Val+(−0.2533)Met+(0.1395)Ile+(0.0515)Phe; 0.793, 0.821, 0.912, 0.834, 0.828, 0.85 0,0.833, (2.6509)+(0.0366)Ser+(−0.1555)Met+(0.0265)Phe+(−0.0 891)Trp;0.782, 0.823, 0.912, 0.831, 0.825, 0.845, 0.831,(2.5358)+(0.0361)Ser+(−0.1575)Met+(0.0056)Orn+(0.0244)Phe+(−0.0884)T rp;0.773, 0.822, 0.912, 0.837, 0.829, 0.855, 0.836, (2.7656)+(0.0363)Ser+(0.0057)Tyr+(−0.1606)Met+(−0.0022)Leu+(0.0264)Phe+(−0.0899)Trp;0.815, 0.853, 0.912, 0.846, 0.838, 0.854, 0.848, (1.8742)+(0.0274)Ser+(0.0093)Gln+(−0.0669)His+(−0.1684)Met+(0.0374)Phe+(−0.0669)Trp; 0.805, 0.845, 0.912, 0.820, 0.796, 0.837, 0.82 6,(3.4001)+(0.0382)Ser+(−0.0523)His+(0.0061)Thr+(−0.1457)Met+(0.0379)Phe+(−0.0630)Trp; 0.791, 0.829, 0.912, 0.852, 0.854, 0. 861,0.848, (1.5432)+(0.0275)Ser+(0.0058)Gln+(−0.1842)Met+(0.0258)Phe+(−0.0984)Trp; 0.818, 0.852, 0.912, 0.798, 0.759, 0.820, 0. 810,(1.4300)+(0.0432)Ser+(−0.0477)His+(−0.1657)Met+(0.0415)Ile+(0.0293)Phe+(−0.0605)Trp;0.779, 0.829, 0.912, 0.853, 0.856, 0.863, 0.849,(1.5550)+(0.0274)Ser+(0.0059)Gln+(−0.1843)Met+(−0.0018)Orn+(0.0265)Phe+(−0.0988)Trp;0.784, 0.823, 0.912, 0.8 36, 0.830, 0.851, 0.835,(2.7434)+(0.0364)Ser+(−0.1543)Met+(−0.0016)Leu+(0.0277)Phe+(−0.0886)Trp; 0.849, 0.879, 0.912, 0.802, 0. 793,0.771, 0.814,(1.2798)+(0.0363)Ser+(−0.0506)Val+(−0.2678)Met+(0.0040)Orn+(0.1367)Ile+(0.0509)Phe;0.776, 0.829, 0.912, 0. 851, 0.853, 0.861, 0.848,(1.5439)+(0.0275)Ser+(0.0058)Gln+(0.0011)Tyr+(−0.1854)Met+(0.0255)Phe+(−0.0987)Trp; 0.796, 0.841, 0. 911,0.864, 0.867, 0.873, 0.860, (1.9967)+(0.0277)Ser+(−0.0557)Asn+(0.0072)Gln+(−0.1368)Met+(0.0276)Phe+(−0.1002)Trp; 0.792, 0.834,0.911, 0.811, 0.789, 0.830, 0.818,(0.6202)+(0.0402)Ser+(−0.1911)Met+(−0.0054)Orn+(0.0461)Ile+(0.0222)Phe+(−0.0873)Trp; 0.853, 0.882, 0.911, 0.802, 0.792, 0.771, 0.815, (1.2814)+(0.0371)Ser+(−0.0525)Val+(−0.2695)Met+(0.1342)Ile+(0.0070)Leu+(0. 0494)Phe;0.770, 0.822, 0.911, 0.832, 0.824, 0.850, 0.832, (2.5316)+(0.0361)Ser+(0.0043)Tyr+(−0.1624)Met+(0.0054)Orn+(0.0231)Phe+(−0.0895)Trp; 0.866, 0.893, 0.911, 0.815, 0.822, 0.760, 0.825,(2.0101)+(0.0383)Ser+(−0.0194)Pro+(−0.0555)Val+(−0.2381)Met+(0.1692)Ile+(0.0552)Phe; 0.771, 0.821, 0.911, 0.835, 0.827, 0.85 3,0.834, (2.6482)+(0.0373)Ser+(−0.0017)Thr+(0.0052)Tyr+(−0.1572)Met+(0.0243)Phe+(−0.0895)Trp; 0.803, 0.842, 0.911, 0.852, 0. 853,0.857, 0.851,(4.4894)+(0.0357)Ser+(−0.0265)Asn+(−0.0138)Val+(−0.1282)Met+(0.0413)Phe+(−0.0729)Trp;0.776, 0.822, 0.910, 0.835, 0.830, 0.850, 0.834,(2.7554)+(0.0371)Ser+(−0.0016)Thr+(−0.1500)Met+(−0.0017)Leu+(0.0272)Phe+(−0.0878)Trp;0.797, 0. 840, 0.910, 0.827, 0.814, 0.836, 0.830,(−0.1760)+(0.0313)Ser+(0.0051)Gln+(−0.2131)Met+(0.0400)Ile+(0.0204)Phe+(−0.0952)Trp; 0.791,0.838, 0.910, 0.848, 0.849, 0.852, 0.846,(4.1952)+(0.0342)Ser+(0.0009)Thr+(−0.0142)Val+(−0.1563)Met+(0.0411)Phe+(−0.0730)Trp; 0.786, 0.831, 0.910, 0.809, 0.786, 0.829, 0.815,(0.6370)+(0.0395)Ser+(0.0024)Tyr+(−0.1934)Met+(0.0432)Ile+(0.0198)Phe+(−0.0875)Trp; 0.855, 0.887, 0.910, 0.804, 0.789, 0.779, 0.818, (1.6257)+(0.0420)Ser+(−0.0043)Gly+(−0.0499)Val+(−0.2682)Met+(0.1382)Ile+(0.0491)Phe; 0.802, 0.838, 0.909, 0.847, 0.849, 0.851, 0. 846,(4.1917)+(0.0346)Ser+(−0.0142)Val+(−0.1540)Met+(0.0408)Phe+(−0.0727)Trp;0.797, 0.845, 0.909, 0.851, 0.846, 0.862, 0.851,(4.2901)+(0.0344)Ser+(0.0172)Tyr+(−0.0153)Val+(−0.1740)Met+(0.0367)Phe+(−0.0756)Trp;0.791, 0.832, 0.909, 0.810, 0.788, 0.82 7, 0.816,(0.6399)+(0.0397)Ser+(−0.0004)Thr+(−0.1897)Met+(0.0433)Ile+(0.0204)Phe+(−0.0867)Trp; 0.783, 0.821, 0.909, 0.833, 0. 828,0.848, 0.832,(2.6569)+(0.0373)Ser+(−0.0016)Thr+(−0.1515)Met+(0.0260)Phe+(−0.0883)Trp;0.798, 0.832, 0.909, 0.810, 0.788, 0.827, 0.816,(0.6369)+(0.0395)Ser+(−0.1907)Met+(0.0433)Ile+(0.0205)Phe+(−0.0869)Trp;0.788, 0.830, 0.908, 0.810, 0.789, 0.82 7, 0.815,(0.6970)+(0.0400)Ser+(−0.0021)Arg+(−0.1869)Met+(0.0430)Ile+(0.0199)Phe+(−0.0857)Trp; 0.799, 0.841, 0.908, 0.814, 0. 787,0.834, 0.821,(3.1997)+(0.0398)Ser+(−0.0514)His+(−0.1338)Met+(0.0102)Orn+(0.0317)Phe+(−0.0594)Trp;0.793, 0.835, 0.908, 0.808, 0.787, 0.823, 0.815,(1.1478)+(0.0401)Ser+(−0.1769)Met+(−0.0056)Lys+(0.0437)Ile+(0.0187)Phe+(−0.0814)Trp;0.788, 0.8 28, 0.908, 0.838, 0.831, 0.853, 0.837,(3.0682)+(0.0378)Ser+(−0.0326)Asn+(0.0005)Thr+(−0.1252)Met+(0.0278)Phe+(−0.0890)Trp; 0. 802,0.845, 0.908, 0.830, 0.819, 0.835, 0.833, (4.3232)+(0.0385)Ser+(−0.0413)His+(−0.0098)Val+(−0.1342)Met+(0.0437)Phe+(−0.05 49)Trp;0.800, 0.844, 0.908, 0.819, 0.798, 0.835, 0.826,(3.3748)+(0.0404)Ser+(−0.0495)His+(0.0004)Arg+(−0.1319)Met+(0.0355)Phe+(−0.0618)Trp; 0.781, 0.827, 0.908, 0.832, 0.827, 0.843, 0.832,(3.1718)+(0.0365)Ser+(0.0015)Thr+(−0.1454)Met+(−0.0056)Lys+(0.0252)Phe+(−0.0843)Trp;0.785, 0.828, 0.908, 0.836, 0.828, 0.85 2, 0.836,(3.0792)+(0.0383)Ser+(−0.0302)Asn+(−0.0020)Arg+(−0.1229)Met+(0.0269)Phe+(−0.0877)Trp; 0.782, 0.829, 0.908, 0.837, 0. 829,0.853, 0.837, (3.0578)+(0.0380)Ser+(−0.0324)Asn+(0.0054)Tyr+(−0.1303)Met+(0.0260)Phe+(−0.0901)Trp; 0.769, 0.819, 0.908, 0.830,0.824, 0.843, 0.829,(2.5234)+(0.0374)Ser+(−0.0033)Thr+(−0.1495)Met+(0.0068)Orn+(0.0228)Phe+(−0.0867)Trp;0.810, 0.8 44, 0.908, 0.819, 0.797, 0.836, 0.826,(3.3810)+(0.0405)Ser+(−0.0494)His+(−0.1313)Met+(0.0353)Phe+(−0.0617)Trp; 0.806, 0.844, 0. 908,0.819, 0.797, 0.836, 0.826, (3.3834)+(0.0405)Ser+(−0.0002)Asn+(−0.0494)His+(−0.1311)Met+(0.0353)Phe+(−0.0617)Trp; 0.842, 0.873,0.908, 0.816, 0.816, 0.784, 0.824,(4.1550)+(0.0238)Thr+(−0.0499)Val+(−0.2634)Met+(0.1320)Ile+(0.0496)Phe+(−0.0243)Trp; 0.795, 0.828, 0.908, 0.838, 0.831, 0.853, 0.837, (3.0653)+(0.0380)Ser+(−0.0322)Asn+(−0.1242)Met+(0.0276)Phe+(−0.0888)Trp; 0. 788, 0.827,0.908, 0.838, 0.831, 0.853, 0.837, (3.0623)+(0.0380)Ser+(−0.0322)Asn+(−0.1242)Met+(0.0001)Leu+(0.0276)Phe+(−0.088 8)Trp;0.803, 0.849, 0.908, 0.818, 0.787, 0.843, 0.826, (3.3971)+(0.0408)Ser+(−0.0528)His+(0.0189)Tyr+(−0.1518)Met+(0.0302)Phe+(−0.0645)Trp;0.777, 0.823, 0.907, 0.834, 0.829, 0.849, 0.833, (2.8679)+(0.0374)Ser+(−0.0049)Arg+(−0.1461)Met+(−0.0022)Leu+(0.0265)Phe+(−0.0858)Trp; 0.775, 0.821, 0.907, 0.832, 0.826, 0.848, 0. 832,(2.7471)+(0.0375)Ser+(0.0006)Thr+(−0.0050)Arg+(−0.1491)Met+(0.0251)Phe+(−0.0867)Trp;0.780, 0.821, 0.907, 0.832, 0.826, 0.846, 0.831,(2.7438)+(0.0377)Ser+(−0.0047)Arg+(−0.1479)Met+(0.0250)Phe+(−0.0865)Trp;0.800, 0.845, 0.907, 0.867, 0.878, 0.86 4, 0.862,(3.0948)+(0.0245)Ser+(0.0063)Gln+(−0.0151)Val+(−0.1849)Met+(0.0410)Phe+(−0.0817)Trp; 0.861, 0.888, 0.906, 0.808, 0. 795,0.779, 0.821, (3.3913)+(0.0305)Ser+(0.0041)Thr+(−0.0388)Val+(−0.2230)Met+(0.1218)Ile+(−0.0241)Trp; 0.790, 0.827, 0.906, 0.833,0.827, 0.845, 0.833,(3.1423)+(0.0371)Ser+(−0.1424)Met+(−0.0053)Lys+(0.0248)Phe+(−0.0839)Trp;0.781, 0.827, 0.906, 0.8 33, 0.827, 0.845, 0.833,(3.1421)+(0.0371)Ser+(−0.1424)Met+(−0.0053)Lys+(0.0000)Leu+(0.0248)Phe+(−0.0839)Trp; 0.785, 0.831, 0. 906,0.850, 0.856, 0.853, 0.847, (2.1609)+(0.0273)Ser+(0.0064)Gln+(−0.1677)Met+(−0.0079)Lys+(0.0233)Phe+(−0.0918)Trp; 0.781, 0.824,0.906, 0.833, 0.826, 0.849, 0.833,(2.9560)+(0.0374)Ser+(−0.0372)Asn+(−0.1222)Met+(0.0084)Orn+(0.0246)Phe+(−0.0878)Trp; 0.777, 0.828, 0.906, 0.833, 0.825, 0.847, 0.833, (3.1277)+(0.0371)Ser+(0.0038)Tyr+(−0.1471)Met+(−0.0052)Lys+(0.0237)Phe+(−0. 0850)Trp;0.772, 0.823, 0.906, 0.832, 0.825, 0.848, 0.832, (2.7349)+(0.0377)Ser+(−0.0047)Arg+(0.0049)Tyr+(−0.1538)Met+(0.0235)Phe+(−0.0878)Trp;0.805, 0.845, 0.906, 0.819, 0.798, 0.835, 0.826,(3.4430)+(0.0405)Ser+(−0.0489)His+(−0.1297)Met+(−0.0007)Lys+(0.0350)Phe+(−0.0612)Trp; 0.804, 0.845, 0.906, 0.820, 0.808, 0.8 22,0.825, (1.1919)+(0.0410)Ser+(−0.0151)Pro+(−0.1612)Met+(0.0598)Ile+(0.0208)Phe+(−0.0943)Trp; 0.803, 0.843, 0.906, 0.814, 0. 789,0.832, 0.822,(3.1179)+(0.0413)Ser+(−0.0509)His+(−0.1343)Met+(0.0051)Leu+(0.0318)Phe+(−0.0623)Trp;0.770, 0.819, 0.906, 0.827, 0.821, 0.839, 0.827,(2.6188)+(0.0374)Ser+(−0.0067)Arg+(−0.1474)Met+(0.0080)Orn+(0.0213)Phe+(−0.0845)Trp;0.794, 0.8 39, 0.906, 0.847, 0.848, 0.851, 0.846,(4.3044)+(0.0348)Ser+(−0.0138)Val+(−0.1499)Met+(−0.0017)Lys+(0.0398)Phe+(−0.0715)Trp; 0.800,0.835, 0.906, 0.811, 0.788, 0.828, 0.817,(1.0631)+(0.0415)Ser+(−0.0424)Asn+(−0.1515)Met+(0.0459)Ile+(0.0216)Phe+(−0.0864)Trp; 0.796, 0.841, 0.906, 0.842, 0.840, 0.845, 0.842,(4.1524)+(0.0328)Ser+(−0.0168)Val+(−0.1591)Met+(0.0156)Orn+(0.0374)Phe+(−0.0679)Trp; 0.779, 0.828, 0.905, 0.833, 0.826, 0.844, 0.833,(3.1338)+(0.0375)Ser+(−0.0019)Arg+(−0.1406)Met+(−0.0048)Lys+(0.0244)Phe+(−0.0834)Trp; 0.778, 0.825, 0.905, 0.829, 0.823, 0.8 39,0.829, (3.0497)+(0.0366)Ser+(−0.1434)Met+(0.0071)Orn+(−0.0058)Lys+(0.0219)Phe+(−0.0826)Trp; 0.888, 0.911, 0.905, 0.814, 0. 811,0.763, 0.828,(3.9212)+(0.0380)Ser+(−0.0160)Ala+(−0.0426)Val+(−0.1846)Met+(0.1388)Ile+(0.0358)Phe;0.866, 0.897, 0.905, 0.811, 0.787, 0.796, 0.827,(3.1432)+(0.0334)Ser+(0.0477)Tyr+(−0.0449)Val+(−0.2823)Met+(0.1298)Ile+(−0.0300)Trp;0.784, 0.83 2, 0.904, 0.853, 0.859, 0.858, 0.850,(1.4842)+(0.0295)Ser+(0.0063)Gln+(−0.0064)Thr+(−0.1698)Met+(0.0236)Phe+(−0.0961)Trp; 0. 795, 0.838,0.904, 0.845, 0.844, 0.851, 0.844, (4.4818)+(0.0350)Ser+(−0.0281)Cit+(−0.0131)Val+(−0.1413)Met+(0.0402)Phe+(−0.07 15)Trp;0.786, 0.826, 0.904, 0.836, 0.831, 0.848, 0.835,(3.4140)+(0.0382)Ser+(−0.0284)Asn+(−0.1173)Met+(−0.0043)Lys+(0.0261)Phe+(−0.0847)Trp;0.788, 0.836, 0.904, 0.845, 0.846, 0.849, 0.844,(4.2580)+(0.0354)Ser+(−0.0039)Arg+(−0.0141)Val+(−0.1477)Met+(0.0394)Phe+(−0.0707)Trp; 0.863, 0.888, 0.903, 0.810, 0.794, 0.7 87,0.823, (3.6413)+(0.0330)Ser+(−0.0331)Cit+(−0.0376)Val+(−0.1994)Met+(0.1223)Ile+(−0.0213)Trp; 0.769, 0.822, 0.903, 0.831, 0. 822,0.849, 0.831, (3.0434)+(0.0416)Ser+(−0.0042)Gly+(0.0011)Tyr+(−0.1575)Met+(0.0237)Phe+(−0.0875)Trp; 0.858, 0.887, 0.903, 0.806,0.793, 0.778, 0.819,(3.3252)+(0.0317)Ser+(−0.0392)Val+(−0.2144)Met+(0.0077)Orn+(0.1179)Ile+(−0.0221)Trp;0.794, 0.8 35, 0.903, 0.806, 0.781, 0.824, 0.813,(1.0512)+(0.0454)Ser+(−0.0049)Gly+(−0.1923)Met+(0.0443)Ile+(0.0175)Phe+(−0.0847)Trp; 0. 791,0.837, 0.903, 0.844, 0.841, 0.852, 0.843, (4.4934)+(0.0388)Ser+(−0.0036)Gly+(−0.0138)Val+(−0.1546)Met+(0.0383)Phe+(−0.07 15)Trp;0.786, 0.833, 0.903, 0.852, 0.857, 0.857, 0.849,(1.5600)+(0.0284)Ser+(0.0071)Gln+(−0.0128)Arg+(−0.1697)Met+(0.0216)Phe+(−0.0935)Trp; 0.772, 0.823, 0.903, 0.830, 0.821, 0.848, 0.830,(3.0737)+(0.0412)Ser+(−0.0046)Gly+(0.0019)Thr+(−0.1612)Met+(0.0244)Phe+(−0.0880)Trp;0.783, 0.822, 0.903, 0.831, 0.822, 0.84 9, 0.831,(3.0498)+(0.0416)Ser+(−0.0043)Gly+(−0.1562)Met+(0.0240)Phe+(−0.0873)Trp; 0.792, 0.836, 0.903, 0.836, 0.824, 0.854, 0. 838,(3.0762)+(0.0358)Ser+(−0.0372)Cit+(0.0053)Arg+(−0.1472)Met+(0.0288)Phe+(−0.0888)Trp;0.777, 0.822, 0.903, 0.833, 0.825, 0.849, 0.832,(3.1720)+(0.0414)Ser+(−0.0043)Gly+(−0.1547)Met+(−0.0021)Leu+(0.0255)Phe+(−0.0866)Trp;0.771, 0.821, 0.903, 0.8 30, 0.821, 0.847, 0.830,(3.0605)+(0.0417)Ser+(−0.0040)Gly+(−0.0020)Arg+(−0.1530)Met+(0.0235)Phe+(−0.0863)Trp; 0.785, 0.836, 0.903,0.853, 0.852, 0.863, 0.851, (1.9995)+(0.0342)Ser+(−0.0072)Gly+(0.0070)Gln+(−0.1910)Met+(0.0214)Phe+(−0.0972)Trp; 0.7 80, 0.831,0.903, 0.839, 0.837, 0.846, 0.838, (3.3346)+(0.0361)Ser+(−0.0097)Pro+(−0.1308)Met+(0.0080)Orn+(0.0251)Phe+(−0.093 4)Trp; 0.819,0.858, 0.902, 0.813, 0.790, 0.819, 0.822, (2.2718)+(0.0320)Ser+(0.0294)Tyr+(−0.2078)Met+(0.1025)Ile+(−0.0485)Leu+(−0.0652)Trp;0.855, 0.888, 0.902, 0.807, 0.795, 0.777, 0.820, (3.3430)+(0.0323)Ser+(0.0006)Arg+(−0.0384)Val+(−0.2135)Met+(0.1206)Ile+(−0.0235)Trp; 0.821, 0.851, 0.902, 0.810, 0.796, 0.805, 0. 817,(2.3989)+(0.0319)Ser+(−0.1700)Met+(0.0944)Ile+(−0.0402)Leu+(−0.0594)Trp

List (1) of Logistic Regression Equations Searched in Example 8

The logistic regression equations searched in Example 8 above are listedbelow. Before each equation, “the value of ROC_AUC for the pancreaticcancer group and the breast cancer group with validation”, “the value ofROC_AUC for the pancreatic cancer group and the breast cancer groupwithout validation”, “the value of ROC_AUC for the pancreatic cancergroup and the healthy group”, “the value of ROC_AUC for the pancreaticcancer group and the other cancers group”, “the value of ROC_AUC for thepancreatic cancer group and the lung cancer group”, “the value ofROC_AUC for the pancreatic cancer group and the colorectal cancergroup”, and “the average value of the value of ROC_AUC for thepancreatic cancer group and the lung cancer group, the value of ROC_AUCfor the pancreatic cancer group and the colorectal cancer group, and thevalue of ROC_AUC for the pancreatic cancer group and the breast cancergroup” obtained for the equation are additionally listed.

0.945, 0.965, 0.856, 0.937, 0.919, 0.922, 0.936,(19.7721)+(−0.1860)Asn+(−0.0214)Gly+(−0.0294)Arg+(0.1519)Tyr+(−0.0325)Val+(−0.1932)Trp; 0.943, 0.962, 0.845, 0.931, 0.915, 0.910, 0.929,(18.2716)+(−0.1808)Asn+(−0.0209)Gly+(0.1319)Tyr+(−0.0291)Val+(−0.0849)Met+(−0.1671)Trp; 0.942, 0.961, 0.843, 0.928, 0.914, 0. 904,0.926,(18.6950)+(−0.2049)Asn+(−0.0227)Gly+(0.1247)Tyr+(−0.0313)Val+(−0.1689)Trp;0.940, 0.964, 0.852, 0.931, 0.908, 0.9 14, 0.929,(18.5628)+(−0.1809)Asn+(−0.0213)Gly+(0.1403)Tyr+(−0.0261)Val+(−0.0149)Lys+(−0.1804)Trp;0.939, 0.967, 0.829, 0.92 5, 0.898, 0.903, 0.922,(19.2936)+(−0.1920)Asn+(−0.0216)Gly+(0.1768)Tyr+(−0.0310)Val+(−0.0428)Orn+(−0.2144)Trp; 0.939, 0.962, 0.843,0.931, 0.916, 0.908, 0.929, (19.1391)+(−0.2047)Asn+(−0.0227)Gly+(0.1279)Tyr+(−0.0303)Val+(−0.0160)Phe+(−0.1678)Trp; 0. 938,0.963, 0.834, 0.929, 0.915, 0.904, 0.927,(18.4477)+(−0.1783)Asn+(−0.0211)Gly+(−0.0102)Ala+(0.1495)Tyr+(−0.0246)Val+(−0.1848)Trp; 0.938, 0.962, 0.838, 0.929, 0.914, 0.904, 0.926, (18.5187)+(−0.1989)Asn+(−0.0223)Gly+(−0.0039)Thr+(0.1257)Tyr+(−0.0307)Val+(−0.1660)Trp; 0.938, 0.961, 0.844, 0.929, 0.913, 0.905, 0. 926,(18.6585)+(−0.2034)Asn+(−0.0223)Gly+(−0.0051)Cit+(0.1250)Tyr+(−0.0309)Val+(−0.1696)Trp; 0.937, 0.960, 0.853, 0.921, 0.9 03,0.893, 0.919,(14.2988)+(−0.0198)Gly+(−0.0185)Ala+(0.1778)Tyr+(−0.0453)Lys+(0.0589)Ile+(−0.2460)Trp;0.936, 0.961, 0.839, 0.926, 0.908, 0.902, 0.924,(15.5250)+(−0.0179)Gly+(−0.0145)Ala+(0.1906)Tyr+(−0.1690)Met+(−0.0266)Lys+(−0.2415)Trp; 0.936, 0. 952,0.832, 0.919, 0.910, 0.886, 0.916,(13.9656)+(−0.0178)Gly+(−0.0153)Ala+(0.1596)Tyr+(−0.2595)Met+(−0.2181)Trp;0.936, 0.96 5, 0.867, 0.929, 0.914, 0.899, 0.926,(16.5833)+(0.0280)Ser+(−0.2436)Asn+(−0.0259)Gly+(0.1294)Tyr+(−0.0295)Val+(−0.1576)Trp; 0.935,0.962, 0.870, 0.941, 0.920, 0.938, 0.940, (18.8523)+(−0.1698)Asn+(−0.0207)Gly+(−0.0278)Arg+(0.1337)Tyr+(−0.0451)Leu+(−0.2089)Trp;0.935, 0.954, 0.827, 0.921, 0.904, 0.898, 0.919, (15.5136)+(−0.0218)Gly+(−0.0152)Ala+(0.1870)Tyr+(−0.0365)Lys+(−0. 2577)Trp;0.935, 0.958, 0.826, 0.917, 0.902, 0.884, 0.914, (15.0724)+(−0.0164)Gly+(−0.0156)Ala+(0.2082)Tyr+(−0.2478)Met+(−0.0445)Orn+(−0.2598)Trp; 0.934, 0.964, 0.850, 0.929, 0.910, 0.907, 0. 927,(17.3759)+(−0.1143)Asn+(−0.0180)Gly+(−0.0144)Ala+(0.1820)Tyr+(−0.0310)Lys+(−0.2361)Trp; 0.934, 0.960, 0.858, 0.926, 0.9 15,0.897, 0.924,(17.5160)+(−0.1971)Asn+(−0.0223)Gly+(0.1061)Tyr+(−0.0379)Val+(0.0390)Ile+(−0.1469)Trp;0.933, 0.956, 0.826, 0.920, 0.911, 0.885, 0.917,(14.7011)+(−0.0195)Gly+(−0.0128)Ala+(0.1600)Tyr+(−0.0115)Val+(−0.2308)Met+(−0.2077)Trp; 0.933, 0. 956,0.846, 0.923, 0.905, 0.899, 0.920,(15.5936)+(−0.0203)Gly+(−0.0275)His+(−0.0142)Ala+(0.1768)Tyr+(−0.0313)Lys+(−0.2379)Trp; 0.933, 0.955, 0.836, 0.919, 0.901, 0.891, 0.916, (16.2475)+(−0.1293)Asn+(−0.0178)Gly+(−0.0149)Ala+(0.1739)Tyr+(−0.0420)Orn+(−0.2480)Trp; 0.933, 0.962, 0.834, 0.925, 0.912, 0.892, 0.922, (18.4104)+(−0.2075)Asn+(−0.0230)Gly+(0.1248)Tyr+(−0.0486)Val+(0.0337)Leu+(−0.1596)Trp; 0.933, 0.957, 0.841, 0.919, 0.910, 0.882, 0. 916,(12.7704)+(0.0158)Ser+(−0.0200)Gly+(−0.0151)Ala+(0.1649)Tyr+(−0.2878)Met+(−0.2158)Trp; 0.933, 0.959, 0.861, 0.928, 0.9 09,0.909, 0.926, (16.6886)+(−0.1353)Asn+(−0.0146)Gly+(−0.0174)Ala+(−0.0709)Cit+(0.1542)Tyr+(−0.2304)Trp; 0.932, 0.956, 0.8 65,0.933, 0.920, 0.919, 0.932,(17.8934)+(−0.1885)Asn+(−0.0219)Gly+(0.1074)Tyr+(−0.0427)Leu+(−0.1860)Trp;0.932, 0.961, 0.846, 0.930, 0.906, 0.919, 0.928,(18.6123)+(−0.1766)Asn+(−0.0211)Gly+(0.1599)Tyr+(−0.0436)Orn+(−0.0448)Leu+(−0.2264)Trp; 0.932, 0. 961,0.892, 0.917, 0.891, 0.892, 0.914,(12.7382)+(−0.0270)Ala+(−0.1091)Cit+(0.1739)Tyr+(−0.0494)Lys+(0.1149)Ile+(−0.2253)Trp; 0.932, 0.958, 0.857, 0.929, 0.914, 0.909, 0.927, (16.6371)+(−0.1199)Asn+(−0.0175)Gly+(−0.0160)Ala+(−0.0322)Arg+(0.1667)Tyr+(−0.2438)Trp;0.932, 0.953, 0.829, 0.920, 0.911, 0.889, 0.918, (14.5685)+(−0.0183)Gly+(−0.0153)Ala+(0.1628)Tyr+(−0.2435)Met+(−0.0186)Phe+(−0.2174)Trp;0.932, 0.957, 0.827, 0.924, 0.908, 0.901, 0.922,(16.1441)+(−0.0220)Gly+(−0.0153)Ala+(0.1898)Tyr+(−0.0347)Lys+(−0.0218)Phe+(−0.2544)Trp; 0.932, 0.955, 0.846, 0.922, 0. 909,0.896, 0.920, (14.8528)+(−0.0153)Gly+(−0.0170)Ala+(−0.0561)Cit+(0.1709)Tyr+(−0.2161)Met+(−0.2359)Trp; 0.932, 0.953, 0.8 30,0.920, 0.912, 0.886, 0.917,(14.3526)+(−0.0184)Gly+(−0.0144)Ala+(0.1591)Tyr+(−0.2409)Met+(−0.0090)Leu+(−0.2174)Trp;0.93 1, 0.960, 0.859, 0.929, 0.903, 0.919, 0.927, (17.4730)+(−0.1593)Asn+(−0.0189)Ala+(−0.0859)Cit+(0.1918)Tyr+(−0.0280)Lys+(−0.22 34)Trp;0.931, 0.960, 0.864, 0.936, 0.914, 0.930, 0.935,(17.7847)+(−0.1585)Asn+(−0.0208)Gly+(0.1310)Tyr+(−0.0193)Lys+(−0.0298)Leu+(−0.2023)Trp; 0.931, 0.955, 0.828, 0.931, 0.917, 0.916, 0.92 9,(15.1833)+(−0.0229)Gly+(−0.0305)Arg+(0.1523)Tyr+(−0.0235)Val+(−0.1789)Met+(−0.2015)Trp; 0.931, 0.951, 0.821, 0.920, 0.903, 0.898,0.918, (15.2754)+(−0.0207)Gly+(−0.0103)Thr+(−0.0148)Ala+(0.1882)Tyr+(−0.0341)Lys+(−0.2458)Trp; 0.931, 0.959, 0.841, 0. 924,0.899, 0.907, 0.922,(16.0715)+(−0.0188)Gly+(−0.0166)Ala+(−0.0509)Cit+(0.1942)Tyr+(−0.0317)Lys+(−0.2679)Trp;0.931, 0. 957, 0.863, 0.935, 0.921, 0.923, 0.934,(18.3571)+(−0.1881)Asn+(−0.0221)Gly+(0.1111)Tyr+(−0.0408)Leu+(−0.0171)Phe+(−0.1843)Irp; 0.931, 0.955, 0.822, 0.920, 0.905, 0.892, 0.917, (15.8004)+(−0.0227)Gly+(−0.0141)Ala+(0.1839)Tyr+(−0.0068)Val+(−0.0331)Lys+(−0.2473)Trp; 0.931, 0.963, 0.819, 0.927, 0.914, 0.895, 0.924, (19.3362)+(−0.2361)Asn+(−0.0246)Gly+(0.0353)His+(0.1325)Tyr+(−0.0382)Val+(−0.1807)Trp; 0.931, 0.957, 0.814, 0.916, 0.884, 0.897, 0. 913,(16.1310)+(−0.0213)Gly+(−0.0146)Ala+(0.2199)Tyr+(−0.0367)Orn+(−0.0311)Lys+(−0.2948)Trp; 0.931, 0.953, 0.839, 0.926, 0.9 13,0.906, 0.924, (14.9224)+(−0.0172)Gly+(−0.0158)Ala+(−0.0269)Arg+(0.1821)Tyr+(−0.2001)Met+(−0.2469)Trp; 0.930, 0.953, 0.8 35,0.918, 0.909, 0.884, 0.915,(13.3776)+(−0.0169)Gly+(−0.0168)Ala+(0.1532)Tyr+(−0.2681)Met+(0.0193)Ile+(−0.2103)Trp;0.930, 0.956, 0.843, 0.922, 0.911, 0.893, 0.920,(15.5012)+(−0.0214)Gly+(−0.0162)Ala+(0.0056)Pro+(0.1831)Tyr+(−0.0401)Lys+(−0.2513)Trp;0.930, 0.963, 0.833, 0.929, 0.910, 0.908, 0.927, (18.6294)+(−0.1987)Asn+(−0.0223)Gly+(−0.0058)Pro+(0.1346)Tyr+(−0.0299)Val+(−0.1767)Trp; 0.930, 0.960, 0.848, 0.930, 0.918, 0.907, 0.928, (17.8737)+(−0.1634)Asn+(−0.0201)Gly+(−0.0124)Ala+(0.1429)Tyr+(−0.0304)Leu+(−0.2040)Trp;0.930, 0.956, 0.824, 0.922, 0.908, 0.895, 0.919,(14.1671)+(−0.0227)Gly+(0.0040)Gln+(−0.0153)Ala+(0.1800)Tyr+(−0.0397)Lys+(−0.2508)Trp; 0.929, 0.956, 0.833, 0.901, 0. 874,0.863, 0.898, (11.0189)+(−0.0238)Ala+(0.1862)Tyr+(−0.0464)Orn+(−0.0480)Lys+(0.0979)Ile+(−0.2219)Trp; 0.929, 0.954, 0.8 28,0.921, 0.904, 0.898, 0.919,(15.4882)+(−0.0218)Gly+(−0.0153)Ala+(0.1873)Tyr+(−0.0368)Lys+(0.0009)Leu+(−0.2582)Trp;0.929, 0.958, 0.834, 0.927, 0.904, 0.913, 0.925,(16.5859)+(−0.0204)Gly+(−0.0162)Ala+(−0.0269)Arg+(0.2107)Tyr+(−0.0310)Lys+(−0.2841)Trp; 0.929, 0.955, 0.830, 0.921, 0.905, 0.896, 0.919,(14.8299)+(0.0085)Ser+(−0.0235)Gly+(−0.0150)Ala+(0.1904)Tyr+(−0.0376)Lys+(−0.2587)Trp;0.929, 0.954, 0.828, 0.918, 0.909, 0.882, 0.915,(13.7957)+(−0.0177)Gly+(−0.0065)Thr+(−0.0149)Ala+(0.1605)Tyr+(−0.2347)Met+(−0.2138)Trp; 0.928, 0.956, 0.848, 0.922, 0.911, 0. 892,0.920,(15.5990)+(−0.1429)Asn+(−0.0194)Gly+(−0.0149)Ala+(0.1291)Tyr+(−0.2079)Trp;0.928, 0.955, 0.859, 0.925, 0.906, 0.90 9, 0.923,(15.7802)+(−0.1780)Asn+(−0.0196)Ala+(−0.1054)Cit+(0.1536)Tyr+(−0.2061)Trp; 0.928, 0.957, 0.883, 0.932, 0.915, 0.919, 0. 930,(15.7143)+(0.0305)Ser+(−0.2338)Asn+(−0.0255)Gly+(0.1141)Tyr+(−0.0410)Leu+(−0.1715)Trp; 0.928, 0.956, 0.848, 0.922, 0.9 11,0.891, 0.919, (14.4104)+(−0.0167)Gly+(−0.0336)His+(−0.0143)Ala+(0.1516)Tyr+(−0.2112)Met+(−0.2011)Trp; 0.928, 0.955, 0.8 18,0.919, 0.888, 0.905, 0.916,(16.1039)+(−0.0202)Gly+(−0.0171)Ala+(−0.0410)Arg+(0.2243)Tyr+(−0.0454)Orn+(−0.3189)Trp;0.92 8, 0.955, 0.882, 0.934, 0.913, 0.929, 0.932, (16.4372)+(−0.1106)Asn+(−0.0192)Gly+(−0.0364)His+(0.1264)Tyr+(−0.0285)Lys+(−0.19 35)Trp;0.928, 0.952, 0.832, 0.919, 0.910, 0.886, 0.916,(13.9641)+(−0.0178)Gly+(−0.0153)Ala+(0.0000)Pro+(0.1595)Tyr+(−0.2595)Met+(−0.2180)Trp;0.927, 0.950, 0.812, 0.919, 0.907, 0.893, 0.917,(13.8882)+(−0.0231)Gly+(0.1310)Tyr+(−0.0217)Val+(−0.2380)Met+(−0.1781)Trp; 0.927, 0.948, 0.796, 0.908, 0.893, 0.877, 0.906, (13.0373)+(−0.0176)Ala+(0.2102)Tyr+(−0.3645)Met+(−0.0525)Orn+(−0.2193)Trp;0.927, 0.962, 0.836, 0.931, 0.919, 0.906, 0.929, (17.0704)+(−0.2285)Asn+(−0.0240)Gly+(0.0056)Gln+(0.1137)Tyr+(−0.0320)Val+(−0.1577)Trp; 0.927, 0.955, 0.866, 0.935, 0.920, 0.926, 0. 934,(17.4567)+(−0.1669)Asn+(−0.0206)Gly+(0.1134)Tyr+(−0.0722)Met+(−0.0394)Leu+(−0.1828)Trp; 0.927, 0.953, 0.834, 0.903, 0.8 82,0.862, 0.899,(10.5201)+(−0.0204)Thr+(−0.0225)Ala+(0.1669)Tyr+(−0.0496)Lys+(0.0851)Ile+(−0.1799)Trp;0.927, 0.952, 0.833, 0.921, 0.904, 0.900, 0.919,(14.6656)+(−0.0213)Gly+(−0.0170)Ala+(−0.0414)Arg+(0.1714)Tyr+(−0.2699)Trp; 0.927, 0.953, 0.868, 0. 936,0.914, 0.938, 0.935,(16.2015)+(−0.1073)Asn+(−0.0194)Gly+(0.1392)Tyr+(−0.0897)Met+(−0.0309)Lys+(−0.2105)Trp;0.926, 0. 955, 0.832, 0.920, 0.912, 0.885, 0.917,(13.2893)+(−0.0180)Gly+(0.0017)Gln+(−0.0153)Ala+(0.1555)Tyr+(−0.2670)Met+(−0.2134)Tr p; 0.926,0.951, 0.813, 0.913, 0.896, 0.885, 0.911, (14.0525)+(−0.0170)Ala+(0.2217)Tyr+(−0.3129)Met+(−0.0447)Orn+(−0.0176)Lys+(−0.2287)Trp;0.926, 0.943, 0.811, 0.902, 0.897, 0.858, 0.899, (12.9309)+(−0.0255)Gly+(−0.0158)Ala+(0.1244)Tyr+(−0.2339)Trp; 0. 926, 0.952,0.864, 0.934, 0.912, 0.934, 0.933,(16.3460)+(−0.1262)Asn+(−0.0207)Gly+(0.1315)Tyr+(−0.0334)Lys+(−0.2145)Trp;0.92 6, 0.956, 0.864, 0.933, 0.920, 0.919, 0.932, (17.9000)+(−0.1886)Asn+(−0.0220)Gly+(0.1076)Tyr+(−0.0002)Ile+(−0.0427)Leu+(−0.18 61)Trp;0.926, 0.953, 0.825, 0.925, 0.907, 0.909, 0.923,(14.7538)+(−0.0224)Gly+(0.1545)Tyr+(−0.0166)Val+(−0.1813)Met+(−0.0217)Lys+(−0.1983)Trp; 0.926, 0.950, 0.827, 0.925, 0.908, 0.912, 0.92 3,(15.6837)+(−0.0262)Gly+(−0.0290)Arg+(0.1608)Tyr+(−0.0204)Val+(−0.0210)Lys+(−0.2305)Trp; 0.926, 0.954, 0.854, 0.918, 0.907, 0.886,0.916, (14.2981)+(−0.0208)Gly+(−0.0676)His+(−0.0139)Ala+(0.1262)Tyr+(−0.1988)Trp; 0.926, 0.946, 0.819, 0.921, 0.909, 0. 904,0.920,(15.3785)+(−0.0281)Gly+(−0.0419)Arg+(0.1444)Tyr+(−0.0269)Val+(−0.2218)Trp;0.926, 0.959, 0.834, 0.914, 0.889, 0.8 86, 0.911,(15.4621)+(−0.0195)Gly+(−0.0639)His+(−0.0141)Ala+(0.1778)Tyr+(−0.0458)Orn+(−0.2444)Trp;0.926, 0.956, 0.851, 0.9 26, 0.917, 0.897, 0.923,(15.5754)+(−0.0969)Asn+(−0.0165)Gly+(−0.0147)Ala+(0.1540)Tyr+(−0.1825)Met+(−0.2075)Trp;0.926, 0.95 5, 0.866, 0.921, 0.911, 0.891, 0.919,(14.1295)+(0.0273)Ser+(−0.1871)Asn+(−0.0231)Gly+(−0.0145)Ala+(0.1350)Tyr+(−0.1992)Trp; 0.926,0.955, 0.846, 0.926, 0.894, 0.924, 0.924, (16.4740)+(−0.1179)Asn+(−0.0198)Gly+(0.1615)Tyr+(−0.0308)Orn+(−0.0315)Lys+(−0.2373)Trp;0.926, 0.954, 0.815, 0.923, 0.908, 0.899, 0.920, (16.9420)+(−0.0245)Gly+(−0.0139)Ala+(−0.0434)Arg+(0.1893)Tyr+(−0.0195)Val+(−0.2614)Trp; 0.926, 0.953, 0.848, 0.914, 0.895, 0.885, 0. 911,(11.9904)+(−0.0221)Ala+(0.1867)Tyr+(−0.2787)Met+(−0.0388)Lys+(0.0756)Ile+(−0.1870)Trp; 0.925, 0.959, 0.869, 0.937, 0.92 1,0.927, 0.935, (17.8321)+(−0.1846)Asn+(−0.0209)Gly+(−0.0167)Cit+(0.1097)Tyr+(−0.0418)Leu+(−0.1871)Trp; 0.925, 0.958, 0.859, 0.926,0.907, 0.907, 0.924, (15.6209)+(−0.0183)Gly+(−0.0567)His+(−0.0149)Ala+(−0.0360)Arg+(0.1653)Tyr+(−0.2352)Trp; 0.925, 0. 956,0.864, 0.935, 0.924, 0.922, 0.934,(16.7684)+(−0.2019)Asn+(−0.0229)Gly+(0.0037)Gln+(0.0987)Tyr+(−0.0427)Leu+(−0.1790)Trp; 0.925, 0.956, 0.832, 0.920, 0.887, 0.910, 0.918, (15.8037)+(−0.2082)Asn+(0.1740)Tyr+(−0.0257)Val+(−0.1788)Met+(−0.0481)Orn+(−0.1578)Trp;0.925, 0.955, 0.798, 0.915, 0.891, 0.891, 0.912, (14.7090)+(−0.0226)Gly+(0.1806)Tyr+(−0.0223)Val+(−0.2174)Met+(−0.0426)Orn+(−0.2171)Trp;0.925, 0.955, 0.873, 0.935, 0.910, 0.936, 0.934,(16.2745)+(−0.1252)Asn+(−0.0195)Gly+(−0.0151)Cit+(0.1319)Tyr+(−0.0326)Lys+(−0.2131)Trp; 0.925, 0.953, 0.843, 0.921, 0. 901,0.904, 0.919, (14.6029)+(−0.0186)Ala+(−0.0729)Cit+(0.1982)Tyr+(−0.2438)Met+(−0.0226)Lys+(−0.2219)Trp; 0.925, 0.951, 0. 813,0.912, 0.891, 0.885, 0.909, (14.2251)+(−0.1875)Asn+(−0.0166)Ala+(0.1617)Tyr+(−0.0542)Orn+(−0.1972)Trp; 0.925, 0.949, 0.8 98,0.928, 0.912, 0.918, 0.927,(13.7121)+(−0.0209)Gly+(−0.0815)His+(−0.0281)Arg+(0.0983)Tyr+(−0.1762)Trp;0.925, 0.958, 0.807, 0.917, 0.897, 0.886, 0.914,(16.4874)+(−0.2226)Asn+(−0.0129)Ala+(0.1765)Tyr+(−0.0193)Val+(−0.0525)Orn+(−0.1802)Trp; 0.925, 0. 958,0.859, 0.928, 0.906, 0.913, 0.926,(15.6232)+(−0.1300)Asn+(−0.0187)Ala+(−0.0890)Cit+(0.1729)Tyr+(−0.1691)Met+(−0.2059)Trp; 0.925, 0.957, 0.859, 0.934, 0.922, 0.918, 0.932, (17.6413)+(−0.1786)Asn+(−0.0212)Gly+(−0.0075)Thr+(0.1100)Tyr+(−0.0417)Leu+(−0.1801)Trp; 0.925, 0.955, 0.823, 0.919, 0.896, 0.897, 0.916, (15.6904)+(−0.1567)Asn+(−0.0176)Ala+(−0.0346)Arg+(0.1966)Tyr+(−0.0486)Orn+(−0.2395)Trp;0.925, 0.954, 0.842, 0.917, 0.905, 0.885, 0.915,(14.0720)+(−0.0193)Gly+(−0.0614)His+(−0.0139)Thr+(−0.0134)Ala+(0.1326)Tyr+(−0.1877)Trp; 0.925, 0.948, 0.797, 0.907, 0. 893,0.872, 0.904, (12.5917)+(−0.0175)Ala+(0.2088)Tyr+(−0.3771)Met+(−0.0531)Orn+(0.0170)Phe+(−0.2220)Trp; 0.925, 0.947, 0.8 44,0.934, 0.920, 0.934, 0.934,(14.4805)+(−0.0223)Gly+(−0.0287)Arg+(0.1367)Tyr+(−0.1646)Met+(−0.0311)Leu+(−0.2103)Trp;0.92 4, 0.954, 0.855, 0.923, 0.904, 0.905, 0.921, (14.8267)+(−0.0185)Gly+(−0.0460)His+(−0.0161)Ala+(−0.0548)Cit+(0.1444)Tyr+(−0.22 56)Trp;0.924, 0.952, 0.830, 0.917, 0.903, 0.890, 0.915,(15.4019)+(−0.1670)Asn+(−0.0176)Ala+(0.1748)Tyr+(−0.0359)Lys+(−0.1844)Trp; 0.924, 0.961, 0.873, 0.928, 0.915, 0.903, 0.926,(16.1644)+(−0.1179)Asn+(−0.0173)Gly+(−0.0477)His+(−0.0138)Ala+(0.1276)Tyr+(−0.1856)Trp

List (1) of Linear Discriminants Searched in Example 8

The linear discriminants searched in Example 8 above are listed below.Before each equation, “the value of ROC_AUC for the pancreatic cancergroup and the breast cancer group with validation”, “the value ofROC_AUC for the pancreatic cancer group and the breast cancer groupwithout validation”, “the value of ROC_AUC for the pancreatic cancergroup and the healthy group”, “the value of ROC_AUC for the pancreaticcancer group and the other cancers group”, “the value of ROC_AUC for thepancreatic cancer group and the lung cancer group”, “the value ofROC_AUC for the pancreatic cancer group and the colorectal cancergroup”, and “the average value of the value of ROC_AUC for thepancreatic cancer group and the lung cancer group, the value of ROC_AUCfor the pancreatic cancer group and the colorectal cancer group, and thevalue of ROC_AUC for the pancreatic cancer group and the breast cancergroup” obtained for the equation are additionally listed.

0.947, 0.963, 0.857, 0.932, 0.910, 0.917, 0.930,(16.5080)+(−0.1847)Asn+(−0.0136)Gly+(0.1059)Tyr+(−0.0166)Val+(−0.0144)Lys+(−0.1261)Trp; 0.947, 0.963, 0.887, 0.926, 0.917, 0.890, 0.923,(15.4522)+(0.0407)Ser+(−0.2621)Asn+(−0.0204)Gly+(0.0901)Tyr+(−0.0238)Val+(−0.1073)Trp; 0.946, 0.961, 0.856, 0.931, 0.916, 0. 911,0.929,(16.3693)+(−0.2032)Asn+(−0.0143)Gly+(0.0911)Tyr+(−0.0205)Val+(−0.1222)Trp;0.946, 0.964, 0.867, 0.938, 0.921, 0.9 25, 0.937,(16.6747)+(−0.1853)Asn+(−0.0142)Gly+(−0.0165)Arg+(0.1002)Tyr+(−0.0198)Val+(−0.1310)Trp;0.945, 0.964, 0.851, 0.9 31, 0.907, 0.914, 0.928,(16.3302)+(−0.1982)Asn+(−0.0137)Gly+(0.1050)Tyr+(−0.0184)Val+(−0.0221)Orn+(−0.1288)Trp; 0.945, 0.962, 0.844,0.930, 0.917, 0.902, 0.927, (16.0086)+(−0.1827)Asn+(−0.0115)Gly+(−0.0089)Ala+(0.1042)Tyr+(−0.0142)Val+(−0.1271)Trp; 0. 945,0.959, 0.858, 0.907, 0.881, 0.869, 0.903,(11.1280)+(−0.0097)Gly+(−0.0205)Ala+(0.1331)Tyr+(−0.0405)Lys+(0.0966)Ile+(−0.1673)Trp; 0.944, 0.960, 0.895, 0.910, 0.882, 0.877, 0.906, (11.7959)+(−0.0251)Ala+(−0.0900)Cit+(0.1411)Tyr+(−0.0407)Lys+(0.1263)Ile+(−0.1856)Trp; 0.944, 0.962, 0.853, 0.934, 0.917, 0.918, 0.93 2,(17.5529)+(−0.2011)Asn+(−0.0145)Gly+(0.1006)Tyr+(−0.0198)Val+(−0.0362)Phe+(−0.1205)Trp; 0.944, 0.961, 0.848, 0.931, 0.914, 0.912,0.929, (16.2146)+(−0.1878)Asn+(−0.0134)Gly+(−0.0126)Thr+(0.0973)Tyr+(−0.0189)Val+(−0.1200)Trp; 0.944, 0.960, 0.854, 0. 930,0.911, 0.912, 0.928,(15.2276)+(−0.1416)Asn+(−0.0098)Gly+(−0.0117)Ala+(0.1260)Tyr+(−0.0207)Lys+(−0.1443)Trp;0.944, 0. 960, 0.858, 0.933, 0.914, 0.920, 0.931,(16.1002)+(−0.1600)Asn+(−0.0131)Gly+(0.1159)Tyr+(−0.0179)Val+(−0.1568)Met+(−0.1278)Trp; 0.943, 0.962, 0.843, 0.931, 0.913, 0.912, 0.929, (16.4600)+(−0.2005)Asn+(−0.0145)Gly+(−0.0054)Pro+(0.0991)Tyr+(−0.0195)Val+(−0.1249)Trp; 0.942, 0.960, 0.867, 0.933, 0.916, 0.918, 0.931, (16.5160)+(−0.1988)Asn+(−0.0140)Gly+(−0.0190)Cit+(0.0919)Tyr+(−0.0186)Val+(−0.1282)Trp;0.941, 0.962, 0.854, 0.932, 0.916, 0.912, 0.930,(14.9371)+(−0.2207)Asn+(−0.0147)Gly+(0.0048)Gln+(0.0831)Tyr+(−0.0217)Val+(−0.1161)Trp; 0.941, 0.960, 0.871, 0.932, 0. 918,0.914, 0.931, (16.5717)+(−0.1866)Asn+(−0.0139)Gly+(−0.0240)His+(0.0870)Tyr+(−0.0167)Val+(−0.1176)Trp; 0.941, 0.954, 0.8 26,0.918, 0.901, 0.889, 0.915,(12.1179)+(−0.0106)Gly+(−0.0117)Ala+(0.1440)Tyr+(−0.2897)Met+(−0.1605)Trp;0.940, 0.956, 0.830, 0.924, 0.906, 0.902, 0.921,(12.7376)+(−0.0103)Gly+(−0.0115)Ala+(0.1511)Tyr+(−0.2252)Met+(−0.0157)Lys+(−0.1579)Trp; 0.940, 0. 955,0.817, 0.919, 0.906, 0.889, 0.917,(12.0399)+(−0.0119)Gly+(−0.0131)Ala+(0.1263)Tyr+(−0.0268)Lys+(−0.1583)Trp;0.940, 0.95 7, 0.868, 0.930, 0.912, 0.916, 0.928,(15.4763)+(−0.1546)Asn+(−0.0097)Gly+(−0.0124)Ala+(−0.0541)Cit+(0.1083)Tyr+(−0.1552)Tr p; 0.940,0.959, 0.855, 0.931, 0.906, 0.922, 0.929, (15.6243)+(−0.1898)Asn+(−0.0134)Gly+(0.1050)Tyr+(−0.0275)Orn+(−0.0239)Leu+(−0.1400)Trp;0.940, 0.955, 0.816, 0.918, 0.902, 0.888, 0.915, (12.3851)+(−0.0099)Gly+(−0.0114)Ala+(0.1608)Tyr+(−0.2771)Met+(−0.0286)Orn+(−0.1649)Trp;0.940, 0.958, 0.854, 0.928, 0.914, 0.905, 0.926,(14.7420)+(−0.1429)Asn+(−0.0107)Gly+(−0.0122)Ala+(−0.0172)Arg+(0.1125)Tyr+(−0.1549)Trp; 0.939, 0.959, 0.843, 0.925, 0. 903,0.907, 0.923, (12.8941)+(−0.0112)Gly+(−0.0131)Ala+(−0.0453)Cit+(0.1270)Tyr+(−0.0236)Lys+(−0.1657)Trp; 0.939, 0.959, 0.8 11,0.924, 0.910, 0.896, 0.922,(13.1099)+(−0.0121)Gly+(−0.0133)Ala+(0.1333)Tyr+(−0.0249)Lys+(−0.0329)Phe+(−0.1560)Trp;0.93 9, 0.955, 0.837, 0.921, 0.902, 0.898, 0.919, (14.6581)+(−0.1573)Asn+(−0.0099)Gly+(−0.0122)Ala+(0.1240)Tyr+(−0.0316)Orn+(−0.15 17)Trp;0.939, 0.955, 0.845, 0.914, 0.907, 0.872, 0.911,(10.6239)+(0.0293)Ser+(−0.0148)Gly+(−0.0125)Ala+(0.1523)Tyr+(−0.3524)Met+(−0.1562)Trp;0.939, 0.955, 0.825, 0.919, 0.905, 0.889, 0.916,(12.5337)+(−0.0111)Gly+(−0.0104)Ala+(0.1436)Tyr+(−0.0056)Val+(−0.2875)Met+(−0.1538)Trp; 0.939, 0.959, 0.854, 0.925, 0.906, 0. 904,0.923,(14.3597)+(−0.1172)Asn+(−0.0097)Gly+(−0.0114)Ala+(0.1303)Tyr+(−0.1746)Met+(−0.1492)Trp;0.939, 0.959, 0.881, 0.9 37, 0.916, 0.934, 0.936,(15.9776)+(−0.1880)Asn+(−0.0136)Gly+(−0.0357)Cit+(0.0894)Tyr+(−0.0223)Leu+(−0.1425)Trp;0.938, 0.95 7, 0.871, 0.939, 0.922, 0.935, 0.938,(15.9323)+(−0.1756)Asn+(−0.0140)Gly+(−0.0180)Arg+(0.0973)Tyr+(−0.0263)Leu+(−0.1424)Tr p; 0.938,0.955, 0.866, 0.919, 0.914, 0.879, 0.916, (13.1790)+(0.0371)Ser+(−0.2085)Asn+(−0.0159)Gly+(−0.0138)Ala+(0.1030)Tyr+(−0.1369)Trp;0.938, 0.960, 0.848, 0.926, 0.911, 0.898, 0.923, (16.3220)+(−0.2038)Asn+(−0.0147)Gly+(0.0915)Tyr+(−0.0362)Val+(0.0305)Leu+(−0.1208)Trp; 0.938, 0.957, 0.869, 0.935, 0.914, 0.931, 0. 934,(15.2147)+(−0.1496)Asn+(−0.0130)Gly+(0.1127)Tyr+(−0.1625)Met+(−0.0211)Leu+(−0.1395)Trp; 0.938, 0.957, 0.857, 0.930, 0.9 08,0.917, 0.928, (15.5841)+(−0.1546)Asn+(−0.0144)Ala+(−0.0496)Cit+(0.1320)Tyr+(−0.0194)Lys+(−0.1521)Trp; 0.938, 0.952, 0.8 44,0.920, 0.907, 0.894, 0.918,(14.3471)+(−0.1601)Asn+(−0.0107)Gly+(−0.0126)Ala+(0.1033)Tyr+(−0.1466)Trp;0.938, 0.958, 0.876, 0.927, 0.913, 0.905, 0.925,(15.6470)+(−0.1385)Asn+(−0.0102)Gly+(−0.0477)His+(−0.0111)Ala+(0.0965)Tyr+(−0.1270)Trp; 0.938, 0. 957,0.870, 0.898, 0.899, 0.826, 0.894,(14.4031)+(−0.1984)Asn+(−0.0182)Ala+(0.0946)Tyr+(−0.0405)Val+(0.1414)Ile+(−0.1133)Trp; 0.938, 0.955, 0.829, 0.893, 0.863, 0.846, 0.888, (10.1586)+(−0.0245)Ala+(0.1579)Tyr+(−0.0387)Orn+(−0.0396)Lys+(0.1157)Ile+(−0.1772)Trp;0.938, 0.955, 0.826, 0.922, 0.896, 0.910, 0.920, (12.5518)+(−0.0137)Gly+(0.1473)Tyr+(−0.0099)Val+(−0.3155)Met+(−0.0247)Orn+(−0.1580)Trp;0.938, 0.957, 0.860, 0.924, 0.911, 0.896, 0.921,(13.3437)+(−0.0116)Gly+(−0.0466)His+(−0.0118)Ala+(0.1118)Tyr+(−0.0191)Lys+(−0.1384)Trp; 0.938, 0.954, 0.800, 0.914, 0. 895,0.883, 0.911, (12.3842)+(−0.0102)Gly+(−0.0213)Thr+(−0.0129)Ala+(0.1337)Tyr+(−0.0221)Lys+(−0.1492)Trp; 0.937, 0.955, 0.8 97,0.926, 0.913, 0.905, 0.924, (14.7173)+(0.0403)Ser+(−0.2536)Asn+(−0.0201)Gly+(0.0863)Tyr+(−0.0344)Leu+(−0.1182)Trp; 0.937, 0.957,0.875, 0.930, 0.917, 0.910, 0.928,(13.9507)+(−0.0120)Gly+(−0.0592)His+(−0.0114)Ala+(−0.0282)Arg+(0.1050)Tyr+(−0.1471)Trp; 0.937, 0.953, 0.829, 0.895, 0.870, 0.849, 0.891,(10.7321)+(−0.0256)Thr+(−0.0233)Ala+(0.1469)Tyr+(−0.0383)Lys+(0.1041)Ile+(−0.1579)Trp;0.937, 0.954, 0.831, 0.918, 0.902, 0.890, 0.915,(12.0889)+(−0.0104)Gly+(−0.0121)Ala+(0.0017)Pro+(0.1426)Tyr+(−0.2931)Met+(−0.1599)Trp; 0.937, 0.954, 0.846, 0.922, 0.907, 0. 899,0.920,(12.9961)+(−0.0100)Gly+(−0.0118)Ala+(−0.0441)Cit+(0.1441)Tyr+(−0.2649)Met+(−0.1673)Trp;0.937, 0.953, 0.882, 0.9 09, 0.904, 0.858, 0.905,(16.0905)+(−0.2100)Asn+(−0.0159)Gly+(0.0744)Tyr+(−0.0462)Val+(0.1138)Ile+(−0.1069)Trp; 0.937, 0.958, 0.824,0.926, 0.909, 0.904, 0.924, (12.5889)+(−0.0119)Gly+(−0.0128)Ala+(−0.0188)Arg+(0.1309)Tyr+(−0.0213)Lys+(−0.1665)Trp; 0. 937,0.949, 0.834, 0.920, 0.900, 0.905, 0.918,(12.4904)+(−0.0144)Gly+(0.1329)Tyr+(−0.0120)Val+(−0.3245)Met+(−0.1515)Trp;0.93 7, 0.954, 0.869, 0.933, 0.916, 0.924, 0.932, (15.5873)+(−0.1951)Asn+(−0.0141)Gly+(0.0873)Tyr+(−0.0276)Leu+(−0.1330)Trp; 0.937, 0.953,0.854, 0.909, 0.893, 0.870, 0.905,(11.0454)+(−0.0094)Gly+(−0.0170)Ala+(0.1417)Tyr+(−0.3112)Met+(0.0646)Ile+(−0.1681)Trp;0.937, 0.954, 0.854, 0.922, 0.907, 0.899, 0.920, (13.3413)+(−0.0105)Gly+(−0.0412)His+(−0.0108)Ala+(0.1291)Tyr+(−0.2305)Met+(−0.1422)Trp; 0.936, 0.957, 0.852, 0.916, 0.900, 0.884, 0.913, (12.9722)+(−0.0118)Gly+(−0.0613)His+(−0.0119)Ala+(0.1048)Tyr+(−0.0249)Orn+(−0.1395)Trp;0.936, 0.956, 0.816, 0.920, 0.906, 0.889, 0.917,(12.0468)+(−0.0119)Gly+(−0.0131)Ala+(0.1262)Tyr+(−0.0001)Val+(−0.0267)Lys+(−0.1582)Trp; 0.936, 0.953, 0.864, 0.917, 0. 908,0.881, 0.914, (12.9335)+(−0.0123)Gly+(−0.0681)His+(−0.0121)Ala+(0.0875)Tyr+(−0.1326)Trp; 0.936, 0.955, 0.901, 0.925, 0.90 1,0.912, 0.923, (13.6542)+(0.0419)Ser+(−0.2060)Asn+(−0.0196)Gly+(0.1123)Tyr+(−0.0301)Lys+(−0.1388)Trp; 0.936, 0.953, 0.842, 0.927,0.913, 0.909, 0.925, (12.8082)+(−0.0106)Gly+(−0.0115)Ala+(−0.0194)Arg+(0.1488)Tyr+(−0.2507)Met+(−0.1681)Trp; 0.936, 0. 956,0.870, 0.934, 0.913, 0.928, 0.932,(15.6590)+(−0.1730)Asn+(−0.0135)Gly+(0.1043)Tyr+(−0.0168)Lys+(−0.0177)Leu+(−0.1380)Irp; 0.936, 0.953, 0.824, 0.919, 0.904, 0.892, 0.916, (12.4561)+(−0.0107)Gly+(−0.0119)Ala+(0.1455)Tyr+(−0.2805)Met+(−0.0109)Phe+(−0.1597)Trp; 0.936, 0.953, 0.919, 0.927, 0.911, 0.911, 0.925, (14.4885)+(0.0371)Ser+(−0.1934)Asn+(−0.0192)Gly+(−0.0699)His+(0.0714)Tyr+(−0.1141)Trp; 0.936, 0.954, 0.856, 0.925, 0.909, 0.905, 0. 923,(14.9924)+(−0.1717)Asn+(−0.0154)Ala+(−0.0627)Cit+(0.1122)Tyr+(−0.1563)Trp; 0.936, 0.957, 0.812, 0.921, 0.907, 0.890, 0.91 8,(11.1096)+(−0.0121)Gly+(0.0026)Gln+(−0.0134)Ala+(0.1238)Tyr+(−0.0287)Lys+(−0.1563)Trp; 0.936, 0.958, 0.839, 0.923, 0.905, 0.896,0.920, (14.8034)+(−0.1502)Asn+(−0.0120)Ala+(0.1354)Tyr+(−0.0098)Val+(−0.1821)Met+(−0.1355)Trp; 0.936, 0.954, 0.808, 0. 916,0.895, 0.889, 0.913,(12.0702)+(−0.0116)Gly+(−0.0130)Ala+(0.1357)Tyr+(−0.0198)Orn+(−0.0236)Lys+(−0.1620)Trp;0.936, 0. 956, 0.838, 0.925, 0.914, 0.898, 0.923,(16.1477)+(−0.1582)Asn+(−0.0109)Gly+(−0.0127)Ala+(0.1174)Tyr+(−0.0509)Phe+(−0.1427)Trp; 0.936, 0.957, 0.863, 0.928, 0.906, 0.914, 0.926, (14.8516)+(−0.1293)Asn+(−0.0140)Ala+(−0.0527)Cit+(0.1374)Tyr+(−0.1708)Met+(−0.1572)Trp; 0.936, 0.957, 0.867, 0.922, 0.905, 0.898, 0.920, (14.7218)+(−0.1226)Asn+(−0.0374)His+(−0.0134)Ala+(0.1252)Tyr+(−0.1562)Met+(−0.1332)Trp;0.936, 0.956, 0.834, 0.920, 0.908, 0.887, 0.917,(12.0287)+(−0.0114)Gly+(−0.0139)Ala+(0.0044)Pro+(0.1231)Tyr+(−0.0287)Lys+(−0.1566)Trp; 0.936, 0.952, 0.843, 0.932, 0. 913,0.929, 0.931, (13.3270)+(−0.0143)Gly+(−0.0226)Arg+(0.1389)Tyr+(−0.0121)Val+(−0.2773)Met+(−0.1600)Trp; 0.936, 0.956, 0. 857,0.928, 0.897, 0.926, 0.926, (14.8306)+(−0.1568)Asn+(−0.0131)Gly+(0.1191)Tyr+(−0.0233)Orn+(−0.0198)Lys+(−0.1540)Trp; 0. 935, 0.956,0.844, 0.928, 0.917, 0.904, 0.926,(15.3753)+(−0.1731)Asn+(−0.0109)Gly+(−0.0106)Ala+(0.1040)Tyr+(−0.0165)Leu+(−0.1356)Trp; 0.935, 0.955, 0.888, 0.932, 0.917, 0.920, 0.931, (16.0507)+(−0.1678)Asn+(−0.0136)Gly+(−0.0415)His+(0.0809)Tyr+(−0.0169)Leu+(−0.1231)Trp; 0.935, 0.955, 0.854, 0.932, 0.912, 0.924, 0. 931,(15.5051)+(−0.1765)Asn+(−0.0130)Gly+(−0.0162)Thr+(0.0958)Tyr+(−0.0254)Leu+(−0.1287)Trp; 0.935, 0.949, 0.872, 0.924, 0.9 02,0.917, 0.923,(13.0474)+(−0.0137)Gly+(−0.0518)His+(0.1132)Tyr+(−0.2621)Met+(−0.1438)Trp;0.935, 0.951, 0.840, 0.919, 0.907, 0.892, 0.917,(11.1397)+(0.0267)Ser+(−0.0184)Gly+(0.1398)Tyr+(−0.0125)Val+(−0.3839)Met+(−0.1473)Trp;0.935, 0.955, 0.817, 0. 920, 0.902, 0.897, 0.918,(12.0468)+(−0.0123)Gly+(−0.0132)Ala+(−0.0301)Arg+(0.1297)Tyr+(−0.0248)Orn+(−0.1789)Trp;0.935, 0. 956, 0.849, 0.927, 0.896, 0.922, 0.925,(14.9546)+(−0.1717)Asn+(0.1391)Tyr+(−0.0155)Val+(−0.2103)Met+(−0.0281)Orn+(−0.1382)Tr p; 0.935,0.955, 0.864, 0.922, 0.911, 0.893, 0.920, (14.3376)+(0.0176)Ser+(−0.1990)Asn+(−0.0167)Ala+(−0.0661)Cit+(0.1131)Tyr+(−0.1522)Trp;0.935, 0.955, 0.801, 0.916, 0.900, 0.883, 0.913, (14.0874)+(−0.1543)Asn+(−0.0185)Thr+(−0.0148)Ala+(0.1343)Tyr+(−0.0276)Orn+(−0.1442)Trp;0.935, 0.952, 0.840, 0.914, 0.900, 0.880, 0.911,(10.8203)+(0.0236)Ser+(−0.0155)Gly+(−0.0140)Ala+(0.1298)Tyr+(−0.0314)Lys+(−0.1545)Trp; 0.935, 0.950, 0.811, 0.914, 0. 900,0.886, 0.912, (12.2540)+(−0.0097)Gly+(−0.0151)Thr+(−0.0119)Ala+(0.1445)Tyr+(−0.2381)Met+(−0.1539)Trp; 0.935, 0.955, 0.8 23,0.919, 0.900, 0.896, 0.917,(14.7476)+(−0.1586)Asn+(−0.0144)Ala+(0.1432)Tyr+(−0.0249)Orn+(−0.0188)Lys+(−0.1482)Trp;0.93 5, 0.957, 0.822, 0.920, 0.900, 0.897, 0.918, (14.0739)+(−0.1276)Asn+(−0.0136)Ala+(0.1568)Tyr+(−0.1877)Met+(−0.0328)Orn+(−0.15 44)Trp;0.935, 0.956, 0.866, 0.923, 0.907, 0.897, 0.920,(13.1599)+(−0.0120)Gly+(−0.0565)His+(−0.0124)Ala+(−0.0288)Cit+(0.0917)Tyr+(−0.1422)Trp; 0.935, 0.954, 0.848, 0.919, 0.912, 0.883, 0.91 6,(14.7472)+(−0.0125)Gly+(−0.0667)His+(−0.0122)Ala+(0.1020)Tyr+(−0.0514)Phe+(−0.1290)Trp; 0.934, 0.956, 0.817, 0.920, 0.903, 0.892,0.917, (15.0014)+(−0.1917)Asn+(−0.0131)Ala+(0.1274)Tyr+(−0.0092)Val+(−0.0307)Orn+(−0.1386)Trp; 0.934, 0.954, 0.826, 0. 918,0.901, 0.889, 0.915,(12.1119)+(−0.0106)Gly+(−0.0118)Ala+(0.1440)Tyr+(−0.2899)Met+(0.0002)Leu+(−0.1606)Trp;0.934, 0.9 53, 0.821, 0.916, 0.904, 0.882, 0.913,(10.9010)+(−0.0107)Gly+(0.0033)Gln+(−0.0120)Ala+(0.1417)Tyr+(−0.3117)Met+(−0.1582)Tr p; 0.934,0.954, 0.862, 0.895, 0.872, 0.845, 0.891, (10.1814)+(−0.0252)Ala+(0.0068)Pro+(0.1339)Tyr+(−0.0472)Lys+(0.1043)Ile+(−0.1663)Trp;0.934, 0.955, 0.840, 0.923, 0.904, 0.905, 0.921, (14.8658)+(−0.1515)Asn+(−0.0183)Thr+(−0.0150)Ala+(−0.0497)Cit+(0.1206)Tyr+(−0.1477)Trp; 0.934, 0.953, 0.851, 0.928, 0.897, 0.929, 0. 926,(14.1169)+(−0.1226)Asn+(−0.0124)Gly+(0.1356)Tyr+(−0.2046)Met+(−0.0316)Orn+(−0.1602)Trp; 0.934, 0.955, 0.818, 0.921, 0.9 05,0.897, 0.919, (14.6476)+(−0.1394)Asn+(−0.0183)Thr+(−0.0143)Ala+(0.1373)Tyr+(−0.0194)Lys+(−0.1376)Trp; 0.934, 0.952, 0.8 99,0.925, 0.909, 0.910, 0.924, (12.5242)+(0.0388)Ser+(−0.1621)Asn+(−0.0187)Gly+(0.1221)Tyr+(−0.2685)Met+(−0.1466)Trp; 0.934, 0.949,0.845, 0.891, 0.865, 0.846, 0.887,(10.1038)+(−0.0243)Ala+(0.1393)Tyr+(−0.0448)Lys+(0.1060)Ile+(−0.1693)Trp;0.934, 0.9 48, 0.834, 0.921, 0.893, 0.918, 0.920,(11.7488)+(−0.0134)Gly+(0.1493)Tyr+(−0.3266)Met+(−0.0313)Orn+(−0.1722)Trp; 0.934, 0.953, 0.828,0.920, 0.908, 0.891, 0.917, (14.4137)+(−0.1406)Asn+(−0.0093)Gly+(−0.0184)Thr+(−0.0125)Ala+(0.1134)Tyr+(−0.1400)Trp; 0. 934,0.951, 0.861, 0.925, 0.901, 0.918, 0.923,(13.0882)+(−0.0131)Gly+(−0.0449)His+(0.1309)Tyr+(−0.2602)Met+(−0.0256)Orn+(−0.1508)Trp; 0.934, 0.952, 0.831, 0.920, 0.908, 0.893, 0.918, (14.6503)+(−0.1578)Asn+(−0.0147)Ala+(0.1316)Tyr+(−0.0230)Lys+(−0.1 437)Trp;0.934, 0.953, 0.830, 0.923, 0.904, 0.907, 0.921, (11.4657)+(−0.0146)Gly+(0.0028)Gln+(0.1308)Tyr+(−0.0122)Val+(−0.3437)Met+(−0.1493)Trp

List (2) of Logistic Regression Equations Searched in Example 8

The logistic regression equations searched in Example 8 above are listedbelow. Before each equation, “the value of ROC_AUC for the pancreaticcancer group and the breast cancer group with validation”, “the value ofROC_AUC for the pancreatic cancer group and the breast cancer groupwithout validation”, “the value of ROC_AUC for the pancreatic cancergroup and the healthy group”, “the value of ROC_AUC for the pancreaticcancer group and the other cancers group”, “the value of ROC_AUC for thepancreatic cancer group and the lung cancer group”, “the value ofROC_AUC for the pancreatic cancer group and the colorectal cancergroup”, and “the average value of the value of ROC_AUC for thepancreatic cancer group and the lung cancer group, the value of ROC_AUCfor the pancreatic cancer group and the colorectal cancer group, and thevalue of ROC_AUC for the pancreatic cancer group and the breast cancergroup” obtained for the equation are additionally listed.

0.878, 0.923, 0.927, 0.909, 0.900, 0.901, 0.908, (9.6001)+(0.0010)Gln+(−0.1052)His+(−0.0386)Arg+(0.0762)Tyr+(0.0049)Ile+(−0.1257)Trp;0.856, 0.914, 0.927, 0.906, 0.919, 0.882, 0.905, (8.8698)+(0.0050)Gln+(−0.1070)His+(−0.0297)Cit+(−0.0255)Arg+(0.0249)Ile+(−0.0876)Trp; 0.878, 0.925, 0.926, 0.915, 0.905, 0.913, 0. 914,(9.4249)+(0.0020)Gln+(−0.0976)His+(−0.0257)Cit+(−0.0351)Arg+(0.0781)Tyr+(−0.1311)Trp; 0.856, 0.909, 0.926, 0.899, 0.91 5,0.871, 0.898, (8.5944)+(0.0042)Gln+(−0.1176)His+(−0.0314)Arg+(0.0224)Ile+(0.0210)Phe+(−0.0870)Trp; 0.883, 0.923, 0.925, 0. 912,0.899, 0.912, 0.911,(9.9732)+(−0.0965)His+(−0.0219)Cit+(−0.0338)Arg+(0.0784)Tyr+(0.0045)Ile+(−0.1313)Trp;0.852, 0.905, 0.925, 0.890, 0.905, 0.857, 0.889,(9.7626)+(−0.0840)His+(−0.0351)Arg+(0.0775)Ile+(−0.0405)Leu+(0.0236)Phe+(−0.0852)Trp; 0.8 59, 0.911,0.924, 0.898, 0.906, 0.872, 0.896, (8.8638)+(0.0075)Gln+(−0.1049)His+(−0.0193)Arg+(−0.0250)Lys+(0.0456)Ile+(−0.080 9)Trp;0.877, 0.922, 0.924, 0.908, 0.907, 0.891, 0.907,(9.8083)+(−0.0784)His+(−0.0460)Arg+(0.0750)Tyr+(0.0530)Ile+(−0.0358)Leu+(−0.1225)Trp; 0.879, 0.923, 0.923, 0.908, 0.898, 0.901, 0.907, (9.8751)+(−0.1039)His+(−0.0376)Arg+(0.0774)Tyr+(0.0043)Ile+(0.0030)Phe+(−0.1276)Trp; 0.852, 0.909, 0.923, 0.898, 0.912, 0.869, 0. 897,(9.6098)+(0.0024)Gln+(−0.0889)His+(−0.0357)Arg+(0.0729)Ile+(−0.0357)Leu+(−0.0792)Trp;0.888, 0.924, 0.923, 0.909, 0.900, 0.901, 0.908,(9.9446)+(−0.1035)His+(−0.0375)Arg+(0.0780)Tyr+(0.0046)Ile+(−0.1272)Trp;0.839, 0.905, 0.922, 0.894, 0.910, 0.86 4, 0.893,(10.3931)+(−0.0806)His+(−0.0101)Cit+(−0.0305)Arg+(0.0755)Ile+(−0.0371)Leu+(−0.0825)Trp; 0.883, 0.924, 0.922, 0.911, 0.901,0.905, 0.910, (9.7155)+(0.0010)Gln+(−0.1041)His+(−0.0384)Arg+(0.0793)Tyr+(−0.1277)Trp; 0.879, 0.923, 0.922, 0.913, 0.90 0,0.914, 0.912,(10.0421)+(−0.0958)His+(−0.0218)Cit+(−0.0337)Arg+(0.0809)Tyr+(0.0010)Phe+(−0.1332)Trp;0.875, 0.923, 0.922, 0.910, 0.901, 0.904, 0.909,(9.5308)+(0.0011)Gln+(−0.1051)His+(−0.0387)Arg+(0.0778)Tyr+(0.0054)Phe+(−0.1280)Trp;0.886, 0.9 23, 0.921, 0.913, 0.900, 0.914, 0.912,(10.0671)+(−0.0956)His+(−0.0220)Cit+(−0.0337)Arg+(0.0812)Tyr+(−0.1331)Trp; 0.867, 0.907, 0.921,0.900, 0.917, 0.873, 0.899, (9.2775)+(0.0038)Gln+(−0.1150)His+(−0.0292)Arg+(0.0247)Ile+(−0.0826)Trp; 0.893, 0.924, 0.9 21,0.910, 0.898, 0.905, 0.909,(10.0339)+(−0.1026)His+(−0.0374)Arg+(0.0809)Tyr+(−0.1290)Trp; 0.883,0.924, 0.920, 0.909, 0.898, 0.903, 0.908,(9.9431)+(−0.1031)His+(−0.0375)Arg+(0.0799)Tyr+(0.0037)Phe+(−0.1294)Trp;0.856, 0.907, 0.920, 0.895, 0.908, 0.86 5, 0.893,(10.4038)+(−0.0830)His+(−0.0327)Arg+(0.0770)Ile+(−0.0383)Leu+(−0.0808)Trp; 0.857, 0.912, 0.920, 0.898, 0.905, 0.872, 0. 897,(8.3365)+(0.0077)Gln+(−0.0942)His+(−0.0392)Cit+(−0.0285)Lys+(0.0450)Ile+(−0.0831)Trp; 0.854, 0.902, 0.918, 0.895, 0.91 3,0.867, 0.894, (10.1863)+(−0.1042)His+(−0.0185)Cit+(−0.0211)Arg+(0.0244)Ile+(0.0154)Phe+(−0.0922)Trp; 0.845, 0.897, 0.918, 0.883,0.897, 0.851, 0.882,(9.0563)+(−0.0936)His+(−0.0351)Cit+(0.0462)Ile+(−0.0209)Leu+(0.0101)Phe+(−0.0839)Trp;0.873, 0.9 03, 0.918, 0.896, 0.913, 0.870, 0.895,(10.6087)+(−0.1088)His+(−0. 0235)Arg+(0.0256)Ile+(−0.0853)Trp; 0.859,0.910, 0.918, 0.890, 0. 896, 0.858, 0.888,(8.0345)+(0.0061)Gln+(−0.1078)His+(−0.0304)Lys+(0.0433)Ile+(0.0228)Phe+(−0.0800)Trp; 0.864, 0.903, 0.917, 0.894,0.910, 0.866, 0.893, (10.1783)+(−0.1106)His+(−0.0248)Arg+(0.0239)Ile+(0.0167)Phe+(−0.0888)Trp; 0.845, 0.912, 0.916, 0.8 93,0.901, 0.863, 0.892,(10.8910)+(−0.0765)His+(−0.0203)Arg+(−0.0162)Lys+(0.0819)Ile+(−0.0320)Leu+(−0.0813)Trp;0.862, 0.90 6, 0.916, 0.892, 0.904, 0.861, 0.890,(10.5355)+(−0.0976)His+(−0.0126)Arg+(−0.0200)Lys+(0.0412)Ile+(0.0220)Phe+(−0.0891)Trp; 0.885,0.921, 0.916, 0.909, 0.900, 0.905, 0.909, (10.2678)+(−0.0925)His+(−0.0396)Arg+(0.0892)Tyr+(−0.0102)Leu+(−0.1337)Trp; 0. 851, 0.895,0.915, 0.885, 0.899, 0.857, 0.884, (9.3770)+(−0.0927)His+(−0.0351)Cit+(0.0470)Ile+(−0.0205)Leu+(−0.0821)Trp; 0.886, 0.936,0.915, 0.926, 0.917, 0.923, 0.925,(11.1011)+(−0.1844)Asn+(0.0062)Gln+(−0.0780)His+(−0.0271)Arg+(0.0716)Tyr+(−0.1071)Trp;0.876, 0.920, 0.915, 0.909, 0.901, 0.903, 0.908, (10.0831)+(−0.0930)His+(−0.0400)Arg+(0.0877)Tyr+(−0.0108)Leu+(0.0084)Phe+(−0.1348)Trp;0.874, 0.921, 0.915, 0.910, 0.901, 0.905, 0.909, (10.1698)+(0.0003)Gln+(−0.0931)His+(−0.0398)Arg+(0.0886)Tyr+(−0.0100)Leu+(−0.1333)Trp; 0.851, 0.905, 0.915, 0.890, 0.899, 0.862, 0. 889,(10.2816)+(−0.0898)His+(−0.0242)Cit+(−0.0225)Lys+(0.0415)Ile+(0.0199)Phe+(−0.0906)Trp; 0.860, 0.902, 0.915, 0.897, 0.91 5,0.872, 0.896, (10.5947)+(−0.1021)His+(−0.0201)Cit+(−0.0197)Arg+(0.0261)Ile+(−0.0894)Trp; 0.848, 0.898, 0.914, 0.879, 0.894, 0.841,0.877,(8.7586)+(−0.1076)His+(0.0447)Ile+(−0.0216)Leu+(0.0086)Phe+(−0.0739)Trp;0.880, 0.923, 0.914, 0.912, 0.900, 0.91 1, 0.911,(10.3061)+(−0.0863)His+(−0.0210)Cit+(−0.0361)Arg+(0.0895)Tyr+(−0.0100)Leu+(−0.1375)Trp; 0.860, 0.914, 0.914, 0.902, 0.919,0.868, 0.900, (8.7347)+(0.0074)Gln+(−0.1182)His+(−0.0271)Arg+(−0.0340)Orn+(0.0347)Ile+(−0.0829)Trp; 0.840, 0.896, 0.9 13,0.886, 0.899, 0.859, 0.885, (8.9963)+(0.0011)Gln+(−0.0949)His+(−0.0380)Cit+(0.0440)Ile+(−0.0187)Leu+(−0.0821)Trp; 0.889, 0.938,0.913, 0.927, 0.909, 0.931, 0.926,(12.9372)+(−0.1672)Asn+(−0.0593)His+(−0.0312)Cit+(−0.0174)Arg+(0.0835)Tyr+(−0.1279)Trp; 0.873, 0.924, 0.913, 0.911, 0.918, 0.887, 0.910,(14.1381)+(−0.1398)Asn+(−0.0613)His+(−0.0223)Cit+(−0.0137)Lys+(0.0219)Ile+(−0.0808)Trp; 0.850, 0.908, 0.913, 0.888, 0.894, 0.858, 0.88 6,(8.9650)+(0.0048)Gln+(−0.0968)His+(−0.0279)Lys+(0.0630)Ile+(−0.0151)Leu+(−0.0723)Trp; 0.829, 0.893, 0.913, 0.880, 0.893, 0. 848,0.878,(6.9815)+(0.0070)Gln+(−0.1203)His+(−0.0170)Arg+(−0.0236)Lys+(0.0803)Ile+(−0.0295)Leu;0.865, 0.906, 0.913, 0.890, 0.897, 0.861, 0.888,(8.8005)+(0.0058)Gln+(−0.1058)His+(−0.0290)Lys+(0.0444)Ile+(−0.0755)Trp; 0.844, 0.903, 0.913, 0.900, 0.91 7,0.880, 0.900, (8.4103)+(0.0059)Gln+(−0.1058)His+(−0.0297)Cit+(−0.0249)Arg+(0.0261)Phe+(−0.0931)Trp; 0.853, 0.897, 0.912, 0. 885,0.895, 0.860, 0.884, (9.5213)+(−0.1040)His+(−0.0362)Cit+(0.0198)Ile+(0.0084)Phe+(−0.0902)Trp; 0.864, 0.906, 0.912, 0.884, 0. 882,0.860, 0.883, (8.2547)+(−0.1087)His+(0.0439)Tyr+(0.0252)Ile+(−0.0164)Leu+(−0.0941)Trp; 0.857, 0.902, 0.912, 0.898, 0.916, 0.875,0.898,(8.8568)+(0.0046)Gln+(−0.1133)His+(−0.0288)Arg+(0.0260)Phe+(−0.0884)Trp;0.850, 0.902, 0.912, 0.898, 0.916, 0.87 5, 0.898,(8.8496)+(0.0046)Gln+(−0.1137)His+(−0.0288)Arg+(0.0004)Leu+(0.0258)Phe+(−0.0884)Trp; 0.854, 0.905, 0.911, 0.893, 0. 904,0.865, 0.892, (11.0651)+(−0.0894)His+(−0.0185)Cit+(−0.0076)Arg+(−0.0192)Lys+(0.0423)Ile+(−0.0880)Trp; 0.858, 0.895, 0.9 11,0.886, 0.898, 0.862, 0.885, (9.7757)+(−0.1031)His+(−0.0363)Cit+(0.0209)Ile+(−0.0885)Trp; 0.843, 0.903, 0.911, 0.888, 0.896, 0. 860,0.886,(10.5209)+(−0.0775)His+(−0.0227)Cit+(−0.0215)Lys+(0.0694)Ile+(−0.0216)Leu+(−0.0811)Trp;0.874, 0.924, 0.911, 0.9 06, 0.912, 0.880, 0.905,(13.6158)+(−0.1402)Asn+(−0.0713)His+(−0.0156)Lys+(0.0215)Ile+(0.0135)Phe+(−0.0766)Trp;0.845, 0.906, 0.911, 0.905, 0.922, 0.886, 0.905,(9.1990)+(0.0055)Gln+(−0.1051)His+(−0.0314)Cit+(−0.0217)Arg+(0.0038)Leu+(−0.0884)Trp; 0. 860, 0.907,0.910, 0.885, 0.882, 0.862, 0.884, (8.3024)+(−0.1085)His+(0.0443)Tyr+(0.0252)Ile+(−0.0163)Leu+(−0.0019)Phe+(−0.09 39)Trp;0.855, 0.898, 0.910, 0.880, 0.893, 0.843, 0.878,(9.0287)+(−0.1068)His+(0.0455)Ile+(−0.0213)Leu+(−0.0722)Trp; 0.838, 0.897, 0.910, 0.877, 0.890, 0.840, 0.875, (9.1904)+(−0.0011)Gln+(−0.1042)His+(0.0479)Ile+(−0.0234)Leu+(0.0083)Phe+(−0.0747)Trp; 0.854,0.907, 0.910, 0.885, 0.890, 0.851, 0.883, (10.4124)+(−0.0856)His+(−0.0229)Lys+(0.0703)Ile+(−0.0224)Leu+(−0.0752)Trp; 0. 848, 0.906,0.910, 0.883, 0.889, 0.849, 0.881, (9.7873)+(−0.0866)His+(−0.0241)Lys+(0.0707)Ile+(−0.0233)Leu+(0.0210)Phe+(−0.07 88)Trp;0.917, 0.952, 0.910, 0.908, 0.888, 0.874, 0.905,(12.0134)+(−0.0750)His+(−0.0226)Ala+(0.1357)Tyr+(−0.0433)Lys+(0.0960)Ile+(−0.1473)Trp;0.864, 0.922, 0.910, 0.906, 0.914, 0.878, 0.905,(13.9693)+(−0.1394)Asn+(−0.0710)His+(−0.0005)Pro+(−0.0147)Lys+(0.0231)Ile+(−0.0734)Trp; 0.861, 0.910, 0.910, 0.891, 0.881, 0. 877,0.889, (8.6416)+(−0.0913)His+(−0.0449)Cit+(0.0518)Tyr+(0.0246)Ile+(−0.0160)Leu+(−0.1099)Trp; 0.846, 0.907, 0.910, 0.891, 0.904,0.857, 0.890, (10.8127)+(−0.0790)His+(−0.0271)Arg+(−0.0252)Orn+(0.0869)Ile+(−0.0403)Leu+(−0.0825)Trp; 0.868, 0.906, 0. 909,0.893, 0.906, 0.862, 0.891, (11.0959)+(−0.0955)His+(−0.0113)Arg+(−0.0192)Lys+(0.0422)Ile+(−0.0847)Trp; 0.857, 0.902, 0.9 09,0.891, 0.901, 0.867, 0.890,(10.8521)+(−0.0882)His+(−0.0242)Cit+(−0.0213)Lys+(0.0424)Ile+(−0.0870)Trp;0.847, 0.897, 0.909, 0.880, 0.893, 0.844, 0.878,(9.4678)+(−0.0011)Gln+(−0.1032)His+(0.0488)Ile+(−0.0232)Leu+(−0.0731)Trp;0.898, 0.934, 0.909, 0.9 21, 0.905, 0.922, 0.921,(9.9364)+(−0.0678)His+(−0.0228)Arg+(0.1032)Tyr+(−0.2902)Met+(0.0304)Phe+(−0.1309)Trp; 0.882, 0.922, 0.909,0.907, 0.915, 0.879, 0.905, (13.9887)+(−0.1405)Asn+(−0.0704)His+(−0.0149)Lys+(0.0224)Ile+(−0.0735)Trp; 0.867, 0.921, 0. 909,0.906, 0.915, 0.879, 0.905, (13.9854)+(−0.1386)Asn+(−0.0701)His+(−0.0064)Met+(−0.0147)Lys+(0.0224)Ile+(−0.0733)Trp; 0. 869, 0.922,0.909, 0.906, 0.915, 0.879, 0.905, (13.9674)+(−0.1414)Asn+(−0.0703)His+(0.0010)Arg+(−0.0152)Lys+(0.0223)Ile+(−0.0 730)Trp;0.848, 0.898, 0.908, 0.888, 0.901, 0.862, 0.887,(8.7919)+(0.0025)Gln+(−0.1058)His+(−0.0429)Cit+(0.0193)Ile+(−0.0876)Trp;0.902, 0.940, 0.908, 0.926, 0.901, 0.934, 0.925, (12.4034)+(−0.1371)Asn+(−0.0424)His+(−0.0386)Cit+(0.0954)Tyr+(−0.1758)Met+(−0.1255)Trp; 0.882, 0.936, 0.908, 0.923, 0.911, 0.919, 0.922, (12.7284)+(0.0009)Ser+(−0.1668)Asn+(−0.0699)His+(−0.0230)Arg+(0.0823)Tyr+(−0.1190)Trp; 0.870, 0.926, 0.908, 0.913, 0.917, 0.894, 0. 912,(13.5663)+(−0.1599)Asn+(−0.0658)His+(−0.0299)Cit+(0.0032)Ile+(0.0120)Phe+(−0.0827)Trp; 0.843, 0.897, 0.908, 0.887, 0.89 8,0.863, 0.886, (8.4470)+(0.0027)Gln+(−0.1069)His+(−0.0432)Cit+(0.0178)Ile+(0.0099)Phe+(−0.0896)Trp; 0.838, 0.890, 0.908, 0. 877,0.890, 0.846, 0.876, (6.1643)+(0.0088)Gln+(−0.1408)His+(−0.0124)Arg+(−0.0275)Lys+(0.0435)Ile+(0.0104)Phe; 0.895, 0.936, 0. 908,0.924, 0.909, 0.926, 0.924, (9.5592)+(0.0028)Gln+(−0.0715)His+(−0.0243)Arg+(0.1018)Tyr+(−0.2678)Met+(−0.1206)Trp; 0.893, 0.936,0.908, 0.923, 0.911, 0.919, 0.922,(12.7996)+(−0.1646)Asn+(−0.0701)His+(−0.0229)Arg+(0.0820)Tyr+(−0.1195)Trp;0.887, 0. 936, 0.908, 0.924, 0.912, 0.923, 0.924,(12.9743)+(−0.1657)Asn+(−0.0693)His+(−0.0222)Arg+(0.0833)Tyr+(−0.0068)Phe+(−0.1184)Trp; 0.872, 0.926, 0.908, 0.917, 0.926, 0.897, 0.916, (10.7486)+(−0.1900)Asn+(0.0100)Gln+(−0.0896)His+(−0.0197)Arg+(0.0165)Phe+(−0.0661)Trp;0.868, 0.921, 0.908, 0.906, 0.912, 0.882, 0.905, (14.1516)+(−0.0023)Ser+(−0.1355)Asn+(−0.0708)His+(−0.0148)Lys+(0.0225)Ile+(−0.0756)Trp;0.858, 0.902, 0.908, 0.900, 0.918, 0.87 7, 0.899,(9.6592)+(0.0042)Gln+(−0.1120)His+(−0.0255)Arg+(0.0026)Leu+(−0.0828)Trp; 0.844, 0.896, 0.907, 0.873, 0.878, 0.839, 0. 871,(7.1016)+(0.0059)Gln+(−0.1236)His+(−0.0282)Lys+(0.0739)Ile+(−0.0244)Leu;0.833, 0.904, 0.907, 0.894, 0.909, 0.865, 0.893,(9.3694)+(0.0046)Gln+(−0.1205)His+(−0.0238)Arg+(−0.0096)Pro+(0.0380)Ile+(−0.0832)Trp; 0.915, 0.952, 0.907, 0.929, 0.911, 0.9 19,0.927,(13.1055)+(0.0246)Ser+(−0.1652)Asn+(−0.0220)Gly+(−0.0550)His+(0.0798)Tyr+(−0.1402)Trp;0.871, 0.924, 0.907, 0.914, 0.918, 0.898, 0.913,(13.8954)+(−0.1569)Asn+(−0.0662)His+(−0.0271)Cit+(−0.0013)Arg+(0.0056)Ile+(−0.0798)Trp; 0.869, 0.926, 0. 907,0.913, 0.917, 0.894, 0.912, (13.7453)+(−0.1599)Asn+(−0.0648)His+(−0.0283)Cit+(−0.0018)Arg+(0.0136)Phe+(−0.0841)Trp; 0. 865, 0.917,0.907, 0.889, 0.895, 0.850, 0.887, (9.5610)+(−0.0680)His+(−0.0515)Arg+(0.0712)Tyr+(−0.0348)Val+(0.0951)Ile+(−0.10 19)Trp;0.854, 0.900, 0.907, 0.897, 0.917, 0.873, 0.897,(8.9866)+(0.0046)Gln+(−0.1077)His+(−0.0288)Arg+(−0.0035)Val+(0.0284)Phe+(−0.0874)Trp;0.850, 0.906, 0.907, 0.905, 0.922, 0.886, 0.905,(9.3514)+(0.0054)Gln+(−0.1016)His+(−0.0302)Cit+(−0.0217)Arg+(−0.0878)Trp; 0.869, 0.907, 0.907, 0.885, 0.879, 0.864, 0.884, (8.4769)+(−0.1175)His+(0.0479)Tyr+(0.0032)Ile+(−0.1006)Trp; 0.8 54, 0.910,0.907, 0.898, 0.906, 0.876, 0.897, (12.5091)+(−0.0195)Ser+(−0.0783)His+(−0.0273)Arg+(0.0748)Ile+(−0.0375)Leu+(−0.0 924)Trp;0.840, 0.897, 0.907, 0.871, 0.875, 0.836, 0.869,(6.6755)+(0.0060)Gln+(−0.1246)His+(−0.0289)Lys+(0.0743)Ile+(−0.0251)Leu+(0.0113)Phe;0.829, 0.894, 0.907, 0.876, 0.884, 0.846, 0.875,(6.7089)+(0.0072)Gln+(−0.1209)His+(−0.0213)Cit+(−0.0284)Lys+(0.0722)Ile+(−0.0224)Leu; 0.879, 0.923, 0.907, 0.909, 0.900, 0.9 02,0.908,(10.4669)+(−0.0816)His+(−0.0193)Cit+(−0.0374)Arg+(0.0952)Tyr+(−0.0094)Val+(−0.1365)Trp;0.876, 0.925, 0.907, 0.9 13, 0.917, 0.894, 0.912,(13.7038)+(−0.1617)Asn+(−0.0645)His+(−0.0298)Cit+(0.0129)Phe+(−0.0835)Trp;0.870, 0.923, 0.907, 0.909, 0.915, 0.887, 0.908,(13.5547)+(−0.1521)Asn+(−0.0781)His+(−0.0086)Arg+(0.0055)Ile+(0.0110)Phe+(−0.0764)Trp; 0.860, 0.901, 0. 906,0.883, 0.892, 0.851, 0.881, (10.1853)+(−0.0988)His+(−0.0238)Lys+(0.0415)Ile+(0.0191)Phe+(−0.0843)Trp; 0.845, 0.907, 0.90 6, 0.876,0.886, 0.828, 0.874, (10.8001)+(−0.0636)His+(−0.0267)Arg+(−0.0353)Val+(−0.0186)Lys+(0.1318)Ile+(−0.0615)Trp; 0.840, 0.901,0.906, 0.874, 0.870, 0.844, 0.872,(6.7544)+(0.0049)Gln+(−0.1223)His+(0.0298)Tyr+(−0.0317)Lys+(0.0706)Ile+(−0.0256)Leu

List (2) of Linear Discriminants Searched in Example 8

The linear discriminants searched in Example 8 above are listed below.Before each equation, “the value of ROC_AUC for the pancreatic cancergroup and the breast cancer group with validation”, “the value ofROC_AUC for the pancreatic cancer group and the breast cancer groupwithout validation”, “the value of ROC_AUC for the pancreatic cancergroup and the healthy group”, “the value of ROC_AUC for the pancreaticcancer group and the other cancers group”, “the value of ROC_AUC for thepancreatic cancer group and the lung cancer group”, “the value ofROC_AUC for the pancreatic cancer group and the colorectal cancergroup”, and “the average value of the value of ROC_AUC for thepancreatic cancer group and the lung cancer group, the value of ROC_AUCfor the pancreatic cancer group and the colorectal cancer group, and thevalue of ROC_AUC for the pancreatic cancer group and the breast cancergroup” obtained for the equation are additionally listed.

0.896, 0.924, 0.943, 0.907, 0.901, 0.893, 0.906, (10.5615)+(0.0037)Gln+(−0.1087)His+(−0.0445)Arg+(0.0653)Tyr+(0.0380)Ile+(−0.1489)Trp;0.895, 0.921, 0.943, 0.902, 0.897, 0.885, 0.901, (11.7120)+(−0.0796)His+(−0.0490)Arg+(0.0724)Tyr+(0.0897)Ile+(−0.0380)Leu+(−0.1510)Trp; 0.882, 0.917, 0.943, 0.902, 0.912, 0.873, 0. 901,(10.4832)+(0.0072)Gln+(−0.1152)His+(−0.0273)Cit+(−0.0334)Arg+(0.0505)Ile+(−0.1141)Trp; 0.883, 0.913, 0.942, 0.900, 0.91 1,0.872, 0.899, (10.5912)+(0.0066)Gln+(−0.1228)His+(−0.0359)Arg+(0.0473)Ile+(−0.1069)Trp; 0.878, 0.910, 0.942, 0.899, 0.911, 0. 874,0.898,(10.3696)+(0.0067)Gln+(−0.1228)His+(−0.0366)Arg+(0.0469)Ile+(0.0053)Phe+(−0.1082)Trp;0.876, 0.911, 0.941, 0.89 3, 0.901, 0.863, 0.892,(11.1623)+(0.0049)Gln+(−0.1018)His+(−0.0405)Arg+(0.0916)Ile+(−0.0320)Leu+(−0.1048)Trp; 0.895, 0.921, 0.940,0.908, 0.898, 0.902, 0.907, (11.7459)+(−0.0948)His+(−0.0213)Cit+(−0.0381)Arg+(0.0714)Tyr+(0.0400)Ile+(−0.1586)Trp; 0. 882, 0.916,0.939, 0.900, 0.909, 0.870, 0.899, (10.2523)+(0.0079)Gln+(−0.1137)His+(−0.0243)Arg+(−0.0173)Lys+(0.0587)Ile+(−0.0 985)Trp;0.876, 0.913, 0.938, 0.900, 0.911, 0.871, 0.898, (10.5605)+(0.0067)Gln+(−0.1234)His+(−0.0349)Arg+(−0.0018)Pro+(0.0491)Ile+(−0.1059)Trp; 0.900, 0.927, 0.937, 0.909, 0.898, 0.898, 0.90 8,(12.6498)+(−0.1023)His+(−0.0383)Arg+(0.0775)Tyr+(0.0388)Ile+(−0.0307)Phe+(−0.1495)Trp; 0.884, 0.914, 0.936, 0.900, 0.914, 0.868,0.899,(9.9586)+(0.0086)Gln+(−0.1245)His+(−0.0316)Arg+(−0.0252)Orn+(0.0559)Ile+(−0.1032)Trp;0.914, 0.939, 0.935, 0.9 20, 0.927, 0.890, 0.919,(11.6880)+(−0.0161)Gly+(0.0087)Gln+(−0.1109)His+(−0.0326)Arg+(0.0504)Ile+(−0.1027)Trp; 0.902, 0.923, 0.934,0.908, 0.898, 0.901, 0.907, (11.6884)+(−0.1016)His+(−0.0405)Arg+(0.0710)Tyr+(0.0375)Ile+(−0.1527)Trp; 0.926, 0.945, 0.9 33,0.925, 0.913, 0.912, 0.923, (13.3589)+(−0.0158)Gly+(−0.0857)His+(−0.0354)Arg+(0.0757)Tyr+(0.0401)Ile+(−0.1518)Trp; 0.885, 0.917,0.933, 0.902, 0.908, 0.878, 0.901,(10.9845)+(−0.0122)Ser+(0.0075)Gln+(−0.1190)His+(−0.0335)Arg+(0.0494)Ile+(−0.1086)Trp; 0.913, 0.936, 0.931, 0.915, 0.923, 0.881, 0.913, (13.5929)+(0.0203)Ser+(−0.0187)Gly+(−0.1029)His+(−0.0261)Arg+(0.0483)Ile+(−0.0997)Trp; 0.893, 0.923, 0.931, 0.905, 0.891, 0.898, 0.904, (11.6722)+(−0.1017)His+(−0.0382)Arg+(−0.0052)Pro+(0.0766)Tyr+(0.0418)Ile+(−0.1536)Trp; 0.886, 0.920, 0.931, 0.897, 0.900, 0.867, 0. 896,(9.8279)+(0.0079)Gln+(−0.0960)His+(−0.0483)Cit+(−0.0254)Lys+(0.0659)Ile+(−0.1057)Trp; 0.878, 0.907, 0.931, 0.891, 0.90 0,0.860, 0.889, (12.7518)+(−0.0908)His+(−0.0349)Arg+(0.0984)Ile+(−0.0366)Leu+(−0.1047)Trp; 0.874, 0.908, 0.931, 0.890, 0.900, 0.857,0.888, (12.3164)+(−0.0891)His+(−0.0367)Arg+(0.0998)Ile+(−0.0383)Leu+(0.0127)Phe+(−0.1077)Trp; 0.874, 0.910, 0.931, 0. 892,0.901, 0.860, 0.891,(12.7898)+(−0.0872)His+(−0.0130)Cit+(−0.0332)Arg+(0.0989)Ile+(−0.0358)Leu+(−0.1082)Trp;0.907, 0. 932, 0.930, 0.913, 0.923, 0.878, 0.911,(14.5433)+(−0.0162)Gly+(−0.0706)His+(−0.0305)Arg+(0.1130)Ile+(−0.0447)Leu+(−0.1001)Irp; 0.892, 0.924, 0.929, 0.895, 0.894, 0.861, 0.893, (11.7007)+(−0.0696)His+(−0.0523)Arg+(0.0755)Tyr+(−0.0280)Val+(0.1034)Ile+(−0.1467)Trp;0.865, 0.907, 0.929, 0.891, 0.900, 0.862, 0.889, (12.7663)+(−0.0909)His+(−0.0341)Arg+(−0.0012)Pro+(0.0997)Ile+(−0.0367)Leu+(−0.1041)Trp;0.876, 0.911, 0.928, 0.892, 0.901, 0.860, 0.891,(12.8033)+(−0.0866)His+(−0.0266)Arg+(−0.0096)Lys+(0.0996)Ile+(−0.0328)Leu+(−0.1003)Trp; 0.872, 0.910, 0.928, 0.893, 0. 901,0.865, 0.892, (12.7713)+(−0.1058)His+(−0.0190)Cit+(−0.0245)Arg+(−0.0005)Pro+(0.0507)Ile+(−0.1120)Trp; 0.885, 0.910, 0.9 28,0.894, 0.903, 0.865, 0.893, (12.7657)+(−0.1057)His+(−0.0191)Cit+(−0.0248)Arg+(0.0503)Ile+(−0.1123)Trp; 0.877, 0.910, 0.928, 0.895,0.904, 0.866, 0.893, (12.9164)+(−0.1059)His+(−0.0192)Cit+(−0.0242)Arg+(0.0506)Ile+(−0.0044)Phe+(−0.1113)Trp; 0.900, 0. 927,0.927, 0.902, 0.886, 0.887, 0.900,(11.5713)+(−0.0828)His+(−0.0250)Arg+(0.0890)Tyr+(−0.0244)Lys+(0.0511)Ile+(−0.1525)Trp; 0.902, 0.930, 0.927, 0.912, 0.911, 0.889, 0.910, (15.7882)+(−0.1398)Asn+(−0.0689)His+(−0.0330)Cit+(−0.0112)Lys+(0.0428)Ile+(−0.0927)Trp;0.879, 0.912, 0.927, 0.888, 0.890, 0.855, 0.886, (9.5328)+(0.0064)Gln+(−0.1093)His+(−0.0254)Lys+(0.0581)Ile+(0.0109)Phe+(−0.0950)Trp; 0.878, 0.911, 0.927, 0.895, 0.901, 0.868, 0. 893,(12.8747)+(−0.0935)His+(−0.0262)Cit+(−0.0122)Arg+(−0.0150)Lys+(0.0611)Ile+(−0.1069)Trp; 0.914, 0.939, 0.926, 0.914, 0.9 16,0.882, 0.912,(11.1729)+(−0.0158)Gly+(0.0080)Gln+(−0.1004)His+(−0.0203)Lys+(0.0589)Ile+(−0.0909)Trp;0.905, 0.936, 0.926, 0.918, 0.914, 0.900, 0.917,(12.6371)+(−0.1861)Asn+(0.0103)Gln+(−0.0831)His+(−0.0526)Cit+(0.0262)Ile+(−0.0947)Trp;0.899, 0. 928, 0.926, 0.911, 0.914, 0.889, 0.910,(15.4137)+(0.0066)Ser+(−0.1637)Asn+(−0.0771)His+(−0.0330)Cit+(0.0287)Ile+(−0.0930)Tr p; 0.897,0.924, 0.926, 0.909, 0.894, 0.906, 0.908, (12.1993)+(−0.0089)Ser+(−0.0975)His+(−0.0379)Arg+(0.0712)Tyr+(0.0391)Ile+(−0.1542)Trp;0.876, 0.914, 0.926, 0.890, 0.899, 0.851, 0.888, (11.0445)+(0.0054)Gln+(−0.0933)His+(−0.0438)Arg+(−0.0246)Val+(0.1058)Ile+(−0.0992)Trp; 0.872, 0.908, 0.926, 0.889, 0.892, 0.862, 0. 887,(12.4787)+(−0.0894)His+(−0.0345)Cit+(0.0014)Pro+(−0.0200)Lys+(0.0613)Ile+(−0.1063)Trp; 0.870, 0.907, 0.926, 0.892, 0.90 4,0.859, 0.890, (12.8262)+(−0.1120)His+(−0.0263)Arg+(−0.0006)Pro+(0.0488)Ile+(−0.0032)Phe+(−0.1062)Trp; 0.876, 0.907, 0.925, 0.889,0.892, 0.861, 0.887, (12.3896)+(−0.0900)His+(−0.0337)Cit+(−0.0195)Lys+(0.0621)Ile+(0.0031)Phe+(−0.1064)Trp; 0.890, 0. 922,0.925, 0.913, 0.905, 0.909, 0.912, (10.9127)+(0.0037)Gln+(−0.0988)His+(−0.0410)Arg+(0.0730)Tyr+(0.0021)Leu+(−0.1470)Trp; 0.888,0.907, 0.925, 0.893, 0.905, 0.862, 0.892, (12.7085)+(−0.1117)His+(−0.0270)Arg+(0.0480)Ile+(−0.1073)Trp; 0.885, 0.915, 0.9 25,0.901, 0.908, 0.876, 0.900, (10.3213)+(0.0091)Gln+(−0.1112)His+(−0.0241)Arg+(−0.1761)Met+(0.0520)Ile+(−0.0913)Trp; 0.881, 0.910,0.925, 0.892, 0.899, 0.862, 0.890,(12.7530)+(−0.1081)His+(−0.0083)Cit+(−0.0224)Arg+(−0.0131)Orn+(0.0535)Ile+(−0.1076)Trp; 0.875, 0.907, 0.925, 0.892, 0.905, 0.861, 0.891,(12.7166)+(−0.1118)His+(−0.0266)Arg+(−0.0007)Pro+(0.0487)Ile+(−0.1069)Trp; 0.874, 0.909, 0.925, 0.891, 0.900, 0.861, 0.890,(12.7260)+(−0.1105)His+(−0.0231)Arg+(0.0004)Pro+(−0.0152)Orn+(0.0529)Ile+(−0.1053)Trp; 0.882, 0.913, 0.925, 0.894, 0.900, 0.863, 0.892,(13.3747)+(−0.0108)Ser+(−0.0849)His+(−0.0320)Arg+(0.1028)Ile+(−0.0384)Leu+(−0.1061)Trp; 0.881, 0.908, 0.925, 0.889, 0.892, 0. 862,0.887,(12.5014)+(−0.0904)His+(−0.0336)Cit+(−0.0192)Lys+(0.0622)Ile+(−0.1058)Trp;0.881, 0.907, 0.925, 0.892, 0.905, 0.86 1, 0.891,(12.8361)+(−0.1119)His+(−0.0266)Arg+(0.0483)Ile+(−0.0037)Phe+(−0.1064)Trp; 0.901, 0.928, 0.924, 0.907, 0.909, 0.878, 0. 905,(16.0042)+(−0.1870)Asn+(−0.0435)His+(−0.0319)Cit+(0.0932)Ile+(−0.0495)Leu+(−0.0864)Trp; 0.895, 0.926, 0.924, 0.912, 0.9 20,0.888, 0.911, (12.6275)+(−0.1644)Asn+(0.0099)Gln+(−0.1006)His+(−0.0174)Arg+(0.0256)Ile+(−0.0849)Trp; 0.893, 0.923, 0.924, 0.915,0.906, 0.914, 0.914,(10.9400)+(0.0039)Gln+(−0.0916)His+(−0.0155)Cit+(−0.0395)Arg+(0.0741)Tyr+(−0.1507)Trp;0.884, 0. 909, 0.924, 0.891, 0.899, 0.861, 0.890,(12.7311)+(−0.1106)His+(−0.0229)Arg+(−0.0149)Orn+(0.0532)Ile+(−0.1051)Trp;0.880, 0.91 0, 0.924, 0.888, 0.893, 0.855, 0.886,(10.0166)+(0.0061)Gln+(−0.1101)His+(−0.0242)Lys+(0.0583)Ile+(−0.0930)Trp; 0.877, 0.909, 0. 924,0.891, 0.899, 0.861, 0.890, (12.7606)+(−0.1107)His+(−0.0228)Arg+(−0.0149)Orn+(0.0533)Ile+(−0.0009)Phe+(−0.1049)Trp; 0. 914, 0.940,0.924, 0.917, 0.921, 0.884, 0.915, (14.4226)+(−0.0151)Gly+(−0.0910)His+(−0.0140)Arg+(−0.0094)Lys+(0.0574)Ile+(−0. 0989)Trp;0.878, 0.912, 0.924, 0.892, 0.901, 0.857, 0.890, (12.7774)+(−0.0892)His+(−0.0305)Arg+(−0.0163)Orn+(0.1051)Ile+(−0.0373)Leu+(−0.1023)Trp; 0.873, 0.910, 0.924, 0.892, 0.902, 0.861, 0. 891,(12.7745)+(−0.1020)His+(−0.0168)Arg+(0.0014)Pro+(−0.0143)Lys+(0.0562)Ile+(−0.1011)Trp; 0.875, 0.904, 0.923, 0.881, 0.88 7,0.847, 0.880, (11.3813)+(−0.0947)His+(−0.0339)Cit+(0.0750)Ile+(−0.0231)Leu+(−0.1108)Trp; 0.897, 0.923, 0.923, 0.913, 0.906, 0.908,0.912, (10.9813)+(0.0035)Gln+(−0.0964)His+(−0.0411)Arg+(0.0739)Tyr+(−0.1469)Trp; 0.883, 0.910, 0.923, 0.892, 0.901, 0.8 61,0.891,(12.7883)+(−0.1027)His+(−0.0164)Arg+(−0.0137)Lys+(0.0571)Ile+(−0.1007)Trp;0.909, 0.934, 0.923, 0.916, 0.920, 0.88 9, 0.914,(14.4257)+(−0.0153)Gly+(−0.0935)His+(−0.0109)Cit+(−0.0199)Arg+(0.0524)Ile+(−0.1063)Trp;0.873, 0.908, 0.923, 0.886, 0.890, 0.855, 0.884,(12.2612)+(−0.0795)His+(−0.0331)Cit+(−0.0188)Lys+(0.0904)Ile+(−0.0219)Leu+(−0.1036)Trp; 0.912, 0.934, 0. 923,0.918, 0.898, 0.921, 0.918, (11.9502)+(−0.0675)His+(−0.0236)Arg+(0.1184)Tyr+(−0.3005)Met+(0.0390)Ile+(−0.1568)Trp; 0.9 10, 0.936,0.923, 0.905, 0.887, 0.887, 0.903, (11.4866)+(−0.0966)His+(−0.0344)Arg+(0.0886)Tyr+(−0.0339)Orn+(0.0467)Ile+(−0.15 91)Trp;0.897, 0.924, 0.923, 0.896, 0.876, 0.884, 0.895,(11.1211)+(−0.0665)His+(−0.0458)Cit+(0.0869)Tyr+(−0.0325)Lys+(0.0581)Ile+(−0.1576)Trp; 0.893, 0.926, 0.923, 0.913, 0.908, 0.903, 0.912,(15.1663)+(−0.1644)Asn+(−0.0654)Cit+(0.0044)Pro+(−0.0184)Lys+(0.0337)Ile+(−0.1159)Trp; 0.878, 0.910, 0.923, 0.892, 0.902, 0. 860,0.891,(12.5796)+(−0.1020)His+(−0.0167)Arg+(−0.0141)Lys+(0.0570)Ile+(0.0061)Phe+(−0.1020)Trp;0.872, 0.910, 0.923, 0.88 4, 0.884, 0.850, 0.881,(10.2978)+(0.0049)Gln+(−0.1007)His+(−0.0230)Lys+(0.0778)Ile+(−0.0152)Leu+(−0.0923)Trp; 0.911, 0.935, 0.922,0.911, 0.911, 0.881, 0.909, (14.1119)+(−0.0150)Gly+(−0.0826)His+(−0.0229)Cit+(−0.0142)Lys+(0.0608)Ile+(−0.1017)Trp; 0. 881,0.913, 0.922, 0.895, 0.900, 0.868, 0.894, (13.1702)+(−0.0067)Ser+(−0.1002)His+(−0.0150)Arg+(−0.0128)Lys+(0.0577)Ile+(−0. 1020)Trp;0.879, 0.912, 0.922, 0.895, 0.907, 0.861, 0.893, (13.1744)+(−0.0786)His+(−0.0232)Arg+(−0.1345)Met+(0.1020)Ile+(−0.0365)Leu+(−0.0929)Trp; 0.869, 0.909, 0.922, 0.888, 0.893, 0.856, 0. 886,(10.0135)+(0.0062)Gln+(−0.1104)His+(−0.0005)Pro+(−0.0240)Lys+(0.0587)Ile+(−0.0929)Trp; 0.930, 0.950, 0.922, 0.918, 0.90 2,0.893, 0.915, (12.5111)+(−0.0154)Gly+(−0.0709)His+(0.0841)Tyr+(−0.0271)Lys+(0.0516)Ile+(−0.1420)Trp; 0.912, 0.936, 0.922, 0.907,0.912, 0.867, 0.905,(13.0273)+(0.0198)Ser+(−0.0184)Gly+(−0.0948)His+(−0.0171)Lys+(0.0557)Ile+(−0.0899)Trp;0.897, 0. 925, 0.922, 0.906, 0.913, 0.877, 0.905,(15.2500)+(0.0073)Ser+(−0.1563)Asn+(−0.0885)His+(−0.0074)Arg+(0.0264)Ile+(−0.0855)Tr p; 0.886,0.918, 0.922, 0.895, 0.905, 0.858, 0.894, (12.4065)+(−0.0962)His+(−0.0161)Arg+(−0.1564)Met+(0.0507)Ile+(0.0231)Phe+(−0.0992)Trp;0.878, 0.910, 0.922, 0.891, 0.900, 0.859, 0.890, (12.7961)+(−0.1028)His+(−0.0145)Arg+(−0.0107)Orn+(−0.0122)Lys+(0.0599)Ile+(−0.0998)Trp;0.928, 0.948, 0.922, 0.914, 0.914, 0.87 4, 0.912,(15.5554)+(0.0353)Ser+(−0.2340)Asn+(−0.0199)Gly+(0.0981)Ile+(−0.0695)Leu+(−0.0719)Trp; 0.875, 0.909, 0.922, 0.886, 0.872,0.873, 0.885, (10.2052)+(0.0008)Gln+(−0.1006)His+(−0.0431)Cit+(0.0477)Tyr+(0.0357)Ile+(−0.1449)Trp; 0.917, 0.936, 0.9 21,0.915, 0.919, 0.886, 0.914, (14.4010)+(−0.0154)Gly+(−0.0969)His+(−0.0212)Arg+(0.0512)Ile+(−0.1034)Trp; 0.883, 0.910, 0.921, 0.895,0.902, 0.869, 0.894, (13.2008)+(−0.0085)Ser+(−0.1078)His+(−0.0244)Arg+(0.0495)Ile+(−0.1085)Trp; 0.869, 0.907, 0.921, 0. 883,0.888, 0.849, 0.881,(10.6236)+(0.0021)Gln+(−0.0990)His+(−0.0380)Cit+(0.0707)Ile+(−0.0202)Leu+(−0.1118)Trp;0.897, 0.92 9, 0.921, 0.912, 0.914, 0.890, 0.911,(15.6380)+(−0.1496)Asn+(−0.0762)His+(−0.0320)Cit+(−0.0023)Arg+(0.0323)Ile+(−0.0959)Tr p; 0.895,0.925, 0.921, 0.903, 0.907, 0.872, 0.901, (15.2549)+(0.0091)Ser+(−0.1546)Asn+(−0.0811)His+(−0.0123)Lys+(0.0350)Ile+(−0.0797)Trp;0.912, 0.936, 0.921, 0.909, 0.912, 0.873, 0.907, (13.6749)+(−0.0160)Gly+(−0.0733)His+(−0.0134)Lys+(0.0991)Ile+(−0.0322)Leu+(−0.0922)Trp;0.911, 0.935, 0.921, 0.915, 0.918, 0.886, 0.913,(14.3947)+(−0.0152)Gly+(−0.0965)His+(−0.0191)Arg+(−0.0077)Orn+(0.0538)Ile+(−0.1023)Trp; 0.880, 0.912, 0.921, 0.885, 0. 872,0.865, 0.883, (10.3226)+(−0.0890)His+(−0.0409)Cit+(0.0473)Tyr+(0.0628)Ile+(−0.0206)Leu+(−0.1422)Trp; 0.896, 0.926, 0.9 21,0.904, 0.906, 0.874, 0.902, (15.5396)+(−0.1387)Asn+(−0.0806)His+(−0.0107)Orn+(−0.0093)Lys+(0.0407)Ile+(−0.0832)Trp; 0.89 6, 0.924,0.921, 0.914, 0.906, 0.909, 0.913, (11.8572)+(0.0028)Gln+(−0.0953)His+(−0.0387)Arg+(0.0796)Tyr+(−0.0208)Phe+(−0.145 3)Trp;0.875, 0.910, 0.920, 0.894, 0.903, 0.866, 0.893,(13.2183)+(−0.0086)Ser+(−0.1080)His+(−0.0238)Arg+(−0.0009)Pro+(0.0505)Ile+(−0.1080)Trp; 0.874, 0.906, 0.920, 0.886, 0.892, 0.857, 0.88 5,(10.2651)+(0.0036)Gln+(−0.1114)His+(−0.0413)Cit+(0.0439)Ile+(−0.1143)Trp; 0.873, 0.907, 0.920, 0.879, 0.880, 0.844, 0.877,(11.6730)+(−0.0896)His+(−0.0196)Lys+(0.0863)Ile+(−0.0227)Leu+(0.0078)Phe+(−0.0957)Trp; 0.928, 0.947, 0.920, 0.930, 0.918, 0. 919,0.928,(12.7898)+(0.0225)Ser+(−0.0193)Gly+(−0.0809)His+(−0.0379)Arg+(0.0840)Tyr+(−0.1457)Trp;0.909, 0.935, 0.920, 0.9 20, 0.907, 0.916, 0.919,(14.4930)+(−0.1522)Asn+(−0.0750)His+(−0.0203)Arg+(0.0765)Tyr+(0.0169)Ile+(−0.1361)Trp;0.908, 0.936, 0.920, 0.926, 0.917, 0.922, 0.925,(12.8808)+(−0.1740)Asn+(0.0072)Gln+(−0.0802)His+(−0.0237)Arg+(0.0696)Tyr+(−0.1255)Trp; 0. 905, 0.929,0.920, 0.912, 0.913, 0.890, 0.911,(15.6038)+(−0.1524)Asn+(−0.0758)His+(−0.0334)Cit+(0.0315)Ile+(−0.0956)Trp;0.91 0, 0.935, 0.920, 0.916, 0.921, 0.888, 0.915, (14.7806)+(−0.0155)Gly+(−0.0974)His+(−0.0200)Arg+(0.0520)Ile+(−0.0109)Phe+(−0.10 07)Trp;0.879, 0.912, 0.920, 0.896, 0.903, 0.868, 0.894,(13.3032)+(−0.0092)Ser+(−0.1008)His+(−0.0215)Cit+(−0.0217)Arg+(0.0522)Ile+(−0.1142)Trp; 0.877, 0.909, 0.920, 0.888, 0.890, 0.860, 0.88 6,(12.4932)+(−0.0923)His+(−0.0283)Cit+(−0.0057)Orn+(−0.0181)Lys+(0.0628)Ile+(−0.1041)Trp

List of Logistic Regression Equations Searched in Example 2 (ROC_AUCvalue: 0.500 or greater)

The logistic regression equations searched in Example 2 above are listedbelow. Before each equation, “the value of ROC_AUC for the pancreaticcancer group and the healthy group with validation”, “the value ofROC_AUC for the pancreatic cancer group and the healthy group withoutvalidation”, “the value of ROC_AUC for the pancreatic cancer group andthe other cancers group”, “the value of ROC_AUC for the pancreaticcancer group and the lung cancer group”, “the value of ROC_AUC for thepancreatic cancer group and the colorectal cancer group”, “the value ofROC_AUC for the pancreatic cancer group and the prostatic cancer group”,“the value of ROC_AUC for the pancreatic cancer group and the breastcancer group”, and “the average value of the value of ROC_AUC for thepancreatic cancer group and the lung cancer group, the value of ROC_AUCfor the pancreatic cancer group and the colorectal cancer group, thevalue of ROC_AUC for the pancreatic cancer group and the prostaticcancer group, and the value of ROC_AUC for the pancreatic cancer groupand the breast cancer group” obtained for the equation are additionallylisted.

0.826, 0.840, 0.800, 0.804, 0.811, 0.753, 0.801, 0.792, (3.2646)+(0.0697)Phe+(−0.1735)Trp; 0.817, 0.828, 0.774, 0.782, 0.778, 0. 801,0.727, 0.772, (3.1922)+(0.0271)Ser+(−0.1525)Trp; 0.812, 0.8 22, 0.774,0.762, 0.777, 0.766, 0.804, 0.777, (4.2601)+(0.0495)Ile +(−0.1715)Trp;0.812, 0.825, 0.809, 0.812, 0.810, 0.827, 0.789, 0.8 09,(8.8631)+(−0.0763)His+(−0.0949)Trp; 0.804, 0.815, 0.736, 0.7 17, 0.737,0.829, 0.719, 0.750, (4.1731)+(0.0357)Ser+(−0.1324)Hi s; 0.802, 0.817,0.816, 0.822, 0.831, 0.822, 0.765, 0.810,(7.5229)+(−0.0626)Cit+(−0.1412)Trp; 0.802, 0.815, 0.793, 0.803, 0.802,0.7 83, 0.754, 0.786, (5.1431)+(0.0173)Orn+(−0.1504)Trp; 0.801, 0.81 4,0.795, 0.806, 0.800, 0.781, 0.766, 0.788,(5.4341)+(0.0049)Pro+(−0.1498)Trp; 0.801, 0.813, 0.781, 0.775, 0.769,0.829, 0.787, 0.79 0, (4.1211)+(0.0092)Gln+(−0.1498)His; 0.799, 0.812,0.792, 0.804, 0.802, 0.788, 0.745, 0.785,(5.3459)+(0.0083)Thr+(−0.1543)Trp; 0. 798, 0.812, 0.808, 0.824, 0.807,0.794, 0.775, 0.800, (4.4293)+(0.0 032)Gln+(−0.1532)Trp; 0.797, 0.811,0.747, 0.721, 0.745, 0.783, 0. 795, 0.761,(4.6715)+(−0.1432)His+(0.0732)Phe; 0.796, 0.806, 0.7 41, 0.704, 0.738,0.798, 0.804, 0.761, (5.5422)+(−0.1341)His+(0.0 453)Ile; 0.795, 0.807,0.819, 0.832, 0.822, 0.807, 0.783, 0.811, (7.2003)+(−0.0494)Asn+(−0.1313)Trp; 0.794, 0.808, 0.803, 0.819, 0.8 06,0.792, 0.765, 0.796, (5.8643)+(−0.0006)Val+(−0.1435)Trp; 0.7 94, 0.808,0.794, 0.802, 0.802, 0.777, 0.770, 0.788, (5.3577)+(0.0086)Leu+(−0.1545)Trp; 0.793, 0.805, 0.816, 0.832, 0.812, 0.816, 0.7 84,0.811, (6.3477)+(−0.0032)Ala+(−0.1356)Trp; 0.793, 0.807, 0.8 02, 0.819,0.804, 0.789, 0.762, 0.793, (5.9803)+(−0.0056)Tyr+(−0. 1416)Trp; 0.792,0.807, 0.802, 0.816, 0.806, 0.788, 0.767, 0.794, (5.7122)+(0.0009)Lys+(−0.1463)Trp; 0.791, 0.806, 0.817, 0.834, 0.82 0,0.811, 0.769, 0.809, (6.9335)+(−0.0867)Met+(−0.1276)Trp; 0.79 1, 0.807,0.805, 0.818, 0.809, 0.790, 0.773, 0.798, (5.9630)+(−0.0009)Gly+(−0.1445)Trp; 0.787, 0.801, 0.748, 0.720, 0.759, 0.808, 0.7 56,0.761, (6.1253)+(−0.1299)His+(0.0330)Orn; 0.784, 0.796, 0.74 5, 0.727,0.750, 0.804, 0.741, 0.756, (6.4709)+(−0.1329)His+(0.01 49)Thr; 0.784,0.802, 0.805, 0.822, 0.812, 0.795, 0.752, 0.795, (6.3448)+(−0.0090)Arg+(−0.1399)Trp; 0.778, 0.788, 0.751, 0.725, 0.75 5,0.801, 0.779, 0.765, (6.5324)+(−0.1304)His+(0.0128)Leu; 0.775, 0.786,0.763, 0.748, 0.762, 0.810, 0.770, 0.772, (6.9613)+(−0.1208)His+(0.0015)Val; 0.775, 0.788, 0.756, 0.747, 0.754, 0.813, 0.742,0.764, (6.6776)+(0.0028)Gly+(−0.1206)His; 0.775, 0.786, 0.775, 0. 766,0.765, 0.822, 0.784, 0.784, (7.3273)+(−0.1124)His+(−0.0021)Ala; 0.773,0.785, 0.752, 0.734, 0.753, 0.797, 0.764, 0.762, (6.6331)+(−0.1215)His+(0.0052)Pro; 0.772, 0.785, 0.769, 0.758, 0.766, 0. 811,0.776, 0.778, (7.3401)+(−0.0143)Asn+(−0.1136)His; 0.772, 0. 783, 0.758,0.744, 0.757, 0.803, 0.766, 0.768, (6.7145)+(−0.1239)H is+(0.0042)Lys;0.770, 0.785, 0.766, 0.757, 0.761, 0.809, 0.768, 0. 774,(7.2279)+(−0.1150)His+(−0.0062)Tyr; 0.767, 0.785, 0.775, 0. 768, 0.771,0.817, 0.773, 0.782, (7.4695)+(−0.1078)His+(−0.0493)Met; 0.766, 0.784,0.766, 0.753, 0.764, 0.812, 0.768, 0.774, (7.2408)+(−0.1161)His+(−0.0036)Arg; 0.761, 0.778, 0.764, 0.750, 0.768, 0.810,0.758, 0.771, (7.3735)+(−0.1115)His+(−0.0257)Cit; 0.760, 0.771, 0.696,0.684, 0.626, 0.781, 0.814, 0.726, (0.9619)+(−0.055 9)Val+(0.1493)Ile;0.755, 0.773, 0.737, 0.764, 0.736, 0.813, 0.613, 0.731,(0.2571)+(0.0364)Ser+(−0.2519)Met; 0.738, 0.754, 0.739, 0. 730, 0.737,0.757, 0.755, 0.745, (1.8923)+(−0.2844)Met+(0.0530)I le; 0.737, 0.752,0.758, 0.772, 0.765, 0.712, 0.734, 0.746, (0.4707)+(−0.3046)Met+(0.0871)Phe; 0.729, 0.744, 0.681, 0.679, 0.631, 0.7 46,0.746, 0.701, (−0.1029)+(0.1443)Ile+(−0.0904)Leu; 0.724, 0.7 43, 0.707,0.720, 0.698, 0.771, 0.648, 0.709, (0.7877)+(0.0397)Ser +(−0.1603)Asn;0.712, 0.731, 0.738, 0.769, 0.748, 0.764, 0.620, 0.7 25,(2.6702)+(0.0178)Thr+(−0.2686)Met; 0.707, 0.725, 0.742, 0.76 1, 0.740,0.745, 0.693, 0.735, (2.9233)+(0.0080)Pro+(−0.2391)Me t; 0.704, 0.721,0.742, 0.762, 0.744, 0.767, 0.671, 0.736,(2.4989)+(−0.2277)Met+(0.0223)Orn; 0.704, 0.723, 0.732, 0.729, 0.642,0.81 9, 0.864, 0.764, (0.0800)+(−0.0136)Ala+(0.0441)Ile; 0.703, 0.722,0.778, 0.814, 0.761, 0.782, 0.713, 0.768,(1.4382)+(0.0045)Gln+(−0.2387)Met; 0.703, 0.719, 0.775, 0.798, 0.775,0.768, 0.721, 0.765, (3.9824)+(−0.0433)Asn+(−0.1605)Met; 0.703, 0.723,0.789, 0.817, 0.767, 0.811, 0.743, 0.785,(3.5534)+(−0.0040)Ala+(−0.1658)Met; 0.699, 0.720, 0.765, 0.781, 0.785,0.773, 0.676, 0.754, (4.3007)+(−0.0614)Cit+(−0.1733)Met; 0.695, 0.716,0.776, 0.813, 0.764, 0.787, 0.697, 0.765,(3.8103)+(−0.0065)Val+(−0.1747)Met; 0.695, 0.713, 0.760, 0.788, 0.758,0.764, 0.685, 0.749, (3.0856)+(0.0006)Gly+(−0.2055)Met; 0.694, 0.712,0.766, 0.794, 0.763, 0.770, 0.694, 0.755,(3.3474)+(−0.1943)Met+(−0.0022)Lys; 0.693, 0.712, 0.759, 0.784, 0.758,0.758, 0.697, 0.749, (3.0295)+(−0.2128)Met+(0.0031)Leu; 0. 692, 0.714,0.766, 0.796, 0.767, 0.768, 0.684, 0.754, (3.5146)+(−0.0079)Arg+(−0.1897)Met; 0.688, 0.708, 0.774, 0.787, 0.761, 0.821, 0. 736,0.776, (3.4870)+(−0.0086)Ala+(−0.0780)Cit; 0.688, 0.710, 0. 759, 0.791,0.753, 0.756, 0.687, 0.747, (3.3052)+(−0.0074)Tyr+(−0. 1906)Met; 0.687,0.707, 0.800, 0.821, 0.762, 0.827, 0.801, 0.803, (4.0397)+(−0.0851)Asn+(−0.0064)Ala; 0.685, 0.709, 0.757, 0.766, 0.7 70,0.754, 0.707, 0.749, (4.3414)+(−0.0921)Asn+(−0.0679)Cit; 0.6 79, 0.702,0.751, 0.796, 0.724, 0.739, 0.696, 0.739, (4.2548)+(−0.0854)Asn+(−0.0363)Tyr; 0.679, 0.698, 0.787, 0.822, 0.763, 0.795, 0. 737,0.779, (4.9678)+(−0.0972)Asn+(−0.0120)Val; 0.675, 0.701, 0. 715, 0.755,0.715, 0.732, 0.596, 0.699, (3.3013)+(−0.0711)Cit+(−0. 0448)Tyr; 0.672,0.699, 0.623, 0.683, 0.584, 0.706, 0.486, 0.615,(−0.4769)+(0.0218)Ser+(−0.0572)Tyr; 0.669, 0.694, 0.704, 0.733, 0. 618,0.847, 0.702, 0.725, (−0.8615)+(0.0218)Ser+(−0.0099)Ala; 0. 668, 0.689,0.736, 0.756, 0.660, 0.815, 0.789, 0.755, (1.0885)+(−0.0125)Ala+(0.0096)Pro; 0.667, 0.689, 0.677, 0.647, 0.668, 0.732, 0. 736,0.696, (1.0698)+(−0.0265)Lys+(0.0364)Ile; 0.667, 0.687, 0.6 27, 0.668,0.570, 0.645, 0.625, 0.627, (0.7224)+(−0.0702)Tyr+(0.0 336)Ile; 0.666,0.689, 0.720, 0.713, 0.712, 0.706, 0.762, 0.723, (2.1733)+(−0.1195)Asn+(0.0213)Ile; 0.665, 0.690, 0.754, 0.775, 0.68 1,0.814, 0.806, 0.769, (0.0534)+(−0.0112)Ala+(0.0327)Phe; 0.662, 0.686,0.728, 0.735, 0.729, 0.725, 0.713, 0.725, (2.5997)+(−0.1214)Asn+(0.0169)Orn; 0.662, 0.685, 0.734, 0.740, 0.734, 0.693, 0.745,0.728, (1.9869)+(−0.1259)Asn+(0.0297)Phe; 0.661, 0.691, 0.639, 0. 647,0.638, 0.762, 0.535, 0.645, (−0.6030)+(0.0285)Ser+(−0.0227)Lys; 0.660,0.680, 0.644, 0.717, 0.589, 0.609, 0.589, 0.626, (0.1635)+(−0.0781)Tyr+(0.0525)Phe; 0.660, 0.685, 0.758, 0.816, 0.687, 0. 821,0.708, 0.758, (2.6325)+(−0.0068)Ala+(−0.0337)Tyr; 0.659, 0. 684, 0.788,0.823, 0.742, 0.845, 0.749, 0.790, (2.4815)+(−0.0080)A la+(−0.0175)Arg;0.659, 0.684, 0.768, 0.792, 0.751, 0.740, 0.760, 0. 761,(1.6188)+(−0.1401)Asn+(0.0047)Gln; 0.656, 0.686, 0.789, 0.8 21, 0.735,0.858, 0.766, 0.795, (2.7346)+(−0.0074)Ala+(−0.0108)L ys; 0.655, 0.686,0.729, 0.802, 0.681, 0.760, 0.611, 0.714, (2.8329)+(−0.0389)Tyr+(−0.0100)Val; 0.655, 0.678, 0.765, 0.796, 0.754, 0. 753,0.718, 0.755, (3.8161)+(−0.1017)Asn+(−0.0101)Leu; 0.654, 0. 681, 0.744,0.765, 0.673, 0.835, 0.770, 0.761, (0.8298)+(−0.0104)A la+(0.0158)Orn;0.653, 0.676, 0.735, 0.758, 0.729, 0.722, 0.695, 0. 726,(2.8947)+(−0.1145)Asn+(0.0017)Gly; 0.653, 0.684, 0.629, 0.6 48, 0.653,0.741, 0.450, 0.623, (−1.5623)+(0.0264)Ser+(−0.0341)A rg; 0.653, 0.681,0.759, 0.776, 0.753, 0.757, 0.730, 0.754, (3.7433)+(−0.0898)Asn+(−0.0085)Lys; 0.652, 0.678, 0.787, 0.837, 0.715, 0. 867,0.743, 0.791, (2.4040)+(−0.0069)Ala+(−0.0089)Val; 0.651, 0. 674, 0.610,0.597, 0.649, 0.696, 0.505, 0.612, (−1.3060)+(0.0227)S er+(−0.0930)Cit;0.648, 0.673, 0.736, 0.752, 0.730, 0.709, 0.724, 0. 729,(2.9528)+(−0.1135)Asn+(0.0018)Pro; 0.646, 0.676, 0.754, 0.7 77, 0.756,0.739, 0.702, 0.743, (3.4803)+(−0.0950)Asn+(−0.0123)A rg; 0.646, 0.674,0.733, 0.748, 0.731, 0.712, 0.709, 0.725, (2.9573)+(−0.1231)Asn+(0.0056)Thr; 0.645, 0.670, 0.771, 0.805, 0.692, 0.8 55,0.783, 0.784, (1.1266)+(0.0006)Gln+(−0.0096)Ala; 0.645, 0.67 4, 0.717,0.771, 0.689, 0.750, 0.606, 0.704, (2.9686)+(−0.0405)Tyr +(−0.0113)Lys;0.644, 0.670, 0.636, 0.601, 0.699, 0.702, 0.553, 0.6 39,(0.0045)+(−0.1113)Cit+(0.0318)Orn; 0.643, 0.676, 0.709, 0.77 4, 0.691,0.729, 0.564, 0.689, (2.8079)+(−0.0184)Arg+(−0.0455)Ty r; 0.642, 0.671,0.727, 0.731, 0.754, 0.773, 0.625, 0.721,(3.2166)+(−0.0736)Cit+(−0.0142)Lys; 0.642, 0.668, 0.777, 0.806, 0.706,0.8 51, 0.797, 0.790, (1.6342)+(−0.0013)Gly+(−0.0093)Ala; 0.642, 0.6 71,0.776, 0.815, 0.703, 0.855, 0.765, 0.785, (1.6244)+(−0.0088)Ala+(−0.0039)Leu; 0.641, 0.665, 0.641, 0.708, 0.600, 0.670, 0.525, 0. 626,(1.2368)+(−0.0616)Tyr+(0.0176)Orn; 0.641, 0.669, 0.777, 0.8 10, 0.701,0.854, 0.794, 0.790, (1.5960)+(−0.0029)Thr+(−0.0090)A la; 0.640, 0.661,0.627, 0.594, 0.664, 0.663, 0.611, 0.633, (−0.0873)+(−0.0926)Cit+(0.0212)Ile; 0.639, 0.663, 0.700, 0.735, 0.637, 0. 754,0.697, 0.706, (1.2645)+(−0.0316)Val+(0.0321)Leu; 0.637, 0.6 60, 0.720,0.746, 0.727, 0.755, 0.612, 0.710, (2.7084)+(−0.0684)Ci t+(−0.0110)Val;0.637, 0.663, 0.642, 0.714, 0.592, 0.658, 0.546, 0. 628,(1.5667)+(0.0048)Pro+(−0.0616)Tyr; 0.635, 0.659, 0.704, 0.7 21, 0.729,0.737, 0.581, 0.692, (1.9881)+(−0.0784)Cit+(−0.0111)L eu; 0.634, 0.668,0.696, 0.775, 0.656, 0.712, 0.562, 0.676, (2.1802)+(−0.0486)Tyr+(−0.0070)Leu; 0.632, 0.661, 0.690, 0.696, 0.729, 0. 716,0.574, 0.679, (1.7181)+(−0.0714)Cit+(−0.0136)Arg; 0.631, 0. 658, 0.670,0.753, 0.618, 0.680, 0.554, 0.651, (1.4409)+(0.0007)Gl n+(−0.0560)Tyr;0.631, 0.656, 0.726, 0.753, 0.730, 0.751, 0.626, 0. 715,(2.3484)+(−0.0162)Arg+(−0.0139)Lys; 0.630, 0.659, 0.690, 0. 692, 0.715,0.705, 0.627, 0.684, (1.4777)+(−0.0058)Thr+(−0.0810) Cit; 0.626, 0.657,0.696, 0.767, 0.645, 0.679, 0.627, 0.679, (2.3462)+(−0.0027)Gly+(−0.0552)Tyr; 0.626, 0.648, 0.652, 0.651, 0.689, 0.689,0.551, 0.645, (0.7903)+(0.0012)Gly+(−0.0878)Cit; 0.626, 0. 657, 0.671,0.750, 0.622, 0.681, 0.554, 0.652, (1.8014)+(−0.0007)T hr+(−0.0540)Tyr;0.625, 0.646, 0.664, 0.662, 0.697, 0.690, 0.582, 0. 657,(1.0033)+(−0.0855)Cit+(−0.0003)Pro; 0.625, 0.651, 0.636, 0. 684, 0.596,0.738, 0.520, 0.635, (−0.5966)+(0.0186)Ser+(−0.0150) Val; 0.624, 0.657,0.689, 0.737, 0.653, 0.756, 0.591, 0.684, (0.8263)+(−0.0178)Val+(0.0220)Orn; 0.623, 0.654, 0.685, 0.689, 0.693, 0. 738,0.620, 0.685, (1.3552)+(0.0218)Orn+(−0.0227)Lys; 0.622, 0.6 47, 0.662,0.660, 0.692, 0.689, 0.583, 0.656, (0.5838)+(0.0008)Gln +(−0.0880)Cit;0.621, 0.653, 0.748, 0.807, 0.728, 0.790, 0.603, 0.7 32,(2.8091)+(−0.0205)Arg+(−0.0129)Val; 0.620, 0.651, 0.689, 0.7 40, 0.641,0.693, 0.652, 0.682, (0.0155)+(−0.0192)Val+(0.0395)Ph e; 0.620, 0.651,0.744, 0.790, 0.716, 0.802, 0.640, 0.737,(2.5515)+(−0.0106)Val+(−0.0108)Lys; 0.617, 0.647, 0.696, 0.701, 0.695,0.7 06, 0.676, 0.695, (0.8491)+(−0.0220)Lys+(0.0271)Phe; 0.615, 0.63 9,0.644, 0.636, 0.681, 0.658, 0.577, 0.638, (0.3037)+(−0.0884)Cit+(0.0129)Phe; 0.611, 0.638, 0.724, 0.742, 0.719, 0.746, 0.673, 0.72 0,(1.9680)+(−0.0011)Gly+(−0.0183)Lys; 0.611, 0.647, 0.722, 0.74 7, 0.709,0.757, 0.656, 0.718, (1.2350)+(0.0014)Gln+(−0.0199)Ly s; 0.611, 0.641,0.708, 0.726, 0.702, 0.744, 0.649, 0.705,(1.6959)+(0.0014)Pro+(−0.0191)Lys; 0.610, 0.635, 0.646, 0.645, 0.666,0.66 5, 0.591, 0.642, (−0.0841)+(−0.0308)Arg+(0.0193)Ile; 0.609, 0.63 8,0.720, 0.742, 0.712, 0.752, 0.657, 0.716, (1.8217)+(−0.0012)Thr+(−0.0180)Lys; 0.607, 0.636, 0.688, 0.743, 0.641, 0.730, 0.608, 0.6 81,(1.2424)+(0.0047)Pro+(−0.0170)Val; 0.605, 0.638, 0.723, 0.75 7, 0.713,0.762, 0.626, 0.715, (1.9476)+(−0.0162)Lys+(−0.0053)Le u; 0.605, 0.635,0.742, 0.794, 0.692, 0.768, 0.691, 0.736,(1.9032)+(−0.0023)Gly+(−0.0149)Val; 0.603, 0.644, 0.599, 0.600, 0.567,0.6 93, 0.597, 0.614, (−2.5189)+(0.0324)Ser+(−0.0236)Thr; 0.599, 0.6 33,0.716, 0.777, 0.669, 0.764, 0.619, 0.707, (1.5073)+(−0.0001)Gln+(−0.0149)Val; 0.596, 0.634, 0.736, 0.792, 0.688, 0.771, 0.661, 0. 728,(1.7582)+(−0.0046)Thr+(−0.0140)Val; 0.596, 0.627, 0.665, 0. 685, 0.698,0.695, 0.525, 0.651, (0.3433)+(−0.0306)Arg+(0.0128)O rn; 0.595, 0.629,0.728, 0.786, 0.733, 0.753, 0.548, 0.705, (1.9642)+(−0.0239)Arg+(−0.0135)Leu; 0.592, 0.622, 0.687, 0.720, 0.705, 0. 691,0.562, 0.670, (0.2892)+(0.0012)Gln+(−0.0295)Arg; 0.591, 0.6 23, 0.701,0.732, 0.713, 0.701, 0.594, 0.685, (0.9755)+(−0.0037)Th r+(−0.0249)Arg;0.590, 0.620, 0.683, 0.713, 0.705, 0.690, 0.555, 0. 666,(0.7635)+(−0.0276)Arg+(0.0001)Pro; 0.590, 0.621, 0.688, 0.7 16, 0.709,0.689, 0.567, 0.671, (0.8327)+(−0.0004)Gly+(−0.0273)A rg; 0.589, 0.623,0.531, 0.479, 0.520, 0.596, 0.644, 0.560, (−3.2575)+(0.0302)Ser+(−0.0083)Gly; 0.583, 0.619, 0.672, 0.697, 0.695, 0. 670,0.556, 0.655, (0.2642)+(−0.0289)Arg+(0.0109)Phe; 0.579, 0.6 24, 0.454,0.413, 0.483, 0.602, 0.395, 0.473, (−1.8253)+(0.0271)Se r+(−0.0049)Gln;0.574, 0.613, 0.577, 0.622, 0.564, 0.677, 0.415, 0. 570,(−1.8132)+(0.0190)Ser+(−0.0170)Leu; 0.572, 0.618, 0.639, 0. 620, 0.603,0.638, 0.767, 0.657, (−0.8939)+(−0.0159)Thr+(0.0180)Ile; 0.569, 0.605,0.394, 0.342, 0.393, 0.534, 0.430, 0.425, (−4.4991)+(0.0200)Ser+(0.0115)Ile; 0.552, 0.621, 0.683, 0.686, 0.656, 0. 698,0.718, 0.690, (−0.4947)+(−0.0157)Thr+(0.0121)Orn; 0.550, 0. 599, 0.467,0.456, 0.465, 0.593, 0.407, 0.480, (−3.4533)+(0.0200)S er+(−0.0027)Pro;0.544, 0.591, 0.705, 0.725, 0.674, 0.674, 0.738, 0. 703,(−0.0754)+(−0.0006)Gly+(−0.0126)Thr; 0.542, 0.586, 0.732, 0. 788, 0.700,0.739, 0.646, 0.718, (0.9960)+(−0.0087)Thr+(−0.0146) Leu; 0.538, 0.593,0.661, 0.721, 0.652, 0.707, 0.486, 0.642, (−0.0989)+(0.0130)Orn+(−0.0199)Leu; 0.538, 0.592, 0.700, 0.722, 0.669, 0. 677,0.723, 0.698, (−0.1305)+(−0.0001)Gln+(−0.0128)Thr; 0.536, 0. 584, 0.656,0.721, 0.640, 0.626, 0.540, 0.632, (−0.7104)+(−0.0235) Leu+(0.0296)Phe;0.534, 0.581, 0.428, 0.406, 0.430, 0.559, 0.387, 0. 445,(−3.6022)+(0.0197)Ser+(−0.0032)Phe; 0.533, 0.576, 0.725, 0. 785, 0.698,0.718, 0.625, 0.707, (0.7956)+(−0.0023)Gly+(−0.0173) Leu; 0.532, 0.593,0.690, 0.708, 0.658, 0.665, 0.725, 0.689, (−0.4103)+(−0.0135)Thr+(0.0056)Phe; 0.530, 0.592, 0.700, 0.723, 0.668, 0. 678,0.723, 0.698, (−0.1545)+(−0.0129)Thr+(0.0000)Pro; 0.524, 0. 572, 0.669,0.742, 0.645, 0.692, 0.510, 0.647, (0.2198)+(0.0018)Pr o+(−0.0186)Leu;0.521, 0.571, 0.437, 0.424, 0.432, 0.546, 0.405, 0. 452,(−3.5449)+(0.0206)Ser+(−0.0062)Orn; 0.521, 0.573, 0.687, 0. 758, 0.671,0.713, 0.515, 0.664, (0.5502)+(−0.0005)Gln+(−0.0169) Leu

0.847, 0.863, 0.807, 0.794, 0.809, 0.813, 0.833, 0.813, (6.1203)+(−0.1057)His+(0.1038)Phe+(−0.1160)Trp; 0.843, 0.861, 0.766, 0.764,0.770, 0.765, 0.763, 0.766, (0.3860)+(0.0285)Ser+(0.0708)Phe+(−0.1800)Trp; 0.841, 0.852, 0.788, 0.762, 0.789, 0.818, 0.835,0.801, (7.5109)+(−0.0925)His+(0.0651)Ile+(−0.1199)Trp; 0.837, 0.851,0.786, 0.780, 0.786, 0.849, 0.754, 0.793,(5.9269)+(0.0370)Ser+(−0.0914)His+(−0.0960)Trp; 0.835, 0.847, 0.775,0.766, 0.739, 0.813, 0.848, 0.791,(5.0718)+(−0.0408)Val+(0.1480)Ile+(−0.138 1)Trp; 0.833, 0.848, 0.787,0.782, 0.771, 0.804, 0.820, 0.795, (4.8174)+(0.1394)Ile+(−0.0646)Leu+(−0.1464)Trp; 0.832, 0.846, 0.821, 0.826,0.811, 0.845, 0.810, 0.823, (5.8821)+(0.0098)Gln+(−0.1088)His+(−0.1000)Trp; 0.830, 0.845, 0.796, 0.793, 0.801, 0.835, 0.76 5,0.798, (8.3046)+(−0.0932)His+(0.0211)Thr+(−0.1065)Trp; 0.82 8, 0.847,0.811, 0.820, 0.813, 0.770, 0.809, 0.803, (3.4267)+(−0.0070)Val+(0.0829)Phe+(−0.1635)Trp; 0.828, 0.843, 0.803, 0.815, 0.8 00,0.838, 0.753, 0.801, (4.9322)+(0.0381)Ser+(−0.0943)Asn+(−0. 1322)Trp;0.828, 0.842, 0.803, 0.816, 0.803, 0.844, 0.739, 0.800, (4.3243)+(0.0350)Ser+(−0.1297)Met+(−0.1329)Trp; 0.827, 0.841, 0.7 44,0.727, 0.745, 0.776, 0.766, 0.753, (1.4558)+(0.0279)Ser+(0.0512)Ile+(−0.1787)Trp; 0.826, 0.839, 0.793, 0.776, 0.804, 0.807, 0.8 07,0.798, (6.0150)+(−0.0807)Cit+(0.0621)Ile+(−0.1723)Trp; 0.8 26, 0.843,0.797, 0.787, 0.806, 0.827, 0.783, 0.801, (8.0435)+(−0.0898)His+(0.0369)Orn+(−0.0989)Trp; 0.825, 0.845, 0.824, 0.830, 0. 832,0.776, 0.826, 0.816, (4.7154)+(−0.0675)Asn+(0.0782)Phe+(−0. 1556)Trp;0.825, 0.837, 0.709, 0.671, 0.711, 0.796, 0.744, 0.731, (0.7000)+(0.0434)Ser+(−0.1690)His+(0.0910)Phe; 0.824, 0.845, 0.80 3, 0.810,0.809, 0.756, 0.806, 0.795, (2.4095)+(0.0022)Gln+(0.0670)Phe+(−0.1787)Trp; 0.824, 0.841, 0.795, 0.796, 0.810, 0.837, 0.72 7,0.793, (4.8137)+(0.0312)Ser+(−0.0712)Cit+(−0.1507)Trp; 0.82 4, 0.837,0.705, 0.655, 0.706, 0.816, 0.756, 0.733, (2.1410)+(0.0395)Ser+(−0.1546)His+(0.0546)Ile; 0.823, 0.844, 0.826, 0.834, 0.83 6,0.786, 0.816, 0.818, (3.9066)+(−0.1992)Met+(0.1112)Phe+(−0.1 427)Trp;0.822, 0.839, 0.811, 0.810, 0.829, 0.788, 0.797, 0.806, (4.6574)+(−0.0877)Cit+(0.0903)Phe+(−0.1721)Trp; 0.822, 0.842, 0.7 92,0.794, 0.807, 0.751, 0.787, 0.785, (3.0429)+(0.0058)Thr+(0.0671)Phe+(−0.1790)Trp; 0.822, 0.839, 0.774, 0.762, 0.781, 0.744, 0.8 13,0.775, (2.9066)+(0.0405)Ile+(0.0456)Phe+(−0.1860)Trp; 0.82 2, 0.841,0.797, 0.801, 0.807, 0.750, 0.800, 0.789, (3.1910)+(0.0022)Pro+(0.0675)Phe+(−0.1750)Trp; 0.821, 0.843, 0.821, 0.828, 0.81 4,0.798, 0.834, 0.819, (3.6992)+(−0.0060)Ala+(0.0835)Phe+(−0.1 607)Trp;0.821, 0.837, 0.798, 0.794, 0.801, 0.814, 0.790, 0.800, (8.4039)+(−0.0805)His+(0.0085)Pro+(−0.1012)Trp; 0.821, 0.835, 0.8 01,0.794, 0.831, 0.824, 0.740, 0.797, (6.8352)+(−0.1114)Cit+(0.0546)Orn+(−0.1576)Trp; 0.821, 0.842, 0.802, 0.808, 0.812, 0.755, 0. 801,0.794, (3.2872)+(−0.0019)Leu+(0.0716)Phe+(−0.1719)Trp; 0. 821, 0.841,0.798, 0.801, 0.809, 0.754, 0.796, 0.790, (3.1971)+(0.0053)Orn+(0.0661)Phe+(−0.1736)Trp; 0.821, 0.839, 0.784, 0.772, 0. 740,0.850, 0.859, 0.805, (4.6883)+(−0.0544)Val+(−0.2751)Met+(0. 1901)Ile;0.821, 0.840, 0.801, 0.805, 0.812, 0.753, 0.803, 0.793, (3.3119)+(−0.0002)Gly+(0.0696)Phe+(−0.1733)Trp; 0.820, 0.845, 0.8 08,0.813, 0.818, 0.767, 0.806, 0.801, (3.5616)+(−0.0050)Lys+(0.0755)Phe+(−0.1678)Trp; 0.818, 0.838, 0.794, 0.811, 0.793, 0.747, 0. 786,0.784, (3.5386)+(−0.0340)Tyr+(0.0898)Phe+(−0.1607)Trp; 0. 817, 0.831,0.794, 0.776, 0.803, 0.814, 0.811, 0.801, (8.3524)+(−0.0941)His+(0.0241)Leu+(−0.1113)Trp; 0.816, 0.833, 0.802, 0.819, 0. 816,0.815, 0.718, 0.792, (6.6981)+(0.0249)Thr+(−0.1682)Met+(−0. 1414)Trp;0.816, 0.830, 0.767, 0.748, 0.754, 0.807, 0.813, 0.780, (2.0184)+(0.0088)Gln+(−0.1733)His+(0.0702)Phe; 0.815, 0.832, 0.79 7, 0.787,0.777, 0.817, 0.852, 0.808, (5.0478)+(−0.0082)Ala+(0.0672)Ile+(−0.1566)Trp; 0.815, 0.830, 0.793, 0.802, 0.785, 0.835, 0.7 56,0.795, (3.7617)+(0.0278)Ser+(−0.0037)Ala+(−0.1426)Trp; 0.8 14, 0.832,0.765, 0.768, 0.772, 0.788, 0.725, 0.763, (2.8485)+(0.0270)Ser+(0.0046)Pro+(−0.1571)Trp; 0.814, 0.837, 0.809, 0.815, 0.8 24,0.761, 0.793, 0.798, (3.9358)+(−0.0169)Arg+(0.0791)Phe+(−0. 1682)Trp;0.814, 0.828, 0.801, 0.799, 0.804, 0.813, 0.791, 0.802, (8.1974)+(−0.0879)His+(0.0110)Lys+(−0.1046)Trp; 0.813, 0.830, 0.7 90,0.789, 0.790, 0.803, 0.786, 0.792, (3.6198)+(0.0383)Ser+(−0.0082)Gly+(−0.1524)Trp; 0.813, 0.830, 0.803, 0.808, 0.804, 0.832, 0. 769,0.803, (8.5172)+(0.0028)Gly+(−0.0799)His+(−0.0940)Trp; 0. 813, 0.826,0.744, 0.719, 0.708, 0.814, 0.834, 0.768, (5.3459)+(−0.0998)His+(−0.0349)Val+(0.1274)Ile; 0.813, 0.826, 0.752, 0.741, 0. 741,0.835, 0.742, 0.765, (2.9114)+(0.0285)Ser+(0.0059)Gln+(−0. 1503)His;0.813, 0.826, 0.757, 0.727, 0.747, 0.817, 0.816, 0.776, (3.0138)+(0.0083)Gln+(−0.1623)His+(0.0428)Ile; 0.812, 0.830, 0.77 1, 0.777,0.777, 0.799, 0.723, 0.769, (2.9095)+(0.0258)Ser+(0.0108)Orn+(−0.1557)Trp; 0.812, 0.828, 0.802, 0.795, 0.811, 0.819, 0.79 3,0.804, (8.6020)+(−0.0875)His+(0.0079)Val+(−0.1054)Trp; 0.81 1, 0.828,0.779, 0.787, 0.782, 0.812, 0.726, 0.777, (3.5040)+(0.0291)Ser+(−0.0048)Lys+(−0.1458)Trp; 0.810, 0.827, 0.777, 0.788, 0.7 77,0.808, 0.724, 0.774, (3.4604)+(0.0273)Ser+(−0.0085)Tyr+(−0. 1480)Trp;0.810, 0.828, 0.763, 0.762, 0.771, 0.788, 0.732, 0.763, (2.5854)+(0.0277)Ser+(0.0099)Leu+(−0.1631)Trp; 0.810, 0.827, 0.77 8, 0.770,0.777, 0.769, 0.807, 0.780, (3.5132)+(0.0019)Gln+(0.0481)Ile+(−0.1761)Trp; 0.810, 0.827, 0.795, 0.786, 0.796, 0.799, 0.81 6,0.799, (5.6954)+(−0.1645)Met+(0.0656)Ile+(−0.1435)Trp; 0.81 0, 0.826,0.777, 0.785, 0.780, 0.805, 0.732, 0.776, (3.1987)+(0.0284)Ser+(−0.0023)Thr+(−0.1503)Trp; 0.810, 0.822, 0.713, 0.674, 0.7 23,0.814, 0.725, 0.734, (3.1069)+(0.0389)Ser+(−0.1528)His+(0.0 197)Leu;0.809, 0.828, 0.774, 0.782, 0.778, 0.801, 0.727, 0.772, (3.1956)+(0.0271)Ser+(−0.0000)Val+(−0.1525)Trp; 0.809, 0.826, 0.8 04,0.807, 0.827, 0.824, 0.734, 0.798, (6.9782)+(0.0146)Thr+(−0.0722)Cit+(−0.1572)Trp; 0.809, 0.825, 0.810, 0.812, 0.810, 0.827, 0. 789,0.810, (8.8689)+(−0.0762)His+(−0.0001)Ala+(−0.0948)Trp; 0. 809, 0.828,0.774, 0.782, 0.778, 0.801, 0.726, 0.772, (3.2050)+(0.0272)Ser+(−0.0000)Gln+(−0.1524)Trp; 0.808, 0.827, 0.726, 0.697, 0. 735,0.826, 0.714, 0.743, (3.7633)+(0.0330)Ser+(−0.1411)His+(0. 0244)Orn;0.808, 0.826, 0.793, 0.784, 0.792, 0.791, 0.821, 0.797, (5.7175)+(−0.0548)Asn+(0.0503)Ile+(−0.1556)Trp; 0.808, 0.827, 0.8 27,0.836, 0.837, 0.829, 0.778, 0.820, (5.3892)+(0.0055)Gln+(−0.0743)Cit+(−0.1543)Trp; 0.808, 0.822, 0.773, 0.761, 0.776, 0.766, 0. 803,0.776, (4.2285)+(0.0012)Orn+(0.0490)Ile+(−0.1716)Trp; 0.8 08, 0.822,0.750, 0.723, 0.734, 0.813, 0.813, 0.771, (5.3562)+(−0.1130)His+(0.1080)Ile+(−0.0454)Leu; 0.808, 0.825, 0.811, 0.814, 0. 810,0.827, 0.789, 0.810, (8.9680)+(−0.0058)Asn+(−0.0747)His+(−0.0944)Trp;0.807, 0.827, 0.809, 0.803, 0.814, 0.829, 0.799, 0.811,(8.5780)+(−0.0825)His+(0.0182)Tyr+(−0.1025)Trp; 0.807, 0.820, 0.769,0.738, 0.748, 0.836, 0.847, 0.792,(5.9932)+(−0.1222)His+(−0.0065)Ala+(0.0581)Ile; 0.807, 0.826, 0.782,0.794, 0.790, 0.81 6, 0.706, 0.777,(3.8894)+(0.0312)Ser+(−0.0178)Arg+(−0.1448)Tr p; 0.806, 0.819, 0.722,0.695, 0.726, 0.819, 0.713, 0.738,(3.6702)+(0.0365)Ser+(−0.1381)His+(0.0064)Pro; 0.806, 0.819, 0.747, 0.724, 0.744, 0.831, 0.754, 0.763, (4.3049)+(0.0422)Ser+(−0.0047)Gly+(−0.1309)His; 0.806, 0.825, 0.769, 0.758, 0.773, 0.764, 0.796, 0.7 73,(4.0910)+(0.0035)Thr+(0.0484)Ile+(−0.1746)Trp; 0.805, 0.82 2, 0.775,0.763, 0.779, 0.767, 0.808, 0.779, (4.3381)+(−0.0004)Gly+(0.0493)Ile+(−0.1712)Trp; 0.805, 0.823, 0.771, 0.769, 0.765, 0.7 66,0.795, 0.774, (4.8101)+(−0.0217)Tyr+(0.0537)Ile+(−0.1610)T rp; 0.805,0.823, 0.804, 0.802, 0.823, 0.808, 0.766, 0.800, (7.1369)+(−0.0711)Cit+(0.0084)Pro+(−0.1501)Trp; 0.804, 0.826, 0.809, 0. 811,0.810, 0.827, 0.789, 0.809, (8.8109)+(−0.0768)His+(0.0012)Arg+(−0.0952)Trp; 0.804, 0.821, 0.753, 0.740, 0.751, 0.839, 0.727, 0.764, (4.8557)+(0.0410)Ser+(−0.0580)Asn+(−0.1163)His; 0.804, 0. 825,0.811, 0.814, 0.811, 0.827, 0.788, 0.810, (8.9122)+(−0.0749)His+(−0.0084)Met+(−0.0941)Trp; 0.804, 0.820, 0.807, 0.818, 0.794, 0.815,0.798, 0.806, (6.0813)+(−0.0065)Ala+(0.0108)Pro+(−0.137 6)Trp; 0.804,0.823, 0.806, 0.819, 0.815, 0.807, 0.753, 0.798, (7.0940)+(−0.0817)Asn+(0.0180)Thr+(−0.1425)Trp; 0.803, 0.824, 0.837, 0.854,0.832, 0.827, 0.813, 0.831, (5.2819)+(−0.0842)Asn+(0.0066)Gln+(−0.1385)Trp; 0.803, 0.818, 0.746, 0.731, 0.738, 0.841, 0.73 0,0.760, (4.3899)+(0.0357)Ser+(−0.1271)His+(−0.0019)Ala; 0.80 3, 0.819,0.805, 0.802, 0.791, 0.846, 0.811, 0.813, (4.5718)+(−0.0590)Asn+(0.0113)Gln+(−0.1379)His; 0.803, 0.820, 0.806, 0.808, 0.7 90,0.849, 0.798, 0.811, (4.3417)+(0.0108)Gln+(−0.1346)His+(−0. 0961)Met;0.803, 0.818, 0.726, 0.699, 0.733, 0.821, 0.717, 0.742, (3.7074)+(0.0371)Ser+(−0.1426)His+(0.0051)Val; 0.803, 0.821, 0.77 5, 0.764,0.777, 0.769, 0.807, 0.779, (4.3262)+(−0.0019)Pro+(0.0518)Ile+(−0.1706)Trp; 0.803, 0.825, 0.760, 0.752, 0.759, 0.850, 0.7 16,0.769, (4.6315)+(0.0395)Ser+(−0.1137)His+(−0.0967)Met; 0.8 03, 0.821,0.803, 0.798, 0.824, 0.798, 0.777, 0.799, (6.9309)+(−0.0715)Cit+(0.0162)Leu+(−0.1593)Trp; 0.803, 0.822, 0.779, 0.765, 0. 781,0.779, 0.808, 0.783, (4.8509)+(−0.0077)Lys+(0.0554)Ile+(−0. 1621)Trp;0.802, 0.817, 0.735, 0.695, 0.733, 0.785, 0.810, 0.756, (4.2572)+(−0.1461)His+(0.0325)Ile+(0.0507)Phe; 0.802, 0.818, 0.82 6, 0.833,0.838, 0.832, 0.777, 0.820, (8.3805)+(−0.0347)Asn+(−0.0578)Cit+(−0.1321)Trp; 0.802, 0.813, 0.768, 0.748, 0.762, 0.819, 0. 798,0.782, (3.5916)+(0.0092)Gln+(−0.1620)His+(0.0129)Leu; 0.8 02, 0.817,0.768, 0.752, 0.765, 0.823, 0.777, 0.779, (3.9165)+(0.0081)Gln+(−0.1538)His+(0.0212)Orn; 0.801, 0.823, 0.813, 0.815, 0.8 19,0.833, 0.779, 0.812, (9.2144)+(−0.0654)His+(−0.0311)Cit+(−0. 0986)Trp;0.801, 0.819, 0.801, 0.815, 0.799, 0.788, 0.773, 0.794, (4.3239)+(0.0027)Gln+(0.0039)Pro+(−0.1561)Trp; 0.801, 0.816, 0.73 2, 0.712,0.733, 0.827, 0.711, 0.746, (4.1517)+(0.0343)Ser+(−0.1354)His+(0.0035)Thr; 0.801, 0.814, 0.729, 0.687, 0.729, 0.796, 0.78 8,0.750, (5.1464)+(−0.1456)His+(0.0119)Thr+(0.0436)Ile; 0.801, 0.818,0.824, 0.832, 0.834, 0.834, 0.778, 0.819, (7.7964)+(−0.0021)Ala+(−0.0603)Cit+(−0.1349)Trp; 0.801, 0.815, 0.793, 0.793, 0.7 74,0.843, 0.798, 0.802, (4.3649)+(0.0093)Gln+(−0.1435)His+(−0. 0024)Ala;0.801, 0.817, 0.811, 0.814, 0.831, 0.812, 0.765, 0.805, (7.2700)+(−0.0686)Cit+(0.0045)Val+(−0.1507)Trp; 0.801, 0.821, 0.7 83,0.765, 0.789, 0.798, 0.809, 0.790, (4.7615)+(−0.1213)His+(−0.1757)Met+(0.1150)Phe; 0.801, 0.820, 0.796, 0.798, 0.790, 0.792, 0. 805,0.796, (5.6507)+(−0.0234)Val+(0.0470)Leu+(−0.1506)Trp; 0. 800, 0.816,0.738, 0.719, 0.737, 0.831, 0.720, 0.752, (4.2496)+(0.0359)Ser+(−0.1311)His+(−0.0011)Lys; 0.800, 0.822, 0.831, 0.852, 0. 824,0.828, 0.791, 0.824, (4.8052)+(0.0061)Gln+(−0.1296)Met+(−0. 1348)Trp;0.800, 0.813, 0.770, 0.762, 0.760, 0.820, 0.775, 0.779, (4.1381)+(0.0083)Gln+(−0.1538)His+(0.0072)Thr; 0.800, 0.820, 0.81 0, 0.819,0.815, 0.799, 0.784, 0.804, (6.8969)+(−0.0563)Asn+(0.0063)Pro+(−0.1355)Trp; 0.800, 0.815, 0.729, 0.706, 0.728, 0.783, 0.7 56,0.743, (3.8156)+(0.0049)Gly+(−0.1500)His+(0.0793)Phe; 0.79 9, 0.817,0.728, 0.697, 0.732, 0.773, 0.770, 0.743, (4.1977)+(−0.1568)His+(0.0141)Thr+(0.0711)Phe; 0.799, 0.818, 0.810, 0.819, 0.81 9,0.805, 0.774, 0.804, (6.6221)+(−0.0626)Asn+(0.0241)Orn+(−0.1 347)Trp;0.799, 0.819, 0.788, 0.797, 0.797, 0.778, 0.755, 0.782, (4.9954)+(0.0033)Pro+(0.0146)Orn+(−0.1529)Trp; 0.799, 0.818, 0.81 0, 0.818,0.826, 0.824, 0.745, 0.804, (7.2294)+(0.0021)Gly+(−0.0662)Cit+(−0.1419)Trp; 0.799, 0.818, 0.788, 0.798, 0.795, 0.781, 0.7 49,0.781, (5.1587)+(0.0066)Thr+(0.0037)Pro+(−0.1561)Trp; 0.79 9, 0.812,0.777, 0.766, 0.768, 0.824, 0.790, 0.787, (3.9080)+(0.0093)Gln+(−0.1550)His+(0.0027)Val; 0.798, 0.817, 0.743, 0.729, 0.74 8,0.833, 0.705, 0.754, (4.6112)+(0.0384)Ser+(−0.1262)His+(−0.0 138)Arg;0.798, 0.813, 0.781, 0.775, 0.769, 0.829, 0.788, 0.790, (4.1316)+(−0.0002)Gly+(0.0093)Gln+(−0.1498)His; 0.798, 0.813, 0.7 82,0.777, 0.770, 0.830, 0.788, 0.791, (4.1650)+(0.0093)Gln+(−0.1490)His+(−0.0008)Lys; 0.798, 0.812, 0.755, 0.749, 0.670, 0.843, 0. 881,0.786, (2.4334)+(−0.0107)Ala+(−0.0528)Val+(0.1714)Ile; 0. 798, 0.819,0.805, 0.816, 0.810, 0.799, 0.771, 0.799, (6.6861)+(0.0096)Pro+(−0.1264)Met+(−0.1290)Trp; 0.798, 0.815, 0.737, 0.720, 0. 736,0.828, 0.717, 0.750, (4.2895)+(0.0356)Ser+(−0.1300)His+(−0. 0046)Tyr;0.798, 0.816, 0.813, 0.819, 0.829, 0.814, 0.762, 0.806, (7.2107)+(−0.0638)Cit+(0.0033)Lys+(−0.1461)Trp; 0.797, 0.811, 0.7 71,0.761, 0.761, 0.820, 0.786, 0.782, (3.9323)+(0.0090)Gln+(−0.1519)His+(0.0037)Pro; 0.797, 0.817, 0.796, 0.808, 0.802, 0.794, 0.7 52,0.789, (5.3565)+(−0.0037)Val+(0.0209)Orn+(−0.1438)Trp; 0.7 97, 0.816,0.823, 0.831, 0.835, 0.828, 0.770, 0.816, (7.9208)+(−0.0559)Cit+(−0.0474)Met+(−0.1314)Trp; 0.797, 0.815, 0.771, 0.752, 0. 756,0.816, 0.818, 0.786, (4.9478)+(−0.1345)His+(−0.0044)Ala+(0. 0817)Phe;0.797, 0.813, 0.738, 0.720, 0.743, 0.830, 0.706, 0.750, (4.4233)+(0.0368)Ser+(−0.1250)His+(−0.0296)Cit; 0.797, 0.816, 0.7 97,0.809, 0.800, 0.787, 0.765, 0.791, (5.6255)+(0.0058)Pro+(−0.0028)Val+(−0.1449)Trp; 0.797, 0.817, 0.817, 0.819, 0.834, 0.822, 0. 771,0.811, (7.3477)+(−0.0649)Cit+(0.0076)Tyr+(−0.1456)Trp; 0. 797, 0.815,0.755, 0.749, 0.740, 0.778, 0.787, 0.764, (4.9925)+(−0.1332)His+(−0.0409)Tyr+(0.0989)Phe; 0.797, 0.817, 0.739, 0.704, 0. 742,0.790, 0.785, 0.755, (4.2734)+(−0.1473)His+(0.0224)Orn+(0. 0642)Phe;0.796, 0.817, 0.799, 0.811, 0.805, 0.789, 0.763, 0.792, (4.2821)+(0.0023)Gln+(0.0135)Orn+(−0.1554)Trp; 0.796, 0.810, 0.76 5, 0.758,0.705, 0.832, 0.859, 0.788, (5.2744)+(−0.1234)Asn+(−0.0559)Val+(0.1648)Ile; 0.796, 0.816, 0.799, 0.814, 0.802, 0.790, 0.7 59,0.791, (4.4453)+(0.0024)Gln+(0.0055)Thr+(−0.1576)Trp; 0.79 6, 0.817,0.816, 0.820, 0.830, 0.823, 0.767, 0.810, (7.3786)+(−0.0655)Cit+(0.0035)Arg+(−0.1428)Trp; 0.796, 0.815, 0.788, 0.797, 0.7 98,0.785, 0.742, 0.781, (4.9842)+(0.0053)Thr+(0.0138)Orn+(−0.1 553)Trp;0.796, 0.818, 0.779, 0.770, 0.785, 0.773, 0.793, 0.780, (5.0473)+(−0.0151)Arg+(0.0524)Ile+(−0.1642)Trp; 0.796, 0.813, 0.7 33,0.688, 0.738, 0.802, 0.793, 0.755, (5.1743)+(−0.1399)His+(0.0207)Orn+(0.0397)Ile; 0.796, 0.814, 0.794, 0.807, 0.801, 0.794, 0.7 43,0.786, (5.5010)+(0.0089)Thr+(−0.0019)Val+(−0.1510)Trp; 0.7 96, 0.815,0.791, 0.799, 0.797, 0.774, 0.773, 0.786, (5.1953)+(0.0039)Pro+(0.0061)Leu+(−0.1559)Trp; 0.795, 0.809, 0.726, 0.689, 0.7 25,0.798, 0.774, 0.747, (4.8966)+(0.0041)Gly+(−0.1388)His+(0.0 479)Ile;0.795, 0.813, 0.755, 0.735, 0.748, 0.789, 0.797, 0.767, (4.7788)+(−0.1369)His+(−0.0061)Val+(0.0850)Phe; 0.795, 0.816, 0.7 98,0.808, 0.803, 0.780, 0.773, 0.791, (5.6160)+(−0.0010)Gly+(0.0049)Pro+(−0.1495)Trp; 0.795, 0.814, 0.794, 0.794, 0.783, 0.842, 0. 780,0.800, (4.2855)+(0.0113)Gln+(−0.1468)His+(−0.0180)Arg; 0. 795, 0.813,0.805, 0.820, 0.800, 0.821, 0.763, 0.801, (5.9142)+(0.0119)Thr+(−0.0044)Ala+(−0.1462)Trp; 0.795, 0.813, 0.807, 0.818, 0. 804,0.814, 0.778, 0.804, (5.7061)+(−0.0046)Ala+(0.0233)Orn+(−0. 1394)Trp;0.794, 0.813, 0.797, 0.806, 0.804, 0.782, 0.768, 0.790, (5.3946)+(−0.0015)Gly+(0.0182)Orn+(−0.1500)Trp; 0.794, 0.807, 0.7 44,0.709, 0.741, 0.801, 0.804, 0.764, (5.6225)+(−0.1339)His+(−0.0017)Pro+(0.0476)Ile; 0.794, 0.811, 0.748, 0.722, 0.746, 0.785, 0. 793,0.761, (4.6778)+(−0.1427)His+(−0.0011)Leu+(0.0746)Phe; 0. 794, 0.815,0.789, 0.795, 0.798, 0.776, 0.761, 0.783, (4.9700)+(0.0150)Orn+(0.0051)Leu+(−0.1554)Trp; 0.794, 0.814, 0.792, 0.808, 0. 793,0.783, 0.756, 0.785, (5.7771)+(0.0063)Pro+(−0.0142)Tyr+(−0. 1432)Trp;0.794, 0.814, 0.805, 0.816, 0.812, 0.811, 0.756, 0.799, (6.2480)+(−0.1144)Met+(0.0265)Orn+(−0.1300)Trp; 0.794, 0.811, 0.8 16,0.831, 0.817, 0.796, 0.788, 0.808, (6.8947)+(−0.0617)Asn+(0.0064)Lys+(−0.1383)Trp; 0.794, 0.814, 0.792, 0.806, 0.801, 0.793, 0. 740,0.785, (5.5662)+(0.0100)Thr+(−0.0030)Lys+(−0.1515)Trp; 0. 794, 0.811,0.783, 0.782, 0.767, 0.827, 0.785, 0.790, (4.2965)+(0.0093)Gln+(−0.1450)His+(−0.0093)Tyr; 0.794, 0.813, 0.797, 0.807, 0. 808,0.783, 0.761, 0.790, (5.6920)+(−0.0024)Gly+(0.0101)Thr+(−0. 1556)Trp;0.793, 0.811, 0.744, 0.716, 0.743, 0.780, 0.794, 0.758, (4.6082)+(−0.1435)His+(0.0014)Pro+(0.0715)Phe; 0.793, 0.816, 0.79 4, 0.805,0.804, 0.786, 0.752, 0.787, (5.3204)+(0.0192)Orn+(−0.0025)Lys+(−0.1469)Trp; 0.793, 0.815, 0.795, 0.807, 0.800, 0.783, 0.7 65,0.789, (5.4706)+(0.0049)Pro+(−0.0004)Lys+(−0.1493)Trp; 0.7 93, 0.814,0.765, 0.735, 0.765, 0.808, 0.814, 0.781, (6.2924)+(−0.1115)His+(−0.1437)Met+(0.0614)Ile; 0.793, 0.811, 0.809, 0.828, 0. 807,0.797, 0.776, 0.802, (4.5282)+(0.0032)Gln+(−0.0014)Val+(−0. 1505)Trp;0.793, 0.807, 0.747, 0.712, 0.746, 0.801, 0.806, 0.766, (5.8441)+(−0.0156)Asn+(−0.1291)His+(0.0452)Ile; 0.793, 0.813, 0.8 25,0.844, 0.811, 0.828, 0.802, 0.821, (4.7615)+(0.0040)Gln+(−0.0042)Ala+(−0.1437)Trp; 0.793, 0.815, 0.800, 0.812, 0.801, 0.785, 0. 779,0.794, (4.1968)+(0.0029)Gln+(0.0070)Leu+(−0.1604)Trp; 0.7 92, 0.810,0.758, 0.736, 0.756, 0.789, 0.801, 0.770, (5.1249)+(−0.0297)Asn+(−0.1346)His+(0.0762)Phe; 0.792, 0.813, 0.788, 0.807, 0. 793,0.786, 0.731, 0.779, (5.6817)+(0.0106)Thr+(−0.0143)Tyr+(−0. 1488)Trp;0.792, 0.813, 0.807, 0.829, 0.801, 0.797, 0.769, 0.799, (4.6193)+(0.0036)Gln+(−0.0114)Tyr+(−0.1477)Trp; 0.792, 0.814, 0.7 85,0.792, 0.796, 0.774, 0.750, 0.778, (5.0110)+(0.0075)Thr+(0.0072)Leu+(−0.1615)Trp; 0.792, 0.811, 0.791, 0.805, 0.795, 0.790, 0.7 45,0.784, (5.4696)+(−0.0144)Tyr+(0.0208)Orn+(−0.1432)Trp; 0.7 92, 0.806,0.825, 0.841, 0.821, 0.824, 0.793, 0.820, (7.3985)+(−0.0434)Asn+(−0.0021)Ala+(−0.1270)Trp; 0.792, 0.813, 0.810, 0.828, 0. 809,0.798, 0.775, 0.802, (4.5134)+(0.0034)Gln+(−0.0019)Lys+(−0. 1508)Trp;0.792, 0.810, 0.745, 0.721, 0.734, 0.792, 0.795, 0.761, (6.1180)+(−0.1249)His+(−0.0267)Tyr+(0.0521)Ile; 0.791, 0.812, 0.8 15,0.830, 0.814, 0.792, 0.793, 0.807, (4.6372)+(−0.0022)Gly+(0.0036)Gln+(−0.1532)Trp; 0.791, 0.814, 0.767, 0.764, 0.774, 0.827, 0. 717,0.770, (7.1487)+(−0.1158)His+(0.0279)Thr+(−0.1455)Met; 0. 791, 0.810,0.749, 0.723, 0.747, 0.787, 0.795, 0.763, (4.8024)+(−0.1410)His+(−0.0023)Lys+(0.0755)Phe; 0.791, 0.810, 0.786, 0.779, 0. 777,0.835, 0.785, 0.794, (4.2753)+(0.0099)Gln+(−0.1424)His+(−0. 0345)Cit;0.790, 0.808, 0.819, 0.834, 0.822, 0.808, 0.784, 0.812, (7.2274)+(−0.0493)Asn+(−0.0003)Val+(−0.1307)Trp; 0.790, 0.811, 0. 797,0.810, 0.806, 0.789, 0.750, 0.789, (6.0790)+(−0.0122)Arg+(0.0062)Pro+(−0.1447)Trp; 0.790, 0.807, 0.744, 0.707, 0.742, 0.801, 0. 804,0.763, (5.7493)+(−0.1302)His+(−0.0034)Lys+(0.0477)Ile; 0. 790, 0.808,0.822, 0.837, 0.825, 0.816, 0.780, 0.815, (7.4464)+(−0.0291)Asn+(−0.0612)Met+(−0.1251)Trp; 0.790, 0.811, 0.725, 0.737, 0.728,0.755, 0.665, 0.721, (−3.8956)+(0.0461)Ser+(−0.3860)Met+(0.1074)Phe;0.790, 0.808, 0.813, 0.828, 0.816, 0.801, 0.771, 0.804,(6.4637)+(−0.1161)Met+(0.0086)Lys+(−0.1362)Trp; 0.790, 0.810, 0.817,0.832, 0.820, 0.809, 0.779, 0.810,(7.1177)+(−0.0507)Asn+(0.0006)Gly+(−0.1311)Trp; 0.790, 0.808, 0.764,0.741, 0.764, 0.82 8, 0.780, 0.778,(6.4775)+(−0.1222)His+(−0.0034)Ala+(0.0360)Or n; 0.789, 0.808, 0.810,0.818, 0.815, 0.792, 0.790, 0.804,(6.7362)+(−0.0523)Asn+(0.0099)Leu+(−0.1411)Trp; 0.788, 0.812, 0.817, 0.838, 0.817, 0.809, 0.764, 0.807, (4.7182)+(0.0047)Gln+(−0.0162)Arg+(−0.1483)Trp; 0.788, 0.808, 0.820, 0.833, 0.823, 0.807, 0.786, 0. 812,(7.1489)+(−0.0506)Asn+(0.0027)Tyr+(−0.1325)Trp; 0.788, 0. 808, 0.711,0.692, 0.713, 0.786, 0.704, 0.724, (−2.2756)+(0.0463)Ser+(−0.3598)Met+(0.0667)Ile; 0.787, 0.807, 0.751, 0.726, 0.752, 0. 785,0.788, 0.763, (4.9596)+(−0.1397)His+(−0.0076)Arg+(0.0755) Phe; 0.787,0.805, 0.742, 0.708, 0.742, 0.797, 0.796, 0.761, (5.7860)+(−0.1311)His+(−0.0055)Arg+(0.0456)Ile; 0.787, 0.810, 0.790, 0.807,0.807, 0.793, 0.708, 0.779, (6.1198)+(0.0151)Thr+(−0.0190)Arg+(−0.1520)Trp; 0.787, 0.808, 0.802, 0.817, 0.806, 0.791, 0.76 5,0.794, (5.7631)+(−0.0011)Val+(0.0014)Lys+(−0.1448)Trp; 0.78 7, 0.807,0.821, 0.838, 0.823, 0.819, 0.777, 0.814, (7.0144)+(−0.0012)Ala+(−0.0771)Met+(−0.1262)Trp; 0.786, 0.807, 0.807, 0.813, 0. 800,0.806, 0.804, 0.806, (5.8190)+(−0.0048)Ala+(0.0147)Leu+(−0. 1472)Trp;0.786, 0.808, 0.735, 0.708, 0.746, 0.805, 0.735, 0.749, (5.8708)+(−0.1387)His+(0.0106)Thr+(0.0275)Orn; 0.786, 0.809, 0.82 3, 0.833,0.831, 0.815, 0.786, 0.816, (6.7016)+(0.0220)Tyr+(−0.1228)Met+(−0.1333)Trp; 0.786, 0.807, 0.797, 0.804, 0.804, 0.777, 0.7 80,0.791, (5.5030)+(−0.0008)Gly+(0.0085)Leu+(−0.1541)Trp; 0.7 86, 0.804,0.817, 0.832, 0.813, 0.816, 0.787, 0.812, (6.4245)+(−0.0005)Gly+(−0.0032)Ala+(−0.1355)Trp; 0.786, 0.805, 0.819, 0.834, 0. 822,0.808, 0.780, 0.811, (7.2801)+(−0.0464)Asn+(−0.0027)Arg+(−0.1306)Trp;0.786, 0.807, 0.802, 0.819, 0.803, 0.790, 0.762, 0.794,(5.9934)+(−0.0053)Tyr+(−0.0002)Val+(−0.1413)Trp; 0.786, 0.808, 0.794,0.806, 0.808, 0.796, 0.735, 0.786,(5.8391)+(−0.0158)Arg+(0.0243)Orn+(−0.1443)Trp; 0.786, 0.804, 0.814,0.829, 0.810, 0.81 5, 0.786, 0.810,(6.2303)+(−0.0036)Ala+(0.0019)Val+(−0.1384)Tr p; 0.786, 0.805, 0.814,0.829, 0.808, 0.813, 0.786, 0.809,(6.0922)+(−0.0036)Ala+(0.0030)Lys+(−0.1395)Trp; 0.785, 0.806, 0.800, 0.817, 0.801, 0.785, 0.762, 0.791, (5.8544)+(−0.0071)Tyr+(0.0017)Lys+(−0.1435)Trp; 0.785, 0.806, 0.816, 0.834, 0.820, 0.811, 0.766, 0. 808,(6.8851)+(0.0003)Gly+(−0.0874)Met+(−0.1276)Trp; 0.785, 0. 809, 0.795,0.802, 0.803, 0.777, 0.772, 0.788, (5.4835)+(−0.0018)Lys+(0.0097)Leu+(−0.1528)Trp; 0.785, 0.807, 0.805, 0.819, 0.808, 0. 790,0.774, 0.798, (6.0235)+(−0.0009)Gly+(−0.0006)Val+(−0.143 2)Trp; 0.785,0.801, 0.761, 0.751, 0.755, 0.824, 0.756, 0.772, (6.7803)+(−0.1262)His+(0.0162)Thr+(−0.0030)Ala; 0.785, 0.808, 0.792, 0.804,0.795, 0.776, 0.767, 0.786, (5.6121)+(−0.0103)Tyr+(0.0100)Leu+(−0.1501)Trp; 0.785, 0.806, 0.817, 0.831, 0.812, 0.820, 0.78 8,0.813, (6.2724)+(−0.0034)Ala+(0.0036)Tyr+(−0.1371)Trp; 0.78 5, 0.806,0.804, 0.821, 0.806, 0.786, 0.770, 0.796, (6.1519)+(−0.0009)Gly+(−0.0057)Tyr+(−0.1412)Trp; 0.785, 0.797, 0.756, 0.731, 0. 749,0.809, 0.798, 0.772, (6.6774)+(−0.1230)His+(−0.0200)Val+(0. 0435)Leu;0.784, 0.800, 0.741, 0.703, 0.746, 0.798, 0.792, 0.760, (5.8176)+(−0.1253)His+(−0.0340)Cit+(0.0475)Ile; 0.784, 0.804, 0.8 18,0.835, 0.815, 0.818, 0.776, 0.811, (6.6717)+(−0.0028)Ala+(−0.0065)Arg+(−0.1332)Trp; 0.784, 0.804, 0.740, 0.714, 0.751, 0.809, 0. 735,0.752, (5.8436)+(0.0022)Gly+(−0.1317)His+(0.0321)Orn; 0.7 84, 0.802,0.740, 0.706, 0.751, 0.804, 0.760, 0.755, (5.8858)+(−0.1364)His+(0.0294)Orn+(0.0081)Leu; 0.784, 0.806, 0.804, 0.817, 0.8 09,0.787, 0.773, 0.797, (5.8656)+(−0.0009)Gly+(0.0011)Lys+(−0. 1462)Trp;0.783, 0.802, 0.757, 0.744, 0.761, 0.810, 0.745, 0.765, (7.1127)+(−0.0416)Asn+(−0.1237)His+(0.0189)Thr; 0.783, 0.800, 0.7 31,0.703, 0.737, 0.793, 0.749, 0.745, (5.9361)+(−0.1454)His+(0.0149)Thr+(0.0130)Leu; 0.783, 0.806, 0.814, 0.830, 0.820, 0.805, 0.7 69,0.806, (6.7969)+(0.0022)Val+(−0.0927)Met+(−0.1308)Trp; 0.7 83, 0.806,0.817, 0.835, 0.820, 0.810, 0.767, 0.808, (6.9855)+(−0.0014)Arg+(−0.0843)Met+(−0.1273)Trp; 0.783, 0.801, 0.748, 0.721, 0. 752,0.783, 0.787, 0.761, (4.9427)+(−0.1364)His+(−0.0316)Cit+(0. 0770)Phe;0.783, 0.802, 0.751, 0.725, 0.760, 0.810, 0.759, 0.764, (6.2198)+(−0.1266)His+(−0.0021)Val+(0.0348)Orn; 0.783, 0.805, 0.8 05,0.811, 0.813, 0.792, 0.780, 0.799, (6.3971)+(−0.1169)Met+(0.0160)Leu+(−0.1379)Trp; 0.782, 0.802, 0.741, 0.711, 0.751, 0.805, 0. 754,0.755, (5.9329)+(−0.1309)His+(0.0030)Pro+(0.0306)Orn; 0.7 82, 0.803,0.756, 0.730, 0.767, 0.814, 0.761, 0.768, (6.5383)+(−0.0242)Asn+(−0.1227)His+(0.0345)Orn; 0.782, 0.799, 0.746, 0.738, 0. 746,0.803, 0.725, 0.753, (6.8094)+(−0.1265)His+(0.0175)Thr+(−0. 0178)Tyr;0.781, 0.805, 0.751, 0.731, 0.757, 0.809, 0.749, 0.762, (6.5160)+(−0.1228)His+(−0.0191)Tyr+(0.0379)Orn; 0.781, 0.796, 0.7 44,0.726, 0.749, 0.803, 0.740, 0.754, (6.4251)+(−0.1340)His+(0.0148)Thr+(0.0007)Val; 0.781, 0.807, 0.766, 0.744, 0.777, 0.824, 0.7 58,0.776, (6.6441)+(−0.1159)His+(−0.0764)Met+(0.0375)Orn; 0.7 81, 0.797,0.738, 0.718, 0.744, 0.795, 0.738, 0.749, (6.2349)+(−0.1338)His+(0.0135)Thr+(0.0035)Pro; 0.781, 0.796, 0.740, 0.725, 0.7 44,0.803, 0.728, 0.750, (6.3053)+(0.0014)Gly+(−0.1332)His+(0.0 140)Thr;0.781, 0.797, 0.746, 0.729, 0.751, 0.805, 0.741, 0.756, (6.5100)+(−0.1324)His+(0.0151)Thr+(−0.0006)Lys; 0.780, 0.801, 0.7 48,0.720, 0.759, 0.807, 0.756, 0.760, (6.1382)+(−0.1297)His+(0.0331)Orn+(−0.0002)Lys; 0.779, 0.795, 0.767, 0.746, 0.760, 0.817, 0. 800,0.781, (6.8557)+(−0.1243)His+(−0.0038)Ala+(0.0168)Leu; 0. 779, 0.802,0.764, 0.760, 0.734, 0.817, 0.800, 0.778, (3.1078)+(−0.2396)Met+(0.1675)Ile+(−0.0812)Leu; 0.778, 0.802, 0.805, 0.822, 0. 812,0.795, 0.753, 0.795, (6.3459)+(−0.0090)Arg+(−0.0000)Val+(−0.1399)Trp;0.778, 0.797, 0.768, 0.770, 0.693, 0.843, 0.864, 0.793,(1.7786)+(−0.0118)Ala+(0.1676)Ile+(−0.0861)Leu; 0.778, 0.798, 0.748,0.736, 0.758, 0.808, 0.716, 0.754,(6.9726)+(−0.1297)His+(0.0192)Thr+(−0.0139)Arg; 0.778, 0.804, 0.796,0.806, 0.806, 0.77 9, 0.760, 0.788,(5.9216)+(−0.0104)Arg+(0.0097)Leu+(−0.1501)Tr p; 0.778, 0.793, 0.738,0.714, 0.743, 0.801, 0.747, 0.751,(5.9686)+(0.0036)Gly+(−0.1351)His+(0.0144)Leu; 0.777, 0.800, 0.800, 0.817, 0.809, 0.787, 0.746, 0.790, (6.0966)+(−0.0127)Arg+(0.0047)Lys+(−0.1455)Trp; 0.777, 0.802, 0.806, 0.822, 0.814, 0.795, 0.757, 0.7 97,(6.4087)+(−0.0004)Gly+(−0.0088)Arg+(−0.1399)Trp; 0.777, 0. 790, 0.731,0.724, 0.676, 0.807, 0.809, 0.754, (2.9430)+(−0.0292)Arg+(−0.0568)Val+(0.1623)Ile; 0.777, 0.793, 0.768, 0.756, 0.752, 0. 824,0.792, 0.781, (6.9352)+(−0.1113)His+(−0.0052)Ala+(0.0098) Pro; 0.776,0.799, 0.750, 0.724, 0.764, 0.811, 0.744, 0.761, (6.4860)+(−0.1257)His+(−0.0094)Arg+(0.0359)Orn; 0.776, 0.803, 0.805, 0.822,0.811, 0.795, 0.753, 0.795, (6.3683)+(−0.0088)Arg+(−0.0011)Tyr+(−0.1393)Trp; 0.775, 0.796, 0.745, 0.709, 0.771, 0.818, 0.73 0,0.757, (6.3753)+(−0.1195)His+(−0.0645)Cit+(0.0505)Orn; 0.77 3, 0.789,0.746, 0.719, 0.750, 0.794, 0.775, 0.759, (6.3352)+(−0.1304)His+(0.0033)Pro+(0.0107)Leu; 0.773, 0.791, 0.746, 0.729, 0.75 6,0.810, 0.725, 0.755, (6.7791)+(−0.1261)His+(0.0164)Thr+(−0.0 315)Cit;0.773, 0.789, 0.751, 0.739, 0.751, 0.808, 0.741, 0.760, (6.4815)+(0.0030)Gly+(−0.1251)His+(0.0023)Val; 0.773, 0.789, 0.77 3, 0.760,0.766, 0.821, 0.789, 0.784, (7.1829)+(−0.1170)His+(−0.0028)Ala+(0.0033)Val; 0.773, 0.788, 0.757, 0.733, 0.759, 0.801, 0.7 84,0.769, (6.8054)+(−0.0139)Asn+(−0.1260)His+(0.0128)Leu; 0.7 73, 0.790,0.767, 0.762, 0.757, 0.823, 0.759, 0.775, (6.9417)+(0.0027)Gly+(−0.1151)His+(−0.0021)Ala; 0.772, 0.787, 0.751, 0.725, 0. 754,0.801, 0.778, 0.764, (6.4821)+(−0.1311)His+(0.0008)Lys+(0. 0124)Leu;0.771, 0.788, 0.741, 0.726, 0.743, 0.798, 0.736, 0.751, (6.1975)+(0.0030)Gly+(−0.1244)His+(0.0054)Pro; 0.771, 0.787, 0.77 0, 0.760,0.759, 0.818, 0.786, 0.781, (6.9282)+(−0.1189)His+(−0.0026)Ala+(0.0057)Lys; 0.771, 0.788, 0.751, 0.733, 0.748, 0.794, 0.7 72,0.762, (6.8495)+(−0.1257)His+(−0.0142)Tyr+(0.0148)Leu; 0.7 71, 0.785,0.753, 0.736, 0.753, 0.798, 0.765, 0.763, (6.6606)+(−0.1205)His+(0.0054)Pro+(−0.0006)Val; 0.770, 0.791, 0.720, 0.705, 0. 658,0.804, 0.831, 0.749, (2.6163)+(−0.0523)Val+(−0.0156)Lys+(0. 1573)Ile;0.770, 0.785, 0.719, 0.702, 0.667, 0.799, 0.814, 0.746, (2.1097)+(−0.0648)Cit+(−0.0522)Val+(0.1505)Ile; 0.770, 0.787, 0.7 78,0.770, 0.768, 0.820, 0.790, 0.787, (7.5427)+(−0.0118)Asn+(−0.1091)His+(−0.0020)Ala; 0.770, 0.786, 0.767, 0.754, 0.765, 0.811, 0. 775,0.776, (7.2389)+(−0.0133)Asn+(−0.1160)His+(0.0012)Val; 0. 770, 0.788,0.713, 0.718, 0.641, 0.784, 0.799, 0.736, (2.5533)+(−0.0453)Tyr+(−0.0510)Val+(0.1527)Ile; 0.770, 0.788, 0.761, 0.754, 0. 758,0.814, 0.745, 0.768, (7.0163)+(−0.0207)Asn+(0.0033)Gly+(−0. 1146)His;0.769, 0.785, 0.748, 0.730, 0.748, 0.795, 0.764, 0.759, (6.4125)+(−0.1253)His+(0.0048)Pro+(0.0030)Lys; 0.769, 0.788, 0.75 9, 0.742,0.759, 0.800, 0.772, 0.768, (6.9636)+(−0.0185)Asn+(−0.1158)His+(0.0055)Pro; 0.769, 0.786, 0.775, 0.767, 0.766, 0.822, 0.7 84,0.785, (7.3567)+(−0.1119)His+(−0.0020)Ala+(−0.0016)Tyr; 0. 769, 0.785,0.749, 0.738, 0.748, 0.804, 0.743, 0.758, (6.3294)+(0.0028)Gly+(−0.1262)His+(0.0042)Lys; 0.769, 0.787, 0.752, 0.743, 0. 747,0.794, 0.755, 0.760, (6.9241)+(−0.1148)His+(0.0068)Pro+(−0. 0162)Tyr;0.769, 0.784, 0.758, 0.743, 0.757, 0.803, 0.767, 0.768, (6.6973)+(−0.1245)His+(0.0005)Val+(0.0040)Lys; 0.769, 0.788, 0.75 3, 0.729,0.756, 0.800, 0.774, 0.765, (6.6793)+(−0.1286)His+(−0.0030)Arg+(0.0127)Leu; 0.768, 0.793, 0.765, 0.755, 0.763, 0.805, 0.7 64,0.772, (7.1084)+(−0.1057)His+(0.0082)Pro+(−0.0867)Met; 0.7 68, 0.790,0.765, 0.745, 0.769, 0.800, 0.783, 0.774, (7.0516)+(−0.1178)His+(−0.0865)Met+(0.0181)Leu; 0.768, 0.787, 0.757, 0.751, 0. 754,0.811, 0.740, 0.764, (6.7995)+(0.0027)Gly+(−0.1186)His+(−0. 0040)Tyr;0.768, 0.790, 0.764, 0.787, 0.762, 0.818, 0.668, 0.759, (1.4313)+(0.0426)Ser+(−0.0855)Asn+(−0.1762)Met; 0.768, 0.783, 0.7 64,0.750, 0.762, 0.801, 0.776, 0.772, (7.0329)+(−0.0227)Asn+(−0.1189)His+(0.0057)Lys; 0.767, 0.786, 0.763, 0.752, 0.760, 0.806, 0. 768,0.772, (7.1377)+(−0.1181)His+(−0.0089)Tyr+(0.0023)Val; 0. 767, 0.791,0.768, 0.765, 0.763, 0.822, 0.744, 0.774, (7.0860)+(0.0032)Gly+(−0.1098)His+(−0.0546)Met; 0.767, 0.786, 0.756, 0.750, 0. 755,0.812, 0.736, 0.763, (6.8908)+(0.0031)Gly+(−0.1181)His+(−0. 0051)Arg;0.767, 0.787, 0.779, 0.773, 0.771, 0.822, 0.782, 0.787, (7.5575)+(−0.1062)His+(−0.0013)Ala+(−0.0403)Met; 0.766, 0.787, 0. 775,0.766, 0.766, 0.822, 0.784, 0.784, (7.4498)+(−0.1112)His+(−0.0020)Ala+(−0.0027)Arg; 0.765, 0.784, 0.770, 0.762, 0.764, 0.810, 0. 773,0.777, (7.4515)+(−0.0130)Asn+(−0.1115)His+(−0.0052)Tyr; 0. 765, 0.782,0.759, 0.751, 0.752, 0.801, 0.765, 0.767, (6.8983)+(−0.1206)His+(−0.0119)Tyr+(0.0059)Lys; 0.765, 0.781, 0.754, 0.746, 0. 759,0.815, 0.722, 0.761, (6.9164)+(0.0038)Gly+(−0.1134)His+(−0. 0312)Cit;0.764, 0.787, 0.772, 0.761, 0.770, 0.812, 0.773, 0.779, (7.3339)+(−0.1117)His+(0.0029)Val+(−0.0571)Met; 0.764, 0.785, 0.7 54,0.737, 0.756, 0.800, 0.758, 0.763, (6.8590)+(−0.1188)His+(−0.0052)Arg+(0.0055)Pro; 0.764, 0.785, 0.764, 0.749, 0.764, 0.810, 0. 768,0.773, (7.1366)+(−0.1188)His+(−0.0036)Arg+(0.0015)Val; 0. 763, 0.780,0.751, 0.725, 0.761, 0.797, 0.768, 0.763, (6.8232)+(−0.1237)His+(−0.0274)Cit+(0.0134)Leu; 0.763, 0.785, 0.775, 0.768, 0. 771,0.817, 0.774, 0.782, (7.4745)+(−0.0004)Asn+(−0.1078)His+(−0.0490)Met;0.763, 0.780, 0.714, 0.734, 0.660, 0.765, 0.738, 0.724,(2.1382)+(−0.0567)Tyr+(0.1557)Ile+(−0.0852)Leu; 0.763, 0.776, 0.670,0.653, 0.601, 0.781, 0.779, 0.704,(−0.7855)+(0.0165)Ser+(−0.0556)Val+(0.1474)Ile; 0.763, 0.784, 0.769,0.758, 0.766, 0.81 1, 0.775, 0.777,(7.4187)+(−0.0123)Asn+(−0.1129)His+(−0.0024)A rg; 0.762, 0.786, 0.771,0.762, 0.769, 0.808, 0.771, 0.777, (6.9998)+(−0.1142)His+(−0.0846)Met+(0.0096)Lys; 0.762, 0.780, 0.752, 0. 732,0.759, 0.801, 0.755, 0.762, (6.9361)+(−0.1148)His+(−0.0268)Cit+(0.0054)Pro; 0.761, 0.775, 0.709, 0.696, 0.638, 0.785, 0.839, 0.740, (1.5523)+(−0.0030)Gly+(−0.0562)Val+(0.1505)Ile; 0.761, 0. 779,0.776, 0.767, 0.773, 0.825, 0.772, 0.784, (7.6847)+(−0.1047)His+(−0.0024)Ala+(−0.0275)Cit; 0.761, 0.774, 0.697, 0.679, 0.636, 0.779,0.815, 0.727, (2.5091)+(−0.0032)Gln+(−0.0562)Val+(0.155 0)Ile; 0.760,0.783, 0.767, 0.758, 0.762, 0.810, 0.768, 0.774, (7.3600)+(−0.1138)His+(−0.0031)Arg+(−0.0055)Tyr; 0.760, 0.773, 0.69 8, 0.692,0.627, 0.783, 0.800, 0.726, (1.1194)+(−0.0448)Val+(0.1770)Ile+(−0.0364)Leu; 0.760, 0.775, 0.708, 0.699, 0.636, 0.790, 0.8 20,0.736, (1.2005)+(−0.0053)Pro+(−0.0558)Val+(0.1564)Ile; 0.7 60, 0.785,0.775, 0.767, 0.770, 0.816, 0.773, 0.782, (7.4896)+(−0.1077)His+(−0.0005)Arg+(−0.0486)Met; 0.759, 0.785, 0.775, 0.765, 0. 772,0.817, 0.776, 0.783, (7.4082)+(−0.1085)His+(0.0049)Tyr+(−0. 0574)Met;0.759, 0.778, 0.761, 0.744, 0.767, 0.805, 0.758, 0.769, (7.2302)+(−0.1151)His+(−0.0269)Cit+(0.0022)Val; 0.759, 0.780, 0.7 58,0.744, 0.760, 0.800, 0.761, 0.766, (6.9309)+(−0.1226)His+(−0.0077)Arg+(0.0062)Lys; 0.758, 0.778, 0.769, 0.757, 0.773, 0.812, 0. 764,0.777, (7.6368)+(−0.0137)Asn+(−0.1072)His+(−0.0256)Cit; 0. 758, 0.775,0.758, 0.743, 0.763, 0.801, 0.757, 0.766, (7.0221)+(−0.1172)His+(−0.0256)Cit+(0.0042)Lys; 0.758, 0.774, 0.693, 0.680, 0. 620,0.777, 0.819, 0.724, (0.3392)+(−0.0570)Val+(0.1469)Ile+(0. 0168)Phe;0.757, 0.778, 0.766, 0.757, 0.768, 0.808, 0.758, 0.773, (7.5009)+(−0.1091)His+(−0.0253)Cit+(−0.0051)Tyr; 0.757, 0.781, 0. 775,0.767, 0.779, 0.817, 0.761, 0.781, (7.7415)+(−0.1023)His+(−0.0246)Cit+(−0.0459)Met; 0.757, 0.772, 0.707, 0.696, 0.636, 0.788, 0. 823,0.736, (1.4159)+(−0.0063)Thr+(−0.0547)Val+(0.1495)Ile; 0. 755, 0.775,0.752, 0.752, 0.709, 0.799, 0.805, 0.767, (3.2170)+(−0.0959)Asn+(0.1425)Ile+(−0.0828)Leu; 0.755, 0.778, 0.760, 0.774, 0. 745,0.814, 0.718, 0.763, (0.5617)+(0.0467)Ser+(−0.0073)Gly+(−0. 2492)Met;0.755, 0.778, 0.764, 0.750, 0.768, 0.810, 0.758, 0.771, (7.3593)+(−0.1116)His+(−0.0260)Cit+(0.0004)Arg; 0.754, 0.779, 0.7 49,0.762, 0.770, 0.821, 0.619, 0.743, (1.6186)+(0.0369)Ser+(−0.0672)Cit+(−0.2258)Met; 0.754, 0.778, 0.773, 0.765, 0.744, 0.811, 0. 827,0.787, (2.3927)+(−0.0080)Ala+(−0.2302)Met+(0.0660)Ile; 0. 754, 0.777,0.759, 0.786, 0.742, 0.844, 0.661, 0.758, (0.6519)+(0.0352)Ser+(−0.0029)Ala+(−0.2233)Met; 0.754, 0.780, 0.733, 0.760, 0. 740,0.816, 0.586, 0.726, (0.2631)+(0.0340)Ser+(0.0084)Thr+(−0. 2814)Met;0.752, 0.772, 0.690, 0.675, 0.624, 0.781, 0.805, 0.721, (0.7114)+(−0.0565)Val+(0.0086)Orn+(0.1475)Ile; 0.752, 0.775, 0.74 7, 0.737,0.755, 0.734, 0.768, 0.749, (0.0520)+(−0.3443)Met+(0.0421)Ile+(0.0671)Phe; 0.751, 0.775, 0.708, 0.724, 0.707, 0.784, 0.61 2,0.707, (−0.2763)+(0.0394)Ser+(0.0104)Pro+(−0.3014)Met; 0.75 0, 0.776,0.723, 0.740, 0.727, 0.791, 0.620, 0.720, (−0.4704)+(0.0391)Ser+(−0.2831)Met+(0.0104)Leu; 0.750, 0.769, 0.783, 0.805, 0.7 79,0.749, 0.758, 0.773, (1.1531)+(−0.0138)Val+(−0.2755)Met+(0. 1120)Phe;0.747, 0.769, 0.762, 0.783, 0.724, 0.845, 0.724, 0.769, (1.7482)+(0.0379)Ser+(−0.1364)Asn+(−0.0056)Ala; 0.746, 0.776, 0.7 27,0.748, 0.729, 0.810, 0.610, 0.724, (−0.1296)+(0.0353)Ser+(−0.2683)Met+(0.0164)Orn; 0.746, 0.774, 0.740, 0.769, 0.736, 0.814, 0. 619,0.735, (−0.0743)+(0.0352)Ser+(0.0011)Gln+(−0.2585)Met; 0. 746, 0.773,0.738, 0.763, 0.738, 0.815, 0.615, 0.733, (0.1400)+(0.0368)Ser+(0.0045)Tyr+(−0.2607)Met; 0.746, 0.770, 0.731, 0.741, 0. 741,0.797, 0.638, 0.729, (2.1540)+(0.0396)Ser+(−0.1421)Asn+(−0. 0700)Cit;0.746, 0.771, 0.738, 0.765, 0.738, 0.820, 0.608, 0.732, (0.4582)+(0.0365)Ser+(−0.2389)Met+(−0.0028)Lys; 0.745, 0.773, 0.7 41,0.771, 0.748, 0.816, 0.597, 0.733, (0.7127)+(0.0374)Ser+(−0.0122)Arg+(−0.2308)Met; 0.745, 0.774, 0.746, 0.776, 0.741, 0.830, 0. 621,0.742, (0.7664)+(0.0349)Ser+(−0.0036)Val+(−0.2345)Met; 0. 744, 0.763,0.725, 0.741, 0.743, 0.697, 0.663, 0.711, (−0.4451)+(0.0224)Thr+(−0.3883)Met+(0.0934)Phe; 0.744, 0.762, 0.781, 0.796, 0. 772,0.761, 0.777, 0.777, (0.8574)+(−0.0052)Ala+(−0.2608)Met+(0. 0912)Phe;0.744, 0.765, 0.752, 0.739, 0.748, 0.779, 0.772, 0.760, (2.6270)+(−0.2513)Met+(−0.0101)Lys+(0.0585)Ile; 0.742, 0.766, 0.7 53,0.735, 0.770, 0.774, 0.748, 0.757, (3.0275)+(−0.0670)Cit+(−0.2520)Met+(0.0553)Ile; 0.742, 0.764, 0.716, 0.706, 0.691, 0.800, 0. 738,0.733, (1.6755)+(−0.0852)Cit+(0.1568)Ile+(−0.0897)Leu; 0. 741, 0.761,0.771, 0.794, 0.767, 0.729, 0.747, 0.759, (−1.3017)+(0.0045)Gln+(−0.3394)Met+(0.0874)Phe; 0.740, 0.764, 0.748, 0.759, 0. 757,0.709, 0.730, 0.739, (0.3020)+(0.0070)Pro+(−0.3324)Met+(0. 0853)Phe;0.740, 0.760, 0.761, 0.742, 0.729, 0.830, 0.832, 0.783, (2.1633)+(−0.0140)Ala+(−0.0933)Cit+(0.0592)Ile; 0.740, 0.760, 0.7 69,0.780, 0.778, 0.736, 0.746, 0.760, (0.9836)+(−0.2817)Met+(−0.0070)Lys+(0.0910)Phe; 0.740, 0.763, 0.691, 0.690, 0.687, 0.732, 0. 672,0.695, (−1.2217)+(0.0446)Ser+(−0.1933)Asn+(0.0490)Phe; 0. 738, 0.760,0.750, 0.749, 0.739, 0.768, 0.763, 0.755, (0.3569)+(0.0040)Gln+(−0.3138)Met+(0.0524)Ile; 0.738, 0.756, 0.717, 0.709, 0. 723,0.744, 0.706, 0.721, (1.3103)+(0.0177)Thr+(−0.3453)Met+(0. 0533)Ile;0.737, 0.756, 0.747, 0.737, 0.746, 0.760, 0.766, 0.752, (2.3078)+(−0.0199)Asn+(−0.2612)Met+(0.0511)Ile; 0.737, 0.757, 0.7 50,0.767, 0.761, 0.718, 0.703, 0.737, (0.0077)+(0.0025)Gly+(−0.3154)Met+(0.0905)Phe; 0.737, 0.763, 0.713, 0.703, 0.673, 0.777, 0.7 73,0.732, (1.5790)+(−0.0149)Lys+(0.1433)Ile+(−0.0805)Leu; 0.7 37, 0.754,0.768, 0.782, 0.777, 0.721, 0.747, 0.757, (1.2362)+(−0.0369)Asn+(−0.2652)Met+(0.0849)Phe; 0.736, 0.757, 0.738, 0.728, 0. 737,0.752, 0.757, 0.743, (1.8799)+(0.0023)Pro+(−0.2903)Met+(0. 0503)Ile;0.736, 0.757, 0.752, 0.764, 0.761, 0.720, 0.724, 0.742, (0.2273)+(−0.3116)Met+(0.0129)Orn+(0.0820)Phe; 0.735, 0.762, 0.75 3, 0.782,0.729, 0.825, 0.677, 0.753, (2.6428)+(0.0370)Ser+(−0.1453)Asn+(−0.0107)Val; 0.734, 0.754, 0.735, 0.725, 0.734, 0.757, 0.7 50,0.741, (1.7322)+(−0.2876)Met+(0.0071)Orn+(0.0504)Ile; 0.73 4, 0.757,0.729, 0.721, 0.728, 0.755, 0.732, 0.734, (1.5227)+(0.0022)Gly+(−0.2920)Met+(0.0545)Ile; 0.734, 0.759, 0.725, 0.759, 0.70 5,0.784, 0.637, 0.721, (1.8544)+(0.0382)Ser+(−0.1364)Asn+(−0.0 309)Tyr;0.732, 0.756, 0.674, 0.657, 0.664, 0.754, 0.685, 0.690, (−0.6580)+(0.0427)Ser+(−0.1756)Asn+(0.0295)Ile; 0.732, 0.754, 0.74 6, 0.738,0.747, 0.760, 0.754, 0.750, (2.2765)+(−0.0085)Arg+(−0.2689)Met+(0.0528)Ile; 0.731, 0.753, 0.725, 0.730, 0.697, 0.783, 0.7 25,0.734, (2.2252)+(−0.0321)Arg+(0.1596)Ile+(−0.0944)Leu; 0.7 30, 0.751,0.754, 0.742, 0.760, 0.826, 0.725, 0.763, (2.8460)+(−0.0116)Ala+(−0.1225)Cit+(0.0535)Orn; 0.729, 0.754, 0.764, 0.782, 0. 774,0.723, 0.727, 0.751, (0.8766)+(−0.0094)Arg+(−0.2888)Met+(0. 0877)Phe;0.729, 0.751, 0.764, 0.784, 0.771, 0.720, 0.728, 0.751, (0.6223)+(−0.2897)Met+(−0.0090)Leu+(0.0957)Phe; 0.729, 0.752, 0.7 01,0.700, 0.649, 0.763, 0.768, 0.720, (0.2540)+(−0.0070)Pro+(0.1559)Ile+(−0.0916)Leu; 0.728, 0.749, 0.778, 0.774, 0.725, 0.835, 0. 861,0.799, (2.7575)+(−0.0883)Asn+(−0.0105)Ala+(0.0457)Ile; 0. 727, 0.749,0.717, 0.716, 0.666, 0.767, 0.792, 0.735, (1.1557)+(−0.0150)Thr+(0.1545)Ile+(−0.0920)Leu; 0.727, 0.751, 0.760, 0.751, 0. 699,0.833, 0.858, 0.785, (2.0924)+(−0.0111)Ala+(−0.0196)Lys+(0. 0576)Ile;0.727, 0.751, 0.749, 0.776, 0.746, 0.704, 0.719, 0.736, (0.7541)+(−0.0268)Tyr+(−0.2652)Met+(0.0949)Phe; 0.726, 0.752, 0.7 58,0.763, 0.784, 0.735, 0.710, 0.748, (1.4416)+(−0.0644)Cit+(−0.2735)Met+(0.0916)Phe; 0.726, 0.751, 0.733, 0.731, 0.723, 0.746, 0. 749,0.737, (2.1541)+(−0.0156)Tyr+(−0.2573)Met+(0.0542)Ile; 0. 725, 0.754,0.782, 0.791, 0.756, 0.816, 0.787, 0.787, (4.0489)+(−0.0363)Val+(−0.2236)Met+(0.0626)Leu; 0.725, 0.752, 0.722, 0.745, 0. 721,0.783, 0.623, 0.718, (1.2211)+(0.0406)Ser+(−0.1411)Asn+(−0. 0154)Arg;0.725, 0.751, 0.747, 0.764, 0.779, 0.783, 0.606, 0.733, (3.9391)+(0.0228)Thr+(−0.0713)Cit+(−0.2554)Met; 0.724, 0.753, 0.7 51,0.744, 0.789, 0.795, 0.656, 0.746, (3.5164)+(−0.0968)Cit+(−0.2017)Met+(0.0460)Orn; 0.724, 0.749, 0.745, 0.729, 0.780, 0.787, 0. 688,0.746, (3.7326)+(−0.1110)Asn+(−0.1028)Cit+(0.0450)Orn; 0. 723, 0.747,0.681, 0.674, 0.635, 0.748, 0.747, 0.701, (0.5731)+(−0.0014)Gln+(0.1452)Ile+(−0.0899)Leu; 0.723, 0.748, 0.772, 0.785, 0. 744,0.806, 0.767, 0.776, (3.5498)+(−0.0079)Ala+(0.0140)Pro+(−0. 1927)Met;0.723, 0.746, 0.671, 0.666, 0.620, 0.730, 0.751, 0.692,(−1.1447)+(0.1442)Ile+(−0.0959)Leu+(0.0285)Phe; 0.723, 0.747, 0. 641,0.632, 0.592, 0.741, 0.691, 0.664, (−1.9553)+(0.0163)Ser+(0.1425)Ile+(−0.0887)Leu; 0.723, 0.750, 0.720, 0.735, 0.711, 0.798, 0. 644,0.722, (1.3728)+(0.0403)Ser+(−0.1361)Asn+(−0.0091)Lys; 0. 720, 0.746,0.715, 0.728, 0.703, 0.777, 0.661, 0.717, (0.7730)+(0.0412)Ser+(−0.1516)Asn+(−0.0046)Thr; 0.720, 0.747, 0.700, 0.706, 0. 695,0.769, 0.642, 0.703, (0.4568)+(0.0394)Ser+(−0.1693)Asn+(0. 0136)Orn;0.720, 0.744, 0.724, 0.721, 0.710, 0.772, 0.725, 0.732, (1.0301)+(0.0475)Ser+(−0.1581)Asn+(−0.0059)Gly; 0.719, 0.743, 0.7 56,0.781, 0.768, 0.765, 0.654, 0.742, (3.6825)+(−0.0587)Asn+(0.0207)Thr+(−0.2199)Met; 0.719, 0.744, 0.696, 0.690, 0.644, 0.748, 0. 780,0.715, (0.4305)+(−0.0026)Gly+(0.1447)Ile+(−0.0907)Leu; 0. 718, 0.744,0.682, 0.680, 0.630, 0.746, 0.748, 0.701, (−0.0598)+(−0.0014)Orn+(0.1448)Ile+(−0.0903)Leu; 0.718, 0.747, 0.724, 0.744, 0. 710,0.792, 0.651, 0.724, (1.2781)+(0.0386)Ser+(−0.1542)Asn+(−0. 0057)Leu;0.716, 0.739, 0.692, 0.699, 0.684, 0.757, 0.641, 0.695, (0.5591)+(0.0400)Ser+(−0.1649)Asn+(0.0029)Pro; 0.715, 0.737, 0.75 9, 0.787,0.749, 0.803, 0.676, 0.754, (3.2559)+(−0.0103)Val+(−0.1926)Met+(0.0321)Orn; 0.714, 0.736, 0.802, 0.831, 0.789, 0.794, 0.7 56,0.792, (2.0338)+(−0.0691)Asn+(0.0063)Gln+(−0.1839)Met; 0.7 14, 0.740,0.716, 0.733, 0.702, 0.775, 0.661, 0.718, (0.2302)+(0.0382)Ser+(−0.1720)Asn+(0.0021)Gln; 0.714, 0.736, 0.724, 0.747, 0.7 33,0.750, 0.626, 0.714, (2.4827)+(0.0158)Thr+(0.0071)Pro+(−0.2 907)Met;0.713, 0.742, 0.766, 0.799, 0.756, 0.811, 0.669, 0.759, (3.0994)+(0.0185)Thr+(−0.0043)Ala+(−0.2318)Met; 0.713, 0.739, 0.7 85,0.809, 0.764, 0.755, 0.784, 0.778, (3.3010)+(−0.1273)Asn+(−0.0191)Val+(0.0755)Phe; 0.712, 0.742, 0.759, 0.799, 0.760, 0.807, 0. 614,0.745, (3.4295)+(0.0193)Thr+(−0.0077)Val+(−0.2413)Met; 0. 711, 0.737,0.679, 0.668, 0.585, 0.815, 0.811, 0.720, (−2.4641)+(0.0235)Ser+(−0.0143)Ala+(0.0473)Ile; 0.710, 0.734, 0.734, 0.745, 0. 719,0.830, 0.668, 0.740, (1.1144)+(0.0249)Ser+(−0.0091)Ala+(−0. 0852)Cit;0.710, 0.732, 0.730, 0.744, 0.729, 0.758, 0.676, 0.727, (2.4003)+(0.0067)Pro+(−0.2523)Met+(0.0184)Orn; 0.709, 0.734, 0.76 8, 0.789,0.746, 0.810, 0.727, 0.768, (2.8987)+(−0.0050)Ala+(−0.1855)Met+(0.0261)Orn; 0.709, 0.734, 0.697, 0.714, 0.715, 0.757, 0.5 71,0.689, (2.6812)+(−0.1070)Cit+(−0.0592)Tyr+(0.0475)Orn; 0.7 09, 0.732,0.756, 0.771, 0.757, 0.751, 0.719, 0.749, (3.6758)+(−0.0395)Asn+(0.0076)Pro+(−0.1974)Met; 0.709, 0.733, 0.758, 0.771, 0. 762,0.773, 0.706, 0.753, (3.3754)+(−0.0499)Asn+(−0.1796)Met+(0. 0244)Orn;0.709, 0.732, 0.753, 0.754, 0.696, 0.815, 0.827, 0.773, (1.2719)+(−0.0122)Ala+(−0.0207)Arg+(0.0470)Ile; 0.709, 0.734, 0.7 70,0.794, 0.754, 0.802, 0.716, 0.767, (4.6800)+(−0.1161)Asn+(−0.0166)Val+(0.0369)Orn; 0.709, 0.735, 0.790, 0.801, 0.755, 0.804, 0. 825,0.796, (2.4449)+(−0.1032)Asn+(−0.0085)Ala+(0.0518)Phe; 0. 709, 0.734,0.752, 0.790, 0.749, 0.772, 0.640, 0.738, (1.3967)+(0.0035)Gln+(0.0152)Thr+(−0.2857)Met; 0.709, 0.735, 0.752, 0.761, 0. 771,0.766, 0.680, 0.745, (4.0694)+(−0.0632)Cit+(0.0086)Pro+(−0. 2096)Met;0.707, 0.731, 0.729, 0.754, 0.740, 0.765, 0.615, 0.719, (2.2980)+(0.0140)Thr+(−0.2706)Met+(0.0156)Orn; 0.706, 0.736, 0.67 7, 0.708,0.681, 0.756, 0.530, 0.669, (0.9989)+(0.0246)Ser+(−0.0785)Cit+(−0.0478)Tyr; 0.705, 0.732, 0.801, 0.813, 0.789, 0.829, 0.7 72,0.801, (5.3131)+(−0.0674)Asn+(−0.0063)Ala+(−0.0676)Cit; 0. 705, 0.732,0.782, 0.807, 0.787, 0.792, 0.696, 0.770, (2.1230)+(0.0061)Gln+(−0.0732)Cit+(−0.2136)Met; 0.705, 0.730, 0.741, 0.771, 0. 750,0.762, 0.630, 0.728, (2.7756)+(−0.0008)Gly+(0.0183)Thr+(−0. 2684)Met;0.705, 0.730, 0.801, 0.837, 0.764, 0.827, 0.761, 0.797, (1.8230)+(0.0045)Gln+(−0.0041)Ala+(−0.2001)Met; 0.705, 0.727, 0.7 48,0.765, 0.751, 0.782, 0.673, 0.743, (2.9347)+(−0.2023)Met+(0.0268)Orn+(−0.0070)Lys; 0.705, 0.732, 0.596, 0.620, 0.546, 0.685, 0. 573,0.606, (−1.7471)+(0.0230)Ser+(−0.0738)Tyr+(0.0362)Ile; 0. 704, 0.729,0.753, 0.779, 0.739, 0.758, 0.707, 0.746, (1.3604)+(0.0041)Gln+(0.0074)Pro+(−0.2675)Met; 0.704, 0.732, 0.736, 0.772, 0. 755,0.765, 0.579, 0.718, (3.2808)+(0.0223)Thr+(−0.0164)Arg+(−0. 2560)Met;0.704, 0.729, 0.736, 0.781, 0.708, 0.684, 0.716, 0.722, (2.5464)+(−0.1004)Asn+(−0.0629)Tyr+(0.0685)Phe; 0.704, 0.733, 0.7 41,0.776, 0.699, 0.849, 0.660, 0.746, (0.1779)+(0.0266)Ser+(−0.0082)Ala+(−0.0243)Arg; 0.704, 0.729, 0.755, 0.784, 0.740, 0.773, 0. 695,0.748, (3.8632)+(0.0111)Pro+(−0.0102)Val+(−0.2081)Met; 0. 704, 0.727,0.746, 0.765, 0.745, 0.751, 0.696, 0.739, (3.1772)+(0.0082)Pro+(−0.2263)Met+(−0.0031)Lys; 0.703, 0.730, 0.738, 0.770, 0. 748,0.772, 0.611, 0.725, (3.0415)+(0.0190)Thr+(−0.2511)Met+(−0. 0051)Lys;0.703, 0.733, 0.612, 0.568, 0.614, 0.739, 0.631, 0.638,(−1.9031)+(0.0330)Ser+(−0.0328)Lys+(0.0445)Ile; 0.703, 0.730, 0. 733,0.760, 0.744, 0.753, 0.623, 0.720, (2.4849)+(0.0180)Thr+(−0.2794)Met+(0.0037)Leu; 0.703, 0.728, 0.773, 0.787, 0.730, 0.793, 0. 810,0.780, (5.3423)+(−0.1196)Asn+(−0.0393)Val+(0.0550)Leu; 0. 703, 0.732,0.737, 0.719, 0.750, 0.748, 0.747, 0.741, (3.2433)+(−0.1014)Asn+(−0.0751)Cit+(0.0287)Ile; 0.702, 0.732, 0.718, 0.689, 0. 777,0.813, 0.601, 0.720, (2.9594)+(−0.1128)Cit+(0.0544)Orn+(−0. 0225)Lys;0.702, 0.726, 0.738, 0.759, 0.739, 0.745, 0.678, 0.730, (2.7991)+(0.0008)Gly+(0.0081)Pro+(−0.2412)Met; 0.702, 0.731, 0.73 4, 0.773,0.739, 0.759, 0.602, 0.718, (2.8884)+(0.0185)Thr+(−0.0121)Tyr+(−0.2498)Met; 0.702, 0.735, 0.796, 0.812, 0.797, 0.819, 0.7 33,0.790, (4.8035)+(−0.0046)Ala+(−0.0642)Cit+(−0.1280)Met; 0. 702, 0.728,0.720, 0.716, 0.630, 0.805, 0.856, 0.752, (0.0336)+(−0.0148)Ala+(0.0055)Pro+(0.0392)Ile; 0.702, 0.726, 0.720, 0.742, 0. 633,0.786, 0.796, 0.739, (1.5289)+(−0.0105)Ala+(−0.0464)Tyr+(0. 0519)Ile;0.702, 0.729, 0.747, 0.765, 0.759, 0.776, 0.657, 0.739, (2.9766)+(−0.0132)Arg+(−0.2080)Met+(0.0262)Orn; 0.701, 0.726, 0.7 58,0.787, 0.746, 0.782, 0.690, 0.751, (1.3109)+(0.0034)Gln+(−0.2490)Met+(0.0176)Orn; 0.701, 0.724, 0.760, 0.760, 0.741, 0.818, 0.7 56,0.769, (3.2929)+(−0.0124)Ala+(−0.0844)Cit+(0.0123)Pro; 0.7 01, 0.724,0.777, 0.787, 0.736, 0.820, 0.807, 0.787, (3.8514)+(−0.0890)Asn+(−0.0097)Ala+(0.0106)Pro; 0.701, 0.727, 0.719, 0.787, 0. 665,0.699, 0.666, 0.704, (0.9960)+(−0.0670)Tyr+(−0.0154)Val+(0. 0803)Phe;0.700, 0.727, 0.775, 0.790, 0.793, 0.775, 0.698, 0.764, (4.9949)+(−0.0392)Asn+(−0.0594)Cit+(−0.1347)Met; 0.700, 0.727, 0. 763,0.769, 0.740, 0.804, 0.766, 0.770, (1.6184)+(−0.0109)Ala+(−0.0852)Cit+(0.0489)Phe; 0.700, 0.722, 0.771, 0.797, 0.770, 0.771, 0. 703,0.760, (3.8178)+(−0.0463)Asn+(0.0014)Gly+(−0.1606)Met; 0. 700, 0.725,0.798, 0.822, 0.780, 0.809, 0.762, 0.793, (4.3442)+(−0.0428)Asn+(−0.0039)Ala+(−0.1241)Met; 0.699, 0.728, 0.737, 0.764, 0.728,0.740, 0.680, 0.728, (3.1978)+(0.0089)Pro+(−0.0158)Tyr+(−0.2140)Met;0.699, 0.728, 0.748, 0.769, 0.751, 0.753, 0.685, 0.73 9,(3.3247)+(−0.0092)Arg+(0.0083)Pro+(−0.2236)Met; 0.699, 0.72 9, 0.793,0.837, 0.769, 0.810, 0.714, 0.783,(2.0695)+(0.0046)Gln+(−0.0069)Val+(−0.2098)Met; 0.699, 0.726, 0.756,0.777, 0.779, 0.7 80, 0.637, 0.743,(3.9881)+(0.0026)Gly+(−0.0659)Cit+(−0.1770)M et; 0.698, 0.720, 0.743,0.762, 0.744, 0.767, 0.674, 0.737, (2.5228)+(−0.0002)Gly+(−0.2274)Met+(0.0224)Orn; 0.698, 0.724, 0.743, 0. 762,0.741, 0.746, 0.692, 0.735, (2.9703)+(0.0082)Pro+(−0.2366)Met+(−0.0011)Leu; 0.697, 0.724, 0.745, 0.741, 0.663, 0.817, 0.873, 0.773, (0.5464)+(−0.0075)Thr+(−0.0128)Ala+(0.0466)Ile; 0.697, 0. 722,0.783, 0.817, 0.767, 0.795, 0.715, 0.773, (1.6816)+(0.0048)Gln+(−0.2216)Met+(−0.0045)Lys; 0.697, 0.730, 0.678, 0.693, 0.665, 0. 709,0.644, 0.678, (2.1992)+(−0.0781)Cit+(−0.0618)Tyr+(0.0398)Ile; 0.697,0.722, 0.743, 0.763, 0.744, 0.768, 0.671, 0.736, (2.5402)+(−0.2249)Met+(0.0228)Orn+(−0.0012)Leu; 0.697, 0.722, 0.732, 0.727,0.644, 0.817, 0.864, 0.763, (0.3244)+(−0.0005)Gln+(−0.0134)Ala+(0.0445)Ile; 0.696, 0.725, 0.732, 0.729, 0.643, 0.818, 0.864,0.763, (−0.2114)+(−0.0139)Ala+(0.0420)Ile+(0.0088)Phe; 0.696, 0.718,0.775, 0.799, 0.775, 0.769, 0.719, 0.766, (4.0295)+(−0.0427)Asn+(−0.1579)Met+(−0.0007)Lys; 0.696, 0.721, 0.782, 0.794, 0.7 49,0.827, 0.786, 0.789, (3.5468)+(−0.0971)Asn+(−0.0075)Ala+(0. 0246)Orn;0.696, 0.722, 0.783, 0.823, 0.771, 0.791, 0.694, 0.770, (1.6766)+(0.0054)Gln+(−0.0142)Arg+(−0.2204)Met; 0.696, 0.723, 0.7 87,0.816, 0.765, 0.812, 0.737, 0.783, (3.4744)+(0.0005)Gly+(−0.0040)Ala+(−0.1671)Met; 0.696, 0.722, 0.791, 0.818, 0.769, 0.816, 0. 744,0.787, (3.6265)+(−0.0040)Ala+(−0.1620)Met+(−0.0010)Lys; 0. 695, 0.723,0.795, 0.830, 0.770, 0.824, 0.735, 0.790, (3.9431)+(−0.0031)Ala+(−0.0048)Val+(−0.1526)Met; 0.695, 0.721, 0.782, 0.817, 0.764,0.783, 0.724, 0.772, (1.4961)+(−0.0009)Gly+(0.0046)Gln+(−0.2380)Met;0.695, 0.721, 0.816, 0.843, 0.770, 0.843, 0.820, 0.81 9,(2.5124)+(−0.1142)Asn+(0.0050)Gln+(−0.0067)Ala; 0.695, 0.72 1, 0.685,0.682, 0.714, 0.795, 0.556, 0.687,(1.0121)+(0.0298)Ser+(−0.0794)Cit+(−0.0192)Lys; 0.695, 0.720, 0.760,0.772, 0.780, 0.7 67, 0.678, 0.750,(4.0944)+(−0.0627)Cit+(−0.1866)Met+(0.0050)L eu; 0.695, 0.721, 0.730,0.727, 0.640, 0.817, 0.862, 0.762, (0.0306)+(−0.0136)Ala+(0.0020)Orn+(0.0433)Ile; 0.695, 0.727, 0.750, 0.7 49,0.769, 0.724, 0.730, 0.743, (2.8641)+(−0.1101)Asn+(−0.0727)Cit+(0.0411)Phe; 0.695, 0.719, 0.774, 0.795, 0.774, 0.766, 0.722, 0. 764,(3.9071)+(−0.0426)Asn+(−0.1649)Met+(0.0013)Leu; 0.694, 0. 724, 0.814,0.854, 0.777, 0.826, 0.777, 0.809, (3.3276)+(−0.1300)Asn+(0.0057)Gln+(−0.0132)Val; 0.694, 0.722, 0.735, 0.731, 0.648, 0. 817,0.867, 0.766, (0.1922)+(−0.0006)Gly+(−0.0135)Ala+(0.0439)Ile; 0.694,0.720, 0.712, 0.740, 0.668, 0.708, 0.729, 0.711, (3.2246)+(−0.0883)Asn+(−0.0521)Tyr+(0.0357)Ile; 0.693, 0.723, 0.784, 0.803,0.780, 0.780, 0.746, 0.777, (2.3580)+(−0.1318)Asn+(0.0071)Gln+(−0.0812)Cit; 0.693, 0.725, 0.604, 0.659, 0.557, 0.641, 0.52 6,0.596, (−2.3653)+(0.0237)Ser+(−0.0836)Tyr+(0.0567)Phe; 0.69 3, 0.721,0.735, 0.763, 0.729, 0.759, 0.656, 0.726, (2.7186)+(−0.0146)Tyr+(−0.2029)Met+(0.0242)Orn; 0.693, 0.718, 0.776, 0.800, 0.7 79,0.770, 0.713, 0.766, (4.1345)+(−0.0399)Asn+(−0.0050)Arg+(−0. 1545)Met;0.693, 0.721, 0.774, 0.809, 0.757, 0.776, 0.712, 0.764, (1.3401)+(0.0044)Gln+(−0.2452)Met+(0.0024)Leu; 0.693, 0.719, 0.79 3, 0.825,0.779, 0.802, 0.729, 0.784, (4.9530)+(−0.0537)Asn+(−0.0078)Val+(−0.1146)Met; 0.693, 0.724, 0.784, 0.806, 0.764, 0.806, 0. 755,0.783, (3.2879)+(−0.0046)Ala+(−0.1795)Met+(0.0070)Leu; 0. 693, 0.720,0.766, 0.782, 0.785, 0.776, 0.676, 0.755, (4.3747)+(−0.0612)Cit+(−0.1690)Met+(−0.0010)Lys; 0.692, 0.724, 0.767, 0.796, 0.767,0.766, 0.694, 0.756, (5.2257)+(−0.0737)Asn+(−0.0616)Cit+(−0.0299)Tyr;0.692, 0.718, 0.772, 0.801, 0.767, 0.762, 0.712, 0.76 0,(4.2145)+(−0.0452)Asn+(−0.0107)Tyr+(−0.1389)Met; 0.691, 0.7 28, 0.732,0.758, 0.679, 0.859, 0.680, 0.744, (0.4512)+(0.0274)Ser+(−0.0071)Ala+(−0.0153)Lys; 0.691, 0.717, 0.734, 0.787, 0.658, 0. 753,0.738, 0.734, (0.8325)+(−0.0083)Ala+(−0.0578)Tyr+(0.0647)Phe; 0.691,0.723, 0.776, 0.797, 0.789, 0.792, 0.682, 0.765, (4.6715)+(−0.0572)Cit+(−0.0044)Val+(−0.1559)Met; 0.691, 0.720, 0.774, 0.817,0.752, 0.778, 0.705, 0.763, (1.5803)+(0.0045)Gln+(−0.0077)Tyr+(−0.2246)Met; 0.691, 0.720, 0.741, 0.761, 0.755, 0.759, 0.64 3,0.730, (4.0158)+(−0.0997)Asn+(0.0041)Gly+(−0.0739)Cit; 0.69 1, 0.720,0.794, 0.824, 0.777, 0.815, 0.733, 0.787, (3.8364)+(−0.0039)Ala+(−0.0068)Arg+(−0.1543)Met; 0.690, 0.721, 0.686, 0.720, 0. 637,0.733, 0.668, 0.689, (0.3358)+(0.0362)Ser+(−0.0104)Gly+(−0. 0620)Tyr;0.690, 0.715, 0.709, 0.711, 0.732, 0.790, 0.601, 0.708, (1.9860)+(−0.1027)Cit+(−0.0155)Val+(0.0491)Orn; 0.690, 0.721, 0.7 64,0.779, 0.783, 0.770, 0.678, 0.753, (4.2287)+(−0.0635)Cit+(0.0025)Arg+(−0.1767)Met; 0.690, 0.719, 0.777, 0.804, 0.759, 0.818, 0. 713,0.774, (4.1831)+(−0.0068)Ala+(−0.0720)Cit+(−0.0230)Tyr; 0. 690, 0.725,0.672, 0.728, 0.664, 0.767, 0.476, 0.659, (0.4665)+(0.0269)Ser+(−0.0255)Arg+(−0.0457)Tyr; 0.689, 0.722, 0.788, 0.817, 0. 765,0.810, 0.741, 0.783, (3.5905)+(−0.0040)Ala+(−0.0023)Tyr+(−0.1621)Met;0.688, 0.718, 0.705, 0.751, 0.673, 0.698, 0.657, 0.695,(1.4875)+(−0.0652)Tyr+(−0.0158)Lys+(0.0658)Phe; 0.688, 0.714, 0.763,0.792, 0.762, 0.770, 0.687, 0.753,(3.2655)+(0.0005)Gly+(−0.1956)Met+(−0.0022)Lys; 0.688, 0.720, 0.765,0.783, 0.783, 0.773, 0.672, 0.753,(4.3828)+(−0.0611)Cit+(−0.0047)Tyr+(−0.1648)Me t; 0.688, 0.715, 0.810,0.842, 0.774, 0.844, 0.778, 0.809,(5.0618)+(−0.0850)Asn+(−0.0039)Ala+(−0.0089)Val; 0.688, 0.717, 0.776, 0.813, 0.764, 0.789, 0.694, 0.765, (3.7789)+(0.0002)Gly+(−0.0065)Val+(−0.1753)Met; 0.687, 0.714, 0.756, 0.781, 0.755, 0.759, 0.687, 0.746, (2.9155)+(0.0007)Gly+(−0.2150)Met+(0.0033)Leu; 0.687, 0.7 11,0.779, 0.797, 0.756, 0.825, 0.748, 0.781, (2.1936)+(0.0031)Gln+(−0.0093)Ala+(−0.0855)Cit; 0.686, 0.715, 0.762, 0.784, 0.761, 0. 767,0.699, 0.753, (3.2479)+(−0.2017)Met+(−0.0038)Lys+(0.0050)Leu; 0.686,0.715, 0.726, 0.763, 0.705, 0.729, 0.667, 0.716, (3.8237)+(−0.0965)Asn+(−0.0456)Tyr+(0.0270)Orn; 0.686, 0.717, 0.787, 0.809,0.753, 0.827, 0.772, 0.790, (3.9179)+(−0.1048)Asn+(0.0102)Thr+(−0.0071)Ala; 0.686, 0.715, 0.790, 0.828, 0.746, 0.812, 0.76 4,0.787, (4.6033)+(−0.0747)Asn+(−0.0050)Ala+(−0.0236)Tyr; 0.6 86, 0.712,0.763, 0.793, 0.764, 0.769, 0.673, 0.750, (3.4071)+(0.0008)Gly+(−0.0081)Arg+(−0.1909)Met; 0.685, 0.710, 0.766, 0.784, 0. 754,0.822, 0.707, 0.767, (3.2394)+(0.0017)Gly+(−0.0086)Ala+(−0. 0810)Cit;0.685, 0.713, 0.767, 0.796, 0.768, 0.771, 0.684, 0.755, (3.5609)+(−0.0075)Arg+(−0.1869)Met+(−0.0008)Lys; 0.685, 0.716, 0. 775,0.813, 0.762, 0.786, 0.696, 0.764, (3.7237)+(−0.0069)Val+(−0.1803)Met+(0.0017)Lys; 0.685, 0.713, 0.780, 0.806, 0.776, 0.794, 0. 713,0.772, (5.6126)+(−0.0859)Asn+(−0.0552)Cit+(−0.0093)Val; 0. 684, 0.715,0.763, 0.789, 0.766, 0.762, 0.687, 0.751, (3.3782)+(−0.0078)Arg+(−0.1982)Met+(0.0030)Leu; 0.683, 0.717, 0.776, 0.815, 0. 763,0.788, 0.695, 0.765, (3.8382)+(−0.0020)Tyr+(−0.0064)Val+(−0.1715)Met;0.683, 0.713, 0.774, 0.826, 0.737, 0.759, 0.727, 0.762,(2.6567)+(−0.1160)Asn+(0.0055)Gln+(−0.0404)Tyr; 0.683, 0.713, 0.770,0.806, 0.754, 0.790, 0.697, 0.762,(4.9807)+(−0.1229)Asn+(0.0129)Thr+(−0.0140)Val; 0.683, 0.711, 0.784,0.829, 0.753, 0.79 9, 0.721, 0.775,(5.2932)+(−0.0855)Asn+(−0.0208)Tyr+(−0.0097)V al; 0.683, 0.714, 0.788,0.802, 0.779, 0.839, 0.734, 0.789, (4.2447)+(−0.0074)Ala+(−0.0738)Cit+(−0.0069)Lys; 0.683, 0.708, 0.766, 0. 780,0.754, 0.817, 0.719, 0.768, (3.2644)+(0.0044)Thr+(−0.0091)Ala+(−0.0812)Cit; 0.683, 0.711, 0.748, 0.752, 0.762, 0.748, 0.706, 0.742, (4.1503)+(−0.0959)Asn+(−0.0691)Cit+(0.0029)Pro; 0.683, 0. 717,0.711, 0.762, 0.636, 0.836, 0.647, 0.720, (0.3637)+(0.0223)Ser+(−0.0070)Ala+(−0.0355)Tyr; 0.682, 0.712, 0.758, 0.791, 0.752, 0. 758,0.681, 0.746, (3.2465)+(0.0003)Gly+(−0.0070)Tyr+(−0.1921)Met; 0.682,0.715, 0.741, 0.749, 0.762, 0.748, 0.670, 0.732, (4.2078)+(−0.1131)Asn+(0.0102)Thr+(−0.0722)Cit; 0.682, 0.708, 0.771, 0.780,0.756, 0.816, 0.741, 0.773, (3.3435)+(−0.0090)Ala+(−0.0795)Cit+(0.0030)Leu; 0.682, 0.713, 0.683, 0.700, 0.646, 0.721, 0.691,0.689, (2.3941)+(−0.0530)Tyr+(−0.0191)Lys+(0.0466)Ile; 0.682, 0.711,0.762, 0.794, 0.757, 0.766, 0.688, 0.751, (3.4544)+(−0.0068)Tyr+(−0.1828)Met+(−0.0020)Lys; 0.682, 0.710, 0.797, 0.822, 0.7 59,0.828, 0.785, 0.799, (3.8919)+(−0.0879)Asn+(0.0012)Gly+(−0. 0064)Ala;0.682, 0.711, 0.735, 0.720, 0.726, 0.756, 0.778, 0.745, (2.9314)+(−0.0856)Asn+(−0.0161)Lys+(0.0340)Ile; 0.682, 0.714, 0.6 94,0.712, 0.608, 0.811, 0.741, 0.718, (−2.3006)+(0.0224)Ser+(−0.0118)Ala+(0.0340)Phe; 0.681, 0.708, 0.778, 0.791, 0.766, 0.823, 0. 733,0.778, (3.5964)+(−0.0084)Ala+(−0.0752)Cit+(−0.0030)Arg; 0. 681, 0.707,0.694, 0.659, 0.717, 0.761, 0.692, 0.707, (2.4775)+(−0.0814)Cit+(−0.0233)Lys+(0.0444)Ile; 0.680, 0.711, 0.697, 0.773, 0. 653,0.660, 0.617, 0.676, (0.5611)+(−0.0730)Tyr+(−0.0189)Leu+(0. 0764)Phe;0.680, 0.711, 0.698, 0.734, 0.695, 0.718, 0.592, 0.685, (3.1112)+(−0.0727)Cit+(0.0059)Pro+(−0.0535)Tyr; 0.680, 0.713, 0.7 64,0.797, 0.762, 0.764, 0.677, 0.750, (3.6363)+(−0.0078)Arg+(−0.0069)Tyr+(−0.1771)Met; 0.680, 0.706, 0.780, 0.799, 0.763, 0.827, 0. 729,0.780, (3.7935)+(−0.0075)Ala+(−0.0727)Cit+(−0.0040)Val; 0. 680, 0.712,0.709, 0.770, 0.670, 0.766, 0.585, 0.698, (2.3261)+(−0.0462)Tyr+(−0.0132)Val+(0.0294)Orn; 0.680, 0.712, 0.687, 0.730, 0. 675,0.675, 0.607, 0.671, (1.4091)+(−0.0758)Cit+(−0.0711)Tyr+(0. 0632)Phe;0.680, 0.707, 0.765, 0.796, 0.739, 0.776, 0.730, 0.760, (4.9611)+(−0.1058)Asn+(0.0081)Pro+(−0.0155)Val; 0.680, 0.710, 0.7 55,0.785, 0.751, 0.751, 0.687, 0.743, (3.1642)+(−0.0082)Tyr+(−0.1987)Met+(0.0034)Leu; 0.679, 0.708, 0.707, 0.752, 0.696, 0.815, 0. 531,0.699, (0.6244)+(0.0249)Ser+(−0.0278)Arg+(−0.0126)Val; 0. 679, 0.714,0.779, 0.819, 0.771, 0.790, 0.685, 0.766, (4.1123)+(−0.0072)Arg+(−0.0064)Val+(−0.1618)Met; 0.679, 0.710, 0.729, 0.769, 0.701,0.716, 0.690, 0.719, (4.1127)+(−0.0887)Asn+(0.0061)Pro+(−0.0449)Tyr;0.678, 0.712, 0.686, 0.678, 0.668, 0.762, 0.690, 0.69 9,(−0.0670)+(0.0404)Ser+(−0.0088)Gly+(−0.0230)Lys; 0.678, 0.7 09, 0.804,0.826, 0.770, 0.837, 0.795, 0.807, (4.2986)+(−0.0769)Asn+(−0.0060)Ala+(−0.0041)Lys; 0.677, 0.707, 0.766, 0.782, 0.777, 0. 769,0.700, 0.757, (4.7394)+(−0.0877)Asn+(−0.0650)Cit+(−0.006 0)Leu; 0.677,0.710, 0.766, 0.776, 0.780, 0.775, 0.704, 0.759, (4.8155)+(−0.0775)Asn+(−0.0656)Cit+(−0.0063)Lys; 0.677, 0.704, 0.72 7, 0.772,0.650, 0.788, 0.722, 0.733, (2.5799)+(−0.0100)Ala+(0.0124)Pro+(−0.0425)Tyr; 0.677, 0.708, 0.727, 0.734, 0.653, 0.833, 0.7 86,0.752, (−0.4582)+(0.0313)Ser+(−0.0074)Gly+(−0.0098)Ala; 0. 676, 0.711,0.729, 0.777, 0.711, 0.725, 0.641, 0.714, (4.2199)+(−0.1080)Asn+(0.0132)Thr+(−0.0445)Tyr; 0.676, 0.703, 0.722, 0.770, 0. 711,0.739, 0.606, 0.707, (2.1176)+(0.0030)Gln+(−0.0782)Cit+(−0. 0497)Tyr;0.676, 0.711, 0.805, 0.830, 0.773, 0.826, 0.788, 0.804, (4.2511)+(−0.0760)Asn+(−0.0061)Ala+(−0.0079)Arg; 0.676, 0.707, 0. 802,0.825, 0.765, 0.830, 0.797, 0.804, (4.1313)+(−0.0846)Asn+(−0.0062)Ala+(−0.0017)Leu; 0.676, 0.710, 0.776, 0.790, 0.734, 0.820, 0. 795,0.785, (1.3332)+(−0.0091)Ala+(−0.0150)Lys+(0.0464)Phe; 0. 675, 0.712,0.729, 0.755, 0.647, 0.850, 0.745, 0.749, (−0.6360)+(0.0289)Ser+(−0.0137)Thr+(−0.0082)Ala; 0.675, 0.699, 0.667, 0.664, 0.680,0.740, 0.595, 0.670, (−0.6502)+(0.0316)Ser+(−0.0176)Thr+(−0.0815)Cit;0.675, 0.709, 0.757, 0.766, 0.770, 0.754, 0.707, 0.74 9,(4.3427)+(−0.0921)Asn+(−0.0678)Cit+(−0.0001)Arg; 0.674, 0.7 15, 0.667,0.713, 0.646, 0.770, 0.516, 0.661, (0.6099)+(0.0268)Ser+(−0.0375)Tyr+(−0.0156)Lys; 0.674, 0.707, 0.758, 0.773, 0.721, 0. 829,0.745, 0.767, (2.3528)+(−0.0082)Ala+(0.0271)Orn+(−0.0155)Lys; 0.674,0.711, 0.675, 0.696, 0.685, 0.785, 0.521, 0.672, (−0.0125)+(0.0307)Ser+(−0.0212)Arg+(−0.0172)Lys; 0.673, 0.703, 0.749, 0.796,0.722, 0.741, 0.686, 0.736, (4.1822)+(−0.0869)Asn+(0.0005)Gly+(−0.0359)Tyr; 0.673, 0.702, 0.783, 0.821, 0.758, 0.796, 0.72 2,0.774, (4.8438)+(−0.0993)Asn+(0.0010)Gly+(−0.0120)Val; 0.67 3, 0.706,0.762, 0.809, 0.734, 0.757, 0.698, 0.749, (4.4799)+(−0.0838)Asn+(−0.0330)Tyr+(−0.0045)Leu; 0.672, 0.703, 0.759, 0.781, 0. 727,0.823, 0.725, 0.764, (1.9774)+(−0.0092)Ala+(−0.0226)Arg+(0. 0240)Orn;0.672, 0.706, 0.679, 0.692, 0.595, 0.814, 0.726, 0.707,(−1.1331)+(0.0214)Ser+(−0.0129)Ala+(0.0096)Pro; 0.672, 0.705, 0. 756,0.759, 0.756, 0.739, 0.760, 0.753, (2.5668)+(−0.1010)Asn+(−0.0124)Lys+(0.0408)Phe; 0.671, 0.701, 0.755, 0.773, 0.702, 0.821, 0. 771,0.767, (2.6204)+(−0.0106)Ala+(0.0106)Pro+(−0.0123)Lys; 0. 671, 0.703,0.762, 0.786, 0.759, 0.707, 0.742, 0.748, (2.4528)+(−0.1206)Asn+(−0.0205)Leu+(0.0570)Phe; 0.671, 0.704, 0.673, 0.738, 0. 628,0.765, 0.526, 0.664, (0.6891)+(0.0202)Ser+(−0.0421)Tyr+(−0. 0094)Val;0.671, 0.698, 0.701, 0.745, 0.703, 0.725, 0.560, 0.683, (3.1206)+(0.0047)Thr+(−0.0736)Cit+(−0.0492)Tyr; 0.670, 0.700, 0.7 22,0.764, 0.722, 0.744, 0.594, 0.706, (3.4706)+(−0.0698)Cit+(−0.0422)Tyr+(−0.0033)Leu; 0.670, 0.703, 0.672, 0.668, 0.677, 0.734, 0. 626,0.676, (−1.1998)+(0.0359)Ser+(−0.0073)Gly+(−0.0333)Arg; 0. 670, 0.702,0.757, 0.798, 0.734, 0.753, 0.697, 0.746, (4.4701)+(−0.0780)Asn+(−0.0329)Tyr+(−0.0040)Lys; 0.670, 0.700, 0.765, 0.804, 0.695,0.801, 0.782, 0.771, (0.6504)+(−0.0085)Ala+(−0.0136)Val+(0.0552)Phe;0.670, 0.701, 0.773, 0.796, 0.733, 0.806, 0.772, 0.776,(0.9830)+(−0.0100)Ala+(−0.0207)Arg+(0.0413)Phe; 0.670, 0.704, 0.758,0.803, 0.738, 0.748, 0.690, 0.745,(4.4809)+(−0.0762)Asn+(−0.0086)Arg+(−0.0342)Tyr; 0.669, 0.700, 0.749,0.770, 0.748, 0.7 63, 0.688, 0.742,(3.4810)+(−0.1136)Asn+(0.0253)Orn+(−0.0150)L eu; 0.669, 0.697, 0.757,0.780, 0.706, 0.818, 0.754, 0.765, (2.2570)+(−0.0113)Ala+(−0.0190)Arg+(0.0105)Pro; 0.668, 0.698, 0.732, 0. 773,0.653, 0.869, 0.687, 0.746, (0.2214)+(0.0209)Ser+(−0.0075)Ala+(−0.0085)Val; 0.668, 0.701, 0.714, 0.755, 0.714, 0.732, 0.593, 0.698, (3.2818)+(0.0001)Gly+(−0.0713)Cit+(−0.0447)Tyr; 0.668, 0. 703,0.694, 0.710, 0.628, 0.846, 0.678, 0.716, (−0.0649)+(0.0255)Ser+(−0.0025)Gln+(−0.0093)Ala; 0.668, 0.701, 0.739, 0.784, 0.731, 0.767,0.616, 0.724, (3.9012)+(−0.0636)Cit+(−0.0350)Tyr+(−0.00 70)Val; 0.667,0.704, 0.657, 0.707, 0.615, 0.733, 0.558, 0.653, (−0.4991)+(0.0281)Ser+(−0.0121)Thr+(−0.0460)Tyr; 0.667, 0.702, 0.6 15,0.661, 0.594, 0.703, 0.475, 0.608, (0.2513)+(0.0257)Ser+(−0.0025)Gln+(−0.0533)Tyr; 0.667, 0.698, 0.788, 0.826, 0.767, 0.800, 0. 722,0.779, (5.1565)+(−0.0882)Asn+(−0.0076)Arg+(−0.0116)Val; 0. 667, 0.699,0.787, 0.823, 0.761, 0.795, 0.738, 0.779, (4.9413)+(−0.0995)Asn+(−0.0124)Val+(0.0011)Lys; 0.667, 0.703, 0.622, 0.613, 0. 623,0.728, 0.566, 0.633, (−2.0771)+(0.0314)Ser+(−0.0282)Lys+(0. 0370)Phe;0.667, 0.699, 0.728, 0.742, 0.651, 0.797, 0.803, 0.748, (0.0729)+(−0.0134)Ala+(0.0085)Pro+(0.0255)Phe; 0.666, 0.700, 0.76 0, 0.784,0.675, 0.847, 0.811, 0.779, (2.2684)+(−0.0078)Ala+(−0.0291)Val+(0.0409)Leu; 0.666, 0.698, 0.742, 0.743, 0.750, 0.764, 0.7 06,0.741, (3.3712)+(−0.0951)Asn+(0.0256)Orn+(−0.0128)Lys; 0.6 65, 0.700,0.593, 0.649, 0.554, 0.672, 0.468, 0.586, (−0.6777)+(0.0217)Ser+(0.0049)Pro+(−0.0642)Tyr; 0.665, 0.699, 0.717, 0.770, 0. 653,0.759, 0.677, 0.715, (2.6975)+(−0.0414)Tyr+(−0.0275)Val+(0. 0346)Leu;0.665, 0.696, 0.692, 0.677, 0.694, 0.733, 0.700, 0.701, (1.6389)+(−0.0168)Arg+(−0.0217)Lys+(0.0367)Ile; 0.664, 0.690, 0.6 62,0.697, 0.631, 0.683, 0.618, 0.657, (1.8322)+(−0.0214)Arg+(−0.0607)Tyr+(0.0365)Ile; 0.664, 0.696, 0.728, 0.777, 0.664, 0.800, 0. 680,0.730, (2.0851)+(−0.0076)Ala+(−0.0411)Tyr+(0.0233)Orn; 0. 664, 0.701,0.739, 0.772, 0.745, 0.771, 0.617, 0.726, (4.1175)+(−0.0671)Cit+(−0.0342)Tyr+(−0.0086)Lys; 0.664, 0.694, 0.690, 0.682, 0.739,0.762, 0.556, 0.685, (1.3113)+(−0.1091)Cit+(0.0421)Orn+(−0.0173)Leu;0.664, 0.699, 0.724, 0.765, 0.728, 0.741, 0.596, 0.70 7,(3.5317)+(−0.0650)Cit+(−0.0065)Arg+(−0.0423)Tyr; 0.664, 0.6 97, 0.648,0.648, 0.689, 0.738, 0.497, 0.643, (−0.5081)+(0.0262)Ser+(−0.0723)Cit+(−0.0209)Arg; 0.663, 0.699, 0.745, 0.747, 0.731, 0. 729,0.783, 0.748, (0.9948)+(−0.1452)Asn+(0.0042)Gln+(0.0190)I le; 0.663,0.692, 0.750, 0.785, 0.677, 0.827, 0.752, 0.760, (2.3233)+(−0.0100)Ala+(0.0120)Pro+(−0.0114)Val; 0.663, 0.701, 0.611, 0. 669,0.573, 0.694, 0.474, 0.603,(−0.6651)+(0.0203)Ser+(−0.0614)Tyr+(0.0110)Orn; 0.663, 0.702, 0.684,0.713, 0.665, 0.810, 0.552, 0. 685,(0.3394)+(0.0258)Ser+(−0.0086)Val+(−0.0166)Lys; 0.662, 0. 698, 0.756,0.792, 0.694, 0.843, 0.726, 0.764, (1.8353)+(−0.0076)Ala+(−0.0121)Val+(0.0269)Orn; 0.662, 0.700, 0.755, 0.772, 0.741, 0. 710,0.772, 0.749, (0.7250)+(−0.1522)Asn+(0.0045)Gln+(0.0268)P he; 0.661,0.694, 0.791, 0.827, 0.768, 0.781, 0.750, 0.782, (2.3138)+(−0.1314)Asn+(0.0051)Gln+(−0.0117)Leu; 0.661, 0.693, 0.722, 0. 735,0.723, 0.695, 0.705, 0.714, (1.6206)+(−0.1332)Asn+(0.0025)Gly+(0.0324)Phe; 0.661, 0.696, 0.774, 0.835, 0.711, 0.842, 0.699, 0. 771,(3.1741)+(−0.0054)Ala+(−0.0274)Tyr+(−0.0067)Val; 0.661, 0. 697, 0.685,0.751, 0.654, 0.661, 0.595, 0.665, (1.1401)+(−0.0212)Arg+(−0.0698)Tyr+(0.0586)Phe; 0.661, 0.697, 0.723, 0.714, 0.723, 0. 699,0.767, 0.726, (1.7288)+(−0.1267)Asn+(0.0164)Ile+(0.0178)P he; 0.661,0.697, 0.726, 0.727, 0.731, 0.700, 0.733, 0.723, (1.8171)+(−0.1311)Asn+(0.0129)Orn+(0.0242)Phe; 0.661, 0.696, 0.784, 0.8 10,0.763, 0.780, 0.760, 0.778, (2.2172)+(−0.1171)Asn+(0.0053)Gln+(−0.0105)Lys; 0.661, 0.700, 0.695, 0.718, 0.616, 0.836, 0.700, 0. 718,(−1.0863)+(0.0206)Ser+(−0.0105)Ala+(0.0099)Orn; 0.660, 0. 696, 0.733,0.733, 0.731, 0.727, 0.741, 0.733, (2.5602)+(−0.1007)Asn+(−0.0152)Arg+(0.0236)Ile; 0.660, 0.694, 0.717, 0.709, 0.714, 0. 713,0.746, 0.721, (2.0377)+(−0.1242)Asn+(0.0102)Orn+(0.0175)I le; 0.660,0.687, 0.617, 0.665, 0.558, 0.611, 0.616, 0.612, (−0.1331)+(−0.0822)Tyr+(0.0257)Ile+(0.0356)Phe; 0.660, 0.699, 0.774, 0. 827,0.726, 0.826, 0.698, 0.769,(3.3584)+(−0.0060)Ala+(−0.0144)Arg+(−0.0289)Tyr; 0.660, 0.685, 0.647,0.685, 0.587, 0.648, 0.670, 0.648,(1.2520)+(−0.0023)Gly+(−0.0705)Tyr+(0.0331)Ile; 0.659, 0.687, 0.626,0.666, 0.569, 0.643, 0.624, 0.625,(0.7200)+(0.0002)Pro+(−0.0704)Tyr+(0.0334)Ile; 0.659, 0.699, 0.638,0.705, 0.599, 0.720, 0.480, 0.626,(−0.1000)+(0.0213)Ser+(−0.0523)Tyr+(−0.00 56)Leu; 0.659, 0.695, 0.722,0.735, 0.648, 0.812, 0.778, 0.743, (0.7227)+(−0.0128)Ala+(0.0088)Pro+(0.0109)Orn; 0.659, 0.688, 0.690, 0.667,0.675, 0.745, 0.742, 0.707, (1.2211)+(−0.0044)Pro+(−0.0262)Lys+(0.0427)Ile; 0.658, 0.692, 0.704, 0.703, 0.698, 0.707, 0.717,0.707, (1.8408)+(−0.1259)Asn+(0.0025)Gly+(0.0229)Ile; 0.658, 0. 693,0.691, 0.731, 0.678, 0.741, 0.579, 0.682, (2.6442)+(−0.0469)Tyr+(0.0291)Orn+(−0.0161)Lys; 0.658, 0.690, 0.696, 0.764, 0.645, 0. 722,0.603, 0.683, (2.7831)+(0.0084)Pro+(−0.0475)Tyr+(−0.0126) Val; 0.658,0.698, 0.741, 0.756, 0.672, 0.809, 0.797, 0.759, (−0.1640)+(−0.0116)Ala+(0.0115)Orn+(0.0280)Phe; 0.658, 0.686, 0.625, 0. 664,0.570, 0.643, 0.626, 0.626,(0.8474)+(−0.0003)Gln+(−0.0698)Tyr+(0.0339)Ile; 0.658, 0.689, 0.678,0.647, 0.669, 0.733, 0.739, 0. 697,(1.0995)+(−0.0002)Gly+(−0.0265)Lys+(0.0363)Ile; 0.658, 0. 692, 0.680,0.653, 0.668, 0.731, 0.741, 0.698, (0.7503)+(0.0008)Gln+(−0.0273)Lys+(0.0361)Ile; 0.657, 0.689, 0.743, 0.759, 0.669, 0. 816,0.801, 0.761, (1.3334)+(−0.0013)Gly+(−0.0124)Ala+(0.0097)Pro; 0.657,0.696, 0.710, 0.742, 0.627, 0.856, 0.694, 0.730, (−0.6636)+(0.0216)Ser+(−0.0094)Ala+(−0.0029)Leu; 0.657, 0.692, 0.754, 0.769,0.746, 0.742, 0.743, 0.750, (1.4785)+(−0.1437)Asn+(0.0041)Gln+(0.0121)Orn; 0.657, 0.689, 0.686, 0.657, 0.674, 0.735, 0.751,0.704, (1.1759)+(−0.0033)Thr+(−0.0252)Lys+(0.0370)Ile; 0.657, 0.685,0.618, 0.657, 0.564, 0.645, 0.606, 0.618, (0.5682)+(−0.0718)Tyr+(0.0074)Orn+(0.0311)Ile; 0.657, 0.689, 0.746, 0.764, 0.672, 0.815,0.802, 0.763, (1.5255)+(−0.0063)Thr+(−0.0119)Ala+(0.010 4)Pro; 0.657,0.693, 0.600, 0.562, 0.659, 0.712, 0.494, 0.607, (−1.8027)+(0.0200)Ser+(−0.1129)Cit+(0.0254)Orn; 0.657, 0.690, 0.736, 0.754,0.660, 0.815, 0.788, 0.754, (1.1851)+(−0.0002)Gln+(−0.0124)Ala+(0.0097)Pro; 0.657, 0.694, 0.674, 0.650, 0.743, 0.737, 0.552,0.670, (0.8893)+(−0.0969)Cit+(−0.0171)Arg+(0.0349)Orn; 0.656, 0.694,0.774, 0.824, 0.719, 0.840, 0.710, 0.773, (3.3375)+(−0.0059)Ala+(−0.0269)Tyr+(−0.0077)Lys; 0.656, 0.684, 0.637, 0.675, 0.5 81,0.649, 0.645, 0.637, (0.8708)+(−0.0031)Thr+(−0.0675)Tyr+(0. 0342)Ile;0.656, 0.686, 0.720, 0.732, 0.721, 0.725, 0.682, 0.715, (2.4533)+(−0.1245)Asn+(0.0014)Gly+(0.0166)Orn; 0.656, 0.685, 0.68 1, 0.735,0.672, 0.721, 0.528, 0.664, (2.3664)+(−0.0236)Arg+(−0.0538)Tyr+(0.0257)Orn; 0.656, 0.695, 0.681, 0.723, 0.693, 0.786, 0.4 69,0.668, (−0.3477)+(0.0254)Ser+(−0.0309)Arg+(−0.0124)Leu; 0. 656, 0.694,0.746, 0.760, 0.753, 0.709, 0.722, 0.736, (2.3290)+(−0.1089)Asn+(−0.0146)Arg+(0.0332)Phe; 0.655, 0.700, 0.628, 0.626, 0. 638,0.754, 0.521, 0.635, (−0.8227)+(0.0273)Ser+(0.0163)Orn+(−0. 0256)Lys;0.655, 0.691, 0.665, 0.630, 0.664, 0.726, 0.712, 0.683, (0.8771)+(0.0133)Orn+(−0.0283)Lys+(0.0330)Ile; 0.655, 0.690, 0.67 5, 0.644,0.666, 0.729, 0.736, 0.694, (0.8061)+(−0.0273)Lys+(0.0344)Ile+(0.0090)Phe; 0.655, 0.689, 0.716, 0.709, 0.711, 0.703, 0.75 1,0.719, (2.1464)+(−0.1254)Asn+(0.0029)Thr+(0.0204)Ile; 0.654, 0.688,0.764, 0.798, 0.695, 0.807, 0.785, 0.771, (0.2354)+(−0.0099)Ala+(−0.0119)Leu+(0.0455)Phe; 0.654, 0.688, 0.744, 0.771, 0.67 3,0.820, 0.766, 0.758, (1.5477)+(−0.0115)Ala+(0.0106)Pro+(−0.0 079)Leu;0.654, 0.694, 0.739, 0.750, 0.755, 0.744, 0.675, 0.731, (3.0146)+(−0.1030)Asn+(−0.0164)Arg+(0.0212)Orn; 0.654, 0.690, 0.7 92,0.833, 0.741, 0.838, 0.756, 0.792, (1.5232)+(0.0025)Gln+(−0.0085)Ala+(−0.0213)Arg; 0.654, 0.689, 0.759, 0.778, 0.687, 0.815, 0. 816,0.774, (0.2429)+(−0.0009)Gly+(−0.0111)Ala+(0.0322)Phe; 0. 653, 0.688,0.726, 0.763, 0.722, 0.800, 0.584, 0.717, (2.3817)+(−0.0266)Arg+(−0.0168)Val+(0.0320)Orn; 0.653, 0.684, 0.629, 0.697, 0. 581,0.609, 0.561, 0.612, (−0.0701)+(−0.0807)Tyr+(0.0119)Orn+(0. 0481)Phe;0.653, 0.685, 0.628, 0.697, 0.574, 0.602, 0.578, 0.613, (0.1053)+(0.0032)Pro+(−0.0814)Tyr+(0.0497)Phe; 0.653, 0.690, 0.75 4, 0.774,0.682, 0.814, 0.807, 0.769, (0.1270)+(−0.0002)Gln+(−0.0112)Ala+(0.0330)Phe; 0.653, 0.689, 0.761, 0.783, 0.689, 0.811, 0.8 19,0.776, (0.3087)+(−0.0049)Thr+(−0.0107)Ala+(0.0348)Phe; 0.6 53, 0.697,0.659, 0.681, 0.656, 0.759, 0.536, 0.658, (−1.3617)+(0.0325)Ser+(−0.0144)Thr+(−0.0254)Arg; 0.653, 0.682, 0.667, 0.682, 0. 676,0.756, 0.541, 0.664, (0.4470)+(0.0218)Ser+(−0.0760)Cit+(−0. 0106)Val;0.652, 0.686, 0.727, 0.733, 0.727, 0.722, 0.712, 0.723, (2.5793)+(−0.1218)Asn+(0.0004)Pro+(0.0166)Orn; 0.652, 0.690, 0.58 8, 0.573,0.609, 0.703, 0.498, 0.596, (−2.7706)+(0.0280)Ser+(−0.0386)Arg+(0.0237)Ile; 0.652, 0.687, 0.760, 0.824, 0.679, 0.823, 0.7 13,0.760, (1.9241)+(0.0017)Gln+(−0.0071)Ala+(−0.0363)Tyr; 0.6 52, 0.687,0.777, 0.812, 0.764, 0.760, 0.726, 0.766, (1.8410)+(−0.1232)Asn+(0.0058)Gln+(−0.0181)Arg; 0.652, 0.688, 0.723, 0.718, 0. 713,0.714, 0.765, 0.728, (2.1977)+(−0.1179)Asn+(−0.0018)Pro+(0. 0237)Ile;0.652, 0.685, 0.764, 0.791, 0.746, 0.741, 0.745, 0.756, (1.5790)+(−0.1410)Asn+(0.0007)Gly+(0.0046)Gln; 0.651, 0.693, 0.68 4, 0.653,0.732, 0.739, 0.624, 0.687, (0.8315)+(−0.0118)Thr+(−0.1077)Cit+(0.0391)Orn; 0.651, 0.693, 0.629, 0.630, 0.631, 0.752, 0.5 30,0.636, (−0.7616)+(0.0289)Ser+(0.0024)Pro+(−0.0238)Lys; 0.6 51, 0.679,0.633, 0.610, 0.661, 0.696, 0.591, 0.639, (−1.1438)+(0.0291)Ser+(−0.0052)Gly+(−0.0870)Cit; 0.651, 0.690, 0.793, 0.828, 0. 752,0.851, 0.744, 0.794, (3.1003)+(−0.0070)Ala+(−0.0125)Arg+(−0.0076)Lys;0.650, 0.681, 0.695, 0.710, 0.650, 0.759, 0.702, 0.705,(−0.0269)+(0.0302)Ser+(−0.0090)Gly+(−0.0151)Val; 0.650, 0.694, 0.632,0.635, 0.638, 0.757, 0.523, 0.638,(−0.1023)+(0.0307)Ser+(−0.0017)Gln+(−0.0214)Lys; 0.650, 0.686, 0.725,0.732, 0.727, 0.6 86, 0.733, 0.719,(1.9238)+(−0.1357)Asn+(0.0047)Thr+(0.0287)Ph e; 0.650, 0.686, 0.732,0.739, 0.733, 0.691, 0.744, 0.727,(1.9784)+(−0.1262)Asn+(0.0003)Pro+(0.0293)Phe; 0.649, 0.688, 0.793, 0.832, 0.730, 0.860, 0.773, 0.799, (1.9157)+(0.0022)Gln+(−0.0077)Ala+(−0.0128)Lys; 0.649, 0.684, 0.764, 0.787, 0.746, 0.736, 0.758, 0.7 57,(1.5901)+(−0.1407)Asn+(0.0047)Gln+(0.0007)Pro; 0.649, 0.69 6, 0.657,0.667, 0.643, 0.771, 0.581, 0.665, (−0.6144)+(0.0325)Ser+(−0.0110)Thr+(−0.0182)Lys; 0.649, 0.681, 0.760, 0.794, 0.749, 0. 754,0.700, 0.749, (3.6586)+(−0.1046)Asn+(0.0012)Gly+(−0.0098)Leu; 0.649,0.681, 0.643, 0.716, 0.589, 0.609, 0.588, 0.626, (0.1787)+(−0.0000)Gln+(−0.0781)Tyr+(0.0525)Phe; 0.649, 0.686, 0.725, 0.732,0.727, 0.722, 0.706, 0.722, (2.5807)+(−0.1257)Asn+(0.0023)Thr+(0.0157)Orn; 0.649, 0.677, 0.646, 0.651, 0.676, 0.730, 0.511,0.642, (−0.3162)+(0.0223)Ser+(−0.0859)Cit+(−0.0104)Leu; 0.649, 0.685,0.761, 0.783, 0.748, 0.736, 0.746, 0.754, (1.6120)+(−0.1463)Asn+(0.0045)Gln+(0.0033)Thr; 0.649, 0.684, 0.789, 0.823, 0.744, 0.841,0.757, 0.791, (2.5406)+(−0.0004)Gly+(−0.0080)Ala+(−0.01 73)Arg; 0.649,0.684, 0.750, 0.762, 0.745, 0.751, 0.728, 0.747, (3.6181)+(−0.0921)Asn+(0.0030)Pro+(−0.0094)Lys; 0.649, 0.682, 0.76 8, 0.822,0.701, 0.812, 0.733, 0.767, (3.0178)+(−0.0019)Gly+(−0.0066)Ala+(−0.0346)Tyr; 0.649, 0.681, 0.666, 0.733, 0.611, 0.612, 0. 641,0.649, (0.7056)+(−0.0025)Gly+(−0.0786)Tyr+(0.0525)Phe; 0. 648, 0.688,0.786, 0.814, 0.734, 0.854, 0.772, 0.794, (2.6655)+(−0.0077)Ala+(−0.0118)Lys+(0.0030)Leu; 0.648, 0.685, 0.755, 0.785, 0. 751,0.751, 0.690, 0.744, (3.7436)+(−0.1170)Asn+(0.0075)Thr+(−0. 0113)Leu;0.648, 0.686, 0.780, 0.818, 0.737, 0.842, 0.728, 0.781, (2.3527)+(0.0036)Thr+(−0.0084)Ala+(−0.0196)Arg; 0.648, 0.684, 0.7 98,0.848, 0.751, 0.857, 0.717, 0.793, (3.3069)+(−0.0059)Ala+(−0.0157)Arg+(−0.0081)Val; 0.648, 0.680, 0.750, 0.778, 0.739, 0.738, 0. 706,0.740, (3.7264)+(−0.1055)Asn+(0.0044)Pro+(−0.0131)Leu; 0. 647, 0.691,0.641, 0.649, 0.638, 0.763, 0.535, 0.646, (−0.5867)+(0.0285)Ser+(−0.0225)Lys+(−0.0003)Leu; 0.647, 0.681, 0.571, 0.527, 0.613,0.675, 0.525, 0.585, (−2.4726)+(0.0230)Ser+(−0.1000)Cit+(0.0226)Ile;0.647, 0.686, 0.731, 0.746, 0.687, 0.798, 0.734, 0.741,(2.6236)+(−0.0298)Val+(−0.0142)Lys+(0.0398)Leu; 0.647, 0.686, 0.748,0.809, 0.677, 0.817, 0.685, 0.747,(2.5029)+(0.0031)Thr+(−0.0070)Ala+(−0.0362)Tyr; 0.647, 0.689, 0.613,0.624, 0.638, 0.711, 0.464, 0.609,(−2.4918)+(0.0275)Ser+(−0.0369)Arg+(0.0181)Phe; 0.647, 0.681, 0.647,0.719, 0.592, 0.610, 0.596, 0.629,(0.2123)+(−0.0010)Thr+(−0.0772)Tyr+(0.0525)Phe; 0.647, 0.683, 0.676,0.745, 0.644, 0.719, 0.530, 0.660,(1.7456)+(−0.0545)Tyr+(0.0227)Orn+(−0.0110)Leu; 0.647, 0.684, 0.731,0.806, 0.680, 0.761, 0.614, 0.71 5,(2.2816)+(0.0013)Gln+(−0.0412)Tyr+(−0.0103)Val; 0.646, 0.68 2, 0.681,0.742, 0.659, 0.697, 0.556, 0.663, (2.6606)+(−0.0199)Arg+(0.0059)Pro+(−0.0535)Tyr; 0.646, 0.685, 0.793, 0.822, 0.740, 0.8 53,0.780, 0.799, (2.8889)+(−0.0009)Gly+(−0.0074)Ala+(−0.0107)Lys; 0.646,0.683, 0.750, 0.817, 0.700, 0.758, 0.670, 0.736, (3.4045)+(−0.0027)Gly+(−0.0396)Tyr+(−0.0099)Val; 0.646, 0.685, 0.764, 0.785,0.761, 0.765, 0.713, 0.756, (3.9062)+(−0.0829)Asn+(−0.0087)Arg+(−0.0068)Lys; 0.645, 0.684, 0.792, 0.831, 0.747, 0.848, 0.73 9,0.791, (2.6329)+(−0.0076)Ala+(−0.0173)Arg+(−0.0027)Leu; 0.6 45, 0.685,0.750, 0.817, 0.722, 0.793, 0.598, 0.732, (3.6600)+(−0.0161)Arg+(−0.0321)Tyr+(−0.0092)Val; 0.645, 0.687, 0.795, 0.839, 0. 739,0.871, 0.740, 0.797, (3.0632)+(−0.0062)Ala+(−0.0066)Val+(−0.0074)Lys;0.645, 0.685, 0.758, 0.816, 0.686, 0.821, 0.708, 0.758,(2.6269)+(−0.0068)Ala+(−0.0338)Tyr+(0.0001)Leu; 0.645, 0.683, 0.752,0.773, 0.746, 0.760, 0.704, 0.746,(3.5770)+(−0.0931)Asn+(0.0013)Gly+(−0.0083)Lys; 0.645, 0.684, 0.623,0.640, 0.649, 0.73 5, 0.447, 0.618,(−1.6470)+(0.0265)Ser+(−0.0346)Arg+(0.0009)Pr o; 0.645, 0.685, 0.782,0.816, 0.728, 0.855, 0.749, 0.787,(2.6443)+(0.0036)Thr+(−0.0076)Ala+(−0.0121)Lys; 0.645, 0.682, 0.755, 0.772, 0.691, 0.827, 0.793, 0.771, (1.2016)+(−0.0075)Thr+(−0.0097)Ala+(0.0206)Orn; 0.644, 0.677, 0.753, 0.768, 0.687, 0.832, 0.793, 0. 770,(1.1321)+(−0.0018)Gly+(−0.0103)Ala+(0.0166)Orn; 0.644, 0. 686, 0.618,0.628, 0.649, 0.731, 0.447, 0.614, (−0.9345)+(0.0290)Ser+(−0.0020)Gln+(−0.0315)Arg; 0.644, 0.677, 0.724, 0.745, 0.717, 0.710,0.691, 0.716, (2.7479)+(−0.1177)Asn+(0.0018)Gly+(0.002 0)Pro; 0.644,0.677, 0.603, 0.583, 0.647, 0.699, 0.493, 0.605, (−0.5312)+(0.0259)Ser+(−0.0023)Gln+(−0.0876)Cit; 0.644, 0.687, 0.72 2, 0.797,0.676, 0.756, 0.596, 0.706, (2.7471)+(0.0021)Thr+(−0.0407)Tyr+(−0.0102)Val; 0.644, 0.682, 0.746, 0.775, 0.748, 0.745, 0.6 64,0.733, (3.2769)+(−0.0985)Asn+(0.0019)Gly+(−0.0127)Arg; 0.6 43, 0.687,0.719, 0.746, 0.706, 0.796, 0.620, 0.717, (2.1246)+(−0.0131)Val+(0.0301)Orn+(−0.0147)Lys; 0.643, 0.679, 0.790, 0.844, 0. 712,0.870, 0.750, 0.794, (1.9236)+(0.0011)Gln+(−0.0071)Ala+(−0. 0091)Val;0.643, 0.676, 0.633, 0.651, 0.580, 0.748, 0.610, 0.647,(−0.7525)+(0.0187)Ser+(−0.0322)Val+(0.0328)Leu; 0.643, 0.678, 0. 726,0.748, 0.722, 0.715, 0.681, 0.716, (2.8137)+(−0.1251)Asn+(0.0014)Gly+(0.0051)Thr; 0.643, 0.680, 0.693, 0.743, 0.664, 0.720, 0. 601,0.682, (2.8587)+(0.0057)Pro+(−0.0480)Tyr+(−0.0123)Lys; 0. 642, 0.679,0.766, 0.792, 0.757, 0.759, 0.719, 0.757, (4.0030)+(−0.0908)Asn+(−0.0056)Lys+(−0.0066)Leu; 0.642, 0.675, 0.795, 0.842, 0.726,0.858, 0.769, 0.799, (2.6892)+(−0.0015)Gly+(−0.0068)Ala+(−0.0089)Val;0.642, 0.681, 0.743, 0.762, 0.675, 0.834, 0.767, 0.75 9,(0.9937)+(−0.0004)Gln+(−0.0103)Ala+(0.0164)Orn; 0.642, 0.67 6, 0.677,0.701, 0.623, 0.758, 0.669, 0.688, (0.6592)+(−0.0344)Val+(0.0218)Orn+(0.0318)Leu; 0.642, 0.682, 0.727, 0.783, 0.710, 0.74 8,0.598, 0.710, (3.3389)+(−0.0133)Arg+(−0.0381)Tyr+(−0.0078)L ys; 0.641,0.686, 0.625, 0.638, 0.655, 0.741, 0.445, 0.620, (−1.7250)+(0.0257)Ser+(−0.0355)Arg+(0.0065)Orn; 0.641, 0.674, 0.617, 0. 568,0.676, 0.688, 0.572, 0.626, (−0.5498)+(−0.1116)Cit+(0.0266)Orn+(0.0142)Ile; 0.641, 0.672, 0.593, 0.573, 0.632, 0.667, 0.513, 0.596, (−2.2208)+(0.0233)Ser+(−0.0974)Cit+(0.0168)Phe; 0.641, 0. 680,0.746, 0.766, 0.748, 0.731, 0.698, 0.736, (3.3356)+(−0.0975)Asn+(−0.0131)Arg+(0.0025)Pro; 0.641, 0.673, 0.612, 0.599, 0.649, 0. 696,0.505, 0.612, (−1.2775)+(0.0227)Ser+(−0.0928)Cit+(−0.000 3)Pro; 0.641,0.676, 0.653, 0.625, 0.713, 0.719, 0.557, 0.653, (0.2902)+(−0.1121)Cit+(−0.0033)Pro+(0.0350)Orn; 0.640, 0.672, 0.701, 0.712,0.722, 0.751, 0.594, 0.695, (1.9962)+(−0.0195)Arg+(0.0255)Orn+(−0.0181)Lys; 0.640, 0.667, 0.704, 0.715, 0.694, 0.754, 0.65 9,0.705, (2.4618)+(−0.0642)Cit+(−0.0261)Val+(0.0287)Leu; 0.64 0, 0.678,0.741, 0.758, 0.739, 0.753, 0.693, 0.736, (3.6877)+(−0.1041)Asn+(0.0093)Thr+(−0.0106)Lys; 0.639, 0.678, 0.770, 0.803, 0.7 68,0.761, 0.693, 0.756, (4.1198)+(−0.0885)Asn+(−0.0110)Arg+(−0. 0092)Leu;0.639, 0.679, 0.751, 0.782, 0.686, 0.836, 0.739, 0.761, (1.1714)+(−0.0094)Ala+(0.0192)Orn+(−0.0076)Leu; 0.639, 0.678, 0.7 16,0.789, 0.687, 0.736, 0.569, 0.695, (1.7627)+(0.0029)Gln+(−0.0230)Arg+(−0.0490)Tyr; 0.638, 0.675, 0.736, 0.747, 0.753, 0.790, 0. 636,0.731, (1.9404)+(0.0036)Gln+(−0.0815)Cit+(−0.0173)Lys; 0. 638, 0.678,0.725, 0.786, 0.688, 0.760, 0.616, 0.713, (2.1046)+(0.0025)Gln+(−0.0429)Tyr+(−0.0134)Lys; 0.638, 0.671, 0.654, 0.630, 0. 696,0.689, 0.606, 0.655, (0.6815)+(−0.0762)Cit+(−0.0162)Arg+(0. 0238)Ile;0.638, 0.670, 0.630, 0.598, 0.694, 0.698, 0.534, 0.631,(−0.1067)+(0.0008)Gly+(−0.1123)Cit+(0.0316)Orn; 0.638, 0.676, 0. 716,0.724, 0.746, 0.777, 0.586, 0.708, (2.9874)+(0.0017)Gly+(−0.0766)Cit+(−0.0144)Lys; 0.637, 0.676, 0.743, 0.762, 0.754, 0.790, 0. 634,0.735, (3.6206)+(−0.0661)Cit+(−0.0073)Val+(−0.0094)Lys; 0. 637, 0.670,0.664, 0.636, 0.685, 0.688, 0.676, 0.671, (0.5203)+(−0.0087)Thr+(−0.0861)Cit+(0.0243)Ile; 0.637, 0.675, 0.706, 0.698, 0. 737,0.739, 0.640, 0.704, (1.8805)+(−0.0786)Cit+(−0.0192)Lys+(0. 0413)Phe;0.637, 0.679, 0.786, 0.837, 0.714, 0.868, 0.742, 0.790, (2.3947)+(0.0002)Thr+(−0.0069)Ala+(−0.0089)Val; 0.637, 0.679, 0.7 40,0.802, 0.705, 0.785, 0.618, 0.728, (3.3349)+(−0.0334)Tyr+(−0.0079)Val+(−0.0069)Lys; 0.637, 0.674, 0.718, 0.717, 0.747, 0.765, 0. 624,0.713, (3.0730)+(−0.0746)Cit+(0.0026)Pro+(−0.0151)Lys; 0. 637, 0.675,0.729, 0.743, 0.729, 0.708, 0.711, 0.723, (2.8856)+(−0.1236)Asn+(0.0051)Thr+(0.0012)Pro; 0.637, 0.677, 0.673, 0.748, 0. 629,0.696, 0.552, 0.656, (2.1275)+(0.0066)Pro+(−0.0554)Tyr+(−0. 0106)Leu;0.636, 0.673, 0.734, 0.783, 0.714, 0.739, 0.643, 0.720, (1.2547)+(−0.0239)Arg+(−0.0179)Val+(0.0494)Phe; 0.636, 0.668, 0.7 23,0.746, 0.751, 0.755, 0.582, 0.709, (2.5804)+(−0.0664)Cit+(−0.0121)Arg+(−0.0102)Leu; 0.635, 0.679, 0.687, 0.755, 0.677, 0.720, 0. 502,0.663, (2.6760)+(0.0075)Thr+(−0.0228)Arg+(−0.0510)Tyr; 0. 635, 0.675,0.681, 0.717, 0.635, 0.785, 0.603, 0.685, (−0.4725)+(0.0269)Ser+(−0.0153)Thr+(−0.0117)Val; 0.635, 0.674, 0.638, 0.600, 0.705,0.706, 0.550, 0.640, (0.4236)+(−0.0010)Gln+(−0.1102)Cit+(0.0336)Orn;0.635, 0.671, 0.727, 0.760, 0.696, 0.748, 0.690, 0.724,(1.1048)+(−0.0147)Val+(−0.0140)Lys+(0.0489)Phe; 0.635, 0.672, 0.620,0.654, 0.581, 0.693, 0.562, 0.622,(−2.1273)+(0.0193)Ser+(−0.0196)Val+(0.0411)Phe; 0.635, 0.676, 0.565,0.522, 0.534, 0.66 6, 0.668, 0.598,(−3.9146)+(0.0361)Ser+(−0.0293)Thr+(0.0273)Il e; 0.634, 0.670, 0.623,0.691, 0.576, 0.657, 0.518, 0.610,(1.1391)+(0.0037)Pro+(−0.0659)Tyr+(0.0154)Orn; 0.634, 0.670, 0.673, 0.738, 0.617, 0.662, 0.623, 0.660, (2.1797)+(−0.0029)Gly+(0.0050)Pro+(−0.0625)Tyr; 0.634, 0.667, 0.699, 0.717, 0.702, 0.719, 0.632, 0.6 92,(1.0527)+(−0.0712)Cit+(−0.0157)Val+(0.0466)Phe; 0.634, 0.6 71, 0.730,0.736, 0.757, 0.775, 0.624, 0.723, (3.2572)+(−0.0732)Cit+(−0.0136)Lys+(−0.0014)Leu; 0.634, 0.675, 0.736, 0.761, 0.746, 0. 724,0.655, 0.721, (3.3851)+(−0.1100)Asn+(0.0094)Thr+(−0.0161)Arg; 0.634,0.669, 0.734, 0.764, 0.743, 0.770, 0.612, 0.722, (3.2372)+(−0.0576)Cit+(−0.0109)Arg+(−0.0106)Val; 0.634, 0.674, 0.699, 0.759,0.675, 0.743, 0.559, 0.684, (2.8790)+(0.0061)Thr+(−0.0442)Tyr+(−0.0133)Lys; 0.634, 0.672, 0.738, 0.769, 0.734, 0.766, 0.64 1,0.728, (1.4062)+(0.0027)Gln+(−0.0196)Arg+(−0.0156)Lys; 0.63 4, 0.670,0.726, 0.732, 0.754, 0.771, 0.622, 0.720, (3.2458)+(−0.0720)Cit+(−0.0018)Arg+(−0.0138)Lys; 0.633, 0.669, 0.633, 0.597, 0. 696,0.696, 0.552, 0.635, (−0.1111)+(−0.1114)Cit+(0.0313)Orn+(0. 0025)Phe;0.633, 0.660, 0.609, 0.578, 0.650, 0.664, 0.567, 0.615,(−0.4475)+(0.0020)Gly+(−0.0965)Cit+(0.0224)Ile; 0.633, 0.669, 0. 674,0.730, 0.629, 0.678, 0.613, 0.663, (1.9469)+(−0.0037)Gly+(−0.0636)Tyr+(0.0205)Orn; 0.633, 0.680, 0.725, 0.793, 0.707, 0.754, 0. 561,0.704, (3.1195)+(−0.0178)Arg+(−0.0410)Tyr+(−0.0058)Leu; 0. 632, 0.671,0.729, 0.779, 0.697, 0.745, 0.649, 0.718, (3.3215)+(−0.0019)Gly+(−0.0415)Tyr+(−0.0107)Lys; 0.632, 0.671, 0.780, 0.810, 0.704,0.851, 0.808, 0.793, (1.2611)+(−0.0017)Gly+(0.0009)Gln+(−0.0096)Ala;0.632, 0.661, 0.629, 0.596, 0.666, 0.669, 0.613, 0.63 6,(0.0296)+(−0.0922)Cit+(0.0221)Ile+(−0.0031)Phe; 0.632, 0.66 6, 0.685,0.717, 0.628, 0.707, 0.703, 0.689, (0.2354)+(−0.0313)Val+(0.0254)Leu+(0.0294)Phe; 0.632, 0.666, 0.723, 0.753, 0.658, 0.75 6,0.758, 0.731, (1.7106)+(−0.0023)Gly+(−0.0315)Val+(0.0320)Le u; 0.631,0.673, 0.717, 0.721, 0.749, 0.775, 0.600, 0.711,(3.1124)+(0.0045)Thr+(−0.0761)Cit+(−0.0160)Lys; 0.631, 0.661, 0.641, 0.613, 0.672, 0.680, 0.621, 0.646, (0.1161)+(−0.0915)Cit+(−0.0047)Pro+(0.0278)Ile; 0.631, 0.673, 0.718, 0.772, 0.690, 0.751, 0.605, 0. 705,(2.9800)+(−0.0403)Tyr+(−0.0111)Lys+(−0.0005)Leu; 0.631, 0. 661, 0.718,0.744, 0.725, 0.757, 0.605, 0.708, (2.6635)+(0.0003)Gly+(−0.0689)Cit+(−0.0110)Val; 0.631, 0.668, 0.780, 0.809, 0.708, 0. 854,0.802, 0.793, (1.7446)+(−0.0010)Gly+(−0.0023)Thr+(−0.009 1)Ala; 0.631,0.660, 0.702, 0.724, 0.705, 0.747, 0.608, 0.696, (2.5068)+(−0.0687)Cit+(0.0049)Pro+(−0.0131)Val; 0.631, 0.661, 0.723, 0.748,0.728, 0.757, 0.620, 0.713, (2.7662)+(−0.0009)Thr+(−0.0679)Cit+(−0.0108)Val; 0.631, 0.674, 0.721, 0.782, 0.699, 0.722, 0.60 4,0.702, (3.0951)+(−0.0016)Gly+(−0.0175)Arg+(−0.0464)Tyr; 0.6 31, 0.666,0.660, 0.721, 0.619, 0.688, 0.566, 0.648, (1.4204)+(−0.0049)Thr+(−0.0581)Tyr+(0.0204)Orn; 0.631, 0.671, 0.780, 0.815, 0. 700,0.852, 0.803, 0.793, (1.1791)+(0.0011)Gln+(−0.0042)Thr+(−0. 0092)Ala;0.630, 0.662, 0.717, 0.735, 0.737, 0.743, 0.611, 0.707, (2.2249)+(−0.0035)Thr+(−0.0761)Cit+(−0.0102)Leu; 0.630, 0.660, 0. 696,0.713, 0.719, 0.730, 0.580, 0.685, (1.8697)+(−0.0791)Cit+(0.0027)Pro+(−0.0130)Leu; 0.630, 0.672, 0.645, 0.629, 0.608, 0.695, 0. 727,0.665, (−2.1524)+(0.0417)Ser+(−0.0072)Gly+(−0.0229)Thr; 0. 630, 0.672,0.738, 0.774, 0.703, 0.787, 0.679, 0.736, (2.5885)+(−0.0203)Arg+(−0.0301)Val+(0.0333)Leu; 0.630, 0.661, 0.711, 0.725, 0. 719,0.728, 0.646, 0.704, (1.3493)+(−0.0174)Arg+(−0.0174)Lys+(0. 0299)Phe;0.630, 0.661, 0.627, 0.594, 0.664, 0.664, 0.611, 0.633,(−0.0980)+(0.0000)Gln+(−0.0927)Cit+(0.0212)Ile; 0.630, 0.662, 0. 723,0.752, 0.720, 0.766, 0.621, 0.715, (1.9553)+(0.0017)Gln+(−0.0725)Cit+(−0.0114)Val; 0.630, 0.664, 0.699, 0.729, 0.643, 0.752, 0. 701,0.706, (1.7076)+(−0.0009)Gln+(−0.0318)Val+(0.0332)Leu; 0. 630, 0.671,0.777, 0.820, 0.699, 0.856, 0.767, 0.786, (1.2964)+(0.0007)Gln+(−0.0089)Ala+(−0.0043)Leu; 0.629, 0.664, 0.640, 0.706, 0. 603,0.667, 0.522, 0.625, (1.3865)+(−0.0004)Gln+(−0.0611)Tyr+(0. 0182)Orn;0.629, 0.658, 0.683, 0.714, 0.622, 0.735, 0.688, 0.690, (1.1178)+(0.0035)Pro+(−0.0321)Val+(0.0301)Leu; 0.629, 0.662, 0.68 8, 0.703,0.711, 0.695, 0.592, 0.675, (0.6462)+(−0.0820)Cit+(−0.0192)Leu+(0.0407)Phe; 0.629, 0.659, 0.699, 0.718, 0.726, 0.740, 0.5 65,0.687, (1.8733)+(0.0007)Gly+(−0.0796)Cit+(−0.0109)Leu; 0.6 28, 0.667,0.783, 0.817, 0.714, 0.854, 0.785, 0.793, (1.8980)+(−0.0014)Gly+(−0.0087)Ala+(−0.0041)Leu; 0.628, 0.661, 0.680, 0.685, 0. 708,0.711, 0.587, 0.673, (1.2728)+(0.0019)Gly+(−0.0067)Thr+(−0. 0836)Cit;0.627, 0.665, 0.643, 0.717, 0.590, 0.657, 0.547, 0.628, (1.4184)+(0.0003)Gln+(0.0047)Pro+(−0.0621)Tyr; 0.627, 0.662, 0.70 3, 0.707,0.720, 0.714, 0.651, 0.698, (0.7401)+(0.0020)Gln+(−0.0081)Thr+(−0.0848)Cit; 0.627, 0.664, 0.678, 0.687, 0.720, 0.717, 0.5 38,0.665, (1.5037)+(0.0015)Gly+(−0.0736)Cit+(−0.0139)Arg; 0.6 26, 0.671,0.780, 0.819, 0.706, 0.856, 0.777, 0.790, (1.7696)+(−0.0024)Thr+(−0.0085)Ala+(−0.0034)Leu; 0.625, 0.660, 0.708, 0.731, 0. 724,0.742, 0.588, 0.696, (1.3034)+(0.0016)Gln+(−0.0822)Cit+(−0. 0120)Leu;0.625, 0.669, 0.698, 0.782, 0.649, 0.715, 0.566, 0.678, (1.7190)+(0.0011)Gln+(−0.0502)Tyr+(−0.0077)Leu; 0.625, 0.659, 0.6 86,0.690, 0.726, 0.712, 0.573, 0.675, (1.6569)+(−0.0715)Cit+(−0.0139)Arg+(0.0007)Pro; 0.624, 0.664, 0.715, 0.748, 0.651, 0.757, 0. 727,0.721, (1.5590)+(−0.0043)Thr+(−0.0307)Val+(0.0320)Leu; 0. 624, 0.668,0.675, 0.715, 0.637, 0.701, 0.629, 0.671, (−0.3879)+(−0.0213)Val+(0.0192)Orn+(0.0358)Phe; 0.623, 0.658, 0.717, 0.741, 0. 724,0.742, 0.622, 0.708, (2.2409)+(−0.0168)Arg+(0.0021)Pro+(−0. 0146)Lys;0.623, 0.663, 0.705, 0.779, 0.644, 0.684, 0.651, 0.690, (1.7768)+(−0.0035)Gly+(0.0016)Gln+(−0.0585)Tyr; 0.623, 0.659, 0.6 88,0.686, 0.713, 0.705, 0.629, 0.683, (1.4265)+(−0.0061)Thr+(−0.0812)Cit+(0.0008)Pro; 0.622, 0.654, 0.728, 0.754, 0.733, 0.749, 0. 633,0.718, (2.4127)+(−0.0004)Gly+(−0.0160)Arg+(−0.0139)Lys; 0. 622, 0.666,0.723, 0.795, 0.680, 0.712, 0.631, 0.705, (2.7777)+(−0.0027)Gly+(−0.0491)Tyr+(−0.0071)Leu; 0.621, 0.664, 0.652, 0.722, 0.601,0.661, 0.569, 0.638, (1.6786)+(−0.0022)Thr+(0.0050)Pro+(−0.0598)Tyr;0.621, 0.657, 0.716, 0.743, 0.727, 0.748, 0.602, 0.70 5,(2.2883)+(0.0033)Thr+(−0.0178)Arg+(−0.0149)Lys; 0.621, 0.66 0, 0.624,0.651, 0.606, 0.748, 0.504, 0.627,(0.3633)+(0.0233)Ser+(−0.0030)Gln+(−0.0139)Val; 0.620, 0.664, 0.760,0.822, 0.733, 0.8 02, 0.620, 0.744,(1.9317)+(0.0023)Gln+(−0.0241)Arg+(−0.0135)V al; 0.620, 0.661, 0.678,0.671, 0.688, 0.712, 0.649, 0.680, (0.6381)+(0.0193)Orn+(−0.0251)Lys+(0.0224)Phe; 0.620, 0.662, 0.720, 0.7 56,0.680, 0.761, 0.678, 0.719, (1.4259)+(−0.0034)Gly+(−0.0180)Val(0.0244)Orn; 0.619, 0.658, 0.693, 0.706, 0.724, 0.715, 0.580, 0. 681,(0.8227)+(0.0022)Gln+(−0.0743)Cit+(−0.0169)Arg; 0.618, 0. 648, 0.653,0.653, 0.690, 0.691, 0.552, 0.646, (0.8148)+(0.0012)Gly+(−0.0876)Cit+(−0.0002)Pro; 0.618, 0.663, 0.702, 0.705, 0.707, 0. 747,0.647, 0.702, (1.4906)+(−0.0051)Thr+(0.0241)Orn+(−0.0210)Lys; 0.618,0.662, 0.697, 0.704, 0.731, 0.719, 0.590, 0.686, (1.8192)+(−0.0020)Thr+(−0.0710)Cit+(−0.0123)Arg; 0.618, 0.656, 0.724, 0.775,0.703, 0.767, 0.600, 0.711, (2.6680)+(−0.0222)Arg+(0.0061)Pro+(−0.0155)Val; 0.617, 0.666, 0.720, 0.757, 0.683, 0.776, 0.66 1,0.719, (1.3333)+(−0.0095)Thr+(−0.0166)Val+(0.0278)Orn; 0.61 7, 0.668,0.696, 0.774, 0.656, 0.712, 0.561, 0.676, (2.1779)+(0.0000)Thr+(−0.0487)Tyr+(−0.0070)Leu; 0.617, 0.663, 0.634, 0.675, 0.5 98,0.752, 0.512, 0.634, (−0.7619)+(0.0162)Ser+(−0.0169)Val+(0. 0149)Orn;0.615, 0.656, 0.752, 0.803, 0.736, 0.797, 0.620, 0.739, (3.1437)+(−0.0166)Arg+(−0.0109)Val+(−0.0059)Lys; 0.615, 0.648, 0. 655,0.655, 0.688, 0.691, 0.558, 0.648, (0.5282)+(0.0010)Gly+(0.0006)Gln+(−0.0891)Cit; 0.615, 0.648, 0.733, 0.771, 0.735, 0.760, 0. 609,0.719, (2.5834)+(−0.0169)Arg+(−0.0110)Lys+(−0.0064)Leu; 0. 615, 0.648,0.666, 0.666, 0.696, 0.692, 0.583, 0.659, (0.6154)+(0.0009)Gln+(−0.0878)Cit+(−0.0006)Pro; 0.614, 0.659, 0.685, 0.724, 0. 660,0.760, 0.580, 0.681, (1.5065)+(−0.0016)Gln+(−0.0176)Val+(0. 0249)Orn;0.614, 0.658, 0.690, 0.761, 0.640, 0.678, 0.618, 0.674, (2.3071)+(−0.0030)Gly+(0.0019)Thr+(−0.0571)Tyr; 0.614, 0.658, 0.6 78,0.760, 0.622, 0.686, 0.574, 0.661, (1.4409)+(0.0009)Gln+(−0.0018)Thr+(−0.0547)Tyr; 0.614, 0.654, 0.709, 0.750, 0.730, 0.759, 0. 519,0.689, (1.5995)+(−0.0286)Arg+(0.0234)Orn+(−0.0180)Leu; 0. 614, 0.653,0.617, 0.659, 0.577, 0.718, 0.515, 0.617, (−0.7319)+(0.0181)Ser+(0.0042)Pro+(−0.0168)Val; 0.613, 0.659, 0.751, 0.801, 0. 714,0.810, 0.653, 0.745, (1.9753)+(0.0015)Gln+(−0.0107)Val+(−0. 0123)Lys;0.613, 0.655, 0.668, 0.668, 0.710, 0.682, 0.572, 0.658, (0.8739)+(−0.0733)Cit+(−0.0151)Arg+(0.0179)Phe; 0.613, 0.655, 0.6 74,0.668, 0.697, 0.679, 0.634, 0.670, (0.7006)+(−0.0071)Thr+(−0.0833)Cit+(0.0173)Phe; 0.612, 0.640, 0.631, 0.624, 0.671, 0.665, 0. 544,0.626, (−0.0117)+(0.0016)Gly+(−0.0915)Cit+(0.0143)Phe; 0. 612, 0.651,0.656, 0.662, 0.626, 0.717, 0.655, 0.665, (−1.2187)+(0.0302)Ser+(−0.0087)Gly+(−0.0174)Leu; 0.611, 0.653, 0.698, 0.698, 0.705,0.737, 0.660, 0.700, (1.6400)+(−0.0018)Gly+(0.0228)Orn+(−0.0225)Lys;0.611, 0.655, 0.720, 0.759, 0.691, 0.779, 0.635, 0.71 6,(2.4074)+(0.0053)Pro+(−0.0128)Val+(−0.0115)Lys; 0.611, 0.65 4, 0.685,0.689, 0.693, 0.738, 0.620, 0.685,(1.3546)+(0.0000)Pro+(0.0218)Orn+(−0.0227)Lys; 0.611, 0.650, 0.756,0.812, 0.735, 0.78 7, 0.633, 0.742,(2.9984)+(−0.0011)Gly+(−0.0199)Arg+(−0.0130)V al; 0.610, 0.653, 0.698,0.716, 0.704, 0.754, 0.597, 0.693, (1.5613)+(0.0238)Orn+(−0.0196)Lys+(−0.0078)Leu; 0.609, 0.655, 0.672, 0. 716,0.632, 0.742, 0.590, 0.670, (0.7196)+(0.0034)Pro+(−0.0189)Val(0.0201)Orn; 0.609, 0.655, 0.742, 0.800, 0.727, 0.793, 0.579, 0. 725,(2.7162)+(0.0035)Thr+(−0.0226)Arg+(−0.0135)Val; 0.608, 0. 650, 0.710,0.754, 0.663, 0.692, 0.705, 0.704, (0.4073)+(−0.0019)Gly+(−0.0190)Val+(0.0387)Phe; 0.608, 0.648, 0.669, 0.670, 0.675, 0. 678,0.648, 0.668, (0.1708)+(−0.0062)Thr+(−0.0268)Arg+(0.0210)Ile; 0.608,0.650, 0.758, 0.799, 0.727, 0.797, 0.683, 0.752, (2.8271)+(−0.0016)Gly+(−0.0108)Val+(−0.0104)Lys; 0.608, 0.653, 0.688, 0.694,0.692, 0.740, 0.625, 0.688,(1.1885)+(0.0005)Gln+(0.0212)Orn+(−0.0230)Lys; 0.607, 0.652, 0.742,0.788, 0.714, 0.803, 0.634, 0.735,(2.5172)+(0.0013)Thr+(−0.0107)Val+(−0.0114)Lys; 0.607, 0.645, 0.701,0.704, 0.701, 0.704, 0.692, 0.700, (0.9834)+(−0.0007)Gly+(−0.0219)Lys+(0.0268)Phe; 0.606, 0.654, 0.716, 0.764, 0.66 3,0.706, 0.708, 0.710, (0.3654)+(−0.0061)Thr+(−0.0181)Val+(0.0 415)Phe;0.606, 0.644, 0.660, 0.661, 0.675, 0.680, 0.609, 0.656, (0.0297)+(−0.0300)Arg+(−0.0036)Pro+(0.0240)Ile; 0.606, 0.639, 0.6 45,0.638, 0.680, 0.661, 0.578, 0.639, (0.1051)+(0.0005)Gln+(−0.0896)Cit+(0.0121)Phe; 0.605, 0.647, 0.710, 0.735, 0.702, 0.716, 0.6 53,0.701, (0.8139)+(−0.0182)Lys+(−0.0124)Leu+(0.0393)Phe; 0.6 05, 0.648,0.673, 0.723, 0.622, 0.682, 0.643, 0.667, (−0.0138)+(0.0031)Pro+(−0.0201)Val+(0.0363)Phe; 0.605, 0.649, 0.696, 0.700, 0. 695,0.706, 0.676, 0.694, (0.8463)+(0.0001)Pro+(−0.0221)Lys+(0. 0270)Phe;0.605, 0.649, 0.702, 0.708, 0.699, 0.710, 0.687, 0.701, (0.9024)+(−0.0020)Thr+(−0.0212)Lys+(0.0275)Phe; 0.604, 0.654, 0.5 85,0.575, 0.573, 0.687, 0.561, 0.599, (−1.6078)+(0.0349)Ser+(−0.0026)Gln+(−0.0209)Thr; 0.604, 0.646, 0.719, 0.771, 0.728, 0.704, 0. 572,0.694, (0.7574)+(−0.0269)Arg+(−0.0217)Leu+(0.0410)Phe; 0. 604, 0.649,0.701, 0.708, 0.695, 0.714, 0.685, 0.700, (0.5105)+(0.0010)Gln+(−0.0228)Lys+(0.0260)Phe; 0.604, 0.649, 0.688, 0.734, 0. 648,0.690, 0.650, 0.680, (0.4529)+(−0.0011)Gln+(−0.0190)Val+(0. 0416)Phe;0.603, 0.637, 0.647, 0.641, 0.683, 0.661, 0.576, 0.640, (0.3469)+(−0.0879)Cit+(−0.0013)Pro+(0.0149)Phe; 0.602, 0.646, 0.7 36,0.756, 0.722, 0.755, 0.697, 0.732, (1.3798)+(−0.0018)Gly+(0.0018)Gln+(−0.0199)Lys; 0.601, 0.640, 0.717, 0.732, 0.710, 0.742, 0. 672,0.714, (1.8809)+(−0.0011)Gly+(0.0014)Pro+(−0.0189)Lys; 0. 601, 0.655,0.647, 0.676, 0.611, 0.749, 0.575, 0.653, (−1.4968)+(0.0299)Ser+(−0.0198)Thr+(−0.0105)Leu; 0.600, 0.648, 0.734, 0.759, 0.717,0.762, 0.681, 0.730, (1.2324)+(0.0016)Gln+(−0.0028)Thr+(−0.0189)Lys;0.600, 0.646, 0.715, 0.738, 0.703, 0.750, 0.655, 0.71 1,(1.2098)+(0.0013)Gln+(0.0011)Pro+(−0.0202)Lys; 0.600, 0.636, 0.641,0.642, 0.663, 0.665, 0.577, 0.637,(−0.1569)+(0.0004)Gly+(−0.0311)Arg+(0.0196)Ile; 0.600, 0.654, 0.586,0.580, 0.553, 0.66 7, 0.612, 0.603,(−3.3757)+(0.0338)Ser+(−0.0259)Thr+(0.0165)Ph e; 0.599, 0.638, 0.726,0.744, 0.720, 0.748, 0.678, 0.722,(1.9796)+(−0.0011)Gly+(−0.0006)Thr+(−0.0180)Lys; 0.599, 0.639, 0.641, 0.637, 0.669, 0.670, 0.571, 0.637,(−0.2096)+(−0.0320)Arg+(0.0066)Orn+(0.0171)Ile; 0.598, 0.637, 0.714,0.762, 0.660, 0.737, 0.682, 0. 710,(1.7211)+(−0.0024)Gly+(0.0048)Pro+(−0.0170)Val; 0.598, 0. 635, 0.649,0.651, 0.668, 0.670, 0.590, 0.645, (−0.3177)+(0.0006)Gln+(−0.0318)Arg+(0.0189)Ile; 0.597, 0.643, 0.713, 0.731, 0.704, 0. 745,0.662, 0.711, (1.7506)+(−0.0020)Thr+(0.0017)Pro+(−0.0183)Lys; 0.597,0.645, 0.696, 0.711, 0.718, 0.724, 0.593, 0.686, (0.6085)+(−0.0073)Thr+(−0.0267)Arg+(0.0168)Orn; 0.595, 0.635, 0.734, 0.763,0.724, 0.757, 0.660, 0.726, (2.1797)+(−0.0013)Gly+(−0.0158)Lys+(−0.0056)Leu; 0.594, 0.644, 0.408, 0.325, 0.446, 0.563, 0.44 0,0.443, (−2.6256)+(0.0293)Ser+(−0.0060)Gln+(0.0198)Ile; 0.59 3, 0.641,0.527, 0.472, 0.537, 0.609, 0.593, 0.553, (−1.6391)+(0.0354)Ser+(−0.0072)Gly+(−0.0043)Gln; 0.593, 0.638, 0.711, 0.743, 0. 702,0.751, 0.620, 0.704, (1.8560)+(0.0026)Pro+(−0.0165)Lys+(−0. 0071)Leu;0.593, 0.637, 0.746, 0.800, 0.692, 0.766, 0.698, 0.739, (1.7261)+(−0.0025)Gly+(0.0004)Gln+(−0.0151)Val; 0.593, 0.635, 0.6 85,0.738, 0.641, 0.728, 0.606, 0.678, (1.5239)+(−0.0006)Gln+(0.0049)Pro+(−0.0168)Val; 0.592, 0.652, 0.592, 0.581, 0.565, 0.697, 0. 601,0.611, (−2.8016)+(0.0323)Ser+(−0.0261)Thr+(0.0104)Orn; 0. 592, 0.645,0.730, 0.769, 0.713, 0.767, 0.637, 0.721, (1.3757)+(0.0015)Gln+(−0.0175)Lys+(−0.0056)Leu; 0.591, 0.636, 0.647, 0.644, 0. 667,0.668, 0.594, 0.643, (0.0425)+(−0.0305)Arg+(0.0204)Ile+(−0. 0037)Phe;0.591, 0.635, 0.735, 0.796, 0.735, 0.761, 0.556, 0.712, (1.1864)+(0.0021)Gln+(−0.0272)Arg+(−0.0146)Leu; 0.591, 0.644, 0.5 83,0.576, 0.555, 0.675, 0.595, 0.600, (−2.7073)+(0.0330)Ser+(−0.0251)Thr+(0.0022)Pro; 0.590, 0.638, 0.726, 0.759, 0.716, 0.762, 0. 632,0.717, (1.9844)+(−0.0011)Thr+(−0.0157)Lys+(−0.0053)Leu; 0. 590, 0.631,0.673, 0.694, 0.705, 0.705, 0.529, 0.658, (0.4140)+(−0.0303)Arg+(−0.0011)Pro+(0.0137)Orn; 0.589, 0.627, 0.672, 0.688, 0. 703,0.698, 0.548, 0.659, (0.4351)+(−0.0006)Gly+(−0.0303)Arg+(0. 0130)Orn;0.588, 0.633, 0.502, 0.429, 0.492, 0.580, 0.658, 0.540,(−3.8716)+(0.0301)Ser+(−0.0081)Gly+(0.0098)Ile; 0.587, 0.635, 0. 707,0.758, 0.657, 0.736, 0.658, 0.702, (1.6617)+(−0.0065)Thr+(0.0055)Pro+(−0.0160)Val; 0.587, 0.629, 0.566, 0.530, 0.549, 0.628, 0. 652,0.590, (−2.9399)+(0.0304)Ser+(−0.0082)Gly+(−0.0026)Pro; 0. 585, 0.634,0.750, 0.802, 0.699, 0.767, 0.705, 0.743, (2.0426)+(−0.0018)Gly+(−0.0034)Thr+(−0.0142)Val; 0.585, 0.627, 0.667, 0.688, 0.697,0.695, 0.530, 0.652, (0.1680)+(0.0005)Gln+(−0.0312)Arg+(0.0121)Orn;0.585, 0.627, 0.736, 0.789, 0.740, 0.750, 0.577, 0.714,(2.1260)+(−0.0009)Gly+(−0.0234)Arg+(−0.0136)Leu; 0.584, 0.623, 0.689,0.722, 0.706, 0.694, 0.562, 0.671,(0.2990)+(0.0012)Gln+(−0.0295)Arg+(−0.0002)Pro; 0.584, 0.627, 0.712,0.748, 0.715, 0.711, 0.614, 0.697,(0.3627)+(0.0017)Gln+(−0.0053)Thr+(−0.0268)Arg; 0.583, 0.636, 0.740,0.799, 0.689, 0.773, 0.667, 0.732, (1.5339)+(0.0006)Gln+(−0.0053)Thr+(−0.0140)Val; 0.583, 0.622, 0.694, 0.726, 0.708,0.689, 0.586, 0.677, (0.3474)+(−0.0008)Gly+(0.0013)Gln+(−0.0294)Arg;0.583, 0.627, 0.709, 0.763, 0.716, 0.734, 0.535, 0.68 7,(1.8698)+(−0.0251)Arg+(0.0037)Pro+(−0.0161)Leu; 0.582, 0.62 2, 0.702,0.733, 0.713, 0.700, 0.597, 0.686, (0.9886)+(−0.0001)Gly+(−0.0037)Thr+(−0.0249)Arg; 0.582, 0.629, 0.729, 0.786, 0.735, 0. 753,0.551, 0.706, (1.9831)+(−0.0006)Thr+(−0.0235)Arg+(−0.013 3)Leu; 0.581,0.621, 0.687, 0.716, 0.708, 0.689, 0.566, 0.670, (0.8214)+(−0.0004)Gly+(−0.0274)Arg+(0.0001)Pro; 0.579, 0.622, 0.697, 0.727,0.709, 0.697, 0.593, 0.681, (0.9313)+(−0.0041)Thr+(−0.0250)Arg+(0.0007)Pro; 0.579, 0.626, 0.662, 0.680, 0.695, 0.685, 0.531,0.648, (0.0884)+(−0.0311)Arg+(0.0117)Orn+(0.0062)Phe; 0.579, 0. 635,0.565, 0.580, 0.576, 0.699, 0.404, 0.565, (−0.7368)+(0.0244)Ser+(−0.0035)Gln+(−0.0142)Leu; 0.576, 0.625, 0.562, 0.600, 0.548, 0.628,0.441, 0.554, (−2.8622)+(0.0193)Ser+(−0.0236)Leu+(0.030 1)Phe; 0.575,0.619, 0.673, 0.698, 0.695, 0.670, 0.559, 0.656, (0.2853)+(−0.0001)Gly+(−0.0288)Arg+(0.0108)Phe; 0.575, 0.624, 0.693, 0.719,0.704, 0.682, 0.606, 0.678, (0.4214)+(−0.0046)Thr+(−0.0260)Arg+(0.0128)Phe; 0.574, 0.621, 0.676, 0.704, 0.696, 0.675, 0.560,0.659, (−0.0683)+(0.0009)Gln+(−0.0304)Arg+(0.0096)Phe; 0.573, 0.623,0.544, 0.498, 0.532, 0.616, 0.641, 0.572, (−2.8896)+(0.0303)Ser+(−0.0084)Gly+(−0.0061)Phe; 0.573, 0.620, 0.675, 0.703, 0.6 97,0.673, 0.556, 0.657, (0.2802)+(−0.0287)Arg+(−0.0006)Pro+(0. 0117)Phe;0.570, 0.625, 0.713, 0.749, 0.693, 0.746, 0.637, 0.706, (0.6602)+(−0.0129)Thr+(0.0215)Orn+(−0.0178)Leu; 0.569, 0.623, 0.4 56,0.415, 0.443, 0.597, 0.489, 0.486, (−4.2643)+(0.0205)Ser+(−0.0060)Pro+(0.0197)Ile; 0.566, 0.627, 0.465, 0.428, 0.491, 0.612, 0. 399,0.483, (−1.7722)+(0.0270)Ser+(−0.0048)Gln+(−0.0008)Pro; 0. 565, 0.624,0.435, 0.388, 0.468, 0.572, 0.395, 0.456, (−2.1461)+(0.0276)Ser+(−0.0052)Gln+(0.0074)Phe; 0.561, 0.616, 0.541, 0.497, 0. 526,0.597, 0.646, 0.566, (−3.0559)+(0.0308)Ser+(−0.0082)Gly+(−0.0051)Orn;0.556, 0.618, 0.637, 0.618, 0.600, 0.638, 0.764, 0.655,(−0.9160)+(0.0001)Gly+(−0.0160)Thr+(0.0181)Ile; 0.555, 0.618, 0.634,0.609, 0.605, 0.633, 0.761, 0.652,(−0.6774)+(−0.0006)Gln+(−0.0152)Thr+(0.0184)Ile; 0.555, 0.617, 0.650,0.634, 0.612, 0.65 9, 0.766, 0.668,(−0.8340)+(−0.0148)Thr+(−0.0033)Pro+(0.0223)I le; 0.555, 0.628, 0.449,0.405, 0.481, 0.599, 0.390, 0.469, (−1.8542)+(0.0270)Ser+(−0.0050)Gln+(0.0018)Orn; 0.555, 0.618, 0.574, 0. 618,0.565, 0.680, 0.402, 0.566, (−1.8983)+(0.0182)Ser+(0.0055)Orn+(−0.0181)Leu; 0.554, 0.608, 0.565, 0.607, 0.552, 0.663, 0.407, 0.558, (−1.8728)+(0.0189)Ser+(0.0014)Pro+(−0.0180)Leu; 0.553, 0. 606,0.714, 0.763, 0.684, 0.671, 0.676, 0.698, (−0.0661)+(−0.0103)Thr+(−0.0212)Leu+(0.0341)Phe; 0.550, 0.626, 0.635, 0.607, 0.606, 0.648,0.756, 0.654, (−1.0019)+(−0.0170)Thr+(0.0065)Orn+(0.016 1)Ile; 0.549,0.615, 0.643, 0.624, 0.608, 0.653, 0.764, 0.662, (−0.5794)+(−0.0153)Thr+(0.0207)Ile+(−0.0092)Phe; 0.547, 0.601, 0.41 0, 0.361,0.403, 0.575, 0.439, 0.444, (−3.9086)+(0.0198)Ser+(0.0164)Ile+(−0.0150)Phe; 0.538, 0.621, 0.688, 0.688, 0.664, 0.693, 0.7 34,0.695, (−0.4056)+(−0.0007)Gly+(−0.0154)Thr+(0.0122)Orn; 0. 533, 0.621,0.674, 0.672, 0.656, 0.690, 0.706, 0.681, (−0.2638)+(−0.0006)Gln+(−0.0151)Thr+(0.0128)Orn; 0.530, 0.584, 0.742, 0.794, 0. 711,0.728, 0.679, 0.728, (1.1970)+(−0.0013)Gly+(−0.0079)Thr+(−0.0148)Leu;0.530, 0.594, 0.701, 0.747, 0.685, 0.716, 0.603, 0.688,(0.4425)+(−0.0030)Gly+(0.0151)Orn+(−0.0204)Leu; 0.528, 0.582, 0.708,0.759, 0.674, 0.715, 0.641, 0.697,(0.9378)+(−0.0101)Thr+(0.0034)Pro+(−0.0167)Leu; 0.528, 0.622, 0.686,0.692, 0.661, 0.70 0, 0.715, 0.692,(−0.4550)+(−0.0154)Thr+(−0.0008)Pro+(0.0126)O rn; 0.528, 0.599, 0.466,0.456, 0.465, 0.591, 0.408, 0.480, (−3.4755)+(0.0200)Ser+(−0.0027)Pro+(0.0004)Phe; 0.527, 0.589, 0.737, 0. 797,0.696, 0.742, 0.659, 0.724, (0.7102)+(0.0007)Gln+(−0.0096)Ihr+(−0.0149)Leu; 0.526, 0.621, 0.681, 0.683, 0.655, 0.695, 0.719, 0.688, (−0.5559)+(−0.0158)Thr+(0.0118)Orn+(0.0015)Phe; 0.526, 0. 590,0.414, 0.372, 0.404, 0.520, 0.467, 0.441, (−4.2575)+(0.0216)Ser+(−0.0122)Orn+(0.0157)Ile; 0.525, 0.591, 0.706, 0.726, 0.675, 0. 675,0.739, 0.704, (−0.0943)+(−0.0006)Gly+(0.0001)Gln+(−0.012 6)Thr; 0.524,0.590, 0.691, 0.745, 0.671, 0.638, 0.631, 0.671, (−0.2627)+(−0.0021)Gly+(−0.0233)Leu+(0.0289)Phe; 0.522, 0.596, 0.63 8, 0.694,0.630, 0.632, 0.512, 0.617, (−0.9720)+(0.0108)Orn+(−0.0252)Leu+(0.0272)Phe; 0.519, 0.597, 0.655, 0.701, 0.662, 0.705, 0.4 80,0.637, (0.4763)+(−0.0013)Gln+(0.0154)Orn+(−0.0194)Leu; 0.5 18, 0.592,0.695, 0.711, 0.666, 0.661, 0.739, 0.694, (−0.3335)+(−0.0004)Gly+(−0.0132)Thr+(0.0052)Phe; 0.516, 0.590, 0.705, 0.726, 0. 674,0.674, 0.737, 0.703, (−0.0734)+(−0.0006)Gly+(−0.0126)Thr+(−0.0000)Pro;0.516, 0.592, 0.469, 0.462, 0.463, 0.587, 0.413, 0.48 1,(−3.3459)+(0.0204)Ser+(−0.0023)Pro+(−0.0039)Orn; 0.515, 0.5 94, 0.688,0.705, 0.659, 0.664, 0.722, 0.688, (−0.3432)+(−0.0002)Gln+(−0.0133)Thr+(0.0059)Phe; 0.514, 0.581, 0.647, 0.712, 0.630, 0. 616,0.532, 0.622, (−0.7417)+(0.0011)Pro+(−0.0241)Leu+(0.0289)Phe; 0.513,0.592, 0.700, 0.722, 0.669, 0.678, 0.723, 0.698, (−0.1324)+(−0.0001)Gln+(−0.0129)Thr+(0.0000)Pro; 0.511, 0.573, 0.707, 0.767,0.678, 0.696, 0.614, 0.689, (0.7028)+(−0.0024)Gly+(0.0019)Pro+(−0.0187)Leu; 0.511, 0.590, 0.651, 0.711, 0.641, 0.696, 0.48 0,0.632, (−0.1366)+(0.0010)Pro+(0.0124)Orn+(−0.0205)Leu; 0.51 0, 0.585,0.652, 0.706, 0.646, 0.627, 0.542, 0.630, (−0.2737)+(−0.0010)Gln+(−0.0231)Leu+(0.0313)Phe; 0.509, 0.576, 0.725, 0.786, 0. 698,0.718, 0.627, 0.707, (0.7731)+(−0.0024)Gly+(0.0001)Gln+(−0. 0173)Leu;0.505, 0.594, 0.692, 0.710, 0.661, 0.668, 0.725, 0.691,(−0.4065)+(−0.0134)Thr+(−0.0003)Pro+(0.0060)Phe; 0.501, 0.572, 0. 438,0.425, 0.434, 0.547, 0.404, 0.452, (−3.5143)+(0.0206)Ser+(−0.0060)Orn+(−0.0006)Phe 0.868, 0.887, 0.812, 0.814, 0.816, 0.826, 0.787,0.811, (−0.69 36)+(0.0495)Ser+(−0.2897)Met+(0.1345)Phe+(−0.1458)Trp;0.867, 0.887, 0.767, 0.742, 0.767, 0.829, 0.787, 0.781,(1.8981)+(0.0482)Ser+(−0.1330)His+(0.1211)Phe+(−0.1189)Trp; 0.859,0.880, 0.788, 0.765, 0.799, 0.810, 0.807, 0.795,(5.5872)+(−0.1248)His+(0.022 7)Thr+(0.1034)Phe+(−0.1281)Trp; 0.859,0.879, 0.818, 0.810, 0.81 2, 0.831, 0.842, 0.824,(3.3687)+(0.0094)Gln+(−0.1373)His+(0.10 16)Phe+(−0.1198)Trp; 0.858,0.873, 0.755, 0.719, 0.757, 0.828, 0.7 95, 0.775,(3.8688)+(0.0418)Ser+(−0.1122)His+(0.0756)Ile+(−0. 1226)Trp; 0.858,0.878, 0.802, 0.806, 0.796, 0.815, 0.796, 0.803, (1.4379)+(0.0468)Ser+(−0.1406)Asn+(0.0925)Phe+(−0.1494)Trp; 0.8 57, 0.876,0.767, 0.742, 0.776, 0.835, 0.770, 0.781, (−0.3631)+(0.0601)Ser+(−0.1472)His+(−0.2802)Met+(0.1624)Phe; 0.852, 0.871, 0. 791,0.760, 0.793, 0.812, 0.852, 0.804, (5.7984)+(−0.1096)His+(0.0488)Ile+(0.0764)Phe+(−0.1294)Trp; 0.852, 0.870, 0.796, 0.784, 0. 752,0.839, 0.888, 0.816, (1.7025)+(−0.0640)Val+(−0.3892)Met+(0.2012)Ile+(0.1197)Phe; 0.852, 0.872, 0.808, 0.798, 0.778, 0.844, 0. 873,0.823, (6.6666)+(−0.0432)Val+(−0.1839)Met+(0.1753)Ile+(−0.1070)Trp;0.852, 0.870, 0.782, 0.766, 0.781, 0.831, 0.788, 0.792,(1.7250)+(0.0453)Ser+(−0.2355)Met+(0.0785)Ile+(−0.1464)Trp; 0.851,0.868, 0.777, 0.768, 0.743, 0.797, 0.861, 0.792,(3.1638)+(−0.0441)Val+(0.1421)Ile+(0.0684)Phe+(−0.1578)Trp; 0.850,0.867, 0.771, 0.744, 0.784, 0.822, 0.777, 0.782,(2.8932)+(0.0351)Ser+(−0.0931)Cit+(0.0687)Ile+(−0.1868)Trp; 0.850,0.866, 0.799, 0.780, 0.793, 0.829, 0.842, 0.811,(4.9396)+(0.0088)Gln+(−0.1221)His+(0.0645)Ile+(−0.1245)Trp; 0.849,0.864, 0.776, 0.748, 0.778, 0.82 0, 0.816, 0.791,(7.0898)+(−0.1081)His+(0.0181)Thr+(0.0644)Ile +(−0.1288)Trp; 0.848,0.868, 0.770, 0.751, 0.729, 0.872, 0.831, 0.7 96,(1.0778)+(0.0407)Ser+(−0.0537)Val+(−0.3400)Met+(0.1986)I le; 0.847,0.868, 0.801, 0.781, 0.810, 0.815, 0.825, 0.808, (5.9199)+(−0.1114)His+(0.0225)Orn+(0.0932)Phe+(−0.1159)Trp; 0.847, 0. 868,0.809, 0.812, 0.833, 0.786, 0.764, 0.799, (2.8552)+(0.0368)Thr+(−0.3410)Met+(0.1295)Phe+(−0.1602)Trp; 0.847, 0.862, 0.797, 0. 791,0.746, 0.844, 0.886, 0.817,(5.8480)+(−0.0079)Ala+(−0.0409)Val+(0.1684)Ile+(−0.1273)Trp; 0.847,0.867, 0.796, 0.784, 0.797, 0.820, 0.809, 0.803,(5.3440)+(0.0046)Gly+(−0.1128)His+(0.108 8)Phe+(−0.1149)Trp; 0.846,0.862, 0.782, 0.765, 0.756, 0.825, 0.85 3, 0.800,(7.1512)+(−0.0690)His+(−0.0299)Val+(0.1370)Ile+(−0. 1095)Trp; 0.846,0.872, 0.778, 0.777, 0.780, 0.783, 0.771, 0.778, (0.6197)+(0.0338)Ser+(−0.0124)Lys+(0.0844)Phe+(−0.1674)Trp; 0.8 46, 0.864,0.788, 0.783, 0.771, 0.792, 0.832, 0.794, (2.9278)+(0.1367)Ile+(−0.0728)Leu+(0.0636)Phe+(−0.1605)Trp; 0.845, 0.867, 0. 802,0.786, 0.806, 0.808, 0.832, 0.808, (5.9787)+(−0.1062)His+(0.0042)Pro+(0.0998)Phe+(−0.1185)Trp; 0.845, 0.864, 0.781, 0.768, 0. 740,0.868, 0.837, 0.803, (3.9962)+(0.0311)Thr+(−0.0608)Val+(−0.3891)Met+(0.2090)Ile; 0.845, 0.867, 0.776, 0.782, 0.770, 0.777, 0. 773,0.776, (0.5852)+(0.0287)Ser+(−0.0073)Val+(0.0843)Phe+(−0. 1708)Trp;0.845, 0.863, 0.807, 0.793, 0.809, 0.812, 0.833, 0.812, (6.1244)+(−0.1061)His+(0.0006)Val+(0.1029)Phe+(−0.1166)Trp; 0.8 45, 0.861,0.795, 0.776, 0.784, 0.827, 0.844, 0.808, (7.2040)+(−0.0764)His+(0.1160)Ile+(−0.0374)Leu+(−0.1146)Trp; 0.844, 0.861, 0. 769,0.754, 0.773, 0.835, 0.754, 0.779, (5.3551)+(0.0386)Ser+(−0.0976)His+(0.0099)Pro+(−0.1040)Trp; 0.844, 0.862, 0.791, 0.776, 0. 764,0.835, 0.855, 0.807, (6.2375)+(−0.0640)Cit+(−0.0362)Val+(0.1489)Ile+(−0.1415)Trp; 0.843, 0.865, 0.812, 0.801, 0.814, 0.818, 0. 835,0.817, (6.3125)+(−0.0124)Asn+(−0.1023)His+(0.1040)Phe+(−0.1146)Trp;0.843, 0.864, 0.818, 0.808, 0.814, 0.830, 0.843, 0.824,(6.2917)+(−0.1021)His+(−0.0028)Ala+(0.1090)Phe+(−0.1131)Tr p; 0.843,0.863, 0.803, 0.783, 0.809, 0.810, 0.836, 0.809,(6.1579)+(−0.1100)His+(0.0102)Leu+(0.0940)Phe+(−0.1216)Trp; 0.843, 0.860, 0.777, 0.768, 0.793, 0.797, 0.754, 0.778, (1.1802)+(0.0372)Ser+(−0.1027)Cit+(0.0987)Phe+(−0.1854)Trp; 0.843, 0.859, 0.809, 0. 805,0.775, 0.843, 0.867, 0.822, (5.7424)+(−0.0082)Ala+(0.1610)Ile+(−0.0664)Leu+(−0.1350)Trp; 0.842, 0.859, 0.798, 0.791, 0.758, 0.840,0.870, 0.815, (6.8143)+(−0.0695)Asn+(−0.0424)Val+(0.1546)Ile+(−0.1154)Trp; 0.842, 0.866, 0.827, 0.817, 0.834, 0.827, 0.83 8,0.829, (6.1768)+(−0.0922)His+(−0.1319)Met+(0.1301)Phe+(−0. 1062)Trp;0.842, 0.862, 0.780, 0.766, 0.788, 0.847, 0.750, 0.788, (5.5527)+(0.0338)Ser+(−0.1006)His+(0.0284)Orn+(−0.0991)Trp; 0.8 41, 0.859,0.783, 0.752, 0.791, 0.822, 0.823, 0.797, (7.2352)+(−0.1007)His+(0.0228)Orn+(0.0594)Ile+(−0.1205)Trp; 0.841, 0.861, 0. 756,0.742, 0.720, 0.817, 0.821, 0.775, (2.7061)+(0.0256)Ser+(−0.0402)Val+(0.1469)Ile+(−0.1474)Trp; 0.841, 0.857, 0.801, 0.779, 0. 791,0.838, 0.855, 0.816, (7.8145)+(−0.0856)His+(−0.0049)Ala+(0.0743)Ile+(−0.1162)Trp; 0.840, 0.862, 0.803, 0.788, 0.805, 0.810, 0. 830,0.808, (5.9127)+(−0.1100)His+(0.0052)Lys+(0.1000)Phe+(−0. 1200)Trp;0.840, 0.863, 0.781, 0.785, 0.792, 0.786, 0.746, 0.777, (0.8091)+(0.0353)Ser+(−0.0284)Arg+(0.0879)Phe+(−0.1742)Trp; 0.8 40, 0.856,0.799, 0.800, 0.792, 0.852, 0.776, 0.805, (4.6131)+(0.0288)Ser+(0.0066)Gln+(−0.1102)His+(−0.0990)Trp; 0.840, 0.857, 0. 773,0.753, 0.784, 0.834, 0.758, 0.782, (5.1823)+(0.0402)Ser+(−0.1098)His+(0.0120)Val+(−0.1100)Trp; 0.839, 0.857, 0.760, 0.729, 0. 772,0.825, 0.768, 0.774, (4.7218)+(0.0420)Ser+(−0.1164)His+(0.0313)Leu+(−0.1150)Trp; 0.839, 0.857, 0.776, 0.763, 0.768, 0.823, 0. 792,0.787, (2.8672)+(0.0433)Ser+(−0.1153)Asn+(0.0572)Ile+(−0. 1517)Trp;0.839, 0.862, 0.744, 0.704, 0.745, 0.841, 0.776, 0.767, (2.1986)+(0.0514)Ser+(−0.1264)His+(−0.2196)Met+(0.0830)Ile; 0.8 39, 0.861,0.793, 0.795, 0.778, 0.811, 0.806, 0.798, (0.7514)+(0.0301)Ser+(−0.0068)Ala+(0.0855)Phe+(−0.1659)Trp; 0.839, 0.857, 0. 769,0.745, 0.789, 0.808, 0.760, 0.775, (3.7383)+(−0.1490)His+(0.0429)Thr+(−0.3207)Met+(0.1423)Phe; 0.839, 0.856, 0.798, 0.797, 0. 796,0.859, 0.764, 0.804, (6.4883)+(0.0411)Ser+(−0.0461)Asn+(−0.0805)His+(−0.0932)Trp; 0.838, 0.859, 0.763, 0.753, 0.746, 0.814, 0. 791,0.776, (2.2558)+(0.0259)Ser+(0.1387)Ile+(−0.0624)Leu+(−0. 1558)Trp;0.838, 0.861, 0.763, 0.761, 0.766, 0.761, 0.763, 0.763, (0.3487)+(0.0284)Ser+(0.0015)Pro+(0.0693)Phe+(−0.1812)Trp; 0.83 8, 0.861,0.767, 0.768, 0.770, 0.766, 0.762, 0.766, (0.4098)+(0.0285)Ser+(−0.0019)Leu+(0.0727)Phe+(−0.1786)Trp; 0.838, 0.862, 0.8 10,0.798, 0.812, 0.817, 0.831, 0.815, (6.2982)+(−0.1037)His+(−0.0050)Arg+(0.1052)Phe+(−0.1153)Trp; 0.838, 0.854, 0.778, 0.753, 0. 777,0.821, 0.814, 0.791, (6.9014)+(0.0041)Gly+(−0.0990)His+(0.0678)Ile+(−0.1183)Trp; 0.838, 0.861, 0.774, 0.774, 0.773, 0.775, 0. 776,0.774, (0.2426)+(0.0325)Ser+(−0.0071)Thr+(0.0745)Phe+(−0. 1744)Trp;0.838, 0.863, 0.808, 0.801, 0.806, 0.814, 0.830, 0.813, (6.1545)+(−0.1031)His+(−0.0154)Tyr+(0.1119)Phe+(−0.1109)Trp; 0. 838, 0.855,0.804, 0.799, 0.786, 0.826, 0.841, 0.813, (6.0808)+(−0.0486)Asn+(0.1377)Ile+(−0.0625)Leu+(−0.1335)Trp; 0.837, 0.858, 0.779,0.771, 0.783, 0.848, 0.740, 0.785,(6.0131)+(0.0326)Ser+(−0.0989)His+(0.0111)Thr+(−0.1019)Trp; 0.837,0.857, 0.790, 0.782, 0.820, 0.841, 0.713, 0.789,(4.6027)+(0.0276)Ser+(−0.1146)Cit+(0.0484)Orn+(−0.1654)Trp; 0.837,0.859, 0.766, 0.776, 0.760, 0.76 4, 0.753, 0.763,(0.5464)+(0.0307)Ser+(−0.0422)Tyr+(0.0961)Phe +(−0.1664)Trp; 0.837,0.854, 0.809, 0.798, 0.807, 0.831, 0.824, 0.8 15,(5.3566)+(0.0099)Gln+(−0.1282)His+(0.0250)Leu+(−0.1168)I rp; 0.837,0.855, 0.786, 0.791, 0.787, 0.828, 0.738, 0.786, (3.6885)+(0.0399)Ser+(0.0129)Pro+(−0.1933)Met+(−0.1350)Trp; 0.836, 0. 853,0.789, 0.762, 0.789, 0.817, 0.836, 0.801, (7.4907)+(−0.0926)His+(0.0006)Pro+(0.0644)Ile+(−0.1201)Trp; 0.836, 0.852, 0.788, 0. 762,0.788, 0.818, 0.835, 0.801, (7.4632)+(0.0027)Asn+(−0.0934)His+(0.0653)Ile+(−0.1202)Trp; 0.836, 0.862, 0.761, 0.756, 0.767, 0. 766,0.756, 0.761, (0.7507)+(0.0312)Ser+(−0.0017)Gln+(0.0730)Phe+(−0.1768)Trp; 0.836, 0.856, 0.796, 0.795, 0.795, 0.860, 0.757, 0.802, (6.1565)+(0.0388)Ser+(−0.0829)His+(−0.0539)Met+(−0.092 2)Trp;0.836, 0.851, 0.736, 0.697, 0.715, 0.844, 0.803, 0.765, (2.4233)+(0.0412)Ser+(−0.1423)His+(−0.0074)Ala+(0.0706)Ile; 0.836, 0.855,0.800, 0.787, 0.789, 0.836, 0.828, 0.810, (6.1927)+(−0.0732)Cit+(0.1445)Ile+(−0.0583)Leu+(−0.1486)Trp; 0.836, 0.853, 0.7 87,0.760, 0.788, 0.816, 0.836, 0.800, (7.3754)+(−0.0953)His+(0.0030)Lys+(0.0633)Ile+(−0.1220)Trp; 0.836, 0.856, 0.806, 0.799, 0. 790,0.832, 0.838, 0.815, (6.1190)+(−0.1498)Met+(0.1521)Ile+(−0.0618)Leu+(−0.1243)Trp; 0.836, 0.857, 0.743, 0.725, 0.748, 0.752, 0. 778,0.750, (0.0321)+(0.0282)Ser+(0.0410)Ile+(0.0467)Phe+(−0. 1924)Trp;0.835, 0.860, 0.781, 0.770, 0.785, 0.764, 0.812, 0.783, (0.8860)+(0.0394)Ser+(−0.0080)Gly+(0.0665)Phe+(−0.1768)Trp; 0.8 35, 0.852,0.835, 0.842, 0.825, 0.856, 0.823, 0.836, (6.2303)+(−0.0477)Asn+(0.0114)Gln+(−0.1009)His+(−0.0967)Trp; 0.835, 0.861, 0. 768,0.767, 0.771, 0.764, 0.766, 0.767, (0.3827)+(0.0289)Ser+(−0.0037)Orn+(0.0733)Phe+(−0.1799)Trp; 0.835, 0.853, 0.774, 0.758, 0. 750,0.828, 0.827, 0.791, (2.0142)+(0.0307)Ser+(−0.0093)Ala+(0.0731)Ile+(−0.1641)Trp; 0.835, 0.854, 0.783, 0.770, 0.788, 0.847, 0. 763,0.792, (5.6027)+(0.0377)Ser+(−0.0990)His+(0.0199)Tyr+(−0. 1043)Trp;0.835, 0.854, 0.793, 0.765, 0.798, 0.825, 0.832, 0.805, (7.7949)+(−0.0751)His+(−0.0448)Cit+(0.0687)Ile+(−0.1275)Trp; 0. 834, 0.851,0.785, 0.780, 0.786, 0.848, 0.753, 0.792, (5.9101)+(0.0370)Ser+(−0.0917)His+(0.0002)Ala+(−0.0962)Trp; 0.834, 0.852, 0. 782,0.774, 0.783, 0.844, 0.754, 0.789, (5.6352)+(0.0358)Ser+(−0.0975)His+(0.0063)Lys+(−0.1016)Trp; 0.834, 0.851, 0.810, 0.813, 0. 803,0.842, 0.791, 0.812, (6.0421)+(0.0082)Gln+(−0.1143)His+(0.0137)Thr+(−0.1073)Trp; 0.834, 0.855, 0.808, 0.812, 0.815, 0.847, 0. 755,0.807, (8.8275)+(−0.0828)His+(0.0309)Thr+(−0.1132)Met+(−0.1022)Trp;0.834, 0.853, 0.816, 0.812, 0.814, 0.836, 0.818, 0.820,(5.4534)+(0.0102)Gln+(−0.1239)His+(0.0097)Val+(−0.1123)Trp; 0.834,0.854, 0.814, 0.819, 0.823, 0.859, 0.750, 0.813, (6.0473)+(0.0405)Ser+(−0.0809)Asn+(−0.0633)Cit+(−0.1326)Trp; 0.834, 0.854, 0.788,0.777, 0.800, 0.831, 0.761, 0.792,(7.8145)+(−0.1004)His+(0.0165)Thr+(0.0288)Orn+(−0.1072)Trp; 0.834,0.850, 0.738, 0.70 9, 0.738, 0.810, 0.762, 0.755,(1.2617)+(0.0555)Ser+(−0.1047)Asn +(−0.1496)His+(0.1097)Phe; 0.833,0.852, 0.810, 0.808, 0.810, 0.8 38, 0.797, 0.813,(5.7609)+(0.0085)Gln+(−0.1139)His+(0.0253)Or n+(−0.1025)Trp; 0.833,0.852, 0.788, 0.762, 0.789, 0.818, 0.835, 0. 801,(7.5060)+(−0.0927)His+(0.0004)Tyr+(0.0650)Ile+(−0.1200)Trp; 0.833,0.859, 0.812, 0.797, 0.821, 0.819, 0.825, 0.815, (6.4158)+(−0.0901)His+(−0.0521)Cit+(0.1152)Phe+(−0.1253)Trp; 0.833, 0.852,0.773, 0.763, 0.739, 0.812, 0.842, 0.789, (4.8036)+(−0.0417)Val+(0.0115)Orn+(0.1461)Ile+(−0.1393)Trp; 0.833, 0.851, 0.81 1, 0.812,0.805, 0.835, 0.805, 0.814, (5.7123)+(0.0094)Gln+(−0.1120)His+(0.0071)Pro+(−0.1050)Trp; 0.833, 0.847, 0.789, 0.784, 0.7 93,0.822, 0.768, 0.792, (8.0392)+(−0.0941)His+(0.0187)Thr+(0.0059)Pro+(−0.1095)Trp; 0.833, 0.851, 0.789, 0.764, 0.790, 0.820, 0. 834,0.802, (7.5890)+(−0.0916)His+(−0.0019)Arg+(0.0652)Ile+(−0.1195)Trp;0.832, 0.849, 0.793, 0.785, 0.791, 0.845, 0.783, 0.801,(6.0170)+(0.0442)Ser+(−0.0053)Gly+(−0.0883)His+(−0.0968)Tr p; 0.832,0.853, 0.791, 0.785, 0.798, 0.856, 0.747, 0.797,(6.2172)+(0.0386)Ser+(−0.0802)His+(−0.0357)Cit+(−0.0996)Trp; 0.832, 0.848, 0.801, 0.788, 0.830, 0.803, 0.771, 0.798, (4.5988)+(−0.1254)Cit+(0.0457)Orn+(0.0749)Phe+(−0.1801)Trp; 0.832, 0.848, 0.776, 0. 768,0.739, 0.811, 0.847, 0.791, (4.7921)+(0.0007)Gln+(−0.0405)Val(0.1467)Ile+(−0.1401)Trp; 0.832, 0.858, 0.813, 0.801, 0.807, 0. 833,0.839, 0.820,(0.8683)+(0.0127)Gln+(−0.1563)His+(−0.2363)Met+(0.1260)Phe; 0.832,0.849, 0.777, 0.757, 0.790, 0.811, 0.778, 0. 784,(7.7615)+(−0.1131)His+(0.0218)Thr+(0.0251)Leu+(−0.1231)Trp; 0.832,0.850, 0.770, 0.761, 0.736, 0.811, 0.838, 0.786, (4.8075)+(0.0056)Thr+(−0.0413)Val+(0.1476)Ile+(−0.1427)Trp; 0.831, 0.847,0.777, 0.768, 0.739, 0.812, 0.852, 0.793, (5.1738)+(−0.0006)Gly+(−0.0408)Val+(0.1480)Ile+(−0.1376)Trp; 0.831, 0.849, 0.8 04,0.803, 0.809, 0.839, 0.769, 0.805, (8.9090)+(−0.0386)Asn+(−0.0857)His+(0.0248)Thr+(−0.1052)Trp; 0.831, 0.849, 0.804, 0.787, 0. 813,0.816, 0.820, 0.809, (4.2918)+(0.0047)Gln+(−0.0911)Cit+(0.0618)Ile+(−0.1841)Trp; 0.831, 0.850, 0.780, 0.774, 0.800, 0.824, 0. 722,0.780, (4.3970)+(0.0326)Ser+(−0.0821)Cit+(0.0095)Pro+(−0. 1628)Trp;0.831, 0.849, 0.789, 0.788, 0.769, 0.805, 0.820, 0.796, (3.9802)+(0.0021)Gln+(0.1386)Ile+(−0.0651)Leu+(−0.1514)Trp; 0.8 31, 0.847,0.823, 0.829, 0.812, 0.847, 0.812, 0.825, (5.9272)+(0.0099)Gln+(−0.1077)His+(−0.0006)Ala+(−0.0993)Trp; 0.831, 0.848, 0. 776,0.769, 0.737, 0.816, 0.845, 0.792, (5.0725)+(−0.0343)Val+(0.1637)Ile+(−0.0217)Leu+(−0.1350)Trp; 0.831, 0.847, 0.813, 0.797, 0.805,0.839, 0.853, 0.824,(6.6077)+(−0.0078)Ala+(−0.0782)Cit+(0.0801)Ile+(−0.1575)Trp; 0.830,0.846, 0.699, 0.649, 0.698, 0.80 1, 0.761, 0.727,(0.2117)+(0.0436)Ser+(−0.1732)His+(0.0360)Ile +(0.0678)Phe; 0.830,0.848, 0.777, 0.767, 0.740, 0.818, 0.850, 0.79 4,(5.3363)+(−0.0402)Val+(−0.0038)Lys+(0.1498)Ile+(−0.1338)T rp; 0.830,0.848, 0.775, 0.769, 0.737, 0.810, 0.844, 0.790, (5.3708)+(−0.0126)Tyr+(−0.0400)Val+(0.1488)Ile+(−0.1327)Trp; 0.830, 0. 851,0.831, 0.838, 0.819, 0.856, 0.816, 0.833, (5.9044)+(0.0108)Gln+(−0.1018)His+(−0.0566)Met+(−0.0952)Trp; 0.830, 0.849, 0.787, 0.781,0.770, 0.805, 0.820, 0.794,(4.7452)+(0.0028)Orn+(0.1385)Ile+(−0.0647)Leu+(−0.1466)Trp; 0.830,0.855, 0.840, 0.851, 0.842, 0.798, 0.834, 0.831,(1.6077)+(0.0063)Gln+(−0.2432)Met+(0.112 4)Phe+(−0.1488)Trp; 0.830,0.848, 0.789, 0.796, 0.788, 0.826, 0.75 0, 0.790,(4.4666)+(0.0401)Ser+(−0.1088)Asn+(0.0079)Pro+(−0.1 356)Trp; 0.830,0.855, 0.841, 0.851, 0.841, 0.802, 0.844, 0.835, (3.1099)+(−0.0982)Asn+(0.0059)Gln+(0.0746)Phe+(−0.1606)Trp; 0.8 29, 0.845,0.789, 0.765, 0.814, 0.815, 0.784, 0.794, (5.7602)+(−0.1121)Cit+(0.0395)Orn+(0.0510)Ile+(−0.1782)Trp; 0.829, 0.854, 0. 799,0.776, 0.800, 0.828, 0.837, 0.810, (7.7863)+(−0.0798)His+(−0.0851)Met+(0.0715)Ile+(−0.1120)Trp; 0.829, 0.848, 0.793, 0.773, 0. 807,0.786, 0.822, 0.797, (4.1507)+(−0.0952)Cit+(0.0503)Ile+(0.0657)Phe+(−0.1880)Trp; 0.829, 0.847, 0.821, 0.826, 0.811, 0.845, 0. 809,0.823, (5.8736)+(0.0001)Gly+(0.0098)Gln+(−0.1089)His+(−0. 1000)Trp;0.829, 0.846, 0.791, 0.780, 0.803, 0.823, 0.773, 0.795, (8.0622)+(−0.1033)His+(0.0205)Thr+(0.0074)Val+(−0.1153)Trp; 0.8 29, 0.850,0.811, 0.816, 0.824, 0.858, 0.738, 0.809, (5.3014)+(0.0362)Ser+(−0.0595)Cit+(−0.1015)Met+(−0.1322)Trp; 0.829, 0.850, 0. 788,0.784, 0.790, 0.851, 0.749, 0.793, (6.1599)+(0.0387)Ser+(−0.0885)His+(−0.0087)Arg+(−0.0935)Trp; 0.829, 0.846, 0.731, 0.701, 0.720,0.823, 0.770, 0.753,(0.9324)+(0.0445)Ser+(−0.1600)His+(−0.0048)Ala+(0.0994)Phe; 0.829,0.848, 0.783, 0.776, 0.747, 0.82 2, 0.845, 0.798,(6.0528)+(−0.0187)Arg+(−0.0425)Val+(0.1569)Il e+(−0.1281)Trp; 0.829,0.852, 0.802, 0.811, 0.802, 0.763, 0.807, 0. 796,(3.3228)+(0.0042)Pro+(−0.0082)Val+(0.0808)Phe+(−0.1647)Trp; 0.829,0.846, 0.787, 0.766, 0.804, 0.809, 0.790, 0.792, (5.6036)+(0.0109)Thr+(−0.0876)Cit+(0.0608)Ile+(−0.1828)Trp; 0.829, 0.846,0.715, 0.674, 0.703, 0.823, 0.768, 0.742,(2.2744)+(0.0369)Ser+(−0.1381)His+(0.1008)Ile+(−0.0337)Leu; 0.828,0.848, 0.787, 0.783, 0.770, 0.805, 0.820, 0.794,(4.7835)+(0.0007)Thr+(0.1389)Ile+(−0.0644)Leu+(−0.1470)Trp; 0.828,0.846, 0.776, 0.768, 0.739, 0.813, 0.849, 0.792,(5.1250)+(−0.0016)Pro+(−0.0407)Val+(0.150 0)Ile+(−0.1376)Trp; 0.828,0.849, 0.788, 0.783, 0.772, 0.804, 0.82 4, 0.796,(4.9098)+(−0.0005)Gly+(0.1392)Ile+(−0.0645)Leu+(−0. 1461)Trp; 0.828,0.847, 0.816, 0.819, 0.808, 0.838, 0.809, 0.818, (5.6906)+(0.0092)Gln+(−0.1127)His+(0.0057)Lys+(−0.1046)Trp; 0.8 28, 0.848,0.820, 0.821, 0.813, 0.845, 0.815, 0.824, (5.7459)+(0.0097)Gln+(−0.1148)His+(0.0152)Tyr+(−0.1061)Trp; 0.828, 0.848, 0. 828,0.828, 0.841, 0.808, 0.817, 0.823, (5.6837)+(−0.0504)Asn+(−0.0816)Cit+(0.0953)Phe+(−0.1596)Trp; 0.828, 0.846, 0.726, 0.683, 0. 724,0.827, 0.772, 0.752, (2.8591)+(0.0473)Ser+(−0.0729)Asn+(−0.1376)His+(0.0587)Ile; 0.828, 0.843, 0.724, 0.689, 0.726, 0.812, 0. 747,0.744, (1.1550)+(0.0475)Ser+(−0.1605)His+(−0.0124)Lys+(0. 1035)Phe;0.828, 0.847, 0.812, 0.828, 0.808, 0.849, 0.754, 0.810, (5.1227)+(0.0391)Ser+(−0.0638)Asn+(−0.0785)Met+(−0.1277)Trp; 0. 828, 0.849,0.791, 0.777, 0.804, 0.820, 0.783, 0.796, (7.8247)+(−0.0917)His+(0.0061)Pro+(0.0327)Orn+(−0.1030)Trp; 0.827, 0.849, 0. 799,0.811, 0.807, 0.845, 0.716, 0.795, (4.6547)+(0.0294)Ser+(0.0152)Thr+(−0.1745)Met+(−0.1408)Trp; 0.827, 0.845, 0.809, 0.822, 0. 802,0.847, 0.761, 0.808, (5.0939)+(0.0377)Ser+(−0.0893)Asn+(−0.0015)Ala+(−0.1295)Trp; 0.827, 0.852, 0.801, 0.802, 0.794, 0.769, 0. 836,0.800, (3.4551)+(−0.0264)Val+(0.0414)Leu+(0.0783)Phe+(−0. 1718)Trp;0.827, 0.847, 0.818, 0.834, 0.811, 0.847, 0.772, 0.816, (4.0201)+(0.0346)Ser+(−0.1139)Asn+(0.0041)Gln+(−0.1359)Trp; 0.8 27, 0.850,0.786, 0.776, 0.793, 0.806, 0.784, 0.790, (5.1661)+(0.0248)Thr+(−0.2423)Met+(0.0661)Ile+(−0.1533)Trp; 0.827, 0.848, 0. 799,0.808, 0.799, 0.837, 0.747, 0.798, (4.5281)+(0.0374)Ser+(−0.1072)Asn+(0.0208)Orn+(−0.1346)Trp; 0.827, 0.844, 0.714, 0.665, 0. 717,0.824, 0.759, 0.741, (2.5591)+(0.0437)Ser+(−0.1436)His+(−0.0125)Lys+(0.0645)Ile; 0.827, 0.845, 0.793, 0.787, 0.800, 0.826, 0. 768,0.795, (8.0144)+(−0.0971)His+(0.0190)Thr+(0.0053)Lys+(−0. 1096)Trp;0.827, 0.847, 0.787, 0.782, 0.771, 0.805, 0.820, 0.795, (4.9183)+(−0.0014)Lys+(0.1392)Ile+(−0.0637)Leu+(−0.1450)Trp; 0. 827, 0.846,0.785, 0.785, 0.764, 0.804, 0.813, 0.791, (5.3062)+(−0.0195)Tyr+(0.1428)Ile+(−0.0641)Leu+(−0.1374)Trp; 0.827, 0.846, 0.799,0.800, 0.800, 0.841, 0.769, 0.802,(8.4236)+(−0.0912)His+(0.0218)Thr+(−0.0013)Ala+(−0.1053)Trp; 0.827,0.851, 0.833, 0.8 32, 0.850, 0.810, 0.815, 0.827,(4.9049)+(−0.0733)Cit+(−0.1545)M et+(0.1213)Phe+(−0.1501)Trp; 0.827,0.847, 0.829, 0.834, 0.822, 0. 856, 0.811, 0.831,(6.0384)+(0.0103)Gln+(−0.0971)His+(−0.0361)Cit+(−0.1033)Trp; 0.827,0.844, 0.721, 0.703, 0.711, 0.796, 0.737, 0.737,(0.9223)+(0.0443)Ser+(−0.1561)His+(−0.0445)Tyr+(0.116 7)Phe; 0.827,0.852, 0.834, 0.843, 0.836, 0.792, 0.833, 0.826, (4.9195)+(−0.0704)Asn+(−0.0076)Val+(0.0926)Phe+(−0.1432)Trp; 0.82 7, 0.849,0.799, 0.809, 0.805, 0.762, 0.789, 0.791, (3.1688)+(0.0077)Thr+(−0.0081)Val+(0.0811)Phe+(−0.1696)Trp; 0.827, 0.850, 0.8 08,0.799, 0.815, 0.787, 0.835, 0.809, (3.5338)+(−0.2354)Met+(0.0529)Ile+(0.0869)Phe+(−0.1526)Trp; 0.827, 0.845, 0.826, 0.834, 0. 817,0.849, 0.806, 0.827, (6.0110)+(0.0113)Gln+(−0.1081)His+(−0.0133)Arg+(−0.0973)Trp; 0.826, 0.848, 0.800, 0.798, 0.811, 0.841, 0. 754,0.801, (8.6973)+(−0.0816)His+(0.0235)Thr+(−0.0402)Cit+(−0.1118)Trp;0.826, 0.846, 0.789, 0.786, 0.771, 0.812, 0.821, 0.797,(4.9708)+(−0.0039)Pro+(0.1460)Ile+(−0.0657)Leu+(−0.1450)Tr p; 0.826,0.849, 0.806, 0.816, 0.809, 0.770, 0.797, 0.798,(3.3064)+(−0.0084)Val+(0.0116)Orn+(0.0776)Phe+(−0.1620)Trp; 0.826, 0.842, 0.716, 0.678, 0.690, 0.828, 0.790, 0.747, (2.4994)+(0.0345)Ser+(−0.1225)His+(−0.0289)Val+(0.1190)Ile; 0.826, 0.845, 0.795, 0. 793,0.800, 0.835, 0.762, 0.797, (8.2697)+(0.0003)Gly+(−0.0934)His+(0.0209)Thr+(−0.1063)Trp; 0.826, 0.851, 0.813, 0.827, 0.811, 0. 771,0.810, 0.805, (2.5428)+(0.0024)Gln+(−0.0073)Val+(0.0802)Phe+(−0.1689)Trp; 0.826, 0.844, 0.724, 0.693, 0.719, 0.804, 0.760, 0.744, (−0.0269)+(0.0379)Ser+(0.0042)Gln+(−0.1801)His+(0.0873)Phe; 0.826,0.846, 0.796, 0.786, 0.742, 0.867, 0.884, 0.820, (4.8910)+(−0.0055)Ala+(−0.0528)Val+(−0.2382)Met+(0.1962)Ile; 0.826, 0.847,0.785, 0.764, 0.754, 0.849, 0.858, 0.806, (6.4465)+(−0.0623)His+(−0.0425)Val+(−0.2014)Met+(0.1680)Ile; 0.826, 0.847, 0.7 51,0.730, 0.749, 0.797, 0.774, 0.762, (1.9569)+(0.0345)Ser+(−0.0151)Lys+(0.0633)Ile+(−0.1628)Trp; 0.826, 0.845, 0.759, 0.734, 0. 761,0.778, 0.808, 0.770, (1.8343)+(0.0391)Ser+(−0.0078)Gly+(0.0503)Ile+(−0.1780)Trp; 0.826, 0.852, 0.813, 0.816, 0.826, 0.783, 0. 799,0.806, (4.7103)+(−0.1025)Asn+(0.0179)Thr+(0.0754)Phe+(−0. 1634)Trp;0.826, 0.841, 0.721, 0.678, 0.716, 0.823, 0.771, 0.747, (1.3899)+(0.0338)Ser+(0.0043)Gln+(−0.1663)His+(0.0516)Ile; 0.82 6, 0.846,0.782, 0.771, 0.805, 0.819, 0.738, 0.783, (3.9934)+(0.0327)Ser+(−0.0816)Cit+(0.0184)Leu+(−0.1713)Trp; 0.826, 0.847, 0.7 88,0.762, 0.804, 0.818, 0.798, 0.796, (7.8351)+(−0.1031)His+(0.0312)Orn+(0.0199)Leu+(−0.1126)Trp; 0.825, 0.845, 0.796, 0.786, 0. 825,0.790, 0.765, 0.792, (4.2249)+(0.0140)Thr+(−0.0971)Cit+(0.0876)Phe+(−0.1863)Trp; 0.825, 0.839, 0.716, 0.677, 0.717, 0.799, 0. 760,0.738, (0.8595)+(0.0474)Ser+(−0.0029)Gly+(−0.1674)His+(0. 0891)Phe;0.825, 0.849, 0.796, 0.807, 0.800, 0.838, 0.731, 0.794, (3.8520)+(0.0340)Ser+(−0.1511)Met+(0.0222)Orn+(−0.1358)Trp; 0.8 25, 0.839,0.768, 0.750, 0.719, 0.839, 0.869, 0.794, (5.6712)+(−0.0866)His+(−0.0066)Ala+(−0.0356)Val+(0.1435)Ile; 0.825, 0.850, 0. 816,0.819, 0.826, 0.777, 0.811, 0.808, (3.7488)+(0.0077)Pro+(−0.2244)Met+(0.1082)Phe+(−0.1441)Trp; 0.825, 0.847, 0.786, 0.786, 0. 793,0.820, 0.749, 0.787, (2.9723)+(0.0407)Ser+(−0.1830)Met+(0.0237)Leu+(−0.1459)Trp; 0.825, 0.844, 0.779, 0.764, 0.740, 0.851, 0. 850,0.801, (4.2474)+(−0.0569)Val+(−0.2918)Met+(0.0254)Orn+(0. 1891)Ile;0.825, 0.848, 0.801, 0.792, 0.781, 0.809, 0.863, 0.811, (3.4695)+(−0.0094)Ala+(0.0570)Ile+(0.0568)Phe+(−0.1709)Trp; 0.8 25, 0.848,0.832, 0.843, 0.838, 0.792, 0.821, 0.823, (4.0106)+(−0.0055)Val+(−0.1937)Met+(0.1205)Phe+(−0.1359)Trp; 0.825, 0.846, 0. 796,0.792, 0.803, 0.833, 0.768, 0.799, (8.2465)+(−0.0944)His+(0.0205)Thr+(0.0050)Tyr+(−0.1083)Trp; 0.825, 0.845, 0.799, 0.809, 0. 799,0.840, 0.742, 0.798, (5.0944)+(0.0351)Ser+(−0.1065)Asn+(0.0084)Thr+(−0.1374)Trp; 0.825, 0.839, 0.715, 0.663, 0.715, 0.816, 0. 778,0.743, (2.2774)+(0.0451)Ser+(−0.0039)Gly+(−0.1532)His+(0. 0536)Ile;0.824, 0.842, 0.804, 0.817, 0.803, 0.846, 0.741, 0.802, (4.3447)+(0.0349)Ser+(−0.0002)Ala+(−0.1279)Met+(−0.1326)Trp; 0. 824, 0.845,0.814, 0.821, 0.810, 0.839, 0.787, 0.814, (4.6255)+(0.0454)Ser+(−0.0076)Gly+(−0.1269)Met+(−0.1326)Trp; 0.824, 0.842, 0.813,0.805, 0.840, 0.835, 0.762, 0.811,(7.9934)+(−0.0506)Asn+(−0.1077)Cit+(0.0583)Orn+(−0.1443)Trp; 0.824,0.844, 0.829, 0.8 37, 0.838, 0.791, 0.820, 0.821,(4.2708)+(−0.0186)Asn+(−0.1817)M et+(0.1099)Phe+(−0.1408)Trp; 0.824,0.843, 0.802, 0.815, 0.804, 0. 837, 0.740, 0.799,(4.1442)+(0.0340)Ser+(−0.1451)Met+(0.0047)L ys+(−0.1372)Trp; 0.824,0.843, 0.802, 0.814, 0.799, 0.834, 0.755, 0. 800,(4.8290)+(0.0376)Ser+(−0.1001)Asn+(0.0030)Lys+(−0.1352)Trp; 0.824,0.843, 0.793, 0.783, 0.804, 0.828, 0.769, 0.796, (7.7986)+(0.0020)Gly+(−0.0922)His+(0.0361)Orn+(−0.0980)Trp; 0.824, 0.845,0.795, 0.781, 0.807, 0.823, 0.784, 0.799, (7.9900)+(−0.0956)His+(0.0047)Val+(0.0337)Orn+(−0.1050)Trp; 0.824, 0.842, 0.74 4, 0.714,0.709, 0.805, 0.848, 0.769, (3.8311)+(−0.1147)His+(−0.0364)Val+(0.1156)Ile+(0.0627)Phe; 0.824, 0.846, 0.794, 0.773, 0.7 82,0.847, 0.838, 0.810, (3.0854)+(0.0111)Gln+(−0.1404)His+(−0.1937)Met+(0.0647)Ile; 0.824, 0.847, 0.812, 0.828, 0.809, 0.847, 0. 752,0.809, (3.5073)+(0.0315)Ser+(0.0032)Gln+(−0.1476)Met+(−0. 1366)Trp;0.823, 0.840, 0.749, 0.733, 0.692, 0.855, 0.830, 0.778, (2.6416)+(0.0435)Ser+(−0.1848)Asn+(−0.0564)Val+(0.1742)Ile; 0.8 23, 0.842,0.751, 0.733, 0.748, 0.785, 0.783, 0.762, (1.3069)+(0.0339)Ser+(−0.0098)Thr+(0.0550)Ile+(−0.1714)Trp; 0.823, 0.844, 0. 796,0.798, 0.805, 0.835, 0.748, 0.796, (8.7711)+(−0.0909)His+(0.0252)Thr+(−0.0126)Arg+(−0.1062)Trp; 0.823, 0.847, 0.811, 0.820, 0.813,0.770, 0.810, 0.803,(3.4357)+(−0.0000)Gly+(−0.0070)Val+(0.0829)Phe+(−0.1635)Trp; 0.823,0.848, 0.758, 0.725, 0.766, 0.82 6, 0.780, 0.774,(5.8041)+(−0.1283)His+(0.0327)Thr+(−0.2487)Me t+(0.0694)Ile; 0.823,0.848, 0.809, 0.817, 0.793, 0.788, 0.838, 0.8 09,(3.6329)+(−0.0084)Ala+(0.0088)Pro+(0.0794)Phe+(−0.1620)T rp; 0.823,0.849, 0.799, 0.800, 0.815, 0.768, 0.785, 0.792, (3.4271)+(0.0104)Thr+(−0.0090)Lys+(0.0753)Phe+(−0.1737)Trp; 0.823, 0. 843,0.793, 0.795, 0.811, 0.835, 0.719, 0.790, (4.8416)+(0.0291)Ser+(0.0048)Thr+(−0.0742)Cit+(−0.1554)Trp; 0.823, 0.845, 0.836, 0. 843,0.830, 0.813, 0.846, 0.833,(4.8475)+(−0.0576)Asn+(−0.0048)Ala+(0.0879)Phe+(−0.1481)Trp; 0.823,0.843, 0.814, 0.817, 0.809, 0.836, 0.799, 0.815,(5.2563)+(0.0481)Ser+(−0.0913)Asn+(−0.007 3)Gly+(−0.1336)Trp; 0.823,0.842, 0.803, 0.809, 0.811, 0.850, 0.74 1, 0.803,(5.0720)+(0.0313)Ser+(−0.0023)Ala+(−0.0684)Cit+(−0. 1435)Trp; 0.823,0.847, 0.810, 0.816, 0.805, 0.795, 0.815, 0.808, (3.3924)+(0.0108)Thr+(−0.0071)Ala+(0.0812)Phe+(−0.1693)Trp; 0.8 23, 0.843,0.816, 0.824, 0.840, 0.842, 0.725, 0.808, (7.7700)+(0.0280)Thr+(−0.0628)Cit+(−0.1480)Met+(−0.1411)Trp; 0.823, 0.840, 0. 781,0.764, 0.794, 0.808, 0.779, 0.786, (5.3945)+(0.0040)Gly+(−0.0885)Cit+(0.0647)Ile+(−0.1744)Trp; 0.823, 0.846, 0.811, 0.815, 0. 817,0.854, 0.756, 0.810, (3.7672)+(0.0377)Ser+(0.0329)Tyr+(−0.1848)Met+(−0.1427)Trp; 0.822, 0.841, 0.781, 0.786, 0.762, 0.834, 0. 769,0.788, (3.4525)+(0.0283)Ser+(−0.0071)Ala+(0.0112)Pro+(−0. 1448)Trp;0.822, 0.836, 0.713, 0.680, 0.711, 0.799, 0.742, 0.733, (0.7961)+(0.0431)Ser+(−0.1648)His+(−0.0035)Val+(0.0969)Phe; 0.8 22, 0.841,0.746, 0.719, 0.725, 0.795, 0.827, 0.767, (3.5737)+(−0.1257)His+(0.1043)Ile+(−0.0558)Leu+(0.0707)Phe; 0.822, 0.844, 0. 802,0.793, 0.807, 0.832, 0.790, 0.806, (8.1624)+(−0.0874)His+(−0.0014)Ala+(0.0381)Orn+(−0.0971)Trp; 0.822, 0.839, 0.797, 0.787, 0. 826,0.822, 0.742, 0.794, (6.6466)+(−0.1136)Cit+(0.0053)Pro+(0.0516)Orn+(−0.1628)Trp; 0.822, 0.840, 0.793, 0.775, 0.804, 0.806, 0. 808,0.798, (5.9868)+(−0.0815)Cit+(0.0013)Pro+(0.0607)Ile+(−0. 1730)Trp;0.822, 0.847, 0.819, 0.827, 0.827, 0.778, 0.812, 0.811, (4.4054)+(−0.0721)Asn+(0.0019)Gly+(0.0801)Phe+(−0.1554)Trp; 0.8 22, 0.842,0.804, 0.789, 0.812, 0.817, 0.818, 0.809, (6.8072)+(−0.0327)Asn+(−0.0753)Cit+(0.0612)Ile+(−0.1629)Trp; 0.822, 0.847, 0. 822,0.831, 0.832, 0.787, 0.801, 0.813, (3.4599)+(0.0022)Gly+(−0.2067)Met+(0.1140)Phe+(−0.1427)Trp; 0.822, 0.838, 0.811, 0.804, 0. 832,0.841, 0.760, 0.809, (7.3871)+(−0.0047)Ala+(−0.1128)Cit+(0.0607)Orn+(−0.1448)Trp; 0.822, 0.843, 0.794, 0.781, 0.804, 0.824, 0. 782,0.798, (7.7222)+(−0.0961)His+(0.0329)Orn+(0.0072)Lys+(−0. 1051)Trp;0.822, 0.845, 0.802, 0.793, 0.810, 0.830, 0.786, 0.805, (8.2801)+(−0.0150)Asn+(−0.0858)His+(0.0377)Orn+(−0.0977)Trp; 0. 822, 0.840,0.746, 0.728, 0.746, 0.776, 0.771, 0.755, (1.5426)+(0.0288)Ser+(−0.0073)Orn+(0.0543)Ile+(−0.1783)Trp; 0.822, 0.845, 0. 753,0.740, 0.757, 0.799, 0.746, 0.761, (2.0871)+(0.0350)Ser+(−0.0260)Arg+(0.0585)Ile+(−0.1705)Trp; 0.822, 0.841, 0.789, 0.785, 0. 812,0.826, 0.726, 0.787, (4.3822)+(0.0320)Ser+(−0.0794)Cit+(0.0060)Val+(−0.1629)Trp; 0.822, 0.840, 0.795, 0.783, 0.783, 0.822, 0. 835,0.805, (2.3417)+(−0.0780)Asn+(0.0116)Gln+(−0.1598)His+(0. 0775)Phe;0.821, 0.844, 0.804, 0.813, 0.802, 0.840, 0.759, 0.803, (4.7828)+(0.0384)Ser+(−0.0983)Asn+(0.0068)Tyr+(−0.1350)Trp; 0.8 21, 0.848,0.813, 0.822, 0.816, 0.774, 0.811, 0.806, (3.5653)+(−0.0064)Val+(−0.0026)Lys+(0.0847)Phe+(−0.1614)Trp; 0.821, 0.838, 0. 798,0.791, 0.830, 0.828, 0.732, 0.795, (6.6189)+(0.0070)Thr+(−0.1126)Cit+(0.0506)Orn+(−0.1639)Trp; 0.821, 0.845, 0.792, 0.791, 0. 777,0.812, 0.812, 0.798, (5.8598)+(−0.0193)Arg+(0.1507)Ile+(−0.0691)Leu+(−0.1367)Trp; 0.821, 0.843, 0.801, 0.812, 0.799, 0.836, 0. 753,0.800, (4.7908)+(0.0383)Ser+(−0.0950)Asn+(0.0013)Val+(−0. 1345)Trp;0.821, 0.843, 0.817, 0.815, 0.834, 0.801, 0.802, 0.813, (4.9214)+(−0.0877)Cit+(−0.0042)Lys+(0.0951)Phe+(−0.1677)Trp; 0. 821, 0.841,0.707, 0.666, 0.711, 0.799, 0.740, 0.729, (0.6425)+(0.0422)Ser+(−0.1707)His+(0.0097)Orn+(0.0874)Phe; 0.821, 0.839, 0. 782,0.758, 0.755, 0.850, 0.854, 0.804, (3.4009)+(0.0083)Gln+(−0.1498)His+(−0.0065)Ala+(0.0558)Ile; 0.821, 0.837, 0.707, 0.668, 0. 709,0.794, 0.742, 0.728, (0.6625)+(0.0434)Ser+(−0.1693)His+(0.0012)Pro+(0.0895)Phe; 0.821, 0.840, 0.792, 0.785, 0.745, 0.860, 0. 861,0.812, (3.2291)+(0.0039)Gln+(−0.0540)Val+(−0.3077)Met+(0. 1887)Ile;0.821, 0.838, 0.707, 0.668, 0.709, 0.796, 0.745, 0.729, (0.6638)+(0.0436)Ser+(−0.1704)His+(0.0029)Leu+(0.0876)Phe; 0.82 1, 0.847,0.824, 0.834, 0.813, 0.798, 0.841, 0.822, (2.5743)+(0.0032)Gln+(−0.0066)Ala+(0.0806)Phe+(−0.1673)Trp; 0.821, 0.850, 0.8 15,0.823, 0.820, 0.773, 0.816, 0.808, (2.5403)+(0.0031)Gln+(−0.0073)Lys+(0.0744)Phe+(−0.1724)Trp; 0.821, 0.844, 0.800, 0.793, 0. 801,0.773, 0.838, 0.801, (4.3282)+(−0.0658)Asn+(0.0395)Ile+(0.0549)Phe+(−0.1688)Trp; 0.821, 0.843, 0.786, 0.776, 0.742, 0.849, 0. 859,0.807, (4.3158)+(−0.0570)Val+(−0.3044)Met+(0.0078)Lys+(0. 1925)Ile;0.821, 0.840, 0.803, 0.801, 0.798, 0.826, 0.803, 0.807, (8.6130)+(−0.0758)His+(−0.0035)Ala+(0.0116)Pro+(−0.0986)Trp; 0. 821, 0.845,0.817, 0.818, 0.830, 0.796, 0.804, 0.812, (3.0066)+(0.0045)Gln+(−0.0964)Cit+(0.0862)Phe+(−0.1806)Trp; 0.821, 0.839, 0. 798,0.780, 0.808, 0.814, 0.816, 0.804, (6.4963)+(−0.0800)Cit+(−0.0063)Lys+(0.0668)Ile+(−0.1650)Trp; 0.821, 0.844, 0.799, 0.784, 0. 824,0.837, 0.760, 0.801, (8.4227)+(−0.0693)His+(−0.0798)Cit+(0.0587)Orn+(−0.1115)Trp; 0.821, 0.841, 0.804, 0.817, 0.804, 0.843, 0. 744,0.802, (5.0975)+(0.0394)Ser+(−0.0859)Asn+(−0.0090)Arg+(−0.1298)Trp;0.821, 0.846, 0.826, 0.832, 0.833, 0.781, 0.825, 0.818,(4.7404)+(−0.0676)Asn+(−0.0021)Leu+(0.0802)Phe+(−0.1539)Tr p; 0.821,0.837, 0.708, 0.659, 0.708, 0.815, 0.759, 0.735,(2.1978)+(0.0395)Ser+(−0.1543)His+(−0.0018)Pro+(0.0571)Ile; 0.821, 0.849, 0.818, 0.821, 0.827, 0.773, 0.824, 0.811, (4.6563)+(−0.0699)Asn+(0.0034)Pro+(0.0750)Phe+(−0.1574)Trp; 0.821, 0.843, 0.826, 0. 828,0.829, 0.817, 0.824, 0.825,(4.9871)+(−0.0055)Ala+(−0.0855)Cit+(0.1039)Phe+(−0.1612)Trp; 0.821,0.839, 0.808, 0.803, 0.833, 0.830, 0.751, 0.804,(5.5816)+(0.0035)Gln+(−0.1140)Cit+(0.049 8)Orn+(−0.1651)Trp; 0.821,0.842, 0.803, 0.816, 0.806, 0.844, 0.73 2, 0.800,(4.5256)+(0.0364)Ser+(−0.0086)Arg+(−0.1186)Met+(−0. 1304)Trp; 0.821,0.837, 0.711, 0.673, 0.712, 0.798, 0.745, 0.732, (0.6824)+(0.0442)Ser+(−0.1678)His+(−0.0016)Thr+(0.0916)Phe; 0.8 21, 0.840,0.791, 0.789, 0.793, 0.818, 0.770, 0.793, (8.0410)+(0.0028)Gly+(−0.0842)His+(0.0085)Pro+(−0.0999)Trp; 0.821, 0.838, 0. 803,0.795, 0.835, 0.830, 0.740, 0.800, (7.2015)+(−0.1128)Cit+(0.0582)Orn+(−0.0045)Lys+(−0.1516)Trp; 0.821, 0.843, 0.797, 0.786, 0.806,0.827, 0.785, 0.801,(7.9860)+(−0.0911)His+(0.0054)Tyr+(0.0356)Orn+(−0.1010)Trp; 0.820,0.841, 0.739, 0.717, 0.743, 0.77 7, 0.762, 0.750,(1.8760)+(0.0309)Ser+(−0.0018)Gln+(0.0529)Ile +(−0.1751)Trp; 0.820,0.844, 0.822, 0.828, 0.832, 0.788, 0.807, 0.8 14,(3.7571)+(−0.2062)Met+(0.0121)Orn+(0.1044)Phe+(−0.1418)T rp; 0.820,0.843, 0.787, 0.789, 0.788, 0.818, 0.759, 0.789, (4.0203)+(0.0409)Ser+(−0.1056)Asn+(0.0150)Leu+(−0.1436)Trp; 0.820, 0. 846,0.819, 0.824, 0.827, 0.780, 0.815, 0.812, (4.6656)+(−0.0728)Asn+(0.0119)Orn+(0.0709)Phe+(−0.1547)Trp; 0.820, 0.845, 0.833, 0. 841,0.836, 0.801, 0.829, 0.827,(4.0312)+(−0.0024)Ala+(−0.1819)Met+(0.1131)Phe+(−0.1403)Trp; 0.820,0.841, 0.803, 0.795, 0.822, 0.782, 0.797, 0.799,(4.5507)+(−0.0914)Cit+(0.0052)Pro+(0.085 5)Phe+(−0.1756)Trp; 0.820,0.840, 0.792, 0.784, 0.798, 0.809, 0.79 3, 0.796,(7.8709)+(−0.0898)His+(0.0076)Pro+(0.0095)Lys+(−0.1 092)Trp; 0.820,0.841, 0.796, 0.799, 0.811, 0.839, 0.726, 0.794, (4.9275)+(0.0317)Ser+(−0.0703)Cit+(−0.0017)Lys+(−0.1483)Trp; 0. 820, 0.838,0.720, 0.688, 0.730, 0.802, 0.727, 0.737, (0.9230)+(0.0488)Ser+(−0.1613)His+(−0.0224)Arg+(0.1010)Phe; 0.820, 0.837, 0. 708,0.659, 0.708, 0.814, 0.760, 0.735, (2.1004)+(0.0413)Ser+(−0.1519)His+(−0.0037)Thr+(0.0557)Ile; 0.820, 0.842, 0.802, 0.806, 0. 815,0.840, 0.735, 0.799, (4.1992)+(0.0279)Ser+(0.0024)Gln+(−0.0755)Cit+(−0.1555)Trp; 0.820, 0.838, 0.790, 0.771, 0.799, 0.810, 0. 810,0.797, (8.1128)+(−0.0944)His+(0.0055)Pro+(0.0210)Leu+(−0. 1135)Trp;0.820, 0.844, 0.826, 0.835, 0.818, 0.800, 0.835, 0.822, (3.7508)+(−0.0053)Ala+(−0.0041)Val+(0.0896)Phe+(−0.1563)Trp; 0. 820, 0.835,0.796, 0.791, 0.826, 0.826, 0.727, 0.792, (6.5880)+(0.0017)Gly+(−0.1135)Cit+(0.0543)Orn+(−0.1581)Trp; 0.820, 0.842, 0. 746,0.738, 0.740, 0.778, 0.758, 0.754, (2.0254)+(0.0284)Ser+(−0.0242)Tyr+(0.0558)Ile+(−0.1671)Trp; 0.820, 0.839, 0.793, 0.775, 0. 804,0.806, 0.808, 0.798, (5.9893)+(−0.0812)Cit+(0.0007)Arg+(0.0620)Ile+(−0.1726)Trp; 0.819, 0.840, 0.814, 0.814, 0.829, 0.791, 0. 800,0.809, (4.6843)+(−0.0860)Cit+(−0.0021)Val+(0.0935)Phe+(−0.1689)Trp;0.819, 0.840, 0.747, 0.731, 0.747, 0.782, 0.766, 0.757,(1.5135)+(0.0281)Ser+(−0.0027)Pro+(0.0546)Ile+(−0.1775)Trp; 0.819,0.842, 0.795, 0.805, 0.800, 0.833, 0.734, 0.793, (3.8344)+(0.0366)Ser+(0.0051)Val+(−0.1446)Met+(−0.1402)Trp; 0.819, 0.842, 0.808,0.792, 0.818, 0.821, 0.821, 0.813,(6.6752)+(−0.0659)Cit+(−0.1095)Met+(0.0690)Ile+(−0.1520)Trp; 0.819,0.836, 0.784, 0.7 60, 0.770, 0.836, 0.837, 0.801,(3.4714)+(−0.0644)Asn+(0.0107)Gl n+(−0.1505)His+(0.0434)Ile; 0.819,0.841, 0.780, 0.768, 0.737, 0. 849, 0.850, 0.801,(4.3739)+(0.0021)Gly+(−0.0544)Val+(−0.2823)Met+(0.1909)Ile; 0.819,0.837, 0.781, 0.763, 0.744, 0.845, 0.856, 0. 802,(5.8218)+(−0.0986)His+(−0.0072)Ala+(0.1275)Ile+(−0.049 0)Leu; 0.819,0.845, 0.797, 0.801, 0.807, 0.753, 0.795, 0.789, (2.4413)+(0.0018)Gln+(0.0038)Thr+(0.0659)Phe+(−0.1813)Trp; 0.819, 0.840,0.795, 0.807, 0.806, 0.810, 0.726, 0.787,(6.4477)+(0.0236)Thr+(0.0085)Pro+(−0.1986)Met+(−0.1414)Trp; 0.819,0.835, 0.801, 0.794, 0.831, 0.824, 0.740, 0.797,(6.8299)+(−0.1115)Cit+(0.000 1)Val+(0.0545)Orn+(−0.1579)Trp; 0.819,0.837, 0.712, 0.669, 0.71 9, 0.819, 0.738, 0.736,(2.4734)+(0.0444)Ser+(−0.1468)His+(−0.0 188)Arg+(0.0578)Ile; 0.819,0.845, 0.790, 0.777, 0.751, 0.855, 0.8 61, 0.811,(5.1987)+(−0.0400)Cit+(−0.0526)Val+(−0.2529)Met+(0. 1872)Ile; 0.819,0.835, 0.783, 0.768, 0.792, 0.817, 0.781, 0.789, (7.7903)+(0.0040)Gly+(−0.1008)His+(0.0259)Leu+(−0.1106)Trp; 0.8 19, 0.837,0.797, 0.787, 0.804, 0.812, 0.795, 0.800, (8.2935)+(−0.0874)His+(0.0069)Pro+(0.0056)Val+(−0.1076)Trp; 0.819, 0.846, 0. 806,0.814, 0.811, 0.759, 0.806, 0.798, (2.4211)+(0.0023)Gln+(−0.0027)Leu+(0.0696)Phe+(−0.1766)Trp; 0.819, 0.844, 0.807, 0.814, 0. 813,0.757, 0.814, 0.799, (2.5496)+(−0.0011)Gly+(0.0024)Gln+(0.0660)Phe+(−0.1783)Trp; 0.819, 0.838, 0.710, 0.674, 0.703, 0.807, 0. 752,0.734, (2.6390)+(0.0390)Ser+(−0.1448)His+(−0.0245)Tyr+(0. 0606)Ile;0.819, 0.837, 0.808, 0.801, 0.837, 0.834, 0.749, 0.805, (7.3107)+(−0.1036)Cit+(−0.0665)Met+(0.0563)Orn+(−0.1431)Trp; 0. 819, 0.842,0.778, 0.768, 0.783, 0.745, 0.815, 0.778, (2.3450)+(0.0015)Gln+(0.0396)Ile+(0.0442)Phe+(−0.1894)Trp; 0.819, 0.840, 0. 802,0.800, 0.813, 0.831, 0.765, 0.802, (4.9203)+(0.0384)Ser+(−0.0055)Gly+(−0.0648)Cit+(−0.1503)Trp; 0.819, 0.841, 0.789, 0.778, 0.743,0.854, 0.866, 0.810,(5.4149)+(−0.0352)Asn+(−0.0549)Val+(−0.2354)Met+(0.1889)Ile; 0.818,0.841, 0.787, 0.771, 0.747, 0.85 1, 0.864, 0.808,(4.4779)+(0.0172)Tyr+(−0.0562)Val+(−0.3039)Me t+(0.1932)Ile; 0.818,0.837, 0.784, 0.773, 0.740, 0.852, 0.853, 0.8 05,(4.7133)+(−0.0495)Val+(−0.2688)Met+(0.2025)Ile+(−0.0173)Leu; 0.818,0.846, 0.800, 0.808, 0.804, 0.752, 0.805, 0.792, (2.4110)+(0.0021)Gln+(0.0014)Pro+(0.0657)Phe+(−0.1794)Trp; 0.818, 0. 843,0.816, 0.821, 0.811, 0.795, 0.828, 0.814, (3.6151)+(−0.0064)Ala+(0.0105)Orn+(0.0767)Phe+(−0.1602)Trp; 0.818, 0.844, 0.821, 0. 828,0.814, 0.797, 0.832, 0.818, (3.6279)+(0.0004)Gly+(−0.0060)Ala+(0.0838)Phe+(−0.1610)Trp; 0.818, 0.844, 0.786, 0.771, 0.790, 0. 766,0.831, 0.789, (3.4864)+(−0.0111)Lys+(0.0475)Ile+(0.0550)Phe+(−0.1761)Trp; 0.818, 0.842, 0.777, 0.794, 0.779, 0.742, 0.755, 0.767, (3.1694)+(0.0120)Thr+(−0.0445)Tyr+(0.0907)Phe+(−0.1687)Trp; 0.818,0.842, 0.795, 0.796, 0.812, 0.836, 0.727, 0.793, (4.7061)+(0.0312)Ser+(−0.0726)Cit+(0.0049)Tyr+(−0.1536)Trp; 0.818, 0.840,0.796, 0.799, 0.812, 0.839, 0.725, 0.794, (4.9229)+(0.0319)Ser+(−0.0672)Cit+(−0.0046)Arg+(−0.1489)Trp; 0.818, 0.835, 0.75 5, 0.726,0.742, 0.808, 0.824, 0.775, (1.8011)+(0.0083)Gln+(−0.1742)His+(0.0298)Ile+(0.0498)Phe; 0.818, 0.836, 0.796, 0.784, 0.82 7,0.815, 0.749, 0.794, (6.5469)+(−0.1141)Cit+(0.0515)Orn+(0.0098)Leu+(−0.1682)Trp; 0.818, 0.843, 0.792, 0.797, 0.819, 0.760, 0.7 49,0.781, (3.7422)+(0.0153)Thr+(−0.0270)Arg+(0.0783)Phe+(−0. 1803)Trp;0.818, 0.845, 0.802, 0.794, 0.811, 0.833, 0.782, 0.805, (8.1896)+(−0.0845)His+(−0.0339)Met+(0.0384)Orn+(−0.0957)Trp; 0. 818, 0.838,0.704, 0.653, 0.707, 0.816, 0.754, 0.732, (2.1105)+(0.0385)Ser+(−0.1565)His+(0.0077)Orn+(0.0522)Ile; 0.818, 0.838, 0. 801,0.797, 0.803, 0.816, 0.795, 0.803, (8.5784)+(−0.0102)Asn+(−0.0777)His+(0.0086)Pro+(−0.1004)Trp; 0.817, 0.839, 0.798, 0.799, 0. 819,0.787, 0.762, 0.792, (4.0024)+(0.0037)Gly+(−0.0942)Cit+(0.0934)Phe+(−0.1738)Trp; 0.817, 0.843, 0.798, 0.818, 0.791, 0.752, 0. 792,0.788, (2.4214)+(0.0031)Gln+(−0.0376)Tyr+(0.0880)Phe+(−0. 1667)Trp;0.817, 0.837, 0.792, 0.776, 0.800, 0.809, 0.805, 0.798, (6.1603)+(−0.0786)Cit+(−0.0073)Tyr+(0.0630)Ile+(−0.1686)Trp; 0. 817, 0.842,0.798, 0.802, 0.808, 0.750, 0.803, 0.791, (3.2524)+(−0.0003)Gly+(0.0022)Pro+(0.0673)Phe+(−0.1748)Trp; 0.817, 0.844, 0. 826,0.833, 0.837, 0.780, 0.815, 0.816, (4.8783)+(−0.0571)Asn+(−0.0093)Arg+(0.0818)Phe+(−0.1554)Trp; 0.817, 0.842, 0.790, 0.792, 0. 805,0.747, 0.786, 0.783, (3.0209)+(0.0052)Thr+(0.0012)Pro+(0.0661)Phe+(−0.1793)Trp; 0.817, 0.839, 0.812, 0.810, 0.829, 0.787, 0. 797,0.806, (4.6997)+(−0.0867)Cit+(−0.0013)Arg+(0.0906)Phe+(−0.1716)Trp;0.817, 0.837, 0.818, 0.824, 0.839, 0.837, 0.745, 0.811,(8.3908)+(−0.0711)Asn+(0.0226)Thr+(−0.0679)Cit+(−0.1462)Tr p; 0.817,0.842, 0.795, 0.795, 0.810, 0.750, 0.794, 0.787,(3.2765)+(−0.0014)Gly+(0.0069)Thr+(0.0658)Phe+(−0.1792)Trp; 0.817, 0.841, 0.782, 0.771, 0.739, 0.847, 0.856, 0.803, (4.6877)+(0.0034)Pro+(−0.0546)Val+(−0.2834)Met+(0.1866)Ile; 0.817, 0.844, 0.799, 0. 804,0.807, 0.752, 0.800, 0.791, (3.2164)+(0.0025)Pro+(−0.0031)Leu+(0.0702)Phe+(−0.1726)Trp; 0.817, 0.839, 0.816, 0.834, 0.821, 0. 833,0.743, 0.808, (5.1219)+(0.0047)Gln+(0.0218)Thr+(−0.1900)Met+(−0.1459)Trp; 0.817, 0.844, 0.794, 0.798, 0.807, 0.753, 0.785, 0.786, (3.0698)+(0.0060)Thr+(−0.0028)Leu+(0.0697)Phe+(−0.1769)Trp; 0.817,0.838, 0.809, 0.805, 0.803, 0.815, 0.828, 0.813, (3.7503)+(0.0055)Gln+(−0.2027)Met+(0.0651)Ile+(−0.1494)Trp; 0.817, 0.843,0.825, 0.831, 0.834, 0.784, 0.817, 0.816, (3.8804)+(−0.2014)Met+(0.0028)Leu+(0.1088)Phe+(−0.1444)Trp; 0.817, 0.839, 0.77 4, 0.762,0.781, 0.743, 0.814, 0.775, (2.9276)+(−0.0001)Gly+(0.0405)Ile+(0.0455)Phe+(−0.1859)Trp; 0.817, 0.839, 0.809, 0.804, 0.8 27,0.786, 0.799, 0.804, (4.6225)+(−0.0886)Cit+(0.0037)Leu+(0.0868)Phe+(−0.1750)Trp; 0.817, 0.837, 0.787, 0.776, 0.763, 0.831, 0. 837,0.802, (2.2663)+(0.0089)Gln+(−0.1642)His+(−0.0045)Ala+(0. 0782)Phe;0.817, 0.846, 0.803, 0.806, 0.814, 0.763, 0.804, 0.797, (3.5025)+(0.0027)Pro+(−0.0056)Lys+(0.0734)Phe+(−0.1691)Trp; 0.8 17, 0.842,0.796, 0.799, 0.806, 0.750, 0.798, 0.788, (3.1515)+(0.0018)Pro+(0.0040)Orn+(0.0651)Phe+(−0.1748)Trp; 0.817, 0.844, 0.8 22,0.828, 0.830, 0.773, 0.825, 0.814, (4.6894)+(−0.0697)Asn+(0.0012)Lys+(0.0772)Phe+(−0.1565)Trp; 0.817, 0.843, 0.821, 0.830, 0. 831,0.776, 0.811, 0.812, (3.6313)+(−0.2158)Met+(0.0056)Lys+(0.1086)Phe+(−0.1471)Trp; 0.817, 0.843, 0.827, 0.835, 0.836, 0.787, 0. 813,0.818, (4.0199)+(−0.0030)Arg+(−0.1938)Met+(0.1115)Phe+(−0.1425)Trp;0.817, 0.833, 0.709, 0.660, 0.715, 0.816, 0.746, 0.734,(2.3089)+(0.0414)Ser+(−0.1445)His+(−0.0406)Cit+(0.0570)Ile; 0.817,0.835, 0.811, 0.825, 0.825, 0.825, 0.735, 0.802,(7.4658)+(−0.0458)Asn+(0.0267)Thr+(−0.1335)Met+(−0.1382)Trp; 0.816, 0.842, 0.804, 0.824, 0.798, 0.761, 0.794, 0.794, (3.6487)+(−0.0319)Tyr+(−0.0061)Val+(0.1000)Phe+(−0.1528)Trp; 0.816, 0.842, 0.784, 0. 800,0.779, 0.738, 0.781, 0.775, (3.4300)+(0.0048)Pro+(−0.0388)Tyr+(0.0875)Phe+(−0.1622)Trp; 0.816, 0.833, 0.767, 0.750, 0.756, 0. 839,0.787, 0.783, (2.9524)+(0.0361)Ser+(−0.0059)Gly+(0.0065)Gln+(−0.1506)His; 0.816, 0.845, 0.802, 0.809, 0.809, 0.757, 0.805, 0.795, (2.4243)+(0.0021)Gln+(0.0019)Orn+(0.0658)Phe+(−0.1785)T rp; 0.816,0.842, 0.792, 0.794, 0.805, 0.751, 0.788, 0.784, (3.0333)+(0.0054)Thr+(0.0017)Orn+(0.0660)Phe+(−0.1787)Trp; 0.816, 0.8 37, 0.774,0.772, 0.752, 0.803, 0.804, 0.783, (2.1541)+(0.0090)Gln+(−0.1616)His+(−0.0425)Tyr+(0.0965)Phe; 0.816, 0.836, 0.795, 0. 785,0.774, 0.817, 0.852, 0.807, (5.0005)+(−0.0095)Ala+(0.0053)Pro+(0.0631)Ile+(−0.1567)Trp; 0.816, 0.845, 0.805, 0.809, 0.815, 0. 767,0.799, 0.797, (3.5182)+(0.0091)Orn+(−0.0064)Lys+(0.0708)Phe+(−0.1665)Trp; 0.816, 0.834, 0.776, 0.759, 0.764, 0.814, 0.819, 0.789, (2.2648)+(0.0094)Gln+(−0.1690)His+(−0.0069)Lys+(0.0763)Phe; 0.816,0.836, 0.801, 0.794, 0.832, 0.826, 0.738, 0.798, (6.9766)+(−0.1092)Cit+(−0.0036)Arg+(0.0554)Orn+(−0.1563)Trp; 0.816, 0.840,0.799, 0.803, 0.810, 0.753, 0.799, 0.791, (3.2922)+(−0.0005)Gly+(0.0056)Orn+(0.0655)Phe+(−0.1733)Trp; 0.816, 0.841, 0.79 7, 0.788,0.809, 0.828, 0.775, 0.800, (8.2720)+(−0.0875)His+(−0.0064)Arg+(0.0391)Orn+(−0.0980)Trp; 0.816, 0.844, 0.818, 0.829, 0. 827,0.774, 0.799, 0.807, (2.5685)+(0.0042)Gln+(−0.0228)Arg+(0.0772)Phe+(−0.1758)Trp; 0.816, 0.840, 0.772, 0.759, 0.781, 0.742, 0. 809,0.773, (2.8028)+(0.0026)Thr+(0.0397)Ile+(0.0449)Phe+(−0. 1881)Trp;0.816, 0.840, 0.771, 0.773, 0.763, 0.744, 0.805, 0.771, (3.2319)+(−0.0388)Tyr+(0.0434)Ile+(0.0670)Phe+(−0.1733)Trp; 0.8 16, 0.838,0.776, 0.763, 0.783, 0.745, 0.821, 0.778, (2.9617)+(−0.0060)Orn+(0.0424)Ile+(0.0488)Phe+(−0.1866)Trp; 0.816, 0.832, 0. 760,0.737, 0.737, 0.824, 0.820, 0.780, (3.1450)+(0.0073)Gln+(−0.1412)His+(0.0960)Ile+(−0.0379)Leu; 0.816, 0.835, 0.799, 0.793, 0. 804,0.816, 0.794, 0.802, (8.3239)+(−0.0827)His+(0.0077)Pro+(0.0077)Tyr+(−0.1038)Trp; 0.816, 0.837, 0.814, 0.812, 0.806, 0.809, 0. 840,0.817, (4.2955)+(−0.0872)Asn+(0.0055)Gln+(0.0477)Ile+(−0. 1600)Trp;0.816, 0.835, 0.785, 0.781, 0.772, 0.858, 0.769, 0.795, (3.3460)+(0.0340)Ser+(−0.0879)Asn+(0.0084)Gln+(−0.1328)His; 0.8 16, 0.842,0.800, 0.805, 0.809, 0.757, 0.795, 0.792, (3.2198)+(0.0062)Orn+(−0.0030)Leu+(0.0684)Phe+(−0.1712)Trp; 0.816, 0.842, 0. 803,0.808, 0.814, 0.755, 0.803, 0.795, (3.3373)+(−0.0002)Gly+(−0.0019)Leu+(0.0715)Phe+(−0.1717)Trp; 0.815, 0.845, 0.808, 0.813, 0. 818,0.766, 0.806, 0.801, (3.5543)+(0.0000)Gly+(−0.0050)Lys+(0.0755)Phe+(−0.1678)Trp; 0.815, 0.842, 0.818, 0.822, 0.811, 0.798, 0. 836,0.817, (3.6653)+(−0.0064)Ala+(0.0046)Leu+(0.0799)Phe+(−0. 1637)Trp;0.815, 0.839, 0.808, 0.815, 0.819, 0.787, 0.786, 0.802, (4.7872)+(−0.0837)Cit+(−0.0245)Tyr+(0.1037)Phe+(−0.1626)Trp; 0. 815, 0.836,0.778, 0.772, 0.779, 0.791, 0.784, 0.782, (3.2510)+(0.0387)Ser+(−0.0084)Gly+(0.0052)Pro+(−0.1578)Trp; 0.815, 0.842, 0. 824,0.831, 0.817, 0.801, 0.836, 0.822, (3.8272)+(−0.0058)Ala+(−0.0023)Lys+(0.0855)Phe+(−0.1585)Trp; 0.815, 0.829, 0.732, 0.700, 0. 731,0.822, 0.751, 0.751, (2.0457)+(0.0320)Ser+(0.0054)Gln+(−0.1677)His+(0.0183)Leu; 0.815, 0.836, 0.802, 0.796, 0.775, 0.824, 0. 856,0.813, (3.8876)+(0.0031)Gln+(−0.0089)Ala+(0.0663)Ile+(−0. 1635)Trp;0.815, 0.844, 0.828, 0.834, 0.839, 0.790, 0.819, 0.820, (3.8949)+(0.0043)Tyr+(−0.2057)Met+(0.1101)Phe+(−0.1435)Trp; 0.8 15, 0.836,0.790, 0.779, 0.770, 0.819, 0.839, 0.802, (4.7362)+(0.0087)Thr+(−0.0090)Ala+(0.0661)Ile+(−0.1638)Trp; 0.815, 0.837, 0. 766,0.760, 0.761, 0.805, 0.765, 0.773, (3.0161)+(0.0274)Ser+(−0.0229)Val+(0.0464)Leu+(−0.1591)Trp; 0.815, 0.834, 0.769, 0.740, 0. 743,0.835, 0.853, 0.793, (4.6064)+(−0.1341)His+(−0.0072)Ala+(0.0453)Ile+(0.0556)Phe; 0.815, 0.835, 0.771, 0.756, 0.780, 0.811, 0. 762,0.777, (3.6828)+(0.0072)Gly+(−0.1310)His+(−0.1994)Met+(0. 1297)Phe;0.815, 0.831, 0.764, 0.745, 0.723, 0.832, 0.849, 0.787, (6.4118)+(−0.0589)Asn+(−0.0765)His+(−0.0398)Val+(0.1396)Ile; 0. 814, 0.838,0.747, 0.729, 0.753, 0.843, 0.714, 0.760, (3.9919)+(0.0440)Ser+(−0.1143)His+(0.0126)Pro+(−0.1592)Met; 0.814, 0.837, 0. 777,0.744, 0.784, 0.810, 0.829, 0.792, (4.2846)+(−0.1217)His+(−0.2243)Met+(0.0477)Ile+(0.0942)Phe; 0.814, 0.834, 0.799, 0.794, 0. 827,0.826, 0.735, 0.796, (6.9713)+(−0.1105)Cit+(−0.0070)Tyr+(0.0559)Orn+(−0.1538)Trp; 0.814, 0.845, 0.808, 0.812, 0.818, 0.766, 0. 806,0.800, (3.5631)+(−0.0052)Lys+(0.0008)Leu+(0.0749)Phe+(−0. 1683)Trp;0.814, 0.838, 0.783, 0.773, 0.739, 0.849, 0.857, 0.804, (4.7993)+(−0.0029)Arg+(−0.0544)Val+(−0.2685)Met+(0.1899)Ile; 0. 814, 0.840,0.815, 0.830, 0.813, 0.771, 0.810, 0.806, (4.7289)+(−0.0585)Asn+(−0.0268)Tyr+(0.0925)Phe+(−0.1473)Trp; 0.814, 0.844, 0.819,0.830, 0.826, 0.780, 0.802, 0.810,(4.0493)+(−0.0160)Arg+(−0.0065)Val+(0.0907)Phe+(−0.1591)Trp; 0.814,0.838, 0.850, 0.8 62, 0.851, 0.855, 0.816, 0.846,(6.0237)+(−0.0754)Asn+(0.0086)Gl n+(−0.0705)Cit+(−0.1410)Trp; 0.814,0.830, 0.770, 0.756, 0.755, 0. 809, 0.812, 0.783,(2.1781)+(0.0086)Gln+(−0.1681)His+(−0.0044)Val+(0.0785)Phe; 0.814,0.832, 0.793, 0.787, 0.802, 0.822, 0.768, 0. 795,(8.1194)+(0.0035)Gly+(−0.0936)His+(0.0088)Val+(−0.1049)Trp; 0.814,0.839, 0.812, 0.827, 0.800, 0.782, 0.818, 0.807, (3.7956)+(−0.0049)Ala+(−0.0235)Tyr+(0.0945)Phe+(−0.1539)Trp; 0.814, 0.838,0.786, 0.786, 0.773, 0.862, 0.756, 0.794,(3.0692)+(0.0317)Ser+(0.0076)Gln+(−0.1310)His+(−0.1234)Met; 0.814,0.832, 0.791, 0.773, 0.800, 0.805, 0.807, 0.797,(8.0392)+(−0.0985)His+(0.006 2)Lys+(0.0213)Leu+(−0.1151)Trp; 0.814,0.836, 0.798, 0.795, 0.80 1, 0.814, 0.787, 0.800,(8.4970)+(−0.0796)His+(−0.0022)Arg+(0.0 086)Pro+(−0.1009)Trp; 0.814,0.832, 0.754, 0.733, 0.715, 0.825, 0. 838, 0.778,(3.6783)+(0.0055)Gln+(−0.1227)His+(−0.0298)Val+(0. 1135)Ile; 0.814,0.839, 0.804, 0.800, 0.808, 0.819, 0.793, 0.805, (8.5953)+(−0.0732)His+(0.0099)Pro+(−0.0468)Met+(−0.0979)Trp; 0. 813, 0.830,0.774, 0.761, 0.708, 0.860, 0.885, 0.803, (3.6750)+(−0.0113)Ala+(−0.0708)Cit+(−0.0492)Val+(0.1781)Ile; 0.813, 0.833, 0.795,0.795, 0.798, 0.818, 0.772, 0.796,(7.8532)+(0.0026)Gly+(−0.0911)His+(0.0109)Lys+(−0.1036)Trp; 0.813,0.831, 0.767, 0.739, 0.756, 0.827, 0.822, 0.786,(3.3314)+(0.0090)Gln+(−0.1557)His+(−0.0081)Lys+(0.0483)Ile; 0.813,0.835, 0.808, 0.799, 0.795, 0.82 4, 0.847, 0.816,(5.9042)+(−0.0054)Ala+(−0.1299)Met+(0.0744)Il e+(−0.1398)Trp; 0.813,0.840, 0.755, 0.737, 0.764, 0.848, 0.715, 0. 766,(4.2088)+(0.0378)Ser+(−0.1210)His+(−0.1223)Met+(0.0316) Orn; 0.813,0.837, 0.790, 0.780, 0.791, 0.796, 0.805, 0.793, (5.7044)+(−0.0810)Asn+(0.0138)Thr+(0.0470)Ile+(−0.1606)Trp; 0.813, 0.832,0.711, 0.674, 0.718, 0.798, 0.732, 0.730, (0.8705)+(0.0447)Ser+(−0.1603)His+(−0.0351)Cit+(0.0938)Phe; 0.813, 0.836, 0.777, 0.765,0.784, 0.748, 0.816, 0.778, (2.9742)+(−0.0025)Pro+(0.0432)Ile+(0.0463)Phe+(−0.1850)Trp; 0.813, 0.834, 0.804, 0.798, 0.81 2,0.829, 0.788, 0.807, (8.7544)+(−0.0673)His+(−0.0366)Cit+(0.0095)Pro+(−0.1075)Trp; 0.813, 0.832, 0.799, 0.782, 0.803, 0.822, 0. 818,0.807, (8.4947)+(−0.0914)His+(−0.0020)Ala+(0.0259)Leu+(−0.1094)Trp;0.813, 0.838, 0.795, 0.812, 0.793, 0.748, 0.787, 0.785,(3.5466)+(−0.0339)Tyr+(−0.0009)Leu+(0.0906)Phe+(−0.1600)Tr p; 0.813,0.830, 0.767, 0.748, 0.755, 0.808, 0.813, 0.781,(2.0217)+(0.0088)Gln+(−0.1733)His+(−0.0004)Pro+(0.0707)Phe; 0.813, 0.828, 0.744, 0.723, 0.740, 0.831, 0.743, 0.759, (2.4500)+(0.0299)Ser+(0.0059)Gln+(−0.1606)His+(0.0051)Val; 0.812, 0.833, 0.808, 0.7 99,0.789, 0.826, 0.856, 0.818, (5.9288)+(−0.0368)Asn+(−0.0072)Ala+(0.0657)Ile+(−0.1481)Trp; 0.812, 0.830, 0.767, 0.748, 0.755, 0. 808,0.813, 0.781,(2.0207)+(0.0088)Gln+(−0.1732)His+(−0.0003)Leu+(0.0705)Phe; 0.812,0.831, 0.794, 0.775, 0.803, 0.815, 0.810, 0. 801,(8.3222)+(0.0017)Asn+(−0.0946)His+(0.0241)Leu+(−0.1115)Trp; 0.812,0.833, 0.737, 0.706, 0.710, 0.813, 0.823, 0.763, (4.9279)+(−0.1071)His+(−0.0356)Val+(0.0258)Orn+(0.1225)Ile; 0.812, 0.827,0.735, 0.708, 0.701, 0.812, 0.821, 0.760, (5.0451)+(−0.1089)His+(0.0091)Thr+(−0.0341)Val+(0.1239)Ile; 0.812, 0.832, 0.80 2, 0.819,0.815, 0.812, 0.723, 0.792, (6.4831)+(0.0235)Thr+(−0.1775)Met+(0.0040)Lys+(−0.1444)Trp; 0.812, 0.833, 0.781, 0.768, 0.7 73,0.819, 0.804, 0.791, (1.9858)+(0.0116)Gln+(−0.1727)His+(−0.0231)Arg+(0.0777)Phe; 0.812, 0.832, 0.757, 0.736, 0.746, 0.800, 0. 802,0.771, (2.0544)+(0.0079)Gln+(−0.1767)His+(0.0067)Thr+(0. 0696)Phe;0.812, 0.838, 0.795, 0.812, 0.793, 0.746, 0.790, 0.785, (3.6285)+(−0.0004)Gly+(−0.0341)Tyr+(0.0896)Phe+(−0.1603)Trp; 0. 812, 0.833,0.795, 0.773, 0.806, 0.817, 0.815, 0.803, (8.2111)+(−0.0968)His+(0.0103)Tyr+(0.0231)Leu+(−0.1151)Trp; 0.812, 0.831, 0. 798,0.788, 0.807, 0.809, 0.796, 0.800, (8.1159)+(−0.0945)His+(0.0062)Val+(0.0090)Lys+(−0.1112)Trp; 0.812, 0.828, 0.758, 0.728, 0. 735,0.835, 0.830, 0.782, (5.5845)+(−0.1345)His+(0.0136)Thr+(−0.0070)Ala+(0.0568)Ile; 0.812, 0.826, 0.738, 0.719, 0.723, 0.844, 0. 746,0.758, (3.9273)+(0.0374)Ser+(−0.1280)His+(−0.0056)Ala+(0. 0115)Pro;0.812, 0.831, 0.743, 0.722, 0.742, 0.833, 0.736, 0.758, (2.8050)+(0.0276)Ser+(0.0050)Gln+(−0.1543)His+(0.0188)Orn; 0.81 2, 0.827,0.761, 0.732, 0.749, 0.819, 0.819, 0.780, (3.0899)+(0.0084)Gln+(−0.1622)His+(−0.0030)Pro+(0.0468)Ile; 0.812, 0.833, 0.7 64,0.772, 0.763, 0.795, 0.718, 0.762, (3.2489)+(0.0273)Ser+(0.0063)Pro+(−0.0169)Tyr+(−0.1497)Trp; 0.812, 0.829, 0.785, 0.781, 0. 714,0.862, 0.891, 0.812,(5.4739)+(−0.1006)Asn+(−0.0074)Ala+(−0.0541)Val+(0.1787)Ile; 0.812,0.833, 0.767, 0.771, 0.768, 0.796, 0.735, 0.768,(2.7816)+(0.0302)Ser+(−0.0057)Thr+(0.0057)Pro+(−0.1527)Trp; 0.812,0.832, 0.796, 0.787, 0.775, 0.818, 0.850, 0.80 8,(4.9433)+(0.0006)Gly+(−0.0083)Ala+(0.0675)Ile+(−0.1568)Tr p; 0.811,0.829, 0.758, 0.740, 0.746, 0.805, 0.797, 0.772,(1.8310)+(0.0020)Gly+(0.0083)Gln+(−0.1741)His+(0.0728)Phe; 0.811, 0.842, 0.803, 0.808, 0.817, 0.758, 0.790, 0.793, (3.8711)+(−0.0184)Arg+(0.0037)Pro+(0.0761)Phe+(−0.1703)Trp; 0.811, 0.833, 0.807, 0.8 25,0.815, 0.826, 0.728, 0.799, (6.8213)+(0.0251)Thr+(−0.0015)Ala+(−0.1577)Met+(−0.1396)Trp; 0.811, 0.839, 0.825, 0.834, 0.822, 0. 799,0.824, 0.820,(4.1970)+(−0.0054)Ala+(−0.0140)Arg+(0.0902)Phe+(−0.1577)Trp; 0.811,0.831, 0.808, 0.823, 0.821, 0.812, 0.736, 0.798,(7.0422)+(−0.0024)Gly+(0.0268)Thr+(−0.1690)Met+(−0.14 24)Trp; 0.811,0.828, 0.731, 0.695, 0.726, 0.835, 0.762, 0.755, (3.3756)+(0.0398)Ser+(−0.1462)His+(−0.0044)Ala+(0.0244)Leu; 0.81 1, 0.834,0.807, 0.818, 0.825, 0.822, 0.731, 0.799, (6.5035)+(0.0244)Thr+(0.0176)Tyr+(−0.1936)Met+(−0.1464)Trp; 0.811, 0.829, 0.7 65,0.758, 0.748, 0.848, 0.759, 0.778, (3.1230)+(0.0283)Ser+(0.0061)Gln+(−0.1446)His+(−0.0022)Ala; 0.811, 0.837, 0.789, 0.805, 0. 788,0.744, 0.777, 0.779, (3.4379)+(−0.0363)Tyr+(0.0096)Orn+(0.0843)Phe+(−0.1600)Trp; 0.811, 0.834, 0.770, 0.778, 0.777, 0.808, 0. 705,0.767, (3.5483)+(0.0320)Ser+(−0.0216)Arg+(0.0070)Pro+(−0. 1506)Trp;0.811, 0.836, 0.740, 0.708, 0.752, 0.829, 0.735, 0.756, (3.3118)+(0.0473)Ser+(−0.1330)His+(−0.1623)Met+(0.0304)Leu; 0.8 11, 0.832,0.803, 0.804, 0.794, 0.827, 0.801, 0.806, (4.0489)+(0.0380)Ser+(−0.0076)Gly+(−0.0031)Ala+(−0.1436)Trp; 0.811, 0.832, 0. 790,0.772, 0.791, 0.815, 0.818, 0.799, (8.3663)+(−0.0902)His+(−0.0165)Val+(0.0504)Leu+(−0.1084)Trp; 0.811, 0.834, 0.818, 0.819, 0. 823,0.834, 0.795, 0.818, (7.7200)+(−0.0062)Ala+(−0.0702)Cit+(0.0142)Pro+(−0.1382)Trp; 0.811, 0.832, 0.761, 0.738, 0.752, 0.809, 0. 805,0.776, (2.0033)+(0.0083)Gln+(−0.1735)His+(0.0107)Orn+(0. 0661)Phe;0.811, 0.833, 0.795, 0.785, 0.777, 0.815, 0.847, 0.806, (4.9222)+(−0.0084)Ala+(0.0064)Orn+(0.0649)Ile+(−0.1571)Trp; 0.8 11, 0.833,0.767, 0.770, 0.772, 0.800, 0.723, 0.766, (3.1908)+(0.0297)Ser+(0.0056)Pro+(−0.0064)Lys+(−0.1489)Trp; 0.811, 0.838, 0. 798,0.814, 0.796, 0.752, 0.790, 0.788, (3.6783)+(−0.0324)Tyr+(−0.0026)Lys+(0.0918)Phe+(−0.1582)Trp; 0.811, 0.830, 0.804, 0.803, 0. 804,0.819, 0.795, 0.805, (8.2595)+(−0.0867)His+(−0.0008)Ala+(0.0113)Lys+(−0.1036)Trp; 0.810, 0.837, 0.803, 0.809, 0.819, 0.765, 0. 778,0.793, (3.8918)+(−0.0199)Arg+(0.0130)Orn+(0.0718)Phe+(−0. 1678)Trp;0.810, 0.828, 0.770, 0.748, 0.761, 0.828, 0.807, 0.786, (3.1225)+(0.0109)Gln+(−0.1602)His+(−0.0209)Arg+(0.0449)Ile; 0.8 10, 0.825,0.752, 0.720, 0.743, 0.816, 0.808, 0.772, (3.0409)+(0.0078)Gln+(−0.1646)His+(0.0044)Thr+(0.0422)Ile; 0.810, 0.831, 0.8 16,0.824, 0.833, 0.826, 0.755, 0.810, (5.5175)+(0.0042)Gln+(0.0100)Thr+(−0.0780)Cit+(−0.1625)Trp; 0.810, 0.835, 0.842, 0.856, 0. 845,0.850, 0.793, 0.836, (5.4438)+(0.0073)Gln+(−0.0645)Cit+(−0.0924)Met+(−0.1392)Trp; 0.810, 0.834, 0.786, 0.783, 0.789, 0.796, 0. 780,0.787, (3.3162)+(0.0370)Ser+(−0.0084)Gly+(0.0122)Orn+(−0. 1560)Trp;0.810, 0.834, 0.779, 0.758, 0.763, 0.833, 0.830, 0.796, (6.1820)+(−0.0886)His+(−0.1511)Met+(0.1324)Ile+(−0.0501)Leu; 0. 810, 0.836,0.783, 0.776, 0.793, 0.753, 0.805, 0.782, (3.6270)+(−0.0194)Arg+(0.0424)Ile+(0.0553)Phe+(−0.1799)Trp; 0.810, 0.834, 0. 776,0.770, 0.752, 0.800, 0.826, 0.787, (0.2209)+(−0.3247)Met+(0.1744)Ile+(−0.0961)Leu+(0.1055)Phe; 0.810, 0.831, 0.743, 0.720, 0. 742,0.843, 0.734, 0.760, (4.0623)+(0.0328)Ser+(−0.1341)His+(−0.0031)Ala+(0.0278)Orn; 0.810, 0.829, 0.771, 0.766, 0.767, 0.851, 0. 735,0.780, (3.0439)+(0.0309)Ser+(0.0082)Gln+(−0.1468)His+(−0. 0224)Arg;0.810, 0.834, 0.797, 0.811, 0.810, 0.816, 0.720, 0.789, (6.2620)+(0.0216)Thr+(−0.1736)Met+(0.0173)Orn+(−0.1415)Trp; 0.8 10, 0.826,0.740, 0.720, 0.736, 0.828, 0.738, 0.756, (2.6042)+(0.0298)Ser+(0.0055)Gln+(−0.1538)His+(0.0053)Pro; 0.810, 0.825, 0.7 38,0.713, 0.703, 0.815, 0.821, 0.763, (5.0639)+(0.0019)Gly+(−0.1025)His+(−0.0340)Val+(0.1261)Ile; 0.810, 0.831, 0.772, 0.762, 0. 715,0.823, 0.881, 0.795, (3.8224)+(−0.1505)Asn+(−0.0607)Val+(0.1632)Ile+(0.0631)Phe; 0.810, 0.829, 0.759, 0.749, 0.748, 0.843, 0. 746,0.771, (3.0972)+(0.0291)Ser+(0.0062)Gln+(−0.1468)His+(−0. 0038)Lys;0.810, 0.830, 0.739, 0.705, 0.744, 0.830, 0.751, 0.758, (3.9002)+(0.0395)Ser+(−0.0047)Gly+(−0.1396)His+(0.0244)Orn; 0.8 10, 0.829,0.807, 0.806, 0.809, 0.815, 0.799, 0.808, (8.5292)+(−0.0228)Asn+(−0.0833)His+(0.0125)Lys+(−0.1041)Trp; 0.810, 0.826, 0. 753,0.742, 0.742, 0.836, 0.744, 0.766, (2.9040)+(0.0286)Ser+(0.0060)Gln+(−0.1501)His+(−0.0005)Thr; 0.810, 0.832, 0.763, 0.767, 0. 771,0.786, 0.722, 0.761, (2.7135)+(0.0261)Ser+(0.0038)Pro+(0.0076)Orn+(−0.1585)Trp; 0.810, 0.830, 0.804, 0.808, 0.804, 0.833, 0. 770,0.804, (8.5238)+(0.0028)Gly+(−0.0797)His+(−0.0001)Ala+(−0.0940)Trp;0.810, 0.833, 0.794, 0.776, 0.802, 0.812, 0.812, 0.801,(8.2462)+(−0.0954)His+(0.0024)Arg+(0.0242)Leu+(−0.1119)Trp; 0.810,0.827, 0.806, 0.800, 0.810, 0.825, 0.801, 0.809,(8.7168)+(−0.0860)His+(−0.0014)Ala+(0.0087)Val+(−0.1042)Trp; 0.810, 0.837, 0.806, 0.813, 0.822, 0.762, 0.785, 0.796,(3.7751)+(0.0009)Gly+(−0.0174)Arg+(0.0801)Phe+(−0.1687)Trp; 0.810,0.830, 0.791, 0.7 99, 0.782, 0.834, 0.755, 0.793,(3.4755)+(0.0260)Ser+(−0.0048)Al a+(0.0174)Orn+(−0.1451)Trp; 0.810,0.830, 0.768, 0.773, 0.773, 0. 795, 0.725, 0.766,(3.0252)+(0.0269)Ser+(0.0053)Pro+(−0.0021)V al+(−0.1536)Trp; 0.809,0.825, 0.752, 0.722, 0.742, 0.816, 0.807, 0. 772,(2.9319)+(0.0012)Gly+(0.0080)Gln+(−0.1625)His+(0.0435)I le; 0.809,0.825, 0.744, 0.720, 0.708, 0.814, 0.832, 0.769, (5.3081)+(−0.0979)His+(−0.0325)Val+(0.1336)Ile+(−0.0085)Leu; 0.809, 0. 830,0.792, 0.801, 0.785, 0.835, 0.753, 0.794, (3.7787)+(0.0271)Ser+(0.0014)Thr+(−0.0038)Ala+(−0.1437)Trp; 0.809, 0.831, 0.732, 0. 704,0.743, 0.830, 0.711, 0.747, (4.0471)+(0.0341)Ser+(−0.1364)His+(0.0276)Orn+(−0.0051)Lys; 0.809, 0.830, 0.797, 0.795, 0.820, 0. 812,0.742, 0.792, (6.7657)+(0.0118)Thr+(−0.0771)Cit+(0.0068)Pro+(−0.1612)Trp; 0.809, 0.829, 0.806, 0.812, 0.806, 0.834, 0.771, 0.806, (8.6863)+(−0.0109)Asn+(0.0030)Gly+(−0.0772)His+(−0.093 1)Trp;0.809, 0.830, 0.796, 0.788, 0.775, 0.815, 0.849, 0.807, (5.1510)+(−0.0079)Ala+(−0.0053)Tyr+(0.0676)Ile+(−0.1546)Trp; 0.80 9, 0.839,0.810, 0.817, 0.825, 0.763, 0.794, 0.799, (3.9502)+(−0.0169)Arg+(−0.0013)Leu+(0.0804)Phe+(−0.1672)Trp; 0.809, 0.833, 0. 801,0.817, 0.816, 0.813, 0.717, 0.791, (6.6421)+(0.0247)Thr+(0.0008)Val+(−0.1696)Met+(−0.1424)Trp; 0.809, 0.831, 0.804, 0.792, 0. 814,0.819, 0.801, 0.807, (8.4259)+(−0.0904)His+(0.0126)Tyr+(0.0071)Val+(−0.1097)Trp; 0.809, 0.832, 0.775, 0.782, 0.781, 0.810, 0. 721,0.774, (3.2415)+(0.0283)Ser+(0.0157)Orn+(−0.0073)Lys+(−0. 1466)Trp;0.809, 0.832, 0.762, 0.764, 0.770, 0.790, 0.723, 0.761, (3.0270)+(0.0281)Ser+(−0.0007)Gln+(0.0049)Pro+(−0.1559)Trp; 0.8 09, 0.832,0.810, 0.810, 0.814, 0.822, 0.795, 0.810, (8.3905)+(−0.0822)His+(−0.0596)Met+(0.0146)Lys+(−0.1023)Trp; 0.809, 0.829, 0. 731,0.695, 0.741, 0.822, 0.739, 0.749, (3.8159)+(0.0451)Ser+(−0.0632)Asn+(−0.1372)His+(0.0209)Leu; 0.809, 0.827, 0.761, 0.743, 0. 741,0.813, 0.810, 0.777, (3.4909)+(0.0084)Gln+(−0.1515)His+(−0.0270)Tyr+(0.0495)Ile; 0.809, 0.831, 0.815, 0.813, 0.830, 0.816, 0. 788,0.812, (5.0136)+(0.0051)Gln+(−0.0817)Cit+(0.0146)Leu+(−0. 1696)Trp;0.809, 0.829, 0.744, 0.725, 0.725, 0.780, 0.806, 0.759, (4.6402)+(−0.1371)His+(−0.0491)Tyr+(0.0390)Ile+(0.0786)Phe; 0.8 08, 0.830,0.732, 0.724, 0.724, 0.764, 0.744, 0.739, (4.3880)+(−0.1500)His+(0.0218)Thr+(−0.0566)Tyr+(0.1046)Phe; 0.808, 0.831, 0. 802,0.819, 0.820, 0.820, 0.704, 0.791, (7.1418)+(0.0288)Thr+(−0.0132)Arg+(−0.1612)Met+(−0.1394)Trp; 0.808, 0.830, 0.790, 0.789, 0.790,0.803, 0.787, 0.792,(3.6192)+(0.0384)Ser+(−0.0082)Gly+(−0.0002)Thr+(−0.1522)Trp; 0.808,0.830, 0.781, 0.779, 0.771, 0.8 22, 0.775, 0.787,(2.9611)+(0.0292)Ser+(−0.0056)Ala+(0.0171)Le u+(−0.1552)Trp; 0.808,0.831, 0.746, 0.722, 0.755, 0.839, 0.723, 0. 760,(4.4635)+(0.0392)Ser+(−0.0690)Asn+(−0.1235)His+(0.0287)Orn; 0.808,0.825, 0.724, 0.682, 0.730, 0.815, 0.757, 0.746, (3.2667)+(0.0444)Ser+(−0.0040)Gly+(−0.1508)His+(0.0189)Leu; 0.808, 0.823,0.717, 0.680, 0.717, 0.815, 0.746, 0.740,(3.3138)+(0.0383)Ser+(−0.1448)His+(−0.0176)Val+(0.0456)Leu; 0.808,0.828, 0.802, 0.794, 0.811, 0.818, 0.793, 0.804,(8.5804)+(0.0012)Asn+(−0.087 8)His+(0.0080)Val+(−0.1055)Trp; 0.808,0.826, 0.720, 0.679, 0.73 1, 0.821, 0.730, 0.740,(3.4087)+(0.0421)Ser+(−0.1472)His+(−0.0 090)Lys+(0.0248)Leu; 0.808,0.831, 0.794, 0.803, 0.787, 0.839, 0.7 53, 0.796,(3.8930)+(0.0288)Ser+(−0.0034)Ala+(−0.0026)Lys+(−0. 1398)Trp; 0.808,0.827, 0.815, 0.815, 0.829, 0.818, 0.783, 0.811, (8.0818)+(−0.0400)Asn+(−0.0653)Cit+(0.0090)Pro+(−0.1401)Trp; 0. 808, 0.831,0.794, 0.784, 0.795, 0.796, 0.815, 0.797, (5.6821)+(0.0029)Pro+(−0.1724)Met+(0.0626)Ile+(−0.1434)Trp; 0.808, 0.833, 0. 778,0.768, 0.782, 0.788, 0.789, 0.782, (3.0340)+(0.0387)Ser+(−0.0081)Gly+(0.0093)Leu+(−0.1623)Trp; 0.808, 0.830, 0.793, 0.785, 0. 822,0.804, 0.749, 0.790, (6.4457)+(0.0135)Thr+(−0.0795)Cit+(0.0150)Leu+(−0.1727)Trp; 0.808, 0.830, 0.802, 0.796, 0.808, 0.836, 0. 780,0.805, (8.1309)+(0.0032)Gly+(−0.0876)His+(0.0203)Tyr+(−0. 1020)Trp;0.808, 0.829, 0.795, 0.809, 0.793, 0.837, 0.732, 0.793, (4.2202)+(0.0312)Ser+(−0.0028)Ala+(−0.0153)Arg+(−0.1382)Trp; 0. 808, 0.827,0.747, 0.723, 0.711, 0.817, 0.836, 0.772, (5.4084)+(−0.0995)His+(−0.0018)Pro+(−0.0348)Val+(0.1296)Ile; 0.808, 0.827, 0.710,0.666, 0.721, 0.818, 0.724, 0.732,(2.9965)+(0.0366)Ser+(−0.1553)His+(0.0164)Orn+(0.0166)Leu; 0.808, 0.827,0.754, 0.722, 0.747, 0.815, 0.812, 0.774,(3.0101)+(0.0079)Gln+(−0.1632)His+(0.0081)Orn+(0.0404)Ile; 0.808, 0.828,0.837, 0.849, 0.840, 0.846, 0.794, 0.832,(5.5839)+(0.0060)Gln+(−0.0030)Ala+(−0.0710)Cit+(−0.1465)Trp; 0.808,0.825, 0.756, 0.728, 0.734, 0.836, 0.818, 0.77 9,(5.3494)+(0.0041)Gly+(−0.1269)His+(−0.0066)Ala+(0.0608)Il e; 0.808,0.828, 0.792, 0.782, 0.796, 0.798, 0.809, 0.796,(5.4986)+(−0.1707)Met+(0.0099)Orn+(0.0623)Ile+(−0.1436)Trp; 0.808, 0.831, 0.825, 0.841, 0.825, 0.824, 0.784, 0.819, (5.5542)+(−0.1088)Asn+(0.0056)Gln+(0.0151)Thr+(−0.1462)Trp; 0.808, 0.831, 0.796, 0. 806,0.786, 0.836, 0.759, 0.797, (3.5343)+(0.0265)Ser+(0.0009)Gln+(−0.0039)Ala+(−0.1440)Trp; 0.808, 0.830, 0.793, 0.794, 0.792, 0. 814,0.781, 0.795,(3.9816)+(0.0406)Ser+(−0.0084)Gly+(−0.0052)Lys+(−0.1450)Trp; 0.808,0.824, 0.742, 0.711, 0.728, 0.810, 0.801, 0.763,(5.1458)+(−0.1220)His+(0.0072)Thr+(0.1016)Ile+(−0.041 5)Leu; 0.808,0.832, 0.794, 0.797, 0.787, 0.849, 0.762, 0.799, (4.5995)+(0.0092)Gln+(−0.1364)His+(0.0221)Thr+(−0.1690)Met; 0.808, 0.831,0.801, 0.791, 0.780, 0.823, 0.853, 0.812, (5.4072)+(−0.0079)Ala+(−0.0051)Lys+(0.0704)Ile+(−0.1512)Trp; 0.807, 0.835, 0.7 56,0.749, 0.762, 0.850, 0.694, 0.764, (4.8062)+(0.0348)Ser+(−0.1177)His+(0.0181)Thr+(−0.1569)Met; 0.807, 0.832, 0.764, 0.762, 0. 769,0.797, 0.734, 0.766, (2.8281)+(0.0322)Ser+(−0.0098)Lys+(0.0160)Leu+(−0.1558)Trp; 0.807, 0.829, 0.797, 0.788, 0.799, 0.799, 0. 817,0.801, (5.8591)+(−0.0084)Asn+(−0.1562)Met+(0.0649)Ile+(−0.1427)Trp;0.807, 0.831, 0.815, 0.821, 0.831, 0.843, 0.747, 0.811,(7.3461)+(0.0173)Thr+(−0.0036)Ala+(−0.0701)Cit+(−0.1494)Tr p; 0.807,0.828, 0.771, 0.751, 0.763, 0.816, 0.807, 0.784,(2.0475)+(0.0097)Gln+(−0.1673)His+(−0.0421)Cit+(0.0760)Phe; 0.807, 0.826, 0.746, 0.721, 0.709, 0.815, 0.835, 0.770, (5.4947)+(−0.0969)His+(−0.0349)Val+(−0.0026)Lys+(0.1294)Ile; 0.807, 0.824, 0.757, 0. 746,0.751, 0.842, 0.736, 0.769, (3.0133)+(0.0294)Ser+(0.0066)Gln+(−0.1431)His+(−0.0360)Cit; 0.807, 0.830, 0.814, 0.818, 0.826, 0. 816,0.776, 0.809, (5.2929)+(0.0050)Gln+(−0.0816)Cit+(0.0074)Pro+(−0.1613)Trp; 0.807, 0.825, 0.747, 0.729, 0.707, 0.815, 0.829, 0.770, (5.7567)+(−0.0932)His+(−0.0208)Tyr+(−0.0340)Val+(0.131 0)Ile;0.807, 0.830, 0.790, 0.788, 0.790, 0.802, 0.786, 0.792, (3.6027)+(0.0383)Ser+(−0.0082)Gly+(0.0002)Val+(−0.1527)Trp; 0.807, 0.829,0.790, 0.782, 0.791, 0.799, 0.803, 0.794, (5.3784)+(0.0018)Gly+(−0.1712)Met+(0.0667)Ile+(−0.1429)Trp; 0.807, 0.826, 0.755, 0.740,0.731, 0.809, 0.807, 0.772, (5.8998)+(−0.1026)His+(−0.0278)Tyr+(0.1161)Ile+(−0.0460)Leu; 0.807, 0.829, 0.772, 0.782, 0.77 4,0.806, 0.714, 0.769, (3.2676)+(0.0258)Ser+(−0.0144)Tyr+(0.0142)Orn+(−0.1491)Trp; 0.807, 0.829, 0.776, 0.781, 0.779, 0.806, 0.7 36,0.775, (2.8373)+(0.0286)Ser+(−0.0055)Thr+(0.0138)Orn+(−0. 1513)Trp;0.807, 0.831, 0.806, 0.810, 0.813, 0.840, 0.753, 0.804, (8.7794)+(0.0040)Gly+(−0.0687)His+(−0.0364)Cit+(−0.0982)Trp; 0. 807, 0.831,0.759, 0.757, 0.767, 0.783, 0.731, 0.759, (2.4883)+(0.0274)Ser+(0.0033)Pro+(0.0077)Leu+(−0.1642)Trp; 0.807, 0.829, 0. 743,0.709, 0.733, 0.816, 0.804, 0.766, (5.0254)+(−0.1197)His+(0.0212)Orn+(0.1025)Ile+(−0.0454)Leu; 0.807, 0.831, 0.775, 0.782, 0. 781,0.802, 0.724, 0.772, (3.0725)+(0.0254)Ser+(−0.0019)Val+(0.0126)Orn+(−0.1525)Trp; 0.807, 0.823, 0.760, 0.729, 0.755, 0.818, 0. 812,0.778, (3.0007)+(0.0094)Gln+(−0.1544)His+(−0.0459)Cit+(0. 0473)Ile;0.807, 0.827, 0.736, 0.712, 0.752, 0.833, 0.696, 0.748, (4.2235)+(0.0363)Ser+(−0.1345)His+(−0.0183)Arg+(0.0296)Orn; 0.8 07, 0.828,0.739, 0.718, 0.744, 0.829, 0.724, 0.754, (4.3549)+(0.0427)Ser+(−0.0662)Asn+(−0.1212)His+(0.0078)Pro; 0.807, 0.833, 0. 779,0.788, 0.791, 0.817, 0.700, 0.774, (3.5973)+(0.0299)Ser+(−0.0224)Arg+(0.0192)Orn+(−0.1488)Trp; 0.806, 0.831, 0.792, 0.791, 0. 791,0.804, 0.788, 0.794, (3.4870)+(0.0377)Ser+(−0.0083)Gly+(0.0005)Gln+(−0.1533)Trp; 0.806, 0.827, 0.762, 0.725, 0.747, 0.836, 0. 836,0.786, (5.6514)+(−0.1284)His+(−0.0068)Ala+(0.0226)Orn+(0. 0522)Ile;0.806, 0.831, 0.799, 0.782, 0.808, 0.817, 0.812, 0.805, (8.5247)+(−0.0884)His+(−0.0400)Met+(0.0255)Leu+(−0.1078)Trp; 0. 806, 0.828,0.718, 0.684, 0.728, 0.822, 0.712, 0.737, (3.4414)+(0.0340)Ser+(−0.1439)His+(0.0048)Pro+(0.0207)Orn; 0.806, 0.830, 0. 802,0.796, 0.807, 0.817, 0.798, 0.805, (8.0929)+(−0.0900)His+(0.0105)Tyr+(0.0098)Lys+(−0.1081)Trp; 0.806, 0.827, 0.779, 0.787, 0. 782,0.813, 0.725, 0.777, (3.5121)+(0.0289)Ser+(0.0004)Thr+(−0.0049)Lys+(−0.1460)Trp; 0.806, 0.825, 0.755, 0.748, 0.743, 0.837, 0. 743,0.768, (3.0494)+(0.0282)Ser+(0.0060)Gln+(−0.1469)His+(−0. 0065)Tyr;0.806, 0.823, 0.709, 0.666, 0.719, 0.813, 0.726, 0.731, (2.9629)+(0.0389)Ser+(−0.1532)His+(0.0033)Pro+(0.0174)Leu; 0.80 6, 0.830,0.791, 0.794, 0.788, 0.807, 0.779, 0.792, (3.9719)+(0.0389)Ser+(−0.0084)Gly+(−0.0115)Tyr+(−0.1460)Trp; 0.806, 0.826, 0. 804,0.807, 0.827, 0.825, 0.733, 0.798, (6.9470)+(0.0003)Gly+(0.0144)Thr+(−0.0725)Cit+(−0.1571)Trp; 0.806, 0.823, 0.733, 0.702, 0. 735,0.822, 0.749, 0.752, (3.8136)+(0.0430)Ser+(−0.0047)Gly+(−0.1366)His+(0.0063)Pro; 0.806, 0.823, 0.746, 0.720, 0.715, 0.820, 0. 827,0.770, (5.6289)+(−0.0914)His+(−0.0344)Cit+(−0.0350)Val+(0.1308)Ile;0.806, 0.827, 0.778, 0.771, 0.777, 0.768, 0.809, 0.781,(3.5241)+(0.0020)Gln+(−0.0020)Orn+(0.0489)Ile+(−0.1762)Trp; 0.806,0.827, 0.797, 0.779, 0.813, 0.817, 0.800, 0.802,(8.6915)+(−0.0810)His+(−0.0365)Cit+(0.0254)Leu+(−0.1175)Trp; 0.806, 0.838, 0.809, 0.815, 0.825, 0.762, 0.794, 0.799, (3.9508)+(−0.0166)Arg+(−0.0005)Lys+(0.0795)Phe+(−0.1678)Trp; 0.806, 0.828, 0.777, 0. 779,0.766, 0.773, 0.798, 0.779, (3.9166)+(0.0024)Gln+(−0.0244)Tyr+(0.0522)Ile+(−0.1656)Trp; 0.806, 0.831, 0.769, 0.772, 0.777, 0. 801,0.720, 0.767, (3.0920)+(0.0268)Ser+(−0.0007)Gln+(0.0117)Orn+(−0.1544)Trp; 0.806, 0.835, 0.801, 0.816, 0.804, 0.760, 0.780, 0.790, (4.0243)+(−0.0135)Arg+(−0.0287)Tyr+(0.0939)Phe+(−0.158 0)Trp;0.806, 0.830, 0.794, 0.802, 0.786, 0.835, 0.757, 0.795, (3.7298)+(0.0278)Ser+(−0.0038)Ala+(0.0015)Tyr+(−0.1432)Trp; 0.806, 0.829,0.802, 0.793, 0.811, 0.818, 0.796, 0.805, (8.5338)+(−0.0882)His+(0.0015)Arg+(0.0080)Val+(−0.1058)Trp; 0.806, 0.834, 0.74 2, 0.733,0.714, 0.839, 0.754, 0.760, (−0.5532)+(0.0402)Ser+(−0.3095)Met+(0.1705)Ile+(−0.0749)Leu; 0.806, 0.828, 0.792, 0.782, 0. 793,0.793, 0.815, 0.796, (5.6139)+(−0.0593)Asn+(0.0086)Orn+(0.0471)Ile+(−0.1553)Trp; 0.806, 0.828, 0.723, 0.690, 0.734, 0.822, 0. 715,0.740, (3.5910)+(0.0339)Ser+(−0.1449)His+(0.0023)Val+(0. 0222)Orn;0.806, 0.821, 0.738, 0.708, 0.741, 0.824, 0.750, 0.756, (3.8853)+(0.0430)Ser+(−0.0044)Gly+(−0.1400)His+(0.0045)Val; 0.8 06, 0.827,0.777, 0.788, 0.778, 0.810, 0.725, 0.775, (3.4438)+(0.0277)Ser+(−0.0008)Thr+(−0.0079)Tyr+(−0.1476)Trp; 0.805, 0.828, 0. 806,0.810, 0.829, 0.830, 0.733, 0.800, (7.1581)+(0.0157)Thr+(−0.0719)Cit+(−0.0023)Lys+(−0.1552)Trp; 0.805, 0.829, 0.800, 0.794, 0.784,0.817, 0.842, 0.809,(5.5251)+(−0.0077)Ala+(−0.0104)Arg+(0.0683)Ile+(−0.1526)Trp; 0.805,0.828, 0.813, 0.814, 0.829, 0.81 8, 0.773, 0.809,(7.7121)+(−0.0607)Cit+(0.0108)Pro+(−0.0833)Me t+(−0.1355)Trp; 0.805,0.829, 0.789, 0.796, 0.782, 0.831, 0.756, 0. 791,(3.5070)+(0.0282)Ser+(−0.0043)Ala+(0.0031)Val+(−0.1469) Trp; 0.805,0.828, 0.794, 0.785, 0.795, 0.798, 0.814, 0.798, (5.6131)+(−0.1691)Met+(0.0017)Lys+(0.0647)Ile+(−0.1449)Trp; 0.805, 0.829,0.788, 0.788, 0.784, 0.793, 0.790, 0.789, (5.1604)+(−0.0270)Val+(0.0218)Orn+(0.0479)Leu+(−0.1519)Trp; 0.805, 0.825, 0.81 1, 0.814,0.811, 0.827, 0.789, 0.810, (8.9674)+(−0.0058)Asn+(−0.0747)His+(0.0000)Ala+(−0.0944)Trp; 0.805, 0.827, 0.828, 0.838, 0. 839,0.831, 0.779, 0.822, (5.4327)+(0.0057)Gln+(−0.0742)Cit+(−0.0010)Lys+(−0.1532)Trp; 0.805, 0.826, 0.801, 0.801, 0.828, 0.816, 0. 734,0.795, (6.8094)+(0.0138)Thr+(−0.0759)Cit+(0.0033)Val+(−0. 1631)Trp;0.805, 0.828, 0.776, 0.783, 0.780, 0.810, 0.725, 0.774, (3.3635)+(0.0296)Ser+(0.0018)Val+(−0.0057)Lys+(−0.1480)Trp; 0.8 05, 0.826,0.798, 0.789, 0.819, 0.797, 0.779, 0.796, (6.7541)+(−0.0761)Cit+(0.0066)Pro+(0.0126)Leu+(−0.1622)Trp; 0.805, 0.828, 0. 781,0.790, 0.783, 0.815, 0.729, 0.779, (3.3702)+(0.0284)Ser+(0.0005)Gln+(−0.0051)Lys+(−0.1464)Trp; 0.805, 0.829, 0.766, 0.766, 0. 771,0.790, 0.741, 0.767, (2.5362)+(0.0301)Ser+(−0.0043)Thr+(0.0108)Leu+(−0.1599)Trp; 0.805, 0.830, 0.844, 0.863, 0.837, 0.842, 0. 812,0.838, (5.2885)+(−0.0564)Asn+(0.0076)Gln+(−0.0913)Met+(−0.1317)Trp;0.805, 0.830, 0.803, 0.808, 0.804, 0.832, 0.770, 0.803,(8.5141)+(0.0027)Gly+(−0.0799)His+(0.0001)Arg+(−0.0941)Trp; 0.805,0.826, 0.826, 0.835, 0.836, 0.830, 0.775, 0.819, (5.3574)+(0.0004)Gly+(0.0055)Gln+(−0.0749)Cit+(−0.1543)Trp; 0.805, 0.829, 0.778,0.755, 0.788, 0.807, 0.801, 0.788,(4.3758)+(−0.1254)His+(−0.1794)Met+(0.0247)Orn+(0.1050)Phe; 0.805,0.828, 0.728, 0.69 8, 0.737, 0.828, 0.717, 0.745,(3.7556)+(0.0336)Ser+(−0.1402)His +(−0.0014)Thr+(0.0251)Orn; 0.805,0.823, 0.712, 0.673, 0.722, 0.8 13, 0.724, 0.733,(3.1098)+(0.0383)Ser+(−0.1539)His+(0.0014)Th r+(0.0196)Leu; 0.805,0.822, 0.793, 0.778, 0.786, 0.835, 0.820, 0.8 05,(4.0394)+(−0.0611)Asn+(0.0114)Gln+(−0.1504)His+(0.0132)L eu; 0.804,0.824, 0.759, 0.732, 0.745, 0.817, 0.821, 0.779, (5.7670)+(−0.0218)Asn+(−0.1057)His+(0.1096)Ile+(−0.0464)Leu; 0.804, 0. 828,0.782, 0.775, 0.781, 0.768, 0.813, 0.784, (3.6405)+(−0.0012)Gly+(0.0021)Gln+(0.0476)Ile+(−0.1760)Trp; 0.804, 0.827, 0.778, 0. 790,0.790, 0.813, 0.696, 0.772, (3.9836)+(0.0292)Ser+(0.0049)Thr+(−0.0204)Arg+(−0.1485)Trp; 0.804, 0.825, 0.737, 0.709, 0.742, 0. 780,0.769, 0.750,(4.6210)+(−0.1532)His+(0.0179)Thr+(−0.0086)Lys+(0.0790)Phe; 0.804,0.825, 0.806, 0.797, 0.823, 0.818, 0.789, 0. 807,(8.9569)+(−0.0754)His+(−0.0377)Cit+(0.0092)Val+(−0.112 2)Trp; 0.804,0.821, 0.739, 0.711, 0.723, 0.814, 0.790, 0.760, (4.8848)+(0.0031)Gly+(−0.1178)His+(0.1065)Ile+(−0.0430)Leu; 0.804, 0.828,0.775, 0.767, 0.775, 0.767, 0.803, 0.778,(3.5135)+(0.0017)Gln+(0.0016)Thr+(0.0477)Ile+(−0.1771)Trp; 0.804, 0.831,0.806, 0.811, 0.807, 0.834, 0.770, 0.806, (8.5901)+(0.0029)Gly+(−0.0776)His+(−0.0143)Met+(−0.0927)Trp; 0.804, 0.826, 0.813, 0.807, 0.8 15,0.836, 0.805, 0.816, (8.6540)+(−0.0811)His+(−0.0012)Ala+(0.0209)Tyr+(−0.1020)Trp; 0.804, 0.822, 0.740, 0.717, 0.738, 0.838, 0. 738,0.758, (3.8950)+(0.0378)Ser+(−0.1383)His+(−0.0034)Ala+(0. 0075)Val;0.804, 0.830, 0.800, 0.786, 0.805, 0.804, 0.823, 0.805, (5.5396)+(0.0151)Tyr+(−0.1889)Met+(0.0648)Ile+(−0.1468)Trp; 0.8 04, 0.830,0.763, 0.762, 0.772, 0.789, 0.729, 0.763, (2.5017)+(0.0268)Ser+(0.0069)Orn+(0.0083)Leu+(−0.1635)Trp; 0.804, 0.827, 0.7 64,0.763, 0.757, 0.767, 0.777, 0.766, (4.5967)+(0.0074)Thr+(−0.0274)Tyr+(0.0525)Ile+(−0.1651)Trp; 0.804, 0.819, 0.718, 0.687, 0. 725,0.816, 0.715, 0.736, (3.4756)+(0.0371)Ser+(−0.1430)His+(0.0055)Pro+(0.0029)Val; 0.804, 0.822, 0.793, 0.790, 0.782, 0.842, 0. 793,0.801, (4.7632)+(−0.0783)Asn+(0.0102)Gln+(−0.1415)His+(0. 0133)Thr;0.804, 0.828, 0.797, 0.784, 0.790, 0.841, 0.814, 0.807, (3.6372)+(0.0114)Gln+(−0.1481)His+(−0.1400)Met+(0.0212)Leu; 0.8 04, 0.825,0.746, 0.731, 0.748, 0.838, 0.715, 0.758, (4.9208)+(0.0385)Ser+(−0.0688)Asn+(−0.1209)His+(0.0090)Thr; 0.804, 0.828, 0. 778,0.790, 0.777, 0.807, 0.725, 0.775, (3.3878)+(0.0269)Ser+(0.0003)Gln+(−0.0089)Tyr+(−0.1484)Trp; 0.804, 0.826, 0.803, 0.808, 0. 825,0.823, 0.729, 0.796, (7.0519)+(0.0152)Thr+(−0.0713)Cit+(−0.0043)Tyr+(−0.1554)Trp; 0.804, 0.826, 0.820, 0.825, 0.835, 0.822, 0. 775,0.814, (5.1891)+(0.0054)Gln+(−0.0796)Cit+(0.0041)Val+(−0. 1625)Trp;0.804, 0.825, 0.802, 0.813, 0.810, 0.803, 0.757, 0.796, (6.8961)+(−0.0843)Asn+(0.0163)Thr+(0.0043)Pro+(−0.1438)Trp; 0.8 04, 0.820,0.736, 0.729, 0.646, 0.849, 0.860, 0.771, (0.3125)+(0.0208)Ser+(−0.0116)Ala+(−0.0520)Val+(0.1708)Ile; 0.804, 0.828, 0. 779,0.789, 0.781, 0.815, 0.721, 0.777, (3.6205)+(0.0289)Ser+(−0.0050)Tyr+(−0.0041)Lys+(−0.1440)Trp; 0.804, 0.827, 0.790, 0.781, 0.788,0.792, 0.812, 0.793,(5.5169)+(−0.0584)Asn+(0.0014)Gly+(0.0508)Ile+(−0.1551)Trp; 0.804,0.826, 0.753, 0.763, 0.754, 0.78 2, 0.707, 0.751,(−2.7237)+(0.0542)Ser+(−0.0949)Asn+(−0.3071)M et+(0.1089)Phe; 0.803,0.821, 0.767, 0.735, 0.745, 0.833, 0.848, 0. 790,(5.8863)+(−0.1211)His+(−0.0075)Ala+(0.0039)Pro+(0.0547)Ile; 0.803,0.819, 0.722, 0.695, 0.726, 0.820, 0.713, 0.738, (3.6668)+(0.0367)Ser+(−0.1378)His+(−0.0005)Thr+(0.0065)Pro; 0.803, 0.827,0.775, 0.786, 0.775, 0.805, 0.723, 0.772,(3.3948)+(0.0274)Ser+(−0.0093)Tyr+(0.0008)Val+(−0.1492)Trp; 0.803,0.827, 0.778, 0.786, 0.779, 0.805, 0.733, 0.776,(3.1455)+(0.0282)Ser+(0.0002)Gln+(−0.0025)Thr+(−0.1505)Trp; 0.803,0.821, 0.718, 0.678, 0.719, 0.787, 0.774, 0.740,(3.3468)+(0.0050)Gly+(−0.1532)His+(0.033 7)Ile+(0.0562)Phe; 0.803,0.821, 0.731, 0.703, 0.739, 0.828, 0.717, 0.747,(3.8861)+(0.0385)Ser+(−0.1400)His+(0.0063)Val+(−0.004 3)Lys; 0.803,0.824, 0.792, 0.781, 0.784, 0.841, 0.800, 0.802, (4.3829)+(−0.0626)Asn+(0.0102)Gln+(−0.1414)His+(0.0227)Orn; 0.803, 0.821,0.745, 0.724, 0.750, 0.832, 0.727, 0.758,(4.4239)+(0.0422)Ser+(−0.0562)Asn+(−0.1259)His+(0.0045)Val; 0.803,0.827, 0.811, 0.805, 0.815, 0.830, 0.801, 0.813,(8.7447)+(−0.0101)Asn+(−0.079 9)His+(0.0191)Tyr+(−0.1021)Trp; 0.803,0.821, 0.721, 0.686, 0.73 4, 0.818, 0.715, 0.738,(3.5066)+(0.0420)Ser+(−0.1462)His+(−0.0 141)Arg+(0.0198)Leu; 0.803,0.824, 0.756, 0.730, 0.737, 0.819, 0.8 19, 0.776,(5.4911)+(−0.1122)His+(−0.0033)Pro+(0.1143)Ile+(−0. 0465)Leu; 0.803,0.821, 0.757, 0.739, 0.747, 0.843, 0.764, 0.773, (4.5186)+(0.0422)Ser+(−0.0047)Gly+(−0.1256)His+(−0.0019)Ala; 0. 803, 0.825,0.793, 0.784, 0.792, 0.792, 0.820, 0.797, (5.7215)+(−0.0545)Asn+(−0.0004)Pro+(0.0508)Ile+(−0.1555)Trp; 0.803, 0.822, 0.748,0.727, 0.715, 0.817, 0.825, 0.771,(5.9235)+(−0.0906)His+(−0.0137)Arg+(−0.0375)Val+(0.1359)Ile; 0.803,0.828, 0.817, 0.8 34, 0.812, 0.812, 0.787, 0.811,(4.7049)+(0.0058)Gln+(0.0089)Pro +(−0.1649)Met+(−0.1355)Trp; 0.803,0.826, 0.788, 0.794, 0.808, 0. 796, 0.729, 0.782,(5.9811)+(0.0259)Thr+(−0.2020)Met+(0.0171)L eu+(−0.1511)Trp; 0.803,0.827, 0.777, 0.784, 0.779, 0.804, 0.732, 0. 775,(3.1557)+(0.0285)Ser+(−0.0025)Thr+(0.0004)Val+(−0.1509)Trp; 0.803,0.827, 0.806, 0.799, 0.813, 0.821, 0.796, 0.807, (8.7196)+(−0.0843)His+(0.0083)Val+(−0.0221)Met+(−0.1036)Trp; 0.803, 0.821,0.743, 0.719, 0.741, 0.828, 0.750, 0.759,(4.2903)+(0.0407)Ser+(−0.0049)Gly+(−0.1344)His+(0.0042)Thr; 0.803,0.827, 0.806, 0.804, 0.815, 0.823, 0.782, 0.806,(8.5235)+(−0.0772)His+(−0.029 7)Cit+(0.0107)Lys+(−0.1074)Trp; 0.803,0.822, 0.759, 0.747, 0.75 5, 0.845, 0.735, 0.770,(4.9822)+(0.0408)Ser+(−0.0558)Asn+(−0.1 136)His+(−0.0013)Ala; 0.803,0.829, 0.829, 0.842, 0.828, 0.825, 0. 802, 0.824,(5.1398)+(−0.0902)Asn+(0.0057)Gln+(0.0178)Orn+(−0. 1401)Trp; 0.803,0.825, 0.727, 0.692, 0.753, 0.833, 0.691, 0.742, (3.9437)+(0.0338)Ser+(−0.1318)His+(−0.0643)Cit+(0.0430)Orn; 0.8 03, 0.824,0.796, 0.795, 0.816, 0.811, 0.743, 0.791, (6.7942)+(0.0025)Gly+(−0.0756)Cit+(0.0086)Pro+(−0.1510)Trp; 0.803, 0.828, 0. 788,0.803, 0.794, 0.818, 0.712, 0.782, (3.4831)+(0.0292)Ser+(0.0017)Gln+(−0.0197)Arg+(−0.1474)Trp; 0.803, 0.825, 0.801, 0.801, 0. 806,0.810, 0.784, 0.800, (8.4039)+(−0.0867)His+(−0.0069)Arg+(0.0126)Lys+(−0.1045)Trp; 0.803, 0.824, 0.761, 0.744, 0.758, 0.838, 0. 758,0.774, (4.9336)+(0.0467)Ser+(−0.0558)Asn+(−0.0042)Gly+(−0.1154)His;0.803, 0.822, 0.726, 0.700, 0.730, 0.823, 0.715, 0.742,(3.8546)+(0.0374)Ser+(−0.1345)His+(0.0068)Pro+(−0.0033)Lys; 0.803,0.827, 0.829, 0.843, 0.824, 0.819, 0.809, 0.824,(5.1932)+(−0.0885)Asn+(0.0062)Gln+(0.0050)Pro+(−0.1413)Trp; 0.803,0.829, 0.730, 0.709, 0.737, 0.826, 0.706, 0.744,(4.0882)+(0.0323)Ser+(−0.1352)His+(−0.0147)Tyr+(0.0285)Orn; 0.803,0.830, 0.746, 0.733, 0.737, 0.785, 0.773, 0.757,(4.5795)+(−0.1375)His+(−0.0471)Tyr+(0.0290)Orn+(0.0905)Phe; 0.803,0.829, 0.796, 0.800, 0.799, 0.815, 0.765, 0.795,(4.3066)+(0.0418)Ser+(−0.0080)Gly+(−0.0169)Arg+(−0.1455)Trp; 0.803,0.826, 0.811, 0.814, 0.811, 0.827, 0.792, 0.81 1,(8.9100)+(−0.0074)Asn+(−0.0751)His+(0.0019)Arg+(−0.0948)T rp; 0.803,0.824, 0.745, 0.716, 0.753, 0.780, 0.779, 0.757, (4.9500)+(−0.0613)Asn+(−0.1456)His+(0.0202)Thr+(0.0768)Phe; 0.803, 0. 820,0.727, 0.702, 0.718, 0.788, 0.769, 0.744, (5.7341)+(−0.1368)His+(0.0165)Thr+(−0.0366)Tyr+(0.0524)Ile; 0.802, 0.824, 0.815, 0. 811,0.825, 0.817, 0.802, 0.814,(7.2581)+(−0.0042)Ala+(−0.0693)Cit+(0.0214)Leu+(−0.1523)Trp; 0.802,0.820, 0.750, 0.729, 0.746, 0.834, 0.755, 0.766,(4.4427)+(0.0428)Ser+(−0.0049)Gly+(−0.128 3)His+(−0.0020)Lys; 0.802,0.829, 0.748, 0.729, 0.757, 0.836, 0.71 6, 0.760,(3.9412)+(0.0435)Ser+(−0.1262)His+(0.0089)Val+(−0.1 253)Met; 0.802,0.827, 0.790, 0.791, 0.784, 0.786, 0.804, 0.791, (5.4591)+(0.0052)Pro+(−0.0246)Val+(0.0457)Leu+(−0.1523)Trp; 0.8 02, 0.825,0.780, 0.791, 0.789, 0.813, 0.705, 0.775, (3.7700)+(0.0314)Ser+(−0.0181)Arg+(0.0012)Val+(−0.1470)Trp; 0.802, 0.824, 0. 809,0.824, 0.817, 0.815, 0.749, 0.801, (7.3471)+(−0.0828)Asn+(0.0189)Thr+(−0.0027)Val+(−0.1379)Trp; 0.802, 0.823, 0.803, 0.800, 0.823,0.805, 0.766, 0.799,(7.0482)+(−0.0731)Cit+(0.0079)Pro+(0.0020)Val+(−0.1536)Trp; 0.802,0.820, 0.820, 0.824, 0.832, 0.82 5, 0.783, 0.816,(7.5701)+(−0.0033)Ala+(−0.0679)Cit+(0.0067)Va l+(−0.1453)Trp; 0.802,0.829, 0.789, 0.783, 0.785, 0.786, 0.813, 0. 792,(3.8693)+(0.0029)Gln+(−0.0101)Lys+(0.0551)Ile+(−0.1666)Trp; 0.802,0.827, 0.793, 0.786, 0.786, 0.844, 0.789, 0.801, (4.1831)+(0.0096)Gln+(−0.1379)His+(−0.1094)Met+(0.0258)Orn; 0.802, 0.829,0.760, 0.758, 0.768, 0.787, 0.730, 0.761,(2.7470)+(0.0287)Ser+(−0.0007)Gln+(0.0103)Leu+(−0.1621)Trp; 0.802,0.826, 0.772, 0.760, 0.776, 0.766, 0.802, 0.776,(4.2587)+(−0.0011)Gly+(0.004 4)Thr+(0.0478)Ile+(−0.1749)Trp; 0.802,0.825, 0.810, 0.813, 0.81 2, 0.826, 0.787, 0.810,(8.9054)+(−0.0749)His+(0.0001)Ala+(−0.0 091)Met+(−0.0942)Trp; 0.802,0.823, 0.816, 0.830, 0.816, 0.830, 0. 767, 0.811,(7.4091)+(−0.0752)Asn+(0.0199)Thr+(−0.0033)Ala+(−0.1380)Trp; 0.802,0.822, 0.782, 0.772, 0.768, 0.840, 0.796, 0.794,(4.2396)+(0.0081)Gln+(−0.1461)His+(−0.0034)Ala+(0.0246)Orn; 0.802,0.819, 0.743, 0.728, 0.736, 0.842, 0.724, 0.757, (4.3920)+(0.0337)Ser+(−0.1305)His+(0.0049)Thr+(−0.0022)Ala; 0.802, 0.827, 0.795,0.786, 0.797, 0.800, 0.813, 0.799,(5.7694)+(−0.0019)Arg+(−0.1610)Met+(0.0656)Ile+(−0.1431)Trp; 0.802,0.826, 0.764, 0.7 56, 0.764, 0.852, 0.722, 0.773,(4.9352)+(0.0419)Ser+(−0.0371)As n+(−0.1085)His+(−0.0702)Met; 0.802,0.825, 0.770, 0.758, 0.773, 0. 765, 0.797, 0.773,(4.1099)+(0.0037)Thr+(−0.0011)Orn+(0.0487)I le+(−0.1747)Trp; 0.802,0.823, 0.818, 0.829, 0.831, 0.837, 0.751, 0. 812,(8.0816)+(−0.0409)Asn+(0.0034)Gly+(−0.0628)Cit+(−0.131 5)Trp; 0.802,0.826, 0.810, 0.812, 0.810, 0.827, 0.789, 0.810, (8.8185)+(−0.0766)His+(−0.0001)Ala+(0.0012)Arg+(−0.0950)Trp; 0.80 2, 0.823,0.769, 0.766, 0.764, 0.767, 0.790, 0.772, (4.7063)+(−0.0235)Tyr+(0.0060)Orn+(0.0517)Ile+(−0.1608)Trp; 0.802, 0.826, 0.7 83,0.784, 0.779, 0.791, 0.779, 0.783, (5.2381)+(0.0101)Thr+(−0.0254)Val+(0.0483)Leu+(−0.1597)Trp; 0.802, 0.828, 0.770, 0.773, 0. 783,0.799, 0.712, 0.767, (3.2251)+(0.0323)Ser+(−0.0195)Arg+(0.0120)Leu+(−0.1570)Trp; 0.802, 0.829, 0.763, 0.739, 0.753, 0.818, 0. 808,0.780, (4.5620)+(−0.1380)His+(−0.0050)Ala+(0.0252)Orn+(0. 0724)Phe;0.802, 0.826, 0.805, 0.815, 0.815, 0.806, 0.754, 0.798, (6.7049)+(−0.0856)Asn+(0.0148)Thr+(0.0168)Orn+(−0.1426)Trp; 0.8 02, 0.822,0.722, 0.676, 0.726, 0.779, 0.793, 0.743, (3.8819)+(−0.1579)His+(0.0122)Thr+(0.0301)Ile+(0.0507)Phe; 0.802, 0.821, 0.7 71,0.739, 0.751, 0.837, 0.848, 0.794, (6.1476)+(−0.0081)Asn+(−0.1200)His+(−0.0064)Ala+(0.0579)Ile; 0.802, 0.822, 0.800, 0.810, 0. 787,0.815, 0.792, 0.801, (5.6100)+(−0.0071)Ala+(0.0093)Pro+(0.0187)Orn+(−0.1406)Trp; 0.802, 0.820, 0.811, 0.812, 0.792, 0.854, 0. 820,0.819, (4.7431)+(−0.0558)Asn+(0.0112)Gln+(−0.1340)His+(−0.0018)Ala;0.802, 0.829, 0.763, 0.766, 0.768, 0.786, 0.728, 0.762,(2.8994)+(0.0282)Ser+(−0.0145)Tyr+(0.0120)Leu+(−0.1575)Trp; 0.802,0.822, 0.775, 0.762, 0.778, 0.766, 0.807, 0.778,(4.3096)+(−0.0005)Gly+(0.0016)Orn+(0.0487)Ile+(−0.1714)Trp; 0.802,0.821, 0.715, 0.681, 0.721, 0.809, 0.723, 0.733,(3.4061)+(0.0390)Ser+(−0.1472)His+(−0.0156)Tyr+(0.0220)Leu; 0.802,0.827, 0.780, 0.774, 0.778, 0.771, 0.809, 0.783,(3.5339)+(0.0020)Gln+(−0.0025)Pro+(0.0511)Ile+(−0.1754)Trp; 0.801,0.827, 0.827, 0.836, 0.837, 0.83 0, 0.778, 0.820,(5.3899)+(0.0055)Gln+(−0.0743)Cit+(−0.0001)Ty r+(−0.1543)Trp; 0.801,0.827, 0.793, 0.783, 0.792, 0.794, 0.821, 0. 798,(5.7796)+(−0.0505)Asn+(−0.0023)Lys+(0.0519)Ile+(−0.154 0)Trp; 0.801,0.825, 0.789, 0.785, 0.783, 0.789, 0.813, 0.793, (5.9106)+(−0.0486)Asn+(−0.0142)Tyr+(0.0530)Ile+(−0.1505)Trp; 0.80 1, 0.827,0.828, 0.838, 0.839, 0.830, 0.775, 0.820, (5.4297)+(0.0059)Gln+(−0.0715)Cit+(−0.0043)Arg+(−0.1532)Trp; 0.801, 0.826, 0. 782,0.794, 0.790, 0.816, 0.706, 0.777, (3.8862)+(0.0312)Ser+(−0.0178)Arg+(0.0001)Lys+(−0.1449)Trp; 0.801, 0.820, 0.801, 0.797, 0. 789,0.842, 0.809, 0.809, (4.4220)+(−0.0579)Asn+(0.0113)Gln+(−0.1416)His+(0.0018)Val; 0.801, 0.828, 0.774, 0.782, 0.778, 0.801, 0. 726,0.772, (3.2066)+(0.0272)Ser+(−0.0000)Gln+(−0.0000)Val+(−0.1524)Trp;0.801, 0.820, 0.786, 0.770, 0.769, 0.840, 0.823, 0.801,(3.8574)+(0.0094)Gln+(−0.1553)His+(−0.0041)Ala+(0.0170)Leu; 0.801,0.826, 0.805, 0.809, 0.829, 0.826, 0.727, 0.798, (7.1633)+(0.0164)Thr+(−0.0679)Cit+(−0.0064)Arg+(−0.1564)Trp; 0.801, 0.821, 0.807,0.811, 0.790, 0.851, 0.801, 0.813,(4.3833)+(0.0108)Gln+(−0.1339)His+(−0.0005)Ala+(−0.0924)Met; 0.801,0.829, 0.710, 0.69 0, 0.711, 0.769, 0.716, 0.722,(−5.2379)+(0.0523)Ser+(−0.4475)Me t+(0.0549)Ile+(0.0871)Phe; 0.801,0.821, 0.770, 0.739, 0.748, 0.8 38, 0.846, 0.793,(6.0890)+(−0.1204)His+(−0.0065)Ala+(−0.0017)Lys+(0.0592)Ile; 0.801,0.825, 0.811, 0.815, 0.811, 0.828, 0.789, 0. 811,(8.9760)+(−0.0046)Asn+(−0.0741)His+(−0.0051)Met+(−0.094 0)Trp; 0.801,0.818, 0.765, 0.762, 0.694, 0.839, 0.868, 0.791, (3.7346)+(−0.0093)Ala+(−0.0220)Arg+(−0.0546)Val+(0.1810)Ile; 0.80 1, 0.821,0.732, 0.692, 0.733, 0.803, 0.788, 0.754, (5.5649)+(−0.1403)His+(0.0148)Thr+(−0.0077)Lys+(0.0482)Ile; 0.801, 0.819, 0.7 22,0.704, 0.721, 0.818, 0.704, 0.737, (3.9411)+(0.0364)Ser+(−0.1312)His+(0.0082)Pro+(−0.0163)Tyr; 0.801, 0.824, 0.846, 0.863, 0. 832,0.848, 0.826, 0.842, (5.4530)+(−0.0767)Asn+(0.0068)Gln+(−0.0027)Ala+(−0.1339)Trp; 0.801, 0.829, 0.772, 0.758, 0.775, 0.781, 0. 794,0.777, (4.6947)+(0.0083)Thr+(−0.0107)Lys+(0.0549)Ile+(−0. 1663)Trp;0.801, 0.825, 0.804, 0.798, 0.814, 0.807, 0.798, 0.804, (6.9437)+(−0.0646)Cit+(−0.0165)Val+(0.0426)Leu+(−0.1550)Trp; 0. 801, 0.822,0.750, 0.723, 0.734, 0.813, 0.813, 0.771, (5.3817)+(−0.1127)His+(−0.0004)Lys+(0.1081)Ile+(−0.0452)Leu; 0.801, 0.826, 0.782,0.795, 0.790, 0.816, 0.705, 0.777,(3.9043)+(0.0312)Ser+(−0.0177)Arg+(−0.0006)Tyr+(−0.1445)Trp; 0.801,0.826, 0.759, 0.75 2, 0.759, 0.849, 0.716, 0.769,(4.6196)+(0.0395)Ser+(−0.1138)His +(0.0001)Ala+(−0.0979)Met; 0.801,0.820, 0.754, 0.740, 0.737, 0.8 17, 0.783, 0.769,(4.1104)+(0.0049)Gly+(−0.1412)His+(−0.0044)A la+(0.0875)Phe; 0.801,0.823, 0.803, 0.801, 0.822, 0.807, 0.765, 0. 799,(6.9920)+(−0.0715)Cit+(0.0083)Pro+(0.0016)Lys+(−0.1523)Trp; 0.801,0.819, 0.768, 0.743, 0.744, 0.830, 0.838, 0.789, (6.2948)+(−0.1179)His+(−0.0058)Ala+(−0.0165)Tyr+(0.0607)Ile; 0.801, 0.819,0.725, 0.698, 0.732, 0.822, 0.714, 0.741,(3.7173)+(0.0363)Ser+(−0.1437)His+(0.0018)Thr+(0.0049)Val; 0.800, 0.825,0.806, 0.812, 0.814, 0.799, 0.777, 0.800, (6.4936)+(−0.0657)Asn+(0.0044)Pro+(0.0208)Orn+(−0.1371)Trp; 0.800, 0.823, 0.794, 0.790, 0.81 7,0.800, 0.753, 0.790, (6.4992)+(0.0029)Gly+(−0.0769)Cit+(0.0171)Leu+(−0.1611)Trp; 0.800, 0.820, 0.737, 0.713, 0.734, 0.784, 0.7 72,0.751, (4.2970)+(−0.1503)His+(0.0150)Thr+(−0.0069)Val+(0. 0842)Phe;0.800, 0.817, 0.732, 0.693, 0.731, 0.801, 0.790, 0.753, (5.2730)+(−0.1464)His+(0.0129)Thr+(−0.0033)Pro+(0.0479)Ile; 0.8 00, 0.818,0.774, 0.755, 0.767, 0.826, 0.802, 0.788, (3.7650)+(0.0097)Gln+(−0.1592)His+(−0.0050)Lys+(0.0153)Leu; 0.800, 0.819, 0. 772,0.757, 0.769, 0.827, 0.780, 0.783, (4.0868)+(0.0083)Gln+(−0.1509)His+(0.0232)Orn+(−0.0035)Lys; 0.800, 0.817, 0.715, 0.676, 0. 731,0.812, 0.716, 0.734, (3.3301)+(0.0402)Ser+(−0.1449)His+(−0.0325)Cit+(0.0202)Leu; 0.800, 0.817, 0.803, 0.801, 0.788, 0.847, 0. 807,0.811, (4.5374)+(−0.0599)Asn+(0.0007)Gly+(0.0111)Gln+(−0. 1377)His;0.800, 0.822, 0.809, 0.820, 0.819, 0.805, 0.761, 0.801, (7.2315)+(−0.0803)Asn+(−0.0011)Gly+(0.0186)Thr+(−0.1434)Trp; 0. 800, 0.827,0.790, 0.788, 0.790, 0.785, 0.796, 0.790, (3.7945)+(0.0039)Gln+(−0.0212)Arg+(0.0512)Ile+(−0.1710)Trp; 0.800, 0.820, 0. 804,0.808, 0.790, 0.849, 0.794, 0.810, (4.3284)+(0.0003)Gly+(0.0108)Gln+(−0.1346)His+(−0.0964)Met; 0.800, 0.825, 0.783, 0.762, 0. 789,0.796, 0.814, 0.790, (4.4203)+(−0.1277)His+(−0.1970)Met+(0.0074)Lys+(0.1142)Phe; 0.800, 0.819, 0.737, 0.699, 0.737, 0.800, 0. 793,0.757, (5.7928)+(−0.0411)Asn+(−0.1372)His+(0.0163)Thr+(0. 0433)Ile;0.800, 0.823, 0.813, 0.815, 0.799, 0.852, 0.808, 0.819, (4.5541)+(−0.0365)Asn+(0.0117)Gln+(−0.1310)His+(−0.0710)Met; 0. 800, 0.822,0.795, 0.792, 0.783, 0.839, 0.794, 0.802, (4.0639)+(0.0109)Gln+(−0.1343)His+(0.0083)Pro+(−0.1328)Met; 0.800, 0.823, 0. 768,0.755, 0.763, 0.849, 0.754, 0.780, (4.7071)+(0.0455)Ser+(−0.0045)Gly+(−0.1119)His+(−0.0945)Met; 0.800, 0.822, 0.801, 0.806, 0.788,0.808, 0.811, 0.803,(5.7028)+(−0.0073)Ala+(0.0096)Pro+(0.0114)Leu+(−0.1467)Trp; 0.800,0.821, 0.818, 0.828, 0.808, 0.82 2, 0.807, 0.816,(7.1980)+(−0.0466)Asn+(−0.0054)Ala+(0.0110)Pr o+(−0.1281)Trp; 0.800,0.825, 0.741, 0.725, 0.715, 0.828, 0.777, 0. 761,(−1.7307)+(0.0453)Ser+(−0.0075)Ala+(−0.3100)Met+(0.079 8)Ile; 0.800,0.823, 0.752, 0.723, 0.753, 0.814, 0.780, 0.768, (5.5659)+(0.0057)Gly+(−0.1171)His+(−0.1599)Met+(0.0673)Ile; 0.800, 0.825,0.840, 0.857, 0.833, 0.833, 0.813, 0.834, (5.3972)+(−0.0844)Asn+(0.0067)Gln+(−0.0016)Val+(−0.1355)Trp; 0.800, 0.825, 0.7 77,0.755, 0.785, 0.791, 0.807, 0.785, (4.5021)+(−0.1195)His+(0.0062)Pro+(−0.1985)Met+(0.1122)Phe; 0.800, 0.822, 0.781, 0.754, 0. 767,0.833, 0.843, 0.799,(6.5161)+(−0.1062)His+(−0.0050)Ala+(−0.1211)Met+(0.0688)Ile; 0.800,0.825, 0.801, 0.808, 0.791, 0.799, 0.808, 0.802,(4.6487)+(0.0026)Gln+(−0.0227)Val+(0.0443)Leu+(−0.1564)Trp; 0.800,0.825, 0.816, 0.809, 0.823, 0.840, 0.804, 0.81 9,(8.7198)+(−0.0769)His+(0.0277)Tyr+(−0.0504)Met+(−0.1018)I rp; 0.800,0.824, 0.804, 0.802, 0.823, 0.808, 0.766, 0.800, (7.1151)+(−0.0715)Cit+(0.0006)Arg+(0.0084)Pro+(−0.1503)Trp; 0.800, 0. 823,0.816, 0.828, 0.821, 0.817, 0.776, 0.810, (6.9239)+(−0.0647)Asn+(−0.0045)Val+(0.0289)Orn+(−0.1262)Trp 0.902, 0.923, 0.809, 0.790,0.778, 0.870, 0.878, 0.829, (−1.32 17)+(00.0545)Ser+(−0.0544)Val+(−0.3973)Met+(0.1922)Ile+(0.1506)Phe+(−0.1179)Trp; 0.900, 0.919, 0.800, 0.780, 0.815, 0.860, 0.7 77,0.808, (1.1114)+(0.0530)Ser+(−0.1384)His+(0.0420)Thr+(−0.3641)Met+(0.1993)Phe+(−0.1237)Trp; 0.899, 0.917, 0.812, 0.798, 0. 789,0.854, 0.864, 0.826, (2.2454)+(0.0452)Thr+(−0.0612)Val+(−0.4741)Met+(0.2021)Ile+(0.1569)Phe+(−0.1267)Trp; 0.894, 0.918, 0. 783,0.749, 0.760, 0.870, 0.859, 0.810, (−1.8219)+(0.0622)Ser+(−0.1003)His+(−0.0447)Val+(−0.4105)Met+(0.1701)Ile+(0.1621)Phe; 0.891,0.913, 0.825, 0.813, 0.822, 0.870, 0.830, 0.834,(−0.7646)+(0.0539)Ser+(0.0080)Gln+(−0.1367)His+(−0.2716)Met+(0.1766)Phe+(−0.1028)Trp; 0.891, 0.910, 0.793, 0.765, 0.776, 0.856, 0.858, 0.814, (2.3264)+(−0.0966)His+(0.0489)Thr+(−0.0552)Val+(−0.4896)Met+(0.1897)Ile+(0.1580)Phe; 0.890, 0.916, 0.807, 0.794, 0.791, 0.854,0.841, 0.820, (−1.8334)+(0.0536)Ser+(−0.3463)Met+(0.1735)Ile+(−0.0820)Leu+(0.1380)Phe+(−0.1330)Trp; 0.890, 0.912, 0.7 85,0.765, 0.749, 0.870, 0.849, 0.808, (−3.2110)+(0.0409)Ser+(0.0284)Thr+(−0.0697)Val+(−0.5814)Met+(0.2181)Ile+(0.1512)Phe; 0. 890,0.914, 0.791, 0.754, 0.794, 0.854, 0.836, 0.810, (−0.4856)+(0.0659)Ser+(−0.1214)His+(−0.2902)Met+(0.0720)Ile+(0.1503)Phe+(−0.1121)Trp;0.889, 0.910, 0.831, 0.819, 0.840, 0.854, 0.829, 0.83 5,(2.1791)+(0.0103)Gln+(−0.1446)His+(0.0467)Thr+(−0.3603)Met+(0.1795)Phe+(−0.1251)Trp; 0.888, 0.909, 0.797, 0.783, 0.752, 0. 872,0.876, 0.821, (−2.0528)+(0.0623)Ser+(−0.1191)Asn+(−0.0671)Val+(−0.3897)Met+(0.2086)Ile+(0.1559)Phe; 0.887, 0.911, 0.79 4, 0.768,0.802, 0.853, 0.801, 0.806, (0.2218)+(0.0663)Ser+(−0.1176)His+(0.0128)Pro+(−0.2882)Met+(0.1713)Phe+(−0.1063)Trp; 0. 885, 0.906,0.770, 0.736, 0.762, 0.850, 0.821, 0.792, (−2.1269)+(0.0641)Ser+(−0.1326)His+(−0.3520)Met+(0.1518)Ile+(−0.0632)Leu+(0.1622)Phe; 0.885, 0.908, 0.812, 0.789, 0.821, 0.865, 0.815, 0.82 2,(0.6585)+(0.0637)Ser+(−0.1191)His+(0.0234)Tyr+(−0.2771)Met+(0.1715)Phe+(−0.1085)Trp; 0.884, 0.906, 0.805, 0.777, 0.785, 0. 883,0.862, 0.827, (2.1234)+(0.0509)Ser+(0.0590)Tyr+(−0.0488)Val+(−0.3619)Met+(0.1995)Ile+(−0.1244)Trp; 0.884, 0.905, 0.810, 0.795,0.815, 0.858, 0.807, 0.819, (1.0354)+(0.0642)Ser+(−0.0298)Asn+(−0.1127)His+(−0.2223)Met+(0.1737)Phe+(−0.1009)Trp; 0. 884, 0.909,0.795, 0.777, 0.745, 0.877, 0.887, 0.821, (−3.0328)+(0.0510)Ser+(−0.0050)Ala+(−0.0625)Val+(−0.4487)Met+(0.2107)Ile+(0.1401)Phe; 0.883, 0.907, 0.791, 0.769, 0.747, 0.865, 0.888, 0.81 7,(−3.0576)+(0.0592)Ser+(−0.0056)Gly+(−0.0640)Val+(−0.4783)Met+(0.2055)Ile+(0.1405)Phe; 0.882, 0.903, 0.805, 0.787,0.810, 0. 855, 0.804, 0.814, (0.7088)+(0.0622)Ser+(−0.1177)His+(0.0009)Ala+(−0.2474)Met+(0.1748)Phe+(−0.1026)Trp; 0.882, 0.906, 0.804, 0.785,0.812, 0.858, 0.803, 0.814, (0.7718)+(0.0609)Ser+(−0.1195)His+(−0.2422)Met+(0.0111)Orn+(0.1700)Phe+(−0.1017)Trp; 0.8 82, 0.905,0.799, 0.771, 0.809, 0.852, 0.813, 0.811, (0.5016)+(0.0636)Ser+(−0.1239)His+(−0.2582)Met+(0.0196)Leu+(0.1610)Phe+(−0.1091)Trp;0.881, 0.904, 0.802, 0.772, 0.819, 0.829, 0.825, 0.811,(4.6013)+(−0.1241)His+(0.0491)Thr+(−0.3361)Met+(0.0575)Ile+(0.1484)Phe+(−0.1339)Trp;0.881, 0.904, 0.805, 0.787, 0.811, 0.85 2, 0.806, 0.814,(0.5622)+(0.0605)Ser+(−0.1208)His+(−0.2627)Met+(0.0083)Lys+(0.1749)Phe+(−0.1088)Trp; 0.881, 0.906, 0.790, 0. 769,0.755, 0.871, 0.860, 0.814,(−2.7772)+(0.0534)Ser+(−0.0583)Cit+(−0.0611)Val+(−0.4725)Met+(0.2025)Ile+(0.1483)Phe;0.881, 0.903, 0.805, 0.784, 0.812, 0.856, 0.807, 0.815,(0.7259)+(0.0625)Ser+(−0.1217)His+(0.0048)Val+(−0.2448)Met+(0.1692)Phe+(−0.1064)Trp; 0.881, 0.902, 0.798, 0.784, 0.760, 0.859, 0.869, 0.818, (1.4747)+(−0.0872)Asn+(0.0451)Thr+(−0.0745)Val+(−0.4746)Met+(0.2248)Ile+(0.1468)Phe; 0.880, 0.904, 0.810, 0.792, 0.812, 0.857, 0. 817,0.819,(0.8210)+(0.0648)Ser+(−0.0022)Gly+(−0.1140)His+(−0.2398)Met+(0.1738)Phe+(−0.1039)Trp;0.880, 0.905, 0.809, 0.792, 0.817, 0.858, 0.800, 0.817,(0.8548)+(0.0627)Ser+(−0.1030)His+(−0.0434)Cit+(−0.2268)Met+(0.1810)Phe+(−0.1120)Trp;0.880, 0. 902, 0.804, 0.783, 0.783, 0.880, 0.849, 0.824,(3.5594)+(0.0437)Ser+(−0.0504)Cit+(−0.0373)Val+(−0.2208)Met+(0.1758)Ile+(−0.11 70)Trp;0.880, 0.901, 0.798, 0.783, 0.774, 0.878, 0.833, 0.817, (3.5083)+(0.0341)Ser+(0.0217)Thr+(−0.0447)Val+(−0.3282)Met+(0.1883)Ile+(−0.1110)Trp; 0.880, 0.900, 0.831, 0.825, 0.800, 0.853, 0. 898,0.844, (1.6131)+(0.0057)Gln+(−0.0525)Val+(−0.3431)Met+(0.1808)Ile+(0.1304)Phe+(−0.1173)Trp; 0.880, 0.904, 0.789, 0.773, 0. 750,0.855, 0.866, 0.811, (1.3300)+(0.0530)Ser+(−0.1787)Asn+(−0.0502)Val+(0.1586)Ile+(0.1013)Phe+(−0.1205)Trp; 0.879, 0.903, 0. 784,0.768, 0.742, 0.863, 0.861, 0.808, (−3.3275)+(0.0510)Ser+(−0.0566)Val+(−0.4745)Met+(0.2287)Ile+(−0.0295)Leu+(0.1461)Phe; 0.879,0.906, 0.789, 0.765, 0.751, 0.871, 0.874, 0.815,(−3.4771)+(0.0531)Ser+(0.0228)Tyr+(−0.0672)Val+(−0.5232)Met+(0.2117)Ile+(0.1378)Phe; 0.878, 0.903, 0.801, 0.777, 0.813, 0.835, 0.817, 0. 811,(−1.3020)+(0.0581)Ser+(−0.0917)Cit+(−0.3118)Met+(0.0708)Ile+(0.1355)Phe+(−0.1702)Trp; 0.878, 0.905, 0.782, 0.763, 0.74 1,0.862, 0.860, 0.807, (−3.2369)+(0.0521)Ser+(0.0053)Pro+(−0.0643)Val+(−0.4981)Met+(0.1980)Ile+(0.1419)Phe; 0.878, 0.904, 0. 807,0.792, 0.812, 0.857, 0.802, 0.816, (0.8772)+(0.0632)Ser+(−0.1150)His+(−0.0075)Arg+(−0.2326)Met+(0.1756)Phe+(−0.1014)Tr p; 0.878,0.898, 0.758, 0.725, 0.747, 0.823, 0.821, 0.779,(1.1231)+(0.0472)Ser+(−0.1274)His+(0.1065)Ile+(−0.0390)Leu+(0.1044)Phe+(−0.1281)Trp; 0.877, 0.903, 0.807, 0.797, 0.795, 0.855, 0.824, 0.818,(1.0488)+(0.0524)Ser+(−0.1170)Asn+(0.0077)Gln+(−0.1332)His+(0.1277)Phe+(−0.1078)Trp;0.877, 0.900, 0.754, 0.707, 0.768, 0.840, 0.783, 0.775,(−1.3972)+(0.0567)Ser+(−0.1699)His+(0.0295)Thr+(−0.4330)Met+(0.0672)Ile+(0.1506)Phe; 0.877, 0.904, 0.78 2, 0.761,0.740, 0.865, 0.866, 0.808, (−2.9436)+(0.0528)Ser+(−0.0012)Gln+(−0.0642)Val+(−0.4767)Met+(0.2056)Ile+(0.1425)Phe; 0. 877,0.900, 0.812, 0.798, 0.791, 0.876, 0.848, 0.828, (6.5712)+(0.0336)Thr+(−0.0519)Cit+(−0.0438)Val+(−0.2732)Met+(0.1832)Ile+(−0.1144)Trp;0.877, 0.903, 0.819, 0.801, 0.795, 0.849, 0.894, 0.83 5,(4.9139)+(−0.0543)His+(−0.0452)Val+(−0.2526)Met+(0.1687)Ile+(0.1312)Phe+(−0.0958)Trp; 0.877, 0.900, 0.797, 0.784, 0.755, 0. 863,0.875, 0.819,(0.3843)+(0.0393)Thr+(−0.0042)Ala+(−0.0697)Val+(−0.5055)Met+(0.2222)Ile+(0.1346)Phe;0.877, 0.899, 0.803, 0.787, 0.768, 0.879, 0.865, 0.824,(3.2446)+(0.0417)Ser+(−0.0046)Ala+(−0.0407)Val+(−0.2260)Met+(0.1885)Ile+(−0.1079)Trp; 0. 877, 0.896,0.806, 0.783, 0.828, 0.827, 0.804, 0.811, (5.1385)+(−0.1262)His+(0.0512)Thr+(−0.3199)Met+(0.0154)Leu+(0.1582)Phe+(−0.1315)Trp;0.877, 0.895, 0.811, 0.802, 0.778, 0.873, 0.862, 0.82 8,(6.3171)+(0.0318)Thr+(−0.0048)Ala+(−0.0466)Val+(−0.2706)Met+(0.1948)Ile+(−0.1108)Trp; 0.877, 0.901, 0.770, 0.737, 0.753, 0. 844,0.841, 0.794,(1.5645)+(0.0502)Ser+(−0.1331)His+(−0.0071)Ala+(0.0682)Ile+(0.1022)Phe+(−0.1303)Trp;0.877, 0.904, 0.787, 0.767, 0.744, 0.867, 0.870, 0.812,(−3.2265)+(0.0513)Ser+(−0.0640)Val+(−0.4840)Met+(−0.0021)Orn+(0.2050)Ile+(0.1430)Phe; 0.8 76, 0.899,0.796, 0.776, 0.772, 0.871, 0.847, 0.817, (3.1391)+(0.0431)Ser+(0.0063)Pro+(−0.0420)Val+(−0.2707)Met+(0.1750)Ile+(−0.1119)Trp;0.876, 0.896, 0.800, 0.782, 0.782, 0.859, 0.843, 0.817,(7.1237)+(−0.0566)His+(0.0346)Thr+(−0.0375)Val+(−0.2613)Met+(0.1722)Ile+(−0.0947)Trp; 0.876, 0.900, 0.789, 0.772, 0.802, 0.8 20,0.788, 0.796, (−1.7780)+(0.0469)Ser+(0.0220)Thr+(−0.4185)Met+(0.0601)Ile+(0.1200)Phe+(−0.1623)Trp; 0.876, 0.900, 0.814, 0. 814,0.828, 0.840, 0.768, 0.812, (0.3731)+(0.0463)Ser+(−0.0799)Asn+(0.0272)Thr+(−0.3209)Met+(0.1461)Phe+(−0.1531)Trp; 0.876, 0.898,0.813, 0.799, 0.830, 0.833, 0.801, 0.816, (5.1380)+(−0.1164)His+(0.0508)Thr+(−0.0016)Val+(−0.3109)Met+(0.1713)Phe+(−0. 1240)Trp;0.876, 0.898, 0.781, 0.748, 0.787, 0.859, 0.796, 0.798, (4.0210)+(0.0445)Ser+(−0.1021)His+(0.0220)Thr+(−0.2402)Met+(0.0941)Ile+(−0.1075)Trp; 0.876, 0.898, 0.804, 0.786, 0.774, 0.882, 0. 856,0.824,(3.7945)+(0.0469)Ser+(−0.0611)Asn+(−0.0421)Val+(−0.2051)Met+(0.1806)Ile+(−0.1024)Trp;0.876, 0.899, 0.803, 0.783, 0.772, 0.871, 0.868, 0.824,(3.1847)+(0.0513)Ser+(−0.0059)Gly+(−0.0407)Val+(−0.2496)Met+(0.1795)Ile+(−0.1110)Trp;0.876, 0. 898, 0.815, 0.806, 0.785, 0.847, 0.882, 0.830,(3.0411)+(0.0040)Gly+(−0.0542)Val+(−0.3097)Met+(0.1869)Ile+(0.1305)Phe+(−0.112 3)Trp;0.876, 0.899, 0.777, 0.739, 0.777, 0.852, 0.825, 0.798, (−3.0222)+(0.0578)Ser+(0.0068)Gln+(−0.1683)His+(−0.3616)Met+(0.0626)Ile+(0.1415)Phe; 0.876, 0.900, 0.792, 0.772, 0.765, 0.863, 0.8 51,0.813, (0.6553)+(0.0436)Thr+(−0.0620)Cit+(−0.0694)Val+(−0.5305)Met+(0.2201)Ile+(0.1426)Phe; 0.875, 0.898, 0.808, 0.802, 0. 833,0.838, 0.750, 0.806, (0.0690)+(0.0437)Ser+(0.0320)Thr+(−0.0895)Cit+(−0.3650)Met+(0.1686)Phe+(−0.1704)Trp; 0.875, 0.898, 0.810,0.795, 0.828, 0.831, 0.799, 0.813,(5.0416)+(0.0077)Asn+(−0.1194)His+(0.0503)Thr+(−0.3161)Met+(0.1699)Phe+(−0.1255)Trp; 0.875, 0.899, 0.825, 0.817, 0.787, 0.854, 0.906, 0.841,(3.9291)+(−0.0044)Ala+(−0.0534)Val+(−0.2665)Met+(0.1920)Ile+(0.1248)Phe+(−0.1088)Trp;0.875, 0.897, 0.794, 0.778, 0.763, 0.875, 0.845, 0.815,(4.6063)+(0.0465)Ser+(−0.1092)Asn+(−0.0635)Cit+(−0.0374)Val+(0.1596)Ile+(−0.1266)Trp; 0.875, 0.899, 0.781, 0.761, 0.7 83,0.844, 0.786, 0.793, (2.7059)+(0.0543)Ser+(−0.1114)Asn+(−0.1258)His+(0.0185)Thr+(0.1304)Phe+(−0.1179)Trp; 0.875, 0.903, 0. 785,0.768, 0.746, 0.863, 0.855, 0.808, (−3.1220)+(0.0548)Ser+(−0.0162)Arg+(−0.0640)Val+(−0.4578)Met+(0.2053)Ile+(0.1464)Phe; 0.875,0.898, 0.806, 0.793, 0.824, 0.832, 0.786, 0.809, (4.7360)+(0.0034)Gly+(−0.1236)His+(0.0487)Thr+(−0.3151)Met+(0.1724)Phe+(−0.1208)Trp;0.875, 0.904, 0.786, 0.767, 0.743, 0.868, 0.870, 0.81 2,(−3.2133)+(0.0512)Ser+(−0.0641)Val+(−0.4828)Met+(−0.0003)Lys+(0.2046)Ile+(0.1423)Phe;0.875, 0.895, 0.792, 0.776, 0.753, 0. 867, 0.864, 0.815,(3.8125)+(0.0350)Ser+(−0.0086)Ala+(−0.0759)Cit+(−0.0342)Val+(0.1732)Ile+(−0.1444)Trp;0.875, 0.898, 0.808, 0.792, 0.825, 0.827, 0.799, 0.811,(5.0167)+(−0.1163)His+(0.0493)Thr+(0.0042)Pro+(−0.3173)Met+(0.1656)Phe+(−0.1257)Trp; 0.8 74, 0.892,0.811, 0.795, 0.789, 0.870, 0.856, 0.827, (5.8798)+(0.0306)Thr+(0.0275)Tyr+(−0.0494)Val+(−0.3312)Met+(0.1907)Ile+(−0.1191)Trp;0.874, 0.898, 0.811, 0.797, 0.829, 0.831, 0.799, 0.814,(5.1472)+(−0.1179)His+(0.0507)Thr+(−0.0017)Tyr+(−0.3085)Met+(0.1695)Phe+(−0.1249)Trp; 0.874, 0.898, 0.788, 0.761, 0.770, 0.8 65,0.842, 0.810, (3.8623)+(0.0473)Ser+(−0.0629)His+(−0.0301)Val+(−0.2091)Met+(0.1648)Ile+(−0.0919)Trp; 0.874, 0.898, 0.792, 0.790,0.806, 0.814, 0.751, 0.790, (−1.0344)+(0.0456)Ser+(0.0230)Thr+(0.0098)Pro+(−0.4138)Met+(0.1413)Phe+(−0.1577)Trp; 0.8 74, 0.895,0.788, 0.774, 0.751, 0.854, 0.859, 0.809, (0.0531)+(0.0005)Gly+(0.0394)Thr+(−0.0716)Val+(−0.5394)Met+(0.2193)Ile+(0. 1383)Phe;0.874, 0.897, 0.812, 0.798, 0.830, 0.831, 0.801, 0.815, (5.1552)+(−0.1177)His+(0.0509)Thr+(−0.3113)Met+(−0.0016)Orn+(0.1700)Phe+(−0.1256)Trp; 0.874, 0.896, 0.754, 0.722, 0.735, 0.823, 0. 828,0.777, (1.3999)+(0.0456)Ser+(−0.1187)His+(−0.0254)Val+(0.1124)Ile+(0.1002)Phe+(−0.1271)Trp; 0.874, 0.895, 0.768, 0.727, 0. 765,0.852, 0.820, 0.791,(−1.5196)+(0.0660)Ser+(−0.1481)His+(−0.0042)Ala+(−0.3256)Met+(0.0732)Ile+(0.1382)Phe;0.873, 0.897, 0.812, 0.814, 0.827, 0.835, 0.756, 0.808,(−0.1619)+(0.0395)Ser+(0.0286)Thr+(−0.0081)Val+(−0.3801)Met+(0.1583)Phe+(−0.1520)Trp;0.873, 0.895, 0.802, 0.787, 0.773, 0.876, 0.850, 0.821, (3.6154)+(0.0371)Ser+(−0.0090)Ala+(−0.0871)Cit+(0.1770)Ile+(−0.0599)Leu+(−0.1475)Trp; 0.873, 0.897, 0.812, 0.798, 0.829, 0.832, 0.8 00,0.815, (5.1575)+(−0.1177)His+(0.0505)Thr+(−0.0002)Ala+(−0.3093)Met+(0.1691)Phe+(−0.1253)Trp; 0.873, 0.896, 0.799, 0.783, 0. 771,0.872, 0.851, 0.819, (3.0224)+(0.0410)Ser+(−0.0428)Val+(−0.2747)Met+(0.0061)Lys+(0.1815)Ile+(−0.1138)Trp; 0.873, 0.897, 0. 810,0.795, 0.829, 0.825, 0.801, 0.812, (4.9661)+(−0.1202)His+(0.0488)Thr+(−0.3182)Met+(0.0049)Lys+(0.1679)Phe+(−0.1273)Trp; 0.873,0.896, 0.821, 0.812, 0.790, 0.844, 0.896, 0.836,(3.8662)+(−0.0081)Asn+(−0.0538)Val+(−0.2881)Met+(0.1849)Ile+(0.1257)Phe+(−0.1096)Trp; 0.873, 0.897, 0.811, 0.799, 0.833, 0.830, 0.787, 0. 812,(5.5816)+(−0.1144)His+(0.0550)Thr+(−0.0157)Arg+(−0.3019)Met+(0.1705)Phe+(−0.1270)Trp; 0.873, 0.896, 0.801, 0.784, 0.77 3,0.874, 0.851, 0.821, (2.9282)+(0.0409)Ser+(0.0009)Gln+(−0.0410)Val+(−0.2589)Met+(0.1794)Ile+(−0.1121)Trp; 0.873, 0.898, 0. 818,0.808, 0.788, 0.842, 0.891, 0.832, (3.7193)+(0.0050)Pro+(−0.0540)Val+(−0.3080)Met+(0.1806)Ile+(0.1269)Phe+(−0.1125)Trp; 0.873,0.900, 0.837, 0.818, 0.833, 0.859, 0.882, 0.848, (2.0349)+(0.0121)Gln+(−0.1284)His+(−0.2378)Met+(0.0584)Ile+(0.1200)Phe+(−0.1165)Trp;0.873, 0.894, 0.796, 0.777, 0.771, 0.871, 0.843, 0.81 6,(3.1019)+(0.0405)Ser+(−0.0430)Val+(−0.2624)Met+(0.0147)Orn+(0.1798)Ile+(−0.1110)Trp; 0.873, 0.898, 0.769, 0.735, 0.765, 0. 837,0.822, 0.790,(1.7038)+(0.0588)Ser+(−0.0844)Asn+(−0.1247)His+(0.0537)Ile+(0.1038)Phe+(−0.1227)Trp;0.872, 0.895, 0.789, 0.774, 0.751, 0.853, 0.860, 0.809,(0.1187)+(0.0392)Thr+(−0.0702)Val+(−0.5356)Met+(0.2227)Ile+(−0.0048)Leu+(0.1384)Phe; 0.8 72, 0.897,0.808, 0.807, 0.808, 0.826, 0.795, 0.809, (−0.3872)+(0.0586)Ser+(−0.0695)Asn+(0.0110)Pro+(−0.2845)Met+(0.1316)Phe+(−0.1409)Trp;0.872, 0.897, 0.818, 0.807, 0.789, 0.844, 0.891, 0.83 3,(3.6639)+(−0.0543)Val+(−0.2976)Met+(0.0093)Orn+(0.1841)Ile+(0.1213)Phe+(−0.1100)Trp; 0.872, 0.892, 0.805, 0.794, 0.778, 0. 865,0.849, 0.821,(6.2184)+(−0.0009)Gly+(0.0321)Thr+(−0.0472)Val+(−0.2963)Met+(0.1870)Ile+(−0.1125)Trp;0.872, 0.896, 0.789, 0.773, 0.751, 0.854, 0.860, 0.810,(0.1211)+(0.0396)Thr+(0.0010)Pro+(−0.0716)Val+(−0.5408)Met+(0.2183)Ile+(0.1378)Phe;0.872, 0.898, 0.791, 0.775, 0.753, 0.853, 0.864, 0.811,(0.1174)+(0.0429)Thr+(−0.0717)Val+(−0.5487)Met+(−0.0139)Orn+(0.2238)Ile+(0.1444)Phe; 0.872, 0.895, 0.804, 0.803, 0.823, 0.830, 0.751, 0.802, (−0.3855)+(0.0418)Ser+(0.0273)Thr+(−0.3721)Met+(−0.0047)Lys+(0.1470)Phe+(−0.1560)Trp; 0.872, 0.896, 0.792, 0.778, 0.754, 0.855, 0. 861,0.812,(−0.4936)+(0.0017)Gln+(0.0386)Thr+(−0.0713)Val+(−0.5505)Met+(0.2181)Ile+(0.1387)Phe;0.872, 0.892, 0.810, 0.801, 0.783, 0.867, 0.850, 0.825,(5.1257)+(0.0031)Gln+(0.0295)Thr+(−0.0462)Val+(−0.3115)Met+(0.1835)Ile+(−0.1169)Trp;0.872, 0.89 7, 0.784, 0.770, 0.755, 0.853, 0.836, 0.803,(0.6618)+(0.0508)Thr+(−0.0287)Arg+(−0.0751)Val+(−0.5262)Met+(0.2298)Ile+(0.1475)Phe;0.872, 0.893, 0.823, 0.823, 0.831, 0.842, 0.795, 0.823, (0.7735)+(0.0580)Ser+(−0.0672)Asn+(−0.0788)Cit+(−0.2115)Met+(0.1522)Phe+(−0.1461)Trp; 0.872, 0.895, 0.804, 0.805, 0.831, 0.829, 0.7 26,0.798, (−0.0447)+(0.0437)Ser+(0.0341)Thr+(−0.0257)Arg+(−0.3805)Met+(0.1530)Phe+(−0.1579)Trp; 0.871, 0.893, 0.767, 0.741, 0. 747,0.824, 0.833, 0.787, (0.6532)+(0.0399)Ser+(−0.1010)Cit+(−0.0387)Val+(0.1447)Ile+(0.0903)Phe+(−0.1830)Trp; 0.871, 0.895, 0. 801,0.789, 0.816, 0.826, 0.782, 0.803, (−0.4540)+(0.0581)Ser+(−0.0898)Cit+(0.0143)Pro+(−0.3145)Met+(0.1525)Phe+(−0.1610)Trp; 0.871,0.894, 0.798, 0.781, 0.770, 0.870, 0.848, 0.817, (3.1438)+(0.0420)Ser+(−0.0384)Val+(−0.2517)Met+(0.1878)Ile+(−0.0099)Leu+(−0.1101)Trp; 0.871, 0.895, 0.820, 0.810, 0.790, 0.843, 0.890, 0.8 33,(3.6738)+(−0.0474)Val+(−0.2911)Met+(0.1986)Ile+(−0.0204)Leu+(0.1266)Phe+(−0.1089)Trp;0.871, 0.897, 0.818, 0.811, 0.786, 0.839, 0.890, 0.832,(3.2462)+(−0.0581)Val+(−0.3358)Met+(0.0125)Lys+(0.1891)Ile+(0.1268)Phe+(−0.1163)Trp; 0.871, 0.895, 0.76 2, 0.726,0.756, 0.827, 0.820, 0.782, (0.8269)+(0.0429)Ser+(0.0039)Gln+(−0.1493)His+(0.0532)Ile+(0.0925)Phe+(−0.1345)Trp; 0.8 71, 0.897,0.801, 0.802, 0.797, 0.825, 0.786, 0.803, (−0.8865)+(0.0535)Ser+(0.0137)Pro+(−0.0091)Val+(−0.3360)Met+(0.1445)Phe+(−0.1393)Trp;0.871, 0.892, 0.810, 0.800, 0.783, 0.867, 0.851, 0.82 5,(6.8120)+(−0.0424)Asn+(0.0335)Thr+(−0.0480)Val+(−0.2646)Met+(0.1872)Ile+(−0.1073)Trp; 0.871, 0.895, 0.795, 0.779, 0.786, 0. 855,0.811, 0.808,(2.4257)+(0.0586)Ser+(−0.0850)Asn+(−0.1155)His+(−0.0026)Ala+(0.1346)Phe+(−0.1062)Trp;0.871, 0.888, 0.811, 0.791, 0.810, 0.856, 0.834, 0.823,(5.0596)+(0.0087)Gln+(−0.1134)His+(0.0284)Thr+(−0.2241)Met+(0.0791)Ile+(−0.1159)Trp; 0.8 71, 0.897,0.815, 0.798, 0.841, 0.833, 0.792, 0.816, (5.2824)+(−0.1036)His+(0.0517)Thr+(−0.0508)Cit+(−0.2946)Met+(0.1765)Phe+(−0.1356)Trp;0.871, 0.895, 0.756, 0.716, 0.752, 0.827, 0.816, 0.77 8,(1.5449)+(0.0511)Ser+(−0.1339)His+(−0.0108)Lys+(0.0614)Ile+(0.1007)Phe+(−0.1260)Trp; 0.871, 0.897, 0.797, 0.789, 0.772, 0. 840,0.837, 0.810, (0.8635)+(0.0485)Ser+(−0.1466)Asn+(0.1404)Ile+(−0.0731)Leu+(0.0917)Phe+(−0.1395)Trp; 0.871, 0.900, 0.825, 0.810,0.799, 0.852, 0.900, 0.840, (3.6620)+(0.0189)Tyr+(−0.0547)Val+(−0.3223)Met+(0.1869)Ile+(0.1221)Phe+(−0.1142)Trp; 0.8 71, 0.898,0.802, 0.787, 0.804, 0.828, 0.819, 0.810, (−1.1859)+(0.0587)Ser+(−0.0576)Asn+(−0.2971)Met+(0.0598)Ile+(0.1109)Phe+(−0.1476)Trp;0.871, 0.896, 0.787, 0.774, 0.749, 0.851, 0.858, 0.80 8,(0.1420)+(0.0403)Thr+(−0.0082)Tyr+(−0.0709)Val+(−0.5292)Met+(0.2182)Ile+(0.1402)Phe; 0.870, 0.895, 0.784, 0.741, 0.795, 0. 857,0.820, 0.803, (2.8514)+(0.0578)Ser+(−0.0991)His+(0.0424)Tyr+(−0.2438)Met+(0.0940)Ile+(−0.1184)Trp; 0.870, 0.894, 0.804, 0.802,0.796, 0.833, 0.806, 0.809, (−0.9039)+(0.0533)Ser+(−0.0048)Ala+(0.0145)Pro+(−0.3144)Met+(0.1326)Phe+(−0.1433)Trp; 0.8 70, 0.894,0.786, 0.758, 0.779, 0.860, 0.821, 0.805, (3.6476)+(0.0495)Ser+(−0.0805)His+(−0.1772)Met+(0.1341)Ile+(−0.0304)Leu+(−0.1014)Trp;0.870, 0.890, 0.805, 0.795, 0.779, 0.864, 0.844, 0.82 1,(5.9503)+(0.0300)Thr+(−0.0479)Val+(−0.3079)Met+(0.0045)Lys+(0.1867)Ile+(−0.1141)Trp; 0.870, 0.896, 0.756, 0.713, 0.762, 0. 830,0.803, 0.777,(0.9717)+(0.0559)Ser+(−0.1185)His+(−0.0763)Cit+(0.0654)Ile+(0.1134)Phe+(−0.1581)Trp;0.870, 0.897, 0.813, 0.806, 0.811, 0.826, 0.828, 0.818,(2.2784)+(0.0315)Thr+(−0.3586)Met+(0.1475)Ile+(−0.0720)Leu+(0.1298)Phe+(−0.1440)Trp; 0.8 70, 0.892,0.804, 0.793, 0.779, 0.863, 0.847, 0.820, (6.0995)+(0.0325)Thr+(−0.0501)Val+(−0.3037)Met+(0.1815)Ile+(0.0092)Leu+(−0.1132)Trp;0.870, 0.895, 0.816, 0.810, 0.829, 0.822, 0.798, 0.815,(−0.0766)+(0.0525)Ser+(−0.0089)Gly+(0.0286)Thr+(−0.3786)Met+(0.1447)Phe+(−0.1642)Trp; 0.870, 0.895, 0.772, 0.751, 0.758, 0.8 41,0.807, 0.789, (1.9594)+(0.0504)Ser+(−0.1286)His+(−0.0061)Ala+(0.0101)Pro+(0.1227)Phe+(−0.1212)Trp; 0.870, 0.894, 0.797, 0. 771,0.790, 0.864, 0.830, 0.814, (2.4540)+(0.0435)Ser+(0.0062)Gln+(−0.1068)His+(−0.1908)Met+(0.0901)Ile+(−0.1059)Trp; 0.870, 0.891,0.803, 0.793, 0.777, 0.863, 0.843, 0.819,(6.1040)+(0.0310)Thr+(0.0023)Pro+(−0.0473)Val+(−0.3002)Met+(0.1846)Ile+(−0.1123)Trp; 0.870, 0.896, 0.802, 0.784, 0.795, 0.839, 0.834, 0.813, (−1.5943)+(0.0537)Ser+(−0.0051)Ala+(−0.3108)Met+(0.0703)Ile+(0.1090)Phe+(−0.1489)Trp; 0.869, 0.897, 0.803, 0.784, 0.797, 0.875, 0. 813,0.817, (3.1790)+(0.0447)Ser+(−0.0674)Cit+(−0.1848)Met+(0.1607)Ile+(−0.0544)Leu+(−0.1324)Trp; 0.869, 0.893, 0.826, 0.817, 0.824,0.840, 0.846, 0.832,(4.0806)+(−0.0912)Asn+(0.0098)Gln+(−0.1333)His+(0.0236)Thr+(0.1047)Phe+(−0.1234)Trp;0.869, 0.8 94, 0.829, 0.834, 0.826, 0.850, 0.808, 0.830,(0.3755)+(0.0547)Ser+(−0.0756)Asn+(−0.0061)Val+(−0.2286)Met+(0.1454)Phe+(−0.131 8)Trp;0.869, 0.893, 0.790, 0.777, 0.776, 0.846, 0.816, 0.804, (1.2461)+(0.0423)Ser+(0.0050)Gln+(−0.1418)His+(−0.0035)Ala+(0.1239)Phe+(−0.1183)Trp; 0.869, 0.895, 0.780, 0.759, 0.780, 0.836, 0.7 96,0.793, (2.1699)+(0.0590)Ser+(−0.0907)Asn+(−0.1184)His+(0.0057)Pro+(0.1246)Phe+(−0.1119)Trp; 0.869, 0.896, 0.821, 0.811, 0. 790,0.844, 0.894, 0.835,(3.8316)+(−0.0033)Arg+(−0.0537)Val+(−0.2892)Met+(0.1854)Ile+(0.1263)Phe+(−0.1106)Trp;0.869, 0.896, 0.788, 0.772, 0.751, 0.855, 0.859, 0.809,(0.2904)+(0.0414)Thr+(−0.0711)Val+(−0.5313)Met+(−0.0041)Lys+(0.2202)Ile+(0.1389)Phe; 0.869, 0.892, 0.750, 0.709, 0.750, 0.818, 0.807, 0.771,(1.4934)+(0.0466)Ser+(−0.1422)His+(0.0045)Thr+(0.0540)Ile+(0.0946)Phe+(−0.1361)Trp; 0.869, 0.893, 0.800, 0.783, 0.789, 0.871, 0.815, 0. 815,(4.1082)+(0.0451)Ser+(−0.0842)Asn+(−0.0783)Cit+(0.1465)Ile+(−0.0537)Leu+(−0.1444)Trp;0.869, 0.890, 0.770, 0.742, 0.747, 0.875, 0.816, 0.795,(3.1785)+(0.0381)Ser+(−0.0850)His+(0.0248)Thr+(−0.0407)Val+(−0.3478)Met+(0.1847)Ile; 0.869, 0.894, 0.8 05,0.805, 0.823, 0.824, 0.753, 0.801, (−0.7569)+(0.0403)Ser+(0.0008)Gln+(0.0252)Thr+(−0.3816)Met+(0.1444)Phe+(−0.1594)Trp; 0. 869,0.894, 0.780, 0.761, 0.787, 0.844, 0.769, 0.790, (−1.5917)+(0.0454)Ser+(0.0066)Gln+(−0.1764)His+(0.0279)Thr+(−0.3912)Met+(0.1740)Phe;0.869, 0.895, 0.809, 0.809, 0.822, 0.835, 0.763, 0.808,(−0.3426)+(0.0405)Ser+(0.0264)Thr+(−0.0022)Ala+(−0.3665)Met+(0.1466)Phe+(−0.1574)Trp; 0.869, 0.894, 0.805, 0.804, 0.823, 0.8 23,0.754, 0.801, (−0.4795)+(0.0413)Ser+(0.0282)Thr+(−0.3834)Met+(−0.0111)Orn+(0.1519)Phe+(−0.1603)Trp; 0.869, 0.895, 0.787, 0.769,0.786, 0.842, 0.800, 0.799, (2.3090)+(0.0582)Ser+(−0.0870)Asn+(−0.1185)His+(0.0006)Val+(0.1287)Phe+(−0.1090)Trp; 0.8 69, 0.893,0.817, 0.800, 0.786, 0.865, 0.892, 0.836, (0.5258)+(0.0100)Gln+(−0.0985)His+(−0.0458)Val+(−0.3722)Met+(0.1631)Ile+(0.1351)Phe;0.869, 0.890, 0.824, 0.829, 0.825, 0.843, 0.795, 0.823,(0.2250)+(0.0564)Ser+(−0.0653)Asn+(−0.0101)Arg+(−0.2300)Met+(0.1366)Phe+(−0.1375)Trp; 0.869, 0.901, 0.824, 0.809, 0.797, 0.8 54,0.898, 0.840, (4.1844)+(−0.0609)Cit+(−0.0510)Val+(−0.2579)Met+(0.1827)Ile+(0.1353)Phe+(−0.1182)Trp; 0.868, 0.895, 0.788, 0.771,0.791, 0.812, 0.809, 0.796, (−1.9994)+(0.0558)Ser+(0.0057)Pro+(−0.3633)Met+(0.0566)Ile+(0.1109)Phe+(−0.1533)Trp; 0.8 68, 0.892,0.754, 0.707, 0.765, 0.838, 0.798, 0.777, (−1.9080)+(0.0670)Ser+(−0.1511)His+(0.0053)Pro+(−0.3599)Met+(0.0585)Ile+(0.1410)Phe;0.868, 0.895, 0.796, 0.780, 0.770, 0.872, 0.842, 0.816,(3.3463)+(0.0444)Ser+(−0.0119)Arg+(−0.0417)Val+(−0.2311)Met+(0.1832)Ile+(−0.1109)Trp; 0.868, 0.891, 0.829, 0.827, 0.827, 0.8 37,0.833, 0.831, (0.3991)+(0.0648)Ser+(−0.0667)Asn+(−0.0068)Gly+(−0.2386)Met+(0.1341)Phe+(−0.1412)Trp; 0.868, 0.896, 0.801, 0.781,0.802, 0.817, 0.839, 0.810, (−1.5767)+(0.0643)Ser+(−0.0067)Gly+(−0.3335)Met+(0.0613)Ile+(0.1087)Phe+(−0.1557)Trp; 0.8 68, 0.894,0.811, 0.799, 0.833, 0.844, 0.772, 0.812, (0.0980)+(0.0504)Ser+(−0.1092)Cit+(−0.2618)Met+(0.0359)Orn+(0.1442)Phe+(−0.1602)Trp;0.868, 0.889, 0.789, 0.764, 0.779, 0.848, 0.835, 0.806,(3.2684)+(0.0388)Ser+(−0.0118)Ala+(−0.1003)Cit+(0.0118)Pro+(0.0864)Ile+(−0.1745)Trp;0.868, 0.896, 0.785, 0.765, 0.784, 0.84 5, 0.800, 0.798,(2.3402)+(0.0569)Ser+(−0.0913)Asn+(−0.1196)His+(0.0126)Orn+(0.1246)Phe+(−0.1080)Trp; 0.868, 0.891, 0.801, 0. 792,0.776, 0.865, 0.833, 0.817, (6.7713)+(0.0382)Thr+(−0.0212)Arg+(−0.0496)Val+(−0.2765)Met+(0.1948)Ile+(−0.1122)Trp; 0.868, 0.891,0.826, 0.830, 0.822, 0.846, 0.808, 0.826, (0.2060)+(0.0545)Ser+(−0.0705)Asn+(−0.0012)Ala+(−0.2287)Met+(0.1360)Phe+(−0. 1381)Trp;0.868, 0.892, 0.782, 0.772, 0.729, 0.838, 0.877, 0.804, (0.9936)+(0.0306)Ser+(−0.0102)Ala+(−0.0445)Val+(0.1636)Ile+(0.0800)Phe+(−0.1555)Trp; 0.868, 0.892, 0.777, 0.753, 0.782, 0.842, 0. 783,0.790, (−2.4869)+(0.0571)Ser+(0.0073)Gln+(−0.1658)His+(0.0106)Pro+(−0.3511)Met+(0.1619)Phe; 0.868, 0.890, 0.802, 0.791, 0. 778,0.860, 0.842, 0.818, (5.9836)+(0.0294)Thr+(−0.0480)Val+(−0.2963)Met+(0.0107)Orn+(0.1855)Ile+(−0.1124)Trp; 0.868, 0.895, 0. 805,0.799, 0.804, 0.815, 0.815, 0.808, (−0.8311)+(0.0652)Ser+(−0.0078)Gly+(0.0120)Pro+(−0.3325)Met+(0.1286)Phe+(−0.1503)Trp; 0.868,0.891, 0.779, 0.744, 0.782, 0.851, 0.813, 0.797, (3.4931)+(0.0524)Ser+(−0.0928)His+(0.0053)Pro+(−0.1883)Met+(0.0860)Ile+(−0.1064)Trp;0.868, 0.895, 0.832, 0.839, 0.828, 0.844, 0.815, 0.83 1,(−0.6892)+(0.0513)Ser+(−0.0838)Asn+(0.0039)Gln+(−0.2447)Met+(0.1330)Phe+(−0.1425)Trp; 0.868, 0.890, 0.796, 0.783, 0.745, 0. 879,0.874, 0.820,(4.2472)+(0.0428)Ser+(−0.1132)Asn+(−0.0063)Ala+(−0.0417)Val+(0.1750)Ile+(−0.1087)Trp;0.868, 0.891, 0.761, 0.716, 0.775, 0.842, 0.796, 0.782,(−1.6262)+(0.0675)Ser+(−0.1412)His+(−0.0439)Cit+(−0.3459)Met+(0.0672)Ile+(0.1438)Phe; 0.8 68, 0.892,0.767, 0.744, 0.769, 0.829, 0.778, 0.780, (2.2937)+(0.0451)Ser+(−0.1366)His+(0.0115)Thr+(−0.0066)Lys+(0.1247)Phe+(−0.1208)Trp;0.868, 0.894, 0.774, 0.754, 0.767, 0.840, 0.795, 0.789,(2.2525)+(0.0447)Ser+(−0.1350)His+(0.0112)Thr+(−0.0038)Ala+(0.1265)Phe+(−0.1230)Trp;0.867, 0.891, 0.757, 0.715, 0.756, 0.81 9, 0.825, 0.779,(1.5060)+(0.0542)Ser+(−0.0038)Gly+(−0.1366)His+(0.0553)Ile+(0.0939)Phe+(−0.1360)Trp; 0.867, 0.893, 0.780, 0. 755,0.782, 0.838, 0.802, 0.794, (2.2478)+(0.0581)Ser+(−0.0838)Asn+(−0.1233)His+(0.0115)Leu+(0.1186)Phe+(−0.1141)Trp; 0.867, 0.889,0.777, 0.753, 0.774, 0.841, 0.804, 0.793, (2.0388)+(0.0493)Ser+(−0.1334)His+(−0.0039)Ala+(0.0052)Val+(0.1209)Phe+(−0.1 200)Trp;0.867, 0.891, 0.753, 0.722, 0.772, 0.831, 0.741, 0.767, (−0.8189)+(0.0563)Ser+(−0.1611)His+(0.0269)Thr+(0.0098)Pro+(−0.4047)Met+(0.1707)Phe; 0.867, 0.895, 0.803, 0.802, 0.823, 0.824, 0. 751,0.800, (−0.5658)+(0.0414)Ser+(0.0253)Thr+(0.0018)Tyr+(−0.3805)Met+(0.1444)Phe+(−0.1591)Trp; 0.867, 0.895, 0.792, 0.772, 0. 789,0.843, 0.814, 0.804, (2.4275)+(0.0621)Ser+(−0.0859)Asn+(−0.0031)Gly+(−0.1151)His+(0.1283)Phe+(−0.1105)Trp; 0.867, 0.891, 0.752,0.712, 0.751, 0.820, 0.811, 0.774,(1.4074)+(0.0485)Ser+(−0.1393)His+(−0.0010)Pro+(0.0563)Ile+(0.0949)Phe+(−0.1333)Trp; 0.867, 0.893, 0.794, 0.778, 0.794, 0.817, 0.820, 0.802, (−1.9288)+(0.0564)Ser+(−0.3435)Met+(−0.0160)Orn+(0.0684)Ile+(0.1169)Phe+(−0.1541)Trp; 0.867, 0.896, 0.793, 0.775, 0.794, 0.850, 0.794,0.803, (2.3480)+(0.0613)Ser+(−0.0851)Asn+(−0.1000)His+(−0.0562)Cit+(0.1417)Phe+(−0.1226)Trp; 0.867, 0.891, 0.770, 0.749, 0.7 60,0.826, 0.805, 0.785, (−0.0684)+(0.0424)Ser+(−0.1171)Cit+(0.1614)Ile+(−0.0751)Leu+(0.1005)Phe+(−0.1877)Trp; 0.867, 0.890, 0.821,0.824, 0.821, 0.837, 0.803, 0.821,(0.0351)+(0.0542)Ser+(−0.0729)Asn+(−0.2437)Met+(0.0031)Lys+(0.1343)Phe+(−0.1420)Trp; 0.867, 0.891, 0.758, 0.713, 0.766, 0.840, 0.801, 0.780, (−1.6511)+(0.0665)Ser+(−0.0078)Asn+(−0.1508)His+(−0.3388)Met+(0.0649)Ile+(0.1399)Phe; 0.867, 0.888, 0.790, 0.757, 0.799, 0.838, 0.824,0.804, (0.1367)+(0.0102)Gln+(−0.1786)His+(0.0394)Thr+(−0.4136)Met+(0.0524)Ile+(0.1319)Phe; 0.867, 0.892, 0.801, 0.786, 0.785, 0.856,0.836, 0.816, (2.6511)+(0.0525)Ser+(−0.0066)Gly+(−0.2160)Met+(0.1593)Ile+(−0.0571)Leu+(−0.1317)Trp; 0.867, 0.892, 0.7 74,0.753, 0.772, 0.828, 0.794, 0.787, (1.3292)+(0.0396)Ser+(0.0043)Gln+(−0.1484)His+(0.0066)Thr+(0.1172)Phe+(−0.1250)Trp; 0. 867, 0.893,0.800, 0.798, 0.806, 0.823, 0.774, 0.800, (−0.8880)+(0.0556)Ser+(−0.0141)Arg+(0.0115)Pro+(−0.3189)Met+(0.1333)Phe+(−0.1456)Trp;0.867, 0.891, 0.758, 0.711, 0.766, 0.840, 0.804, 0.78 0,(−1.7131)+(0.0671)Ser+(−0.0009)Gly+(−0.1512)His+(−0.3443)Met+(0.0654)Ile+(0.1392)Phe;0.866, 0.893, 0.787, 0.769, 0.784, 0. 842, 0.800, 0.799,(2.2796)+(0.0581)Ser+(−0.0901)Asn+(−0.1183)His+(0.0017)Lys+(0.1287)Phe+(−0.1095)Trp;0.866, 0.889, 0.761, 0.734, 0.766, 0.822, 0.778, 0.775,(2.0257)+(0.0449)Ser+(−0.1406)His+(0.0087)Thr+(0.0023)Val+(0.1167)Phe+(−0.1265)Trp; 0.86 6, 0.893,0.758, 0.714, 0.766, 0.840, 0.800, 0.780, (−1.6271)+(0.0678)Ser+(−0.1484)His+(−0.3320)Met+(−0.0062)Lys+(0.0684)Ile+(0.1411)Phe;0.866, 0.890, 0.787, 0.757, 0.780, 0.862, 0.828, 0.807,(3.6922)+(0.0512)Ser+(−0.0915)His+(−0.0033)Ala+(−0.1574)Met+(0.0972)Ile+(−0.1026)Trp; 0.866, 0.891, 0.795, 0.792, 0.797, 0.8 15,0.784, 0.797, (−1.2230)+(0.0532)Ser+(0.0113)Pro+(−0.3405)Met+(0.0012)Lys+(0.1306)Phe+(−0.1485)Trp; 0.866, 0.892, 0.777, 0. 753,0.772, 0.841, 0.806, 0.793, (2.0937)+(0.0472)Ser+(−0.1310)His+(−0.0036)Ala+(0.0119)Orn+(0.1224)Phe+(−0.1156)Trp; 0.866, 0.894,0.840, 0.838, 0.836, 0.858, 0.841, 0.843,(2.0299)+(0.0044)Gly+(0.0119)Gln+(−0.1319)His+(−0.2072)Met+(0.1476)Phe+(−0.1045)Trp; 0.866, 0.892, 0.784, 0.767, 0.776, 0.836, 0.805, 0.796, (1.2252)+(0.0426)Ser+(0.0051)Gln+(−0.1436)His+(−0.0054)Lys+(0.1216)Phe+(−0.1167)Trp; 0.866, 0.890, 0.785, 0.751, 0.791, 0.860, 0. 806,0.802,(3.7885)+(0.0526)Ser+(−0.0815)His+(−0.0435)Cit+(−0.1576)Met+(0.0935)Ile+(−0.1113)Trp;0.866, 0.892, 0.791, 0.775, 0.793, 0.844, 0.791, 0.801,(2.4370)+(0.0597)Ser+(−0.0754)Asn+(−0.1162)His+(−0.0134)Arg+(0.1334)Phe+(−0.1076)Trp;0.866, 0. 888, 0.801, 0.785, 0.785, 0.825, 0.862, 0.814,(3.1208)+(0.0076)Gln+(−0.1219)His+(0.0989)Ile+(−0.0386)Leu+(0.0840)Phe+(−0.126 5)Trp;0.866, 0.894, 0.793, 0.776, 0.795, 0.823, 0.813, 0.802, (−1.7476)+(0.0555)Ser+(−0.3303)Met+(−0.0055)Lys+(0.0653)Ile+(0.1103)Phe+(−0.1483)Trp; 0.866, 0.895, 0.757, 0.721, 0.760, 0.828, 0. 798,0.777, (1.4925)+(0.0554)Ser+(−0.1343)His+(−0.0241)Arg+(0.0596)Ile+(0.1037)Phe+(−0.1320)Trp; 0.866, 0.891, 0.795, 0.773, 0. 814,0.856, 0.771, 0.803, (3.0257)+(0.0414)Ser+(0.0176)Thr+(−0.0784)Cit+(−0.2548)Met+(0.0840)Ile+(−0.1531)Trp; 0.866, 0.890, 0.776,0.753, 0.775, 0.830, 0.802, 0.790, (1.0534)+(0.0417)Ser+(0.0049)Gln+(−0.1499)His+(0.0040)Val+(0.1119)Phe+(−0.1245)Trp; 0.866,0.889, 0.817, 0.800, 0.799, 0.851, 0.876, 0.832, (3.5835)+(0.0088)Gln+(−0.1319)His+(−0.0062)Ala+(0.0581)Ile+(0.0803)Phe+(−0.1303)Trp;0.866, 0.889, 0.771, 0.744, 0.770, 0.828, 0.806, 0.78 7,(1.0660)+(0.0421)Ser+(0.0048)Gln+(−0.1523)His+(0.0147)Leu+(0.1045)Phe+(−0.1284)Trp; 0.866, 0.890, 0.825, 0.825, 0.832, 0.8 41,0.795, 0.823, (−0.8342)+(0.0482)Ser+(0.0037)Gln+(−0.0860)Cit+(−0.2778)Met+(0.1531)Phe+(−0.1566)Trp; 0.866, 0.895, 0.843, 0.838,0.841, 0.846, 0.859, 0.846, (2.3031)+(0.0124)Gln+(−0.1264)His+(0.0070)Pro+(−0.2170)Met+(0.1381)Phe+(−0.1083)Trp; 0.8 66, 0.889,0.804, 0.792, 0.779, 0.871, 0.839, 0.821, (2.8020)+(0.0416)Ser+(−0.0058)Ala+(−0.1867)Met+(0.1731)Ile+(−0.0597)Leu+(−0.1252)Trp;0.865, 0.888, 0.784, 0.750, 0.784, 0.855, 0.826, 0.80 4,(3.5909)+(0.0564)Ser+(−0.0033)Gly+(−0.0910)His+(−0.1714)Met+(0.0910)Ile+(−0.1063)Trp; 0.865, 0.893, 0.794, 0.779, 0.798, 0. 821,0.808, 0.802, (−1.6680)+(0.0575)Ser+(−0.0151)Arg+(−0.3253)Met+(0.0635)Ile+(0.1129)Phe+(−0.1509)Trp; 0.865, 0.889, 0.78 1, 0.747,0.782, 0.854, 0.815, 0.800, (3.5323)+(0.0511)Ser+(−0.0958)His+(−0.1835)Met+(0.0037)Lys+(0.0906)Ile+(−0.1071)Trp; 0. 865, 0.892,0.798, 0.797, 0.799, 0.816, 0.787, 0.800, (−1.4158)+(0.0521)Ser+(0.0010)Gln+(0.0110)Pro+(−0.3405)Met+(0.1305)Phe+(−0.1484)Trp;0.865, 0.895, 0.769, 0.749, 0.778, 0.834, 0.754, 0.77 9,(2.5338)+(0.0471)Ser+(−0.1358)His+(0.0176)Thr+(−0.0274)Arg+(0.1296)Phe+(−0.1266)Trp; 0.865, 0.891, 0.804, 0.790, 0.766, 0. 843,0.894, 0.823, (5.5204)+(−0.0756)His+(−0.0068)Ala+(−0.0341)Val+(0.1401)Ile+(0.0910)Phe+(−0.1166)Trp; 0.865, 0.891, 0.75 7, 0.713,0.765, 0.840, 0.801, 0.779, (−1.7494)+(0.0664)Ser+(−0.1512)His+(−0.3463)Met+(−0.0033)Orn+(0.0665)Ile+(0.1411)Phe; 0. 865,0.890, 0.773, 0.745, 0.768, 0.840, 0.810, 0.791, (2.0372)+(0.0496)Ser+(−0.1359)His+(−0.0044)Ala+(0.0178)Leu+(0.1135)Phe+(−0.1237)Trp;0.865, 0.895, 0.795, 0.773, 0.801, 0.823, 0.819, 0.80 4,(−2.0581)+(0.0556)Ser+(0.0151)Tyr+(−0.3670)Met+(0.0633)Ile+(0.1059)Phe+(−0.1563)Trp; 0.865, 0.890, 0.758, 0.731, 0.762, 0. 823,0.776, 0.773, (1.9326)+(0.0456)Ser+(−0.1383)His+(0.0072)Thr+(0.0036)Pro+(0.1169)Phe+(−0.1262)Trp; 0.865, 0.889, 0.791, 0. 769,0.797, 0.826, 0.809, 0.800, (1.3487)+(0.0550)Ser+(−0.1235)Asn+(−0.1030)Cit+(0.0544)Ile+(0.0926)Phe+(−0.1805)Trp; 0.865, 0.890,0.771, 0.750, 0.766, 0.827, 0.797, 0.785,(1.0884)+(0.0423)Ser+(0.0045)Gln+(−0.1457)His+(0.0039)Pro+(0.1143)Phe+(−0.1238)Trp; 0.865, 0.889, 0.809, 0.788, 0.838, 0.817, 0.799, 0.811, (2.9169)+(0.0417)Thr+(−0.0943)Cit+(−0.3517)Met+(0.0567)Ile+(0.1356)Phe+(−0.1834)Trp; 0.865, 0.888, 0.796, 0.781, 0.791, 0.853, 0. 804,0.807,(−1.7952)+(0.0557)Ser+(−0.0577)Asn+(0.0089)Gln+(−0.1605)His+(−0.2676)Met+(0.1623)Phe;0.865, 0.892, 0.786, 0.774, 0.779, 0.837, 0.793, 0.796,(2.2847)+(0.0586)Ser+(−0.0854)Asn+(−0.1150)His+(−0.0190)Tyr+(0.1393)Phe+(−0.1025)Trp;0.865, 0. 890, 0.780, 0.759, 0.773, 0.846, 0.801, 0.795,(2.1048)+(0.0494)Ser+(−0.1277)His+(−0.0031)Ala+(−0.0024)Lys+(0.1286)Phe+(−0.11 41)Trp;0.865, 0.889, 0.769, 0.742, 0.772, 0.821, 0.799, 0.783, (2.2494)+(0.0499)Ser+(−0.0043)Gly+(−0.1359)His+(0.0106)Thr+(0.1185)Phe+(−0.1282)Trp; 0.865, 0.888, 0.805, 0.784, 0.803, 0.866, 0. 823,0.819,(2.9717)+(0.0465)Ser+(−0.0060)Ala+(−0.0755)Cit+(−0.1622)Met+(0.0960)Ile+(−0.1444)Trp;0.865, 0.892, 0.852, 0.849, 0.848, 0.857, 0.864, 0.854,(2.5117)+(−0.0105)Asn+(0.0128)Gln+(−0.1258)His+(−0.1885)Met+(0.1391)Phe+(−0.1051)Trp;0.865, 0. 893, 0.799, 0.796, 0.819, 0.820, 0.753, 0.797,(−0.7088)+(0.0421)Ser+(0.0252)Thr+(−0.3842)Met+(0.0058)Leu+(0.1397)Phe+(−0.160 8)Trp;0.865, 0.890, 0.751, 0.711, 0.748, 0.819, 0.812, 0.772, (1.3571)+(0.0491)Ser+(−0.1387)His+(−0.0035)Orn+(0.0561)Ile+(0.0958)Phe+(−0.1340)Trp; 0.865, 0.893, 0.845, 0.835, 0.844, 0.857, 0.8 67,0.851, (2.3748)+(0.0127)Gln+(−0.1335)His+(−0.2057)Met+(0.0145)Leu+(0.1299)Phe+(−0.1120)Trp; 0.865, 0.891, 0.757, 0.714, 0. 767,0.837, 0.791, 0.777,(−1.6794)+(0.0690)Ser+(−0.1484)His+(−0.0117)Arg+(−0.3335)Met+(0.0656)Ile+(0.1416)Phe;0.865, 0.894, 0.794, 0.782, 0.792, 0.842, 0.796, 0.803,(0.9549)+(0.0446)Ser+(0.0073)Gln+(−0.1453)His+(−0.0274)Arg+(0.1274)Phe+(−0.1172)Tr p; 0.865,0.889, 0.821, 0.817, 0.829, 0.835, 0.806, 0.821,(0.1829)+(0.0577)Ser+(−0.0039)Gly+(−0.0750)Cit+(−0.2586)Met+(0.1518)Phe+(−0.1545)Trp;0.865, 0.891, 0.821, 0.824, 0.823, 0.839, 0.799, 0.821,(0.0942)+(0.0544)Ser+(−0.0720)Asn+(−0.2377)Met+(0.0051)Orn+(0.1323)Phe+(−0.1393)Trp; 0.865, 0.890, 0.786, 0.766, 0.78 1,0.828, 0.823, 0.799, (1.2183)+(0.0475)Ser+(−0.0045)Gly+(0.0052)Gln+(−0.1433)His+(0.1159)Phe+(−0.1227)Trp; 0.865, 0.888, 0. 781,0.751, 0.782, 0.830, 0.823, 0.796, (2.7991)+(−0.1308)His+(0.0387)Thr+(−0.3675)Met+(0.1279)Ile+(−0.0562)Leu+(0.1397)Phe; 0.864,0.889, 0.804, 0.791, 0.823, 0.839, 0.772, 0.806, (2.3497)+(0.0518)Ser+(−0.1359)Asn+(−0.1254)Cit+(0.0433)Orn+(0.1044)Phe+(−0.1673)Trp;0.864, 0.890, 0.779, 0.745, 0.783, 0.851, 0.810, 0.79 7,(3.5422)+(0.0504)Ser+(−0.0975)His+(−0.1768)Met+(0.0137)Orn+(0.0882)Ile+(−0.1053)Trp; 0.864, 0.892, 0.797, 0.793, 0.802, 0. 817,0.786, 0.799, (−1.2270)+(0.0537)Ser+(0.0110)Pro+(0.0054)Tyr+(−0.3440)Met+(0.1298)Phe+(−0.1487)Trp; 0.864, 0.888, 0.782, 0.749,0.774, 0.863, 0.827, 0.803, (4.2658)+(0.0461)Ser+(−0.0854)His+(−0.0063)Ala+(−0.0595)Cit+(0.0951)Ile+(−0.1256)Trp; 0. 864, 0.891,0.751, 0.719, 0.744, 0.816, 0.806, 0.771, (1.3876)+(0.0483)Ser+(−0.1346)His+(−0.0247)Tyr+(0.0557)Ile+(0.1074)Phe+(−0.1254)Trp;0.864, 0.887, 0.791, 0.766, 0.788, 0.822, 0.842, 0.80 4,(3.4080)+(0.0072)Gln+(−0.1453)His+(0.0132)Thr+(0.0462)Ile+(0.0770)Phe+(−0.1387)Trp; 0.864, 0.888, 0.815, 0.812, 0.826, 0.8 38,0.783, 0.815, (0.0448)+(0.0526)Ser+(−0.0812)Cit+(−0.2603)Met+(−0.0002)Lys+(0.1539)Phe+(−0.1533)Trp; 0.864, 0.884, 0.775, 0.750,0.743, 0.856, 0.847, 0.799, (4.2402)+(0.0376)Ser+(−0.0802)His+(−0.0058)Ala+(−0.0245)Val+(0.1442)Ile+(−0.1113)Trp; 0. 864, 0.889,0.782, 0.750, 0.782, 0.854, 0.815, 0.800, (3.6743)+(0.0522)Ser+(−0.0094)Asn+(−0.0924)His+(−0.1661)Met+(0.0914)Ile+(−0.1051)Trp;0.864, 0.888, 0.820, 0.803, 0.812, 0.838, 0.866, 0.83 0,(5.0566)+(−0.0729)His+(−0.1924)Met+(0.1327)Ile+(−0.0570)Leu+(0.1232)Phe+(−0.1063)Trp; 0.864, 0.893, 0.793, 0.777, 0.794, 0. 818,0.815, 0.801,(−2.0466)+(0.0535)Ser+(0.0008)Gln+(−0.3468)Met+(0.0622)Ile+(0.1090)Phe+(−0.1534)Trp;0.864, 0.889, 0.825, 0.825, 0.823, 0.829, 0.826, 0.826,(−0.1857)+(0.0596)Ser+(−0.0072)Gly+(−0.0043)Val+(−0.2817)Met+(0.1400)Phe+(−0.1423)Trp; 0. 864, 0.886,0.767, 0.739, 0.769, 0.847, 0.778, 0.784, (−0.8531)+(0.0651)Ser+(−0.1440)His+(−0.0039)Ala+(0.0146)Pro+(−0.3181)Met+(0.1608)Phe; 0.864, 0.886, 0.759, 0.730, 0.762, 0.822, 0.782, 0.77 4,(1.7703)+(0.0486)Ser+(−0.1357)His+(0.0044)Pro+(0.0018)Val+(0.1145)Phe+(−0.1240)Trp; 0.864, 0.889, 0.770, 0.736, 0.767, 0.8 51,0.803, 0.790, (4.0197)+(0.0434)Ser+(−0.0798)His+(−0.0580)Cit+(0.1226)Ile+(−0.0301)Leu+(−0.1288)Trp; 0.864, 0.889, 0.817, 0.815,0.826, 0.840, 0.788, 0.817, (0.1084)+(0.0522)Ser+(−0.0008)Ala+(−0.0807)Cit+(−0.2550)Met+(0.1540)Phe+(−0.1526)Trp; 0. 864, 0.892,0.824, 0.826, 0.825, 0.842, 0.805, 0.825, (0.0360)+(0.0550)Ser+(−0.0689)Asn+(0.0075)Tyr+(−0.2492)Met+(0.1334)Phe+(−0.1414)Trp;0.864, 0.892, 0.849, 0.846, 0.846, 0.856, 0.861, 0.85 2,(2.4120)+(0.0126)Gln+(−0.1277)His+(0.0002)Ala+(−0.1968)Met+(0.1405)Phe+(−0.1055)Trp; 0.864, 0.890, 0.764, 0.737, 0.783, 0. 837,0.741, 0.775, (0.0799)+(0.0530)Ser+(−0.1604)His+(0.0323)Ihr+(−0.3660)Met+(−0.0063)Lys+(0.1763)Phe; 0.864, 0.889, 0.797, 0.776,0.791, 0.861, 0.822, 0.812,(1.8167)+(0.0463)Ser+(0.0346)Tyr+(−0.2758)Met+(0.1638)Ile+(−0.0597)Leu+(−0.1427)Trp;0.86 4, 0.888, 0.810, 0.801, 0.823, 0.832, 0.789, 0.811, (−0.1720)+(0.0535)Ser+(−0.0842)Cit+(−0.2714)Met+(0.0110)Leu+(0.1461)Phe+(−0.1599)Trp;0.864, 0.891, 0.795, 0.792, 0.798, 0.815, 0.785, 0.797,(−1.1994)+(0.0534)Ser+(0.0111)Pro+(−0.3373)Met+(0.0010)Leu+(0.1301)Phe+(−0.1479)Trp;0.864, 0.888, 0.754, 0.718, 0.762, 0.82 0, 0.782, 0.771,(2.0064)+(0.0451)Ser+(−0.1450)His+(0.0090)Thr+(0.0141)Leu+(0.1073)Phe+(−0.1317)Trp; 0.864, 0.887, 0.794, 0.7 69,0.784, 0.857, 0.832, 0.811, (3.2807)+(0.0414)Ser+(−0.0853)Asn+(0.0072)Gln+(−0.1132)His+(0.0727)Ile+(−0.1148)Trp; 0.864, 0. 889,0.820, 0.803, 0.810, 0.841, 0.872, 0.831, (3.5412)+(−0.0498)Asn+(0.0104)Gln+(−0.1311)His+(0.0461)Ile+(0.0770)Phe+(−0.127 0)Trp;0.864, 0.888, 0.815, 0.812, 0.826, 0.837, 0.784, 0.815, (0.0255)+(0.0526)Ser+(−0.0815)Cit+(0.0003)Val+(−0.2612)Met+(0.1534)Phe+(−0.1539)Trp; 0.864, 0.887, 0.774, 0.750, 0.746, 0.858, 0.8 38,0.798, (4.6036)+(0.0464)Ser+(−0.0829)Asn+(−0.0690)His+(−0.0291)Val+(0.1429)Ile+(−0.1011)Trp; 0.864, 0.883, 0.785, 0.761, 0. 768,0.854, 0.836, 0.805, (3.3127)+(0.0353)Ser+(0.0049)Gln+(−0.1169)His+(−0.0056)Ala+(0.0838)Ile+(−0.1203)Trp; 0.864, 0.892, 0.844,0.840, 0.841, 0.848, 0.860, 0.847,(2.0904)+(0.0121)Gln+(−0.1342)His+(−0.2275)Met+(0.0111)Lys+(0.1425)Phe+(−0.1118)Trp; 0.863, 0.886, 0.784, 0.757, 0.779, 0.815, 0.841, 0.798,(4.9673)+(−0.1107)His+(0.0156)Thr+(0.0966)Ile+(−0.0378)Leu+(0.0869)Phe+(−0.1312)Trp; 0.863, 0.885, 0.792, 0.775, 0.767, 0.827, 0.866, 0.809,(3.5146)+(0.0063)Gln+(−0.1107)His+(−0.0256)Val+(0.1070)Ile+(0.0825)Phe+(−0.1245)Trp;0.863, 0.891, 0.757, 0.712, 0.764, 0.839, 0.801, 0.779,(−1.6709)+(0.0656)Ser+(−0.1514)His+(−0.0041)Tyr+(−0.3390)Met+(0.0655)Ile+(0.1408)Phe; 0.863, 0.892, 0.8 49,0.844, 0.846, 0.853, 0.863, 0.851, (2.4047)+(0.0126)Gln+(−0.1304)His+(0.0029)Val+(−0.1969)Met+(0.1366)Phe+(−0.1080)Trp; 0. 863,0.887, 0.774, 0.747, 0.757, 0.817, 0.850, 0.793, (4.8935)+(−0.1028)His+(0.0174)Thr+(−0.0298)Val+(0.1160)Ile+(0.0854)Phe+(−0.1281)Trp;0.863, 0.885, 0.780, 0.755, 0.759, 0.856, 0.837, 0.80 2,(4.1227)+(0.0399)Ser+(−0.0899)His+(−0.0061)Ala+(0.1284)Ile+(−0.0302)Leu+(−0.1135)Trp; 0.863, 0.884, 0.765, 0.734, 0.751, 0. 845,0.817, 0.787,(4.2121)+(0.0410)Ser+(−0.0738)His+(−0.0527)Cit+(−0.0233)Val+(0.1356)Ile+(−0.1258)Trp;0.863, 0.885, 0.780, 0.748, 0.781, 0.850, 0.814, 0.798,(3.0084)+(0.0371)Ser+(0.0059)Gln+(−0.1080)His+(−0.0611)Cit+(0.0802)Ile+(−0.1360)Trp;0.86 3, 0.882, 0.803, 0.790, 0.765, 0.863, 0.875, 0.823, (6.3790)+(0.0162)Thr+(−0.0087)Ala+(−0.0729)Cit+(−0.0371)Val+(0.1714)Ile+(−0.1424)Trp;0.863, 0.885, 0.783, 0.768, 0.732, 0.889, 0.849, 0.810,(1.5650)+(0.0333)Ser+(0.0217)Thr+(−0.0059)Ala+(−0.0563)Val+(−0.3799)Met+(0.2184)Ile;0.863, 0.887, 0.792, 0.775, 0.751, 0.86 7, 0.868, 0.815,(4.3520)+(0.0524)Ser+(−0.1265)Asn+(−0.0061)Gly+(−0.0420)Val+(0.1596)Ile+(−0.1160)Trp; 0.863, 0.889, 0.762, 0. 736,0.763, 0.826, 0.784, 0.777, (1.8943)+(0.0496)Ser+(−0.1317)His+(0.0052)Pro+(−0.0045)Lys+(0.1201)Phe+(−0.1193)Trp; 0.863, 0.888,0.783, 0.760, 0.776, 0.840, 0.817, 0.798,(2.1571)+(0.0537)Ser+(−0.0036)Gly+(−0.1260)His+(−0.0031)Ala+(0.1256)Phe+(−0.1177)Trp; 0.863, 0.888, 0.800, 0.789, 0.766, 0.839, 0.874, 0.817, (4.9568)+(−0.1417)Asn+(0.0221)Thr+(−0.0505)Val+(0.1538)Ile+(0.0842)Phe+(−0.1306)Trp; 0.863, 0.885, 0.774, 0.749, 0.760, 0.852, 0. 812,0.793, (3.4650)+(0.0302)Ser+(−0.1034)Cit+(−0.0349)Val+(0.0353)Orn+(0.1427)Ile+(−0.1640)Trp; 0.863, 0.895, 0.811, 0.805, 0. 802,0.845, 0.820, 0.818,(−0.5507)+(0.0517)Ser+(−0.0339)Val+(−0.3204)Met+(0.0609)Leu+(0.1370)Phe+(−0.1400)Trp;0.863, 0.890, 0.768, 0.743, 0.769, 0.831, 0.788, 0.783,(2.0556)+(0.0477)Ser+(−0.1327)His+(0.0113)Orn+(−0.0050)Lys+(0.1201)Phe+(−0.1146)Trp; 0.863, 0.890, 0.818, 0.824, 0.818, 0.835, 0.792, 0.817, (−0.4446)+(0.0488)Ser+(−0.0006)Ala+(−0.0046)Val+(−0.2805)Met+(0.1422)Phe+(−0.1403)Trp; 0.863, 0.889, 0.813, 0.800, 0.787, 0.841, 0.87 9,0.827, (5.5709)+(−0.0835)His+(−0.0070)Ala+(0.1302)Ile+(−0.0527)Leu+(0.0937)Phe+(−0.1185)Trp; 0.863, 0.888, 0.815, 0.812, 0. 826,0.838, 0.784, 0.815, (0.0233)+(0.0525)Ser+(−0.0816)Cit+(0.0007)Arg+(−0.2617)Met+(0.1538)Phe+(−0.1536)Trp; 0.863, 0.884, 0.771,0.738, 0.757, 0.850, 0.829, 0.794,(4.0266)+(0.0428)Ser+(−0.1045)His+(−0.0070)Ala+(0.0064)Pro+(0.0814)Ile+(−0.1189)Trp; 0.863, 0.889, 0.754, 0.719, 0.774, 0.833, 0.745, 0.768, (−0.4550)+(0.0535)Ser+(−0.1693)His+(0.0310)Thr+(−0.3949)Met+(0.0155)Leu+(0.1606)Phe;0.863, 0.887, 0.792, 0.780, 0.780, 0.852, 0.806, 0. 805,(2.6565)+(0.0384)Ser+(0.0084)Thr+(−0.2437)Met+(0.1554)Ile+(−0.0546)Leu+(−0.1348)Trp; 0.863, 0.889, 0.794, 0.766, 0.784, 0.839,0.853, 0.811, (5.7173)+(−0.1214)His+(0.0225)Thr+(−0.0070)Ala+(0.0585)Ile+(0.0849)Phe+(−0.1386)Trp; 0.863, 0.888, 0.81 6, 0.821,0.818, 0.829, 0.789, 0.814, (−0.5584)+(0.0482)Ser+(−0.0058)Val+(−0.2932)Met+(0.0033)Lys+(0.1427)Phe+(−0.1425)Trp; 0. 863,0.891, 0.818, 0.818, 0.819, 0.834, 0.803, 0.818, (−0.0585)+(0.0554)Ser+(−0.0692)Asn+(−0.2448)Met+(0.0061)Leu+(0.1296)Phe+(−0.1422)Trp;0.863, 0.889, 0.801, 0.785, 0.773, 0.833, 0.879, 0.81 8,(5.7446)+(−0.0428)Asn+(−0.0718)His+(−0.0356)Val+(0.1300)Ile+(0.0895)Phe+(−0.1126)Trp; 0.863, 0.889, 0.768, 0.740, 0.773, 0. 829,0.786, 0.782, (2.0007)+(0.0496)Ser+(−0.1342)His+(0.0043)Val+(−0.0052)Lys+(0.1190)Phe+(−0.1184)Trp; 0.863, 0.891, 0.820, 0.814,0.834, 0.843, 0.791, 0.821, (−0.0691)+(0.0532)Ser+(−0.0814)Cit+(0.0147)Tyr+(−0.2826)Met+(0.1505)Phe+(−0.1569)Trp; 0.8 63, 0.890,0.777, 0.758, 0.771, 0.830, 0.800, 0.790, (1.1804)+(0.0412)Ser+(0.0046)Gln+(−0.1460)His+(0.0048)Orn+(0.1157)Phe+(−0. 1208)Trp;0.863, 0.889, 0.767, 0.737, 0.767, 0.823, 0.801, 0.782, (1.9300)+(0.0545)Ser+(−0.0042)Gly+(−0.1310)His+(0.0055)Pro+(0.1147)Phe+(−0.1255)Trp; 0.862, 0.890, 0.815, 0.807, 0.827, 0.820, 0. 808,0.815, (3.0045)+(0.0478)Thr+(−0.0476)Val+(−0.4018)Met+(0.0773)Leu+(0.1444)Phe+(−0.1555)Trp; 0.862, 0.890, 0.762, 0.737, 0. 765,0.826, 0.778, 0.777, (2.0560)+(0.0441)Ser+(−0.1392)His+(0.0082)Thr+(0.0052)Orn+(0.1178)Phe+(−0.1241)Trp; 0.862, 0.883, 0. 811,0.795, 0.793, 0.852, 0.864, 0.826, (0.0062)+(0.0116)Gln+(−0.1305)His+(−0.3134)Met+(0.1368)Ile+(−0.0627)Leu+(0.1303)Phe; 0.862,0.886, 0.805, 0.785, 0.794, 0.865, 0.835, 0.820, (3.9584)+(0.0461)Ser+(−0.0734)Asn+(−0.0072)Ala+(−0.0832)Cit+(0.0874)Ile+(−0.1536)Trp; 0.862, 0.888, 0.783, 0.757, 0.787, 0.846, 0.800, 0.7 97,(−2.2507)+(0.0539)Ser+(0.0077)Gln+(−0.1716)His+(−0.3210)Met+(0.0132)Leu+(0.1530)Phe;0.862, 0.890, 0.764, 0.741, 0.789, 0. 840, 0.719, 0.772,(0.1342)+(0.0545)Ser+(−0.1584)His+(0.0363)Ihr+(−0.0227)Arg+(−0.3686)Met+(0.1778)Phe; 0.862, 0.888, 0.830, 0.827,0.820, 0.848, 0.843, 0.835, (3.3589)+(−0.0610)Asn+(0.0034)Gly+(0.0107)Gln+(−0.1298)His+(0.1065)Phe+(−0.1130)Trp; 0.8 62, 0.888,0.818, 0.812, 0.768, 0.854, 0.911, 0.836, (5.0118)+(−0.0713)Asn+(−0.0075)Ala+(−0.0478)Val+(0.1664)Ile+(0.0865)Phe+(−0.1230)Trp;0.862, 0.892, 0.796, 0.793, 0.800, 0.813, 0.786, 0.79 8,(−1.1707)+(0.0540)Ser+(0.0117)Pro+(−0.3362)Met+(−0.0057)Orn+(0.1339)Phe+(−0.1477)Trp; 0.862, 0.886, 0.807, 0.793, 0.808, 0. 826,0.829, 0.814, (3.7059)+(0.0079)Gln+(−0.1425)His+(0.0180)Ihr+(−0.0058)Lys+(0.1061)Phe+(−0.1258)Trp; 0.862, 0.886, 0.780, 0.762,0.750, 0.889, 0.810, 0.803,(2.0491)+(0.0334)Ser+(0.0249)Thr+(−0.0577)Cit+(−0.0553)Val+(−0.4016)Met+(0.2076)Ile;0.86 2, 0.885, 0.806, 0.784, 0.798, 0.831, 0.861, 0.819, (3.3636)+(0.0091)Gln+(−0.1363)His+(−0.0053)Lys+(0.0507)Ile+(0.0776)Phe+(−0. 1297)Trp;0.862, 0.894, 0.855, 0.850, 0.855, 0.863, 0.864, 0.858, (2.2508)+(0.0135)Gln+(−0.1156)His+(−0.0544)Cit+(−0.1821)Met+(0.1518)Phe+(−0.1151)Trp; 0.862, 0.891, 0.821, 0.823, 0.824, 0.837, 0. 797,0.820,(−0.5815)+(0.0496)Ser+(0.0134)Tyr+(−0.0052)Val+(−0.3040)Met+(0.1399)Phe+(−0.1435)Trp;0.862, 0.888, 0.759, 0.742, 0.756, 0.819, 0.766, 0.771,(2.0936)+(0.0434)Ser+(−0.1355)His+(0.0137)Thr+(−0.0302)Tyr+(0.1349)Phe+(−0.1183)Trp;0.862, 0.8 88, 0.793, 0.771, 0.806, 0.843, 0.788, 0.802,(2.7887)+(0.0484)Ser+(−0.0749)Cit+(0.0067)Pro+(−0.2175)Met+(0.0776)Ile+(−0.153 1)Trp; 0.862,0.891, 0.767, 0.740, 0.779, 0.836, 0.761, 0.779, (2.1649)+(0.0468)Ser+(−0.1226)His+(0.0155)Thr+(−0.0671)Cit+(0.1359)Phe+(−0.1458)Trp; 0.862, 0.886, 0.788, 0.770, 0.790, 0.845, 0.7 92,0.799, (−2.0421)+(0.0523)Ser+(0.0078)Gln+(−0.1671)His+(0.0005)Ala+(−0.3088)Met+(0.1634)Phe; 0.862, 0.890, 0.801, 0.769, 0. 822,0.853, 0.805, 0.812, (2.0511)+(0.0517)Ser+(−0.0769)Cit+(0.0386)Tyr+(−0.2669)Met+(0.0863)Ile+(−0.1620)Trp; 0.862, 0.887, 0.789,0.772, 0.790, 0.846, 0.794, 0.800,(−1.9995)+(0.0523)Ser+(0.0078)Gln+(−0.1667)His+(0.0002)Val+(−0.3055)Met+(0.1631)Phe; 0.862, 0.883, 0.796, 0.774, 0.786, 0.859, 0.831, 0.813, (3.7707)+(0.0409)Ser+(−0.0083)Ala+(−0.0902)Cit+(−0.0127)Lys+(0.1006)Ile+(−0.1581)Trp; 0.862, 0.887, 0.815, 0.817, 0.817, 0.830, 0.79 4,0.815, (−0.6094)+(0.0489)Ser+(−0.0013)Ala+(−0.2831)Met+(0.0010)Lys+(0.1348)Phe+(−0.1453)Trp; 0.862, 0.892, 0.846, 0.841, 0. 843,0.853, 0.858, 0.849, (2.4961)+(0.0121)Gln+(−0.1282)His+(−0.1947)Met+(0.0089)Orn+(0.1359)Phe+(−0.1050)Trp; 0.862, 0.890, 0. 788,0.769, 0.787, 0.844, 0.801, 0.800, (0.8908)+(0.0444)Ser+(0.0059)Gln+(−0.1300)His+(−0.0634)Cit+(0.1329)Phe+(−0.1355)Trp; 0.862,0.888, 0.825, 0.825, 0.824, 0.823, 0.829, 0.825,(−0.8441)+(0.0579)Ser+(−0.0075)Gly+(0.0021)Gln+(−0.2941)Met+(0.1310)Phe+(−0.1491)Trp; 0.862, 0.883, 0.790, 0.770, 0.758, 0.870, 0.852, 0.813, (5.9999)+(−0.0698)His+(0.0356)Thr+(−0.0035)Ala+(−0.0449)Val+(−0.3132)Met+(0.1885)Ile; 0.862, 0.887, 0.799, 0.785, 0.78 4,0.859, 0.819, 0.812, (3.0000)+(0.0447)Ser+(−0.0404)Asn+(−0.1829)Met+(0.1554)Ile+(−0.0555)Leu+(−0.1287)Trp; 0.862, 0.886, 0. 776,0.745, 0.788, 0.818, 0.801, 0.788, (0.9605)+(0.0456)Ser+(−0.1169)Cit+(−0.0220)Lys+(0.0716)Ile+(0.0939)Phe+(−0.1893)Trp; 0.862,0.884, 0.800, 0.780, 0.799, 0.849, 0.822, 0.812,(7.2924)+(−0.0813)His+(0.0306)Thr+(−0.1943)Met+(0.1154)Ile+(−0.0277)Leu+(−0.1092)Trp; 0.862, 0.886, 0.759, 0.733, 0.776, 0.830, 0.741, 0. 770,(−0.2427)+(0.0522)Ser+(−0.1627)His+(0.0303)Thr+(0.0004)Ala+(−0.3769)Met+(0.1726)Phe;0.862, 0.889, 0.819, 0.825, 0.821, 0.839, 0.782, 0.817,(−0.2673)+(0.0512)Ser+(−0.0124)Arg+(−0.0045)Val+(−0.2696)Met+(0.1437)Phe+(−0.1386)Trp; 0.862, 0.886, 0. 766,0.753, 0.735, 0.815, 0.828, 0.783, (0.7726)+(0.0391)Ser+(−0.0385)Arg+(−0.0478)Val+(0.1588)Ile+(0.0886)Phe+(−0.1566)Trp; 0.862,0.887, 0.764, 0.738, 0.781, 0.835, 0.745, 0.775, (0.0802)+(0.0548)Ser+(−0.0357)Asn+(−0.1569)His+(0.0307)Thr+(−0.3490)Met+(0.1712)Phe; 0.862, 0.884, 0.803, 0.786, 0.804, 0.822, 0.828, 0.81 0,(3.5153)+(0.0077)Gln+(−0.1456)His+(0.0155)Thr+(0.0015)Val+(0.0996)Phe+(−0.1295)Trp; 0.862, 0.887, 0.823, 0.822, 0.825, 0.8 27,0.816, 0.822, (−0.1067)+(0.0621)Ser+(−0.0071)Gly+(−0.0122)Arg+(−0.2722)Met+(0.1352)Phe+(−0.1448)Trp; 0.862, 0.885, 0.836, 0.831,0.828, 0.845, 0.858, 0.841, (3.6527)+(−0.0537)Asn+(0.0112)Gln+(−0.1292)His+(0.0009)Val+(0.1007)Phe+(−0.1149)Trp; 0.8 61, 0.887,0.831, 0.830, 0.814, 0.835, 0.867, 0.837, (1.0670)+(0.0065)Gln+(−0.2951)Met+(0.1623)Ile+(−0.0802)Leu+(0.1153)Phe+(−0.1345)Trp;0.861, 0.888, 0.763, 0.739, 0.778, 0.834, 0.743, 0.773,(−0.1525)+(0.0517)Ser+(−0.1593)His+(0.0310)Thr+(−0.0027)Val+(−0.3728)Met+(0.1768)Phe; 0.861, 0.885, 0.755, 0.720, 0.761, 0.8 19,0.788, 0.772, (1.7702)+(0.0487)Ser+(−0.1391)His+(0.0033)Pro+(0.0126)Leu+(0.1067)Phe+(−0.1278)Trp; 0.861, 0.888, 0.794, 0. 790,0.750, 0.844, 0.861, 0.811, (0.5930)+(0.0316)Ser+(−0.0111)Ala+(0.1686)Ile+(−0.0786)Leu+(0.0776)Phe+(−0.1552)Trp; 0.861, 0.888,0.759, 0.732, 0.761, 0.823, 0.781, 0.774,(1.8109)+(0.0475)Ser+(−0.1354)His+(0.0044)Pro+(0.0067)Orn+(0.1142)Phe+(−0.1223)Trp; 0.861, 0.883, 0.803, 0.793, 0.769, 0.875, 0.851, 0.822, (3.7243)+(0.0406)Ser+(−0.0863)Asn+(−0.0075)Ala+(0.1609)Ile+(−0.0610)Leu+(−0.1278)Trp; 0.861, 0.885, 0.781, 0.746, 0.788, 0.819, 0. 831,0.796, (5.6127)+(−0.1249)His+(0.0234)Thr+(−0.0084)Lys+(0.0507)Ile+(0.0838)Phe+(−0.1363)Trp; 0.861, 0.888, 0.765, 0.738, 0. 767,0.827, 0.787, 0.780, (1.9034)+(0.0471)Ser+(−0.1367)His+(0.0023)Val+(0.0076)Orn+(0.1144)Phe+(−0.1210)Trp; 0.861, 0.887, 0. 817,0.821, 0.821, 0.834, 0.785, 0.815, (−0.3576)+(0.0514)Ser+(−0.0011)Ala+(−0.0127)Arg+(−0.2661)Met+(0.1371)Phe+(−0.1421)Tr p; 0.861,0.887, 0.790, 0.773, 0.790, 0.847, 0.794, 0.801, (−1.9425)+(0.0526)Ser+(0.0078)Gln+(−0.1659)His+(−0.3016)Met+(−0.0014)Lys+(0.1638)Phe; 0.861, 0.887, 0.762, 0.736, 0.778, 0.831, 0.749,0.774, (−0.1607)+(0.0541)Ser+(−0.0016)Gly+(−0.1607)His+(0.0306)Thr+(−0.3737)Met+(0.1711)Phe; 0.861, 0.890, 0.821, 0.829, 0.8 20,0.833, 0.795, 0.819, (−0.9262)+(0.0466)Ser+(0.0019)Gln+(−0.0051)Val+(−0.2928)Met+(0.1412)Phe+(−0.1425)Trp; 0.861, 0.886, 0.781,0.762, 0.729, 0.883, 0.865, 0.810,(1.2558)+(0.0430)Ser+(−0.0082)Ala+(0.0112)Pro+(−0.0516)Val+(−0.3203)Met+(0.1956)Ile; 0.861, 0.885, 0.786, 0.766, 0.773, 0.815, 0.842, 0.799,(4.5917)+(0.0039)Gly+(−0.1006)His+(0.1083)Ile+(−0.0446)Leu+(0.0899)Phe+(−0.1218)Trp; 0.861, 0.889, 0.816, 0.821, 0.816, 0.834, 0.788, 0.815, (−0.4831)+(0.0483)Ser+(−0.0057)Val+(−0.2859)Met+(0.0059)Orn+(0.1402)Phe+(−0.1397)Trp; 0.861, 0.886, 0.821, 0.819, 0.82 2,0.824, 0.825, 0.822, (−0.3110)+(0.0599)Ser+(−0.0072)Gly+(−0.0006)Ala+(−0.2816)Met+(0.1334)Phe+(−0.1465)Trp; 0.861, 0.885, 0.829,0.818, 0.801, 0.875, 0.883, 0.844,(4.9134)+(0.0066)Gln+(−0.0570)Cit+(−0.0378)Val+(−0.1870)Met+(0.1670)Ile+(−0.1228)Trp; 0.861, 0.888, 0.778, 0.766, 0.770, 0.824, 0.792, 0.788, (1.0973)+(0.0421)Ser+(0.0047)Gln+(−0.1408)His+(−0.0206)Tyr+(0.1286)Phe+(−0.1143)Trp;0.861, 0.886, 0.820, 0.818, 0.821, 0.820, 0.824, 0.821,(−0.3653)+(0.0601)Ser+(−0.0073)Gly+(−0.2865)Met+(0.0003)Lys+(0.1330)Phe+(−0.1474)Trp; 0.861, 0.892, 0.852, 0.845, 0.8 51,0.860, 0.867, 0.856, (2.3965)+(0.0128)Gln+(−0.1297)His+(0.0154)Tyr+(−0.2172)Met+(0.1374)Phe+(−0.1094)Trp; 0.861, 0.888, 0. 786,0.766, 0.788, 0.847, 0.792, 0.798, (−1.9641)+(0.0520)Ser+(0.0075)Gln+(−0.1672)His+(−0.3047)Met+(0.0067)Orn+(0.1609)Phe; 0.861,0.887, 0.806, 0.787, 0.814, 0.856, 0.802, 0.815, (1.9876)+(0.0429)Ser+(0.0035)Gln+(−0.0768)Cit+(−0.2133)Met+(0.0837)Ile+(−0.1550)Trp;0.861, 0.881, 0.801, 0.788, 0.762, 0.889, 0.857, 0.82 4,(4.9664)+(0.0347)Thr+(−0.0063)Ala+(−0.0603)Cit+(−0.0556)Val+(−0.3403)Met+(0.2140)Ile; 0.861, 0.885, 0.796, 0.773, 0.789, 0. 830,0.846, 0.810, (3.0453)+(0.0025)Gly+(0.0081)Gln+(−0.1407)His+(0.0485)Ile+(0.0773)Phe+(−0.1323)Trp; 0.861, 0.889, 0.812, 0. 804,0.815, 0.832, 0.812, 0.816, (3.7194)+(0.0101)Gln+(−0.1474)His+(0.0244)Thr+(−0.0319)Arg+(0.1114)Phe+(−0.1300)Trp; 0.861, 0.883,0.801, 0.778, 0.799, 0.853, 0.830, 0.815, (7.6696)+(−0.0927)His+(0.0342)Thr+(−0.0038)Ala+(−0.1808)Met+(0.0834)Ile+(−0. 1139)Trp;0.861, 0.886, 0.765, 0.731, 0.769, 0.821, 0.808, 0.782, (1.9837)+(0.0533)Ser+(−0.0035)Gly+(−0.1361)His+(0.0137)Leu+(0.1076)Phe+(−0.1275)Trp; 0.861, 0.886, 0.834, 0.828, 0.826, 0.843, 0. 855,0.838, (3.6642)+(−0.0551)Asn+(0.0110)Gln+(−0.1281)His+(0.0027)Pro+(0.0996)Phe+(−0.1155)Trp; 0.861, 0.882, 0.800, 0.774, 0. 814,0.848, 0.806, 0.811, (7.6639)+(−0.0823)His+(0.0350)Thr+(−0.0445)Cit+(−0.1880)Met+(0.0786)Ile+(−0.1186)Trp; 0.861, 0.886, 0.801,0.781, 0.810, 0.852, 0.796, 0.810,(3.3523)+(0.0502)Ser+(−0.0450)Asn+(−0.0708)Cit+(−0.1609)Met+(0.0818)Ile+(−0.1466)Trp; 0.861, 0.885, 0.812, 0.796, 0.813, 0.860, 0.819, 0.822, (2.9654)+(0.0423)Ser+(−0.1216)Asn+(0.0056)Gln+(−0.0904)Cit+(0.0693)Ile+(−0.1676)Trp;0.861, 0.884, 0.795, 0.777, 0.749, 0.895, 0.865, 0.821,(1.8695)+(0.0424)Ser+(−0.0068)Ala+(−0.0549)Cit+(−0.0477)Val+(−0.2786)Met+(0.2022)Ile; 0.861, 0.888, 0.820, 0.823, 0.8 20,0.831, 0.801, 0.819, (−0.9915)+(0.0469)Ser+(0.0018)Gln+(−0.0014)Ala+(−0.2873)Met+(0.1338)Phe+(−0.1463)Trp; 0.861, 0.886, 0.763,0.728, 0.769, 0.830, 0.792, 0.780,(2.0265)+(0.0506)Ser+(−0.1363)His+(−0.0081)Lys+(0.0182)Leu+(0.1113)Phe+(−0.1214)Trp; 0.860, 0.884, 0.762, 0.733, 0.773, 0.834, 0.764, 0.776, (−0.8079)+(0.0664)Ser+(−0.0270)Asn+(−0.1442)His+(0.0113)Pro+(−0.3100)Met+(0.1605)Phe; 0.860, 0.887, 0.761, 0.735, 0.785, 0.837, 0.727,0.771, (−0.0384)+(0.0535)Ser+(−0.1543)His+(0.0332)Thr+(−0.0431)Cit+(−0.3756)Met+(0.1756)Phe; 0.860, 0.887, 0.815, 0.819, 0.8 18,0.824, 0.793, 0.814, (−1.1092)+(0.0473)Ser+(0.0017)Gln+(−0.2979)Met+(0.0003)Lys+(0.1331)Phe+(−0.1479)Trp; 0.860, 0.885, 0. 782,0.756, 0.755, 0.875, 0.839, 0.806, (1.9431)+(0.0414)Ser+(0.0045)Gln+(−0.0927)His+(−0.0346)Val+(−0.2781)Met+(0.1652)Ile; 0.860,0.886, 0.768, 0.733, 0.770, 0.850, 0.797, 0.788,(−0.7431)+(0.0624)Ser+(−0.1369)His+(−0.0242)Val+(−0.3243)Met+(0.0509)Leu+(0.1568)Phe;0.860, 0.886, 0.819, 0.816, 0.777, 0.848, 0.896, 0. 834,(3.8148)+(−0.1186)Asn+(0.0045)Gln+(−0.0464)Val+(0.1461)Ile+(0.0803)Phe+(−0.1314)Trp; 0.860, 0.882, 0.755, 0.719, 0.768, 0.833,0.766, 0.772, (−1.1575)+(0.0653)Ser+(−0.1512)His+(0.0106)Pro+(−0.3368)Met+(0.0083)Leu+(0.1545)Phe; 0.860, 0.886, 0.79 2, 0.774,0.789, 0.846, 0.806, 0.804, (−1.9746)+(0.0548)Ser+(−0.0022)Gly+(0.0081)Gln+(−0.1654)His+(−0.3030)Met+(0.1611)Phe; 0. 860,0.890, 0.785, 0.767, 0.782, 0.847, 0.792, 0.797, (2.2499)+(0.0526)Ser+(−0.1244)His+(−0.0028)Ala+(−0.0188)Arg+(0.1339)Phe+(−0.1135)Trp;0.860, 0.890, 0.812, 0.798, 0.770, 0.852, 0.907, 0.83 2,(4.5275)+(−0.0096)Ala+(−0.0840)Cit+(−0.0421)Val+(0.1697)Ile+(0.0958)Phe+(−0.1450)Trp; 0.860, 0.886, 0.760, 0.734, 0.776, 0. 832,0.742, 0.771,(−0.2070)+(0.0521)Ser+(−0.1622)His+(0.0301)Thr+(−0.3736)Met+(0.0006)Orn+(0.1722)Phe;0.860, 0.885, 0.801, 0.785, 0.788, 0.816, 0.861, 0.812,(5.4173)+(−0.0157)Asn+(−0.0885)His+(0.1108)Ile+(−0.0481)Leu+(0.0886)Phe+(−0.1203)Trp; 0.8 60, 0.885,0.793, 0.775, 0.796, 0.853, 0.792, 0.804, (−2.0167)+(0.0523)Ser+(0.0086)Gln+(−0.1570)His+(−0.0401)Cit+(−0.3072)Met+(0.1663)Phe;0.860, 0.883, 0.818, 0.805, 0.793, 0.863, 0.874, 0.834,(5.1525)+(0.0085)Gln+(−0.0724)His+(−0.0293)Val+(−0.1741)Met+(0.1488)Ile+(−0.0978)Trp; 0.860, 0.887, 0.779, 0.749, 0.779, 0.8 52,0.809, 0.797, (3.6799)+(0.0529)Ser+(−0.0928)His+(−0.0064)Arg+(−0.1640)Met+(0.0925)Ile+(−0.1051)Trp; 0.860, 0.886, 0.792, 0.780,0.778, 0.853, 0.810, 0.805,(2.4785)+(0.0425)Ser+(0.0032)Pro+(−0.2281)Met+(0.1543)Ile+(−0.0565)Leu+(−0.1313)Trp;0.86 0, 0.885, 0.777, 0.748, 0.768, 0.850, 0.819, 0.796, (4.2991)+(0.0463)Ser+(−0.0587)Asn+(−0.0873)His+(0.1133)Ile+(−0.0278)Leu+(−0.1114)Trp;0.860, 0.887, 0.819, 0.817, 0.821, 0.822, 0.822, 0.820,(−0.3656)+(0.0600)Ser+(−0.0075)Gly+(−0.2872)Met+(0.0050)Orn+(0.1302)Phe+(−0.1473)Trp; 0.860, 0.883, 0.801, 0.787, 0.801, 0.8 23,0.823, 0.809, (3.4603)+(0.0007)Gly+(0.0075)Gln+(−0.1445)His+(0.0153)Thr+(0.1026)Phe+(−0.1278)Trp; 0.860, 0.888, 0.821, 0. 828,0.824, 0.832, 0.788, 0.818, (−1.0121)+(0.0489)Ser+(0.0025)Gln+(−0.0147)Arg+(−0.2826)Met+(0.1350)Phe+(−0.1456)Trp; 0.860, 0.888,0.764, 0.724, 0.775, 0.849, 0.786, 0.784, (4.0850)+(0.0427)Ser+(−0.0961)His+(−0.0781)Cit+(0.0330)Orn+(0.0735)Ile+(−0.1 376)Trp;0.860, 0.881, 0.781, 0.753, 0.765, 0.858, 0.831, 0.802, (4.3682)+(0.0479)Ser+(−0.0470)Asn+(−0.0963)His+(−0.0050)Ala+(0.0853)Ile+(−0.1108)Trp; 0.860, 0.881, 0.794, 0.773, 0.768, 0.871, 0. 844,0.814, (4.1728)+(0.0062)Gln+(−0.0912)His+(0.0315)Thr+(−0.0414)Val+(−0.3471)Met+(0.1758)Ile; 0.860, 0.884, 0.792, 0.780, 0. 777,0.854, 0.810, 0.805, (2.5110)+(0.0417)Ser+(−0.2194)Met+(0.0019)Orn+(0.1590)Ile+(−0.0575)Leu+(−0.1314)Trp; 0.860, 0.886, 0.772,0.744, 0.774, 0.826, 0.805, 0.787,(2.0103)+(0.0533)Ser+(−0.0037)Gly+(−0.1325)His+(0.0029)Val+(0.1158)Phe+(−0.1234)Trp; 0.860, 0.885, 0.789, 0.771, 0.759, 0.849, 0.858, 0.809,(2.7917)+(0.0065)Gly+(−0.0787)His+(−0.0499)Val+(−0.3366)Met+(0.1743)Ile+(0.1352)Phe;0.860, 0.887, 0.771, 0.731, 0.753, 0.877, 0.841, 0. 800,(1.9178)+(0.0531)Ser+(−0.0836)His+(0.0452)Tyr+(−0.0437)Val+(−0.3490)Met+(0.1874)Ile;0.860, 0.890, 0.821, 0.820, 0.823, 0.839, 0.805, 0.822,(−0.6576)+(0.0498)Ser+(−0.0017)Ala+(0.0141)Tyr+(−0.2981)Met+(0.1323)Phe+(−0.1474)Trp; 0.860, 0.884, 0.7 68,0.737, 0.748, 0.865, 0.823, 0.793, (2.7448)+(0.0448)Ser+(−0.0850)His+(−0.0388)Val+(−0.2722)Met+(0.0225)Orn+(0.1696)Ile; 0. 860,0.887, 0.815, 0.817, 0.817, 0.835, 0.794, 0.816, (−0.5789)+(0.0488)Ser+(−0.0014)Ala+(−0.2804)Met+(0.0030)Orn+(0.1335)Phe+(−0.1442)Trp;0.860, 0.886, 0.803, 0.787, 0.778, 0.862, 0.859, 0.82 1,(7.4713)+(−0.0934)Asn+(0.0232)Thr+(−0.0639)Cit+(−0.0405)Val+(0.1570)Ile+(−0.1314)Trp; 0.860, 0.883, 0.778, 0.757, 0.733, 0. 882,0.852, 0.806, (1.5906)+(0.0437)Ser+(−0.0084)Gly+(0.0244)Ihr+(−0.0590)Val+(−0.4157)Met+(0.2146)Ile; 0.860, 0.888, 0.784, 0.763,0.783, 0.850, 0.795, 0.798, (2.1035)+(0.0517)Ser+(−0.1107)His+(−0.0031)Ala+(−0.0577)Cit+(0.1403)Phe+(−0.1301)Trp; 0. 860, 0.884,0.798, 0.777, 0.801, 0.823, 0.829, 0.807, (3.5421)+(0.0077)Gln+(−0.1497)His+(0.0157)Thr+(0.0118)Leu+(0.0908)Phe+(−0.1341)Trp;0.860, 0.883, 0.803, 0.788, 0.804, 0.823, 0.826, 0.810,(3.5356)+(0.0076)Gln+(−0.1441)His+(0.0156)Thr+(0.0001)Pro+(0.1018)Phe+(−0.1282)Trp;0.860, 0.883, 0.795, 0.773, 0.805, 0.84 8, 0.792, 0.804,(2.9446)+(0.0478)Ser+(−0.0728)Cit+(−0.1839)Met+(−0.0046)Lys+(0.0870)Ile+(−0.1486)Trp; 0.860, 0.883, 0.761, 0. 733,0.770, 0.835, 0.761, 0.775,(−0.9537)+(0.0644)Ser+(−0.1432)His+(0.0125)Pro+(−0.0041)Val+(−0.3310)Met+(0.1664)Phe;0.860, 0.889, 0.819, 0.820, 0.828, 0.835, 0.784, 0.817, (−0.5539)+(0.0526)Ser+(−0.0134)Arg+(0.0138)Tyr+(−0.2941)Met+(0.1336)Phe+(−0. 1464)Trp;0.860, 0.887, 0.777, 0.751, 0.775, 0.830, 0.808, 0.791, (2.1684)+(0.0547)Ser+(−0.0040)Gly+(−0.1270)His+(−0.0045)Lys+(0.1231)Phe+(−0.1170)Trp; 0.859, 0.880, 0.764, 0.733, 0.744, 0.836, 0. 837,0.787,(4.1433)+(0.0453)Ser+(−0.0053)Gly+(−0.0866)His+(−0.0250)Val+(0.1322)Ile+(−0.1159)Trp;0.859, 0.885, 0.778, 0.750, 0.746, 0.877, 0.846, 0.805,(2.7973)+(0.0464)Ser+(−0.0762)His+(−0.0038)Ala+(−0.0362)Val+(−0.2446)Met+(0.1762)Ile;0.859, 0. 887, 0.808, 0.782, 0.802, 0.839, 0.865, 0.822,(2.8036)+(0.0103)Gln+(−0.1235)His+(−0.0714)Cit+(0.0564)Ile+(0.0901)Phe+(−0.147 2)Trp;0.859, 0.884, 0.793, 0.783, 0.750, 0.870, 0.855, 0.814, (3.7777)+(0.0413)Ser+(−0.1453)Asn+(0.0022)Gln+(−0.0420)Val+(0.1583)Ile+(−0.1132)Trp; 0.859, 0.886, 0.801, 0.804, 0.789, 0.819, 0.8 04,0.804, (1.6061)+(0.0489)Ser+(−0.1531)Asn+(0.0071)Pro+(−0.0111)Val+(0.1069)Phe+(−0.1366)Trp; 0.859, 0.885, 0.812, 0.816, 0. 819,0.824, 0.775, 0.809,(−0.5539)+(0.0514)Ser+(−0.0153)Arg+(−0.2837)Met+(0.0043)Lys+(0.1357)Phe+(−0.1463)Trp;0.859, 0.882, 0.788, 0.778, 0.796, 0.860, 0.743, 0.794,(5.9475)+(0.0386)Ser+(−0.0874)His+(0.0182)Thr+(0.0133)Pro+(−0.1731)Met+(−0.1011)Trp; 0.859, 0.885, 0.776, 0.742, 0.780, 0.851, 0.802, 0.794,(4.4375)+(0.0504)Ser+(−0.0491)Asn+(−0.0844)His+(−0.0524)Cit+(0.0802)Ile+(−0.1253)Trp;0.859, 0.886, 0.812, 0.796, 0.806, 0.832, 0.853, 0.822,(3.2648)+(0.0113)Gln+(−0.1398)His+(−0.0221)Arg+(0.0497)Ile+(0.0800)Phe+(−0.1301)Trp; 0.859, 0.885, 0.835, 0.830, 0.82 7,0.843, 0.856, 0.839, (3.6299)+(−0.0601)Asn+(0.0111)Gln+(−0.1293)His+(0.0036)Lys+(0.1000)Phe+(−0.1157)Trp; 0.859, 0.879, 0. 765,0.739, 0.745, 0.840, 0.823, 0.787, (3.5328)+(0.0334)Ser+(0.0030)Gln+(−0.1001)His+(−0.0214)Val+(0.1231)Ile+(−0.1170)Trp; 0.859,0.889, 0.766, 0.746, 0.756, 0.847, 0.783, 0.783,(−4.1346)+(0.0541)Ser+(−0.0945)Cit+(−0.4161)Met+(0.2004)Ile+(−0.1008)Leu+(0.1473)Phe;0.859, 0.887, 0.810, 0.794, 0.815, 0.835, 0.823, 0. 817,(3.4891)+(0.0084)Gln+(−0.1318)His+(0.0202)Thr+(−0.0675)Cit+(0.1196)Phe+(−0.1424)Trp;0.859, 0.881, 0.794, 0.789, 0.744, 0.829, 0.886, 0.812,(3.5371)+(0.0092)Thr+(−0.0098)Ala+(−0.0452)Val+(0.1621)Ile+(0.0747)Phe+(−0.1514)Trp; 0.859, 0.884, 0.75 8, 0.725,0.758, 0.824, 0.796, 0.776, (1.9404)+(0.0483)Ser+(−0.1352)His+(−0.0130)Val+(0.0344)Leu+(0.1087)Phe+(−0.1251)Trp; 0. 859, 0.884,0.798, 0.788, 0.781, 0.856, 0.817, 0.810, (2.0881)+(0.0390)Ser+(0.0021)Gln+(−0.2283)Met+(0.1593)Ile+(−0.0579)Leu+(−0.1337)Trp;0.859, 0.884, 0.784, 0.769, 0.746, 0.869, 0.844, 0.80 7,(4.1978)+(0.0422)Ser+(−0.1479)Asn+(−0.0449)Val+(0.0207)Orn+(0.1609)Ile+(−0.1099)Trp; 0.859, 0.884, 0.762, 0.724, 0.768, 0. 845,0.788, 0.781, (4.1719)+(0.0423)Ser+(−0.0982)His+(0.0077)Thr+(−0.0583)Cit+(0.0798)Ile+(−0.1361)Trp; 0.859, 0.886, 0.783, 0.761,0.761, 0.820, 0.863, 0.801, (5.1584)+(−0.0895)His+(−0.0319)Val+(0.0150)Orn+(0.1199)Ile+(0.0791)Phe+(−0.1185)Trp; 0.85 9, 0.889,0.771, 0.739, 0.788, 0.840, 0.767, 0.784, (1.9869)+(0.0485)Ser+(−0.1126)His+(−0.0888)Cit+(0.0354)Orn+(0.1271)Phe+(−0. 1413)Trp;0.859, 0.883, 0.804, 0.787, 0.764, 0.853, 0.892, 0.824, (6.9809)+(−0.0104)Ala+(−0.0717)Cit+(0.0114)Pro+(−0.0379)Val+(0.1679)Ile+(−0.1306)Trp; 0.859, 0.882, 0.797, 0.791, 0.745, 0.829, 0. 898,0.816, (3.8111)+(−0.0102)Ala+(0.0055)Pro+(−0.0452)Val+(0.1593)Ile+(0.0760)Phe+(−0.1458)Trp; 0.859, 0.888, 0.822, 0.819, 0. 823,0.824, 0.826, 0.823, (−0.4105)+(0.0603)Ser+(−0.0072)Gly+(0.0062)Tyr+(−0.2951)Met+(0.1317)Phe+(−0.1487)Trp; 0.859, 0.887, 0.811,0.813, 0.815, 0.825, 0.786, 0.810,(−0.7233)+(0.0492)Ser+(−0.2923)Met+(0.0014)Orn+(0.0007)Lys+(0.1335)Phe+(−0.1464)Trp; 0.859, 0.884, 0.832, 0.824, 0.827, 0.839, 0.860, 0.837, (3.6550)+(−0.0514)Asn+(0.0112)Gln+(−0.1331)His+(0.0098)Leu+(0.0927)Phe+(−0.1193)Trp;0.859, 0.883, 0.770, 0.748, 0.748, 0.845, 0.822, 0.791,(3.4473)+(0.0335)Ser+(−0.0793)Cit+(0.0027)Pro+(−0.0341)Val+(0.1459)Ile+(−0.1610)Trp; 0.859, 0.882, 0.771, 0.749, 0.74 9,0.847, 0.819, 0.791, (3.5027)+(0.0324)Ser+(0.0016)Thr+(−0.0781)Cit+(−0.0341)Val+(0.1484)Ile+(−0.1603)Trp; 0.859, 0.878, 0. 773,0.742, 0.760, 0.851, 0.826, 0.795, (4.1357)+(0.0433)Ser+(−0.1020)His+(−0.0054)Ala+(−0.0037)Lys+(0.0887)Ile+(−0.1147)Tr p; 0.859,0.884, 0.794, 0.783, 0.778, 0.853, 0.811, 0.806,(2.4701)+(0.0409)Ser+(−0.2281)Met+(0.0037)Lys+(0.1613)Ile+(−0.0597)Leu+(−0.1341)Trp; 0.859, 0.885, 0.805, 0.796, 0.768, 0.837, 0.883, 0.821,(4.9586)+(−0.1011)Asn+(−0.0489)Val+(0.0164)Orn+(0.1501)Ile+(0.0759)Phe+(−0.1251)Trp;0.859, 0.890, 0.851, 0.849, 0.847, 0.857, 0.859, 0.853,(2.4884)+(0.0134)Gln+(−0.1272)His+(−0.0096)Arg+(−0.1820)Met+(0.1400)Phe+(−0.1049)Trp; 0.859, 0.887, 0.8 15,0.806, 0.806, 0.840, 0.840, 0.823, (3.7455)+(0.0077)Gln+(−0.1393)His+(0.0177)Thr+(−0.0042)Ala+(0.1092)Phe+(−0.1273)Trp; 0. 859,0.881, 0.772, 0.751, 0.749, 0.848, 0.820, 0.792, (3.4953)+(0.0332)Ser+(−0.0001)Gln+(−0.0770)Cit+(−0.0340)Val+(0.1486)Ile+(−0.1590)Trp;0.859, 0.884, 0.808, 0.815, 0.800, 0.830, 0.793, 0.81 0,(2.0010)+(0.0443)Ser+(−0.1634)Asn+(0.0114)Thr+(−0.0105)Val+(0.1101)Phe+(−0.1396)Trp; 0.859, 0.890, 0.814, 0.800, 0.785, 0. 844,0.889, 0.830, (5.4054)+(−0.0748)Asn+(−0.0738)Cit+(−0.0445)Val+(0.1518)Ile+(0.0955)Phe+(−0.1352)Trp; 0.859, 0.887, 0.77 5, 0.759,0.766, 0.834, 0.793, 0.788, (1.9978)+(0.0490)Ser+(−0.1267)His+(−0.0024)Ala+(−0.0164)Tyr+(0.1340)Phe+(−0.1118)Trp; 0. 859,0.883, 0.772, 0.745, 0.762, 0.840, 0.816, 0.791, (3.2076)+(0.0334)Ser+(0.0043)Gln+(−0.1132)His+(0.1031)Ile+(−0.0222)Leu+(−0.1212)Trp;0.859, 0.881, 0.771, 0.741, 0.758, 0.853, 0.822, 0.79 3,(4.2345)+(0.0396)Ser+(−0.1084)His+(0.0060)Thr+(−0.0058)Ala+(0.0855)Ile+(−0.1200)Trp; 0.859, 0.885, 0.794, 0.774, 0.784, 0. 814,0.855, 0.807, (5.1846)+(−0.0967)His+(0.0101)Orn+(0.1071)Ile+(−0.0462)Leu+(0.0834)Phe+(−0.1215)Trp; 0.859, 0.886, 0.833, 0.826,0.827, 0.844, 0.852, 0.838, (3.7595)+(−0.0557)Asn+(0.0106)Gln+(−0.1287)His+(0.0112)Orn+(0.0969)Phe+(−0.1137)Trp; 0.8 59, 0.883,0.782, 0.769, 0.742, 0.867, 0.841, 0.805, (4.4002)+(0.0404)Ser+(−0.1498)Asn+(0.0104)Thr+(−0.0441)Val+(0.1631)Ile+(−0.1147)Trp;0.859, 0.884, 0.794, 0.772, 0.811, 0.848, 0.775, 0.802,(4.1272)+(0.0454)Ser+(−0.1034)Asn+(−0.1118)Cit+(0.0376)Orn+(0.0583)Ile+(−0.1654)Trp;0.859, 0.881, 0.781, 0.757, 0.758, 0.86 1, 0.837, 0.803,(5.9442)+(−0.0778)His+(0.0386)Thr+(−0.0513)Val+(−0.3448)Met+(0.1714)Ile+(0.0201)Leu; 0.859, 0.888, 0.766, 0. 742,0.773, 0.829, 0.768, 0.778, (1.9726)+(0.0533)Ser+(−0.1283)His+(−0.0216)Arg+(0.0063)Pro+(0.1242)Phe+(−0.1204)Trp; 0.859, 0.889,0.819, 0.820, 0.823, 0.829, 0.799, 0.818, (−1.2157)+(0.0480)Ser+(0.0018)Gln+(0.0117)Tyr+(−0.3145)Met+(0.1306)Phe+(−0. 1505)Trp;0.859, 0.885, 0.765, 0.745, 0.765, 0.822, 0.779, 0.778, (1.8458)+(0.0487)Ser+(−0.1322)His+(−0.0232)Tyr+(0.0039)Val+(0.1276)Phe+(−0.1152)Trp; 0.859, 0.881, 0.795, 0.777, 0.782, 0.812, 0. 858,0.807, (5.0847)+(−0.0951)His+(0.0029)Lys+(0.1103)Ile+(−0.0482)Leu+(0.0862)Phe+(−0.1240)Trp; 0.859, 0.882, 0.758, 0.728, 0. 770,0.833, 0.759, 0.773, (−1.0184)+(0.0648)Ser+(−0.1479)His+(0.0115)Pro+(−0.3292)Met+(−0.0006)Lys+(0.1612)Phe; 0.859, 0.882, 0.759,0.730, 0.775, 0.833, 0.750, 0.772,(−0.9528)+(0.0674)Ser+(−0.1444)His+(−0.0126)Arg+(0.0117)Pro+(−0.3182)Met+(0.1629)Phe;0.859, 0.881, 0.822, 0.819, 0.851, 0.817, 0.771, 0.815, (4.4312)+(−0.0401)Asn+(0.0450)Thr+(−0.0848)Cit+(−0.2949)Met+(0.1500)Phe+(−0.1699)Trp; 0.859, 0.887, 0.812, 0.816, 0.819, 0.828, 0.7 75,0.810, (−0.4575)+(0.0515)Ser+(−0.0143)Arg+(−0.2747)Met+(0.0065)Orn+(0.1333)Phe+(−0.1429)Trp; 0.859, 0.882, 0.772, 0.740, 0. 759,0.851, 0.826, 0.794, (4.0935)+(0.0410)Ser+(−0.1085)His+(−0.0058)Ala+(0.0133)Orn+(0.0829)Ile+(−0.1178)Trp; 0.858, 0.884, 0. 767,0.736, 0.744, 0.866, 0.824, 0.793, (2.7211)+(0.0481)Ser+(−0.0802)His+(0.0060)Pro+(−0.0377)Val+(−0.2811)Met+(0.1655)Ile; 0.858,0.883, 0.802, 0.787, 0.803, 0.823, 0.826, 0.810, (3.5610)+(0.0075)Gln+(−0.1442)His+(0.0151)Thr+(0.0041)Orn+(0.1001)Phe+(−0.1278)Trp;0.858, 0.886, 0.822, 0.833, 0.805, 0.836, 0.819, 0.82 3,(1.1269)+(0.0450)Ser+(−0.1567)Asn+(0.0028)Gln+(−0.0087)Val+(0.1067)Phe+(−0.1387)Trp; 0.858, 0.883, 0.780, 0.759, 0.756, 0. 820,0.856, 0.798,(4.6904)+(0.0032)Gly+(−0.0903)His+(−0.0305)Val+(0.1205)Ile+(0.0878)Phe+(−0.1214)Trp;0.858, 0.882, 0.760, 0.729, 0.770, 0.833, 0.770, 0.775,(−1.0042)+(0.0667)Ser+(−0.0015)Gly+(−0.1469)His+(0.0116)Pro+(−0.3300)Met+(0.1598)Phe; 0.8 58, 0.885,0.805, 0.783, 0.796, 0.832, 0.860, 0.818, (3.3138)+(0.0088)Gln+(−0.1394)His+(−0.0026)Pro+(0.0506)Ile+(0.0762)Phe+(−0.1317)Trp;0.858, 0.882, 0.794, 0.769, 0.795, 0.858, 0.811, 0.809,(3.4091)+(0.0350)Ser+(−0.0097)Ala+(−0.1213)Cit+(0.0372)Orn+(0.0802)Ile+(−0.1733)Trp;0.858, 0.881, 0.792, 0.769, 0.782, 0.85 3, 0.829, 0.808,(3.3014)+(0.0355)Ser+(0.0039)Thr+(−0.0091)Ala+(−0.0932)Cit+(0.0905)Ile+(−0.1728)Trp; 0.858, 0.886, 0.830, 0. 830,0.854, 0.824, 0.783, 0.823, (1.7119)+(0.0057)Gln+(0.0396)Thr+(−0.0908)Cit+(−0.3538)Met+(0.1541)Phe+(−0.1751)Trp; 0.858, 0.886,0.814, 0.822, 0.801, 0.835, 0.803, 0.815,(1.7293)+(0.0469)Ser+(−0.1517)Asn+(−0.0104)Val+(0.0135)Orn+(0.1053)Phe+(−0.1335)Trp; 0.858, 0.887, 0.787, 0.754, 0.795, 0.819, 0.836, 0.801, (5.8869)+(−0.0436)Asn+(−0.1203)His+(0.0249)Thr+(0.0446)Ile+(0.0818)Phe+(−0.1364)Trp; 0.858, 0.883, 0.821, 0.823, 0.819, 0.837, 0. 806,0.821, (1.1634)+(0.0490)Ser+(−0.1473)Asn+(0.0049)Gln+(−0.0981)Cit+(0.1122)Phe+(−0.1619)Trp; 0.858, 0.879, 0.777, 0.744, 0. 763,0.850, 0.838, 0.799, (4.1338)+(0.0488)Ser+(−0.0041)Gly+(−0.1029)His+(−0.0056)Ala+(0.0859)Ile+(−0.1178)Trp; 0.858, 0.887, 0.759,0.725, 0.764, 0.824, 0.790, 0.776,(1.8774)+(0.0476)Ser+(−0.1400)His+(0.0057)Orn+(0.0135)Leu+(0.1064)Phe+(−0.1258)Trp; 0.858, 0.885, 0.801, 0.794, 0.816, 0.828, 0.766, 0.801,(2.5408)+(0.0494)Ser+(−0.1515)Asn+(0.0174)Thr+(−0.1014)Cit+(0.1158)Phe+(−0.1720)Trp; 0.858, 0.881, 0.757, 0.726, 0.741, 0.837, 0.817, 0.780,(4.0332)+(0.0356)Ser+(−0.0943)His+(−0.0245)Val+(0.0141)Orn+(0.1279)Ile+(−0.1150)Trp;0.858, 0.888, 0.773, 0.745, 0.774, 0.826, 0.806, 0.787,(2.0801)+(0.0519)Ser+(−0.0039)Gly+(−0.1317)His+(0.0098)Orn+(0.1155)Phe+(−0.1208)Trp; 0.858, 0.882, 0.78 0, 0.769,0.710, 0.874, 0.886, 0.810, (0.1991)+(0.0549)Ser+(−0.2232)Asn+(−0.0085)Ala+(−0.0624)Val+(0.1893)Ile+(0.0999)Phe; 0. 858, 0.885,0.760, 0.737, 0.774, 0.830, 0.740, 0.770, (−0.1019)+(0.0513)Ser+(−0.1609)His+(0.0309)Thr+(−0.0093)Tyr+(−0.3611)Met+(0.1744)Phe; 0.858, 0.884, 0.802, 0.780, 0.796, 0.827, 0.859, 0.81 5,(3.2868)+(0.0087)Gln+(−0.1390)His+(−0.0004)Orn+(0.0480)Ile+(0.0751)Phe+(−0.1325)Trp; 0.858, 0.885, 0.772, 0.750, 0.781, 0. 831,0.774, 0.784,(2.0954)+(0.0526)Ser+(−0.1302)His+(−0.0198)Arg+(0.0030)Val+(0.1249)Phe+(−0.1188)Trp;0.858, 0.885, 0.843, 0.841, 0.829, 0.856, 0.866, 0.848,(3.7749)+(−0.0504)Asn+(0.0112)Gln+(−0.1257)His+(−0.0027)Ala+(0.1070)Phe+(−0.1122)Trp; 0. 858, 0.885,0.790, 0.763, 0.742, 0.896, 0.881, 0.821, (0.2928)+(0.0471)Ser+(−0.0070)Ala+(0.0456)Tyr+(−0.0580)Val+(−0.3851)Met+(0.2220)Ile;0.858, 0.885, 0.802, 0.786, 0.810, 0.820, 0.816, 0.808,(6.3084)+(−0.0575)Asn+(−0.1123)His+(0.0289)Thr+(−0.0029)Val+(0.1099)Phe+(−0.1220)Trp; 0.858, 0.881, 0.799, 0.778, 0.787, 0.8 56,0.841, 0.815, (2.7303)+(0.0338)Ser+(0.0023)Gln+(−0.0092)Ala+(−0.0946)Cit+(0.0912)Ile+(−0.1746)Trp; 0.858, 0.882, 0.791, 0. 771,0.792, 0.835, 0.812, 0.802, (2.3447)+(0.0508)Ser+(−0.0079)Gly+(0.0168)Thr+(−0.2813)Met+(0.0775)Ile+(−0.1542)Trp; 0.858, 0.881,0.786, 0.764, 0.765, 0.867, 0.832, 0.807, (6.1882)+(−0.0663)His+(0.0373)Thr+(−0.0377)Cit+(−0.0453)Val+(−0.3291)Met+(0. 1859)Ile;0.858, 0.884, 0.794, 0.782, 0.794, 0.851, 0.784, 0.803,(−2.1711)+(0.0546)Ser+(0.0094)Gln+(−0.1644)His+(−0.0194)Arg+(−0.2873)Met+(0.1659)Phe;0.858, 0.887, 0.756, 0.736, 0.754, 0.81 7, 0.773, 0.770,(1.7109)+(0.0490)Ser+(−0.1289)His+(0.0066)Pro+(−0.0274)Tyr+(0.1291)Phe+(−0.1155)Trp; 0.858, 0.882, 0.777, 0. 744,0.792, 0.831, 0.793, 0.790, (3.3872)+(−0.1359)His+(0.0539)Thr+(−0.0391)Val+(−0.4050)Met+(0.0707)Leu+(0.1467)Phe; 0.858, 0.882,0.761, 0.730, 0.779, 0.831, 0.755, 0.774, (−0.8821)+(0.0657)Ser+(−0.1387)His+(−0.0348)Cit+(0.0119)Pro+(−0.3330)Met+(0. 1633)Phe;0.858, 0.882, 0.756, 0.724, 0.769, 0.833, 0.758, 0.771,(−1.0576)+(0.0639)Ser+(−0.1496)His+(0.0110)Pro+(−0.3284)Met+(0.0068)Orn+(0.1583)Phe;0.858, 0.887, 0.789, 0.772, 0.790, 0.846, 0.794, 0.800,(−1.9957)+(0.0523)Ser+(0.0078)Gln+(−0.1665)His+(0.0004)Tyr+(−0.3058)Met+(0.1634)Phe;0.858, 0.879, 0.784, 0.75 9, 0.760, 0.867, 0.841, 0.807,(5.7978)+(−0.0747)His+(0.0355)Thr+(0.0131)Tyr+(−0.0469)Val+(−0.3490)Met+(0.1867)Ile; 0.858, 0. 876,0.789, 0.773, 0.755, 0.847, 0.859, 0.809, (7.1391)+(−0.0731)His+(0.0176)Thr+(−0.0063)Ala+(−0.0295)Val+(0.1474)Ile+(−0.11 69)Trp;0.858, 0.881, 0.779, 0.756, 0.783, 0.848, 0.781, 0.792, (3.1826)+(0.0321)Ser+(−0.1094)Cit+(0.0282)Orn+(0.1406)Ile+(−0.0556)Leu+(−0.1687)Trp; 0.858, 0.880, 0.794, 0.768, 0.803, 0.836, 0. 816,0.806, (7.2919)+(−0.0981)His+(0.0332)Thr+(−0.2096)Met+(0.0048)Lys+(0.0759)Ile+(−0.1158)Trp; 0.858, 0.880, 0.783, 0.762, 0. 757,0.862, 0.838, 0.805, (5.7417)+(−0.0770)His+(0.0341)Thr+(−0.0463)Val+(−0.3435)Met+(0.0058)Lys+(0.1844)Ile; 0.858, 0.880, 0. 780,0.755, 0.757, 0.861, 0.833, 0.801, (5.7754)+(−0.0777)His+(0.0329)Thr+(−0.0460)Val+(−0.3260)Met+(0.0177)Orn+(0.1805)Ile; 0.858,0.883, 0.788, 0.767, 0.765, 0.820, 0.871, 0.806,(5.2198)+(−0.0850)His+(−0.0319)Val+(−0.0003)Lys+(0.1232)Ile+(0.0852)Phe+(−0.1200)Trp; 0.858, 0.884, 0.793, 0.769, 0.813, 0.851, 0.774, 0. 802,(2.8545)+(0.0447)Ser+(−0.0956)Cit+(−0.1973)Met+(0.0293)Orn+(0.0742)Ile+(−0.1540)Trp;0.858, 0.879, 0.791, 0.765, 0.798, 0.837, 0.813, 0.803,(7.2501)+(0.0128)Asn+(−0.0974)His+(0.0336)Thr+(−0.2084)Met+(0.0789)Ile+(−0.1143)Trp; 0.858, 0.882, 0.7 63,0.725, 0.770, 0.842, 0.794, 0.783, (3.9857)+(0.0454)Ser+(−0.0939)His+(−0.0561)Cit+(0.0028)Pro+(0.0782)Ile+(−0.1350)Trp; 0. 858,0.882, 0.779, 0.756, 0.776, 0.843, 0.804, 0.795, (3.1184)+(0.0379)Ser+(0.0073)Gln+(−0.1247)His+(−0.0249)Arg+(0.0781)Ile+(−0.1227)Trp;0.858, 0.888, 0.815, 0.814, 0.821, 0.828, 0.794, 0.81 4,(−0.8209)+(0.0499)Ser+(0.0115)Tyr+(−0.3091)Met+(0.0009)Lys+(0.1317)Phe+(−0.1493)Trp; 0.858, 0.887, 0.816, 0.810, 0.818, 0. 819,0.822, 0.817, (−0.5151)+(0.0608)Ser+(−0.0072)Gly+(−0.2926)Met+(0.0065)Leu+(0.1272)Phe+(−0.1500)Trp; 0.858, 0.883, 0.82 6, 0.812,0.800, 0.872, 0.883, 0.842, (4.5502)+(0.0053)Gln+(0.0357)Tyr+(−0.0447)Val+(−0.2783)Met+(0.1768)Ile+(−0.1210)Trp; 0. 858, 0.880,0.810, 0.804, 0.840, 0.807, 0.767, 0.805, (3.6186)+(0.0419)Thr+(−0.0877)Cit+(0.0071)Pro+(−0.3424)Met+(0.1493)Phe+(−0.1742)Trp;0.858, 0.888, 0.815, 0.820, 0.818, 0.825, 0.793, 0.81 4,(−1.1037)+(0.0473)Ser+(0.0017)Gln+(−0.2972)Met+(0.0000)Orn+(0.1332)Phe+(−0.1477)Trp; 0.858, 0.883, 0.768, 0.734, 0.768, 0. 844,0.803, 0.787,(4.5473)+(0.0450)Ser+(−0.0670)Asn+(−0.1043)His+(0.0095)Thr+(0.0738)Ile+(−0.1181)Trp;0.858, 0.879, 0.793, 0.768, 0.801, 0.837, 0.814, 0.805,(7.4240)+(−0.0952)His+(0.0340)Thr+(0.0004)Pro+(−0.1990)Met+(0.0772)Ile+(−0.1145)Trp; 0.8 57, 0.889,0.774, 0.752, 0.780, 0.836, 0.772, 0.785, (2.1904)+(0.0506)Ser+(−0.1292)His+(−0.0216)Arg+(0.0140)Orn+(0.1236)Phe+(−0.1160)Trp;0.857, 0.880, 0.784, 0.771, 0.732, 0.853, 0.879, 0.809,(3.3990)+(0.0388)Ser+(−0.0071)Gly+(−0.0086)Ala+(−0.0400)Val+(0.1706)Ile+(−0.1366)Trp; 0.857, 0.881, 0.801, 0.797, 0.749, 0.8 32,0.900, 0.819, (3.4636)+(0.0010)Gln+(−0.0092)Ala+(−0.0446)Val+(0.1614)Ile+(0.0758)Phe+(−0.1471)Trp; 0.857, 0.879, 0.789, 0. 764,0.798, 0.838, 0.803, 0.801, (7.1295)+(0.0025)Gly+(−0.0978)His+(0.0321)Thr+(−0.1996)Met+(0.0796)Ile+(−0.1122)Trp; 0.857, 0.883,0.808, 0.801, 0.768, 0.836, 0.887, 0.823, (4.7636)+(−0.0874)Asn+(−0.0411)Val+(0.1640)Ile+(−0.0203)Leu+(0.0837)Phe+(−0. 1269)Trp;0.857, 0.883, 0.761, 0.741, 0.729, 0.813, 0.842, 0.781, (0.7744)+(0.0334)Ser+(−0.0419)Val+(−0.0160)Lys+(0.1465)Ile+(0.0818)Phe+(−0.1550)Trp; 0.857, 0.882, 0.775, 0.753, 0.753, 0.854, 0. 824,0.796,(3.8270)+(0.0354)Ser+(−0.0752)Cit+(−0.0321)Val+(−0.0096)Lys+(0.1521)Ile+(−0.1491)Trp;0.857, 0.882, 0.816, 0.816, 0.812, 0.844, 0.804, 0.819,(2.2265)+(0.0523)Ser+(−0.1184)Asn+(−0.0039)Ala+(−0.0884)Cit+(0.1228)Phe+(−0.1529)Trp;0.857, 0. 879, 0.752, 0.719, 0.720, 0.846, 0.838, 0.781,(0.7137)+(0.0607)Ser+(−0.1708)Asn+(−0.1013)His+(−0.0429)Val+(0.1346)Ile+(0.111 4)Phe;0.857, 0.882, 0.757, 0.729, 0.766, 0.830, 0.759, 0.771, (−0.9490)+(0.0641)Ser+(−0.1465)His+(0.0119)Pro+(−0.0092)Tyr+(−0.3185)Met+(0.1624)Phe; 0.857, 0.883, 0.790, 0.769, 0.799, 0.846, 0. 783,0.800, (4.1808)+(0.0442)Ser+(−0.1059)Asn+(0.0093)Thr+(−0.0875)Cit+(0.0684)Ile+(−0.1677)Trp; 0.857, 0.884, 0.788, 0.769, 0. 764,0.819, 0.868, 0.805, (5.1163)+(−0.0837)His+(−0.0281)Val+(0.1318)Ile+(−0.0133)Leu+(0.0867)Phe+(−0.1192)Trp; 0.857, 0.880, 0.783,0.762, 0.756, 0.863, 0.839, 0.805,(6.1606)+(−0.0168)Asn+(−0.0706)His+(0.0363)Thr+(−0.0465)Val+(−0.3175)Met+(0.1856)Ile;0.857, 0.881, 0.771, 0.736, 0.779, 0.815, 0.818, 0.787, (4.9239)+(0.0027)Gly+(−0.1303)His+(0.0180)Thr+(0.0479)Ile+(0.0802)Phe+(−0.1368)Trp; 0.857, 0.889, 0.846, 0.840, 0.841, 0.860, 0.86 2,0.851, (3.4876)+(−0.0572)Asn+(0.0125)Gln+(−0.1139)His+(−0.0612)Cit+(0.1171)Phe+(−0.1225)Trp; 0.857, 0.884, 0.795, 0.778, 0. 804,0.821, 0.801, 0.801, (5.8565)+(−0.0585)Asn+(0.0032)Gly+(−0.1181)His+(0.0265)Thr+(0.1083)Phe+(−0.1214)Trp; 0.857, 0.883, 0. 778,0.763, 0.736, 0.884, 0.830, 0.803, (2.7414)+(0.0389)Ser+(−0.0969)Asn+(0.0240)Thr+(−0.0603)Val+(−0.3280)Met+(0.2153)Ile; 0.857,0.882, 0.778, 0.766, 0.723, 0.855, 0.867, 0.803, (3.2069)+(0.0283)Ser+(−0.0104)Ala+(0.0069)Pro+(−0.0402)Val+(0.1646)Ile+(−0.1373)Trp;0.857, 0.880, 0.796, 0.768, 0.807, 0.843, 0.818, 0.80 9,(7.3406)+(−0.0961)His+(0.0337)Thr+(0.0129)Tyr+(−0.2127)Met+(0.0765)Ile+(−0.1184)Trp; 0.857, 0.886, 0.774, 0.754, 0.779, 0. 833,0.774, 0.785,(2.1157)+(0.0523)Ser+(−0.1275)His+(−0.0199)Arg+(0.0004)Lys+(0.1290)Phe+(−0.1164)Trp;0.857, 0.884, 0.801, 0.781, 0.811, 0.821, 0.818, 0.808,(6.2824)+(−0.0524)Asn+(−0.1152)His+(0.0282)Thr+(−0.0006)Lys+(0.1057)Phe+(−0.1248)Trp; 0.8 57, 0.881,0.772, 0.751, 0.749, 0.848, 0.821, 0.792, (3.4759)+(0.0332)Ser+(−0.0772)Cit+(0.0003)Tyr+(−0.0340)Val+(0.1485)Ile+(−0.1592)Trp;0.857, 0.887, 0.765, 0.747, 0.763, 0.822, 0.778, 0.778,(1.9053)+(0.0468)Ser+(−0.1308)His+(−0.0243)Tyr+(0.0121)Orn+(0.1283)Phe+(−0.1112)Trp;0.857, 0.885, 0.802, 0.796, 0.762, 0.83 3, 0.877, 0.817,(4.3870)+(−0.1004)Asn+(0.0033)Gly+(−0.0478)Val+(0.1518)Ile+(0.0869)Phe+(−0.1288)Trp; 0.857, 0.884, 0.784, 0. 770,0.743, 0.865, 0.848, 0.806, (4.1413)+(0.0437)Ser+(−0.1340)Asn+(0.0021)Pro+(−0.0426)Val+(0.1583)Ile+(−0.1127)Trp; 0.857, 0.882,0.789, 0.767, 0.797, 0.843, 0.791, 0.800,(3.9350)+(0.0469)Ser+(−0.0943)Asn+(−0.0846)Cit+(0.0036)Pro+(0.0660)Ile+(−0.1658)Trp; 0.857, 0.882, 0.801, 0.797, 0.750, 0.834, 0.894, 0.819, (3.7620)+(−0.0091)Ala+(−0.0360)Val+(0.1824)Ile+(−0.0292)Leu+(0.0780)Phe+(−0.1401)Trp; 0.857, 0.884, 0.772, 0.765, 0.756, 0.821, 0. 789,0.783, (0.2021)+(0.0422)Ser+(−0.0438)Arg+(0.1730)Ile+(−0.0896)Leu+(0.0885)Phe+(−0.1572)Trp; 0.857, 0.881, 0.768, 0.734, 0. 760,0.837, 0.826, 0.789, (3.9746)+(0.0466)Ser+(−0.0047)Gly+(−0.0970)His+(0.1116)Ile+(−0.0274)Leu+(−0.1202)Trp; 0.857, 0.880, 0.814,0.806, 0.762, 0.863, 0.907, 0.835,(0.1328)+(0.0046)Gln+(−0.0048)Ala+(−0.0622)Val+(−0.3959)Met+(0.2046)Ile+(0.1205)Phe; 0.857, 0.884, 0.804, 0.785, 0.763, 0.858, 0.899, 0.826,(3.6725)+(−0.0654)His+(−0.0034)Ala+(−0.0511)Val+(−0.2948)Met+(0.1801)Ile+(0.1262)Phe; 0.857, 0.882, 0.772, 0.737, 0.760, 0.853, 0.830,0.795, (3.8712)+(0.0437)Ser+(−0.1100)His+(−0.0066)Ala+(0.0186)Tyr+(0.0867)Ile+(−0.1250)Trp; 0.857, 0.877, 0.801, 0.777, 0.80 0,0.843, 0.836, 0.814, (4.9636)+(0.0085)Gln+(−0.1090)His+(0.0125)Thr+(−0.0585)Cit+(0.0712)Ile+(−0.1405)Trp; 0.857, 0.880, 0. 816,0.807, 0.850, 0.822, 0.763, 0.811, (3.6803)+(0.0385)Thr+(−0.1040)Cit+(−0.3120)Met+(0.0256)Orn+(0.1429)Phe+(−0.1738)Trp; 0.857,0.879, 0.779, 0.757, 0.754, 0.860, 0.830, 0.800, (5.7873)+(0.0016)Gly+(−0.0757)His+(0.0348)Thr+(−0.0451)Val+(−0.3314)Met+(0.1843)Ile; 0.857, 0.886, 0.767, 0.740, 0.775, 0.830, 0.778, 0.78 1,(2.0467)+(0.0529)Ser+(−0.1333)His+(−0.0192)Arg+(0.0132)Leu+(0.1173)Phe+(−0.1228)Trp; 0.857, 0.880, 0.803, 0.783, 0.775, 0. 862,0.870, 0.822, (6.4478)+(−0.0085)Ala+(−0.0948)Cit+(−0.0384)Val+(0.0473)Orn+(0.1643)Ile+(−0.1330)Trp; 0.857, 0.881, 0.80 6, 0.783,0.793, 0.861, 0.852, 0.822, (6.6761)+(−0.0728)Cit+(−0.0424)Val+(−0.1513)Met+(0.0443)Orn+(0.1652)Ile+(−0.1168)Trp; 0. 857,0.881, 0.799, 0.794, 0.746, 0.832, 0.898, 0.817, (3.6635)+(0.0007)Gly+(−0.0091)Ala+(−0.0450)Val+(0.1628)Ile+(0.0774)Phe+(−0.1455)Trp;0.857, 0.884, 0.801, 0.781, 0.811, 0.820, 0.818, 0.80 7,(6.2569)+(−0.0529)Asn+(−0.1152)His+(0.0279)Thr+(0.0004)Pro+(0.1049)Phe+(−0.1251)Trp; 0.857, 0.882, 0.799, 0.776, 0.806, 0. 845,0.810, 0.809, (2.8223)+(0.0528)Ser+(−0.0039)Gly+(−0.0663)Cit+(−0.2004)Met+(0.0832)Ile+(−0.1501)Trp; 0.857, 0.886, 0.793, 0.777,0.767, 0.820, 0.869, 0.808, (5.6452)+(−0.0777)His+(−0.0150)Arg+(−0.0351)Val+(0.1316)Ile+(0.0910)Phe+(−0.1172)Trp; 0.8 57, 0.886,0.794, 0.768, 0.775, 0.828, 0.876, 0.812, (5.3532)+(−0.0676)His+(−0.0594)Cit+(−0.0326)Val+(0.1297)Ile+(0.0961)Phe+(−0.1296)Trp;0.857, 0.884, 0.795, 0.770, 0.808, 0.817, 0.818, 0.80 3,(6.2262)+(−0.0489)Asn+(−0.1202)His+(0.0278)Thr+(0.0088)Leu+(0.0971)Phe+(−0.1297)Trp; 0.857, 0.882, 0.785, 0.772, 0.744, 0. 867,0.847, 0.808,(4.1303)+(0.0431)Ser+(−0.1296)Asn+(−0.0397)Val+(0.1666)Ile+(−0.0085)Leu+(−0.1123)Trp;0.857, 0.881, 0.761, 0.728, 0.755, 0.839, 0.807, 0.782,(3.8922)+(0.0384)Ser+(−0.1040)His+(0.0102)Orn+(0.1068)Ile+(−0.0253)Leu+(−0.1193)Trp; 0.8 56, 0.884,0.788, 0.765, 0.778, 0.833, 0.840, 0.804, (0.6766)+(0.0408)Ser+(−0.0107)Ala+(−0.1105)Cit+(0.0798)Ile+(0.0882)Phe+(−0.1919)Trp;0.856, 0.885, 0.760, 0.733, 0.761, 0.818, 0.786, 0.774,(1.8354)+(0.0488)Ser+(−0.1349)His+(−0.0216)Tyr+(0.0142)Leu+(0.1197)Phe+(−0.1191)Trp;0.856, 0.878, 0.824, 0.817, 0.783, 0.87 0, 0.891, 0.840,(5.1343)+(0.0050)Gln+(−0.0049)Ala+(−0.0415)Val+(−0.1882)Met+(0.1790)Ile+(−0.1117)Trp; 0.856, 0.878, 0.778, 0. 747,0.803, 0.839, 0.764, 0.788, (3.7507)+(0.0373)Ser+(−0.1239)Cit+(0.0421)Orn+(−0.0189)Lys+(0.0727)Ile+(−0.1728)Trp; 0.856, 0.880,0.791, 0.776, 0.781, 0.852, 0.804, 0.803,(2.2258)+(0.0394)Ser+(0.0140)Thr+(−0.0054)Ala+(−0.2470)Met+(0.0873)Ile+(−0.1465)Trp; 0.856, 0.885, 0.813, 0.821, 0.799, 0.833, 0.806, 0.815, (1.6629)+(0.0475)Ser+(−0.1468)Asn+(−0.0089)Val+(0.0011)Lys+(0.1087)Phe+(−0.1371)Trp; 0.856, 0.885, 0.806, 0.805, 0.811, 0.823, 0. 787,0.807,(−0.8499)+(0.0504)Ser+(−0.2959)Met+(−0.0007)Lys+(0.0073)Leu+(0.1282)Phe+(−0.1483)Trp;0.856, 0.879, 0.793, 0.77 2, 0.783, 0.851, 0.826, 0.808,(3.2776)+(0.0381)Ser+(−0.0086)Ala+(−0.0874)Cit+(−0.0043)Arg+(0.0909)Ile+(−0.1688)Trp; 0.856, 0. 880,0.791, 0.764, 0.801, 0.838, 0.812, 0.803, (7.3219)+(−0.0985)His+(0.0324)Thr+(−0.1947)Met+(0.0117)Orn+(0.0744)Ile+(−0.114 5)Trp;0.856, 0.886, 0.810, 0.809, 0.812, 0.829, 0.798, 0.812, (−0.7356)+(0.0499)Ser+(−0.0018)Ala+(−0.2854)Met+(0.0083)Leu+(0.1280)Phe+(−0.1473)Trp; 0.856, 0.883, 0.773, 0.753, 0.751, 0.850, 0. 819,0.793, (3.4505)+(0.0332)Ser+(−0.0782)Cit+(−0.0264)Val+(0.1665)Ile+(−0.0245)Leu+(−0.1555)Trp; 0.856, 0.877, 0.804, 0.786, 0.788,0.849, 0.852, 0.819,(5.4168)+(0.0075)Gln+(−0.1189)His+(0.0131)Thr+(−0.0058)Ala+(0.0745)Ile+(−0.1286)Trp;0.856, 0.8 80, 0.820, 0.808, 0.804, 0.859, 0.857, 0.832,(4.7648)+(0.0098)Gln+(−0.0894)His+(−0.1441)Met+(0.1225)Ile+(−0.0340)Leu+(−0.106 7)Trp;0.856, 0.884, 0.805, 0.803, 0.763, 0.827, 0.883, 0.819, (4.8478)+(−0.0820)Asn+(−0.0258)Tyr+(−0.0468)Val+(0.1512)Ile+(0.0955)Phe+(−0.1221)Trp; 0.856, 0.882, 0.795, 0.772, 0.806, 0.848, 0. 791,0.804, (2.7543)+(0.0470)Ser+(−0.0723)Cit+(0.0006)Arg+(−0.2001)Met+(0.0844)Ile+(−0.1507)Trp; 0.856, 0.878, 0.809, 0.795, 0. 777,0.857, 0.877, 0.827,(6.4757)+(−0.0051)Ala+(−0.0454)Val+(−0.1711)Met+(0.0267)Orn+(0.1819)Ile+(−0.1052)Trp;0.856, 0.885, 0.798, 0.777, 0.810, 0.817, 0.814, 0.804,(6.1891)+(−0.0531)Asn+(−0.1168)His+(0.0261)Thr+(0.0121)Orn+(0.1002)Phe+(−0.1242)Trp; 0.856, 0.882, 0.778, 0.750, 0.800, 0.850, 0.753, 0.788, (5.1770)+(0.0417)Ser+(−0.1148)His+(0.0263)Thr+(−0.2043)Met+(0.0405)Leu+(−0.1112)Trp;0.856, 0.879, 0.823, 0.803, 0.809, 0.867, 0.872, 0.838,(5.0639)+(0.0103)Gln+(−0.0961)His+(−0.0061)Ala+(−0.0619)Cit+(0.0861)Ile+(−0.1309)Trp; 0.856, 0.875, 0.791, 0.773, 0.7 63,0.839, 0.864, 0.810, (7.1204)+(−0.0664)His+(−0.0059)Ala+(−0.0319)Val+(0.0265)Orn+(0.1457)Ile+(−0.1069)Trp; 0.856, 0.885, 0. 840,0.838, 0.833, 0.848, 0.851, 0.843, (3.6081)+(−0.0403)Asn+(0.0126)Gln+(−0.1304)His+(−0.0168)Arg+(0.1065)Phe+(−0.1131)Tr p; 0.856,0.878, 0.816, 0.807, 0.773, 0.865, 0.896, 0.835,(5.1604)+(0.0048)Gln+(−0.0086)Ala+(−0.0750)Cit+(−0.0346)Val+(0.1676)Ile+(−0.1413)Trp;0.856, 0.880, 0.773, 0.743, 0.767, 0.839, 0.816, 0.791,(3.2328)+(0.0357)Ser+(0.0051)Gln+(−0.1207)His+(−0.0065)Lys+(0.0770)Ile+(−0.1201)Trp; 0.856, 0.880, 0.781, 0.759, 0.75 6,0.862, 0.834, 0.803, (5.9125)+(−0.0736)His+(0.0356)Thr+(0.0014)Pro+(−0.0457)Val+(−0.3334)Met+(0.1831)Ile; 0.856, 0.884, 0. 801,0.778, 0.805, 0.831, 0.829, 0.811, (4.7474)+(0.0071)Gly+(−0.1069)His+(−0.1966)Met+(0.0607)Ile+(0.1169)Phe+(−0.1116)Trp; 0.856,0.883, 0.785, 0.772, 0.743, 0.866, 0.849, 0.808, (4.1340)+(0.0434)Ser+(−0.1353)Asn+(−0.0427)Val+(0.0017)Lys+(0.1604)Ile+(−0.1133)Trp;0.856, 0.882, 0.827, 0.807, 0.822, 0.863, 0.862, 0.83 9,(4.6608)+(0.0116)Gln+(−0.0963)His+(−0.0517)Cit+(−0.1174)Met+(0.0803)Ile+(−0.1208)Trp; 0.856, 0.881, 0.796, 0.775, 0.782, 0. 840,0.852, 0.812,(5.3343)+(0.0049)Gly+(−0.1109)His+(−0.0061)Ala+(0.0605)Ile+(0.0859)Phe+(−0.1248)Trp;0.856, 0.880, 0.794, 0.771, 0.783, 0.852, 0.838, 0.811,(3.2650)+(0.0401)Ser+(−0.0022)Gly+(−0.0087)Ala+(−0.0876)Cit+(0.0897)Ile+(−0.1696)Trp; 0. 856, 0.882,0.774, 0.744, 0.752, 0.875, 0.826, 0.799, (3.0243)+(0.0470)Ser+(−0.0741)His+(−0.0308)Cit+(−0.0364)Val+(−0.2578)Met+(0.1705)Ile; 0.856, 0.885, 0.762, 0.733, 0.772, 0.828, 0.771, 0.77 6,(1.7543)+(0.0531)Ser+(−0.1148)His+(−0.0636)Cit+(0.0072)Pro+(0.1291)Phe+(−0.1408)Trp; 0.856, 0.884, 0.774, 0.756, 0.768, 0. 821,0.801, 0.786,(2.0152)+(0.0549)Ser+(−0.0046)Gly+(−0.1238)His+(−0.0259)Tyr+(0.1331)Phe+(−0.1130)Trp;0.856, 0.881, 0.799, 0.793, 0.747, 0.832, 0.897, 0.817,(3.7760)+(−0.0091)Ala+(−0.0452)Val+(0.0050)Orn+(0.1621)Ile+(0.0740)Phe+(−0.1441)Trp; 0.85 6, 0.879,0.799, 0.780, 0.786, 0.847, 0.842, 0.814, (2.0914)+(0.0538)Ser+(−0.0059)Gly+(−0.0046)Ala+(−0.2051)Met+(0.0860)Ile+(−0.1425)Trp;0.856, 0.879, 0.788, 0.775, 0.789, 0.841, 0.784, 0.797,(2.7283)+(0.0430)Ser+(−0.0549)Asn+(0.0145)Thr+(−0.2288)Met+(0.0760)Ile+(−0.1481)Trp;0.856, 0.885, 0.821, 0.830, 0.799, 0.84 5, 0.823, 0.824,(1.7674)+(0.0475)Ser+(−0.1363)Asn+(−0.0036)Ala+(−0.0064)Val+(0.1117)Phe+(−0.1349)Trp; 0.856, 0.879, 0.806, 0. 792,0.802, 0.828, 0.834, 0.814, (3.1345)+(0.0025)Gly+(0.0090)Gln+(−0.1445)His+(0.0123)Leu+(0.0927)Phe+(−0.1262)Trp; 0.856, 0. 877,0.745, 0.716, 0.703, 0.850, 0.831, 0.775, (0.0706)+(0.0436)Ser+(−0.1415)His+(−0.0088)Ala+(0.1230)Ile+(−0.0521)Leu+(0.089 6)Phe;0.856, 0.879, 0.778, 0.747, 0.772, 0.838, 0.832, 0.797, (3.1580)+(0.0415)Ser+(−0.0051)Gly+(0.0052)Gln+(−0.1231)His+(0.0717)Ile+(−0.1257)Trp; 0.856, 0.884, 0.763, 0.729, 0.776, 0.828, 0.7 79,0.778, (1.7795)+(0.0530)Ser+(−0.1211)His+(−0.0622)Cit+(0.0171)Leu+(0.1217)Phe+(−0.1439)Trp; 0.856, 0.879, 0.743, 0.719, 0. 714,0.794, 0.826, 0.764, (1.3803)+(0.0352)Ser+(−0.0044)Gln+(−0.0459)Val+(0.1483)Ile+(0.0765)Phe+(−0.1594)Trp; 0.856, 0.882, 0. 823,0.804, 0.792, 0.870, 0.903, 0.842, (6.5043)+(−0.0055)Ala+(0.0372)Tyr+(−0.0454)Val+(−0.2031)Met+(0.1890)Ile+(−0.1131)Tr p; 0.856,0.882, 0.794, 0.770, 0.765, 0.849, 0.880, 0.816,(3.5114)+(−0.0722)His+(−0.0522)Val+(−0.3129)Met+(0.0187)Orn+(0.1728)Ile+(0.1204)Phe;0.856, 0.881, 0.784, 0.763, 0.765, 0.820, 0.852, 0. 800,(3.7440)+(0.0126)Thr+(−0.0913)Cit+(−0.0404)Val+(0.1414)Ile+(0.0809)Phe+(−0.1701)Trp;0.856, 0.878, 0.783, 0.766, 0.774, 0.849, 0.799, 0.797,(2.8688)+(0.0318)Ser+(0.0016)Gln+(−0.0906)Cit+(0.1499)Ile+(−0.0571)Leu+(−0.1684)Trp; 0.856, 0.879, 0.8 15,0.807, 0.776, 0.858, 0.888, 0.832, (6.4428)+(−0.0046)Ala+(−0.0458)Val+(−0.1913)Met+(0.0107)Lys+(0.1853)Ile+(−0.1101)Trp; 0.856,0.878, 0.758, 0.728, 0.739, 0.837, 0.817, 0.780, (4.0982)+(0.0361)Ser+(−0.0922)His+(0.0030)Thr+(−0.0238)Val+(0.1297)Ile+(−0.1164)Trp;0.856, 0.881, 0.790, 0.774, 0.775, 0.849, 0.823, 0.80 5,(1.9503)+(0.0458)Ser+(−0.0069)Ala+(0.0090)Pro+(−0.2221)Met+(0.0800)Ile+(−0.1397)Trp; 0.856, 0.878, 0.798, 0.780, 0.793, 0. 838,0.830, 0.810,(2.5591)+(0.0577)Ser+(−0.0439)Asn+(−0.0062)Gly+(−0.1939)Met+(0.0758)Ile+(−0.1442)Trp;0.856, 0.879, 0.773, 0.744, 0.763, 0.851, 0.813, 0.793,(4.2656)+(0.0462)Ser+(−0.1014)His+(−0.0051)Ala+(−0.0140)Arg+(0.0888)Ile+(−0.1155)Trp; 0. 856, 0.877,0.762, 0.731, 0.754, 0.837, 0.807, 0.782, (3.8951)+(0.0396)Ser+(−0.1008)His+(0.0001)Thr+(0.1096)Ile+(−0.0253)Leu+(−0.1192)Trp;0.856, 0.882, 0.758, 0.753, 0.720, 0.795, 0.826, 0.77 4,(0.8295)+(0.0278)Ser+(−0.0375)Tyr+(−0.0425)Val+(0.1385)Ile+(0.0928)Phe+(−0.1572)Trp; 0.856, 0.889, 0.815, 0.814, 0.821, 0. 831,0.794, 0.815,(−0.7940)+(0.0500)Ser+(0.0114)Tyr+(−0.3066)Met+(0.0006)Orn+(0.1316)Phe+(−0.1485)Trp;0.856, 0.881, 0.792, 0.772, 0.798, 0.846, 0.794, 0.802,(4.0859)+(0.0467)Ser+(−0.0769)Asn+(−0.0827)Cit+(−0.0075)Lys+(0.0758)Ile+(−0.1591)Trp; 0. 856, 0.879,0.784, 0.774, 0.738, 0.861, 0.848, 0.805, (3.6551)+(0.0350)Ser+(−0.0075)Ala+(−0.0251)Arg+(−0.0414)Val+(0.1787)Ile+(−0.1286)Trp;0.856, 0.882, 0.795, 0.786, 0.775, 0.814, 0.850, 0.80 6,(5.1871)+(−0.0876)His+(−0.0315)Tyr+(0.1181)Ile+(−0.0512)Leu+(0.1044)Phe+(−0.1116)Trp; 0.856, 0.884, 0.775, 0.751, 0.782, 0. 839,0.780, 0.788,(2.0499)+(0.0524)Ser+(−0.1119)His+(−0.0586)Cit+(−0.0040)Lys+(0.1377)Phe+(−0.1299)Trp;0.856, 0.886, 0.809, 0.810, 0.816, 0.825, 0.779, 0.807,(−0.6155)+(0.0525)Ser+(−0.0127)Arg+(−0.2811)Met+(0.0065)Leu+(0.1309)Phe+(−0.1462)Trp; 0.8 56, 0.884,0.823, 0.817, 0.809, 0.841, 0.856, 0.831, (3.6143)+(0.0093)Gln+(−0.1316)His+(−0.0050)Ala+(0.0067)Pro+(0.1038)Phe+(−0.1201)Trp;0.856, 0.878, 0.800, 0.783, 0.778, 0.852, 0.851, 0.816,(7.3588)+(−0.0833)His+(0.0168)Thr+(−0.0065)Ala+(0.1221)Ile+(−0.0334)Leu+(−0.1208)Trp;0.856, 0.882, 0.819, 0.806, 0.784, 0.8 64, 0.894, 0.837,(7.3498)+(−0.0056)Ala+(−0.0495)Cit+(−0.0397)Val+(−0.1089)Met+(0.1812)Ile+(−0.1101)Trp; 0.855, 0.880, 0.821, 0.816,0.775, 0.864, 0.898, 0.838, (0.4087)+(−0.0716)Asn+(0.0071)Gln+(−0.0643)Val+(−0.3819)Met+(0.1986)Ile+(0.1252)Phe; 0.8 55, 0.883,0.769, 0.741, 0.780, 0.832, 0.775, 0.782, (1.8219)+(0.0526)Ser+(−0.1188)His+(−0.0627)Cit+(0.0059)Val+(0.1282)Phe+(−0.1407)Trp;0.855, 0.878, 0.827, 0.821, 0.793, 0.869, 0.883, 0.842,(5.3025)+(−0.0454)Asn+(0.0064)Gln+(−0.0421)Val+(−0.1900)Met+(0.1688)Ile+(−0.1083)Trp; 0.855, 0.886, 0.769, 0.752, 0.765, 0.8 26,0.780, 0.781, (1.9243)+(0.0490)Ser+(−0.1276)His+(−0.0206)Tyr+(−0.0020)Lys+(0.1333)Phe+(−0.1110)Trp; 0.855, 0.879, 0.815, 0.805,0.821, 0.850, 0.807, 0.821, (5.6439)+(0.0093)Gln+(−0.1254)His+(0.0305)Thr+(−0.1946)Met+(0.0326)Leu+(−0.1145)Trp; 0.8 55, 0.878,0.757, 0.726, 0.738, 0.837, 0.819, 0.780, (4.0188)+(0.0376)Ser+(−0.0908)His+(0.0013)Pro+(−0.0239)Val+(0.1290)Ile+(−0.1157)Trp;0.855, 0.886, 0.810, 0.795, 0.812, 0.837, 0.828, 0.818,(6.4436)+(−0.0505)Asn+(−0.1115)His+(0.0295)Thr+(−0.0038)Ala+(0.1120)Phe+(−0.1234)Trp; 0.855, 0.883, 0.778, 0.746, 0.791, 0.8 12,0.813, 0.790, (5.9215)+(−0.1251)His+(0.0277)Thr+(−0.0217)Arg+(0.0469)Ile+(0.0846)Phe+(−0.1407)Trp; 0.855, 0.881, 0.766, 0. 731,0.771, 0.844, 0.793, 0.785, (4.1834)+(0.0460)Ser+(−0.0893)His+(−0.0549)Cit+(−0.0055)Lys+(0.0852)Ile+(−0.1289)Trp; 0.855, 0.882,0.799, 0.781, 0.785, 0.818, 0.861, 0.811, (5.2599)+(−0.0929)His+(−0.0029)Pro+(0.1150)Ile+(−0.0482)Leu+(0.0885)Phe+(−0. 1211)Trp;0.855, 0.880, 0.801, 0.791, 0.750, 0.859, 0.889, 0.822, (1.2298)+(0.0042)Gly+(−0.0052)Ala+(−0.0626)Val+(−0.3692)Met+(0.2074)Ile+(0.1218)Phe; 0.855, 0.883, 0.776, 0.754, 0.750, 0.845, 0. 839,0.797,(3.5460)+(0.0381)Ser+(−0.0037)Gly+(−0.0711)Cit+(−0.0342)Val+(0.1476)Ile+(−0.1579)Trp;0.855, 0.877, 0.770, 0.739, 0.765, 0.841, 0.812, 0.789,(3.1552)+(0.0344)Ser+(0.0047)Gln+(−0.1249)His+(0.0007)Thr+(0.0726)Ile+(−0.1247)Trp;0.855, 0.882, 0.789, 0.775, 0.759, 0.816, 0.866, 0.804,(5.2210)+(−0.0814)His+(−0.0232)Tyr+(−0.0318)Val+(0.1246)Ile+(0.0969)Phe+(−0.1136)Trp;0.855, 0.881, 0.812, 0.799, 0.776, 0.855, 0.892, 0.831, (6.9104)+(−0.0067)Ala+(0.0094)Pro+(−0.0436)Val+(−0.1653)Met+(0.1780)Ile+(−0.1044)Trp; 0.855, 0.882, 0.798, 0.780, 0.765, 0.845, 0.8 83,0.818, (3.5141)+(−0.0672)His+(−0.0463)Val+(−0.3125)Met+(0.1883)Ile+(−0.0183)Leu+(0.1296)Phe; 0.855, 0.880, 0.785, 0.757, 0. 799,0.813, 0.811, 0.795, (5.8701)+(−0.1288)His+(0.0256)Thr+(−0.0067)Lys+(0.0138)Leu+(0.0961)Phe+(−0.1322)Trp; 0.855, 0.880, 0. 773,0.738, 0.772, 0.841, 0.819, 0.793, (4.3307)+(0.0531)Ser+(−0.0523)Asn+(−0.0036)Gly+(−0.0985)His+(0.0745)Ile+(−0.1171)Tr p; 0.855,0.880, 0.770, 0.735, 0.771, 0.844, 0.807, 0.789,(4.2739)+(0.0470)Ser+(−0.0602)Asn+(−0.1036)His+(0.0144)Orn+(0.0717)Ile+(−0.1155)Trp; 0.855, 0.879, 0.764, 0.731, 0.773, 0.838, 0.778, 0.780, (−0.5779)+(0.0619)Ser+(−0.1518)His+(−0.0011)Ala+(−0.2920)Met+(0.0147)Leu+(0.1510)Phe; 0.855, 0.882, 0.782, 0.743, 0.797, 0.821,0.824, 0.796, (5.3148)+(−0.1087)His+(0.0240)Thr+(−0.0680)Cit+(0.0508)Ile+(0.0941)Phe+(−0.1555)Trp; 0.855, 0.879, 0.75 7, 0.723,0.763, 0.834, 0.778, 0.774, (4.4331)+(0.0423)Ser+(−0.1122)His+(0.0102)Thr+(−0.0204)Arg+(0.0780)Ile+(−0.1249)Trp; 0. 855, 0.876,0.815, 0.804, 0.788, 0.858, 0.868, 0.829, (5.2356)+(0.0080)Gln+(−0.0952)His+(−0.0058)Ala+(0.1213)Ile+(−0.0333)Leu+(−0.1176)Trp;0.855, 0.879, 0.769, 0.757, 0.737, 0.877, 0.790, 0.79 0,(1.9998)+(0.0356)Ser+(0.0306)Thr+(−0.0255)Arg+(−0.0597)Val+(−0.4011)Met+(0.2161)Ile; 0.855, 0.878, 0.799, 0.787, 0.804, 0. 834,0.799, 0.806, (0.7808)+(0.0102)Gln+(−0.1689)His+(0.0388)Ihr+(−0.0046)Val+(−0.3628)Met+(0.1593)Phe; 0.855, 0.878, 0.818, 0.811,0.785, 0.858, 0.874, 0.832, (4.8797)+(0.0043)Gln+(−0.0442)Val+(−0.2432)Met+(0.0085)Lys+(0.1728)Ile+(−0.1172)Trp; 0.8 55, 0.883,0.786, 0.768, 0.746, 0.869, 0.853, 0.809, (3.9761)+(0.0447)Ser+(−0.1394)Asn+(0.0119)Tyr+(−0.0437)Val+(0.1622)Ile+(−0.1163)Trp;0.855, 0.883, 0.790, 0.769, 0.765, 0.823, 0.871, 0.807,(5.2332)+(−0.0853)His+(−0.0011)Pro+(−0.0319)Val+(0.1242)Ile+(0.0855)Phe+(−0.1197)Trp; 0.855, 0.882, 0.808, 0.808, 0.785, 0.8 39,0.829, 0.815, (1.5564)+(0.0484)Ser+(−0.1360)Asn+(−0.0077)Ala+(0.0102)Pro+(0.0983)Phe+(−0.1441)Trp; 0.855, 0.884, 0.785, 0. 773,0.748, 0.868, 0.837, 0.807, (4.3237)+(0.0457)Ser+(−0.1095)Asn+(−0.0179)Arg+(−0.0435)Val+(0.1672)Ile+(−0.1115)Trp; 0.855, 0.883,0.791, 0.783, 0.778, 0.857, 0.796, 0.803,(2.8173)+(0.0457)Ser+(−0.0176)Arg+(−0.1902)Met+(0.1690)Ile+(−0.0630)Leu+(−0.1267)Trp; 0.855, 0.886, 0.810, 0.811, 0.814, 0.821, 0.792, 0.810,(−1.2236)+(0.0483)Ser+(0.0016)Gln+(−0.3036)Met+(0.0065)Leu+(0.1275)Phe+(−0.1502)Trp; 0.855, 0.881, 0.820, 0.819, 0.848, 0.818, 0. 764,0.812,(3.8129)+(0.0442)Thr+(−0.0807)Cit+(−0.0050)Val+(−0.3265)Met+(0.1586)Phe+(−0.1672)Trp;0.855, 0.879, 0.758, 0.742, 0.723, 0.802, 0.844, 0.778,(0.5017)+(0.0316)Ser+(−0.0077)Thr+(−0.0434)Val+(0.1411)Ile+(0.0731)Phe+(−0.1641)Trp;0.855, 0.8 80, 0.827, 0.820, 0.817, 0.844, 0.858, 0.835,(3.5149)+(0.0098)Gln+(−0.1369)His+(−0.0037)Ala+(0.0040)Val+(0.1017)Phe+(−0.120 8)Trp; 0.855,0.878, 0.823, 0.804, 0.817, 0.859, 0.860, 0.835, (5.0640)+(−0.0436)Asn+(0.0116)Gln+(−0.0984)His+(−0.0571)Cit+(0.0713)Ile+(−0.1302)Trp; 0.855, 0.883, 0.802, 0.794, 0.753, 0.835, 0. 902,0.821,(4.0093)+(−0.0088)Ala+(−0.0445)Val+(−0.0049)Lys+(0.1644)Ile+(0.0800)Phe+(−0.1407)Trp;0.855, 0.877, 0.827, 0.81 9, 0.797, 0.873, 0.877, 0.842,(4.6565)+(0.0062)Gln+(−0.0089)Ala+(−0.0866)Cit+(0.1725)Ile+(−0.0623)Leu+(−0.1483)Trp; 0.855, 0. 881,0.776, 0.741, 0.784, 0.812, 0.827, 0.791, (5.3197)+(−0.1285)His+(0.0196)Thr+(0.0042)Orn+(0.0462)Ile+(0.0771)Phe+(−0.138 7)Trp; 0.855,0.879, 0.817, 0.814, 0.850, 0.811, 0.758, 0.808, (3.9325)+(0.0454)Thr+(−0.0808)Cit+(−0.0080)Arg+(−0.3232)Met+(0.1527)Phe+(−0.1731)Trp; 0.855, 0.879, 0.769, 0.758, 0.743, 0.805, 0. 829,0.784,(−0.2442)+(0.0377)Ser+(−0.0166)Thr+(0.1512)Ile+(−0.0784)Leu+(0.0729)Phe+(−0.1578)Trp;0.855, 0.880, 0.823, 0.819, 0.810, 0.845, 0.844, 0.829,(3.3207)+(0.0022)Gly+(0.0092)Gln+(−0.1349)His+(−0.0032)Ala+(0.1096)Phe+(−0.1176)Trp;0.855, 0.87 8, 0.824, 0.809, 0.810, 0.860, 0.865, 0.836,(4.9673)+(0.0103)Gln+(−0.1050)His+(−0.0033)Ala+(−0.1136)Met+(0.0793)Ile+(−0.1121)Trp; 0.855, 0.879, 0.807, 0.790, 0.784, 0.847, 0.870, 0.823, (7.2186)+(−0.0504)His+(−0.0386)Val+(−0.1835)Met+(0.0134)Lys+(0.1640)Ile+(−0.0984)Trp; 0.855, 0.885, 0.806, 0.786, 0.825, 0.833, 0. 804,0.812,(6.5516)+(−0.0549)Asn+(−0.0993)His+(0.0328)Thr+(−0.0646)Cit+(0.1207)Phe+(−0.1407)Trp;0.855, 0.883, 0.800, 0.784, 0.788, 0.817, 0.855, 0.811,(5.5847)+(−0.0858)His+(−0.0133)Arg+(0.1182)Ile+(−0.0526)Leu+(0.0921)Phe+(−0.1201)Trp;0.855, 0.8 79, 0.816, 0.802, 0.813, 0.829, 0.847, 0.823,(3.4306)+(0.0097)Gln+(−0.1416)His+(−0.0027)Lys+(0.0128)Leu+(0.0912)Phe+(−0.124 7)Trp; 0.855,0.883, 0.814, 0.801, 0.812, 0.862, 0.813, 0.822, (6.3627)+(0.0245)Thr+(−0.0673)Cit+(−0.1927)Met+(0.1422)Ile+(−0.0505)Leu+(−0.1364)Trp; 0.855, 0.881, 0.820, 0.826, 0.809, 0.839, 0. 811,0.821,(1.7532)+(0.0487)Ser+(−0.1173)Asn+(−0.0044)Ala+(−0.0151)Arg+(0.1064)Phe+(−0.1423)Trp;0.855, 0.882, 0.773, 0.745, 0.746, 0.871, 0.833, 0.799,(3.1843)+(0.0489)Ser+(−0.0393)Asn+(−0.0731)His+(−0.0391)Val+(−0.2312)Met+(0.1739)Ile;0.855, 0. 884, 0.799, 0.788, 0.772, 0.846, 0.852, 0.815,(0.9819)+(0.0487)Ser+(−0.1272)Asn+(−0.0085)Ala+(0.0581)Ile+(0.0769)Phe+(−0.153 4)Trp;0.855, 0.881, 0.792, 0.765, 0.785, 0.854, 0.834, 0.810, (2.9927)+(0.0378)Ser+(−0.0097)Ala+(−0.0947)Cit+(0.0140)Tyr+(0.0921)Ile+(−0.1770)Trp; 0.855, 0.874, 0.795, 0.781, 0.761, 0.883, 0.8 44,0.817, (5.7111)+(−0.0568)Asn+(0.0367)Thr+(−0.0517)Cit+(−0.0591)Val+(−0.3285)Met+(0.2073)Ile; 0.855, 0.882, 0.773, 0.754, 0. 751,0.851, 0.814, 0.793, (3.7051)+(0.0364)Ser+(−0.0624)Cit+(−0.0166)Arg+(−0.0361)Val+(0.1562)Ile+(−0.1510)Trp; 0.855, 0.881, 0.799,0.772, 0.795, 0.856, 0.837, 0.815,(1.1291)+(0.0496)Ser+(−0.0066)Ala+(0.0410)Tyr+(−0.2683)Met+(0.0909)Ile+(−0.1529)Trp; 0.855, 0.876, 0.781, 0.772, 0.727, 0.856, 0.865, 0.805,(3.2418)+(0.0284)Ser+(−0.0009)Thr+(−0.0087)Ala+(−0.0394)Val+(0.1687)Ile+(−0.1366)Trp;0.855, 0.880, 0.769, 0.735, 0.768, 0.842, 0.807, 0.788,(4.2456)+(0.0481)Ser+(−0.0554)Asn+(−0.1007)His+(0.0016)Pro+(0.0735)Ile+(−0.1161)Trp; 0.855, 0.877, 0.798, 0.781, 0.78 6,0.853, 0.826, 0.811, (2.4964)+(0.0477)Ser+(−0.0444)Asn+(−0.0048)Ala+(−0.1692)Met+(0.0848)Ile+(−0.1380)Trp; 0.855, 0.882, 0. 802,0.779, 0.794, 0.829, 0.857, 0.815, (5.2018)+(−0.0695)His+(−0.0686)Cit+(0.1252)Ile+(−0.0543)Leu+(0.1034)Phe+(−0.1345)Trp; 0.855,0.880, 0.809, 0.809, 0.812, 0.830, 0.791, 0.810, (2.1574)+(0.0532)Ser+(−0.1274)Asn+(−0.0886)Cit+(−0.0030)Val+(0.1198)Phe+(−0.1542)Trp; 0.855, 0.873, 0.805, 0.793, 0.772, 0.854, 0.872, 0.8 23,(5.5172)+(0.0066)Gln+(−0.0844)His+(−0.0057)Ala+(−0.0246)Val+(0.1345)Ile+(−0.1134)Trp;0.855, 0.884, 0.808, 0.800, 0.770, 0.835, 0.891, 0.824,(4.8756)+(−0.0904)Asn+(−0.0002)Pro+(−0.0475)Val+(0.1509)Ile+(0.0828)Phe+(−0.1287)Trp; 0.855, 0.881, 0.7 74,0.752, 0.736, 0.883, 0.831, 0.801, (0.7960)+(0.0372)Ser+(0.0189)Thr+(0.0306)Tyr+(−0.0627)Val+(−0.4608)Met+(0.2203)Ile; 0. 855, 0.880,0.790, 0.776, 0.734, 0.892, 0.869, 0.818, (2.2893)+(0.0469)Ser+(−0.0795)Asn+(−0.0053)Ala+(−0.0530)Val+(−0.2301)Met+(0.2058)Ile; 0.855, 0.878, 0.809, 0.791, 0.801, 0.846, 0.844, 0.82 0,(5.5425)+(−0.0677)Asn+(0.0093)Gln+(−0.1178)His+(0.0165)Thr+(0.0616)Ile+(−0.1255)Trp; 0.855, 0.883, 0.809, 0.803, 0.771, 0. 832,0.889, 0.824, (5.0451)+(−0.0712)Asn+(−0.0140)Arg+(−0.0484)Val+(0.1545)Ile+(0.0859)Phe+(−0.1280)Trp; 0.855, 0.879, 0.79 8, 0.780,0.779, 0.853, 0.844, 0.814, (3.6531)+(0.0499)Ser+(−0.1008)Asn+(−0.0063)Gly+(0.1375)Ile+(−0.0565)Leu+(−0.1380)Trp; 0. 855,0.879, 0.763, 0.730, 0.756, 0.838, 0.808, 0.783, (3.9448)+(0.0402)Ser+(−0.0994)His+(−0.0023)Lys+(0.1095)Ile+(−0.0241)Leu+(−0.1175)Trp;0.854, 0.881, 0.798, 0.776, 0.782, 0.847, 0.857, 0.81 5,(7.2230)+(−0.0517)His+(−0.0377)Val+(−0.1522)Met+(0.0301)Orn+(0.1593)Ile+(−0.0934)Trp; 0.854, 0.880, 0.772, 0.742, 0.747, 0. 870,0.831, 0.797,(2.7568)+(0.0453)Ser+(−0.0828)His+(−0.0387)Val+(−0.2825)Met+(0.0056)Lys+(0.1733)Ile;0.854, 0.878, 0.757, 0.724, 0.741, 0.838, 0.819, 0.780,(3.8920)+(0.0384)Ser+(−0.0941)His+(0.0108)Tyr+(−0.0244)Val+(0.1304)Ile+(−0.1195)Trp; 0.8 54, 0.884,0.795, 0.787, 0.797, 0.808, 0.800, 0.798, (6.2704)+(−0.0546)Asn+(−0.1134)His+(0.0331)Thr+(−0.0359)Tyr+(0.1238)Phe+(−0.1154)Trp;0.854, 0.879, 0.828, 0.821, 0.791, 0.876, 0.886, 0.84 4,(5.6074)+(−0.0967)Asn+(0.0077)Gln+(−0.0706)Cit+(−0.0363)Val(0.1494)Ile+(−0.1313)Trp; 0.854, 0.885, 0.823, 0.814, 0.813, 0. 835,0.857, 0.830,(3.8946)+(−0.0770)Cit+(−0.1943)Met+(0.1597)Ile+(−0.0756)Leu+(0.1272)Phe+(−0.1367)Trp;0.854, 0.882, 0.780, 0.758, 0.775, 0.856, 0.795, 0.796,(3.5062)+(0.0364)Ser+(−0.0858)Cit+(−0.0076)Lys+(0.1478)Ile+(−0.0513)Leu+(−0.1583)Trp; 0. 854, 0.878,0.794, 0.780, 0.757, 0.852, 0.867, 0.814, (3.0594)+(0.0402)Ser+(−0.0070)Gly+(−0.0092)Ala+(0.1667)Ile+(−0.0651)Leu+(−0.1445)Trp;0.854, 0.880, 0.770, 0.740, 0.746, 0.867, 0.828, 0.79 5,(2.8134)+(0.0467)Ser+(−0.0808)His+(−0.0372)Val+(−0.2643)Met+(0.1712)Ile+(0.0006)Leu; 0.854, 0.877, 0.812, 0.802, 0.784, 0. 855,0.864, 0.826,(5.0964)+(0.0038)Gln+(−0.0440)Val+(−0.2255)Met+(0.0185)Orn+(0.1708)Ile+(−0.1119)Trp;0.854, 0.881, 0.819, 0.815, 0.850, 0.819, 0.764, 0.812,(3.9846)+(0.0449)Thr+(−0.0867)Cit+(−0.3160)Met+(−0.0047)Lys+(0.1543)Phe+(−0.1716)Trp; 0. 854, 0.878,0.814, 0.807, 0.846, 0.807, 0.767, 0.807, (3.6467)+(0.0431)Thr+(−0.0870)Cit+(−0.3295)Met+(0.0063)Leu+(0.1473)Phe+(−0.1770)Trp;0.854, 0.876, 0.781, 0.771, 0.727, 0.856, 0.863, 0.80 4,(3.2400)+(0.0268)Ser+(−0.0090)Ala+(−0.0403)Val+(0.0081)Orn+(0.1674)Ile+(−0.1374)Trp; 0.854, 0.878, 0.792, 0.774, 0.799, 0. 826,0.797, 0.799, (0.5273)+(0.0104)Gln+(−0.1731)His+(0.0375)Ihr+(0.0039)Pro+(−0.3739)Met+(0.1493)Phe; 0.854, 0.886, 0.835, 0. 835,0.823, 0.841, 0.858, 0.839, (3.6089)+(−0.0519)Asn+(0.0112)Gln+(−0.1258)His+(−0.0137)Tyr+(0.1092)Phe+(−0.1092)Trp; 0.854, 0.883,0.808, 0.800, 0.769, 0.832, 0.890, 0.823, (4.8623)+(−0.0953)Asn+(−0.0479)Val+(0.0022)Lys+(0.1502)Ile+(0.0818)Phe+(−0. 1291)Trp;0.854, 0.880, 0.796, 0.776, 0.764, 0.844, 0.884, 0.817, (3.5104)+(0.0069)Asn+(−0.0702)His+(−0.0513)Val+(−0.3217)Met+(0.1759)Ile+(0.1274)Phe; 0.854, 0.878, 0.769, 0.737, 0.766, 0.838, 0. 812,0.788, (3.0663)+(0.0349)Ser+(0.0048)Gln+(−0.1268)His+(0.0055)Tyr+(0.0721)Ile+(−0.1268)Trp; 0.854, 0.881, 0.763, 0.722, 0. 769,0.844, 0.797, 0.783, (3.8897)+(0.0460)Ser+(−0.0970)His+(−0.0561)Cit+(0.0104)Tyr+(0.0803)Ile+(−0.1378)Trp; 0.854, 0.881, 0. 774,0.743, 0.746, 0.868, 0.848, 0.801, (2.8344)+(0.0527)Ser+(−0.0044)Gly+(−0.0777)His+(−0.0378)Val+(−0.2593)Met+(0.1720)Il e; 0.854,0.876, 0.779, 0.753, 0.764, 0.841, 0.835, 0.798,(7.0336)+(−0.0666)His+(0.0181)Thr+(−0.0496)Cit+(−0.0280)Val+(0.1359)Ile+(−0.1266)Trp;0.854, 0.880, 0.819, 0.820, 0.805, 0.828, 0.836, 0.823,(2.1097)+(0.0568)Ser+(−0.1416)Asn+(−0.0066)Gly+(−0.0083)Val+(0.1046)Phe+(−0.1378)Trp; 0.854, 0.879, 0.811, 0.810, 0.8 43,0.812, 0.744, 0.802, (3.2839)+(0.0028)Gly+(0.0419)Thr+(−0.0899)Cit+(−0.3318)Met+(0.1551)Phe+(−0.1709)Trp; 0.854, 0.879, 0. 810,0.805, 0.814, 0.825, 0.804, 0.812, (2.2035)+(0.0559)Ser+(−0.1231)Asn+(−0.0026)Gly+(−0.0873)Cit+(0.1136)Phe+(−0.1602)Tr p; 0.854,0.872, 0.796, 0.787, 0.759, 0.883, 0.837, 0.817,(3.5246)+(0.0033)Gln+(0.0323)Thr+(−0.0613)Cit+(−0.0570)Val+(−0.3960)Met+(0.2045)Ile;0.854, 0.878, 0.779, 0.759, 0.771, 0.849, 0.798, 0. 794,(3.1498)+(0.0370)Ser+(−0.0052)Thr+(−0.0840)Cit+(0.1532)Ile+(−0.0582)Leu+(−0.1608)Trp;0.854, 0.877, 0.802, 0.792, 0.761, 0.860, 0.872, 0.821,(6.3027)+(0.0040)Gly+(−0.0080)Ala+(−0.0714)Cit+(−0.0361)Val+(0.1725)Ile+(−0.1320)Trp; 0.854, 0.877, 0.7 76,0.764, 0.724, 0.854, 0.861, 0.800, (3.5806)+(0.0305)Ser+(−0.0016)Gln+(−0.0085)Ala+(−0.0399)Val+(0.1710)Ile+(−0.1342)Trp; 0.854,0.878, 0.790, 0.775, 0.797, 0.831, 0.783, 0.796, (0.4304)+(0.0032)Gly+(0.0098)Gln+(−0.1764)His+(0.0370)Thr+(−0.3675)Met+(0.1564)Phe;0.854, 0.883, 0.771, 0.748, 0.768, 0.798, 0.817, 0.783,(5.2891)+(−0.1260)His+(0.0248)Thr+(−0.0400)Tyr+(0.0493)Ile+(0.0993)Phe+(−0.1294)Trp;0.854, 0.884, 0.798, 0.780, 0.796, 0.82 6, 0.826, 0.807,(5.7900)+(−0.1179)His+(0.0228)Thr+(−0.0054)Ala+(0.0051)Pro+(0.1075)Phe+(−0.1266)Trp; 0.854, 0.880, 0.817, 0. 807,0.813, 0.830, 0.843, 0.823, (3.3573)+(0.0096)Gln+(−0.1396)His+(0.0026)Val+(−0.0007)Lys+(0.0979)Phe+(−0.1217)Trp; 0.854, 0.877,0.758, 0.727, 0.739, 0.837, 0.820, 0.781,(4.0501)+(0.0376)Ser+(−0.0909)His+(−0.0244)Val+(0.1289)Ile+(0.0021)Leu+(−0.1154)Trp; 0.854, 0.882, 0.782, 0.753, 0.755, 0.888, 0.842, 0.809, (0.8795)+(0.0469)Ser+(−0.0482)Cit+(0.0380)Tyr+(−0.0563)Val+(−0.3958)Met+(0.2067)Ile; 0.854, 0.877, 0.770, 0.740, 0.765, 0.839, 0. 812,0.789, (3.1302)+(0.0347)Ser+(0.0047)Gln+(−0.1247)His+(0.0001)Pro+(0.0726)Ile+(−0.1245)Trp; 0.854, 0.878, 0.769, 0.736, 0. 767,0.844, 0.807, 0.789, (4.2704)+(0.0480)Ser+(−0.0532)Asn+(−0.1003)His+(−0.0008)Lys+(0.0761)Ile+(−0.1150)Trp; 0.854, 0.880, 0.779,0.745, 0.784, 0.818, 0.829, 0.794,(5.4488)+(−0.1299)His+(0.0219)Thr+(−0.0048)Pro+(0.0520)Ile+(0.0813)Phe+(−0.1392)Trp; 0.854, 0.879, 0.765, 0.734, 0.775, 0.834, 0.776, 0.780, (−0.4167)+(0.0638)Ser+(−0.0260)Asn+(−0.1484)His+(−0.2780)Met+(0.0126)Leu+(0.1517)Phe; 0.854, 0.886, 0.775, 0.760, 0.775, 0.830, 0.77 3,0.784, (2.0891)+(0.0525)Ser+(−0.1244)His+(−0.0188)Arg+(−0.0188)Tyr+(0.1388)Phe+(−0.1100)Trp; 0.854, 0.879, 0.810, 0.800, 0. 806,0.829, 0.832, 0.817, (3.1127)+(0.0023)Gly+(0.0090)Gln+(−0.1418)His+(0.0027)Val+(0.0998)Phe+(−0.1223)Trp; 0.854, 0.878, 0. 759,0.728, 0.741, 0.839, 0.820, 0.782, (4.1188)+(0.0381)Ser+(−0.0880)His+(−0.0235)Val+(−0.0032)Lys+(0.1320)Ile+(−0.1129)Tr p; 0.854,0.880, 0.808, 0.805, 0.812, 0.829, 0.788, 0.809,(2.1909)+(0.0530)Ser+(−0.1186)Asn+(−0.0917)Cit+(−0.0036)Lys+(0.1178)Phe+(−0.1570)Trp;0.854, 0.878, 0.802, 0.781, 0.785, 0.860, 0.849, 0.819,(7.3654)+(−0.0740)Asn+(−0.0876)Cit+(−0.0417)Val+(0.0526)Orn+(0.1510)Ile+(−0.1240)Trp; 0.854, 0.882, 0.822, 0.813, 0.7 94,0.854, 0.882, 0.836, (4.3913)+(−0.0099)Ala+(−0.0973)Cit+(0.1736)Ile+(−0.0766)Leu+(0.1048)Phe+(−0.1499)Trp; 0.854, 0.878, 0.782,0.773, 0.730, 0.854, 0.861, 0.805,(3.2733)+(0.0279)Ser+(−0.0088)Ala+(−0.0324)Val+(0.1850)Ile+(−0.0231)Leu+(−0.1348)Irp; 0.854, 0.876, 0.810, 0.792, 0.798, 0.851, 0.852, 0.823, (4.7756)+(0.0091)Gln+(−0.0874)His+(−0.0596)Cit+(0.1172)Ile+(−0.0321)Leu+(−0.1301)Trp; 0.854, 0.879, 0.767, 0.738, 0.776, 0.839, 0.77 2,0.781, (−0.4046)+(0.0589)Ser+(−0.1495)His+(−0.0005)Ala+(−0.2769)Met+(0.0136)Orn+(0.1572)Phe; 0.854, 0.886, 0.810, 0.806, 0. 818,0.825, 0.792, 0.810, (−0.9777)+(0.0509)Ser+(0.0119)Tyr+(−0.3152)Met+(0.0071)Leu+(0.1255)Phe+(−0.1515)Trp; 0.854, 0.876, 0. 803,0.793, 0.826, 0.857, 0.743, 0.805, (5.6485)+(0.0423)Ser+(−0.1097)Asn+(−0.1136)Cit+(0.0082)Pro+(0.0503)Orn+(−0.1503)Trp; 0.854,0.878, 0.787, 0.765, 0.772, 0.829, 0.846, 0.803,(4.0067)+(−0.1092)Cit+(−0.0406)Val+(0.0366)Orn+(0.1365)Ile+(0.0731)Phe+(−0.1600)Trp; 0.854, 0.882, 0.825, 0.833, 0.804, 0.846, 0.833, 0.8 29,(1.0716)+(0.0443)Ser+(−0.1424)Asn+(0.0028)Gln+(−0.0048)Ala+(0.0997)Phe+(−0.1450)Trp; 0.854, 0.880, 0.815, 0.804, 0.810, 0. 826,0.843, 0.821, (3.3393)+(0.0094)Gln+(−0.1392)His+(0.0021)Pro+(0.0018)Val+(0.0967)Phe+(−0.1227)Trp; 0.854, 0.876, 0.804, 0. 802,0.800, 0.859, 0.779, 0.810, (4.1504)+(0.0367)Ser+(0.0071)Gln+(−0.1000)His+(0.0135)Pro+(−0.1443)Met+(−0.0962)Trp; 0.854, 0.881,0.830, 0.826, 0.806, 0.847, 0.876, 0.839, (3.7761)+(−0.0059)Ala+(−0.2055)Met+(0.1677)Ile+(−0.0784)Leu+(0.1105)Phe+(−0. 1244)Trp;0.854, 0.884, 0.772, 0.754, 0.776, 0.828, 0.771, 0.782, (1.8983)+(0.0519)Ser+(−0.1109)His+(−0.0572)Cit+(−0.0201)Tyr+(0.1453)Phe+(−0.1271)Trp; 0.854, 0.886, 0.778, 0.756, 0.783, 0.831, 0. 793,0.790,(2.2574)+(0.0563)Ser+(−0.0032)Gly+(−0.1245)His+(−0.0189)Arg+(0.1274)Phe+(−0.1176)Trp;0.854, 0.872, 0.797, 0.782, 0.795, 0.833, 0.817, 0.807,(5.3433)+(0.0099)Gln+(−0.1289)His+(0.0182)Thr+(−0.0274)Arg+(0.0676)Ile+(−0.1315)Trp;0.854, 0.8 81, 0.808, 0.823, 0.789, 0.825, 0.796, 0.808,(1.6311)+(0.0486)Ser+(−0.1366)Asn+(−0.0289)Tyr+(−0.0076)Val+(0.1228)Phe+(−0.129 7)Trp;0.854, 0.877, 0.803, 0.795, 0.755, 0.866, 0.878, 0.824, (7.0970)+(−0.0928)Asn+(0.0211)Thr+(−0.0069)Ala+(−0.0445)Val+(0.1731)Ile+(−0.1189)Trp; 0.854, 0.877, 0.762, 0.731, 0.754, 0.837, 0. 807,0.782, (3.8953)+(0.0396)Ser+(−0.1007)His+(−0.0001)Pro+(0.1099)Ile+(−0.0254)Leu+(−0.1191)Trp; 0.854, 0.885, 0.806, 0.805, 0.811,0.821, 0.787, 0.806,(−0.8636)+(0.0503)Ser+(−0.2974)Met+(−0.0002)Orn+(0.0070)Leu+(0.1283)Phe+(−0.1487)Trp;0.854, 0.8 82, 0.801, 0.783, 0.817, 0.822, 0.796, 0.805,(6.6511)+(−0.0395)Asn+(−0.1151)His+(0.0328)Thr+(−0.0187)Arg+(0.1099)Phe+(−0.127 3)Trp;0.854, 0.881, 0.788, 0.764, 0.801, 0.814, 0.805, 0.796, (5.6640)+(−0.1249)His+(0.0223)Thr+(0.0131)Orn+(−0.0041)Lys+(0.1008)Phe+(−0.1252)Trp; 0.854, 0.878, 0.802, 0.777, 0.796, 0.856, 0.8 39,0.817, (7.7943)+(−0.0821)His+(0.0234)Thr+(−0.0068)Ala+(−0.0585)Cit+(0.0820)Ile+(−0.1340)Trp; 0.854, 0.878, 0.792, 0.768, 0. 801,0.838, 0.803, 0.802, (7.7380)+(−0.0941)His+(0.0366)Thr+(−0.0091)Arg+(−0.1902)Met+(0.0774)Ile+(−0.1153)Trp; 0.853, 0.882, 0.818,0.801, 0.794, 0.858, 0.882, 0.834,(5.9749)+(0.0333)Tyr+(−0.0488)Val+(−0.2732)Met+(0.0116)Lys+(0.1822)Ile+(−0.1203)Trp; 0.853, 0.882, 0.797, 0.791, 0.793, 0.810, 0.815, 0.802,(3.5467)+(0.0072)Gln+(−0.1396)His+(0.0200)Thr+(−0.0305)Tyr+(0.1177)Phe+(−0.1204)Trp; 0.853, 0.883, 0.816, 0.826, 0.808, 0.833, 0.793, 0.815, (1.8139)+(0.0494)Ser+(−0.1292)Asn+(−0.0154)Arg+(−0.0079)Val+(0.1126)Phe+(−0.1365)Trp; 0.853, 0.883, 0.794, 0.779, 0.79 5,0.826, 0.812, 0.803, (5.5145)+(0.0020)Gly+(−0.1222)His+(0.0231)Thr+(−0.0040)Ala+(0.1120)Phe+(−0.1244)Trp; 0.853, 0.881, 0. 766,0.739, 0.761, 0.838, 0.795, 0.783, (4.1722)+(0.0450)Ser+(−0.0902)His+(−0.0209)Arg+(0.1274)Ile+(−0.0344)Leu+(−0.1159)Tr p; 0.853,0.877, 0.758, 0.718, 0.761, 0.834, 0.799, 0.778,(3.9897)+(0.0416)Ser+(−0.1114)His+(0.0129)Orn+(−0.0060)Lys+(0.0761)Ile+(−0.1189)Trp; 0.853, 0.881, 0.795, 0.788, 0.804, 0.820, 0.779, 0.798, (2.0211)+(0.0545)Ser+(−0.1287)Asn+(−0.0977)Cit+(0.0075)Pro+(0.1091)Phe+(−0.1667)Trp; 0.853, 0.879, 0.769, 0.733, 0.769, 0.844,0.809, 0.789, (4.1621)+(0.0487)Ser+(−0.0572)Asn+(−0.1030)His+(0.0091)Tyr+(0.0745)Ile+(−0.1192)Trp; 0.853, 0.878, 0.76 2, 0.728,0.755, 0.837, 0.808, 0.782, (3.8342)+(0.0399)Ser+(−0.1024)His+(0.0045)Tyr+(0.1091)Ile+(−0.0253)Leu+(−0.1211)Trp; 0. 853, 0.879,0.787, 0.765, 0.798, 0.809, 0.808, 0.795, (5.5664)+(−0.1241)His+(0.0224)Thr+(0.0008)Pro+(−0.0007)Val+(0.1037)Phe+(−0.1276)Trp;0.853, 0.879, 0.796, 0.772, 0.802, 0.844, 0.810, 0.80 7,(1.7687)+(0.0515)Ser+(−0.0472)Asn+(0.0304)Tyr+(−0.2456)Met+(0.0769)Ile+(−0.1522)Trp; 0.853, 0.877, 0.794, 0.775, 0.804, 0. 859,0.775, 0.803, (5.2235)+(0.0478)Ser+(−0.0871)His+(0.0129)Pro+(0.0338)Tyr+(−0.1721)Met+(−0.1070)Trp; 0.853, 0.880, 0.767, 0.739,0.775, 0.838, 0.770, 0.781, (−0.4033)+(0.0585)Ser+(−0.1475)His+(−0.0025)Val+(−0.2779)Met+(0.0150)Orn+(0.1602)Phe; 0.8 53, 0.876,0.817, 0.810, 0.784, 0.859, 0.873, 0.831, (4.9305)+(0.0008)Gly+(0.0047)Gln+(−0.0419)Val+(−0.2217)Met+(0.1715)Ile+(−0.1131)Trp;0.853, 0.879, 0.826, 0.822, 0.813, 0.843, 0.855, 0.833,(3.5052)+(0.0095)Gln+(−0.1340)His+(−0.0033)Ala+(0.0012)Lys+(0.1067)Phe+(−0.1183)Trp;0.853, 0.883, 0.799, 0.781, 0.800, 0.82 9, 0.823, 0.808,(5.8222)+(−0.1210)His+(0.0244)Thr+(−0.0042)Ala+(0.0013)Val+(0.1088)Phe+(−0.1273)Trp; 0.853, 0.880, 0.805, 0. 792,0.780, 0.858, 0.851, 0.820, (6.5462)+(0.0047)Gly+(−0.0529)Cit+(−0.0398)Val+(−0.1568)Met+(0.1732)Ile+(−0.1147)Trp; 0.853, 0.879,0.791, 0.773, 0.735, 0.884, 0.887, 0.820, (1.3510)+(0.0500)Ser+(−0.0061)Gly+(−0.0057)Ala+(−0.0518)Val+(−0.2988)Met+(0. 2055)Ile;0.853, 0.877, 0.786, 0.773, 0.791, 0.849, 0.766, 0.794, (5.1177)+(0.0440)Ser+(−0.0892)His+(0.0149)Pro+(−0.1640)Met+(0.0121)Lys+(−0.1050)Trp; 0.853, 0.879, 0.791, 0.769, 0.801, 0.829, 0. 802,0.800, (0.5373)+(0.0105)Gln+(−0.1793)His+(0.0393)Thr+(−0.3774)Met+(0.0103)Leu+(0.1432)Phe; 0.853, 0.881, 0.827, 0.839, 0. 841,0.808, 0.781, 0.817, (1.6661)+(0.0043)Gln+(0.0376)Thr+(−0.0102)Val+(−0.3675)Met+(0.1471)Phe+(−0.1541)Trp; 0.853, 0.879, 0.806,0.803, 0.811, 0.826, 0.788, 0.807,(2.1018)+(0.0529)Ser+(−0.1251)Asn+(−0.0917)Cit+(0.0000)Arg+(0.1151)Phe+(−0.1595)Trp; 0.853, 0.883, 0.801, 0.784, 0.801, 0.830, 0.821, 0.809,(5.9036)+(−0.1190)His+(0.0256)Thr+(−0.0040)Ala+(−0.0026)Lys+(0.1123)Phe+(−0.1250)Trp; 0.853, 0.880, 0.789, 0.766, 0.801, 0.814, 0.807,0.797, (5.7142)+(−0.1235)His+(0.0240)Thr+(0.0000)Val+(−0.0033)Lys+(0.1058)Phe+(−0.1265)Trp; 0.853, 0.880, 0.783, 0.761, 0.79 3,0.810, 0.798, 0.791, (5.2625)+(0.0022)Gly+(−0.1268)His+(0.0212)Thr+(−0.0001)Val+(0.1054)Phe+(−0.1261)Trp; 0.853, 0.878, 0. 789,0.769, 0.786, 0.830, 0.821, 0.801, (1.9274)+(0.0568)Ser+(−0.0069)Gly+(0.0056)Pro+(−0.2481)Met+(0.0714)Ile+(−0.1480)Trp; 0.853,0.880, 0.760, 0.724, 0.774, 0.836, 0.772, 0.776,(−0.6754)+(0.0610)Ser+(−0.1541)His+(−0.2962)Met+(0.0094)Orn+(0.0121)Leu+(0.1492)Phe; 0.853, 0.881, 0.810, 0.817, 0.826, 0.795, 0.769, 0. 802,(3.0139)+(0.0392)Thr+(0.0082)Pro+(−0.0122)Val+(−0.3683)Met+(0.1471)Phe+(−0.1488)Trp; 0.853, 0.881, 0.783, 0.761, 0.775, 0.848,0.811, 0.799, (3.2888)+(0.0391)Ser+(−0.0034)Gly+(−0.0827)Cit+(0.1481)Ile+(−0.0565)Leu+(−0.1646)Trp; 0.853, 0.884, 0.8 02,0.784, 0.791, 0.826, 0.857, 0.814, (3.2800)+(0.0086)Gln+(−0.1346)His+(−0.0222)Tyr+(0.0491)Ile+(0.0865)Phe+(−0.1254)Trp; 0. 853,0.878, 0.782, 0.770, 0.732, 0.856, 0.861, 0.805, (3.4668)+(0.0310)Ser+(−0.0084)Ala+(−0.0380)Val+(−0.0084)Lys+(0.1711)Ile+(−0.1294)Trp;0.853, 0.879, 0.765, 0.732, 0.784, 0.847, 0.752, 0.77 9,(−0.2887)+(0.0592)Ser+(−0.1395)His+(−0.0565)Cit+(−0.2795)Met+(0.0290)Orn+(0.1555)Phe; 0.853, 0.878, 0.796, 0.781, 0.802, 0. 831,0.797, 0.803, (0.8290)+(0.0106)Gln+(−0.1733)His+(0.0397)Ihr+(−0.3593)Met+(−0.0039)Lys+(0.1535)Phe; 0.853, 0.878, 0.817, 0.810,0.785, 0.857, 0.874, 0.831, (5.0230)+(0.0048)Gln+(0.0038)Pro+(−0.0421)Val+(−0.2294)Met+(0.1676)Ile+(−0.1133)Trp; 0.85 3, 0.873,0.810, 0.799, 0.783, 0.854, 0.867, 0.825, (5.6444)+(−0.0643)Asn+(0.0086)Gln+(−0.0820)His+(−0.0264)Val+(0.1260)Ile+(−0.1061)Trp;0.853, 0.879, 0.778, 0.760, 0.771, 0.849, 0.792, 0.793,(3.2943)+(0.0343)Ser+(−0.0864)Cit+(−0.0040)Tyr+(0.1496)Ile+(−0.0564)Leu+(−0.1629)Trp;0.853, 0.875, 0.756, 0.720, 0.757, 0.8 34, 0.794, 0.776,(4.1211)+(0.0405)Ser+(−0.1107)His+(0.0050)Thr+(−0.0057)Lys+(0.0783)Ile+(−0.1207)Trp; 0.853, 0.877, 0.785, 0. 762,0.764, 0.843, 0.847, 0.804, (7.6402)+(−0.0653)Asn+(−0.0666)His+(0.0222)Thr+(−0.0329)Val+(0.1409)Ile+(−0.1100)Trp; 0.853, 0.874,0.810, 0.793, 0.794, 0.848, 0.862, 0.825,(5.2139)+(0.0088)Gln+(−0.1137)His+(−0.0061)Ala+(0.0042)Pro+(0.0710)Ile+(−0.1230)Trp; 0.853, 0.880, 0.803, 0.807, 0.803, 0.823, 0.779, 0.803, (2.0225)+(0.0538)Ser+(−0.1193)Asn+(−0.0886)Cit+(−0.0255)Tyr+(0.1286)Phe+(−0.1510)Trp; 0.853, 0.880, 0.809, 0.796, 0.780, 0.852, 0. 871,0.825, (6.2637)+(0.0054)Pro+(−0.0470)Val+(−0.2383)Met+(0.0121)Lys+(0.1731)Ile+(−0.1140)Trp; 0.853, 0.881, 0.824, 0.814, 0. 813,0.843, 0.861, 0.833, (3.5808)+(0.0097)Gln+(−0.1388)His+(−0.0040)Ala+(0.0143)Leu+(0.0950)Phe+(−0.1241)Trp; 0.853, 0.876, 0. 763,0.725, 0.763, 0.830, 0.815, 0.783, (4.0817)+(0.0495)Ser+(−0.0044)Gly+(−0.1050)His+(−0.0055)Lys+(0.0785)Ile+(−0.1200)Tr p; 0.853,0.880, 0.789, 0.766, 0.801, 0.813, 0.807, 0.797,(5.6983)+(−0.1233)His+(0.0237)Thr+(0.0006)Pro+(−0.0033)Lys+(0.1052)Phe+(−0.1267)Trp; 0.853, 0.876, 0.780, 0.770, 0.726, 0.854, 0.866, 0.804, (3.0792)+(0.0284)Ser+(−0.0093)Ala+(0.0087)Tyr+(−0.0403)Val+(0.1701)Ile+(−0.1406)Trp; 0.853, 0.879, 0.825, 0.801, 0.823, 0.858,0.865, 0.837, (4.4850)+(0.0111)Gln+(−0.1120)His+(0.0277)Tyr+(−0.1733)Met+(0.0738)Ile+(−0.1210)Trp; 0.853, 0.881, 0.7 66,0.728, 0.771, 0.842, 0.799, 0.785, (4.0528)+(0.0475)Ser+(−0.0017)Gly+(−0.0939)His+(−0.0516)Cit+(0.0804)Ile+(−0.1322)Trp; 0.853,0.879, 0.812, 0.797, 0.809, 0.826, 0.847, 0.820, (3.3749)+(0.0094)Gln+(−0.1422)His+(0.0012)Pro+(0.0110)Leu+(0.0897)Phe+(−0.1262)Trp;0.853, 0.884, 0.807, 0.802, 0.757, 0.837, 0.901, 0.82 4,(4.3817)+(−0.0082)Ala+(−0.0196)Arg+(−0.0475)Val+(0.1702)Ile+(0.0862)Phe+(−0.1360)Trp; 0.853, 0.878, 0.775, 0.747, 0.788, 0. 808,0.798, 0.785, (5.2334)+(0.0025)Gly+(−0.1326)His+(0.0211)Thr+(0.0116)Leu+(0.0948)Phe+(−0.1319)Trp; 0.853, 0.877, 0.768, 0. 738,0.768, 0.843, 0.796, 0.786, (4.3687)+(0.0496)Ser+(−0.0418)Asn+(−0.0997)His+(−0.0116)Arg+(0.0778)Ile+(−0.1155)Trp; 0.853, 0.878,0.766, 0.736, 0.776, 0.838, 0.768, 0.780, (−0.3931)+(0.0595)Ser+(−0.1494)His+(−0.2757)Met+(0.0139)Orn+(−0.0018)Lys+(0. 1576)Phe;0.853, 0.878, 0.765, 0.734, 0.788, 0.805, 0.769, 0.774, (0.7248)+(0.0373)Ser+(−0.1351)Cit+(0.0265)Orn+(0.0486)Ile+(0.0698)Phe+(−0.2088)Trp; 0.853, 0.880, 0.814, 0.805, 0.809, 0.827, 0. 842,0.820, (3.3601)+(0.0093)Gln+(−0.1373)His+(0.0025)Pro+(−0.0002)Lys+(0.0993)Phe+(−0.1211)Trp; 0.853, 0.877, 0.760, 0.721, 0. 761,0.830, 0.812, 0.781, (4.0858)+(0.0458)Ser+(−0.0044)Gly+(−0.1125)His+(0.0049)Thr+(0.0735)Ile+(−0.1262)Trp; 0.853, 0.878, 0. 770,0.739, 0.765, 0.838, 0.810, 0.788, (3.1649)+(0.0344)Ser+(0.0045)Gln+(−0.1254)His+(0.0044)Orn+(0.0715)Ile+(−0.1246)Trp; 0. 853,0.879, 0.804, 0.799, 0.810, 0.825, 0.789, 0.806, (2.0574)+(0.0529)Ser+(−0.1248)Asn+(−0.0928)Cit+(0.0040)Leu+(0.1114)Phe+(−0.1627)Trp;0.853, 0.881, 0.817, 0.824, 0.798, 0.842, 0.821, 0.82 1,(1.6512)+(0.0472)Ser+(−0.1285)Asn+(−0.0046)Ala+(−0.0016)Lys+(0.1025)Phe+(−0.1417)Trp; 0.853, 0.878, 0.827, 0.834, 0.844, 0. 811,0.782, 0.818, (3.9635)+(−0.0513)Asn+(0.0425)Thr+(−0.0111)Val+(−0.3070)Met+(0.1482)Phe+(−0.1449)Trp; 0.853, 0.880, 0.778, 0.758,0.771, 0.848, 0.792, 0.792, (3.2032)+(0.0345)Ser+(−0.0879)Cit+(0.0005)Pro+(0.1488)Ile+(−0.0565)Leu+(−0.1656)Trp; 0.8 53, 0.879,0.779, 0.762, 0.775, 0.853, 0.782, 0.793, (3.4244)+(0.0382)Ser+(−0.0733)Cit+(−0.0168)Arg+(0.1589)Ile+(−0.0613)Leu+(−0.1577)Trp;0.853, 0.878, 0.783, 0.766, 0.760, 0.822, 0.849, 0.79 9,(3.3342)+(0.0045)Gly+(−0.0908)Cit+(−0.0399)Val+(0.1444)Ile+(0.0863)Phe+(−0.1639)Trp; 0.853, 0.880, 0.798, 0.797, 0.743, 0. 830,0.893, 0.816, (3.8580)+(−0.0082)Ala+(−0.0189)Tyr+(−0.0445)Val+(0.1615)Ile+(0.0863)Phe+(−0.1394)Trp; 0.853, 0.880, 0.76 4, 0.731,0.779, 0.839, 0.768, 0.779, (−0.5166)+(0.0631)Ser+(−0.1441)His+(−0.0353)Cit+(−0.2997)Met+(0.0146)Leu+(0.1543)Phe; 0. 853,0.879, 0.800, 0.783, 0.812, 0.837, 0.791, 0.806, (0.7194)+(0.0112)Gln+(−0.1660)His+(0.0394)Thr+(−0.0460)Cit+(−0.3655)Met+(0.1558)Phe;0.853, 0.876, 0.804, 0.796, 0.761, 0.850, 0.883, 0.822,(−0.2433)+(0.0023)Gly+(0.0041)Gln+(−0.0636)Val+(−0.4370)Met+(0.1997)Ile+(0.1242)Phe; 0.853, 0.880, 0.764, 0.728, 0.771, 0.84 2,0.788, 0.782, (4.1408)+(0.0468)Ser+(−0.0937)His+(−0.0484)Cit+(−0.0076)Arg+(0.0823)Ile+(−0.1306)Trp; 0.853, 0.879, 0.814, 0. 798,0.806, 0.852, 0.844, 0.825, (4.5941)+(0.0028)Gly+(0.0100)Gln+(−0.1091)His+(−0.1396)Met+(0.0768)Ile+(−0.1114)Trp; 0.853, 0.877,0.784, 0.767, 0.731, 0.885, 0.864, 0.812, (1.2558)+(0.0413)Ser+(−0.0001)Gln+(−0.0059)Ala+(−0.0515)Val+(−0.3037)Met+(0. 2054)Ile;0.853, 0.877, 0.759, 0.723, 0.765, 0.835, 0.785, 0.777, (4.1643)+(0.0446)Ser+(−0.1109)His+(−0.0183)Arg+(0.0158)Orn+(0.0754)Ile+(−0.1217)Trp; 0.852, 0.878, 0.762, 0.729, 0.773, 0.833, 0. 778,0.778,(−0.6323)+(0.0632)Ser+(−0.0009)Gly+(−0.1518)His+(−0.2972)Met+(0.0136)Leu+(0.1509)Phe;0.852, 0.879, 0.761, 0.72 8, 0.774, 0.835, 0.771, 0.777,(−0.5887)+(0.0630)Ser+(−0.1515)His+(−0.2914)Met+(−0.0030)Lys+(0.0148)Leu+(0.1517)Phe; 0.852, 0. 878,0.768, 0.752, 0.730, 0.872, 0.816, 0.793, (1.3742)+(0.0335)Ser+(0.0207)Thr+(0.0039)Pro+(−0.0585)Val+(−0.4193)Met+(0.206 4)Ile; 0.852,0.877, 0.811, 0.801, 0.773, 0.860, 0.879, 0.828, (6.4716)+(0.0025)Gly+(−0.0048)Ala+(−0.0429)Val+(−0.1624)Met+(0.1843)Ile+(−0.1053)Trp; 0.852, 0.878, 0.781, 0.763, 0.732, 0.883, 0. 859,0.809,(1.1897)+(0.0392)Ser+(−0.0061)Ala+(−0.0532)Val+(−0.3108)Met+(0.0163)Orn+(0.2038)Ile;0.852, 0.877, 0.785, 0.763, 0.794, 0.838, 0.789, 0.796,(1.3956)+(0.0438)Ser+(0.0107)Thr+(0.0265)Tyr+(−0.3095)Met+(0.0781)Ile+(−0.1584)Trp; 0.852, 0.877, 0.808,0.787, 0.788, 0.854, 0.871, 0.825,(6.0830)+(0.0274)Tyr+(−0.0477)Val+(−0.2427)Met+(0.0224)Orn+(0.1787)Ile+(−0.1119)Trp; 0.852, 0.883, 0.799, 0.796, 0.779, 0.833, 0.826, 0.808,(1.7192)+(0.0501)Ser+(−0.1603)Asn+(−0.0338)Val+(0.0531)Leu+(0.1032)Phe+(−0.1381)Trp; 0.852, 0.874, 0.741, 0.706, 0.723, 0.831, 0.803, 0.766, (0.2788)+(0.0567)Ser+(−0.1190)Asn+(−0.1350)His+(0.1092)Ile+(−0.0537)Leu+(0.1080)Phe; 0.852, 0.880, 0.797, 0.779, 0.761, 0.844,0.886, 0.817, (3.1454)+(−0.0745)His+(−0.0547)Val+(−0.3500)Met+(0.0122)Lys+(0.1769)Ile+(0.1281)Phe; 0.852, 0.877, 0.80 4, 0.776,0.810, 0.847, 0.832, 0.816, (4.9631)+(0.0087)Gln+(−0.1038)His+(−0.0743)Cit+(0.0301)Orn+(0.0646)Ile+(−0.1374)Trp; 0. 852, 0.876,0.805, 0.792, 0.780, 0.848, 0.862, 0.820, (6.0536)+(−0.0476)Val+(−0.2262)Met+(0.0210)Orn+(0.0084)Lys+(0.1759)Ile+(−0.1117)Trp;0.852, 0.875, 0.794, 0.777, 0.758, 0.843, 0.877, 0.81 4,(7.3653)+(−0.0580)His+(−0.0071)Ala+(0.0066)Pro+(−0.0320)Val(0.1483)Ile+(−0.1074)Trp; 0.852, 0.879, 0.763, 0.745, 0.725, 0. 803,0.859, 0.783, (0.9591)+(0.0391)Ser+(−0.0079)Gly+(−0.0443)Val+(0.1422)Ile+(0.0645)Phe+(−0.1623)Trp; 0.852, 0.879, 0.810, 0.791,0.788, 0.860, 0.870, 0.827,(5.7756)+(0.0039)Gly+(0.0383)Tyr+(−0.0467)Val+(−0.2569)Met+(0.1836)Ile+(−0.1143)Trp;0.85 2, 0.881, 0.824, 0.817, 0.814, 0.843, 0.851, 0.831, (3.6460)+(0.0090)Gln+(−0.1340)His+(−0.0036)Ala+(0.0128)Orn+(0.1016)Phe+(−0. 1170)Trp;0.852, 0.879, 0.791, 0.783, 0.760, 0.859, 0.824, 0.807, (3.3329)+(0.0378)Ser+(−0.0079)Ala+(−0.0279)Arg+(0.1839)Ile+(−0.0729)Leu+(−0.1355)Trp; 0.852, 0.872, 0.808, 0.791, 0.792, 0.853, 0. 855,0.823, (5.0919)+(0.0015)Gly+(0.0086)Gln+(−0.1152)His+(−0.0052)Ala+(0.0749)Ile+(−0.1217)Trp; 0.852, 0.872, 0.794, 0.776, 0. 783,0.834, 0.835, 0.807, (4.9946)+(0.0071)Gln+(−0.1122)His+(0.0082)Thr+(0.0973)Ile+(−0.0242)Leu+(−0.1247)Trp; 0.852, 0.880, 0.785,0.770, 0.793, 0.854, 0.757, 0.793,(5.2454)+(0.0427)Ser+(−0.0893)His+(0.0128)Pro+(−0.1353)Met+(0.0258)Orn+(−0.0967)Trp; 0.852, 0.876, 0.778, 0.763, 0.781, 0.830, 0.772, 0.787,(1.9164)+(0.0412)Ser+(0.0121)Thr+(0.0039)Pro+(−0.2827)Met+(0.0736)Ile+(−0.1507)Trp; 0.852, 0.881, 0.814, 0.818, 0.799, 0.842, 0.813, 0. 818,(1.9232)+(0.0435)Ser+(−0.1443)Asn+(0.0099)Thr+(−0.0054)Ala+(0.1007)Phe+(−0.1471)Trp; 0.852, 0.878, 0.800, 0.784, 0.806, 0.834,0.804, 0.807, (0.8099)+(−0.0227)Asn+(0.0109)Gln+(−0.1714)His+(0.0386)Thr+(−0.3481)Met+(0.1501)Phe; 0.852, 0.880, 0.79 5, 0.774,0.763, 0.843, 0.882, 0.816, (3.5896)+(−0.0679)His+(0.0029)Pro+(−0.0520)Val+(−0.3232)Met+(0.1738)Ile+(0.1267)Phe; 0. 852, 0.879,0.808, 0.799, 0.804, 0.826, 0.829, 0.814, (3.1456)+(0.0021)Gly+(0.0088)Gln+(−0.1388)His+(0.0023)Pro+(0.1017)Phe+(−0.1212)Trp;0.852, 0.878, 0.811, 0.796, 0.809, 0.828, 0.842, 0.819,(3.4528)+(0.0091)Gln+(−0.1427)His+(0.0078)Orn+(0.0107)Leu+(0.0876)Phe+(−0.1253)Trp;0.852, 0.879, 0.777, 0.748, 0.784, 0.81 3, 0.816, 0.790,(5.6002)+(−0.1272)His+(0.0250)Thr+(−0.0200)Val+(0.0420)Leu+(0.0955)Phe+(−0.1319)Trp; 0.852, 0.874, 0.820, 0. 806,0.804, 0.859, 0.866, 0.834, (5.3744)+(−0.0314)Asn+(0.0100)Gln+(−0.1099)His+(−0.0046)Ala+(0.0719)Ile+(−0.1187)Trp; 0.852, 0.879,0.819, 0.803, 0.810, 0.853, 0.856, 0.831,(4.7484)+(0.0105)Gln+(−0.1072)His+(0.0028)Pro+(−0.1402)Met+(0.0718)Ile+(−0.1131)Trp; 0.852, 0.884, 0.775, 0.753, 0.784, 0.837, 0.773, 0.787, (2.0608)+(0.0535)Ser+(−0.1137)His+(−0.0506)Cit+(−0.0114)Arg+(0.1377)Phe+(−0.1297)Trp; 0.852, 0.882, 0.813, 0.820, 0.804, 0.822, 0. 808,0.813, (0.9136)+(0.0449)Ser+(−0.1460)Asn+(0.0028)Gln+(−0.0037)Lys+(0.0930)Phe+(−0.1491)Trp; 0.852, 0.878, 0.811, 0.804, 0. 806,0.829, 0.831, 0.817, (3.1491)+(0.0022)Gly+(0.0089)Gln+(−0.1389)His+(0.0001)Lys+(0.1040)Phe+(−0.1199)Trp; 0.852, 0.877, 0. 755,0.741, 0.719, 0.803, 0.833, 0.774, (0.4912)+(0.0276)Ser+(−0.0361)Val+(0.1617)Ile+(−0.0281)Leu+(0.0717)Phe+(−0.1623)Trp; 0.852,0.873, 0.801, 0.782, 0.781, 0.848, 0.857, 0.817, (5.1363)+(0.0079)Gln+(−0.0813)His+(−0.0542)Cit+(−0.0222)Val+(0.1252)Ile+(−0.1256)Trp; 0.852, 0.877, 0.797, 0.782, 0.770, 0.825, 0.871, 0.8 12,(3.2245)+(0.0026)Gln+(−0.0878)Cit+(−0.0389)Val+(0.1398)Ile+(0.0798)Phe+(−0.1658)Trp; 0.852, 0.877, 0.762, 0.766, 0.734, 0. 788,0.792, 0.770, (0.3870)+(0.0286)Ser+(−0.0492)Tyr+(0.1432)Ile+(−0.0761)Leu+(0.0967)Phe+(−0.1513)Trp; 0.852, 0.875, 0.815, 0.803,0.798, 0.850, 0.854, 0.826, (5.2074)+(−0.0474)Asn+(0.0096)Gln+(−0.0978)His+(0.1047)Ile+(−0.0303)Leu+(−0.1153)Trp; 0. 852, 0.877,0.796, 0.769, 0.800, 0.836, 0.832, 0.809, (1.3947)+(0.0575)Ser+(−0.0061)Gly+(0.0278)Tyr+(−0.2791)Met+(0.0783)Ile+(−0.1559)Trp;0.852, 0.873, 0.790, 0.766, 0.779, 0.842, 0.841, 0.80 7,(7.4444)+(−0.1007)His+(0.0196)Thr+(−0.0064)Ala+(0.0028)Pro+(0.0730)Ile+(−0.1269)Trp; 0.852, 0.876, 0.784, 0.754, 0.776, 0. 843,0.835, 0.802, (6.9960)+(−0.0578)His+(−0.0728)Cit+(−0.0310)Val+(0.0466)Orn+(0.1347)Ile+(−0.1209)Trp; 0.852, 0.878, 0.79 7, 0.782,0.803, 0.831, 0.800, 0.804, (0.6370)+(0.0106)Gln+(−0.1744)His+(0.0392)Thr+(−0.3678)Met+(−0.0054)Orn+(0.1546)Phe; 0. 852, 0.879,0.791, 0.771, 0.797, 0.844, 0.793, 0.801, (3.9162)+(0.0465)Ser+(−0.0915)Asn+(−0.0822)Cit+(−0.0002)Arg+(0.0699)Ile+(−0.1634)Trp;0.852, 0.877, 0.798, 0.788, 0.809, 0.833, 0.774, 0.80 1,(0.6978)+(0.0125)Gln+(−0.1732)His+(0.0460)Thr+(−0.0267)Arg+(−0.3707)Met+(0.1570)Phe; 0.852, 0.877, 0.779, 0.764, 0.783, 0. 832,0.775, 0.788, (2.0330)+(0.0403)Ser+(0.0138)Thr+(−0.2739)Met+(−0.0048)Orn+(0.0800)Ile+(−0.1513)Trp; 0.852, 0.876, 0.792, 0.776,0.778, 0.850, 0.821, 0.806, (2.0378)+(0.0455)Ser+(−0.0051)Ala+(−0.1965)Met+(−0.0034)Lys+(0.0891)Ile+(−0.1389)Trp; 0. 852, 0.880,0.791, 0.770, 0.798, 0.845, 0.796, 0.802, (3.8552)+(0.0468)Ser+(−0.0941)Asn+(−0.0835)Cit+(0.0047)Tyr+(0.0695)Ile+(−0.1656)Trp;0.852, 0.876, 0.818, 0.814, 0.783, 0.860, 0.873, 0.83 3,(4.9377)+(0.0050)Gln+(−0.0373)Val+(−0.2160)Met+(0.1805)Ile+(−0.0146)Leu+(−0.1124)Trp; 0.852, 0.879, 0.819, 0.804, 0.835, 0. 849,0.801, 0.823, (4.3746)+(0.0057)Gln+(0.0253)Thr+(−0.0817)Cit+(−0.2352)Met+(0.0731)Ile+(−0.1647)Trp; 0.852, 0.880, 0.785, 0.764,0.795, 0.812, 0.797, 0.792, (5.3883)+(0.0021)Gly+(−0.1257)His+(0.0224)Thr+(−0.0028)Lys+(0.1072)Phe+(−0.1249)Trp; 0.8 52, 0.881,0.775, 0.748, 0.758, 0.865, 0.815, 0.796, (1.2623)+(0.0412)Ser+(0.0060)Gln+(−0.1237)His+(−0.2381)Met+(0.1300)Ile+(−0.0348)Leu;0.852, 0.879, 0.767, 0.736, 0.776, 0.838, 0.777, 0.782,(−0.4055)+(0.0610)Ser+(−0.0015)Gly+(−0.1489)His+(−0.2792)Met+(0.0138)Orn+(0.1556)Phe; 0.852, 0.879, 0.823, 0.821, 0.845, 0.8 23,0.778, 0.817, (3.9070)+(0.0434)Thr+(−0.0031)Ala+(−0.0843)Cit+(−0.3053)Met+(0.1543)Phe+(−0.1708)Trp; 0.852, 0.876, 0.806, 0.797,0.775, 0.849, 0.862, 0.821, (5.9610)+(0.0023)Gly+(−0.0463)Val+(−0.2302)Met+(0.0112)Lys+(0.1788)Ile+(−0.1132)Trp; 0.8 52, 0.876,0.761, 0.722, 0.761, 0.829, 0.813, 0.781, (3.9413)+(0.0479)Ser+(−0.0042)Gly+(−0.1096)His+(0.0012)Pro+(0.0732)Ile+(−0.1246)Trp;0.852, 0.881, 0.797, 0.777, 0.774, 0.827, 0.875, 0.813,(4.4418)+(−0.0828)Cit+(−0.0391)Val+(−0.0083)Lys+(0.1468)Ile+(0.0897)Phe+(−0.1526)Trp; 0.852, 0.876, 0.787, 0.773, 0.785, 0.8 35,0.795, 0.797, (2.3472)+(0.0493)Ser+(−0.0490)Asn+(0.0049)Pro+(−0.2083)Met+(0.0706)Ile+(−0.1424)Trp; 0.852, 0.875, 0.815, 0. 803,0.773, 0.864, 0.896, 0.834,(7.5019)+(−0.0309)Asn+(−0.0069)Ala+(−0.0582)Cit+(−0.0383)Val+(0.1722)Ile+(−0.1194)Trp;0.85 2, 0.879, 0.823, 0.807, 0.814, 0.856, 0.860, 0.834, (4.8460)+(−0.0099)Asn+(0.0108)Gln+(−0.1066)His+(−0.1262)Met+(0.0737)Ile+(−0.1124)Trp;0.852, 0.879, 0.808, 0.797, 0.805, 0.831, 0.829, 0.815,(3.2440)+(0.0020)Gly+(0.0085)Gln+(−0.1395)His+(0.0098)Orn+(0.0992)Phe+(−0.1195)Trp;0.852, 0.873, 0.789, 0.763, 0.782, 0.83 9, 0.835, 0.805,(7.3684)+(−0.1059)His+(0.0183)Thr+(−0.0060)Ala+(0.0163)Orn+(0.0713)Ile+(−0.1264)Trp; 0.852, 0.876, 0.768, 0. 743,0.775, 0.835, 0.770, 0.781,(−0.3541)+(0.0601)Ser+(−0.1466)His+(0.0001)Ala+(−0.0006)Val+(−0.2801)Met+(0.1633)Phe;0.852, 0.875, 0.800, 0.778, 0.799, 0.847, 0.829, 0.813,(4.5386)+(0.0039)Gly+(0.0092)Gln+(−0.1055)His+(−0.0620)Cit+(0.0754)Ile+(−0.1355)Trp; 0.852, 0.879, 0.783, 0.756, 0.743, 0.891, 0.856, 0.812, (1.5799)+(0.0508)Ser+(−0.0815)Asn+(0.0362)Tyr+(−0.0607)Val+(−0.3299)Met+(0.2119)Ile; 0.852, 0.875, 0.791, 0.772, 0.787, 0.833, 0. 822,0.803,(2.0568)+(0.0559)Ser+(−0.0066)Gly+(−0.2220)Met+(−0.0032)Lys+(0.0794)Ile+(−0.1451)Trp;0.852, 0.875, 0.754, 0.718, 0.756, 0.830, 0.793, 0.774,(3.9426)+(0.0401)Ser+(−0.1143)His+(0.0033)Thr+(0.0002)Pro+(0.0746)Ile+(−0.1241)Trp;0.852, 0.87 6, 0.816, 0.807, 0.783, 0.855, 0.877, 0.831,(6.7732)+(−0.0293)Asn+(−0.0472)Val+(−0.2023)Met+(0.0130)Lys+(0.1772)Ile+(−0.109 6)Trp; 0.852,0.873, 0.806, 0.792, 0.781, 0.850, 0.861, 0.821, (6.7859)+(−0.0303)Asn+(−0.0466)Val+(−0.1775)Met+(0.0287)Orn+(0.1739)Ile+(−0.1025)Trp; 0.852, 0.871, 0.800, 0.786, 0.764, 0.849, 0. 878,0.819,(7.6985)+(−0.0179)Asn+(−0.0532)His+(−0.0053)Ala+(−0.0328)Val+(0.1541)Ile+(−0.1033)Trp;0.852, 0.879, 0.768, 0.7 41, 0.778, 0.838, 0.770, 0.782,(−0.1745)+(0.0615)Ser+(−0.0340)Asn+(−0.1450)His+(−0.2560)Met+(0.0135)Orn+(0.1559)Phe; 0.852, 0.877,0.793, 0.781, 0.797, 0.827, 0.793, 0.799, (0.7834)+(0.0101)Gln+(−0.1708)His+(0.0391)Thr+(−0.0172)Tyr+(−0.3430)Met+(0.1 564)Phe;0.852, 0.878, 0.771, 0.748, 0.777, 0.838, 0.775, 0.784, (−0.0644)+(0.0625)Ser+(−0.0332)Asn+(−0.1421)His+(−0.0003)Ala+(−0.2542)Met+(0.1614)Phe;0.852, 0.874, 0.798, 0.787, 0.750, 0.885, 0.865, 0.822,(5.2881)+(−0.0564)Asn+(0.0341)Thr+(−0.0049)Ala+(−0.0600)Val+(−0.3106)Met+(0.2147)Ile;0.852, 0.880, 0.773, 0.7 59, 0.750, 0.796, 0.841, 0.786,(0.4540)+(0.0398)Ser+(−0.0085)Gly+(0.1380)Ile+(−0.0723)Leu+(0.0645)Phe+(−0.1674)Trp; 0.852, 0. 879,0.814, 0.802, 0.812, 0.831, 0.840, 0.821, (3.4315)+(0.0090)Gln+(−0.1396)His+(0.0015)Val+(0.0094)Orn+(0.0948)Phe+(−0.121 0)Trp; 0.852,0.879, 0.813, 0.802, 0.773, 0.861, 0.893, 0.832, (−0.4061)+(0.0067)Gln+(−0.0587)Cit+(−0.0616)Val+(−0.4239)Met+(0.1981)Ile+(0.1297)Phe; 0.852, 0.873, 0.788, 0.766, 0.768, 0.835, 0. 850,0.805,(7.3995)+(−0.0418)Asn+(−0.0643)His+(−0.0341)Val+(0.0297)Orn+(0.1378)Ile+(−0.1024)Trp;0.852, 0.879, 0.793, 0.78 7, 0.760, 0.816, 0.864, 0.807,(4.2104)+(−0.0802)Cit+(−0.0345)Tyr+(−0.0405)Val+(0.1468)Ile+(0.1029)Phe+(−0.1473)Trp; 0.852, 0. 878,0.811, 0.798, 0.802, 0.831, 0.852, 0.821, (3.5271)+(0.0091)Gln+(−0.1383)His+(−0.0119)Val+(0.0302)Leu+(0.0917)Phe+(−0.124 7)Trp;0.852, 0.882, 0.818, 0.828, 0.813, 0.824, 0.795, 0.815, (0.9168)+(0.0459)Ser+(−0.1370)Asn+(0.0035)Gln+(−0.0190)Arg+(0.0965)Phe+(−0.1512)Trp; 0.852, 0.873, 0.806, 0.805, 0.798, 0.855, 0.7 92,0.812, (4.6410)+(0.0370)Ser+(−0.0852)Asn+(0.0080)Gln+(−0.1015)His+(0.0097)Pro+(−0.0994)Trp; 0.852, 0.875, 0.800, 0.793, 0. 778,0.852, 0.828, 0.813, (2.9510)+(0.0376)Ser+(−0.1224)Asn+(0.0031)Gln+(0.1383)Ile+(−0.0580)Leu+(−0.1368)Trp; 0.852, 0.883, 0.798,0.779, 0.800, 0.829, 0.820, 0.807,(5.7516)+(−0.1216)His+(0.0224)Thr+(−0.0042)Ala+(0.0134)Orn+(0.1049)Phe+(−0.1251)Trp; 0.851, 0.878, 0.787, 0.770, 0.815, 0.826, 0.745, 0.789, (2.0021)+(0.0389)Ser+(−0.1405)Cit+(0.0490)Orn+(−0.0184)Lys+(0.1042)Phe+(−0.1758)Trp;0.851, 0.879, 0.762, 0.735, 0.745, 0.845, 0.810, 0.784,(4.4039)+(0.0428)Ser+(−0.0811)His+(−0.0219)Arg+(−0.0271)Val+(0.1440)Ile+(−0.1118)Trp; 0.851, 0.877, 0.772, 0.751, 0.7 77,0.839, 0.773, 0.785, (−0.0102)+(0.0625)Ser+(−0.0367)Asn+(−0.1396)His+(−0.0020)Val+(−0.2513)Met+(0.1643)Phe; 0.851, 0.881, 0.811,0.794, 0.789, 0.852, 0.873, 0.827,(7.1486)+(−0.0460)Cit+(0.0055)Pro+(−0.0406)Val+(−0.1585)Met+(0.1664)Ile+(−0.1138)Trp;0.851, 0.875, 0.796, 0.787, 0.752, 0.847, 0.871, 0.814, (1.9807)+(−0.0542)Asn+(0.0051)Gly+(−0.0650)Val+(−0.3525)Met+(0.2017)Ile+(0.1246)Phe; 0.851, 0.876, 0.779, 0.764, 0.781, 0.835, 0.77 2,0.788, (2.1648)+(0.0408)Ser+(0.0145)Thr+(−0.2629)Met+(−0.0055)Lys+(0.0807)Ile+(−0.1477)Trp; 0.851, 0.888, 0.783, 0.773, 0. 738,0.854, 0.849, 0.804,(−4.0834)+(0.0480)Ser+(−0.0079)Ala+(−0.3698)Met+(0.1997)Ile+(−0.0977)Leu+(0.1268)Phe;0.851, 0.877, 0.809, 0.794, 0.779, 0.854, 0.883, 0.827,(7.6850)+(−0.0422)His+(−0.0038)Ala+(−0.0359)Val+(−0.1162)Met+(0.1687)Ile+(−0.0943)Trp; 0.851, 0.879, 0.780, 0.750, 0.795, 0.808, 0.808, 0.790, (5.5569)+(−0.1309)His+(0.0213)Thr+(0.0102)Orn+(0.0100)Leu+(0.0898)Phe+(−0.1327)Trp; 0.851, 0.870, 0.791, 0.770, 0.787, 0.829, 0.82 7,0.803, (5.0167)+(0.0004)Gly+(0.0074)Gln+(−0.1265)His+(0.0106)Thr+(0.0640)Ile+(−0.1293)Trp; 0.851, 0.879, 0.780, 0.755, 0.7 56,0.885, 0.818, 0.803, (1.6919)+(0.0391)Ser+(−0.0696)Cit+(−0.0527)Val+(−0.3268)Met+(0.0328)Orn+(0.1885)Ile; 0.851, 0.879, 0. 794,0.772, 0.798, 0.842, 0.807, 0.805, (3.9604)+(0.0498)Ser+(−0.0904)Asn+(−0.0025)Gly+(−0.0784)Cit+(0.0687)Ile+(−0.1634)Tr p; 0.851,0.874, 0.814, 0.809, 0.792, 0.858, 0.842, 0.825,(6.0479)+(0.0216)Thr+(−0.0062)Ala+(−0.1864)Met+(0.1574)Ile+(−0.0579)Leu+(−0.1307)Trp;0.851, 0.877, 0.830, 0.823, 0.817, 0.866, 0.850, 0.839,(4.2629)+(0.0076)Gln+(−0.0721)Cit+(−0.1497)Met+(0.1562)Ile+(−0.0593)Leu+(−0.1396)Trp; 0.851, 0.878, 0.796, 0.779, 0.8 03,0.830, 0.799, 0.803, (0.6681)+(0.0104)Gln+(−0.1742)His+(0.0382)Thr+(−0.0001)Ala+(−0.3632)Met+(0.1519)Phe; 0.851, 0.871, 0. 793,0.783, 0.744, 0.878, 0.862, 0.817, (4.2961)+(−0.0004)Gly+(0.0317)Thr+(−0.0054)Ala+(−0.0588)Val+(−0.3584)Met+(0.2143)Il e; 0.851,0.883, 0.766, 0.753, 0.748, 0.803, 0.811, 0.778,(0.3092)+(0.0331)Ser+(−0.0136)Lys+(0.1358)Ile+(−0.0650)Leu+(0.0741)Phe+(−0.1596)Trp; 0.851, 0.880, 0.783, 0.766, 0.757, 0.830, 0.848, 0.800,(0.4951)+(0.0384)Ser+(−0.0098)Ala+(−0.0168)Lys+(0.0710)Ile+(0.0694)Phe+(−0.1642)Trp;0.851, 0.882, 0.795, 0.771, 0.796, 0.831, 0.827, 0.806,(5.8685)+(−0.1258)His+(0.0249)Thr+(−0.0048)Ala+(0.0143)Leu+(0.0990)Phe+(−0.1330)Trp; 0.851, 0.877, 0.76 5, 0.748,0.727, 0.874, 0.813, 0.791, (1.7317)+(0.0344)Ser+(−0.0013)Gln+(0.0219)Thr+(−0.0587)Val+(−0.4059)Met+(0.2130)Ile; 0. 851, 0.877,0.817, 0.803, 0.820, 0.857, 0.818, 0.825, (6.5034)+(0.0293)Thr+(−0.0066)Ala+(−0.0787)Cit+(−0.1750)Met+(0.0828)Ile+(−0.1511)Trp;0.851, 0.877, 0.799, 0.782, 0.792, 0.836, 0.831, 0.81 0,(1.4012)+(0.0531)Ser+(−0.0070)Gly+(0.0024)Gln+(−0.2424)Met+(0.0768)Ile+(−0.1501)Trp; 0.851, 0.880, 0.799, 0.801, 0.796, 0. 817,0.788, 0.800, (1.7343)+(0.0447)Ser+(−0.1437)Asn+(0.0082)Thr+(−0.0051)Lys+(0.0941)Phe+(−0.1497)Trp; 0.851, 0.875, 0.806, 0.796,0.764, 0.851, 0.889, 0.825, (−0.0565)+(0.0044)Gln+(−0.0639)Val+(−0.4315)Met+(0.0049)Orn+(0.1988)Ile+(0.1210)Phe; 0.85 1, 0.880,0.815, 0.804, 0.813, 0.833, 0.839, 0.822, (3.4671)+(0.0089)Gln+(−0.1378)His+(0.0107)Orn+(−0.0008)Lys+(0.0970)Phe+(−0. 1189)Trp;0.851, 0.879, 0.786, 0.763, 0.798, 0.812, 0.805, 0.795, (5.5054)+(−0.1253)His+(0.0208)Thr+(−0.0013)Val+(0.0127)Orn+(0.0999)Phe+(−0.1259)Trp; 0.851, 0.878, 0.782, 0.754, 0.797, 0.808, 0. 810,0.792, (5.6269)+(−0.1303)His+(0.0232)Thr+(−0.0007)Pro+(0.0113)Leu+(0.0938)Phe+(−0.1337)Trp; 0.851, 0.877, 0.761, 0.721, 0. 763,0.833, 0.814, 0.783, (3.9640)+(0.0465)Ser+(−0.0041)Gly+(−0.1125)His+(0.0105)Orn+(0.0717)Ile+(−0.1244)Trp; 0.851, 0.875, 0. 815,0.805, 0.776, 0.858, 0.890, 0.832, (6.9793)+(−0.0083)Asn+(−0.0047)Ala+(−0.0430)Val+(−0.1454)Met+(0.1826)Ile+(−0.1040)Tr p; 0.851,0.873, 0.816, 0.821, 0.808, 0.868, 0.786, 0.821,(5.4461)+(0.0299)Ser+(−0.0887)Asn+(0.0080)Gln+(−0.1021)His+(0.0132)Thr+(−0.1009)Trp; 0.851, 0.873, 0.791, 0.781, 0.794, 0.854, 0.768, 0.799,(5.8291)+(0.0466)Ser+(−0.0335)Asn+(−0.0781)His+(0.0141)Pro+(−0.1006)Met+(−0.0962)Trp;0.851, 0.871, 0.783, 0.764, 0.762, 0.831, 0.841, 0.799,(5.3017)+(0.0054)Gln+(−0.0992)His+(0.0106)Thr+(−0.0234)Val+(0.1197)Ile+(−0.1201)Trp; 0.851, 0.881, 0.8 21,0.818, 0.814, 0.841, 0.826, 0.825, (3.0865)+(0.0029)Gly+(0.0112)Gln+(−0.1395)His+(−0.0212)Arg+(0.1112)Phe+(−0.1170)Trp; 0. 851,0.881, 0.824, 0.820, 0.820, 0.834, 0.838, 0.828, (3.3690)+(0.0116)Gln+(−0.1376)His+(−0.0211)Arg+(0.0036)Pro+(0.1040)Phe+(−0.1189)Trp;0.851, 0.876, 0.758, 0.723, 0.763, 0.832, 0.786, 0.77 6,(4.1042)+(0.0462)Ser+(−0.1074)His+(−0.0167)Arg+(0.0022)Pro+(0.0766)Ile+(−0.1218)Trp; 0.851, 0.873, 0.791, 0.768, 0.780, 0. 843,0.839, 0.808,(7.5912)+(−0.1003)His+(0.0213)Thr+(−0.0058)Ala+(−0.0026)Lys+(0.0766)Ile+(−0.1258)Trp;0.851, 0.875, 0.805, 0.795, 0.762, 0.849, 0.887, 0.823,(−0.0824)+(0.0046)Gln+(0.0022)Pro+(−0.0636)Val+(−0.4385)Met+(0.1972)Ile+(0.1225)Phe; 0.8 51, 0.880,0.782, 0.760, 0.792, 0.810, 0.798, 0.790, (5.2454)+(0.0022)Gly+(−0.1267)His+(0.0209)Thr+(0.0006)Pro+(0.1046)Phe+(−0. 1263)Trp;0.851, 0.874, 0.805, 0.799, 0.760, 0.848, 0.885, 0.823,(−0.2290)+(0.0047)Gln+(−0.0552)Val+(−0.4250)Met+(0.2188)Ile+(−0.0279)Leu+(0.1251)Phe;0.851, 0.876, 0.780, 0.766, 0.789, 0.83 6, 0.757, 0.787,(2.4262)+(0.0414)Ser+(0.0179)Thr+(−0.0170)Arg+(−0.2644)Met+(0.0788)Ile+(−0.1496)Trp; 0.851, 0.873, 0.813, 0. 793,0.798, 0.854, 0.867, 0.828, (5.1283)+(0.0090)Gln+(−0.1180)His+(−0.0058)Ala+(0.0126)Tyr+(0.0737)Ile+(−0.1270)Trp; 0.851, 0.877,0.755, 0.738, 0.720, 0.799, 0.837, 0.774,(0.5779)+(0.0291)Ser+(−0.0439)Val+(−0.0092)Orn+(0.1428)Ile+(0.0747)Phe+(−0.1692)Trp; 0.851, 0.873, 0.813, 0.796, 0.797, 0.853, 0.861, 0.827, (5.2317)+(0.0090)Gln+(−0.1137)His+(−0.0051)Ala+(−0.0012)Lys+(0.0748)Ile+(−0.1214)Trp; 0.851, 0.880, 0.781, 0.757, 0.792, 0.811, 0. 797,0.789, (5.2102)+(0.0021)Gly+(−0.1283)His+(0.0194)Thr+(0.0117)Orn+(0.1001)Phe+(−0.1254)Trp; 0.851, 0.874, 0.809, 0.805, 0. 794,0.817, 0.846, 0.816, (4.3123)+(−0.0885)Asn+(0.0106)Thr+(0.1282)Ile+(−0.0692)Leu+(0.0732)Phe+(−0.1469)Trp; 0.851, 0.876, 0.792,0.766, 0.792, 0.845, 0.823, 0.806,(7.1411)+(−0.0729)His+(0.0167)Thr+(−0.0534)Cit+(0.1111)Ile+(−0.0310)Leu+(−0.1311)Trp;0.851, 0.875, 0.742, 0.710, 0.695, 0.849, 0.849, 0.776, (0.4469)+(0.0407)Ser+(−0.1301)His+(−0.0082)Ala+(−0.0306)Val+(0.1215)Ile+(0.0814)Phe; 0.851, 0.880, 0.810, 0.785, 0.794, 0.855, 0.87 8,0.828, (7.3511)+(−0.0459)His+(0.0320)Tyr+(−0.0383)Val+(−0.1833)Met+(0.1663)Ile+(−0.1019)Trp; 0.851, 0.877, 0.769, 0.742, 0. 776,0.835, 0.775, 0.782,(−0.3309)+(0.0615)Ser+(−0.0011)Gly+(−0.1463)His+(0.0000)Ala+(−0.2791)Met+(0.1613)Phe;0.851, 0.880, 0.814, 0.795, 0.790, 0.853, 0.883, 0.830,(6.3936)+(0.0032)Pro+(0.0306)Tyr+(−0.0459)Val+(−0.2384)Met+(0.1768)Ile+(−0.1129)Tr p; 0.851,0.881, 0.784, 0.771, 0.775, 0.818, 0.813, 0.794,(0.9148)+(0.0494)Ser+(−0.1255)Asn+(−0.0095)Lys+(0.0479)Ile+(0.0732)Phe+(−0.1565)Trp; 0.851, 0.878, 0.780, 0.769, 0.784, 0.796, 0.791, 0.785,(5.5484)+(−0.1228)His+(0.0272)Thr+(−0.0349)Tyr+(0.0006)Val+(0.1206)Phe+(−0.1197)Trp;0.851, 0.872, 0.794, 0.773, 0.789, 0.830, 0.831, 0.806,(5.2285)+(0.0077)Gln+(−0.1239)His+(0.0126)Thr+(−0.0055)Lys+(0.0669)Ile+(−0.1273)Trp; 0.851, 0.880, 0.7 86,0.768, 0.748, 0.886, 0.839, 0.810, (2.7468)+(0.0476)Ser+(−0.0793)Asn+(−0.0445)Cit+(−0.0519)Val+(−0.2464)Met+(0.1946)Ile; 0.851,0.875, 0.833, 0.828, 0.814, 0.868, 0.860, 0.843,(4.8479)+(−0.0763)Asn+(0.0085)Gln+(−0.0834)Cit+(0.1455)Ile+(−0.0584)Leu+(−0.1487)Trp; 0.851, 0.871, 0.791, 0.778, 0.754, 0.844, 0.864, 0. 810,(7.0906)+(0.0024)Gly+(−0.0624)His+(−0.0056)Ala+(−0.0304)Val+(0.1505)Ile+(−0.1068)Trp; 0.851, 0.878, 0.814, 0.813, 0.84 5,0.807, 0.759, 0.806, (3.7261)+(0.0437)Thr+(−0.0850)Cit+(−0.0065)Tyr+(−0.3192)Met+(0.1540)Phe+(−0.1719)Trp; 0.851, 0.878, 0. 761,0.729, 0.772, 0.832, 0.772, 0.776, (−0.6177)+(0.0618)Ser+(−0.1521)His+(−0.0036)Tyr+(−0.2930)Met+(0.0137)Leu+(0.1524)Phe; 0.851,0.876, 0.756, 0.717, 0.759, 0.833, 0.794, 0.776, (3.9180)+(0.0395)Ser+(−0.1163)His+(0.0021)Thr+(0.0094)Orn+(0.0725)Ile+(−0.1240)Trp;0.851, 0.875, 0.768, 0.737, 0.782, 0.797, 0.800, 0.77 9,(0.6560)+(0.0427)Ser+(−0.0028)Gly+(−0.1095)Cit+(0.0543)Ile+(0.0736)Phe+(−0.2055)Trp; 0.851, 0.874, 0.805, 0.796, 0.761, 0. 857,0.883, 0.824, (6.8920)+(−0.0692)Asn+(−0.0067)Ala+(−0.0450)Val+(0.0271)Orn+(0.1680)Ile+(−0.1099)Trp; 0.851, 0.874, 0.81 4, 0.805,0.776, 0.856, 0.886, 0.831, (6.8277)+(−0.0049)Ala+(−0.0383)Val+(−0.1479)Met+(0.1921)Ile+(−0.0143)Leu+(−0.1044)Trp; 0.851,0.878, 0.764, 0.734, 0.777, 0.834, 0.766, 0.778,(−0.5475)+(0.0641)Ser+(−0.1493)His+(−0.0106)Arg+(−0.2849)Met+(0.0127)Leu+(0.1540)Phe;0.851, 0.876, 0.809, 0.799, 0.758, 0.859, 0.907, 0. 831,(2.5979)+(−0.0349)Asn+(−0.0047)Ala+(−0.0632)Val+(−0.3179)Met+(0.2059)Ile+(0.1191)Phe; 0.851, 0.874, 0.812, 0.791, 0.808, 0.847,0.852, 0.825, (4.9215)+(0.0105)Gln+(−0.1017)His+(−0.0587)Cit+(−0.0051)Lys+(0.0764)Ile+(−0.1325)Trp; 0.851, 0.871, 0.7 88,0.765, 0.775, 0.841, 0.833, 0.804, (7.2283)+(0.0018)Gly+(−0.1031)His+(0.0189)Thr+(−0.0058)Ala+(0.0762)Ile+(−0.1254)Trp; 0. 851,0.878, 0.817, 0.799, 0.811, 0.854, 0.852, 0.829, (4.8284)+(0.0100)Gln+(−0.1091)His+(−0.1330)Met+(0.0094)Orn+(0.0716)Ile+(−0.1126)Trp;0.851, 0.882, 0.807, 0.813, 0.800, 0.812, 0.800, 0.80 6,(1.0933)+(0.0426)Ser+(−0.1601)Asn+(0.0025)Gln+(0.0055)Thr+(0.0897)Phe+(−0.1540)Trp; 0.851, 0.882, 0.799, 0.786, 0.816, 0.7 83,0.806, 0.798, (2.3486)+(0.0402)Thr+(−0.3781)Met+(−0.0258)Orn+(0.0577)Ile+(0.1213)Phe+(−0.1712)Trp; 0.851, 0.877, 0.817, 0. 798,0.794, 0.858, 0.885, 0.834, (6.5750)+(−0.0108)Asn+(0.0321)Tyr+(−0.0457)Val+(−0.2222)Met+(0.1791)Ile+(−0.1118)Trp; 0.851, 0.870,0.788, 0.775, 0.755, 0.878, 0.824, 0.808,(4.4898)+(0.0015)Gly+(0.0335)Thr+(−0.0572)Cit+(−0.0577)Val+(−0.3796)Met+(0.2061)Ile; 0.851, 0.874, 0.809, 0.790, 0.795, 0.852, 0.858, 0.824, (5.2890)+(0.0084)Gln+(−0.1162)His+(−0.0054)Ala+(0.0119)Orn+(0.0709)Ile+(−0.1221)Trp; 0.851, 0.874, 0.795, 0.772, 0.785, 0.845, 0. 842,0.811,(7.7870)+(−0.0216)Asn+(−0.0979)His+(0.0227)Thr+(−0.0056)Ala+(0.0738)Ile+(−0.1252)Trp;0.851, 0.877, 0.820, 0.803, 0.812, 0.850, 0.858, 0.831,(4.6917)+(0.0103)Gln+(−0.1097)His+(−0.1439)Met+(0.0044)Lys+(0.0727)Ile+(−0.1143)Trp;0.851, 0.8 75, 0.757, 0.720, 0.758, 0.833, 0.797, 0.777,(3.9599)+(0.0428)Ser+(−0.1086)His+(0.0008)Pro+(−0.0047)Lys+(0.0779)Ile+(−0.119 6)Trp; 0.851,0.870, 0.795, 0.780, 0.759, 0.845, 0.872, 0.814, (7.2563)+(−0.0621)His+(−0.0057)Ala+(−0.0315)Val+(0.0041)Lys+(0.1498)Ile+(−0.1093)Trp; 0.851, 0.876, 0.758, 0.742, 0.724, 0.803, 0. 838,0.777, (0.6936)+(0.0274)Ser+(−0.0029)Pro+(−0.0442)Val+(0.1442)Ile+(0.0707)Phe+(−0.1660)Trp; 0.851, 0.878, 0.824, 0.825, 0. 800,0.831, 0.864, 0.830, (3.0094)+(−0.0979)Asn+(0.0053)Gln+(0.1337)Ile+(−0.0717)Leu+(0.0707)Phe+(−0.1472)Trp; 0.851, 0.878, 0.778,0.766, 0.783, 0.798, 0.786, 0.783,(5.4138)+(0.0009)Gly+(−0.1233)His+(0.0265)Thr+(−0.0335)Tyr+(0.1213)Phe+(−0.1187)Trp; 0.851, 0.880, 0.827, 0.823, 0.822, 0.837, 0.839, 0.830,(3.3666)+(0.0118)Gln+(−0.1392)His+(−0.0201)Arg+(0.0018)Val+(0.1041)Phe+(−0.1185)Trp; 0.851, 0.876, 0.792, 0.776, 0.779, 0.849, 0.819, 0.806,(1.9068)+(0.0444)Ser+(−0.0052)Ala+(−0.2068)Met+(0.0033)Orn+(0.0860)Ile+(−0.1415)Trp;0.850, 0.873, 0.804, 0.788, 0.770, 0.854, 0.881, 0.823,(7.7361)+(−0.0414)His+(−0.0062)Ala+(−0.0480)Cit+(−0.0317)Val+(0.1599)Ile+(−0.1121)Trp; 0.850, 0.879, 0. 769,0.740, 0.745, 0.869, 0.821, 0.794, (2.9195)+(0.0484)Ser+(−0.0788)His+(−0.0086)Arg+(−0.0371)Val+(−0.2499)Met+(0.1714)Il e; 0.850,0.877, 0.772, 0.748, 0.779, 0.836, 0.778, 0.785, (−0.0697)+(0.0637)Ser+(−0.0323)Asn+(−0.0009)Gly+(−0.1417)His+(−0.2560)Met+(0.1605)Phe; 0.850, 0.883, 0.806, 0.800, 0.817, 0.798, 0.805,0.805, (0.9631)+(0.0040)Gln+(0.0320)Thr+(−0.3834)Met+(0.0497)Ile+(0.1063)Phe+(−0.1683)Trp; 0.850, 0.880, 0.825, 0.822, 0.79 0,0.851, 0.886, 0.837, (4.5654)+(−0.0476)Asn+(−0.0086)Ala+(0.1569)Ile+(−0.0762)Leu+(0.0802)Phe+(−0.1352)Trp; 0.850, 0.879, 0. 813,0.801, 0.784, 0.855, 0.872, 0.828, (6.7508)+(−0.0406)Cit+(−0.0431)Val+(−0.1861)Met+(0.0096)Lys+(0.1734)Ile+(−0.1157)Trp; 0.850,0.876, 0.767, 0.742, 0.776, 0.835, 0.770, 0.781,(−0.3597)+(0.0602)Ser+(−0.1472)His+(−0.0000)Ala+(−0.2799)Met+(−0.0001)Lys+(0.1624)Phe; 0.850, 0.883, 0.833, 0.841, 0.847, 0.812, 0.799,0.825, (1.8994)+(−0.0663)Asn+(0.0060)Gln+(0.0361)Thr+(−0.3192)Met+(0.1275)Phe+(−0.1595)Trp; 0.850, 0.878, 0.802, 0.790, 0.75 2,0.855, 0.900, 0.824, (1.7946)+(−0.0050)Ala+(−0.0633)Val+(−0.3537)Met+(0.0134)Orn+(0.2046)Ile+(0.1127)Phe; 0.850, 0.874, 0. 762,0.732, 0.780, 0.799, 0.781, 0.773, (0.5142)+(0.0392)Ser+(−0.1143)Cit+(0.0007)Pro+(0.0547)Ile+(0.0743)Phe+(−0.2063)Trp; 0. 850,0.874, 0.810, 0.803, 0.809, 0.857, 0.800, 0.817, (4.2182)+(0.0364)Ser+(−0.0703)Asn+(0.0087)Gln+(−0.1175)His+(0.0116)Val+(−0.1084)Trp;0.850, 0.871, 0.818, 0.813, 0.834, 0.874, 0.755, 0.81 9,(6.1616)+(0.0395)Ser+(−0.0954)Asn+(−0.0032)Ala+(−0.1138)Cit+(0.0591)Orn+(−0.1351)Trp; 0.850, 0.880, 0.812, 0.799, 0.810, 0. 828,0.839, 0.819, (3.4320)+(0.0088)Gln+(−0.1381)His+(0.0019)Pro+(0.0094)Orn+(0.0952)Phe+(−0.1206)Trp; 0.850, 0.879, 0.805, 0. 781,0.793, 0.836, 0.874, 0.821,(6.0874)+(−0.1021)His+(−0.0069)Ala+(0.0039)Pro+(0.0559)Ile+(0.0809)Phe+(−0.1266)Trp;0.850, 0.878, 0.771, 0.742, 0.748, 0.866, 0.824, 0.795,(2.5498)+(0.0480)Ser+(−0.1025)His+(−0.0053)Ala+(−0.1954)Met+(0.1464)Ile+(−0.0392)Leu; 0.850, 0.876, 0.800, 0.791, 0.793, 0.843, 0.812, 0.810, (1.7097)+(0.0452)Ser+(−0.0637)Asn+(0.0036)Gln+(−0.1980)Met+(0.0746)Ile+(−0.1454)Trp; 0.850, 0.881, 0.815, 0.820, 0.797, 0.843, 0. 820,0.820, (1.6419)+(0.0464)Ser+(−0.1343)Asn+(−0.0050)Ala+(0.0087)Orn+(0.0974)Phe+(−0.1419)Trp; 0.850, 0.876, 0.797, 0.783, 0. 782,0.851, 0.826, 0.810, (1.5211)+(0.0425)Ser+(0.0017)Gln+(−0.0051)Ala+(−0.2131)Met+(0.0864)Ile+(−0.1435)Trp; 0.850, 0.874, 0.808,0.796, 0.767, 0.858, 0.889, 0.827,(6.9248)+(−0.0077)Ala+(−0.0627)Cit+(−0.0369)Val+(−0.0010)Lys+(0.1719)Ile+(−0.1278)Trp; 0.850, 0.875, 0.810, 0.802, 0.778, 0.851, 0.868, 0.825, (6.2270)+(−0.0411)Val+(−0.2202)Met+(0.0122)Lys+(0.1894)Ile+(−0.0176)Leu+(−0.1124)Trp; 0.850, 0.882, 0.773, 0.747, 0.780, 0.831, 0. 783,0.785,(1.9568)+(0.0529)Ser+(−0.0010)Gly+(−0.1138)His+(−0.0566)Cit+(0.1339)Phe+(−0.1335)Trp;0.850, 0.877, 0.801, 0.785, 0.801, 0.851, 0.810, 0.812,(3.8707)+(0.0396)Ser+(−0.0791)Asn+(0.0083)Gln+(−0.1211)His+(0.0297)Leu+(−0.1099)Trp;0.850, 0.8 81, 0.797, 0.777, 0.764, 0.844, 0.886, 0.818,(3.5827)+(−0.0688)His+(0.0008)Arg+(−0.0516)Val+(−0.3172)Met+(0.1761)Ile+(0.127 2)Phe; 0.850,0.875, 0.789, 0.781, 0.750, 0.851, 0.845, 0.807, (2.8899)+(0.0293)Ser+(−0.0103)Ala+(0.0045)Pro+(0.1609)Ile+(−0.0645)Leu+(−0.1448)Trp; 0.850, 0.875, 0.785, 0.761, 0.795, 0.840, 0.7 90,0.796, (3.0176)+(0.0360)Ser+(0.0025)Gln+(−0.0959)Cit+(−0.0156)Lys+(0.0809)Ile+(−0.1757)Trp; 0.850, 0.875, 0.802, 0.786, 0. 779,0.845, 0.860, 0.817, (6.3016)+(0.0027)Pro+(−0.0458)Val+(−0.2084)Met+(0.0239)Orn+(0.1721)Ile+(−0.1069)Trp; 0.850, 0.873, 0. 801,0.787, 0.777, 0.846, 0.855, 0.816, (6.1184)+(0.0013)Gly+(−0.0457)Val+(−0.2062)Met+(0.0239)Orn+(0.1752)Ile+(−0.1070)Trp; 0.850,0.872, 0.796, 0.787, 0.746, 0.883, 0.865, 0.820, (3.6212)+(0.0018)Gln+(0.0301)Thr+(−0.0055)Ala+(−0.0584)Val+(−0.3671)Met+(0.2129)Ile; 0.850, 0.879, 0.803, 0.778, 0.795, 0.837, 0.866, 0.81 9,(6.1174)+(−0.1072)His+(−0.0061)Ala+(0.0146)Orn+(0.0557)Ile+(0.0767)Phe+(−0.1253)Trp; 0.850, 0.877, 0.769, 0.754, 0.729, 0. 873,0.817, 0.793, (1.3818)+(0.0327)Ser+(0.0218)Thr+(−0.0595)Val+(−0.4144)Met+(0.2093)Ile+(0.0035)Leu; 0.850, 0.876, 0.762, 0. 723,0.763, 0.830, 0.813, 0.782, (3.9286)+(0.0478)Ser+(−0.0040)Gly+(−0.1103)His+(0.0022)Tyr+(0.0745)Ile+(−0.1248)Trp; 0.850, 0.880,0.786, 0.762, 0.798, 0.810, 0.806, 0.794, (5.5158)+(−0.1263)His+(0.0207)Thr+(0.0001)Pro+(0.0121)Orn+(0.0982)Phe+(−0.1 272)Trp;0.850, 0.874, 0.804, 0.795, 0.752, 0.854, 0.899, 0.825, (1.8321)+(−0.0050)Ala+(−0.0540)Val+(−0.3433)Met+(0.2247)Ile+(−0.0278)Leu+(0.1202)Phe;0.850, 0.874, 0.762, 0.731, 0.779, 0.798, 0.782, 0.773,(0.5921)+(0.0397)Ser+(−0.0004)Gln+(−0.1134)Cit+(0.0555)Ile+(0.0750)Phe+(−0.2054)Trp;0.850, 0.883, 0.807, 0.78 9, 0.817, 0.844, 0.810, 0.815,(6.1079)+(−0.1038)His+(0.0297)Thr+(−0.0048)Ala+(−0.0672)Cit+(0.1290)Phe+(−0.1420)Trp; 0.850, 0. 878,0.817, 0.812, 0.806, 0.826, 0.842, 0.822, (3.3097)+(0.0096)Gln+(−0.1366)His+(−0.0178)Tyr+(0.0030)Val+(0.1061)Phe+(−0.116 6)Trp;0.850, 0.877, 0.766, 0.739, 0.780, 0.838, 0.757, 0.778, (−0.3211)+(0.0614)Ser+(−0.1466)His+(−0.0132)Arg+(−0.2654)Met+(0.0151)Orn+(0.1580)Phe; 0.850, 0.875, 0.770, 0.744, 0.782, 0.840, 0. 765,0.783,(−0.2172)+(0.0610)Ser+(−0.1396)His+(−0.0335)Cit+(0.0008)Val+(−0.2806)Met+(0.1639)Phe;0.850, 0.878, 0.778, 0.76 7, 0.781, 0.794, 0.789, 0.783,(5.4813)+(−0.1216)His+(0.0264)Thr+(0.0025)Pro+(−0.0364)Tyr+(0.1195)Phe+(−0.1192)Trp; 0.850, 0. 876,0.800, 0.787, 0.749, 0.854, 0.900, 0.823, (2.0275)+(−0.0066)Ala+(0.0082)Pro+(−0.0625)Val+(−0.3621)Met+(0.2006)Ile+(0.116 4)Phe;0.850, 0.877, 0.769, 0.743, 0.776, 0.836, 0.775, 0.783, (−0.3105)+(0.0614)Ser+(−0.0011)Gly+(−0.1455)His+(−0.0006)Val+(−0.2782)Met+(0.1622)Phe; 0.850, 0.875, 0.791, 0.779, 0.743, 0.878, 0. 859,0.815, (4.3085)+(0.0306)Thr+(−0.0068)Ala+(0.0070)Pro+(−0.0583)Val+(−0.3630)Met+(0.2072)Ile; 0.850, 0.875, 0.787, 0.761, 0. 776,0.848, 0.836, 0.805, (6.3778)+(−0.0987)Cit+(−0.0364)Val+(0.0503)Orn+(−0.0094)Lys+(0.1464)Ile+(−0.1393)Trp; 0.850, 0.879, 0.814,0.809, 0.802, 0.824, 0.845, 0.820,(2.8738)+(0.0030)Gly+(−0.2531)Met+(0.1595)Ile+(−0.0782)Leu+(0.1134)Phe+(−0.1275)Trp; 0.850, 0.877, 0.778, 0.759, 0.753, 0.860, 0.819, 0.798,(6.4120)+(−0.0704)His+(0.0411)Thr+(−0.0162)Arg+(−0.0475)Val+(−0.3216)Met+(0.1891)Ile; 0.850, 0.878, 0.770, 0.747, 0.776, 0.835, 0.773,0.783, (−0.1149)+(0.0624)Ser+(−0.0332)Asn+(−0.1426)His+(−0.2580)Met+(0.0006)Lys+(0.1612)Phe; 0.850, 0.872, 0.787, 0.769, 0.7 61,0.879, 0.826, 0.808, (4.4153)+(0.0298)Thr+(−0.0688)Cit+(−0.0586)Val+(−0.3688)Met+(0.0270)Orn+(0.1998)Ile; 0.850, 0.875, 0. 792,0.771, 0.790, 0.832, 0.822, 0.804, (1.9264)+(0.0551)Ser+(−0.0067)Gly+(−0.2333)Met+(0.0043)Orn+(0.0761)Ile+(−0.1477)Trp; 0.850,0.875, 0.764, 0.747, 0.769, 0.794, 0.781, 0.773, (0.5898)+(0.0399)Ser+(−0.1090)Cit+(−0.0378)Tyr+(0.0560)Ile+(0.0965)Phe+(−0.1921)Trp;0.850, 0.878, 0.813, 0.805, 0.804, 0.825, 0.845, 0.82 0,(3.3598)+(0.0095)Gln+(−0.1390)His+(−0.0173)Tyr+(0.0118)Leu+(0.0994)Phe+(−0.1202)Trp; 0.850, 0.878, 0.775, 0.758, 0.780, 0. 798,0.793, 0.782,(5.5806)+(−0.1281)His+(0.0275)Thr+(−0.0357)Tyr+(0.0117)Leu+(0.1114)Phe+(−0.1251)Trp;0.850, 0.876, 0.772, 0.746, 0.782, 0.841, 0.767, 0.784,(−0.1681)+(0.0608)Ser+(−0.1383)His+(−0.0003)Ala+(−0.0331)Cit+(−0.2776)Met+(0.1649)Phe; 0. 850, 0.872,0.803, 0.784, 0.786, 0.843, 0.856, 0.818, (7.3380)+(−0.0745)His+(−0.0060)Ala+(0.0228)Orn+(0.1261)Ile+(−0.0410)Leu+(−0.1111)Trp;0.850, 0.879, 0.774, 0.751, 0.783, 0.842, 0.766, 0.78 6,(0.0909)+(0.0635)Ser+(−0.0347)Asn+(−0.1337)His+(−0.0335)Cit+(−0.2541)Met+(0.1641)Phe; 0.850, 0.875, 0.756, 0.742, 0.739, 0. 794,0.799, 0.768, (0.6559)+(0.0315)Ser+(−0.0025)Gln+(0.1380)Ile+(−0.0724)Leu+(0.0689)Phe+(−0.1646)Trp; 0.850, 0.881, 0.820, 0.803,0.820, 0.844, 0.851, 0.829, (3.1785)+(0.0107)Gln+(−0.1293)His+(−0.0615)Cit+(0.0136)Leu+(0.1038)Phe+(−0.1364)Trp; 0.8 50, 0.879,0.782, 0.771, 0.786, 0.802, 0.791, 0.787, (5.6383)+(−0.1212)His+(0.0284)Thr+(−0.0344)Tyr+(−0.0026)Lys+(0.1229)Phe+(−0.1182)Trp;0.850, 0.877, 0.793, 0.778, 0.768, 0.825, 0.862, 0.80 8,(3.9218)+(−0.0869)Cit+(−0.0291)Val+(0.1697)Ile+(−0.0375)Leu+(0.0891)Phe+(−0.1540)Trp; 0.850, 0.874, 0.790, 0.779, 0.769, 0. 847,0.820, 0.804,(3.4041)+(0.0414)Ser+(−0.1018)Asn+(−0.0021)Thr+(0.1405)Ile+(−0.0582)Leu+(−0.1342)Trp;0.850, 0.875, 0.758, 0.724, 0.762, 0.833, 0.787, 0.777,(4.1380)+(0.0463)Ser+(−0.1065)His+(−0.0153)Arg+(−0.0013)Lys+(0.0801)Ile+(−0.1198)Trp; 0. 850, 0.874,0.754, 0.716, 0.757, 0.831, 0.794, 0.775, (3.9002)+(0.0404)Ser+(−0.1150)His+(0.0029)Thr+(0.0029)Tyr+(0.0746)Ile+(−0.1252)Trp;0.850, 0.877, 0.815, 0.797, 0.791, 0.854, 0.883, 0.831,(6.3750)+(0.0315)Tyr+(−0.0433)Val+(−0.2292)Met+(0.1845)Ile+(−0.0076)Leu+(−0.1126)Trp;0.850, 0.881, 0.803, 0.807, 0.795, 0.8 09, 0.805, 0.804,(0.8832)+(0.0451)Ser+(−0.1548)Asn+(0.0024)Gln+(0.0036)Pro+(0.0876)Phe+(−0.1530)Trp; 0.850, 0.878, 0.801, 0. 794,0.797, 0.805, 0.826, 0.806, (1.8218)+(0.0566)Ser+(−0.1413)Asn+(−0.0068)Gly+(0.0043)Pro+(0.0850)Phe+(−0.1528)Trp; 0.850, 0.872,0.809, 0.793, 0.800, 0.847, 0.845, 0.821, (5.0483)+(−0.0464)Asn+(0.0024)Gly+(0.0099)Gln+(−0.1159)His+(0.0642)Ile+(−0. 1189)Trp;0.850, 0.880, 0.797, 0.777, 0.765, 0.845, 0.885, 0.818, (3.6045)+(−0.0686)His+(0.0002)Tyr+(−0.0517)Val+(−0.3159)Met+(0.1762)Ile+(0.1272)Phe; 0.850, 0.880, 0.798, 0.776, 0.766, 0.850, 0. 886,0.820,(3.7214)+(−0.0626)His+(−0.0301)Cit+(−0.0519)Val+(−0.3057)Met+(0.1774)Ile+(0.1294)Phe;0.850, 0.875, 0.790, 0.77 9, 0.772, 0.846, 0.817, 0.803,(3.4481)+(0.0402)Ser+(−0.1079)Asn+(0.0045)Orn+(0.1376)Ile+(−0.0576)Leu+(−0.1349)Trp; 0.850, 0. 874,0.810, 0.798, 0.771, 0.860, 0.886, 0.829, (6.8927)+(−0.0077)Ala+(−0.0638)Cit+(−0.0293)Val+(0.1878)Ile+(−0.0244)Leu+(−0.1 256)Trp;0.850, 0.870, 0.792, 0.772, 0.788, 0.831, 0.829, 0.805, (5.0990)+(0.0075)Gln+(−0.1265)His+(0.0115)Thr+(−0.0022)Pro+(0.0664)Ile+(−0.1293)Trp; 0.850, 0.880, 0.824, 0.816, 0.820, 0.838, 0. 844,0.829, (3.3774)+(0.0117)Gln+(−0.1420)His+(−0.0196)Arg+(0.0102)Leu+(0.0969)Phe+(−0.1221)Trp; 0.850, 0.874, 0.790, 0.775, 0. 786,0.841, 0.798, 0.800, (2.3839)+(0.0486)Ser+(−0.0469)Asn+(−0.1917)Met+(−0.0011)Lys+(0.0769)Ile+(−0.1418)Trp; 0.850, 0.881, 0.824,0.801, 0.820, 0.846, 0.874, 0.835,(6.0142)+(−0.0922)His+(−0.0039)Ala+(−0.1520)Met+(0.0621)Ile+(0.1084)Phe+(−0.1168)Trp;0.850, 0.876, 0.819, 0.813, 0.806, 0.822, 0.857, 0.824, (3.3309)+(0.0043)Asn+(−0.2450)Met+(0.1582)Ile+(−0.0778)Leu+(0.1110)Phe+(−0.1284)Trp; 0.850, 0.878, 0.794, 0.795, 0.791, 0.806, 0.79 1,0.795, (1.4981)+(0.0456)Ser+(−0.1511)Asn+(0.0046)Thr+(0.0034)Pro+(0.0884)Phe+(−0.1531)Trp; 0.850, 0.877, 0.784, 0.769, 0.7 30,0.884, 0.863, 0.811, (1.2949)+(0.0405)Ser+(−0.0060)Ala+(−0.0475)Val+(−0.2975)Met+(0.2168)Ile+(−0.0147)Leu; 0.850, 0.874, 0.789,0.779, 0.786, 0.856, 0.772, 0.798,(5.6071)+(0.0445)Ser+(−0.0808)His+(−0.0024)Ala+(0.0162)Pro+(−0.1163)Met+(−0.0943)Irp; 0.850, 0.878, 0.821, 0.820, 0.804, 0.838, 0.845, 0.827, (1.9949)+(0.0555)Ser+(−0.1290)Asn+(−0.0062)Gly+(−0.0044)Ala+(0.0984)Phe+(−0.1436)Trp; 0.850, 0.878, 0.806, 0.778, 0.812, 0.823, 0.85 5,0.817, (5.1465)+(0.0400)Asn+(−0.1038)His+(−0.2076)Met+(0.0608)Ile+(0.1128)Phe+(−0.1189)Trp; 0.850, 0.874, 0.809, 0.786, 0. 806,0.843, 0.849, 0.821, (4.7956)+(0.0100)Gln+(−0.1052)His+(−0.0566)Cit+(0.0011)Pro+(0.0713)Ile+(−0.1355)Trp; 0.850, 0.871, 0. 788,0.774, 0.755, 0.877, 0.829, 0.809, (4.6427)+(0.0342)Thr+(−0.0547)Cit+(0.0022)Pro+(−0.0580)Val+(−0.3831)Met+(0.2037)Ile

Although the invention has been described with respect to specificembodiments for a complete and clear disclosure, the appended claims arenot to be thus limited but are to be construed as embodying allmodifications and alternative constructions that may occur to oneskilled in the art that fairly fall within the basic teaching herein setforth.

What is claimed is:
 1. A method of evaluating pancreatic cancer,comprising: an obtaining step of obtaining amino acid concentration dataon a concentration value of an amino acid in blood collected from asubject to be evaluated; and an evaluating step of evaluating a state ofpancreatic cancer in the subject by calculating a value of a formulausing (i) the amino acid concentration data of the subject obtained atthe obtaining step and (ii) the formula previously established forevaluating the state of pancreatic cancer, including an explanatoryvariable to be substituted with the concentration value of the aminoacid, wherein the amino acid concentration data includes theconcentration values of at least two amino acids of Asn, His, Thr, Ala,Cit, Arg, Tyr, Val, Met, Lys, Trp, Gly, Pro, Orn, Ile, Leu, Phe, Ser,and Gln, and the formula includes at least two explanatory variables tobe substituted with the concentration values of at least two amino acidsof Asn, His, Thr, Ala, Cit, Arg, Tyr, Val, Met, Lys, Trp, Gly, Pro, Orn,Ile, Leu, Phe, Ser, and Gln.
 2. The method of evaluating pancreaticcancer according to claim 1, wherein the state of pancreatic cancer isthe degree of the possibility of being affected with pancreatic cancer,and evaluating the state of pancreatic cancer in the subject isevaluating the degree of the possibility that the subject is affectedwith pancreatic cancer.
 3. The method of evaluating pancreatic canceraccording to claim 2, wherein a plurality of categories definedconsidering at least the degree of the possibility of being affectedwith pancreatic cancer, and one or more thresholds are previouslyestablished, and evaluating the degree of the possibility that thesubject is affected with pancreatic cancer is classifying the subjectinto any one of the categories using the value of the formula and thethreshold.
 4. The method of evaluating pancreatic cancer according toclaim 3, wherein the categories include at least one category definedconsidering at least the degree of the possibility of being affectedwith pancreatic cancer and the degree of the possibility of beingaffected with a cancer other than pancreatic cancer.
 5. The method ofevaluating pancreatic cancer according to claim 3, wherein thecategories include a category to which a subject with a high possibilityof being affected with pancreatic cancer belongs and a category to whicha subject with a low possibility of being affected with pancreaticcancer belongs.
 6. The method of evaluating pancreatic cancer accordingto claim 5, wherein the category to which a subject with a lowpossibility of being affected with pancreatic cancer belongs is ahealthy category to which a subject with a high possibility of beinghealthy belongs, other cancer category to which a subject with a highpossibility of being affected with a cancer other than pancreatic cancerbelongs, or a healthy/other cancer category to which a subject with ahigh possibility of being healthy and a subject with a high possibilityof being affected with a cancer other than pancreatic cancer belong. 7.The method of evaluating pancreatic cancer according to claim 5, whereinthe category to which a subject with a low possibility of being affectedwith pancreatic cancer belongs includes a healthy category to which asubject with a high possibility of being healthy belongs and othercancer category to which a subject with a high possibility of beingaffected with a cancer other than pancreatic cancer belongs.
 8. Themethod of evaluating pancreatic cancer according to claim 1, wherein theformula is any one of a logistic regression equation, a fractionalexpression, a linear discriminant, a multiple regression equation, aformula prepared by a support vector machine, a formula prepared by aMahalanobis' generalized distance method, a formula prepared bycanonical discriminant analysis, and a formula prepared by a decisiontree.
 9. A pancreatic cancer-evaluating apparatus comprising a controlunit and a memory unit to evaluate a state of pancreatic cancer in asubject to be evaluated, wherein the control unit includes: anevaluating unit that evaluates the state of pancreatic cancer in thesubject by calculating a value of a formula using (i) previouslyobtained amino acid concentration data of the subject on a concentrationvalue of an amino acid and (ii) the formula previously stored in thememory unit for evaluating the state of pancreatic cancer, including anexplanatory variable to be substituted with the concentration value ofthe amino acid, wherein the amino acid concentration data includes theconcentration values of at least two amino acids of Asn, His, Thr, Ala,Cit, Arg, Tyr, Val, Met, Lys, Trp, Gly, Pro, Orn, Ile, Leu, Phe, Ser,and Gln, and the formula includes at least two explanatory variables tobe substituted with the concentration values of at least two amino acidsof Asn, His, Thr, Ala, Cit, Arg, Tyr, Val, Met, Lys, Trp, Gly, Pro, Orn,Ile, Leu, Phe, Ser, and Gln.
 10. A pancreatic cancer-evaluating methodof evaluating a state of pancreatic cancer in a subject to be evaluated,which method is carried out with an information processing apparatusincluding a control unit and a memory unit, the method comprising: anevaluating step of evaluating the state of pancreatic cancer in thesubject by calculating a value of a formula using (i) previouslyobtained amino acid concentration data of the subject on a concentrationvalue of an amino acid and (ii) the formula previously stored in thememory unit for evaluating the state of pancreatic cancer, including anexplanatory variable to be substituted with the concentration value ofthe amino acid, wherein the amino acid concentration data includes theconcentration values of at least two amino acids of Asn, His, Thr, Ala,Cit, Arg, Tyr, Val, Met, Lys, Trp, Gly, Pro, Orn, Ile, Leu, Phe, Ser,and Gln, the formula includes at least two explanatory variables to besubstituted with the concentration values of at least two amino acids ofAsn, His, Thr, Ala, Cit, Arg, Tyr, Val, Met, Lys, Trp, Gly, Pro, Orn,Ile, Leu, Phe, Ser, and Gln, and the evaluating step is executed by thecontrol unit.
 11. A pancreatic cancer-evaluating program product havinga non-transitory computer readable medium including programmedinstructions for making an information processing apparatus including acontrol unit and a memory unit execute a method of evaluating a state ofpancreatic cancer in a subject to be evaluated, the method comprising:an evaluating step of evaluating the state of pancreatic cancer in thesubject by calculating a value of a formula using (i) previouslyobtained amino acid concentration data of the subject on a concentrationvalue of an amino acid and (ii) the formula previously stored in thememory unit for evaluating the state of pancreatic cancer, including anexplanatory variable to be substituted with the concentration value ofthe amino acid, wherein the amino acid concentration data includes theconcentration values of at least two amino acids of Asn, His, Thr, Ala,Cit, Arg, Tyr, Val, Met, Lys, Trp, Gly, Pro, Orn, Ile, Leu, Phe, Ser,and Gln, the formula includes at least two explanatory variables to besubstituted with the concentration values of at least two amino acids ofAsn, His, Thr, Ala, Cit, Arg, Tyr, Val, Met, Lys, Trp, Gly, Pro, Orn,Ile, Leu, Phe, Ser, and Gln, and the evaluating step is executed by thecontrol unit.
 12. A pancreatic cancer-evaluating system comprising (I) apancreatic cancer-evaluating apparatus including a control unit and amemory unit to evaluate a state of pancreatic cancer in a subject to beevaluated and (II) an information communication terminal apparatusincluding a control unit to provide amino acid concentration data of thesubject on a concentration value of an amino acid that are connected toeach other communicatively via a network, wherein the control unit ofthe information communication terminal apparatus includes: an amino acidconcentration data-sending unit that transmits the amino acidconcentration data of the subject to the pancreatic cancer-evaluatingapparatus; and an evaluation result-receiving unit that receives anevaluation result on the state of pancreatic cancer in the subject,transmitted from the pancreatic cancer-evaluating apparatus, and thecontrol unit of the pancreatic cancer-evaluating apparatus includes: anamino acid concentration data-receiving unit that receives the aminoacid concentration data of the subject transmitted from the informationcommunication terminal apparatus; an evaluating unit that evaluates thestate of pancreatic cancer in the subject by calculating a value of aformula using (i) the amino acid concentration data of the subjectreceived by the amino acid concentration data-receiving unit and (ii)the formula previously stored in the memory unit for evaluating thestate of pancreatic cancer, including an explanatory variable to besubstituted with the concentration value of the amino acid; and anevaluation result-sending unit that transmits the evaluation result ofthe subject obtained by the evaluating unit to the informationcommunication terminal apparatus, wherein the amino acid concentrationdata includes the concentration values of at least two amino acids ofAsn, His, Thr, Ala, Cit, Arg, Tyr, Val, Met, Lys, Trp, Gly, Pro, Orn,Ile, Leu, Phe, Ser, and Gln, and the formula includes at least twoexplanatory variables to be substituted with the concentration values ofat least two amino acids of Asn, His, Thr, Ala, Cit, Arg, Tyr, Val, Met,Lys, Trp, Gly, Pro, Orn, Ile, Leu, Phe, Ser, and Gln.
 13. An informationcommunication terminal apparatus comprising a control unit to provideamino acid concentration data of a subject to be evaluated on aconcentration value of an amino acid, being connected communicativelyvia a network to a pancreatic cancer-evaluating apparatus that evaluatesa state of pancreatic cancer in the subject, wherein the control unitincludes: an amino acid concentration data-sending unit that transmitsthe amino acid concentration data of the subject to the pancreaticcancer-evaluating apparatus; and an evaluation result-receiving unitthat receives an evaluation result on the state of pancreatic cancer inthe subject, transmitted from the pancreatic cancer-evaluatingapparatus, wherein the evaluation result is the result of (I) receivingthe amino acid concentration data of the subject transmitted from theinformation communication terminal apparatus and (II) evaluating thestate of pancreatic cancer in the subject by calculating a value of aformula using (i) the received amino acid concentration data of thesubject and (ii) the formula previously stored in the pancreaticcancer-evaluating apparatus for evaluating the state of pancreaticcancer, including an explanatory variable to be substituted with theconcentration value of the amino acid, wherein the (I) and (II) areexecuted by the pancreatic cancer-evaluating apparatus, wherein theamino acid concentration data includes the concentration values of atleast two amino acids of Asn, His, Thr, Ala, Cit, Arg, Tyr, Val, Met,Lys, Trp, Gly, Pro, Orn, Ile, Leu, Phe, Ser, and Gln, and the formulaincludes at least two explanatory variables to be substituted with theconcentration values of at least two amino acids of Asn, His, Thr, Ala,Cit, Arg, Tyr, Val, Met, Lys, Trp, Gly, Pro, Orn, Ile, Leu, Phe, Ser,and Gln.
 14. A pancreatic cancer-evaluating apparatus comprising acontrol unit and a memory unit to evaluate a state of pancreatic cancerin a subject to be evaluated, being connected communicatively via anetwork to an information communication terminal apparatus that providesamino acid concentration data of the subject on a concentration value ofan amino acid, wherein the control unit includes: an amino acidconcentration data-receiving unit that receives the amino acidconcentration data of the subject transmitted from the informationcommunication terminal apparatus; an evaluating unit that evaluates thestate of pancreatic cancer in the subject by calculating a value of aformula using (i) the amino acid concentration data of the subjectreceived by the amino acid concentration data-receiving unit and (ii)the formula previously stored in the memory unit for evaluating thestate of pancreatic cancer, including an explanatory variable to besubstituted with the concentration value of the amino acid; and anevaluation result-sending unit that transmits an evaluation result onthe state of pancreatic cancer in the subject obtained by the evaluatingunit to the information communication terminal apparatus, wherein theamino acid concentration data includes the concentration values of atleast two amino acids of Asn, His, Thr, Ala, Cit, Arg, Tyr, Val, Met,Lys, Trp, Gly, Pro, Orn, Ile, Leu, Phe, Ser, and Gln, and the formulaincludes at least two explanatory variables to be substituted with theconcentration values of at least two amino acids of Asn, His, Thr, Ala,Cit, Arg, Tyr, Val, Met, Lys, Trp, Gly, Pro, Orn, Ile, Leu, Phe, Ser,and Gln.